0000097745-23-000008.txt : 20230223 0000097745-23-000008.hdr.sgml : 20230223 20230223125452 ACCESSION NUMBER: 0000097745-23-000008 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 115 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: THERMO FISHER SCIENTIFIC INC. CENTRAL INDEX KEY: 0000097745 STANDARD INDUSTRIAL CLASSIFICATION: MEASURING & CONTROLLING DEVICES, NEC [3829] IRS NUMBER: 042209186 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-08002 FILM NUMBER: 23658387 BUSINESS ADDRESS: STREET 1: 168 THIRD AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 7816221000 MAIL ADDRESS: STREET 1: 168 THIRD AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: THERMO ELECTRON CORP DATE OF NAME CHANGE: 19920703 10-K 1 tmo-20221231.htm 10-K tmo-20221231
0000097745FALSE2022FYhttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpenseInvestments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrent00000977452022-01-012022-12-310000097745us-gaap:CommonStockMember2022-01-012022-12-310000097745tmo:SeniorNotes0.75Due2024Member2022-01-012022-12-310000097745tmo:SeniorNotes0.125Due2025Member2022-01-012022-12-310000097745tmo:SeniorNotes200Due2025Member2022-01-012022-12-310000097745tmo:SeniorNotes3200Due2026Member2022-01-012022-12-310000097745tmo:SeniorNotes1.40Due2026Member2022-01-012022-12-310000097745tmo:A1.45SeniorNotesDue2027Member2022-01-012022-12-310000097745tmo:SeniorNotes175Due2027Member2022-01-012022-12-310000097745tmo:SeniorNotes0.500Due2028Member2022-01-012022-12-310000097745tmo:SeniorNotes1.375Due2028Member2022-01-012022-12-310000097745tmo:SeniorNotes1.95Due2029Member2022-01-012022-12-310000097745tmo:SeniorNotes0.875Due2031Member2022-01-012022-12-310000097745tmo:SeniorNotes2375Due2032Member2022-01-012022-12-310000097745tmo:SeniorNotes3650Due2034Member2022-01-012022-12-310000097745tmo:SeniorNotes2.875Due2037Member2022-01-012022-12-310000097745tmo:SeniorNotes1.500Due2039Member2022-01-012022-12-310000097745tmo:SeniorNotes1.875Due2049Member2022-01-012022-12-3100000977452022-07-01iso4217:USD00000977452023-02-04xbrli:shares00000977452022-12-3100000977452021-12-31iso4217:USDxbrli:shares0000097745us-gaap:ProductMember2022-01-012022-12-310000097745us-gaap:ProductMember2021-01-012021-12-310000097745us-gaap:ProductMember2020-01-012020-12-310000097745us-gaap:ServiceMember2022-01-012022-12-310000097745us-gaap:ServiceMember2021-01-012021-12-310000097745us-gaap:ServiceMember2020-01-012020-12-3100000977452021-01-012021-12-3100000977452020-01-012020-12-3100000977452020-12-3100000977452019-12-310000097745us-gaap:CommonStockMember2019-12-310000097745us-gaap:AdditionalPaidInCapitalMember2019-12-310000097745us-gaap:RetainedEarningsMember2019-12-310000097745us-gaap:TreasuryStockCommonMember2019-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000097745us-gaap:ParentMember2019-12-310000097745us-gaap:NoncontrollingInterestMember2019-12-310000097745us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000097745us-gaap:ParentMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000097745srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000097745us-gaap:CommonStockMember2020-01-012020-12-310000097745us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310000097745us-gaap:TreasuryStockCommonMember2020-01-012020-12-310000097745us-gaap:ParentMember2020-01-012020-12-310000097745us-gaap:RetainedEarningsMember2020-01-012020-12-310000097745us-gaap:NoncontrollingInterestMember2020-01-012020-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000097745us-gaap:CommonStockMember2020-12-310000097745us-gaap:AdditionalPaidInCapitalMember2020-12-310000097745us-gaap:RetainedEarningsMember2020-12-310000097745us-gaap:TreasuryStockCommonMember2020-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000097745us-gaap:ParentMember2020-12-310000097745us-gaap:NoncontrollingInterestMember2020-12-310000097745us-gaap:CommonStockMember2021-01-012021-12-310000097745us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000097745us-gaap:TreasuryStockCommonMember2021-01-012021-12-310000097745us-gaap:ParentMember2021-01-012021-12-310000097745us-gaap:RetainedEarningsMember2021-01-012021-12-310000097745us-gaap:NoncontrollingInterestMember2021-01-012021-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000097745us-gaap:CommonStockMember2021-12-310000097745us-gaap:AdditionalPaidInCapitalMember2021-12-310000097745us-gaap:RetainedEarningsMember2021-12-310000097745us-gaap:TreasuryStockCommonMember2021-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000097745us-gaap:ParentMember2021-12-310000097745us-gaap:NoncontrollingInterestMember2021-12-310000097745us-gaap:CommonStockMember2022-01-012022-12-310000097745us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000097745us-gaap:TreasuryStockCommonMember2022-01-012022-12-310000097745us-gaap:ParentMember2022-01-012022-12-310000097745us-gaap:RetainedEarningsMember2022-01-012022-12-310000097745us-gaap:NoncontrollingInterestMember2022-01-012022-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000097745us-gaap:CommonStockMember2022-12-310000097745us-gaap:AdditionalPaidInCapitalMember2022-12-310000097745us-gaap:RetainedEarningsMember2022-12-310000097745us-gaap:TreasuryStockCommonMember2022-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000097745us-gaap:ParentMember2022-12-310000097745us-gaap:NoncontrollingInterestMember2022-12-310000097745tmo:PPDSNBLKKMember2022-12-31xbrli:pure0000097745us-gaap:ChangeInAccountingPrincipleOtherMember2021-09-300000097745us-gaap:ChangeInAccountingPrincipleOtherMember2021-10-020000097745us-gaap:ProductMemberus-gaap:ChangeInAccountingPrincipleOtherMember2021-07-042021-10-020000097745tmo:LaboratoryProductsandServicesMemberus-gaap:ChangeInAccountingPrincipleOtherMember2021-10-020000097745us-gaap:ProductMembertmo:LaboratoryProductsandServicesMemberus-gaap:ChangeInAccountingPrincipleOtherMember2021-07-042021-10-020000097745us-gaap:ChangeInAccountingPrincipleOtherMembertmo:SpecialtyDiagnosticsMember2021-10-020000097745us-gaap:ProductMemberus-gaap:ChangeInAccountingPrincipleOtherMembertmo:SpecialtyDiagnosticsMember2021-07-042021-10-020000097745us-gaap:BuildingAndBuildingImprovementsMembersrt:MinimumMember2022-01-012022-12-310000097745us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2022-01-012022-12-310000097745us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2022-01-012022-12-310000097745us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2022-01-012022-12-310000097745us-gaap:LandMember2022-12-310000097745us-gaap:LandMember2021-12-310000097745us-gaap:BuildingAndBuildingImprovementsMember2022-12-310000097745us-gaap:BuildingAndBuildingImprovementsMember2021-12-310000097745us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2022-12-310000097745us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2021-12-310000097745us-gaap:ConstructionInProgressMember2022-12-310000097745us-gaap:ConstructionInProgressMember2021-12-310000097745srt:MaximumMember2022-01-012022-12-310000097745us-gaap:CustomerRelationshipsMember2022-12-310000097745us-gaap:CustomerRelationshipsMember2021-12-310000097745us-gaap:DevelopedTechnologyRightsMember2022-12-310000097745us-gaap:DevelopedTechnologyRightsMember2021-12-310000097745us-gaap:TradeNamesMember2022-12-310000097745us-gaap:TradeNamesMember2021-12-310000097745us-gaap:OrderOrProductionBacklogMember2022-12-310000097745us-gaap:OrderOrProductionBacklogMember2021-12-310000097745us-gaap:TradeNamesMember2022-12-310000097745us-gaap:TradeNamesMember2021-12-310000097745tmo:LifeSciencesSolutionsMember2020-12-310000097745tmo:AnalyticalInstrumentsMember2020-12-310000097745tmo:SpecialtyDiagnosticsMember2020-12-310000097745tmo:LaboratoryProductsandServicesMember2020-12-310000097745tmo:LifeSciencesSolutionsMember2021-01-012021-12-310000097745tmo:AnalyticalInstrumentsMember2021-01-012021-12-310000097745tmo:SpecialtyDiagnosticsMember2021-01-012021-12-310000097745tmo:LaboratoryProductsandServicesMember2021-01-012021-12-310000097745tmo:LifeSciencesSolutionsMember2021-12-310000097745tmo:AnalyticalInstrumentsMember2021-12-310000097745tmo:SpecialtyDiagnosticsMember2021-12-310000097745tmo:LaboratoryProductsandServicesMember2021-12-310000097745tmo:LifeSciencesSolutionsMember2022-01-012022-12-310000097745tmo:AnalyticalInstrumentsMember2022-01-012022-12-310000097745tmo:SpecialtyDiagnosticsMember2022-01-012022-12-310000097745tmo:LaboratoryProductsandServicesMember2022-01-012022-12-310000097745tmo:LifeSciencesSolutionsMember2022-12-310000097745tmo:AnalyticalInstrumentsMember2022-12-310000097745tmo:SpecialtyDiagnosticsMember2022-12-310000097745tmo:LaboratoryProductsandServicesMember2022-12-310000097745us-gaap:AccountingStandardsUpdate201613Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-01-010000097745us-gaap:SubsequentEventMembertmo:TheBindingSiteGroupMember2023-01-032023-01-030000097745us-gaap:SubsequentEventMembertmo:TheBindingSiteGroupMember2023-01-030000097745tmo:EuropeanViralVectorManufacturingBusinessMember2021-01-150000097745tmo:MesaBiotechMember2021-02-250000097745tmo:CSLMember2021-09-300000097745tmo:PPDIncMember2021-12-080000097745tmo:PeproTechIncMember2021-12-300000097745tmo:PPDIncMember2021-12-082021-12-080000097745tmo:PeproTechIncMember2021-12-302021-12-300000097745tmo:EuropeanViralVectorManufacturingBusinessMember2021-01-152021-01-150000097745tmo:MesaBiotechMember2021-02-252021-02-250000097745tmo:CSLMember2021-09-302021-09-300000097745us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-01-012021-12-310000097745us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-12-310000097745us-gaap:CustomerRelationshipsMembertmo:PPDIncMember2021-12-080000097745tmo:PeproTechIncMemberus-gaap:CustomerRelationshipsMember2021-12-300000097745tmo:EuropeanViralVectorManufacturingBusinessMemberus-gaap:CustomerRelationshipsMember2021-01-150000097745tmo:MesaBiotechMemberus-gaap:CustomerRelationshipsMember2021-02-250000097745us-gaap:CustomerRelationshipsMembertmo:CSLMember2021-09-300000097745us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:CustomerRelationshipsMember2021-12-310000097745us-gaap:DevelopedTechnologyRightsMembertmo:PPDIncMember2021-12-080000097745us-gaap:DevelopedTechnologyRightsMembertmo:PeproTechIncMember2021-12-300000097745us-gaap:DevelopedTechnologyRightsMembertmo:EuropeanViralVectorManufacturingBusinessMember2021-01-150000097745us-gaap:DevelopedTechnologyRightsMembertmo:MesaBiotechMember2021-02-250000097745us-gaap:DevelopedTechnologyRightsMembertmo:CSLMember2021-09-300000097745us-gaap:DevelopedTechnologyRightsMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-12-310000097745us-gaap:TradeNamesMembertmo:PPDIncMember2021-12-080000097745us-gaap:TradeNamesMembertmo:PeproTechIncMember2021-12-300000097745tmo:EuropeanViralVectorManufacturingBusinessMemberus-gaap:TradeNamesMember2021-01-150000097745tmo:MesaBiotechMemberus-gaap:TradeNamesMember2021-02-250000097745us-gaap:TradeNamesMembertmo:CSLMember2021-09-300000097745us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:TradeNamesMember2021-12-310000097745us-gaap:OrderOrProductionBacklogMembertmo:PPDIncMember2021-12-080000097745us-gaap:CustomerRelationshipsMember2021-01-012021-12-310000097745us-gaap:DevelopedTechnologyRightsMember2021-01-012021-12-310000097745us-gaap:TradeNamesMember2021-01-012021-12-310000097745us-gaap:OrderOrProductionBacklogMember2021-01-012021-12-310000097745tmo:PPDIncMember2021-01-012021-12-310000097745tmo:PPDIncMember2020-01-012020-12-310000097745tmo:PPDIncMemberus-gaap:AcquisitionRelatedCostsMember2021-01-012021-12-310000097745tmo:PPDIncMemberus-gaap:AcquisitionRelatedCostsMember2020-01-012020-12-310000097745tmo:ConsumablesMember2022-01-012022-12-310000097745tmo:ConsumablesMember2021-01-012021-12-310000097745tmo:ConsumablesMember2020-01-012020-12-310000097745tmo:InstrumentsMember2022-01-012022-12-310000097745tmo:InstrumentsMember2021-01-012021-12-310000097745tmo:InstrumentsMember2020-01-012020-12-310000097745srt:NorthAmericaMember2022-01-012022-12-310000097745srt:NorthAmericaMember2021-01-012021-12-310000097745srt:NorthAmericaMember2020-01-012020-12-310000097745srt:EuropeMember2022-01-012022-12-310000097745srt:EuropeMember2021-01-012021-12-310000097745srt:EuropeMember2020-01-012020-12-310000097745srt:AsiaPacificMember2022-01-012022-12-310000097745srt:AsiaPacificMember2021-01-012021-12-310000097745srt:AsiaPacificMember2020-01-012020-12-310000097745tmo:OtherRegionsMember2022-01-012022-12-310000097745tmo:OtherRegionsMember2021-01-012021-12-310000097745tmo:OtherRegionsMember2020-01-012020-12-3100000977452023-01-012022-12-31tmo:Segment0000097745us-gaap:OperatingSegmentsMembertmo:LifeSciencesSolutionsMember2022-01-012022-12-310000097745us-gaap:OperatingSegmentsMembertmo:LifeSciencesSolutionsMember2021-01-012021-12-310000097745us-gaap:OperatingSegmentsMembertmo:LifeSciencesSolutionsMember2020-01-012020-12-310000097745us-gaap:OperatingSegmentsMembertmo:AnalyticalInstrumentsMember2022-01-012022-12-310000097745us-gaap:OperatingSegmentsMembertmo:AnalyticalInstrumentsMember2021-01-012021-12-310000097745us-gaap:OperatingSegmentsMembertmo:AnalyticalInstrumentsMember2020-01-012020-12-310000097745us-gaap:OperatingSegmentsMembertmo:SpecialtyDiagnosticsMember2022-01-012022-12-310000097745us-gaap:OperatingSegmentsMembertmo:SpecialtyDiagnosticsMember2021-01-012021-12-310000097745us-gaap:OperatingSegmentsMembertmo:SpecialtyDiagnosticsMember2020-01-012020-12-310000097745us-gaap:OperatingSegmentsMembertmo:LaboratoryProductsandServicesMember2022-01-012022-12-310000097745us-gaap:OperatingSegmentsMembertmo:LaboratoryProductsandServicesMember2021-01-012021-12-310000097745us-gaap:OperatingSegmentsMembertmo:LaboratoryProductsandServicesMember2020-01-012020-12-310000097745us-gaap:IntersegmentEliminationMember2022-01-012022-12-310000097745us-gaap:IntersegmentEliminationMember2021-01-012021-12-310000097745us-gaap:IntersegmentEliminationMember2020-01-012020-12-310000097745us-gaap:OperatingSegmentsMember2022-01-012022-12-310000097745us-gaap:OperatingSegmentsMember2021-01-012021-12-310000097745us-gaap:OperatingSegmentsMember2020-01-012020-12-310000097745us-gaap:MaterialReconcilingItemsMember2022-01-012022-12-310000097745us-gaap:MaterialReconcilingItemsMember2021-01-012021-12-310000097745us-gaap:MaterialReconcilingItemsMember2020-01-012020-12-310000097745us-gaap:CorporateAndOtherMember2022-12-310000097745us-gaap:CorporateAndOtherMember2021-12-310000097745us-gaap:CorporateAndOtherMember2020-12-310000097745tmo:LifeSciencesSolutionsMember2020-01-012020-12-310000097745tmo:AnalyticalInstrumentsMember2020-01-012020-12-310000097745tmo:SpecialtyDiagnosticsMember2020-01-012020-12-310000097745tmo:LaboratoryProductsandServicesMember2020-01-012020-12-310000097745us-gaap:CorporateAndOtherMember2022-01-012022-12-310000097745us-gaap:CorporateAndOtherMember2021-01-012021-12-310000097745us-gaap:CorporateAndOtherMember2020-01-012020-12-310000097745country:US2022-01-012022-12-310000097745country:US2021-01-012021-12-310000097745country:US2020-01-012020-12-310000097745country:CN2022-01-012022-12-310000097745country:CN2021-01-012021-12-310000097745country:CN2020-01-012020-12-310000097745tmo:AllOtherCountriesMember2022-01-012022-12-310000097745tmo:AllOtherCountriesMember2021-01-012021-12-310000097745tmo:AllOtherCountriesMember2020-01-012020-12-310000097745country:US2022-12-310000097745country:US2021-12-310000097745country:US2020-12-310000097745tmo:AllOtherCountriesMember2022-12-310000097745tmo:AllOtherCountriesMember2021-12-310000097745tmo:AllOtherCountriesMember2020-12-310000097745us-gaap:InterestRateSwapMemberus-gaap:OtherExpenseMemberus-gaap:CashFlowHedgingMember2020-01-012020-12-310000097745us-gaap:EmployeeStockOptionMembersrt:MinimumMember2022-01-012022-12-310000097745srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310000097745us-gaap:EmployeeStockOptionMember2022-12-310000097745us-gaap:EmployeeStockOptionMember2022-01-012022-12-310000097745us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2022-01-012022-12-310000097745us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2022-01-012022-12-310000097745us-gaap:RestrictedStockUnitsRSUMember2022-12-310000097745us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310000097745srt:MinimumMember2022-12-310000097745srt:MaximumMember2022-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMember2020-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-12-310000097745us-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2022-12-310000097745us-gaap:FixedIncomeFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745srt:MinimumMemberus-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745srt:MaximumMemberus-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FixedIncomeFundsMembersrt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745srt:MaximumMemberus-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745srt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745srt:MaximumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMembersrt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMembersrt:MaximumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel1Membertmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745tmo:USEquityFundsMembercountry:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Membertmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembertmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2022-12-310000097745country:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2022-12-310000097745us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2022-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FixedIncomeFundsMembercountry:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:FixedIncomeFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:MoneyMarketFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:MoneyMarketFundsMembercountry:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:MoneyMarketFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745country:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745tmo:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745tmo:InsuranceContractsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745tmo:InsuranceContractsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Membertmo:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembertmo:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745tmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel1Membertmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:USEquityFundsMembercountry:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Membertmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembertmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2021-12-310000097745us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2021-12-310000097745country:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2021-12-310000097745us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2021-12-310000097745us-gaap:FixedIncomeFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FixedIncomeFundsMembercountry:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:FixedIncomeFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:MoneyMarketFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:MoneyMarketFundsMembercountry:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:MoneyMarketFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745country:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:HedgeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:HedgeFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:HedgeFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:HedgeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:HedgeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2021-12-310000097745us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2021-12-310000097745us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2021-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:AlternativeInvestmentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:AlternativeInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:AlternativeInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Membertmo:AlternativeInvestmentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembertmo:AlternativeInvestmentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:InsuranceContractsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:InsuranceContractsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Membertmo:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembertmo:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DomesticCountryMember2022-01-012022-12-310000097745us-gaap:DomesticCountryMember2022-12-310000097745tmo:DeferredTaxImplicationsMember2021-01-012021-12-310000097745tmo:CapitalLossMember2021-01-012021-12-310000097745us-gaap:DomesticCountryMember2020-01-012020-12-310000097745us-gaap:DomesticCountryMember2020-12-310000097745tmo:DeferredTaxAssetInterestCarryforwardMember2020-01-012020-12-310000097745us-gaap:DomesticCountryMember2022-12-310000097745us-gaap:StateAndLocalJurisdictionMember2022-12-310000097745us-gaap:ForeignCountryMember2022-12-310000097745tmo:DomesticNOLExpiresMember2022-12-310000097745tmo:ForeignCountryNolExpiresMember2022-12-310000097745tmo:ForeignTaxCreditCarryforwardsMember2022-12-310000097745tmo:DeferredTaxAssetInterestCarryforwardMember2022-12-310000097745tmo:ForeignTaxPositionsMember2022-01-012022-12-310000097745tmo:FederalAndStateMember2022-01-012022-12-310000097745tmo:ForeignTaxPositionsMember2021-01-012021-12-310000097745tmo:FederalAndStateMember2021-01-012021-12-310000097745tmo:ForeignTaxPositionsMember2020-01-012020-12-310000097745tmo:FederalAndStateMember2020-01-012020-12-310000097745us-gaap:CommercialPaperMember2022-12-310000097745us-gaap:CommercialPaperMember2021-12-310000097745tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR039SeniorNotesDue2023Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR039SeniorNotesDue2023Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR039SeniorNotesDue2023Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0797Due2023Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0797Due2023Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0797Due2023Member2021-12-310000097745tmo:FloatingRate2YearSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:FloatingRate2YearSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:FloatingRate2YearSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0000Due2023Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0000Due2023Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0000Due2023Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0.75Due2024Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0.75Due2024Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0.75Due2024Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR053SeniorNotesDue2024Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR053SeniorNotesDue2024Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR053SeniorNotesDue2024Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1215Due2024Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1215Due2024Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1215Due2024Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0.125Due2025Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0.125Due2025Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0.125Due2025Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes200Due2025Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes200Due2025Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes200Due2025Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0853Due2025Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0853Due2025Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0853Due2025Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0000Due2025Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0000Due2025Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0000Due2025Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes3.65Due2025Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes3.65Due2025Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes3.65Due2025Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes320Due2026Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes320Due2026Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes320Due2026Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.40Due2026Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.40Due2026Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.40Due2026Member2021-12-310000097745tmo:A1.45SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:A1.45SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:A1.45SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes175Due2027Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes175Due2027Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes175Due2027Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1054Due2027Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1054Due2027Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1054Due2027Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes48Due2027Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes48Due2027Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes48Due2027Member2021-12-310000097745tmo:SeniorNotes0.500Due2028Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes0.500Due2028Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes0.500Due2028Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.375Due2028Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.375Due2028Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.375Due2028Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1750Due2028Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1750Due2028Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1750Due2028Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.95Due2029Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.95Due2029Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.95Due2029Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2.60Due2029Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2.60Due2029Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2.60Due2029Member2021-12-310000097745tmo:SeniorNotes1279Due2029Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes1279Due2029Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes1279Due2029Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes080Due2030Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes080Due2030Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes080Due2030Member2021-12-310000097745tmo:SeniorNotes0.875Due2031Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes0.875Due2031Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes0.875Due2031Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2000Due2031Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2000Due2031Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2000Due2031Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2375Due2032Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2375Due2032Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2375Due2032Member2021-12-310000097745tmo:SeniorNotes149Due2032Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes149Due2032Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes149Due2032Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes495Due2032Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes495Due2032Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes495Due2032Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1125Due2033Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1125Due2033Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1125Due2033Member2021-12-310000097745tmo:SeniorNotes365Due2034Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes365Due2034Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes365Due2034Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2.875Due2037Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2.875Due2037Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2.875Due2037Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.500Due2039Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.500Due2039Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.500Due2039Member2021-12-310000097745tmo:SeniorNotes2800Due2041Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes2800Due2041Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes2800Due2041Memberus-gaap:SeniorNotesMember2021-12-310000097745tmo:SeniorNotes1625Due2041Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes1625Due2041Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes1625Due2041Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2069Due2042Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2069Due2042Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2069Due2042Member2021-12-310000097745tmo:SeniorNotes530Due2044Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes530Due2044Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes530Due2044Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes4.10Due2047Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes4.10Due2047Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes4.10Due2047Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.875Due2049Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.875Due2049Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.875Due2049Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes200Due2051Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes200Due2051Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes200Due2051Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2382Due2052Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2382Due2052Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2382Due2052Member2021-12-310000097745tmo:OtherDebtMember2022-12-310000097745tmo:OtherDebtMember2021-12-310000097745us-gaap:RevolvingCreditFacilityMember2022-12-310000097745us-gaap:RevolvingCreditFacilityMember2022-01-012022-12-310000097745us-gaap:CommercialPaperMembertmo:U.S.CommercialPaperProgramMember2022-01-012022-12-310000097745us-gaap:CommercialPaperMembertmo:EuroCommercialPaperProgramMember2022-01-012022-12-310000097745us-gaap:CommercialPaperMember2022-12-310000097745us-gaap:SeniorNotesMember2022-01-012022-12-310000097745us-gaap:InterestRateSwapMember2022-01-012022-12-31tmo:lease0000097745us-gaap:GuaranteeTypeOtherMember2022-12-310000097745tmo:AnalyticalInstrumentsMemberus-gaap:InventoriesMemberus-gaap:CostOfSalesMember2020-01-012020-12-310000097745us-gaap:StandbyLettersOfCreditMember2022-12-310000097745tmo:SuretyBondsAndOtherGuaranteesMember2022-12-310000097745us-gaap:FinancialGuaranteeMembertmo:BusinessesSoldMember2022-12-310000097745srt:MinimumMembertmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember2022-12-310000097745srt:MaximumMembertmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember2022-12-310000097745tmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember2022-12-310000097745us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000097745us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000097745us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000097745us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310000097745us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310000097745us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-310000097745us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000097745us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000097745us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000097745us-gaap:SubsequentEventMember2023-01-012023-02-230000097745us-gaap:FairValueMeasurementsRecurringMember2022-12-310000097745us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000097745us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000097745us-gaap:FairValueMeasurementsRecurringMember2021-12-310000097745us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000097745us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000097745tmo:ContingentConsiderationMember2021-12-310000097745tmo:ContingentConsiderationMember2020-12-310000097745tmo:ContingentConsiderationMember2022-01-012022-12-310000097745tmo:ContingentConsiderationMember2021-01-012021-12-310000097745tmo:ContingentConsiderationMember2022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2021-12-310000097745us-gaap:ForeignExchangeContractMember2022-12-310000097745us-gaap:ForeignExchangeContractMember2021-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:OtherExpenseMember2022-01-012022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:OtherExpenseMember2021-01-012021-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMember2022-01-012022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMember2021-01-012021-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:OtherExpenseMember2022-01-012022-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:OtherExpenseMember2021-01-012021-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2022-01-012022-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2021-01-012021-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherExpenseMemberus-gaap:CashFlowHedgingMember2022-01-012022-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherExpenseMemberus-gaap:CashFlowHedgingMember2021-01-012021-12-310000097745tmo:ForeigncurrencydenominateddebtMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-01-012022-12-310000097745tmo:ForeigncurrencydenominateddebtMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2021-01-012021-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-01-012022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2021-01-012021-12-310000097745us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-01-012022-12-310000097745us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-01-012021-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:OtherExpenseMemberus-gaap:NondesignatedMember2022-01-012022-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:OtherExpenseMemberus-gaap:NondesignatedMember2021-01-012021-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2020-01-012020-12-310000097745us-gaap:InterestRateSwapMemberus-gaap:OtherExpenseMemberus-gaap:CashFlowHedgingMember2021-01-012021-12-310000097745us-gaap:SeniorNotesMember2022-12-310000097745us-gaap:SeniorNotesMember2021-12-310000097745srt:ScenarioForecastMember2023-02-230000097745us-gaap:CorporateMember2022-01-012022-12-310000097745us-gaap:CorporateMember2021-01-012021-12-310000097745us-gaap:CorporateMember2020-01-012020-12-31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022 or
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission file number 1-8002
THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its charter)
Delaware04-2209186
(State of incorporation)(I.R.S. Employer Identification No.)
168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 622-1000
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $1.00 par valueTMONew York Stock Exchange
0.750% Notes due 2024TMO 24ANew York Stock Exchange
0.125% Notes due 2025TMO 25BNew York Stock Exchange
2.000% Notes due 2025TMO 25New York Stock Exchange
3.200% Notes due 2026TMO 26BNew York Stock Exchange
1.400% Notes due 2026TMO 26ANew York Stock Exchange
1.450% Notes due 2027TMO 27New York Stock Exchange
1.750% Notes due 2027TMO 27BNew York Stock Exchange
0.500% Notes due 2028TMO 28ANew York Stock Exchange
1.375% Notes due 2028TMO 28New York Stock Exchange
1.950% Notes due 2029TMO 29New York Stock Exchange
0.875% Notes due 2031TMO 31New York Stock Exchange
2.375% Notes due 2032TMO 32New York Stock Exchange
3.650% Notes due 2034TMO 34New York Stock Exchange
2.875% Notes due 2037TMO 37New York Stock Exchange
1.500% Notes due 2039TMO 39New York Stock Exchange
1.875% Notes due 2049TMO 49New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:  None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒  No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐  No ☒ 
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months. Yes ☒  No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.      Large accelerated filer ☒             Accelerated filer ☐             Non-accelerated filer ☐ Smaller reporting company ☐        Emerging growth company ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒
As of July 1, 2022, the aggregate market value of the voting stock held by nonaffiliates of the Registrant was approximately $214,582,365,000 (based on the last reported sale of common stock on the New York Stock Exchange Composite Tape reporting system on July 1, 2022).
As of February 4, 2023, the Registrant had 385,430,077 shares of Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Sections of Thermo Fisher’s definitive Proxy Statement for the 2023 Annual Meeting of Shareholders are incorporated by reference into Parts II and III of this report.


THERMO FISHER SCIENTIFIC INC.
ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022
TABLE OF CONTENTS
Page
PART I
PART II
PART III
PART IV

2

THERMO FISHER SCIENTIFIC INC.
PART I

Forward-looking Statements
Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 (the Exchange Act), are made throughout this Annual Report on Form 10-K. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, including without limitation statements regarding: projections of revenues, expenses, earnings, margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, and our liquidity position; cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions or divestitures; growth, declines and other trends in markets we sell into; new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; the expected impact of the COVID-19 pandemic on the company’s business; and any other statements that address events or developments that Thermo Fisher intends or believes will or may occur in the future. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company’s estimates change, and readers should not rely on those forward-looking statements as representing the company’s views as of any date subsequent to the date of the filing of this report. A number of important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements, including those detailed under the heading, “Risk Factors” in Part I, Item 1A.
Item 1.    Business
Description of Business
Thermo Fisher Scientific Inc. (also referred to in this document as “Thermo Fisher,” “we,” the “company,” or the “registrant”) is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. We serve customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
We continuously increase our depth of capabilities across our broad portfolio of innovative products and services and leverage our extensive global channels to address our customers’ needs. We do this through organic investments in research and development, capacity, and through acquisitions. Our goal is to enable our customers to be more productive in an increasingly competitive business environment and enabling them to advance their important work.
Business Segments and Products
We report our business in four segments – Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Life Sciences Solutions Segment
Through our Life Sciences Solutions segment, we provide an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Life Sciences Solutions includes four primary businesses – Biosciences, Genetic Sciences, Clinical Next-Generation Sequencing, and BioProduction.
Our biosciences business includes reagents, instruments and consumables that help our customers conduct biological and medical research in areas such as molecular biology and protein biology, discover new drugs and vaccines, and diagnose infection and disease. Our genetic sciences business combines a wide variety of instruments and related reagents used to provide high-value genomic solutions to assist customer decisions in the research, clinical, healthcare and applied markets. Our clinical next-generation sequencing (NGS) business focuses on delivering simple, fast and cost-effective NGS technology for a range of applications with a particular focus on oncology. Our bioproduction business supports developers and manufacturers of biological-based therapeutics and vaccines with a portfolio of premium solutions and services focused on upstream cell
3

THERMO FISHER SCIENTIFIC INC.
culture, downstream purification, analytics for detection and quantitation of process/product impurities, and a suite of single-use solutions spanning the biologics workflow.
Analytical Instruments Segment
Through our Analytical Instruments segment, we provide a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory. This segment includes three primary businesses – Chromatography and Mass Spectrometry, Chemical Analysis, and Electron Microscopy.
Our chromatography and mass spectrometry business develops and provides analytical instrumentation for organic and inorganic sample analysis across both applied technologies and scientific research. Our chemical analysis products fall into three main categories: production, process and analytics; field and safety instruments; and environmental and process instruments. Our electron microscopy business serves customers in the life sciences, materials science, and semiconductor markets providing integrated workflows that power research development and production solutions.
Specialty Diagnostics Segment
Our Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which improves patient care in a more cost-efficient manner. This segment has five primary businesses – Clinical Diagnostics, ImmunoDiagnostics, Microbiology, Transplant Diagnostics and our Healthcare Market Channel.
Our clinical diagnostics products include a broad offering of liquid, ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls and calibration verification fluids. Such products are used for, among other things, drugs-of-abuse testing, therapeutic drug monitoring, thyroid hormone testing, serum toxicity, first trimester screening, and tumor markers testing. Our immunodiagnostics offerings include developing, manufacturing and marketing complete blood-test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. Our microbiology offerings include dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products and associated products for the microbiology laboratory. Our transplant diagnostics products include human leukocyte antigen (HLA) typing and testing for the organ transplant market. Our healthcare market channel offerings include a broad array of consumables, diagnostic kits and reagents, equipment, instruments, solutions and services for hospitals, clinical laboratories, reference laboratories, physicians’ offices and other clinical testing facilities.
Laboratory Products and Biopharma Services Segment
Our Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more efficient, productive and cost-effective. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing. We serve the pharmaceutical, biotechnology, academic, medical device, government and other research and industrial markets, as well as the clinical laboratory market through five key businesses: Laboratory Products, Laboratory Chemicals, Research and Safety Market Channel, Pharma Services and Clinical Research.
Our laboratory products are used for life science research and drug discovery and development to advance the prevention and cure of diseases and enhance quality of life. Our laboratory chemicals offering comprises a broad range of chemicals, solvents and reagents supporting virtually every laboratory application – from research and drug discovery to development and manufacturing. Our research and safety market channel offers a mix of products that are manufactured by Thermo Fisher, by third parties for us on a private-label basis, and by third parties under their brands but offered for sale through us. Our pharma services business provides the entire spectrum of development, manufacturing and clinical trials services for both small-molecule and large-molecule pharmaceuticals. Our clinical research business offers comprehensive, integrated clinical development and analytical services including all phases of development (i.e., Phases I-IV), peri- and post-approval and site and patient access services.
During 2022, the Life Sciences Solutions and Specialty Diagnostics segments as well as the laboratory products business continued to support COVID-19 diagnostic testing, scaling and evolving their molecular diagnostics solutions and plastic consumables businesses to respond to the on-going COVID-19 pandemic. The biosciences, bioproduction and laboratory equipment and consumables businesses also leveraged their capacity to meet the needs of pharma and biotech customers as they
4

THERMO FISHER SCIENTIFIC INC.
rapidly expanded their own production volumes to meet global vaccine manufacturing requirements. Additionally, through our pharma services business, we provided our pharma and biotech customers with the services they needed to develop and produce vaccines and therapies globally.
Sales and Marketing
We market and sell our products and services through a direct sales force, customer-service professionals, electronic commerce and third-party distributors. Our global team delivers a combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
We have approximately 15,000 sales personnel including highly trained technical specialists who enable us to better meet the needs of our more technical end-users. We also provide customers with product standardization and other supply-chain-management services to reduce procurement costs.
New Products and Research and Development
Our business includes the development and introduction of new products and may include entry into new business segments. We anticipate that we will continue to make significant expenditures for research and development as we seek to provide a continuing flow of innovative products to maintain and improve our competitive position.
Resources
Raw Materials
Our management team believes that we have a readily available supply of raw materials for all of our significant products from various sources. No single supplier is material, although for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design, certain materials components may be sourced from a single supplier or a limited number of suppliers that can readily provide such materials or components.
Raw material and fuel prices are subject to fluctuations due to market conditions. We employ many strategies, including the use of alternative materials, to mitigate the effect of these fluctuations on our results.
Patents, Licenses and Trademarks
Patents are important in many aspects of our business. No particular patent, or related group of patents, is so important, however, that its loss would significantly affect our operations as a whole. Where appropriate, we seek patent protection for inventions and developments made by our personnel that are incorporated into our products or otherwise fall within our fields of interest. Patent rights resulting from work sponsored by outside parties do not always accrue exclusively to the company and may be limited by agreements or contracts.
We protect some of our technology as trade secrets and, where appropriate, we use trademarks or register trademarks used in connection with products. We also enter into license agreements with others to grant and/or receive rights to intellectual property rights.
All trademarks, trade names, product names, graphics and logos of Thermo Fisher contained herein are trademarks or registered trademarks of Thermo Fisher or its subsidiaries, as applicable, in the United States and/or other countries. Solely for convenience, we may refer to trademarks in this Annual Report on Form 10-K without the ™ and ® symbols. Such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted by law, our rights to our trademarks. To the extent other trademarks appear in this Annual Report on Form 10-K, they are the property of their respective owners.
Seasonal Influences
Revenues in the fourth quarter are historically stronger than in other quarters due to the capital spending patterns of industrial, pharmaceutical and government customers. Sales of seasonal products, such as COVID-19, allergy and flu tests and related diagnostic products, vary quarter to quarter and year to year.
Competition
The company encounters aggressive and able competition in virtually all of the markets we serve. Because of the diversity of our products and services, we face many different types of competitors and competition. Our competitors include a broad range of manufacturers, third-party distributors and service providers. Competitive climates in many of the markets we serve are characterized by changing technology and customer demands that require continuing research and development. Our success primarily depends on the following factors:
5

THERMO FISHER SCIENTIFIC INC.
•technical performance and advances in technology that result in new products and improved price/performance ratios;
•product differentiation, availability and reliability;
•the depth of our capabilities;
•our reputation among customers as a quality provider of products and services;
•customer service and support;
•active research and application-development programs; and
•relative prices of our products and services.
Government Regulation
Environmental Regulations
We are subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the United States and other countries. U.S. federal environmental legislation that affects us includes the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the Clean Air Act, the Clean Water Act, the Safe Drinking Water Act, and the Comprehensive Environmental Response Compensation and Liability Act (CERCLA). We are also subject to regulation by the Occupational Safety and Health Administration (OSHA) concerning employee safety and health matters. The United States Environmental Protection Agency (USEPA), OSHA, and other federal agencies have the authority to promulgate regulations that have an effect on our operations.
In addition to these federal laws and regulations, various states have been delegated certain authority under the aforementioned federal statutes and have authority over these matters under state laws. Many state and local governments have adopted environmental and employee safety and health laws and regulations, some of which are similar to federal requirements.
A number of our operations involve the handling, manufacturing, use or sale of substances that are or could be classified as toxic or hazardous materials within the meaning of applicable laws. Consequently, some risk of environmental harm is inherent in our operations and products, as it is with other companies engaged in similar businesses.
Our expenses for environmental requirements are incurred generally for ongoing compliance and historical remediation matters. Based on current information, we believe that these compliance costs are not material. For historical remediation obligations, our expenditures relate primarily to the cost of permitting, installing, and operating and maintaining groundwater-treatment systems and other remedial measures.
Our Fair Lawn and Somerville, New Jersey facilities entered into administrative consent orders with the New Jersey Department of Environmental Protection in 1984 to maintain groundwater-remediation activities at these sites, and are currently under the State’s Licensed Site Remediation Professional Program. As the owner of the Fair Lawn facility, we are listed as a potentially responsible party for remediation within an area called the Fair Lawn Wellfields Superfund Site, and, in 2008, the company and certain other parties entered into a consent order with the USEPA to complete a Remedial Investigation/Feasibility Study. In 2018, the USEPA issued a Record of Decision, setting forth the scope of required remediation work at the site, which includes upgrading a water treatment plant to address constituents such as chlorinated organic compounds, 1,4-dioxane, and perfluorooctanoic acid/perfluorooctane sulfonate (PFOA/PFOS). In 2020, the court approved a consent decree that requires the company and another responsible party to finance and perform the required remediation work with USEPA oversight, which has been ongoing and is pending USEPA’s approval of the water treatment plant design.
In 2011, our Life Technologies subsidiary entered into a consent decree with the USEPA and other responsible parties to implement a groundwater remedy at the former Davis Landfill Superfund site in Smithfield, Rhode Island. After years of additional study, in September, 2020, USEPA revised its cleanup plan by selecting an interim remedial approach that includes groundwater treatment followed by additional monitoring of site conditions. Depending on the results of these treatment and monitoring activities over the next several years, USEPA anticipates selecting a final groundwater remedy for the site. In November 2021, the 2011 consent decree was amended to reflect the parties’ obligations to implement USEPA’s interim remedy, for which pre-design work commenced during 2022.
We record accruals for environmental liabilities based on current interpretations of environmental laws and regulations when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. We calculate estimates based upon several factors, including reports prepared by environmental specialists and management’s knowledge and experience with these environmental matters. We include in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. Accrued liabilities for environmental matters totaled $75 million at December 31, 2022.
These environmental liabilities do not include third-party recoveries to which we may be entitled. We believe that our accrual is adequate for the environmental liabilities we currently expect to incur. As a result we believe that our ultimate
6

THERMO FISHER SCIENTIFIC INC.
liability with respect to environmental matters will not have a material adverse effect on our financial position, results of operations or cash flows. However, we may be subject to remedial or compliance costs due to future events, such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies, changes in the conduct of our operations, and the effect of changes in accounting rules, which could have a material adverse effect on our financial position, results of operations or cash flows. For a discussion of the environmental laws and regulations that the Company’s operations, products and services are subject to and other environmental contingencies, refer to Note 12 to our Consolidated Financial Statements.
Other Laws and Regulations
Our operations, and some of the products and services we offer, are subject to a number of complex and stringent laws and regulations governing the development, testing, approval, production, handling, transportation and distribution of chemicals, drugs and other similar products, including the operating and security standards of the Food and Drug Administration, the Drug Enforcement Administration, the Bureau of Alcohol, Tobacco, Firearms and Explosives, and various state boards of pharmacy as well as comparable state and foreign agencies. As Thermo Fisher’s businesses also include export and import activities, we are subject to pertinent laws enforced by the U.S. Departments of Commerce, State and Treasury. In addition, our logistics activities must comply with the rules and regulations of the Department of Transportation, the Federal Aviation Administration and similar foreign agencies. While we believe we are in compliance in all material respects with such laws and regulations, any noncompliance could result in substantial fines or otherwise restrict our ability to provide competitive distribution services and thereby have an adverse effect on our financial condition. To date, no such laws or regulations have had a material impact on our operations.
We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenues associated with these customers. We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could also result in suspension of these contracts, criminal, civil and administrative penalties or debarment.
For a discussion of risks related to changes in governmental regulations, refer to “Risk Factors” in Part I, Item 1A.
Human Capital
The success of Thermo Fisher is fueled by colleagues who are highly engaged and feel empowered to achieve their goals. Everything we do starts with our Mission – to enable our customers to make the world healthier, cleaner and safer. Our colleagues understand the role they play in fulfilling that Mission and that inspires them to bring their best to work each day. Our Mission is not only a differentiator for us externally, but a motivator for us internally.
Our culture is rooted in our 4i Values of Integrity, Intensity, Innovation and Involvement. Within this framework, we strive to create a safe, fair and positive working environment for our colleagues around the world. We want our teams to feel they have a stake in our success, a voice in our direction and to be empowered to make a difference for the key stakeholders we serve.
Every year, we conduct an Employee Involvement Survey to solicit direct feedback from our colleagues on what we’re doing well and where we need to improve. We then compile the feedback to measure our progress using three key indices: Leadership, Involvement and Inclusion. Our continued focus on enhancing our culture helps position our company to be an even better place to work.
We are committed to maintaining the strongest team in our industry, focusing on developing and retaining our colleagues, while leveraging our leadership to attract new colleagues to our company. As of December 31, 2022, we employed approximately 130,000 colleagues globally, with an approximate regional distribution as follows: 67,000 based in the Americas, 21,000 in the Asia Pacific region, and nearly 42,000 in Europe, the Middle East and Africa (EMEA).
Diversity and Inclusion
We recognize that the future aspirations outlined in our Vision for 2030, which serves as our long-term roadmap, will only be achievable if we have a culture that values diversity and inclusion. While diversity of gender and ethnicity are important – and we’re focused on continuously improving– for us, diversity of backgrounds, experiences and viewpoints is equally vital to our long-term success. When those differences are welcomed and supported, we create an inclusive workplace that unlocks the true benefits of diversity.
Diversity and Inclusion (D&I) is not an initiative at Thermo Fisher. It’s woven into the fabric of our culture, and our colleagues are encouraged to openly share the wide range of perspectives they represent. We work together to create an
7

THERMO FISHER SCIENTIFIC INC.
inclusive culture where our colleagues feel they belong and are empowered to contribute, collaborate and innovate. Embracing individual differences is critical to our success. For example, Thermo Fisher was named as a Top Female Friendly Company, Best Employer for Women, and Best Employer for Veterans by Forbes in 2022, Best Place to Work for Disability Inclusion, as well as a Best Place to Work for LGBTQ Equality for the seventh consecutive year. Establishing this kind of environment is critical in empowering our colleagues so they can contribute their best ideas and bring their true selves to work each day.
Our D&I focus is embedded in every stage of our colleague lifecycle – from recruiting to onboarding, training, development and longer-term career planning. We track our progress on our D&I strategic objectives through a core set of metrics that are reviewed during routine business operating mechanisms, including Quarterly Business Reviews, Human Resource Reviews, Board Reviews and through team dashboards that are shared each month with leaders across the company. This enables frequent, meaningful, data-driven discussions across our businesses and functions on a range of D&I factors, including gender and ethnic representation. This approach also ensures we consistently prioritize our opportunities to improve. We understand the critical role diversity plays in sustained business success, and our teams are empowered to ensure our workforce represents the customers we serve. Further, to provide additional transparency to our U.S. workforce demographics, following our report submission to the U.S. Equal Employment Opportunity Commission, we disclose our EEO-1 report on our website each year.
We are committed to ensuring our colleagues have access to resources, awareness training and internal networks that offer support and guidance. Our D&I strategy is greatly enabled by our Business Resource Groups (BRGs), which bring together individuals with similar interests to share experiences, learn from each other and collaborate to identify solutions to business challenges. Our BRGs reinforce that all colleagues can make a difference for our customers, for each other and for our company. As of December 31, 2022, we had 9 global BRGs, with more than 230 local BRG chapters.
Talent Development
Our overarching goal from a talent perspective is to create opportunities for our colleagues to achieve their full potential and career aspirations here at Thermo Fisher. We focus on the entire lifecycle of a colleague’s career, from their initial recruitment, to onboarding, through ongoing development and training to enhance their skills so they are in the best position to deliver on their goals and achieve their career aspirations.
In today’s environment, we know talent is a key competitive advantage, and that building the strongest team in the industry is critical to our future. From our colleague referral program, summer internships, university relations, to our Graduate Leadership Development Program, we continue to build strong internal and external sourcing channels.
Once on board, talent development at Thermo Fisher is a key organizational capability. We continue to make significant investments to support our colleagues along every step of their career journey to help support their success. Our talent development framework incorporates a multi-faceted approach, including formal and self-paced training, networking opportunities, on-the-job stretch learning, coaching, mentoring and manager training utilizing contemporary technology solutions to support the broad needs of our workforce.
We provide multiple programs at all career levels, from online learning for all colleagues through Thermo Fisher University, to focused trainings for managers at various experience levels, to our Global Leadership Program for executives. We also support our colleagues’ career advancement through our tuition reimbursement program.
In a company our size, we can also actively manage our talent through rotational opportunities across our businesses, functions and geographies that help our colleagues gain new experiences, share knowledge and broaden their skills. Our executives and leaders participate in frequent talent discussions as well as formal reviews, leveraging workforce data and predictive analytics to better anticipate the talent requirements of our business based on our growth opportunities and market demand.
Thermo Fisher is dedicated to talent development to meet our evolving business needs and to provide our colleagues with opportunities for long and fulfilling careers. Our colleagues are passionate about our company, and their role in our success, and it’s our responsibility to help them reach their full potential.
Total Rewards
We offer a comprehensive total rewards package that we regularly evaluate and measure against established benchmarks to ensure its effectiveness in recruiting and retention, and to position Thermo Fisher as an employer of choice. In 2022, we reinvested approximately $350 million of additional compensation payments to our colleagues to help them with the temporary impacts of high inflation.
Our health and wellness programs provide competitive, flexible programs that our global colleagues and their families can count on. For example, for U.S. colleagues, we offer a choice of comprehensive national medical, dental and vision plans; a
8

THERMO FISHER SCIENTIFIC INC.
wellness program, including valuable health incentive opportunities and tax-advantaged savings and spending accounts; as well as commuter benefits, employee assistance programs, optional group legal coverage, and company-paid disability, accident and life insurance. We also offer a company-paid proprietary program for cancer care called the Impact Program, which gives our colleagues and their families access to personalized support and direct lines of communication to experts in cancer genetics and genomics. Similar benefits are available in all countries around the world where we operate.
We also invest in our colleagues’ financial health, helping them to grow and protect their savings, plan for the future and share in the success of the company they are helping to build. We deliver comprehensive rewards, including competitive base pay, and also provide a variety of incentive and equity programs that, by design, directly link the impact of colleague contributions to the company’s overall success.
Disclosure Pursuant to Section 13(r) of the Exchange Act
The Russian Federal Security Service (the FSB) is designated as a blocked party under Executive Order 13382. While we have paused sales and manufacturing operations in Russia and Belarus, in the normal course of business, as authorized by General License 1B issued by the U.S. Department of the Treasury’s Office of Foreign Assets Control, our Russian affiliate responds to regulatory inquiries from the FSB and otherwise engages with the FSB as a licensing authority. These interactions did not result in any revenue or otherwise contribute to our net income for the quarter. Our Russian affiliate may respond to similar regulatory inquiries and otherwise continue to engage with the FSB as a licensing authority in the future, as necessary and to the extent permitted by applicable U.S. sanctions laws and regulations.
Available Information
The company files annual, quarterly and current reports, proxy statements and other documents with the Securities and Exchange Commission (SEC) under the Exchange Act. The SEC maintains a website that contains reports, proxy and information statements and other information that issuers, including the company, file electronically with the SEC. The public can obtain any documents that we file with the SEC at www.sec.gov. We also make available free of charge on or through our own website at www.thermofisher.com our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and, if applicable, amendments to those reports filed or furnished pursuant to Section 13(a) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. In addition, paper copies of these documents may be obtained free of charge by writing to the company care of its Investor Relations Department at our principal executive office located at 168 Third Avenue, Waltham, Massachusetts 02451.
Information about Our Executive Officers
As of February 23, 2023, our executive officers were:
NameAgePresent Title
(Fiscal Year First Became Executive Officer)		Other Positions Held
Marc N. Casper54Chairman, President and Chief Executive Officer (2001)President and Chief Executive Officer (2009-2020)
Chief Operating Officer (2008-2009)
Executive Vice President (2006-2009)
Michel Lagarde49Executive Vice President and Chief Operating Officer (2017)Executive Vice President (2019-2021)
Senior Vice President and President, Pharma Services (2017-2019)
President and Chief Operating Officer, Patheon N.V. (2016-2017)
Managing Director, JLL Partners (2008-2016)
Gianluca Pettiti44Executive Vice President (2021)Senior Vice President and President, Specialty Diagnostics (2019-2021)
President, Biosciences (2018-2019)
President, China (2015-2017)
Michael A. Boxer61Senior Vice President and General Counsel (2018)Senior Vice President, General Counsel and Secretary (2021-2022)
Executive Vice President and Group General Counsel, Luxottica Group S.p.A. (2011-2017)
Stephen Williamson56Senior Vice President and Chief Financial Officer (2015)Vice President, Financial Operations (2008-2015)
Joseph R. Holmes44Vice President and Chief Accounting Officer (2021)Senior Director, Technical Accounting (2017-2021)
9

THERMO FISHER SCIENTIFIC INC.
Item 1A.    Risk Factors
Set forth below are the risks that we believe are material to our investors. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements in Item 1. Business under the caption “Forward-looking Statements”.
Industry and Economic Risks
Our growth would suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality. Our growth depends in part on the growth of the markets which we serve. Any decline or lower than expected growth in our served markets would diminish demand for our products and services, which would adversely affect our financial statements. Certain of our businesses operate in industries that may experience periodic, cyclical downturns.
Our business is affected by general economic conditions and related uncertainties affecting markets in which we operate. Our business is affected by general economic conditions, both inside and outside the U.S. Both domestic and international markets experienced significant inflationary pressures in 2022 and inflation rates in the U.S., as well as in other countries in which we operate, continue at elevated levels for the near-term. If the global economy and financial markets, or economic conditions in Europe, the U.S. or other key markets, continue to be unstable, they could adversely affect the business, results of operations and financial condition of the company and its customers, distributors, and suppliers, having the effect of:
•reducing demand for some of our products;
•increasing the rate of order cancellations or delays;
•increasing the risk of excess and obsolete inventories;
•increasing pressure on the prices for our products and services;
•causing supply interruptions, which could disrupt our ability to produce our products; and
•creating longer sales cycles, and greater difficulty in collecting sales proceeds and slower adoption of new technologies.
Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations. International markets contribute a substantial portion of our revenues, and we intend to continue expanding our presence in these regions. The exposure to fluctuations in currency exchange rates takes on different forms. International revenues and costs are subject to the risk that fluctuations in exchange rates could adversely affect our reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. These fluctuations could also adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses occasionally invoice third-party customers in currencies other than the one in which they primarily do business (which we refer to as the functional currency). Movements in the invoiced currency relative to the functional currency could adversely impact our cash flows and our results of operations. As our international sales grow, exposure to fluctuations in currency exchange rates could have a larger effect on our financial results. In 2022, currency translation had an unfavorable effect of $1.35 billion on revenues due to the strengthening of the U.S. dollar relative to other currencies in which the company sells products and services.
Some emerging market countries may be particularly vulnerable to periods of global and local political, legal, regulatory and financial instability, including issues of geopolitical relations, the imposition of international sanctions in response to certain state actions and/or sovereign debt issues, and may have a higher incidence of corruption and fraudulent business practices. As a result of these and other factors, our strategy to grow in emerging markets may not be successful, and growth rates in these markets may not be sustainable.
In addition, many of our employees, contract manufacturers, suppliers, job functions, outsourcing activities and manufacturing facilities are located outside the U.S. Accordingly, our future results could be harmed by a variety of factors, including:
•interruption to transportation flows for delivery of parts to us and finished goods to our customers;
•changes in a specific country's or region's political, economic or other conditions;
•changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes and sanctions and other trade barriers;
10

THERMO FISHER SCIENTIFIC INC.

•tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, including the tariffs adopted by the U.S. government on various imports from China and by the Chinese government on certain U.S. goods;
•the impact of public health epidemics/pandemics on the global economy, such as the COVID-19 pandemic;
•uncertainties regarding the collectability of accounts receivable;
•the imposition of governmental controls;
•diverse data privacy and protection requirements;
•supply interruptions, which could disrupt our ability to produce our products;
•increases in materials, energy, labor or other manufacturing-related costs or higher supply chain logistics costs;
•negative consequences from changes in tax laws;
•difficulty in staffing and managing widespread operations;
•differing labor regulations;
•differing protection of intellectual property;
•unexpected changes in regulatory requirements; and
•geopolitical uncertainty or turmoil, including terrorism and war.
Demand for some of our products depends on capital spending policies of our customers and on government funding policies. Our customers include pharmaceutical and chemical companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions. Many factors, including public policy spending priorities, available resources, and product and economic cycles, have a significant effect on the capital spending policies of these entities. Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal budget. An impasse in federal government budget decisions could lead to substantial delays or reductions in federal spending.
We are subject to risks associated with public health epidemics and pandemics, such as the ongoing COVID-19 pandemic. Our global operations expose us to risks associated with public health epidemics and pandemics. COVID-19 has had an adverse impact on certain of our operations, supply chains and distribution systems, and we may experience unpredictable reductions in supply and demand for certain of our products and services. National, state and local governments have implemented and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns and other measures. These measures may disrupt normal business operations and may have significant negative impacts on businesses and financial markets worldwide. Our ability to continue to manufacture products is highly dependent on our ability to maintain the safety and health of our factory employees. The ability of our employees to work may be significantly impacted by the COVID-19 pandemic or future epidemics and pandemics. In addition, the duration and extent of future revenues from sales of products related to the COVID-19 response are uncertain and dependent primarily on customer testing demand as well as therapy and vaccine demand.
Business Risks
We must develop new products, adapt to rapid and significant technological change, respond to introductions of new products by competitors and maintain quality to remain competitive. Our growth strategy includes significant investment in and expenditures for product development. We sell our products in several industries that are characterized by rapid and significant technological changes, frequent new product and service introductions and enhancements and evolving industry standards. Competitive factors include technological innovation, price, service and delivery, breadth of product line, customer support, e-business capabilities and the ability to meet the special requirements of customers. Our competitors may adapt more quickly to new technologies and changes in customers’ requirements than we can. Without the timely introduction of new products, services and enhancements, our products and services will likely become technologically obsolete over time, in which case our revenues and operating results would suffer.
Many of our existing products and those under development are technologically innovative and require significant planning, design, development and testing at the technological, safety, quality, product and manufacturing-process levels. Our customers use many of our products to develop, test and manufacture their own products. As a result, we must anticipate industry trends and develop products in advance of the commercialization of our customers’ products. If we fail to adequately develop products or predict our customers’ needs and future activities, we may invest heavily in research and development of products and services that do not lead to significant revenues.
11

THERMO FISHER SCIENTIFIC INC.

It may be difficult for us to implement our strategies for improving internal growth. Our growth depends in part on the growth of the markets which we serve. Any decline or lower than expected growth in our served markets could diminish demand for our products and services, which would adversely affect our results of operations and financial condition. To address this issue, we are pursuing a number of strategies to improve our internal growth, including:
•strengthening our presence in selected geographic markets;
•allocating research and development funding to products with higher growth prospects;
•developing new applications for our technologies;
•expanding our service offerings;
•continuing key customer initiatives;
•combining sales and marketing operations in appropriate markets to compete more effectively;
•finding new markets for our products; and
•continuing the development of commercial tools and infrastructure to increase and support cross-selling opportunities of products and services to take advantage of our depth in product offerings.
We may not be able to successfully implement these strategies, and these strategies may not result in the expected growth of our business.
Because we compete directly with certain of our larger customers and product suppliers, our results of operations could be adversely affected in the short term if these customers or suppliers abruptly discontinue or significantly modify their relationship with us. Our largest customer in the laboratory products business is also a significant competitor. Our business may be harmed in the short term if our competitive relationship in the marketplace with certain of our large customers results in a discontinuation of their purchases from us. In addition, we manufacture products that compete directly with products that we source from third-party suppliers. We also source competitive products from multiple suppliers. Our business could be adversely affected in the short term if any of our large third-party suppliers abruptly discontinues selling products to us.
Our inability to complete any pending acquisitions or to successfully integrate any new or previous acquisitions could have a material adverse effect on our business. Our business strategy includes the acquisition of technologies and businesses that complement or augment our existing products and services. Certain acquisitions may be difficult to complete for a number of reasons, including the need for antitrust and/or other regulatory approvals, as well as disputes or litigation. Any acquisition we may complete may be made at a substantial premium over the fair value of the net identifiable assets of the acquired company. Further, we may not be able to integrate acquired businesses successfully into our existing businesses, make such businesses profitable, or realize anticipated cost savings or synergies, if any, from these acquisitions, which could adversely affect our business.
Moreover, we have acquired many companies and businesses. As a result of these acquisitions, we recorded significant goodwill and indefinite-lived intangible assets (primarily tradenames) on our balance sheet, which amount to approximately $41.20 billion and $1.24 billion, respectively, as of December 31, 2022. In addition, we have definite-lived intangible assets totaling $16.21 billion as of December 31, 2022. We assess the realizability of goodwill and indefinite-lived intangible assets annually as well as whenever events or changes in circumstances indicate that these assets may be impaired. We assess the realizability of definite-lived intangible assets whenever events or changes in circumstances indicate that these assets may be impaired. These events or circumstances would generally include operating losses or a significant decline in earnings associated with the acquired business or asset. Our ability to realize the value of the goodwill and intangible assets will depend on the future cash flows of these businesses. These cash flows in turn depend in part on how well we have integrated these businesses. If we are not able to realize the value of the goodwill and intangible assets, we may be required to incur material charges relating to the impairment of those assets.
Operational Risks
Our reliance upon sole or limited sources of supply for certain materials or components could cause production interruptions, delays and inefficiencies. Some of our businesses purchase certain materials from sole or limited source suppliers for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design. If these or other suppliers encounter financial, operating or other difficulties, or if our relationship with them changes, we might not be able to quickly establish or qualify replacement sources of supply. The supply chains for our businesses could also be disrupted by supplier capacity constraints, bankruptcy or exiting of the business for other reasons, decreased availability or increased cost of key raw materials or commodities, such as energy, and external events such as global economic downturns and macroeconomic trends, natural disasters, pandemic health issues such as COVID-19, war, terrorist actions, governmental
12

THERMO FISHER SCIENTIFIC INC.

actions and legislative or regulatory changes. Any of these factors could result in production interruptions, delays, extended lead times and inefficiencies.
A significant disruption in, or breach in security of, our information technology systems or violation of data privacy laws could adversely affect our business. As a part of our ongoing effort to upgrade our current information systems, we periodically implement new enterprise resource planning software and other software applications to manage certain of our business operations. As we implement and add functionality, problems could arise that we have not foreseen. Such problems could disrupt our ability to provide quotes, take customer orders and otherwise run our business in a timely manner. When we upgrade or change systems, we may suffer interruptions in service, loss of data or reduced functionality. In addition, if our new systems fail to provide accurate pricing and cost data our results of operations and cash flows could be adversely affected.
We also rely on our information technology systems to process, transmit and store electronic information (including sensitive data such as confidential business information and personally identifiable data relating to employees, customers and other business partners) and to manage or support a variety of critical business processes and activities (such as interacting with suppliers, selling our products and services, fulfilling orders and billing, collecting and making payments, shipping products, providing services and support to customers, tracking customer activity, fulfilling contractual obligations and otherwise conducting business). Our systems may be vulnerable to damage or interruption from natural disasters, power loss, telecommunication failures, terrorist attacks, computer hackers, computer viruses, ransomware, phishing, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems. Certain of our systems are not redundant, and our disaster recovery planning is not sufficient for every eventuality. Despite any precautions we may take, such problems could result in, among other consequences, interruptions in our services, which could harm our reputation and financial results. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. Any of the cyber-attacks, breaches or other disruptions or damage described above, if significant, could materially interrupt our operations, delay production and shipments, result in theft of our and our customers’ intellectual property and trade secrets, damage customer, business partner and employee relationships and our reputation or result in defective products or services, legal claims and proceedings, liability and penalties under privacy laws and increased cost for security and remediation, each of which could adversely affect our business and financial results. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.
If we are unable to maintain reliable information technology systems and appropriate controls with respect to global data privacy and security requirements and prevent data breaches, we may suffer regulatory consequences in addition to business consequences. As a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in the course of our business. For example, in the U.S., individual states regulate data breach and security requirements and multiple governmental bodies assert authority over aspects of the protection of personal privacy. European laws require us to have an approved legal mechanism to transfer personal data out of Europe, and the EU General Data Protection Regulation imposes significantly stricter requirements in how we collect and process personal data. Several countries, such as China, have passed laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions. Government enforcement actions can be costly and interrupt the regular operation of our business, and data breaches or violations of data privacy laws can result in fines, reputational damage and civil lawsuits, any of which may adversely affect our business, reputation and financial statements.
We may have difficulty attracting and retaining a highly qualified workforce. Our success is largely dependent upon our ability to attract and retain highly qualified scientific, technical, clinical and management workforce in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes or recruitment by competitors. Our ability to attract and retain key talent also depends in part on how well we maintain a strong workplace culture that is attractive to employees. Macroeconomic conditions, specifically increased competition for employees and wage inflation, could have a material impact on our ability to attract and retain talent, our turnover rate and the cost of operating our business. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.
We may incur unexpected costs from increases in fuel and raw material prices, which could reduce our earnings and cash flows. Our primary commodity exposures are for fuel, petroleum-based resins and steel. The costs for these commodities, as well as the costs of transportation, construction and services necessary for the production and distribution of our products, continue to increase and be volatile. While we may seek to minimize the impact of price increases through higher prices to customers and various cost-saving measures, our earnings and cash flows could be adversely affected in the event these measures are insufficient to cover our costs.
13

THERMO FISHER SCIENTIFIC INC.

Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability. We ship a significant portion of our products to our customers through independent package delivery companies, such as Federal Express in the U.S. and DHL in Europe. We also maintain a small fleet of vehicles dedicated to the delivery of our products and ship our products through other carriers, including national and regional trucking firms, overnight carrier services and the U.S. Postal Service. If one or more of these third-party package-delivery providers were to experience a major work stoppage, preventing our products from being delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with certain of our customers could be adversely affected. In addition, if one or more of these third-party package-delivery providers were to increase prices, and we were not able to find comparable alternatives or make adjustments in our delivery network, our profitability could be adversely affected.
Natural disasters, public health crises, political crises, and other catastrophic events or other events outside of our control may disrupt our facilities or the facilities of third parties on which we depend, and could impact customer spending. We have significant operations in California, near major earthquake faults, which make us susceptible to earthquake risk. An earthquake or other natural disaster (including the effects of climate change such as sea level rise, drought, flooding, wildfires and more intense weather events), could disrupt our operations or impair our critical systems. Any of these disruptions or other events outside of our control, such as strikes or other labor unrest, could have an adverse effect on our results of operations. In addition, if any of our facilities, including our manufacturing or warehouse facilities, or the facilities of our suppliers, third-party service providers, or customers, is affected by natural disasters, such as earthquakes, tsunamis, power shortages or outages, fires, floods or monsoons, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability or other conflict, or other events outside of our control, such as trade protectionism, strikes or other labor unrest, our results of operations could be adversely affected. Moreover, these types of events could negatively impact customer spending in the impacted regions or depending upon the severity, globally, which could also adversely impact our operating results.
Increasing attention to environmental, social and governance matters may impact our business, financial results, stock price or reputation. We face increasing scrutiny from stakeholders related to our environmental, social and governance (ESG) practices and disclosures, including practices and disclosures related to climate change, diversity and inclusion and governance standards. Investor advocacy groups, certain institutional investors, lenders, investment funds and other influential investors are also increasingly focused on ESG practices and disclosures and in recent years have placed increasing importance on the implications and social cost of their investments. In addition, government organizations are enhancing or advancing legal and regulatory requirements specific to ESG matters. The heightened stakeholder focus on ESG issues related to our business requires the continuous monitoring of various and evolving laws, regulations, standards and expectations and the associated reporting requirements. A failure to adequately meet evolving stakeholder expectations may result in noncompliance, the loss of business, reputational impacts, diluted market valuation, an inability to attract customers and an inability to attract and retain top talent. In addition, if legislation or regulations are enacted or promulgated in the U.S. or in any other jurisdiction in which we do business that impose more stringent restrictions and requirements than our current legal or regulatory obligations, we and companies in our supply chain may experience increased compliance burdens and costs to meet the regulatory obligations, which could cause disruption in the sourcing, manufacturing and distribution of our products and adversely affect our business, financial condition or results of operations. In addition, our adoption of certain standards or mandated compliance to certain requirements could necessitate additional investments that could impact our profitability.
Legal, Quality and Regulatory Risks
Changes in governmental regulations may reduce demand for our products or increase our expenses. We compete in many markets in which we and our customers must comply with federal, state, local and international regulations, such as environmental, health and safety and food and drug regulations. We develop, configure and market our products to meet customer needs created by those regulations. Any significant change in regulations could reduce demand for our products or increase our expenses. For example, we manufacture pharmaceuticals and many of our instruments are marketed to the pharmaceutical industry for use in discovering and developing drugs. Changes in the U.S. Food and Drug Administration’s (the FDA) regulation of the drug discovery and development process could have an adverse effect on the demand for these products.
We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenues associated with these customers. We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. The laws governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and conditions that are not applicable to private contracts. We are also subject to investigation for compliance with the
14

THERMO FISHER SCIENTIFIC INC.

regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.
Our pharma services offerings are highly complex, and if we are unable to provide quality and timely offerings to our customers, our business could suffer. Our pharma services offerings are highly exacting and complex, due in part to strict quality and regulatory requirements. Our operating results in this business depend on our ability to execute and, when necessary, improve our quality management strategy and systems, and our ability to effectively train and maintain our employee base with respect to quality management. A failure of our quality control systems could result in problems with facility operations or preparation or provision of products. In each case, such problems could arise for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials or environmental factors and damage to, or loss of, manufacturing operations. Such problems could affect production of a particular batch or series of batches of products, requiring the destruction of such products or a halt of facility production altogether.
In addition, our failure to meet required quality standards may result in our failure to timely deliver products to our customers, which in turn could damage our reputation for quality and service. Any such failure could, among other things, lead to increased costs, lost revenues, reimbursement to customers for lost drug product, registered intermediates, registered starting materials, and active pharmaceutical ingredients, other customer claims, damage to and possibly termination of existing customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. Production problems in our drug and biologic manufacturing operations could be particularly significant because the cost of raw materials for such manufacturing is often high. If problems in preparation or manufacture of a product or failures to meet required quality standards for that product are not discovered before such product is released to the market, we may be subject to adverse regulatory actions, including product recalls, product seizures, injunctions to halt manufacture and distribution, restrictions on our operations, civil sanctions, including monetary sanctions, and criminal actions. In addition, such problems or failures could subject us to litigation claims, including claims from our customers for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of which could be significant.
We are subject to product and other liability risks for which we may not have adequate insurance coverage. We may be named as a defendant in product liability or errors and omissions lawsuits, which may allege that products or services we have provided have resulted or could result in an unsafe condition, property damage or injury to end users or financial loss for consumers. Additionally, products currently or previously sold by our environmental and process instruments and radiation measurement and security instruments businesses include fixed and portable instruments used for chemical, radiation and trace explosives detection. These products are used in airports, embassies, cargo facilities, border crossings and other high-threat facilities for the detection and prevention of terrorist acts. If any of these products were to malfunction, it is possible that explosive or radioactive material could fail to be detected by our product, which could lead to product liability claims. In addition, patients involved in our clinical services trials conducted by our clinical development services business or taking drugs approved on the basis of those trials may also bring personal injury claims against us. There are also many other factors beyond our control that could lead to liability claims, such as the reliability and competence of the customers’ operators and the training of such operators.
Any such product liability claims brought against us could be significant and any adverse determination may result in liabilities subject to insurance policy exclusions where insurance would not respond or in excess of our insurance coverage. Although we carry product liability and errors and omissions insurance, we cannot be certain that our current insurance will be sufficient to cover these claims or that it can be maintained on acceptable terms, if at all.
We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies. We are subject to various local, state, federal, foreign and transnational laws and regulations, which include the operating and security standards of the FDA, the U.S. Drug Enforcement Agency (the DEA), various state boards of pharmacy, state health departments, the U.S. Department of Health and Human Services (the DHHS), the European Medicines Agency (the EMA), the EU member states and other comparable agencies and, in the future, any changes to such laws and regulations could adversely affect us. In particular, we are subject to laws and regulations concerning current good manufacturing practices and drug safety. Our subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with the laws and regulations of, the DEA, the FDA, the DHHS, foreign agencies including the EMA, and other various state boards of pharmacy, state health departments and/or comparable state agencies as well as certain accrediting bodies depending upon the type of operations and location of product distribution, manufacturing and sale.
The manufacture, distribution and marketing of many of our products and services, including medical devices, and our pharma and clinical development services, are subject to extensive ongoing regulation by the FDA, the DEA, the EMA, and other equivalent local, state, federal and non-U.S. regulatory authorities. In addition, we are subject to inspections by these regulatory authorities. Failure by us or by our customers to comply with the requirements of these regulatory authorities,
15

THERMO FISHER SCIENTIFIC INC.

including without limitation, remediating any inspectional observations to the satisfaction of these regulatory authorities, could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, including those relating to products or facilities. In addition, such a failure could expose us to contractual or product liability claims, contractual claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients or personal injury, as well as ongoing remediation and increased compliance costs, any or all of which could be significant. We are the sole manufacturer of a number of pharmaceuticals for many of our customers and a negative regulatory event could impact our customers’ ability to provide products to their customers.
We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the handling, transportation and manufacture of substances that could be classified as hazardous, and we are required to comply with various import laws and export control and economic sanctions laws, which may affect our transactions with certain customers. In certain circumstances, export control and economic sanctions regulations may prohibit the export of certain products, services and technologies. In other circumstances, we may be required to obtain an export license before exporting the controlled item. Compliance with the various import laws that apply to our businesses can restrict our access to, and increase the cost of obtaining, certain products and at times can interrupt our supply of imported inventory. Any noncompliance by us with applicable laws and regulations or the failure to maintain, renew or obtain necessary permits and licenses could result in criminal, civil and administrative penalties and could have an adverse effect on our results of operations.
Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents, business partners or other third parties. We have internal controls and compliance systems to protect the company against acts committed by employees, agents or businesses that we acquire that would violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, employment practices and workplace behavior, export and import compliance, money laundering and data privacy, but these controls and systems may not be sufficient to prevent every such wrongful act. In particular, the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business, and we operate in many parts of the world that have experienced governmental corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in the U.S. and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and criminal, monetary and nonmonetary penalties and could cause us to incur significant legal and investigatory fees. In addition, the government may seek to hold us liable for violations committed by companies which we acquire. We also rely on our suppliers to adhere to our supplier standards of conduct, and material violations of such standards of conduct could occur that could have a material effect on our business, reputation and financial statements. In addition, any allegations of issues resulting from the misuse of our products could, even if untrue, adversely affect our reputation and our customers’ willingness to purchase products from us. Any such allegations could cause us to lose customers and divert our resources from other tasks, which could materially and adversely affect our business and operating results.
Our inability to protect our intellectual property could have a material adverse effect on our business. In addition, third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result. We place considerable emphasis on obtaining patent and trade secret protection for significant new technologies, products and processes because of the length of time and expense associated with bringing new products through the development process and into the marketplace. Our success depends in part on our ability to develop patentable products and obtain and enforce patent protection for our products both in the U.S. and in other countries. We own numerous U.S. and foreign patents, and we intend to file additional applications, as appropriate, for patents covering our products. Patents may not be issued for any pending or future patent applications owned by or licensed to us, and the claims allowed under any issued patents may not be sufficiently broad to protect our technology. Any issued patents owned by or licensed to us may be challenged, invalidated or circumvented, and the rights under these patents may not provide us with competitive advantages. In addition, competitors may design around our technology or develop competing technologies. Intellectual property rights may also be unavailable or limited in some foreign countries, which could make it easier for competitors to capture increased market position. We could incur substantial costs to defend ourselves in suits brought against us or in suits in which we may assert our patent rights against others. An unfavorable outcome of any such litigation could materially adversely affect our business and results of operations.
We also rely on trade secrets and proprietary know-how with which we seek to protect our products, in part, by confidentiality agreements with our collaborators, employees and consultants. These agreements may not adequately protect our trade secrets and other proprietary rights. These agreements may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently developed by our competitors.
16

THERMO FISHER SCIENTIFIC INC.

We also depend in part on our trademarks and the strength of our proprietary brands, which we consider important to our business. If we are unable to protect or preserve the value of our intellectual property rights for any reason, including our inability to successfully defend against counterfeit, knock offs, grey-market, infringing or otherwise unauthorized products, our brand and reputation could be damaged, and our business may be harmed.
Third parties may assert claims against us to the effect that we are infringing on their intellectual property rights. In the event that a claim relating to intellectual property is asserted against us, or third parties not affiliated with us hold pending or issued patents that relate to our products or technology, we may seek licenses to such intellectual property or challenge those patents. However, we may be unable to obtain these licenses on commercially reasonable terms, if at all, and our challenge of the patents may be unsuccessful. Our failure to obtain the necessary licenses or other rights could prevent the sale, manufacture, or distribution of our products and, therefore, could have a material adverse effect on our business, financial condition and results of operations.
Risks Relating to Financial Profile
Fluctuations in our effective tax rate may adversely affect our results of operations and cash flows. As a global company, we are subject to taxation in numerous countries, states and other jurisdictions. In preparing our financial statements, we record the amount of tax that is payable in each of the countries, states and other jurisdictions in which we operate. Our future effective tax rate, however, may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our profitability from country to country, changes in accounting for income taxes, the results of examinations and audits of our tax filings and recently enacted and future changes in tax laws in jurisdictions in which we operate. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, results of operations and cash flows.
Our existing and future indebtedness may restrict our investment opportunities or limit our activities and negatively impact our credit ratings. As of December 31, 2022, we had approximately $34.49 billion in outstanding indebtedness. In addition, we have availability to borrow under a revolving credit facility that provides for up to $5.00 billion of unsecured multi-currency revolving credit (the Facility). We may also obtain additional long-term debt and lines of credit to meet future financing needs, which would have the effect of increasing our total leverage.
Our leverage could have negative consequences, including increasing our vulnerability to adverse economic and industry conditions, limiting our ability to obtain additional financing and limiting our ability to acquire new products and technologies through strategic acquisitions.
Our ability to make scheduled payments, refinance our obligations or obtain additional financing will depend on our future operating performance and on economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient cash flow to meet our obligations. If we are unable to service our debt, refinance our existing debt or obtain additional financing, we may be forced to delay strategic acquisitions, capital expenditures or research and development expenditures.
Additionally, the agreements governing our debt require that we maintain a financial ratio, and contain affirmative and negative covenants that restrict our activities by, among other limitations, limiting our ability to incur additional indebtedness, merge or consolidate with other entities and create liens. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter.
Our ability to comply with these financial restrictions and covenants is dependent on our future performance, which is subject to prevailing economic conditions and other factors, including factors that are beyond our control such as the impact of foreign exchange rates and interest rates. Our failure to comply with any of these restrictions or covenants may result in an event of default under the applicable debt instrument, which could permit acceleration of the debt under that instrument and require us to prepay that debt before its scheduled due date. Also, an acceleration of the debt under certain of our debt instruments would trigger an event of default under other of our debt instruments.
Item 1B.    Unresolved Staff Comments
None.
Item 2.    Properties
The company owns and leases office, engineering, laboratory, production and warehouse space throughout the world.
17

THERMO FISHER SCIENTIFIC INC.
Item 3.    Legal Proceedings
There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See Note 12 to our Consolidated Financial Statements – Commitments and Contingencies.
Item 4.    Mine Safety Disclosures
Not applicable.
PART II
Item 5.    Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Price of Common Stock
Our common stock is traded on the New York Stock Exchange under the symbol TMO.
Holders of Common Stock
As of February 4, 2023, the company had 2,460 holders of record of its common stock. This does not include holdings in street or nominee names.
Issuer Purchases of Equity Securities
A summary of the share repurchase activity for the company's fourth quarter of 2022 follows:
PeriodTotal number of shares purchasedAverage price paid per shareTotal number of shares purchased as part of publicly announced plans or programs (1)Maximum dollar amount of shares that may yet be purchased under the plans or programs (1)
(in millions)
Fiscal October (Oct. 2 - Nov. 5)1,989,832 $502.55 1,989,832 $— 
Fiscal November (Nov. 6 - Dec. 3)— — — 4,000 
Fiscal December (Dec. 4 - Dec. 31)— — — 4,000 
Total fourth quarter1,989,832 $502.55 1,989,832 $4,000 
(1) On September 23, 2021, the Board of Directors authorized the repurchase of up to $3.00 billion of the company’s common stock. All of the shares of common stock repurchased by the company during the fourth quarter were purchased under this program, depleting the 2021 authorization. On November 10, 2022, the Board of Directors authorized the repurchase of up to $4.00 billion of the company’s common stock. Early in the first quarter of 2023, the company repurchased $3.00 billion of the company’s common stock (5.2 million shares). At February 23, 2023, $1.00 billion was available for future repurchases of the company’s common stock under this authorization.
Item 6.    Reserved
Not applicable.
Item 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
Reference is made throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations to Notes to the Consolidated Financial Statements, which begin on page F-1 of this report. Management’s Discussion and Analysis of Financial Condition and Results of Operations for 2020 is included in Item 7 of the company’s 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission.
The company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP measures). These non-GAAP measures are further described and reconciled to their most directly comparable amount or measure under the section “Non-GAAP Measures” later in this Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Overview
Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through
18

THERMO FISHER SCIENTIFIC INC.
diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The company’s operations fall into four segments (Note 4): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.
Consolidated Results
(Dollars in millions except per share amounts)20222021Change
Revenues
$44,915 $39,211 15 %
GAAP operating income$8,393 $10,028 (16)%
GAAP operating income margin18.7 %25.6 %(6.9) pt
Adjusted operating income (non-GAAP measure)
$10,985 $12,138 (9)%
Adjusted operating income margin (non-GAAP measure)
24.5 %31.0 %(6.5) pt
GAAP diluted earnings per share attributable to Thermo Fisher Scientific Inc.$17.63 $19.46 (9)%
Adjusted earnings per share (non-GAAP measure)
$23.24 $25.13 (8)%
Organic Revenue Growth
Revenue growth15 %
Impact of acquisitions18 %
Impact of currency translation(3)%
Organic revenue growth* (non-GAAP measure)
0 %
*    Results may not sum due to rounding.
Since 2020, the Life Sciences Solutions and Specialty Diagnostics segments as well as the laboratory products business have supported COVID-19 diagnostic testing, scaling and evolving their molecular diagnostics solutions and plastic consumables businesses to respond to the ongoing COVID-19 pandemic. The biosciences and bioproduction businesses have expanded their capacity to meet the needs of pharma and biotech customers as they have expanded their own production volumes to meet global vaccine manufacturing requirements. Additionally, our pharma services business has provided our pharma and biotech customers with the services they needed to develop and produce vaccines and therapies globally. While these positive impacts are expected to continue through 2023, the duration and extent of future revenues from such sales are uncertain and dependent primarily on customer testing as well as therapy and vaccine demand. Sales of products related to COVID-19 testing were $3.11 billion and $7.26 billion in 2022 and 2021, respectively.
During 2022 demand from pharma and biotech customers was very strong, driven by our differentiated customer value proposition and trusted partner status. We saw good growth in the academic and government market as we remain well positioned to meet customer needs. The industrial and applied market was strong, driven by robust demand for our analytical instruments serving our semi-conductor and materials science customers. The diagnostics and healthcare market declined due to decreased demand for COVID-19 testing products. During 2022, robust sales growth in North America and the Asia Pacific region, including China, was partially offset by a decline in COVID-19 testing demand. In Europe, strong sales were more than offset during 2022 due to lower COVID-19 testing demand. Contributions to organic revenue during 2022 were driven by the Laboratory Products and Biopharma Services and Analytical Instruments segments, as offset by the Life Sciences Solutions and Specialty Diagnostics segments.
The company continues to execute its proven growth strategy which consists of three pillars:
•Developing high-impact, innovative new products,
•Leveraging our scale in high-growth and emerging markets, and
•Delivering a unique value proposition to our customers.
GAAP operating income margin and adjusted operating income margin decreased in 2022 due primarily to lower COVID-19 testing volumes, continued strategic growth investments, and the expected impact of incorporating recent acquisitions. This was partially offset by strong pricing realization across all segments to address higher inflation while also driving strong productivity. GAAP operating income margin in 2022 was also impacted by higher amortization expense as a result of 2021 acquisitions.
The company’s references to strategic growth investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects and other expenditures to enhance the customer experience, as well as incentive compensation and recognition for employees. The company’s references throughout this discussion to
19

THERMO FISHER SCIENTIFIC INC.
productivity improvements generally refer to improved cost efficiencies from its Practical Process Improvement (PPI) business system including reduced costs resulting from implementing continuous improvement methodologies, global sourcing initiatives, a lower cost structure following restructuring actions, including headcount reductions and consolidation of facilities, and low cost region manufacturing.
Notable Recent Acquisitions
On January 15, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, the Belgium-based European viral vector manufacturing business of Groupe Novasep SAS. The European viral vector manufacturing business provides manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities for cell and gene vaccines and therapies.
On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company. Mesa Biotech has developed and commercialized a PCR based rapid point-of-care testing platform available for detecting infectious diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care.
On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Biopharma Services segment, of a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers as well.
On December 8, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, PPD, Inc., a U.S.-based global provider of clinical research services to the pharma and biotech industry. The addition of PPD’s clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their productivity within the drug development process.
On December 30, 2021, the company acquired, within the Life Sciences Solutions segment, PeproTech, Inc., a U.S.-based developer and manufacturer of recombinant proteins. PeproTech provides bioscience reagents known as recombinant proteins, including cytokines and growth factors. The acquisition expands the segment’s bioscience offerings.
On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma.
Segment Results
The company’s management evaluates segment operating performance using operating income before certain charges/credits as defined in Note 4. Accordingly, the following segment data are reported on this basis.
(Dollars in millions)20222021
Revenues
Life Sciences Solutions
$13,532 $15,631 
Analytical Instruments
6,624 6,069 
Specialty Diagnostics
4,763 5,659 
Laboratory Products and Biopharma Services
22,511 14,862 
Eliminations
(2,515)(3,010)
Consolidated revenues
$44,915 $39,211 
Life Sciences Solutions
Organic* (non-GAAP measure)
(Dollars in millions)20222021Total
Change		Currency
Translation		Acquisitions/ Divestitures
Revenues$13,532 $15,631 (13)%(3)%1 %(12)%
Segment income$5,582 $7,817 (29)%
Segment income margin41.2 %50.0 %(8.8) pt
The decrease in organic revenues in 2022 was primarily due to lower revenue in the genetic sciences business, driven by moderation in testing demand to diagnose COVID-19, partially offset by growth in the bioproduction business. The decrease in segment income margin resulted primarily from business mix and strategic growth investments, partially offset by productivity improvements.
20

THERMO FISHER SCIENTIFIC INC.
Analytical Instruments
Organic* (non-GAAP measure)
(Dollars in millions)20222021Total
Change		Currency
Translation		Acquisitions/ Divestitures
Revenues$6,624 $6,069 9 %(5)%0 %14 %
Segment income1,507 1,197 26 %
Segment income margin22.8 %19.7 %3.1 pt
The increase in organic revenues in 2022 was due to increased demand across all the segment’s businesses, with particular strength in the electron microscopy and chromatography and mass spectrometry businesses. The increase in segment income margin resulted primarily from profit on higher sales, productivity improvements and business mix, offset in part by strategic growth investments.
Specialty Diagnostics
Organic* (non-GAAP measure)
(Dollars in millions)20222021Total
Change		Currency
Translation		Acquisitions/ Divestitures
Revenues$4,763 $5,659 (16)%(3)%0 %(13)%
Segment income1,024 1,280 (20)%
Segment income margin21.5 %22.6 %(1.1) pt
The decrease in organic revenues in 2022 was primarily driven by products addressing diagnosis of COVID-19, partially offset by growth in the immunodiagnostics and transplant diagnostics businesses. The decrease in segment income margin was primarily due to lower COVID-19 testing volume, largely offset by productivity improvements and positive business mix. Segment income margin in 2021 was also impacted by a $13 million credit to cost of product revenue as a result of changing the method of accounting for inventories.
Laboratory Products and Biopharma Services
Organic* (non-GAAP measure)
(Dollars in millions)20222021Total
Change		Currency
Translation		Acquisitions/ Divestitures
Revenues$22,511 $14,862 51 %(3)%45 %10 %
Segment income2,872 1,844 56 %
Segment income margin12.8 %12.4 %0.4 pt
The increase in organic revenues in 2022 was primarily due to higher sales across each of the segment’s businesses, with particular strength in the pharma services business and research and safety market channel. PPD, the company’s clinical research business, contributed $7.11 billion of revenue during 2022. The increase in segment income margin was primarily due to the benefit of recent acquisitions, profit on higher sales, and productivity improvements, offset in part by strategic growth investments. Segment income margin in 2021 was also impacted by a $20 million credit to cost of product revenue as a result of changing the method of accounting for inventories.
*    Results may not sum due to rounding
Non-operating Items
(Dollars in millions)20222021
Net interest expense
$454 $493 
GAAP other income/(expense)(104)(694)
Adjusted other income/(expense) (non-GAAP measure)
13 38 
GAAP tax rate9.0 %12.5 %
Adjusted tax rate (non-GAAP measure)
13.0 %14.6 %

Net interest expense (interest expense less interest income) decreased due primarily to lower average interest rates on debt and higher average interest rates on cash balances, partially offset by the increase in debt to finance the acquisition of PPD and for general corporate purposes. See additional discussion under the caption “Liquidity and Capital Resources” below.
GAAP other income/(expense) and adjusted other income/(expense) includes currency transaction gains, losses on non-operating monetary assets and liabilities, and net periodic pension benefit cost/income, excluding the service cost component. GAAP other income/(expense) in 2022 also includes $160 million of net losses on investments, $26 million of losses on the
21

THERMO FISHER SCIENTIFIC INC.
early extinguishment of debt (Note 10), partially offset by $67 million of net gains on derivative instruments to address certain foreign currency risks and $2 million of net settlement gains on pension plans. GAAP other income/(expense) in 2021 also includes $767 million of losses on the early extinguishment of debt and $36 million of financing costs associated with obtaining bridge financing commitments in connection with the agreement to acquire PPD (Note 2), offset in part by $66 million of net gains on investments.
The company’s GAAP and adjusted tax rates decreased in 2022 compared to 2021 primarily due to releases of valuation allowances of $87 million in 2022 in jurisdictions where the deferred tax assets are now expected to be realized. The company’s 2022 GAAP tax rate was also impacted by changes in tax rates and higher amortization expense as a result of 2021 acquisitions, as well as a net benefit of $208 million resulting from tax audit settlements (see Note 8). The company’s 2021 GAAP and adjusted tax rates were also impacted by income tax benefits on intra-entity transactions totaling $284 million.
The effective tax rate in both 2022 and 2021 was also affected by relatively significant earnings in lower tax jurisdictions. Due primarily to the non-deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes were higher than its income tax expense for financial reporting purposes and totaled $1.23 billion and $2.18 billion in 2022 and 2021, respectively.
The company expects its GAAP effective tax rate in 2023 will be between 7% and 9% based on currently forecasted rates of profitability in the countries in which the company conducts business and expected generation of foreign tax credits. The effective tax rate can vary significantly from period to period as a result of discrete income tax factors and events. The company expects its adjusted tax rate will be approximately 11% in 2023.
The company has operations and a taxable presence in approximately 70 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries. Based on the dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a change in the statutory tax rate in any individual country is not likely to materially affect the company’s income tax provision or net income, aside from any resulting one-time adjustment to the company’s deferred tax balances to reflect a new rate.
Liquidity and Capital Resources
The company’s proven growth strategy has enabled it to generate free cash flow as well as access the capital markets. The company deploys its capital primarily via mergers and acquisitions and secondarily via share buybacks and dividends.
December 31,December 31,
(In millions)20222021
Cash and cash equivalents$8,524 $4,477 
Total debt34,488 34,870 
Approximately half of the company’s cash balances and cash flows from operations are from outside the U.S. The company uses its non-U.S. cash for needs outside of the U.S. including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign subsidiaries. In addition, the company also transfers cash to the U.S. using non-taxable returns of capital as well as dividends where the related U.S. dividend received deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.
The company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing capacity under its revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24 months.
As of December 31, 2022, the company’s short-term debt totaled $5.58 billion. The company has a revolving credit facility with a bank group that provides up to $5.00 billion of unsecured multi-currency revolving credit (Note 10). If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of December 31, 2022, no borrowings were outstanding under the company’s revolving credit facility, although available capacity was reduced by immaterial outstanding letters of credit.
22

THERMO FISHER SCIENTIFIC INC.
(In millions)20222021
Net cash provided by operating activities
$9,154 $9,312 
Net cash used in investing activities
(2,159)(21,932)
Net cash (used in) provided by financing activities
(2,810)6,581 
Free cash flow (non-GAAP measure)
6,935 6,809 
Operating Activities
During 2022, cash provided by income was offset in part by investments in working capital. Increases in accounts receivable and inventories used cash of $0.43 billion and $0.83 billion, respectively, primarily to support growth in sales. An increase in accounts payable provided cash of $0.65 billion. Cash payments for income taxes were $1.23 billion during 2022.
During 2021, cash provided by income was offset in part by investments in working capital. Increases in accounts receivable and inventories used cash of $0.20 billion and $1.07 billion, respectively, primarily to support growth in sales. An increase in accounts payable provided cash of $0.48 billion. Changes in other assets and other liabilities used cash of $0.72 billion primarily due to the timing of tax and incentive compensation payments. Cash payments for income taxes were $2.18 billion during 2021.
The company is contingently liable with respect to certain legal proceedings and related matters. An unfavorable outcome that differs materially from current accrual estimates, if any, for one or more of the matters described under the heading “Product Liability, Workers Compensation and Other Personal Injury Matters,” in Note 12 could have a material adverse effect on the company’s financial position as well as its results of operations and cash flows.
Investing Activities
During 2022, acquisitions used cash of $0.04 billion. The company’s investing activities were principally for the purchase of property, plant and equipment for capacity and capability investments.
During 2021, acquisitions used cash of $19.40 billion. The company’s investing activities also included the purchase of $2.52 billion of property, plant and equipment.
The company expects that for all of 2023, expenditures for property, plant and equipment, net of disposals, will be approximately $2.0 billion.
Financing Activities
During 2022, issuance of senior notes provided $3.19 billion in cash. Repayment of senior notes and net commercial paper activity used cash of $0.38 billion and $2.16 billion, respectively. The company’s financing activities also included the repurchase of $3.00 billion of the company’s common stock (5.3 million shares) and the payment of $0.46 billion in cash dividends. On September 23, 2021, the Board of Directors authorized the repurchase of up to $3.00 billion of the company’s common stock. All of the shares of common stock repurchased by the company during the fourth quarter of 2022 were purchased under this program, depleting the 2021 authorization. On November 10, 2022, the Board of Directors authorized the repurchase of up to $4.00 billion of the company’s common stock. Early in the first quarter of 2023, the company repurchased $3.00 billion of the company's common stock (5.2 million shares). At February 23, 2023, authorization remained for $1.00 billion of future repurchases of the company’s common stock.
During 2021, issuance of senior notes provided $18.14 billion of cash. A net increase in commercial paper obligations provided cash of $2.51 billion. Repayment of debt used cash of $11.74 billion, including $4.30 billion to repay the debt assumed in the acquisition of PPD. The company’s financing activities also included the repurchase of $2.00 billion of the company's common stock (4.1 million shares) and the payment of $0.40 billion in cash dividends.
In addition to the obligations on the balance sheet at December 31, 2022, which include, but are not limited to, debt (Note 10), unrecognized tax benefits (Note 8), operating leases (Note 11), pension obligations (Note 7) and contingent consideration (Note 14), the company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or fixed assets and to pay royalties (Note 12).
Non-GAAP Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects of currency translation. We report organic revenue growth because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures and foreign currency translation on
23

THERMO FISHER SCIENTIFIC INC.
revenues. Thermo Fisher management uses organic revenue growth to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.
We report adjusted operating income, adjusted operating income margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:
•Certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction/acquisition-related costs, including changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.
•Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities and large-scale abandonment of product lines are not indicative of our normal operating costs.
•Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
•The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.
•The tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.
We report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.
The non-GAAP financial measures of the company’s results of operations and cash flows included in this Form 10-K are not meant to be considered superior to or a substitute for the company’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth within the “Overview” and “Results of Operations” sections and below.
(Dollars in millions except per share amounts)20222021
Reconciliation of adjusted operating income and adjusted operating income margin
GAAP operating income$8,393 18.7 %$10,028 25.6 %
Cost of revenues adjustments (a)
46 0.1 %8 0.0 %
Selling, general and administrative expenses adjustments (b)
37 0.1 %144 0.4 %
Restructuring and other costs (c)
114 0.3 %197 0.5 %
Amortization of acquisition-related intangible assets2,395 5.3 %1,761 4.5 %
Adjusted operating income (non-GAAP measure)
$10,985 24.5 %$12,138 31.0 %
Reconciliation of adjusted other income/(expense)
GAAP other income/(expense)$(104)$(694)
Adjustments (d)117 732 
Adjusted other income/(expense) (non-GAAP measure)
$13 $38 
24

THERMO FISHER SCIENTIFIC INC.
(Dollars in millions except per share amounts)20222021
Reconciliation of adjusted tax rate
GAAP tax rate9.0 %12.5 %
Adjustments (e)4.0 %2.1 %
Adjusted tax rate (non-GAAP measure)
13.0 %14.6 %
Reconciliation of adjusted earnings per share
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific Inc.$17.63 $19.46 
Cost of revenues adjustments (a)0.12 0.02 
Selling, general and administrative expenses adjustments (b)0.09 0.36 
Restructuring and other costs (c)0.29 0.50 
Amortization of acquisition-related intangible assets6.07 4.43 
Other income/expense adjustments (d)0.30 1.84 
Provision for income taxes adjustments (e)(1.70)(1.49)
Equity in earnings/losses of unconsolidated entities0.44 0.01 
Adjusted EPS (non-GAAP measure)
$23.24 $25.13 
Reconciliation of free cash flow
GAAP net cash provided by operating activities$9,154 $9,312 
Purchases of property, plant and equipment(2,243)(2,523)
Proceeds from sale of property, plant and equipment24 20 
Free cash flow (non-GAAP measure)
$6,935 $6,809 
(a) Adjusted results exclude charges for the sale of inventories revalued at the date of acquisition. Adjusted results in 2022 also exclude $27 million of inventory write-downs associated with large-scale abandonment of product lines.
(b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges associated with product liability litigation.
(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, charges/credits for environmental-related matters, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Adjusted results in 2022 also exclude $14 million of gain on the sale of intellectual property. Adjusted results in 2021 also exclude $122 million of charges for impairments of acquired intangible assets and $35 million of charges for compensation due to employees at recently acquired businesses at the date of acquisition.
(d) Adjusted results exclude net gains/losses on investments and losses on the early extinguishment of debt. Adjusted results in 2022 also exclude $67 million of net gains on derivative instruments to address certain foreign currency risks and $2 million of net settlement gains for pension plans. Adjusted results in 2021 also exclude $36 million of charges for amortization of bridge loan commitment fees related to a pending acquisition.
(e) Adjusted provision for income taxes excludes incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements (including a $658 million benefit from an audit settlement in 2022). Adjusted results in 2022 also exclude a $423 million charge for the impact of deferred tax realizability assessments as a result of audit settlements.
Critical Accounting Policies and Estimates
The company’s discussion and analysis of its financial condition and results of operations is based upon its financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent liabilities. On an on-going basis, management evaluates its estimates, including those related to acquisition-related measurements and income taxes. Management believes the most complex and sensitive judgments, because of their significance to the consolidated financial statements, result primarily from the need to make estimates about the effects of matters that are inherently uncertain. Management bases its estimates on historical experience, current market and economic conditions and other assumptions that management believes are reasonable. The results of these estimates form the basis for judgments about the carrying value of assets and liabilities where the values are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
25

THERMO FISHER SCIENTIFIC INC.
The company believes the following represent its critical accounting policies and estimates used in the preparation of its financial statements:
Acquisition-related Measurements
Business Combinations
The company uses assumptions and estimates in determining the fair value of assets acquired and liabilities assumed in a business combination. The determination of the fair value of intangible assets, which represent a significant portion of the purchase price in many of the company’s acquisitions, requires the use of significant judgment with regard to (i) the fair value and (ii) whether such intangibles are amortizable or non-amortizable and, if the former, the period and the method by which the intangible asset will be amortized. The company estimates the fair value of acquisition-related intangible assets principally based on projections of cash flows that will arise from identifiable intangible assets of acquired businesses, which include estimates of customer attrition and technology obsolescence rates. The projected cash flows are discounted to determine the present value of the assets at the dates of acquisition. See Note 2 for additional information about our recent business combinations.
Goodwill and Indefinite-lived Intangible Assets
The company evaluates goodwill and indefinite-lived intangible assets for impairment annually and when events occur or circumstances change that would more likely than not reduce the fair value of an asset below its carrying amount. Events or circumstances that might require an interim evaluation include unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities, loss of key personnel and acts by governments and courts, among others. Goodwill and indefinite-lived intangible assets totaled $41.20 billion and $1.24 billion, respectively, at December 31, 2022 (see Note 1 for additional information). Estimates of discounted future cash flows require assumptions related to revenue and operating income growth rates, discount rates and other factors. For the goodwill impairment tests, the company also considers (i) peer revenues and earnings trading multiples from companies that have operational and financial characteristics that are similar to the respective reporting units and (ii) estimated weighted average costs of capital. Different assumptions from those made in the company’s analysis could materially affect projected cash flows and the company’s evaluation of goodwill and indefinite-lived intangible assets for impairment.
Except as described below, the company performed the quantitative goodwill impairment test for all of its reporting units and indefinite-lived intangible assets. Determinations of fair value based on projections of discounted cash flows, which decreased from the prior year projections primarily due to higher discount rates, and based on peer revenues and earnings trading multiples, which also decreased from the prior year, were sufficient to conclude that no impairments of goodwill or indefinite-lived intangible assets existed at the end of the tenth fiscal month of 2022, the date of the company’s annual impairment testing. There were no interim impairments of goodwill or indefinite-lived intangible assets in 2022. There can be no assurance, however, that adverse events or conditions will not cause the fair values of these assets to decline. Should the fair values of the company’s reporting units or indefinite-lived intangible assets decline because of reduced operating performance, market declines, or other indicators of impairment, or as a result of changes in the discount rates, charges for impairment may be necessary.
With the completion of the PPD acquisition in December 2021, the company established two new reporting units that solely consist of the legacy PPD businesses, the book carrying values of which equaled their fair values as of the acquisition date. During its annual 2022 goodwill impairment assessments, the company performed qualitative assessments of these reporting units and determined that no events had occurred and no circumstances had changed that would more-likely-than-not reduce the fair values of the reporting units below their carrying amounts. As a result, the company did not perform the quantitative goodwill impairment tests for these reporting units. Given that the fair values of the reporting units were unlikely to be substantially in excess of their carrying values as of the annual 2022 assessment date, relatively small decreases in future cash flows versus anticipated results, decreases in peer trading multiples and/or increases in weighted average costs of capital could result in impairment of goodwill. The reporting units consisting of the legacy PPD businesses had $13.41 billion of goodwill, and an overall carrying value of $19.30 billion as of December 31, 2022.
Definite-lived Intangible Assets
Definite-lived intangible assets totaled $16.21 billion at December 31, 2022 (see Note 1 for additional information). Certain definite-lived intangible assets have largely independent cash flows. The company reviews these definite-lived intangible assets for impairment individually when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. Actual cash flows arising from a particular intangible asset could vary from projected cash flows, which could imply different carrying values from those established at the dates of acquisition and which could result in impairment of such asset. Most of the company’s definite-lived intangible assets are used in conjunction with other assets, such as property, plant and equipment and operating lease right-of-use assets. In these situations, the company considers
26

THERMO FISHER SCIENTIFIC INC.
the asset groups to be the units of account for impairment testing. The company recorded impairments of $0.12 billion in 2021 (see Note 16).
Income Taxes
Unrecognized Tax Benefits
In the ordinary course of business there is inherent uncertainty in quantifying the company’s income tax positions. The company assesses income tax positions and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the company has recorded the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Should tax return positions that the company expects are sustainable not be sustained upon audit, the company could be required to record an incremental tax provision for such taxes. The company’s liability for these unrecognized tax benefits totaled $0.57 billion at December 31, 2022, compared to $1.12 billion at December 31, 2021, primarily as a result of an audit settlement (see Note 8).
The company operates in numerous countries under many legal forms and, as a result, is subject to the jurisdiction of numerous domestic and non-U.S. tax authorities, as well as to tax agreements and treaties among these governments. Determination of taxable income in any jurisdiction requires the company to interpret the related tax laws and regulations and the use of estimates and assumptions regarding significant future events, such as the amount, timing and character of deductions, permissible revenue recognition methods under the tax law and the sources and character of income and tax credits. Changes in tax laws, regulations, agreements and treaties, currency exchange restrictions or the company’s level of operations or profitability in each taxing jurisdiction could have an impact upon the amount of current and deferred tax balances and hence the company’s net income.
Valuation Allowances
The company estimates the degree to which tax assets will result in a benefit, after consideration of all positive and negative evidence, and provides a valuation allowance for tax assets that it believes will more likely than not go unused. In situations in which the company has been able to determine that its deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. If it becomes more likely than not that a tax asset will be used, the company reverses the related valuation allowance. Any such reversals are recorded as a reduction of the company’s tax provision. The company’s tax valuation allowance totaled $1.32 billion at December 31, 2022, compared to $0.97 billion at December 31, 2021, primarily driven by the assessment of additional tax assets resulting from an audit settlement during the year (see Note 8). Should the company’s actual future taxable income by tax jurisdiction vary from estimates, additional allowances or reversals thereof may be necessary.
Recent Accounting Pronouncements
A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.
Item 7A.    Quantitative and Qualitative Disclosures About Market Risk
The company is exposed to market risk from changes in interest rates and currency exchange rates, which could affect its future results of operations and financial condition. The company manages its exposure to these risks through its regular operating and financing activities. The company has periodically hedged interest rate risks of fixed-rate instruments with offsetting interest rate swaps. Additionally, the company uses short-term forward and option contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates. Such exposures result from purchases, sales, cash and intercompany loans that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Singapore dollars, Japanese yen, Hong Kong dollars, Czech koruna and Swedish krona. Income and losses arising from these derivative contracts are recognized as offsets to losses and income resulting from the underlying exposure being hedged. The company does not enter into speculative derivative agreements.
Interest Rates
The company is exposed to changes in interest rates while conducting normal business operations as a result of ongoing investing and financing activities, which affect the company’s debt as well as cash and cash equivalents. As of December 31, 2022, the company’s debt portfolio was comprised primarily of fixed rate borrowings. The fair market value of the company’s fixed interest rate debt is subject to interest rate risk. Generally, the fair market value of fixed interest rate debt will increase as
27

THERMO FISHER SCIENTIFIC INC.
interest rates fall and decrease as interest rates rise. The total estimated fair value of the company’s debt at December 31, 2022 was $30.29 billion (Note 14). Fair values were determined from available market prices using current interest rates and terms to maturity. If interest rates were to decrease by 100 basis points, the fair value of the company’s debt at December 31, 2022 would increase by approximately $2.00 billion. If interest rates were to increase by 100 basis points, the fair value of the company’s debt at December 31, 2022 would decrease by approximately $1.75 billion.
In addition, interest rate changes would result in a change in the company’s interest expense due to variable-rate debt instruments including swap arrangements. In 2022, a 100 basis point increase in interest rates on the swap arrangements and variable-rate debt would have increased the company’s annual pre-tax interest expense by approximately $35 million.
Currency Exchange Rates
The company views its investment in international subsidiaries with a functional currency other than the U.S. dollar as permanent. The company’s investment in international subsidiaries is sensitive to fluctuations in currency exchange rates. The functional currencies of the company’s international subsidiaries are principally denominated in euro, British pounds sterling, Swedish krona, Canadian dollars, Norwegian kroner and Danish kroner. The effect of a change in the period ending currency exchange rates on the company’s net investment in international subsidiaries is reflected in the “accumulated other comprehensive items” component of shareholders’ equity. The company also uses foreign currency-denominated debt to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A 10% depreciation in year-end 2022 functional currencies, relative to the U.S. dollar, would result in a reduction of shareholders’ equity of approximately $1.45 billion.
The fair value of forward currency-exchange contracts is sensitive to changes in currency exchange rates. The fair value of forward currency-exchange contracts is the estimated amount that the company would pay or receive upon termination of the contract, taking into account the change in currency exchange rates. A 10% depreciation in year-end 2022 non-functional currency exchange rates related to the company’s contracts would result in an additional unrealized loss on forward currency-exchange contracts of $9 million. A 10% appreciation in year-end 2022 non-functional currency exchange rates related to the company’s contracts would result in an unrealized gain on forward currency-exchange contracts of $9 million. The unrealized gains or losses on forward currency-exchange contracts resulting from changes in currency exchange rates are expected to approximately offset losses or gains on the exposures being hedged.
Certain of the company’s cash and cash equivalents are denominated in currencies other than the functional currency of the depositor and are sensitive to changes in currency exchange rates. A 10% depreciation in the related year-end 2022 non-functional currency exchange rates applied to such cash balances would result in a negative impact of $21 million on the company’s net income.
Item 8.    Financial Statements and Supplementary Data
This data is submitted as a separate section to this report. See Item 15 “Exhibits and Financial Statement Schedules.”
Item 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
Item 9A.    Controls and Procedures
Management’s Evaluation of Disclosure Controls and Procedures
The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, the company’s chief executive officer and chief financial officer concluded that, as of the end of such period, the company’s disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended December 31, 2022, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial reporting.
28

THERMO FISHER SCIENTIFIC INC.
Management’s Annual Report on Internal Control Over Financial Reporting
The company’s management, including the company’s chief executive officer and chief financial officer, is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The company’s management conducted an assessment of the effectiveness of the company’s internal control over financial reporting as of December 31, 2022 based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, the company’s management concluded that, as of December 31, 2022, the company’s internal control over financial reporting was effective.
The company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the company’s internal control over financial reporting as of December 31, 2022, as stated in their report that appears on page F-2 of this Annual Report on Form 10-K.
Item 9B.    Other Information
On February 22, 2023, the Board of Directors of the company amended and restated the company’s By-Laws, effective immediately, to conform the By-laws to the Securities and Exchange Commission’s universal proxy rules contained in Rule 14a-19 under the Securities Exchange Act of 1934, and certain 2022 amendments to the General Corporation Law of the State of Delaware (the DGCL). The amendments to the By-laws include additions to Article I, Section 9 to implement the requirements of Rule 14a-19 regarding the nomination and solicitation of proxies for director candidates. The amendments to the By-laws also include revisions to Article I, Sections 4 and 8 to conform with the 2022 DGCL amendments. The foregoing description of the amendments to the By-laws does not purport to be complete and is qualified in its entirety by reference to the full text of the By-laws, as amended and restated, a copy of which is attached as Exhibit 3.4 and incorporated by reference herein.
On February 22, 2023, the company entered into a consulting agreement with Mark P. Stevenson, former Executive Vice President and Chief Operating Officer of the company, relating to services that Mr. Stevenson will provide to the company. Under the consulting agreement, which has a term ending March 1, 2024, Mr. Stevenson will serve on the company’s Scientific Advisory Board and will also provide ongoing advice and services as requested by the company. During the term of the consulting agreement, Mr. Stevenson will receive compensation of $8,000 per month. The agreement also contains provisions that restrict Mr. Stevenson’s ability during the term of the consulting agreement (i) to work for or provide consulting services to, any competitor of the company, and (ii) to solicit for hire employees or consultants of the company or to solicit customers or clients of the company.
Item 9C.     Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
PART III
Item 10.    Directors, Executive Officers and Corporate Governance
The information with respect to directors required by this Item will be contained in our definitive proxy statement to be filed with the SEC not later than 120 days after the close of business of the fiscal year (2023 Definitive Proxy Statement) including under “Corporate governance,” and is incorporated in this report by reference.
The information with respect to executive officers required by this Item is included in Item 1 of Part I of this report.
The other information required by this Item will be contained in our 2023 Definitive Proxy Statement including under “Corporate governance,” and is incorporated in this report by reference.
Item 11.    Executive Compensation
The information required by this Item will be contained in our 2023 Definitive Proxy Statement including under “Corporate governance,” and “Executive compensation,” and is incorporated in this report by reference.
Item 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item will be contained in our 2023 Definitive Proxy Statement including under “Information about stock ownership,” and is incorporated in this report by reference.
29

THERMO FISHER SCIENTIFIC INC.
Item 13.    Certain Relationships and Related Transactions, and Director Independence
The information required by this Item will be contained in our 2023 Definitive Proxy Statement including under “Corporate governance,” and is incorporated in this report by reference.
Item 14.    Principal Accountant Fees and Services
The information required by this Item will be contained in our 2023 Definitive Proxy Statement including under “Audit matters,” and is incorporated in this report by reference.
PART IV
Item 15.    Exhibits and Financial Statement Schedules
(a) The following documents are filed as part of this report:
(1) Consolidated Financial Statements (see Index on page F-1 of this report)
(2) All schedules are omitted because they are not applicable or not required, or because the required information is included either in the consolidated financial statements or in the notes thereto.
(b) Exhibits
See the Exhibit Index on page 31.
Item 16.    Form 10-K Summary
None.
30

THERMO FISHER SCIENTIFIC INC.
EXHIBIT INDEX

Exhibit NumberDescription of Exhibit
2.1
Agreement and Plan of Merger, dated as of April 15, 2021, by and among Thermo Fisher Scientific Inc., Powder Acquisition Corp. and PPD, Inc. (filed as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed April 16, 2021 [File No. 1-8002] and incorporated in this document by reference).
3.1
Amended and Restated Certificate of Incorporation of the Registrant (filed as Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2005 [File No. 1-8002] and incorporated in this document by reference).
3.2
Amendment to Thermo Fisher Scientific Inc.’s Third Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed November 14, 2006 [File No. 1-8002] and incorporated in this document by reference).
3.3
Certificate of Elimination of the Series B Junior Participating Preferred Stock of the Company, dated November 13, 2015 (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed November 16, 2015 [File No. 1-8002] and incorporated in this document by reference).
3.4
The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with respect to long-term debt of the Registrant or its consolidated subsidiaries.
4.1
Indenture dated as of November 20, 2009 between the Company and The Bank of New York Mellon Trust Company, N.A. (filed as Exhibit 99.1 to the Registrant’s Current Report on Form 8-K filed November 20, 2009 [File No. 1-8002] and incorporated in this document by reference).
4.2
Sixth Supplemental Indenture, dated as of December 11, 2013, between the Company and The Bank of New York Mellon Trust Company, N.A. (filed as Exhibit 99.2 to the Registrant’s Current Report on Form 8-K filed December 11, 2013 [File No. 1-8002] and incorporated in this document by reference).
4.3
Eighth Supplemental Indenture, dated as of November 24, 2014, among the Company, The Bank of New York Mellon Trust Company, N.A., as trustee, and The Bank of New York Mellon, London Branch, as paying agent (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 24, 2014 [File No. 1-8002] and incorporated in this document by reference).
4.4
Thirteenth Supplemental Indenture, dated as of September 12, 2016, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed September 12, 2016 [File No. 1-8002] and incorporated in this document by reference).
4.5
Fifteenth Supplemental Indenture, dated as of March 16, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed March 16, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.6
Sixteenth Supplemental Indenture, dated as of July 24, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed July 24, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.7
Seventeenth Supplemental Indenture, dated as of August 14, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed August 14, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.8
Eighteenth Supplemental Indenture, dated as of September 30, 2019, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed September 30, 2019 [File No. 1-8002] and incorporated in this document by reference).
4.9
Nineteenth Supplemental Indenture, dated as of October 8, 2019, between the Company, and the Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 8, 2019 [File No. 1-8002] and incorporated in this document by reference).
4.10
Twenty-First Supplemental Indenture, dated as of April 2, 2020, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed April 2, 2020 [File No. 1-8002] and incorporated in this document by reference).
4.11
Twenty-Second Supplemental Indenture, dated as of August 23, 2021, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed August 23, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.12
Twenty-Third Supplemental Indenture, dated as of October 22, 2021, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 22, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.13
Twenty-Fourth Supplemental Indenture, dated as of October 20, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 20, 2022 [File No. 1-8002] and incorporated in this document by reference).
4.14
Twenty-Fifth Supplemental Indenture, dated as of November 21, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 21, 2022 [File No. 1-8002] and incorporated in this document by reference).
4.15
Twenty-Sixth Supplemental Indenture, dated as of November 21, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.3 to the Registrant’s Current Report on Form 8-K filed November 21, 2022 [File No. 1-8002] and incorporated in this document by reference).
31

THERMO FISHER SCIENTIFIC INC.
EXHIBIT INDEX

Exhibit NumberDescription of Exhibit
4.16
Indenture, dated as of August 9, 2016, among Thermo Fisher International, as issuer, the Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed August 9, 2016 [File No. 1-8002] and incorporated in this document by reference).
4.17
Third Supplemental Indenture, dated as of October 18, 2021, among Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), as issuer, the Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 18, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.18
4.19
10.1
Thermo Fisher Scientific Inc. Deferred Compensation Plan for Directors of the Registrant, as amended and restated effective November 10, 2006 (filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 29, 2007 [File No. 1‑8002] and incorporated in this document by reference).*
10.2
Thermo Electron Corporation Deferred Compensation Plan, effective November 1, 2001 (filed as Exhibit 10.13 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 29, 2001 [File No. 1-8002] and incorporated in this document by reference).*
10.3
Form of Amended and Restated Indemnification Agreement between the Registrant and its directors and officers (filed as Exhibit 10.2 to the Registrant’s Registration Statement on Form S-4 [Reg. No. 333-90661] and incorporated in this document by reference).*
10.4
Summary of Thermo Fisher Scientific Inc. Annual Non-Management Director Compensation (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed February 24, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.5
Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers, effective as of January 1, 2009 (filed as Exhibit 10.25 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.6Retirement Plan for Non-Employee Directors of Fisher Scientific International Inc. (filed as Exhibit 10.12 to Fisher Scientific International Inc.’s Annual Report on Form 10-K for the year ended December 31, 1992 [File No. 1-10920] and incorporated in this document by reference).*
10.7
First Amendment to the Fisher Scientific International Inc. Retirement Plan for Non-Employee Directors (filed as Exhibit 10.04 to Fisher Scientific International Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 [File No. 1-10920] and incorporated in this document by reference).*
10.8
Amendment to Retirement Plan for Non-Employee Directors of Fisher Scientific International Inc. (filed as Exhibit 10.02 to Fisher Scientific International Inc.’s Current Report on Form 8-K filed March 7, 2006 [File No. 1-10920] and incorporated in this document by reference).*
10.9
Thermo Fisher Scientific Inc. Amended and Restated 2005 Deferred Compensation Plan, effective January 1, 2020 (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 27, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.10
2009 Restatement of Executive Severance Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009 (filed as Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.11
Executive Change In Control Retention Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009 (filed as Exhibit 10.6 to the Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.12
Noncompetition Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009 (filed as Exhibit 10.7 to the Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.13
Amendment No. 1 to 2009 Restatement of Executive Severance Agreement, dated February 25, 2010, between the Registrant and Marc N. Casper (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed February 25, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.14
Amendment No. 2 to 2009 Restatement of Executive Severance Agreement, dated November 30, 2010, between the Registrant and Marc N. Casper (filed as Exhibit 10.55 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.15
Amendment No. 1 to Executive Change In Control Retention Agreement, dated November 30, 2010, between Marc N. Casper and the Registrant (filed as Exhibit 10.56 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.16
Amendment No. 2 to Executive Change in Control Retention Agreement, dated March 16, 2018, between Marc N. Casper and the Registrant (filed as Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 [File No. 1-8002] and incorporated in this document by reference).*
32

THERMO FISHER SCIENTIFIC INC.
EXHIBIT INDEX

Exhibit NumberDescription of Exhibit
10.17
Form of Executive Change in Control Retention Agreement for Officers (other than Marc N. Casper) (filed as Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 [File No. 1-8002] and incorporated in this document by reference).*
10.18
Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement for Directors (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended April 2, 2011 [File No. 1-8002] and incorporated in this document by reference).*
10.19
Form of Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective February 26, 2013 (filed as Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed February 27, 2013 [File No. 1-8002] and incorporated in this document by reference).*
10.20
Thermo Fisher Scientific Inc. 2013 Stock Incentive Plan (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed May 23, 2013 [File No. 1-8002] and incorporated in this document by reference).*
10.21
Supplemental Executive Retirement Plan effective as of December 31, 2005, as amended and restated as of August 28, 2006 (filed as Exhibit 10.3 to Applera Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2006 [File No. 1-04389] and incorporated in this document by reference).*
10.22
Amendment to Supplemental Executive Retirement Plan, effective as of January 1, 2010 (filed as Exhibit 10.1 to Life Technologies Corporation’s Current Report on Form 8-K filed December 18, 2009 [File No. 000-25317] and incorporated in this document by reference).*
10.23
Noncompetition Agreement between the Registrant and Mark P. Stevenson, dated September 10, 2015 (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 26, 2015 [File No. 1-8002] and incorporated in this document by reference).*
10.24
Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement for Officers (filed as Exhibit 10.44 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2016 [File No. 1-8002] and incorporated in this document by reference).*
10.25
Patheon N.V. 2016 Omnibus Incentive Plan (filed as Exhibit 10.2 to the Current Report on Form 8-K filed by Patheon N.V. on July 26, 2016 [File No. 001-37837] and incorporated in this document by reference).*
10.26
Amendment to Patheon N.V. 2016 Omnibus Incentive Plan, dated March 7, 2017 (filed as Exhibit 4.5 to the Registrant's Registration Statement on Form S-8 filed August 29, 2017 [File No. 1-8002] and incorporated in this document by reference).*
10.27
Amendment to Patheon N.V. 2016 Omnibus Incentive Plan, dated August 23, 2017 (filed as Exhibit 4.6 to the Registrant's Registration Statement on Form S-8 filed August 29, 2017 [File No. 1-8002] and incorporated in this document by reference).*
10.28
10.29
Letter Agreement between the Registrant and Michel Lagarde dated August 28, 2017 (filed as Exhibit 10.39 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.30
Option Agreement Under the Patheon N.V. 2016 Omnibus Incentive Plan between Patheon N.V. and Michel Lagarde dated July 20, 2016 (filed as Exhibit 10.40 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.31
Option Agreement Under the Patheon N.V. 2016 Omnibus Incentive Plan between Patheon N.V. and Michel Lagarde dated March 23, 2017 (filed as Exhibit 10.42 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.32
Thermo Fisher Scientific Inc. Executive Severance Policy (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 29, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.33
Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers (filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 29, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.34
Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement effective as of February 25, 2020 (filed as Exhibit 10.45 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.35
Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement effective as of February 25, 2020 (filed as Exhibit 10.46 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.36
Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement for Officers effective as of February 25, 2020 (filed as Exhibit 10.47 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
33

THERMO FISHER SCIENTIFIC INC.
EXHIBIT INDEX

Exhibit NumberDescription of Exhibit
10.37
Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020 (filed as Exhibit 10.48 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.38
Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020 (filed as Exhibit 10.49 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.39
Form of Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020 (filed as Exhibit 10.50 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.40
Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.47 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.41
Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.48 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.42
Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement (filed as Exhibit 10.49 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.43
PPD, Inc. 2020 Omnibus Incentive Plan (filed as Exhibit 10.38 to PPD Inc.’s Form S-1/A filed January 27, 2020 [File No. 333-235860] and incorporated in this document by reference).*
10.44
Consulting Agreement between the Registrant and Mark P. Stevenson, dated February 24, 2022 (filed as Exhibit 10.49 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2021 [File No. 1-8002] and incorporated in this document by reference).*
10.45
10.46
10.47
21
22
23.1
31.1
31.2
32.1
32.2
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema Document.
101.CALXBRL Taxonomy Calculation Linkbase Document.
101.DEFXBRL Taxonomy Definition Linkbase Document.
101.LABXBRL Taxonomy Label Linkbase Document.
101.PREXBRL Taxonomy Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
_______________________
*Indicates management contract or compensatory plan, contract or arrangement.
** Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.
34

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date:February 23, 2023THERMO FISHER SCIENTIFIC INC.
By:/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated, as of February 23, 2023.
By:
/s/ Marc N. Casper
By:
/s/ R. Alexandra Keith
Marc N. Casper
R. Alexandra Keith
Chairman, President and Chief Executive OfficerDirector
(Principal Executive Officer)
By:
/s/ Stephen Williamson
By:
/s/ Jim P. Manzi
Stephen WilliamsonJim P. Manzi
Senior Vice President and Chief Financial OfficerDirector
(Principal Financial Officer)
By:
/s/ Joseph R. Holmes
By:
/s/ James C. Mullen
Joseph R. HolmesJames C. Mullen
Vice President and Chief Accounting OfficerDirector
(Principal Accounting Officer)
By:
/s/ Nelson J. Chai
By:
/s/ Lars R. Sørensen
Nelson J. Chai
Lars R. Sørensen
DirectorDirector
By:
/s/ Ruby R. Chandy
By:
/s/ Debora L. Spar
Ruby R. Chandy
Debora L. Spar
DirectorDirector
By:
/s/ C. Martin Harris
By:
/s/ Scott M. Sperling
C. Martin HarrisScott M. Sperling
DirectorDirector
By:
/s/ Tyler E. JacksBy:/s/ Dion J. Weisler
Tyler E. JacksDion J. Weisler
DirectorDirector

35

THERMO FISHER SCIENTIFIC INC.
INDEX OF CONSOLIDATED FINANCIAL STATEMENTS
 
The following Consolidated Financial Statements of the Registrant and its subsidiaries are required to be included in Item 15:
 Page
  
Report of Independent Registered Public Accounting Firm (PCAOB ID 238)
Consolidated Balance Sheet as of December 31, 2022 and 2021
Consolidated Statement of Income for the years ended December 31, 2022, 2021 and 2020
Consolidated Statement of Comprehensive Income for the years ended December 31, 2022, 2021 and 2020
Consolidated Statement of Cash Flows for the years ended December 31, 2022, 2021 and 2020
Consolidated Statement of Redeemable Noncontrolling Interest and Equity for the years ended December 31, 2022, 2021 and 2020
Notes to Consolidated Financial Statements

F-1

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of Thermo Fisher Scientific Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheet of Thermo Fisher Scientific Inc. and its subsidiaries (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of income, of comprehensive income, of redeemable noncontrolling interest and equity and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Annual Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely
F-2

detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Income taxes
As described in Note 8 to the consolidated financial statements, the Company’s provision for income taxes for the year ended December 31, 2022 was $703 million. The Company has deferred tax liabilities, net, of $1,984 million (including a valuation allowance of $1,322 million) and unrecognized tax benefits of $572 million as of December 31, 2022. As disclosed by management, the Company operates in numerous countries under many legal forms and, as a result, is subject to the jurisdiction of numerous domestic and non-U.S. tax authorities, as well as to tax agreements and treaties among these governments. Determination of taxable income in any jurisdiction requires management to interpret the related tax laws and regulations and to use estimates and assumptions regarding significant future events, such as the amount, timing and character of deductions, permissible revenue recognition methods under the tax law and the sources and character of income and tax credits. Management assesses income tax positions and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, management has recorded the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Management estimates the degree to which tax assets will result in a benefit, after consideration of all positive and negative evidence, and provides a valuation allowance for tax assets that it believes will more likely than not go unused. In situations in which management has been able to determine that the Company’s deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. If it becomes more likely than not that a tax asset will be used, management reverses the related valuation allowance.
The principal considerations for our determination that performing procedures relating to income taxes is a critical audit matter are (i) the significant judgment by management when interpreting the numerous and complex tax laws and regulations as it relates to determining the provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits, (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to the provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits, and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits. These procedures also included, among others (i) testing the accuracy of the provision for income taxes, including the rate reconciliation and permanent and temporary differences, (ii) evaluating whether the data utilized in the calculations of the provision for income taxes, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits were appropriate and consistent with evidence obtained in other areas of the audit, (iii) evaluating management’s assessment of the realizability of deferred tax assets on a jurisdictional basis, (iv)
F-3

evaluating the identification of liabilities for unrecognized tax benefits and the reasonableness of the more likely than not determination in consideration of court decisions, legislative actions, statutes of limitations, and developments in tax examinations by jurisdiction, (v) testing the calculation of the liability for unrecognized tax benefits by jurisdiction, including estimates of the amount of income tax benefit expected to be sustained, and (vi) evaluating the adequacy of the Company’s disclosures. Professionals with specialized skill and knowledge were used to assist in evaluating the reasonableness of management’s judgments and estimates related to the application of foreign and domestic tax laws and regulations.


/s/PricewaterhouseCoopers LLP
Boston, Massachusetts
February 23, 2023

We have served as the Company’s auditor since 2002.
F-4

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED BALANCE SHEET
 December 31,December 31,
(In millions except share and per share amounts)20222021
Assets
Current assets:
Cash and cash equivalents$8,524 $4,477 
Accounts receivable, less allowances of $189 and $150
8,115 7,977 
Inventories5,634 5,051 
Contract assets, net1,312 968 
Other current assets1,644 1,640 
Total current assets
25,229 20,113 
Property, plant and equipment, net9,280 8,333 
Acquisition-related intangible assets, net17,442 20,113 
Other assets4,007 4,640 
Goodwill41,196 41,924 
Total assets
$97,154 $95,123 
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations$5,579 $2,537 
Accounts payable3,381 2,867 
Accrued payroll and employee benefits2,095 2,427 
Contract liabilities2,601 2,655 
Other accrued expenses3,354 2,950 
Total current liabilities
17,010 13,436 
Deferred income taxes2,849 3,837 
Other long-term liabilities4,238 4,540 
Long-term obligations28,909 32,333 
Commitments and contingencies (Note 12)
Redeemable noncontrolling interest116 122 
Equity:
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 440,668,112 and 439,154,741 shares issued
441 439 
Capital in excess of par value16,743 16,174 
Retained earnings41,910 35,431 
Treasury stock at cost, 50,157,275 and 44,720,112 shares
(12,017)(8,922)
Accumulated other comprehensive items(3,099)(2,329)
Total Thermo Fisher Scientific Inc. shareholders’ equity43,978 40,793 
Noncontrolling interests54 62 
Total equity
44,032 40,855 
Total liabilities, redeemable noncontrolling interest and equity
$97,154 $95,123 

The accompanying notes are an integral part of these consolidated financial statements.
F-5

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENT OF INCOME
 Year Ended
 December 31,December 31,December 31,
(In millions except per share amounts)202220212020
Revenues
Product revenues
$28,548 $30,361 $25,306 
Service revenues
16,367 8,850 6,912 
Total revenues
44,915 39,211 32,218 
Costs and operating expenses:
Cost of product revenues
14,247 13,594 11,407 
Cost of service revenues
11,697 5,979 4,807 
Selling, general and administrative expenses
8,993 8,007 6,930 
Research and development expenses
1,471 1,406 1,181 
Restructuring and other costs
114 197 99 
Total costs and operating expenses
36,522 29,183 24,424 
Operating income8,393 10,028 7,794 
Interest income272 43 65 
Interest expense(726)(536)(553)
Other income/(expense)
(104)(694)(76)
Income before income taxes
7,835 8,841 7,230 
Provision for income taxes
(703)(1,109)(850)
Equity in earnings/(losses) of unconsolidated entities(172)(4)(3)
Net income6,960 7,728 6,377 
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest10 3 2 
Net income attributable to Thermo Fisher Scientific Inc.$6,950 $7,725 $6,375 
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic
$17.75 $19.62 $16.09 
Diluted
$17.63 $19.46 $15.96 
Weighted average shares
Basic
392 394 396 
Diluted
394 397 399 

The accompanying notes are an integral part of these consolidated financial statements.

F-6

THERMO FISHER SCIENTIFIC INC.
 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
 Year Ended
 December 31,December 31,December 31,
(In millions)202220212020
Comprehensive income
Net income
$6,960 $7,728 $6,377 
Other comprehensive items:
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $173, $231 and $(221))
(822)373 (118)
Unrealized gains and losses on hedging instruments:
Unrealized losses on hedging instruments (net of tax benefit of $0, $0 and $20)
— — (65)
Reclassification adjustment for losses included in net income (net of tax benefit of $1, $17 and $14)
2 56 45 
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $9, $11 and $(1))
38 36 (8)
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $3, $6 and $4)
5 13 18 
Total other comprehensive items
(777)478 (128)
Comprehensive income
6,183 8,206 6,249 
Less: comprehensive income attributable to noncontrolling interests and redeemable noncontrolling interest
3 2 2 
Comprehensive income attributable to Thermo Fisher Scientific Inc.
$6,180 $8,204 $6,247 

The accompanying notes are an integral part of these consolidated financial statements.

F-7

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
Year Ended
December 31,December 31,December 31,
(In millions)202220212020
Operating activities
Net income
$6,960 $7,728 $6,377 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment
986 831 658 
Amortization of acquisition-related intangible assets
2,395 1,761 1,667 
Change in deferred income taxes
(995)(647)(552)
Stock-based compensation
307 230 196 
Loss on early extinguishment of debt26 767 — 
Other non-cash expenses
524 190 338 
Changes in assets and liabilities, excluding the effects of acquisitions and disposition:
Accounts receivable
(430)(204)(1,302)
Inventories
(825)(1,065)(508)
Accounts payable
648 479 59 
Contributions to retirement plans
(41)(34)(96)
Other(401)(724)1,452 
Net cash provided by operating activities
9,154 9,312 8,289 
Investing activities
   
Acquisitions, net of cash acquired
(39)(19,395)(38)
Purchase of property, plant and equipment
(2,243)(2,523)(1,474)
Proceeds from sale of property, plant and equipment
24 20 8 
Other investing activities, net
99 (34)(6)
Net cash used in investing activities
(2,159)(21,932)(1,510)
Financing activities
Net proceeds from issuance of debt
3,193 18,137 3,464 
Repayment of debt
(375)(11,738)(710)
Proceeds from issuance of commercial paper
1,526 2,512 383 
Repayments of commercial paper
(3,690)— (387)
Purchases of company common stock
(3,000)(2,000)(1,500)
Dividends paid
(455)(395)(337)
Other financing activities, net
(9)65 46 
Net cash (used in) provided by financing activities
(2,810)6,581 959 
Exchange rate effect on cash
(139)194 176 
Increase (decrease) in cash, cash equivalents and restricted cash
4,046 (5,845)7,914 
Cash, cash equivalents and restricted cash at beginning of year
4,491 10,336 2,422 
Cash, cash equivalents and restricted cash at end of year
$8,537 $4,491 $10,336 
The accompanying notes are an integral part of these consolidated financial statements.
F-8

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENT OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY
 Redeemable Noncontrolling InterestCommon StockCapital in Excess of Par ValueRetained EarningsTreasury StockAccumulated Other Comprehensive ItemsTotal
Thermo Fisher Scientific Inc. Shareholders’ Equity		Noncontrolling InterestsTotal Equity
(In millions)SharesAmountSharesAmount
Balance at December 31, 2019$— 434 $434 $15,064 $22,092 36 $(5,236)$(2,679)$29,675 $9 $29,684 
Cumulative effect of accounting changes
— — — — (1)— — — (1)— (1)
Issuance of shares under employees' and directors' stock plans
— 3 3 319 — — (82)— 240 — 240 
Stock-based compensation
— — — 196 — — — — 196 — 196 
Purchases of company common stock
— — — — — 4 (1,500)— (1,500)— (1,500)
Dividends declared ($0.88 per share)
— — — — (350)— — — (350)— (350)
Net income
— — — — 6,375 — — — 6,375 2 6,377 
Other comprehensive items
— — — — — — — (128)(128)— (128)
Contributions from (distributions to) noncontrolling interests— — — — — — — — — (1)(1)
Balance at December 31, 2020— 437 437 15,579 28,116 40 (6,818)(2,807)34,507 10 34,517 
Issuance of shares under employees' and directors' stock plans
— 2 2 324 — 1 (104)— 222 — 222 
Stock-based compensation
— — — 230 — — — — 230 — 230 
Purchases of company common stock
— — — — — 4 (2,000)— (2,000)— (2,000)
Dividends declared ($1.04 per share)
— — — — (410)— — — (410)— (410)
Recognition upon acquisition122 — — — — — — — — — — 
Net income
1 — — — 7,725 — — — 7,725 2 7,727 
Other comprehensive items
(1)— — — — — — 478 478 — 478 
Contributions from (distributions to) noncontrolling interests— — — — — — — — — 50 50 
Other
— — — 41 — — — — 41 — 41 
Balance at December 31, 2021122 439 439 16,174 35,431 45 (8,922)(2,329)40,793 62 40,855 
Issuance of shares under employees' and directors' stock plans
— 2 2 262 — — (95)— 169 — 169 
Stock-based compensation
— — — 307 — — — — 307 — 307 
Purchases of company common stock
— — — — — 5 (3,000)— (3,000)— (3,000)
Dividends declared ($1.20 per share)
— — — — (471)— — — (471)— (471)
Net income
15 — — — 6,950 — — — 6,950 (5)6,945 
Other comprehensive items
(6)— — — — — — (770)(770)(1)(771)
Contributions from (distributions to) noncontrolling interests(15)— — — — — — — — (2)(2)
Balance at December 31, 2022$116 441 $441 $16,743 $41,910 50 $(12,017)$(3,099)$43,978 $54 $44,032 
The accompanying notes are an integral part of these consolidated financial statements.
F-9

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1.    Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.
Principles of Consolidation
The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At December 31, 2022 and 2021, the company had such investments with carrying amounts of $369 million and $576 million, respectively. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method. At December 31, 2022 and 2021, the fair value of such investments was $7 million and $217 million, respectively.
Redeemable Noncontrolling Interest
The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events.
Presentation
Certain reclassifications of prior year amounts have been made to conform to the current year presentation.
Revenue Recognition
Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year.
Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date.
Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.
F-10

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Contract-related Balances
Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.
Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional.
Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract.
Warranty Obligations
The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred.
Leases
Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations.
Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense.
Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.
As a lessee, the company accounts for the lease and non-lease components as a single lease component.
Research and Development
The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.
Restructuring Costs
Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment
F-11

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.
From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to generate revenues. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period.
Income Taxes
The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused.
The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.
Earnings per Share
Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units.
Cash and Cash Equivalents
Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value.
Inventories
Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income. The components of inventories are as follows:
December 31,December 31,
(In millions)20222021
Raw materials$2,405 $1,922 
Work in process660 676 
Finished goods2,569 2,453 
Inventories$5,634 $5,051 
Prior to the third quarter of 2021, certain of the company’s businesses utilized the LIFO method of accounting for inventories. During the third quarter of 2021, these businesses, which comprised approximately 5% of consolidated inventories, changed from the LIFO method to the FIFO method. The company believes this change is preferable as it will provide a consistent, uniform costing method for all inventories across the company, better reflect the current value of inventories, and improve comparability with peers. Prior financial statements have not been retrospectively adjusted due to immateriality. The cumulative pre-tax effect of this change in accounting principle of $33 million was recorded as an increase to inventories and a decrease to cost of product revenues in the third quarter of 2021. This change was recorded in the Laboratory Products and
F-12

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Biopharma Services ($20 million) and Specialty Diagnostics ($13 million) segments. Reductions to cost of revenues as a result of the liquidation of LIFO inventories were nominal during 2020 and the first half of 2021.
Property, Plant and Equipment
Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income. Property, plant and equipment consists of the following:
December 31,December 31,
(In millions)20222021
Land$454 $431 
Buildings and improvements3,153 2,575 
Machinery, equipment and leasehold improvements7,967 7,020 
Construction in progress2,695 2,567 
Property, plant and equipment, at cost14,269 12,593 
Less: Accumulated depreciation and amortization4,989 4,260 
Property, plant and equipment, net$9,280 $8,333 
Acquisition-related Intangible Assets
Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.
In addition, the company has tradenames and in-process research and development that have indefinite lives and which are not amortized. Intangible assets with indefinite lives are reviewed for impairment annually or whenever events or changes in circumstances indicate they may be impaired. The company may perform an optional qualitative assessment. If the company determines that the fair value of the indefinite-lived intangible asset is more likely than not greater than its carrying amount, no additional testing is necessary. If not, or if the company bypasses the optional qualitative assessment, it writes the carrying value down to the fair value, if applicable.
Acquisition-related intangible assets are as follows:
Balance at December 31, 2022Balance at December 31, 2021
(In millions)GrossAccumulated AmortizationNetGrossAccumulated AmortizationNet
Definite lived:
Customer relationships
$21,792 $(8,330)$13,462 $22,802 $(7,792)$15,010 
Product technology
5,882 (4,360)1,522 6,041 (3,977)2,064 
Tradenames
1,635 (1,008)627 1,722 (919)803 
Backlog
1,038 (442)596 1,060 (59)1,001 
30,347 (14,140)16,207 31,625 (12,747)18,878 
Indefinite lived:
Tradenames
1,235 N/A1,235 1,235 N/A1,235 
Acquisition-related intangible assets
$31,582 $(14,140)$17,442 $32,860 $(12,747)$20,113 
F-13

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2022 is as follows:
(In millions)
2023 $2,279 
2024 1,863 
2025 1,582 
2026 1,322 
2027 1,296 
2028 and thereafter7,865 
Estimated future amortization expense of definite-lived intangible assets$16,207 
Other Assets
Other assets in the accompanying balance sheet include operating lease right-of-use assets, investments, deferred tax assets, pension assets, cash surrender value of life insurance, insurance recovery receivables related to product liability matters, certain intangible assets and other assets.
At December 31, 2022 and 2021, the company had $36 million and $33 million, respectively, of intangible assets not derived from acquisitions, net of accumulated amortization, which are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years.
Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments. At December 31, 2022 and 2021, the company had such investments with carrying amounts of $55 million and $22 million, respectively, and investments measured at NAV of $22 million and $16 million, respectively, which are included in other assets.
Goodwill
The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2022, 2021 or 2020.
The changes in the carrying amount of goodwill by segment are as follows:
(In millions)Life Sciences
Solutions		Analytical
Instruments		Specialty
Diagnostics		Laboratory
Products and
Biopharma Services		Total
Balance at December 31, 2020
$8,590 $5,079 $3,370 $9,002 $26,041 
Acquisitions
1,560 56 8 14,400 16,024 
Currency translation
(7)(92)(101)59 (141)
Balance at December 31, 2021
10,143 5,043 3,277 23,461 41,924 
Acquisitions
— 24 — — 24 
Finalization of purchase price allocations for 2021 acquisitions
9 — — 168 177 
Currency translation
(6)(102)(186)(635)(929)
Balance at December 31, 2022
$10,146 $4,965 $3,091 $22,994 $41,196 
F-14

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Loss Contingencies
Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.
Currency Translation
All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period. Currency transaction gains are included in the accompanying statement of income and in aggregate were $62 million, $25 million and $24 million in 2022, 2021 and 2020, respectively.
Derivative Contracts
The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.
The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Singapore dollars, Japanese yen, Hong Kong dollars, Czech koruna and Swedish krona. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management.
Cash flow hedges. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item.
Fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings.
Net investment hedges. The company uses foreign currency-denominated debt, certain foreign-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
Government Assistance
From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement. Such amounts were not material to the consolidated financial statements as of and for the year ended December 31, 2022.
F-15

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic materially adversely affected certain of the company’s businesses in 2020, particularly in the Analytical Instruments segment and, to a lesser extent, some businesses within the other three segments. The negative impacts significantly lessened in 2021 and 2022. The extent and duration of negative impacts in the future, which may include inflationary pressures and supply chain disruptions, are uncertain and may require changes to estimates. Actual results could differ from those estimates.
Recent Accounting Pronouncements
In September 2022, the FASB issued new guidance to require entities to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under these programs for each period presented. The company will adopt some aspects of this guidance in 2023 using a retrospective method and other aspects in 2024 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures; however, the impact in future periods will be dependent on the extent of arrangements of this nature entered into by the company
In November 2021, the FASB issued new guidance to require entities to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. The company adopted this guidance in the fourth quarter of 2022 using a prospective method. The adoption of this guidance did not have a material impact on the company’s disclosures; however, the impact in future periods will be dependent on the extent of future transactions of this nature entered into by the company.
In October 2021, the FASB amended guidance to recognize and measure contract assets and contract liabilities acquired in a business combination. Generally, this new guidance will result in the company recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The company adopted this guidance in the fourth quarter of 2021 retrospectively to all business combinations completed in the first three quarters of 2021 and prospectively to all future business combinations. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements for acquisitions that closed in 2021 and 2022; however, the impact in future periods will be dependent on the contract assets and contract liabilities acquired in future business combinations.
In July 2021, the FASB amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. The company adopted the guidance in the third quarter of 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements.
In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company adopted this guidance in 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates.
In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. The company adopted the guidance in 2020 using a modified retrospective method. The adoption of this guidance reduced accounts receivable and retained earnings by $1 million on January 1, 2020.
Note 2.    Acquisitions
The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining
F-16

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.
Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.
2023
On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not expected to be tax deductible.
The components of the purchase price and net assets acquired are as follows:
(In billions)The Binding Site
Purchase price
Cash paid
$2.42 
Debt settled
0.31 
Cash acquired
(0.02)
$2.71 
Net assets acquired
Definite-lived intangible assets
$1.07 
Goodwill
1.77 
Net tangible assets
0.15 
Deferred tax assets (liabilities)
(0.28)
$2.71 
The weighted-average amortization period for definite-lived intangible assets is 17 years.
The preliminary allocation of the purchase price for the acquisition of The Binding Site is based on estimates of the fair value of the net assets acquired and is subject to adjustment upon finalization, largely with respect to acquired intangible assets and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions.
2022
In 2022, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Fourier-transform infrared gas analysis technologies.
2021
On January 15, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, the Belgium-based European viral vector manufacturing business of Groupe Novasep SAS. The European viral vector manufacturing business provides manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities for cell and gene vaccines and therapies. The goodwill recorded as a result of this business combination is not tax deductible.
On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company. Mesa Biotech has developed and commercialized a polymerase chain reaction (PCR) based rapid point-of-care testing platform available for detecting infectious diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care. The goodwill recorded as a result of this business combination is not tax deductible.
On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Biopharma Services segment, of a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers as well. The goodwill recorded as a result of this business combination is not tax deductible.
F-17

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
On December 8, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, PPD, Inc., a U.S.-based global provider of clinical research services to the pharma and biotech industry. The addition of PPD’s clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their productivity within the drug development process. The goodwill recorded as a result of this business combination is not tax deductible.
On December 30, 2021, the company acquired, within the Life Sciences Solutions segment, PeproTech, Inc., a U.S.-based developer and manufacturer of recombinant proteins. PeproTech provides bioscience reagents known as recombinant proteins, including cytokines and growth factors. The acquisition expands the segment’s bioscience offerings. The goodwill recorded as a result of this business combination is not tax deductible.
In addition, in 2021, the company acquired, within the Life Sciences Solutions segment, cell sorting technology assets, an Ireland-based life sciences distributor and a developer of a digital PCR platform; within the Analytical Instruments segment, a Belgium-based developer of micro-chip based technology for liquid chromatography columns; and within the Specialty Diagnostics segment, a transplant diagnostics information system provider.
The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:
(In millions)PPDPeproTechEuropean Viral Vector BusinessMesa BiotechLengnau biologics manufacturing facilityOther
Purchase price
Cash paid
$17,237 $1,946 $848 $421 $17 $298 
Fair value of equity awards exchanged
43 — — — — — 
Fair value of contingent consideration
— — — 65 1 117 
Cash acquired
(1,244)(83)(18)(14)— (12)
$16,036 $1,863 $830 $472 $18 $403 
Net assets acquired
Current assets
$2,477 $58 $39 $54 $— $12 
Property, plant and equipment
527 18 59 2 93 2 
Definite-lived intangible assets:
Customer relationships
6,257 510 302 — — 2 
Product technology
— 282 25 279 — 224 
Tradenames
594 — — 2 — 2 
Backlog1,038 — — — — — 
Goodwill
13,949 1,198 600 237 18 198 
Other assets
1,060 11 3 3 364 2 
Contract liabilities(1,539)— (59)— — (1)
Deferred tax assets (liabilities)
(1,782)(192)(80)(72)— (27)
Finance lease liabilities
(90)— (24)— (82)— 
Debt assumed
(4,299)— — — — — 
Other liabilities assumed
(2,034)(22)(35)(33)(375)(11)
Redeemable noncontrolling interest(122)— — — — — 
$16,036 $1,863 $830 $472 $18 $403 
During 2022, we finalized the allocations of the purchase price for the Lengnau biologics manufacturing facility, PPD, Inc. and PeproTech, Inc., largely with respect to definite-lived intangible assets, property, plant and equipment, contract liabilities,
F-18

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
equity method investments, asset retirement obligations, defined benefit pension plans, assumed contingent consideration and the related deferred taxes. The adjustments to the income statement recorded during 2022 were not material.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2021 are 17 years for customer relationships, 11 years for product technology, 7 years for tradenames and 3 years for backlog. The weighted average amortization period for all definite-lived intangible assets acquired in 2021 is 14 years.
Unaudited Pro Forma Information
The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020:
 Year Ended
 December 31,December 31,
(In millions)20212020
Revenues$44,886 $36,887 
Net income attributable to Thermo Fisher Scientific Inc.$7,369 $5,361 
The historical consolidated financial information of the company and PPD has been adjusted in the pro forma information to give effect to pro forma events that are directly attributable to the acquisitions and related financing arrangements and are factually supportable.
To reflect the acquisition of PPD as if it had occurred on January 1, 2020, the unaudited pro forma results include adjustments to reflect, among other things, the incremental intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset and the interest expense from debt financings obtained to partially fund the cash consideration transferred. Pro forma adjustments were tax effected at the company's historical statutory rates in effect for the respective periods. The unaudited pro forma amounts are not necessarily indicative of the combined results of operations that would have been realized had the acquisitions and related financings occurred on the aforementioned dates, nor are they meant to be indicative of any anticipated combined results of operations that the company will experience after the transaction. In addition, the amounts do not include any adjustments for actions that may be taken following the completion of the transaction, such as expected cost savings, operating synergies, or revenue enhancements that may be realized subsequent to the transaction.
Pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2021, excludes $312 million of transaction costs, initial restructuring costs, and debt extinguishment costs directly attributable to the PPD acquisition that were included in the determination of net income attributable to Thermo Fisher Scientific Inc. for that period. These items have reduced pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2020, by $197 million.
The company’s results would not have been materially different from its pro forma results had the company’s other 2021 acquisitions occurred at the beginning of 2020.
PPD’s revenues and losses attributable to Thermo Fisher Scientific Inc. in 2021, subsequent to the acquisition date, were $378 million and $(60) million, respectively. The loss includes non-recurring transaction and compensation costs.
2020
In 2020, the company acquired, within the Life Sciences Solutions segment, a U.S.-based provider of a spectral dye platform for high-resolution biology applications which will extend the company’s existing tools for protein and cell analysis applications.
F-19

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 3.    Revenues and Contract-related Balances
Disaggregated Revenues
Revenues by type are as follows:
(In millions)202220212020
Revenues
Consumables
$20,624 $22,608 $18,527 
Instruments
7,924 7,753 6,779 
Services
16,367 8,850 6,912 
Consolidated revenues
$44,915 $39,211 $32,218 
Revenues by geographic region based on customer location are as follows:
(In millions)202220212020
Revenues
North America
$24,594 $19,659 $17,081 
Europe
10,762 11,134 8,284 
Asia-Pacific
8,115 7,218 5,822 
Other regions
1,444 1,200 1,031 
Consolidated revenues
$44,915 $39,211 $32,218 
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data.
Remaining Performance Obligations
The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2022 was $26.97 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 55% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.
Contract-related Balances
Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows:
December 31,December 31,
(In millions)20222021
Current contract assets, net$1,312 $968 
Noncurrent contract assets, net7 9 
Current contract liabilities2,601 2,655 
Noncurrent contract liabilities1,179 1,238 
Substantially all of the current contract liabilities balance at December 31, 2021 and 2020 was recognized in revenues during 2022 and 2021, respectively.
Note 4.    Business Segment and Geographical Information
The company’s financial performance is reported in four segments. A description of each segment follows.
Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Analytical Instruments: provides a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. These products and services are used by customers in
F-20

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory.
Specialty Diagnostics: offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which improves patient care in a more cost-efficient manner.
Laboratory Products and Biopharma Services: offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more efficient, productive and cost-effective. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing.
The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation.
Business Segment Information
(In millions)202220212020
Revenues
Life Sciences Solutions
$13,532 $15,631 $12,168 
Analytical Instruments
6,624 6,069 5,124 
Specialty Diagnostics
4,763 5,659 5,343 
Laboratory Products and Biopharma Services
22,511 14,862 12,245 
Eliminations
(2,515)(3,010)(2,662)
Consolidated revenues
44,915 39,211 32,218 
Segment Income
Life Sciences Solutions
5,582 7,817 6,109 
Analytical Instruments
1,507 1,197 808 
Specialty Diagnostics
1,024 1,280 1,368 
Laboratory Products and Biopharma Services
2,872 1,844 1,271 
Subtotal reportable segments
10,985 12,138 9,556 
Cost of revenues adjustments
(46)(8)(6)
Selling, general and administrative expenses adjustments
(37)(144)10 
Restructuring and other costs
(114)(197)(99)
Amortization of acquisition-related intangible assets
(2,395)(1,761)(1,667)
Consolidated operating income
8,393 10,028 7,794 
Interest income272 43 65 
Interest expense(726)(536)(553)
Other income/(expense)
(104)(694)(76)
Consolidated income before taxes
$7,835 $8,841 $7,230 
Depreciation
Life Sciences Solutions
$214 $197 $140 
Analytical Instruments
83 83 76 
Specialty Diagnostics
75 128 100 
Laboratory Products and Biopharma Services
614 423 342 
Consolidated depreciation
$986 $831 $658 
F-21

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of significant transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges/credits related to product liability litigation.
(In millions)202220212020
Total assets
Life Sciences Solutions
$21,848 $22,751 $20,209 
Analytical Instruments
10,019 9,692 9,773 
Specialty Diagnostics
5,542 6,010 6,534 
Laboratory Products and Biopharma Services
51,281 52,639 22,711 
Corporate/other (a)
8,464 4,031 9,825 
Consolidated total assets
$97,154 $95,123 $69,052 
Capital expenditures
Life Sciences Solutions
$490 $810 $392 
Analytical Instruments
140 79 74 
Specialty Diagnostics
112 167 175 
Laboratory Products and Biopharma Services
1,403 1,327 772 
Corporate/other
98 140 61 
Consolidated capital expenditures
$2,243 $2,523 $1,474 
(a)Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
Geographical Information
(In millions)202220212020
Revenues (b)
United States
$23,820 $18,907 $16,435 
China
3,793 3,444 2,797 
Other
17,302 16,860 12,986 
Consolidated revenues
$44,915 $39,211 $32,218 
Long-lived Assets (c)
United States
$6,308 $5,578 $3,686 
Other
4,565 4,286 3,001 
Consolidated long-lived assets
$10,873 $9,864 $6,687 
(b)Revenues are attributed to countries based on customer location.
(c)Includes property, plant and equipment, net, and operating lease ROU assets.
Note 5.    Other Income/(Expense)
In all periods, other income/(expense) includes currency transaction gains and losses on non-operating monetary assets and liabilities and net periodic pension benefit cost/income, excluding the service cost component which is included in operating expenses on the accompanying statement of income. In 2022, other income/(expense) includes $161 million of net losses on investments, $67 million of net gains on derivative instruments to address certain foreign currency risks, $26 million of losses on the early extinguishment of debt (Note 10), and $2 million of net settlement gains on pension plans.
In 2021, other income/(expense) includes $767 million of losses on the early extinguishment of debt (Note 10), $36 million of financing costs associated with obtaining bridge financing commitments in connection with the agreement to acquire PPD (Note 2), offset in part by $66 million of net gains on investments. The company had a cash outlay of $36 million in 2021 associated with obtaining the bridge financing commitments, included in other financing activities, net, in the accompanying statement of cash flows.
F-22

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
In 2020, other income/(expense) includes $81 million of financing costs for a terminated acquisition, primarily for loan commitment fees and entering into hedging contracts and $42 million reclassified from accumulated other comprehensive items related to a hedge arrangement (Note 14), offset in part by $10 million of net gains on investments. The company had a cash outlay of $51 million in 2020 associated with obtaining the loan commitments included in other financing activities, net, in the accompanying statement of cash flows.
Note 6.    Stock-based Compensation Expense
The company has stock-based compensation plans for its key employees, directors and others. These plans permit the grant of a variety of stock and stock-based awards, including restricted stock units, stock options or performance-based shares, as determined by the compensation committee of the company’s Board of Directors or, for certain non-officer grants, by the company’s employee equity committee, which consists of its chief executive officer. The company generally issues new shares of its common stock to satisfy option exercises and restricted unit vesting. Grants of stock options and restricted units generally provide that in the event of both a change in control of the company and a qualifying termination of an option or unit holder’s employment, all options and service-based restricted unit awards held by the recipient become immediately vested (unless an employment or other agreement with the employee provides for different treatment).
Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses.
Stock Options
The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate was calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.
The weighted average assumptions used in the Black-Scholes option pricing model are as follows: 
202220212020
Expected stock price volatility
26 %26 %22 %
Risk free interest rate
2.0 %0.8 %1.1 %
Expected life of options (years)
4.74.34.3
Expected annual dividend
0.2 %0.2 %0.3 %
The weighted average per share grant-date fair values of options granted during 2022, 2021 and 2020 were $135.07, $123.97 and $61.19, respectively. The total intrinsic value of options exercised during the same periods was $336 million, $501 million and $457 million, respectively. The intrinsic value is the difference between the market value of the shares on the exercise date and the exercise price of the option.
F-23

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
A summary of the company’s option activity for the year ended December 31, 2022 is presented below:
Shares
(in millions)		Weighted average exercise priceWeighted average remaining contractual term
(in years)		Aggregate intrinsic
value
(in millions)
Outstanding at December 31, 2021
6.0 $319.95 
Granted
0.8 530.48 
Exercised
(0.9)199.85 
Canceled/expired
(0.3)503.76 
Outstanding at December 31, 2022
5.6 $359.27 4.2$1,125 
Vested and unvested expected to vest at December 31, 2022
5.3 $351.97 4.7$1,114 
Exercisable at December 31, 2022
2.9 $251.44 2.8$891 
As of December 31, 2022, there was $228 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be recognized through 2026 with a weighted average amortization period of 2.4 years.
Restricted Share/Unit Awards
Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.
A summary of the company’s restricted unit activity for the year ended December 31, 2022 is presented below:
 Units
(in millions)		Weighted
average
grant-date
fair value
Unvested at December 31, 2021
0.8 $425.39 
Granted
0.4 520.83 
Vested
(0.4)375.77 
Forfeited
(0.1)510.37 
Unvested at December 31, 2022
0.7 $495.39 
The total fair value of shares vested during 2022, 2021 and 2020 was $163 million, $151 million and $126 million, respectively.
As of December 31, 2022, there was $200 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is expected to be recognized through 2026 with a weighted average amortization period of 1.9 years.
Employee Stock Purchase Plans
Qualifying employees are eligible to participate in an employee stock purchase plan sponsored by the company. Shares may be purchased under the program at 95% of the fair market value at the end of the purchase period and the shares purchased are not subject to a holding period. Shares are purchased through payroll deductions of up to 10% of each participating employee’s qualifying gross wages. The company issued 0.2 million, 0.1 million and 0.2 million shares, respectively, of its common stock in 2022, 2021 and 2020 under the employee stock purchase plan.
F-24

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 7.    Pension and Other Postretirement Benefit Plans
401(k) Savings Plan and Other Defined Contribution Plans
The company’s 401(k) savings and other defined contribution plans cover the majority of the company’s eligible U.S. and certain non-U.S. employees. Contributions to the plans are made by both the employee and the company. Company contributions are based on the level of employee contributions. Company contributions to these plans are based on formulas determined by the company. In 2022, 2021 and 2020, the company charged to expense $402 million, $299 million and $254 million, respectively, related to its defined contribution plans.
Defined Benefit Pension Plans
Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented.
The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.
When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.
The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined. During 2022, 2021 and 2020, the company made cash contributions of approximately $41 million, $34 million and $96 million, respectively. Contributions to the plans included in the following table are estimated at between $30 and $50 million for 2023.
The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans:
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)2022202120222021
Accumulated benefit obligation
$995 $1,260 $1,016 $1,475 
Change in projected benefit obligations
Projected benefit obligation at beginning of year
$1,260 $1,302 $1,552 $1,486 
Acquisitions
— — 51 170 
Service costs
— — 34 27 
Interest costs
27 23 20 11 
Settlements
— — (31)(7)
Plan participants' contributions
— — 9 6 
Actuarial (gains) losses
(210)20 (447)(57)
Benefits paid
(82)(85)(19)(30)
Currency translation and other
— — (100)(54)
Projected benefit obligation at end of year
$995 $1,260 $1,069 $1,552 
F-25

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)2022202120222021
Change in fair value of plan assets
Fair value of plan assets at beginning of year
$1,226 $1,267 $1,302 $1,160 
Acquisitions— — 14 158 
Actual return on plan assets
(212)37 (347)14 
Employer contributions
5 7 36 27 
Settlements
— — (31)(7)
Plan participants' contributions
— — 9 6 
Benefits paid
(82)(85)(19)(30)
Currency translation and other
— — (96)(26)
Fair value of plan assets at end of year$937 $1,226 $868 $1,302 
Funded status
$(58)$(34)$(201)$(250)
Amounts recognized in balance sheet
Noncurrent assets
$— $32 $81 $205 
Current liability
(6)(7)(11)(10)
Noncurrent liabilities
(52)(59)(271)(445)
Net amount recognized
$(58)$(34)$(201)$(250)
Amounts recognized in accumulated other comprehensive items
Net actuarial loss
$200 $157 $74 $167 
Prior service credits
— — (4)(3)
Net amount recognized
$200 $157 $70 $164 
For domestic pension plans, actuarial gains experienced in 2022 were driven by increases in the weighted average discount rates used to determine the projected benefit obligation, as well as differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns. For non-U.S. pension plans, actuarial gains experienced in 2022 were principally driven by increases in the weighted average discount rates used to determine the projected benefit obligation.
For domestic pension plans, actuarial losses experienced in 2021 were driven by differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns, which were partially offset by actuarial gains due to increases in the weighted average discount rates used to determine the projected benefit obligation differences. For non-U.S. pension plans, actuarial gains experienced in 2021 were principally driven by increases in the weighted average discount rates used to determine the projected benefit obligation.
The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2022 and 2021 and are as follows:
 Domestic pension benefitsNon-U.S. pension benefits
 2022202120222021
Weighted average assumptions used to determine projected benefit obligations
Discount rate for determining benefit obligation
5.01 %2.70 %3.91 %1.45 %
Interest crediting rate for cash balance plans
4.96 %2.58 %2.19 %1.25 %
Average rate of increase in employee compensation
N/AN/A2.78 %2.73 %
F-26

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year, as presented in the following table:
 Domestic pension benefitsNon-U.S. pension benefits
 202220212020202220212020
Weighted average assumptions used to determine net benefit cost (income)
Discount rate - service cost
N/AN/AN/A1.00 %0.65 %1.21 %
Discount rate - interest cost
2.70 %2.33 %3.13 %1.36 %0.80 %1.44 %
Average rate of increase in employee compensation
N/AN/AN/A2.73 %2.30 %2.27 %
Expected long-term rate of return on assets
4.75 %4.25 %5.00 %2.33 %2.02 %2.33 %
The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.
The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows.
The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.
Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements.
The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases.
The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows:
 Pension plans
(In millions)20222021
Pension plans with projected benefit obligations in excess of plan assets
Projected benefit obligation
$1,636 $2,010 
Fair value of plan assets
1,296 1,521 
The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows:
 Pension plans
(In millions)20222021
Pension plans with accumulated benefit obligations in excess of plan assets
Accumulated benefit obligation
$1,583 $1,937 
Fair value of plan assets
1,294 1,521 
The measurement date used to determine benefit information is December 31 for all plan assets and benefit obligations.
F-27

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The net periodic pension benefit cost (income) includes the following components:
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)202220212020202220212020
Components of net benefit cost (income)
Service cost
$— $— $— $34 $27 $24 
Interest cost on benefit obligation
27 23 35 20 11 18 
Expected return on plan assets
(45)(40)(47)(26)(19)(19)
Amortization of actuarial net loss
4 7 6 7 12 10 
Amortization of prior service benefit
— — — (1)— (1)
Settlement/curtailment loss
— — — (2)— 8 
Net periodic benefit cost (income)
$(14)$(10)$(6)$32 $31 $40 
Expected benefit payments are estimated using the same assumptions used in determining the company’s benefit obligation at December 31, 2022. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows:
(In millions)Domestic pension benefitsNon-U.S. pension benefits
Expected benefit payments
2023 $85 $47 
2024 81 48 
2025 81 51 
2026 80 55 
2027 79 55 
2028-2032373 313 
Domestic Pension Plan Assets
The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.
Non-U.S. Pension Plan Assets
The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds, multi-asset funds, alternative investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% - 90% for fixed income funds, 0% - 35% for multi-asset funds, and 0% - 45% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.
F-28

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The fair values of the company’s plan assets at December 31, 2022 and 2021, by asset category are as follows:
 December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs		Not subject to leveling (a)
(In millions)2022(Level 1)(Level 2)(Level 3)
Domestic pension plan assets
U.S. equity funds
$89 $— $— $— $89 
International equity funds
91 — — — 91 
Fixed income funds
739 — — — 739 
Money market funds
18 — — — 18 
Total domestic pension plans
$937 $— $— $— $937 
Non-U.S. pension plan assets
Equity funds
$8 $— $— $— $8 
Fixed income funds
299 — — — 299 
Multi-asset funds
56 — — — 56 
Derivative funds
190 — — — 190 
Insurance contracts
306 — 306 — — 
Cash / money market funds
9 4 — — 5 
Total non-U.S. pension plans
$868 $4 $306 $— $558 
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
 December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs		Not subject to leveling (a)
(In millions)2021(Level 1)(Level 2)(Level 3)
Domestic pension plan assets
U.S. equity funds
$124 $— $— $— $124 
International equity funds
117 — — — 117 
Fixed income funds
966 — — — 966 
Money market funds
19 — — — 19 
Total domestic pension plans$1,226 $— $— $— $1,226 
Non-U.S. pension plan assets
Equity funds
$17 $— $— $— $17 
Fixed income funds
651 — — — 651 
Hedge funds
3 — — — 3 
Multi-asset funds
73 — — — 73 
Derivative funds
253 — — — 253 
Alternative investments
1 — — — 1 
Insurance contracts
295 — 295 — — 
Cash / money market funds
9 5 — — 4 
Total non-U.S. pension plans$1,302 $5 $295 $— $1,002 
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
The tables above present the fair value of the company’s plan assets in accordance with the fair value hierarchy (Note 14). Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. The fair value amounts of these investments presented in the above tables are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension plan assets. These investments were also redeemable at the balance sheet date or within limited time restrictions.
F-29

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 8.    Income Taxes
The components of income before provision for income taxes are as follows:
(In millions)202220212020
U.S.$3,859 $3,340 $4,762 
Non-U.S.3,976 5,501 2,468 
Income before income taxes
$7,835 $8,841 $7,230 
The components of the provision for income taxes are as follows:
(In millions)202220212020
Current income tax provision
Federal$813 $446 $521 
Non-U.S.633 1,148 423 
State254 160 175 
1,700 1,754 1,119 
Deferred income tax provision (benefit)
Federal$(611)$(227)$(237)
Non-U.S.(314)(399)(18)
State(72)(19)(14)
 (997)(645)(269)
Provision for income taxes
$703 $1,109 $850 
The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following:
(In millions)202220212020
Statutory federal income tax rate
21 %21 %21 %
Provision for income taxes at statutory rate
$1,645 $1,857 $1,518 
Increases (decreases) resulting from:
Foreign rate differential
(329)(255)(223)
Income tax credits
(202)(315)(335)
Global intangible low-taxed income
96 76 86 
Foreign-derived intangible income
(149)(119)(156)
Excess tax benefits from stock options and restricted stock units
(80)(124)(114)
Provision for (reversal of) tax reserves, net
(544)(17)(26)
Intra-entity transfers
(18)(284)— 
Domestication transaction— — (263)
Valuation allowances
344 36 379 
Withholding taxes
84 164 115 
Tax return reassessments and settlements
(210)1 (196)
State income taxes, net of federal tax111 82 147 
Other, net
(45)7 (82)
Provision for income taxes
$703 $1,109 $850 
The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate.
During 2022, the company settled an IRS audit relating to the 2017 and 2018 tax years. The company recorded a $208 million net tax benefit primarily from this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $658 million. The company recorded $49 million of charges for expired tax credits and other related components of the settlement. The company recorded a charge of $395 million to establish a valuation allowance against
F-30

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
certain U.S. foreign tax credits which the company believes will more likely than not expire unutilized. The company also recorded $101 million of additional net unrecognized tax benefit liabilities related to other tax audits.
During 2021, the company recorded a $188 million income tax benefit related to the deferred tax implications of an intra-entity transfer of assets. Also in 2021, the company recorded a $96 million income tax benefit related to a capital loss resulting from certain intra-entity transactions.
During 2020, the company settled an IRS audit relating to the 2014, 2015, and 2016 tax years. The company recorded a $25 million net tax benefit primarily from this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $378 million, of which $144 million was reclassified to income taxes payable. The company recorded $53 million of charges for expired tax credits and other related components of the settlement. The company recorded a charge of $156 million to establish a valuation allowance against certain U.S. foreign tax credits which the company believes will more likely than not expire unutilized.
In 2020, the company recorded a $263 million income tax benefit related to a domestication transaction involving the transfer of certain non-U.S. subsidiaries to the U.S., including interest expense of those subsidiaries. The company also recorded a valuation allowance of $212 million against the amount of interest expense that the company believes will more likely than not go unused.
The foreign tax credits discussed below are the result of foreign earnings and profits remitted or deemed remitted to the U.S. during the reporting year and the U.S. treatment of taxes paid in the foreign jurisdictions in the years those profits were originally earned.
In 2020, the company implemented foreign tax credit planning in Sweden which resulted in $96 million of foreign tax credits, with no related incremental U.S. income tax expense.
The company generally receives a tax deduction upon the exercise of non-qualified stock options by employees, or the vesting of restricted stock units held by employees, for the difference between the exercise price and the market price of the underlying common stock on the date of exercise. The company uses the incremental tax benefit approach for utilization of tax attributes. These excess tax benefits reduce the tax provision. In 2022, 2021 and 2020, the company's tax provision was reduced by $80 million, $124 million and $114 million, respectively, of such benefits.
Net deferred tax asset (liability) in the accompanying balance sheet consists of the following:
(In millions)20222021
Deferred tax asset (liability)
Depreciation and amortization
$(4,277)$(4,687)
Net operating loss and credit carryforwards
1,951 1,652 
Reserves and accruals
140 162 
Accrued compensation
259 318 
Inventory basis difference
364 181 
Deferred interest445 295 
Research and development and other capitalized costs
220 — 
Unrealized (gains) losses on hedging instruments
(199)(33)
Other, net
435 251 
Deferred tax liabilities, net before valuation allowance
(662)(1,861)
Less: Valuation allowance
1,322 968 
Deferred tax liabilities, net
$(1,984)$(2,829)
The company estimates the degree to which tax assets and loss and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2022, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense.
F-31

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The changes in the valuation allowance are as follows:
 Year Ended December 31,
(In millions)202220212020
Beginning balance
$968 $933 $408 
Additions (reductions) charged to income tax provision, net
344 24 514 
Additions due to acquisitions
14 30 — 
Currency translation and other
(4)(19)11 
Ending balance$1,322 $968 $933 
At December 31, 2022, the company had net federal, state and non-U.S. net operating loss carryforwards of $68 million, $97 million and $1.16 billion, respectively. Use of the carryforwards is limited based on the future income of certain subsidiaries. Of the federal net operating loss carryforwards, $33 million expire in the years 2023 through 2037, and the remainder do not expire. The state net operating loss carryforwards expire in the years 2023 through 2042. Of the net non-U.S. net operating loss carryforwards, $422 million expire in the years 2025 through 2042, and the remainder do not expire.
At December 31, 2022, the company had foreign tax credit carryforwards of $551 million and deferred interest carryforwards of $445 million. The foreign tax credit carryforwards will expire in the years 2025 through 2032 while deferred interest carryforwards do not expire.
U.S. federal taxes have been recorded on approximately $29 billion of undistributed foreign earnings as of December 31, 2022. A provision has not been made for certain U.S. state income taxes or additional non-U.S. taxes that would be due when cash is repatriated to the U.S. as the company’s undistributed foreign earnings are intended to be reinvested outside of the U.S. indefinitely. The determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed. The company’s intent is to only make distributions from non-U.S. subsidiaries in the future when they can be made at no net tax cost.
Unrecognized Tax Benefits
As of December 31, 2022, the company had $0.57 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate.
A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:
(In millions)202220212020
Beginning balance
$1,124 $1,091 $1,552 
Additions due to acquisitions
15 26 — 
Additions for tax positions of current year
104 32 8 
Additions for tax positions of prior years
24 60 — 
Reductions for tax positions of prior years
(659)(5)(296)
Closure of tax years
(4)(27)— 
Settlements
(32)(53)(173)
Ending balance
$572 $1,124 $1,091 
Substantially all of the unrecognized tax benefits are classified as long-term liabilities. The company does not expect its unrecognized tax benefits to change significantly over the next twelve months.
During 2022, the company’s unrecognized tax benefits increased by $143 million as a result of uncertain tax positions relating to foreign tax positions and decreased $610 million relating to U.S. federal and state tax positions which included $658 million from the settlement of the IRS audit of the 2017 and 2018 tax years. The company also assumed $15 million of uncertain tax benefits as part of the acquisition of PPD.
During 2021, the company’s unrecognized tax benefits increased by $80 million as a result of uncertain tax positions relating to foreign tax positions and decreased $75 million relating to U.S. federal and state tax positions. The company also assumed $26 million of uncertain tax benefits as part of the acquisition of PPD.
During 2020, the company’s unrecognized tax benefits decreased $51 million as a result of uncertain tax positions relating to foreign tax positions and $410 million relating to U.S. federal and state tax positions which included $378 million from the settlement of the IRS audit of the 2014, 2015 and 2016 tax years.
F-32

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The company classified interest and penalties related to unrecognized tax benefits as income tax expense. The total amount of interest and penalties related to uncertain tax positions and recognized in the balance sheet as of December 31, 2022 and 2021 was $74 million and $59 million, respectively.
The company conducts business globally and, as a result, Thermo Fisher or one or more of its subsidiaries files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the company is subject to examination by taxing authorities throughout the world, including such major jurisdictions as Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, the United Kingdom and the United States. With few exceptions, the company is no longer subject to U.S. state and local or non-U.S. income tax examinations for years before 2012 and no longer subject to U.S. federal income tax examinations for years before 2019.
Note 9.    Earnings per Share
(In millions except per share amounts)202220212020
Net income attributable to Thermo Fisher Scientific Inc.
$6,950 $7,725 $6,375 
Basic weighted average shares
392 394 396 
Plus effect of: stock options and restricted stock units
2 3 3 
Diluted weighted average shares
394 397 399 
Basic earnings per share
$17.75 $19.62 $16.09 
Diluted earnings per share
$17.63 $19.46 $15.96 
Antidilutive stock options excluded from diluted weighted average shares
2 1 1 
Note 10.    Debt and Other Financing Arrangements
Effective interest rate at December 31,December 31,December 31,
(Dollars in millions)202220222021
Commercial Paper2.60 %$310 $2,522 
Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023
1,000 1,000 
Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023
500 500 
0.797% 2-Year Senior Notes, Due 10/18/2023
1.03 %1,350 1,350 
Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
1.85 %1,819 1,933 
0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
0.06 %589 625 
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
0.93 %1,071 1,137 
Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024
500 500 
1.215% 3-Year Senior Notes, Due 10/18/2024
1.42 %2,500 2,500 
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
0.40 %857 910 
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
2.09 %686 728 
0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated)
1.05 %170 — 
0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)
0.15 %589 625 
3.65% 10-Year Senior Notes, Due 12/15/2025
— 350 
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)
3.38 %535 — 
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
1.52 %749 796 
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
1.65 %535 568 
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
1.96 %642 682 
1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)
1.18 %221 — 
4.80% 5-Year Senior Notes, Due 11/21/2027
5.00 %600 — 
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
0.77 %857 910 
F-33

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Effective interest rate at December 31,December 31,December 31,
(Dollars in millions)202220222021
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
1.46 %642 682 
1.750% 7-Year Senior Notes, Due 10/15/2028
1.89 %700 700 
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
2.07 %749 796 
2.60% 10-Year Senior Notes, Due 10/1/2029
2.74 %900 900 
1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)
1.44 %36 — 
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)
0.88 %1,873 1,990 
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
1.13 %963 1,023 
2.00% 10-Year Senior Notes, Due 10/15/2031
2.23 %1,200 1,200 
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
2.54 %642 682 
1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)
1.60 %48 — 
4.95% 10-Year Senior Notes, Due 11/21/2032
5.09 %600 — 
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)
1.20 %1,606 1,706 
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)
3.76 %803 — 
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
2.94 %749 796 
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
1.73 %963 1,023 
2.80% 20-Year Senior Notes, Due 10/15/2041
2.90 %1,200 1,200 
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)
1.77 %1,339 1,421 
2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)
2.13 %111 — 
5.30% 30-Year Senior Notes, Due 2/1/2044
5.37 %400 400 
4.10% 30-Year Senior Notes, Due 8/15/2047
4.23 %750 750 
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
1.98 %1,071 1,137 
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)
2.06 %803 853 
2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)
2.43 %254 — 
Other 79 76 
Total borrowings at par value
34,561 34,971 
Unamortized discount
(112)(117)
Unamortized debt issuance costs
(171)(184)
Total borrowings at carrying value
34,278 34,670 
Finance lease liabilities
210 200 
Less: Short-term obligations and current maturities
5,579 2,537 
Long-term obligations$28,909 $32,333 
SOFR - Secured Overnight Financing Rate
EURIBOR - Euro Interbank Offered Rate
The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs.
See Note 14 for fair value information pertaining to the company’s long-term borrowings.
F-34

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
As of December 31, 2022, the annual repayment requirements for debt obligations are as follows:
(In millions)BorrowingsFinance Lease Liabilities
2023 $5,583 $11 
2024 4,071 16 
2025 2,298 12 
2026 1,285 11 
2027 1,999 10 
2028 and thereafter19,325 150 
$34,561 $210 
In addition to available borrowings under the company’s revolving credit agreements, discussed below, the company had unused lines of credit of $72 million as of December 31, 2022. These unused lines of credit generally provide for short-term unsecured borrowings at various interest rates.
Credit Facilities
The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term SOFR, a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of December 31, 2022, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit.
Commercial Paper Programs
The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of December 31, 2022, there were $0.31 billion of outstanding borrowings under these programs.
Senior Notes
Interest is payable quarterly on the floating rate senior notes, annually on the euro-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the fixed rate senior notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. Except for the euro-denominated floating rate senior notes, which may not be redeemed early, the floating rate senior notes may be redeemed in whole or in part on or after their applicable call dates at a redemption price of 100% of the principal amount plus accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements. The company was in compliance with all covenants at December 31, 2022.
In 2022 the company completed the full allocation of an amount equal to the net proceeds from the 0.000% senior notes due 2025 to finance or refinance, in whole or in part, certain COVID-19 response projects.
In 2022, the company redeemed all of its 3.650% Senior Notes due 2025. In connection with the redemption, the company incurred $26 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income.
In 2021, the company redeemed some of its existing senior notes. In connection with these redemptions, the company incurred $767 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income. Upon redemption of the senior notes, the company terminated the related fixed to floating rate interest rate
F-35

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
swap arrangements and received $22 million, included in other financing activities, net, in the accompanying statement of cash flows.
Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the Floating Rate Senior Notes due 2023, the 0.00% Senior Notes due 2023, the 0.00% Senior Notes due 2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051 included in the table above (collectively, the “Euronotes”) in registered public offerings. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company.
Note 11.    Leases
As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally for 1 to 10 years) or have options to terminate the arrangement within 1 year.
The company has guaranteed the residual value of three leased operating facilities with lease terms ending in 2023, 2024 and 2025. The company has agreed with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 10). The aggregate maximum guarantee under these three lease arrangements is $147 million. Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated balance sheet as of December 31, 2022, but exclude any amounts for residual value guarantees.
As a lessee, the consolidated financial statements include the following relating to operating leases:
(Dollars in millions)202220212020
Statement of income
Operating lease costs
$351 $254 $224 
Variable lease costs
109 66 49 
Statement of cash flows
Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities$289 $288 $222 
Operating lease ROU assets obtained in exchange for new operating lease liabilities430 293 202 
Balance sheet
ROU assets$1,593 $1,531 
Operating lease liabilities - current272 266 
Operating lease liabilities - noncurrent1,313 1,203 
Weighted average at end of year
Remaining operating lease term9.4 years9.9 years
Discount rate3.2 %2.6 %
ROU assets are classified in other assets in the consolidated balance sheet. Operating lease liabilities are classified in other accrued expenses and other long-term liabilities, respectively, in the consolidated balance sheet.
Lease costs arising from finance leases, short-term leases, and sublease income are not material. See Note 10 for additional information relating to finance leases.
F-36

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
As of December 31, 2022, future payments of operating lease liabilities are as follows:
(In millions)
2023 $321 
2024 293 
2025 220 
2026 172 
2027 136 
2028 and thereafter730 
Total lease payments1,872 
Less: imputed interest
287 
Total operating lease liability$1,585 
As a lessor, operating leases, sales-type leases and direct financing leases are not material.
Note 12.    Commitments and Contingencies
Purchase Obligations
The company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or fixed assets and to pay royalties that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable at any time without penalty. The aggregate amount of the company’s unconditional purchase obligations totaled $2.40 billion at December 31, 2022 and the majority of these obligations are expected to be settled during 2023.
The Analytical Instruments segment recorded a charge to cost of product revenues for $108 million in 2020 related to an existing supply contract for components of electron microscopy instruments. The agreement requires the company to make future minimum purchases through 2025. The company developed and launched an alternative product beginning in 2020 and based on the expected demand for the internally developed product vs. the third-party product, the company does not expect to use all of the product it will be required to buy, resulting in a loss on the purchase commitment.
Letters of Credit, Guarantees and Other Commitments
Outstanding letters of credit and bank guarantees totaled $297 million at December 31, 2022. Substantially all of these letters of credit and guarantees expire before 2040.
Outstanding surety bonds and other guarantees totaled $84 million at December 31, 2022. The expiration of these bonds and guarantees ranges through 2024.
The letters of credit, bank guarantees and surety bonds principally secure performance obligations, and allow the holder to draw funds up to the face amount of the letter of credit, bank guarantee or surety bond if the applicable business unit does not perform as contractually required.
The company is a guarantor of pension plan obligations of a divested business. The purchaser of the divested business has agreed to pay for the pension benefits, however the company was required to guarantee payment of these pension benefits should the purchaser fail to do so. The amount of the guarantee at December 31, 2022 was $28 million.
In connection with the sale of businesses of the company, the buyers have assumed certain contractual obligations of such businesses and have agreed to indemnify the company with respect to those assumed liabilities. In the event a third-party to a transferred contract does not recognize the transfer of obligations or a buyer defaults on its obligations under the transferred contract, the company could be liable to the third-party for such obligations. However, in such event, the company would be entitled to seek indemnification from the buyer.
Indemnifications
In conjunction with certain transactions, primarily divestitures, the company has agreed to indemnify the other parties with respect to certain liabilities related to the businesses that were sold or leased properties that were abandoned (e.g., retention of certain environmental, tax, employee and product liabilities). The scope and duration of such indemnity obligations vary from transaction to transaction. Where probable, an obligation for such indemnifications is recorded as a liability. Generally, a
F-37

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
maximum obligation cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, historically the company has not made significant payments for these indemnifications.
In connection with the company’s efforts to reduce the number of facilities that it occupies, the company has vacated some of its leased facilities or sublet them to third parties. When the company sublets a facility to a third-party, it remains the primary obligor under the master lease agreement with the owner of the facility. As a result, if a third-party vacates the sublet facility, the company would be obligated to make lease or other payments under the master lease agreement. The company believes that the financial risk of default by sublessors is individually and in the aggregate not material to the company’s financial position or results of operations.
In connection with the sale of products in the ordinary course of business, the company often makes representations affirming, among other things, that its products do not infringe on the intellectual property rights of others and agrees to indemnify customers against third-party claims for such infringement. The company has not been required to make material payments under such provisions.
Environmental Matters
The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At December 31, 2022, the company’s total environmental liability was approximately $75 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows.
Litigation and Related Contingencies
The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows.
Product Liability, Workers Compensation and Other Personal Injury Matters
The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. The range of probable loss for product liability, workers compensation and other personal injury matters of the company’s continuing operations at December 31, 2022, was
F-38

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
approximately $223 million to $384 million on an undiscounted basis. The portion of these liabilities assumed in the 2006 merger with Fisher was recorded at its fair (present) value at the date of merger. The company’s accrual for all such matters in total, including the discounted liabilities, was $229 million at December 31, 2022 (or $232 million undiscounted). The accrual includes estimated defense costs and is gross of estimated amounts due from insurers of $95 million at December 31, 2022 (or $98 million undiscounted) that are included in other assets in the accompanying balance sheet. The portion of these insurance assets assumed in the merger with Fisher was also recorded at its fair value at the date of merger. In addition to the above accrual, as of December 31, 2022, the company had a product liability accrual of $17 million (undiscounted) relating to divested businesses.
Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis.
Note 13.    Comprehensive Income and Shareholders' Equity
Comprehensive Income (Loss)
Changes in each component of accumulated other comprehensive items, net of tax are as follows:
(In millions)Currency
translation
adjustment		Unrealized
losses on
hedging
instruments		Pension and
other
postretirement
benefit
liability
adjustment		Total
Balance at December 31, 2021$(2,065)$(35)$(229)$(2,329)
Other comprehensive items before reclassifications
(822)— 38 (784)
Amounts reclassified from accumulated other comprehensive items
7 2 5 14 
Net other comprehensive items
(815)2 43 (770)
Balance at December 31, 2022$(2,880)$(33)$(186)$(3,099)
Shareholders’ Equity
At December 31, 2022, the company had reserved 22 million unissued shares of its common stock for possible issuance under stock-based compensation plans.
Early in the first quarter of 2023, the company repurchased $3.00 billion of the company's common stock (5.2 million shares).
Note 14.    Fair Value Measurements and Fair Value of Financial Instruments
Fair Value Measurements
The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2022. The company’s financial assets and liabilities carried at fair value are primarily comprised of investments in publicly traded securities, insurance contracts, investments in derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration.
Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access.
Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves.
Level 3: Inputs are unobservable data points that are not corroborated by market data.
F-39

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:
December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs
(In millions)2022(Level 1)(Level 2)(Level 3)
Assets
Cash equivalents
$5,804 $5,804 $— $— 
Investments
25 25 — — 
Warrants
12 — 12 — 
Insurance contracts
162 — 162 — 
Derivative contracts
79 — 79 — 
Total assets
$6,082 $5,829 $253 $— 
Liabilities
Derivative contracts
$101 $— $101 $— 
Contingent consideration
174 — — 174 
Total liabilities
$275 $— $101 $174 
December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs
(In millions)2021(Level 1)(Level 2)(Level 3)
Assets
Cash equivalents
$2,210 $2,210 $— $— 
Investments
298 298 — — 
Warrants
15 — 15 — 
Insurance contracts
181 — 181 — 
Derivative contracts
36 — 36 — 
Total assets
$2,740 $2,508 $232 $— 
Liabilities
Derivative contracts
$1 $— $1 $— 
Contingent consideration
317 — — 317 
Total liabilities
$318 $— $1 $317 
The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense.
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration.
F-40

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In millions)20222021
Contingent consideration
Beginning balance
$317 $70 
Acquisitions (including assumed balances)
(18)403 
Payments
(66)(109)
Changes in fair value included in earnings
(59)(47)
Ending balance
$174 $317 
Derivative Contracts
The following table provides the aggregate notional value of outstanding derivative contracts.
December 31,December 31,
(In millions)20222021
Notional amount
Cross-currency interest rate swaps - designated as net investment hedges
$2,100 $900 
Currency exchange contracts
2,434 2,149 
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheet and statement of income.
 Fair value – assetsFair value – liabilities
 December 31,December 31,December 31,December 31,
(In millions)2022202120222021
Derivatives designated as hedging instruments
Cross-currency interest rate swaps (a)
$77 $25 $85 $— 
Derivatives not designated as hedging instruments
Currency exchange contracts (b)
2 11 16 1 
Total derivatives
$79 $36 $101 $1 
(a)The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities.
(b)The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.
 Gain (loss) recognized
(In millions)20222021
Fair value hedging relationships
Cross-currency interest rate swaps
Hedged long-term obligations - included in other income/(expense)
$77 $— 
Derivatives designated as hedging instruments - included in other income/(expense)
(81)— 
Interest rate swaps
Hedged long-term obligations - included in other income/(expense)
— 25 
Derivatives designated as hedging instruments - included in other income/(expense)
— (3)
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to other income/(expense)
(3)(73)
F-41

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 Gain (loss) recognized
(In millions)20222021
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in currency translation adjustment within other comprehensive items
695 922 
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive items
52 71 
Included in other income/(expense)
19 8 
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues
6 12 
Included in other income/(expense)
102 162 
Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions.
The company uses foreign currency-denominated debt, certain foreign-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
See Note 1 and Note 10 for additional information on the company’s risk management objectives and strategies.
Cash Flow Hedge Arrangements
In 2020 the company entered into interest rate swap arrangements to mitigate the risk of interest rates rising prior to completion of debt offerings. Based on the company's conclusion that the debt offerings were probable, the swaps hedged the cash flow risk for each of the interest payments on the planned fixed-rate debt issues. The aggregate fair value of the terminated hedges, net of tax, has been classified as a reduction to accumulated other comprehensive items and will be amortized to interest expense over the term of the related debt issuances. The company had cash outlays aggregating $85 million in 2020 associated with termination of the arrangements, included in other financing activities, net, in the accompanying statement of cash flows.
In late 2020, the company determined that the previously anticipated debt offerings were probable of not occurring and reclassified $42 million from accumulated other comprehensive items to other income/(expense). During 2021, in connection with the extinguishment of debt (Note 10), the company reclassified $65 million from accumulated other comprehensive items to other income/(expense).
Fair Value of Other Financial Instruments
The carrying value and fair value of the company’s debt instruments are as follows:
December 31, 2022December 31, 2021
CarryingFairCarryingFair
(In millions)valuevaluevaluevalue
Senior notes
$33,889 $29,901 $32,072 $33,449 
Commercial paper
310 310 2,522 2,522 
Other
79 79 76 76 
$34,278 $30,290 $34,670 $36,047 
The fair value of debt instruments was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.
F-42

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 15.    Supplemental Cash Flow Information
(In millions)202220212020
Cash paid for:
Interest
$667 $555 $471 
Income taxes
1,234 2,182 1,324 
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment
393 379 347 
Fair value of equity awards exchanged— 43 — 
Fair value of acquisition contingent consideration— 183 — 
Finance lease ROU assets obtained in exchange for new finance lease liabilities33 15 5 
Declared but unpaid dividends
119 104 89 
Issuance of stock upon vesting of restricted stock units
241 265 217 
Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:
 December 31,December 31,
(In millions)20222021
Cash and cash equivalents$8,524 $4,477 
Restricted cash included in other current assets12 13 
Restricted cash included in other assets1 1 
Cash, cash equivalents and restricted cash$8,537 $4,491 
Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.
Note 16.    Restructuring and Other Costs
Restructuring and other costs in 2022 primarily included impairment of long-lived assets and continuing charges for headcount reductions and facility consolidations in an effort to streamline operations. In 2022, severance actions associated with facility consolidations and cost reduction measures affected less than 2% of the company’s workforce.
Restructuring and other costs in 2021 primarily included charges for impairments of an acquired technology asset and a tradename asset, and, to a lesser extent, compensation due to employees at acquired businesses on the date of acquisition. In 2021, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.
Restructuring and other costs in 2020 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, and charges for the write-off of acquired technology. In 2020, severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce.
As of February 23, 2023, the company has identified restructuring actions that will result in additional charges of approximately $60 million, primarily in 2023, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred.
F-43

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Restructuring and other costs by segment are as follows:
(In millions)202220212020
Life Sciences Solutions
$30 $129 $34 
Analytical Instruments
1 6 26 
Specialty Diagnostics
68 18 9 
Laboratory Products and Biopharma Services
12 35 23 
Corporate
3 9 7 
$114 $197 $99 
The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.
(In millions)Total (a)
Balance at December 31, 2019$34 
Net restructuring charges incurred in 2020 (b)
51 
Payments
(57)
Currency translation
(7)
Balance at December 31, 202021 
Net restructuring charges incurred in 2021 (c)
37 
Payments
(40)
Currency translation
(1)
Balance at December 31, 202117 
Net restructuring charges incurred in 2022 (d)
68 
Payments
(44)
Balance at December 31, 2022$41 
(a)The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.
(b)Excludes $48 million of charges, principally $32 million for impairment of acquired technology in the Life Sciences Solutions segment resulting from a reduction in expected cash flows and, to a lesser extent, charges across the company’s segments for fixed asset writedowns and costs associated with environmental remediation at abandoned/previously owned facilities.
(c)Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segment, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
(d)Excludes $46 million of net charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.
The company expects to pay accrued restructuring costs primarily through 2023.
F-44
 EX-3.4 2 q4202210-kex34.htm AMENDED AND RESTATED BY-LAWS OF THE REGISTRANT Document
Exhibit 3.4
As amended and restated effective as of February 22, 2023

Thermo Fisher Scientific Inc.

BY-LAWS

TABLE OF CONTENTS
TitlePage
ARTICLE I - STOCKHOLDERS1
Section 1.Annual Meeting1
Section 2.Special Meetings1
Section 3.Notice of Meetings3
Section 4.Quorum; Adjournments4
Section 5.Voting; Proxies4
Section 6.Inspectors of Elections5
Section 7.Presiding Officer and Secretary5
Section 8.List of Stockholders6
Section 9.Advance Notice of Stockholder Nominations and Proposals6
Section 10.Proxy Access11
Section 11.Action Without Meeting17
Section 12.Meeting by Remote Communication17
Section 13.Delivery to the Corporation18
ARTICLE II - DIRECTORS18
Section 1.General Powers18
Section 2.Number and Qualification18
Section 3.Terms of Office18
Section 4.Removal18
Section 5.Vacancies19
Section 6.Resignations19
Section 7.Meetings19
Section 8.Notice of Meetings19
Section 9.Quorum19
Section 10.Action at Meeting19
Section 11.Action by Consent20
Section 12.Meetings by Telephone Conference Call20
Section 13.Compensation of Directors20
Section 14.Committees20
Section 15.Emergency Bylaws21
i



TitlePage
ARTICLE III - OFFICERS21
Section 1.General Provisions; Qualification21
Section 2.Election21
Section 3.Tenure21
Section 4.Resignation and Removal21
Section 5.Vacancies21
Section 6.The Chief Executive Officer22
Section 7.The President22
Section 8.Vice Presidents22
Section 9.Chief Financial Officer22
Section 10.General Counsel22
Section 11.The Treasurer22
Section 12.The Secretary22
Section 13.Assistant Treasurers23
Section 14.Assistant Secretaries23
Section 15.Other Officers23
Section 16.Delegation of Duties23
Section 17.Salaries23
ARTICLE IV - CAPITAL STOCK23
Section 1.Shares of Stock23
Section 2.Transfer of Shares of Stock23
Section 3.Lost, Stolen or Destroyed Certificates24
Section 4.Record Date24
Section 5.Regulations25
ARTICLE V - GENERAL PROVISIONS25
Section 1.Fiscal Year25
Section 2.Corporate Seal25
Section 3.Waiver of Notice25
Section 4.Voting of Securities25
Section 5.Evidence of Authority26
Section 6.Certificate of Incorporation26
Section 7.Transactions with Interested Parties26
Section 8.Severability26
Section 9.Limitation on Stock Option Repricing26
ARTICLE VI - AMENDMENTS27
Section 1.By the Board of Directors27
ii



TitlePage
Section 2.By the Stockholders27
Section 3.Certain Provisions27


iii



THERMO FISHER SCIENTIFIC INC.
BY-LAWS
ARTICLE I - STOCKHOLDERS
Section 1. Annual Meeting. The annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, if any, on such date, and at such time as the Board of Directors may each year fix. The Board of Directors may postpone, reschedule or cancel any previously scheduled annual meeting.
Section 2. Special Meetings.
1.    Except as otherwise provided in paragraph 2 of Section 2 of this Article I, special meetings of stockholders may be called only by the Board of Directors, the Chairman of the Board of Directors, or the Chief Executive Officer. Business transacted at any special meeting of stockholders called pursuant to this paragraph 1 of Section 2 of Article I shall be limited to matters relating to the purpose or purposes stated in the notice of meeting.
2.    A special meeting of stockholders shall be called by the Secretary upon written request (a “Special Meeting Request”) of one or more holders of record representing not less than 15% of the outstanding shares of Common Stock of the Corporation (the “Requisite Percentage”), provided that such shares have been “Owned” (as defined in paragraphs 7 and 8 of Section 10 of this Article I) continuously by such holders for at least one year prior to the date of the Special Meeting Request (the “One Year Period”), who have complied in full with the requirements set forth in these By-laws.
(i)    A Special Meeting Request must be delivered to the attention of the Secretary at the principal executive offices of the Corporation. A Special Meeting Request shall be valid only if it is signed and dated by each stockholder of record submitting the Special Meeting Request and the beneficial owners, if any, on whose behalf the Special Meeting Request is being made, or such stockholder’s or beneficial owner’s duly authorized agent (each, a “Requesting Stockholder”) collectively representing the Requisite Percentage, and includes (A) a statement of the specific purpose(s) of the special meeting and the reasons for conducting such business at the special meeting; (B) as to any director nominations proposed to be presented at the special meeting and any matter (other than a director nomination) proposed to be conducted at the special meeting and as to each Requesting Stockholder, the information, statements, representations, agreements and other documents that would be required to be set forth in or included with a stockholder’s notice of a nomination pursuant to Section 9 of this Article I (including any nominee’s written consent to being named in the Corporation’s proxy statement as a nominee and to serving as a director if elected) and/or a stockholder’s notice of business proposed to be brought before a meeting pursuant to Section 9 of this Article I, as applicable; (C) a representation that a Requesting Stockholder or a qualified representative (as defined in Section 9 of this Article I) thereof intends to appear in person or by proxy at the special meeting to present the nomination(s) or business to be brought before the special meeting; (D) an agreement by each Requesting Stockholder to notify the Corporation promptly
1



in the event of any disposition prior to the date of the special meeting of shares of the Corporation owned beneficially or of record and an acknowledgement that any such disposition shall be deemed to be a revocation of such Special Meeting Request with respect to such disposed shares; and (E) documentary evidence that each Requesting Stockholder has Owned continuously for the One Year Period the Requisite Percentage; provided, however, that if the Requesting Stockholders are not the beneficial owners of the shares representing the Requisite Percentage, then to be valid, the Special Meeting Request must also include documentary evidence (or, if not simultaneously provided with the Special Meeting Request, such documentary evidence must be delivered to the Secretary within 10 days after the date on which the Special Meeting Request is delivered to the Secretary) that the beneficial owners on whose behalf the Special Meeting Request is made beneficially have Owned the Requisite Percentage continuously for the One Year Period. In addition, each Requesting Stockholder shall (x) further update and supplement the information provided in the Special Meeting Request, if necessary, so that the information provided or required to be provided therein shall be true and correct as of the record date for the special meeting and as of the date that is 10 business days prior to the special meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to the Secretary at the principal executive offices of the Corporation not later than five business days after the later of the record date for the meeting or the date notice of the record date is first publicly disclosed in the case of the update and supplement required to be made as of the record date and not later than 10 business days prior to the date of the special meeting or any adjournment or postponement thereof in the case of the update and supplement required to be made as of 10 business days prior to the special meeting or any adjournment or postponement thereof and (y) promptly provide any other information reasonably requested by the Corporation.
(ii)    A Special Meeting Request shall not be valid, and a special meeting requested by stockholders shall not be held, if (A) the Special Meeting Request does not comply with this Section 2; (B) the Special Meeting Request relates to an item of business that is not a proper subject for stockholder action under applicable law (as determined in good faith by the Board of Directors); (C) the Special Meeting Request is delivered during the period commencing 90 days prior to the first anniversary of the date of the immediately preceding annual meeting of stockholders and ending on the earlier of the date of the next annual meeting of stockholders and the date that is 90 days after the first anniversary of the date of the immediately preceding annual meeting of stockholders; (D) an identical or substantially similar item (as determined in good faith by the Board of Directors, a “Similar Item”), other than the election of directors, was presented at an annual or special meeting of stockholders held not more than 12 months before the Special Meeting Request is delivered; (E) a Similar Item was presented at an annual or special meeting of stockholders held not more than 120 days before the Special Meeting Request is delivered (and, for purposes of this clause (E), the election of directors shall be deemed to be a “Similar Item” with respect to all items of business involving the election or removal of directors, changing the size of the Board of Directors and the filling of vacancies and/or newly created directorships resulting from any increase in the authorized number of directors); (F) a Similar Item is included in the Corporation’s notice of meeting as an item of business to be brought before an annual or special meeting of stockholders that has been called but not yet held or that is called for a date within 90 days of the receipt by the Corporation of a Special Meeting Request; or (G) the Special Meeting Request was made in a manner that involved a violation of Regulation 14A under the Exchange Act or other applicable law.
2



(iii)    Special meetings of stockholders called pursuant to this Section 2 shall be held at such place, if any, on such date, and at such time as the Board of Directors shall fix; provided, however, that the special meeting shall not be held more than 90 days after receipt by the Corporation of a valid Special Meeting Request.
(iv)    The Requesting Stockholders may revoke a Special Meeting Request by written revocation delivered to the Secretary at the principal executive offices of the Corporation at any time prior to the special meeting. If, at any point after 60 days of the first date on which a Special Meeting Request is delivered to the Corporation the unrevoked requests from Requesting Stockholders (whether by specific written revocation or deemed revocation pursuant to clause (D) of paragraph 2(i) of this Section 2) represent in the aggregate less than the Requisite Percentage, the Board of Directors, in its discretion, may cancel the special meeting.
(v)    In determining whether a special meeting of stockholders has been requested by the Requesting Stockholders representing in the aggregate at least the Requisite Percentage, multiple Special Meeting Requests delivered to the Secretary of the Corporation will be considered together only if (A) each Special Meeting Request identifies substantially the same purpose or purposes of the special meeting and substantially the same matters proposed to be acted on at the special meeting, in each case as determined by the Board of Directors (which, if such purpose is the election or removal of directors, changing the size of the Board of Directors and/or the filling of vacancies and/or newly created directorships resulting from any increase in the authorized number of directors, will mean that the exact same person or persons are proposed for election or removal in each relevant Stockholder Meeting Request), and (B) such Special Meeting Requests have been dated and delivered to the Secretary of the Corporation within 60 days of the first date on which a Special Meeting Request is delivered to the Corporation.
(vi)    If none of the Requesting Stockholders appear or send a qualified representative (as defined in Section 9 of this Article I) to present the nomination and/or business to be presented for consideration as specified in the Special Meeting Request, the Corporation need not present such nomination and/or business for a vote at the special meeting, notwithstanding that proxies in respect of such nomination and/or business may have been received by the Corporation.
(vii)    Business transacted at any special meeting called pursuant to this paragraph 2 of Section 2 shall be limited to (A) the purpose(s) stated in the valid Special Meeting Request received from the Requisite Percentage of record holders and (B) any additional matters that the Board of Directors determines to include in the Corporation’s notice of the special meeting.
3.    The Board of Directors may postpone, reschedule or cancel any previously scheduled special meeting.
Section 3. Notice of Meetings. Notice of the place, date, and time of all meetings of the stockholders and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting shall be given, not less than ten (10) nor more than sixty (60) days before the date on which the meeting is to be held, to each stockholder entitled to vote at such meeting, except as otherwise required by the Delaware General Corporation Law (meaning, here and hereinafter, the General Corporation Law of the State of Delaware, as amended and in effect from time to time, the “Delaware General Corporation Law”).
3




Section 4. Quorum; Adjournments. At any meeting of the stockholders, the holders of a majority in voting power of all of the shares of the stock entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole discretion, or represented by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be required by the Certificate of Incorporation or the Delaware General Corporation Law. Where a separate vote by a class or classes or series is required, a majority of the shares of such class or classes or series present in person, present by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole discretion, or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. A quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum.
Any meeting of stockholders may be adjourned from time to time to reconvene at any other time and to any other place at which a meeting of stockholders may be held under these Bylaws by the presiding officer. When a meeting is adjourned to another place or time (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), notice need not be given of the adjourned meeting if the place, if any, and time thereof and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting are (i) announced at the meeting at which the adjournment is taken, (ii) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or (iii) set forth in the notice of meeting given in accordance with Section 3 hereof; provided, however, that if the date of any adjourned meeting is more than thirty (30) days after the date for which the meeting was originally noticed, or if a new record date is fixed for the adjourned meeting, notice of the place, if any, date, and time of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting shall be given in conformity herewith. At any adjourned meeting, any business may be transacted that could have been transacted at the original meeting.
Section 5. Voting; Proxies. Each stockholder shall have one vote for each share of stock entitled to vote held of record by such stockholder unless otherwise provided by the Delaware General Corporation Law or the Certificate of Incorporation. Each stockholder of record entitled to vote at a meeting of stockholders, or to express consent or dissent to corporate action in writing without a meeting, may vote or express such consent or dissent in person or may authorize another person or persons to vote or act for the stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law, delivered in accordance with the procedure established for the meeting. No such proxy shall be voted or acted upon after three years from the date of its execution, unless the proxy expressly provides for a longer period.

4



When a quorum is present at any meeting, the affirmative vote of holders of a majority in voting power of the stock present or represented and entitled to vote and voting affirmatively or negatively on a matter (or if there are two or more classes or series of stock entitled to vote as separate classes, then in the case of each such class or series, the holders of a majority of the stock of that class present or represented and voting affirmatively or negatively on a matter) shall constitute stockholder action on any matter to be voted upon by the stockholders at such meeting, except when a different or minimum vote is required by the Delaware General Corporation Law, the Certificate of Incorporation, these By-laws, the rules and regulations of any stock exchange applicable to the Corporation, or any law or regulation application to the Corporation or its securities, in which case, such different or minimum vote shall be the applicable vote on the matter. Except as may be otherwise required by the Certificate of Incorporation, a nominee for director shall be elected to the Board of Directors if the votes cast for such nominee’s election exceed the votes cast against such nominee’s election (with “abstentions” and “broker nonvotes” not counted as a vote cast either “for” or “against” that director’s election), provided that if, on the tenth business day before the Corporation first mails its notice of meeting for such meeting to the stockholders, the number of nominees exceeds the number of directors to be elected, the directors shall be elected by the vote of a plurality of the shares represented in person or by proxy at any such meeting and entitled to vote on the election of directors. If directors are to be elected by a plurality of the votes cast, stockholders shall not be permitted to vote against a nominee.
Section 6. Inspectors of Elections. The Corporation shall, in advance of any meeting of the stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof and perform the other duties of inspectors at meetings of stockholders as set forth in the Delaware General Corporation Law. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting shall appoint one or more persons to act as inspector at the meeting. Each inspector, before entering the discharge of the inspector’s duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of the inspector’s ability.
Section 7. Presiding Officer and Secretary. The Chairman of the Board, or in the Chairman’s absence, the Chief Executive Officer, or in the Chief Executive Officer’s absence, the President, or in the President’s absence, the Chief Financial Officer, in such order, or, in the absence of all of them, any person designated by the Board of the Directors, shall call meetings of the stockholders to order, and shall act as presiding officer of such meeting. The Board of Directors may adopt by resolution such rules and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the presiding officer shall have the power to convene and (for any or no reason) to recess or adjourn meetings to another place, if any, or time, to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such presiding officer, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the presiding officer, may include, without limitation, the following: (i) the establishment of an agenda or order of business for the meeting; (ii) rules and procedures for maintaining order at the meeting and the safety of those present; (iii) limitations on attendance at or participation in the meeting to stockholders entitled to vote at the meeting, their duly authorized and constituted
5



proxies or such other persons as the presiding officer shall determine; (iv) restrictions on entry to the meeting after the time fixed for the commencement thereof; and (v) limitations on the time allotted to questions or comments by participants. The presiding officer, in addition to making any other determinations that may be appropriate to the conduct of the meeting, shall, if the facts warrant, determine and declare to the meeting that a matter or business was not properly brought before the meeting and if such presiding officer should so determine, such presiding officer shall so declare to the meeting and any such matter or business not properly brought before the meeting shall not be transacted or considered. Unless and to the extent determined by the Board of Directors or the presiding officer, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting. The Secretary of the Corporation, or in the Secretary’s absence, any Assistant Secretary, shall act as the secretary at all meetings of the stockholders, but in the absence of the Secretary and any Assistant Secretary, the presiding officer may appoint any person to act as secretary of the meeting.
Section 8. List of Stockholders. The Corporation shall prepare, at least 10 days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of 10 days ending on the day before the meeting date (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of meeting or (ii) during ordinary business hours at the principal place of business of the Corporation.
Section 9. Advance Notice of Stockholder Nominations and Proposals.
1.Nominations of persons for election to the Board of Directors and the proposal of business to be transacted by the stockholders may be made at an annual meeting of stockholders only (a) pursuant to the Corporation’s notice with respect to such meeting, (b) by or at the direction of the Board, (c) by any stockholder of record of the Corporation who was a stockholder of record at the time of the giving of the notice provided for in the following paragraph, who is entitled to vote at the meeting and who has complied with the notice procedures set forth in this Section 9 or (d) by an Eligible Stockholder (as defined in Section 10 of this Article I) whose Stockholder Nominee (as defined in Section 10 of this Article I) is included in the Corporation’s proxy materials for the relevant annual meeting of stockholders pursuant to Section 10 of this Article I.
2.For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to clause (c) of the foregoing paragraph, (1) the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation, (2) such business must be a proper matter for stockholder action under the Delaware General Corporation Law, (3) if the stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, and/or the respective affiliates and associates of, or others acting in concert with, such stockholder and such beneficial owner (each, a “Stockholder Associated Person”), has provided the Corporation with a Solicitation Notice, as that term is defined in subclause (c)(iii) of this paragraph, such stockholder, beneficial owner and/or Stockholder Associated Person must, in the case of a proposal, have delivered a proxy statement and form of proxy to holders of at least the percentage of the Corporation’s voting shares required under the Delaware General Corporation Law to carry any such proposal, or, in the case of a
6



nomination or nominations, have delivered a proxy statement and form of proxy to holders of a percentage of the Corporation’s voting shares reasonably believed by such stockholder, beneficial owner and/or Stockholder Associated Person to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder or such beneficial owner, and must, in either case, have included in such materials the Solicitation Notice, and (4) if no Solicitation Notice relating thereto has been timely provided pursuant to this Section 9, the stockholder or beneficial owner proposing such business or nomination must not have solicited a number of proxies or votes sufficient to have required the delivery of such a Solicitation Notice under this Section 9. To be timely, a stockholder’s notice shall be delivered to the Secretary at the principal executive offices of the Corporation not less than 60 or more than 75 days prior to the first anniversary (the “Anniversary”) of the date on which the Corporation first mailed its proxy materials for the preceding year’s annual meeting of stockholders; provided, however, that if the date of the annual meeting is advanced more than 30 days prior to or delayed (other than as a result of adjournment) by more than 30 days after the anniversary of the preceding year’s annual meeting, notice by the stockholder to be timely must be so delivered not later than the close of business on the later of (i) the 90th day prior to such annual meeting or (ii) the 10th day following the day on which public announcement of the date of such meeting is first made. In no event shall the adjournment or postponement of an annual meeting (or the public announcement thereof) commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described above. The number of nominees a stockholder may nominate for election at the annual meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the annual meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such annual meeting. Such stockholder’s notice shall set forth (a) as to each person whom the stockholder proposes to nominate for election or reelection as a director all information relating to such person as would be required to be disclosed in solicitations of proxies for the election of such nominees as directors pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and such person’s written consent to being named in the Corporation’s proxy statement as a nominee of the stockholder and to serve as a director if elected; (b) as to any other business that the stockholder proposes to bring before the meeting, a brief description of such business, the text of the proposal or business (including the exact text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend the By-laws, the exact text of the proposed amendment), the reasons for conducting such business at the meeting and any material interest in such business of such stockholder, such beneficial owner, and/or any Stockholder Associated Person; (c) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination is made (i) the name and address of such stockholder, as they appear on the Corporation’s books, and of such beneficial owner, (ii) the class, series and number of shares of the Corporation that are, directly or indirectly, owned beneficially and of record by such stockholder and such beneficial owner, (iii) whether either such stockholder, beneficial owner and/or Stockholder Associated Person intends to deliver a proxy statement and form of proxy to holders of, in the case of a proposal, at least the percentage of the Corporation’s voting shares required under the Delaware General Corporation Law to carry the proposal or, in the case of a nomination or nominations, a sufficient number of holders of the Corporation’s voting shares to elect such nominee or nominees (an affirmative statement of such intent, a “Solicitation Notice”), (iv) a representation as to whether or not such stockholder, such beneficial owner and/or any Stockholder Associated Person intends to solicit proxies in support of any director nominees other than the Corporation’s nominees in accordance with Rule 14a-19 promulgated under the Exchange Act, and, where such stockholder, beneficial owner, and/or Stockholder
7



Associated Person intends to so solicit proxies, the notice and information required by Rule 14a-19(b) under the Exchange Act, and a statement that such stockholder, beneficial owner, and/or Stockholder Associated Person has otherwise complied or will otherwise comply with the requirements of Rule 14a-19 under the Exchange Act, (v) a description of any agreement, arrangement or understanding with respect to the nomination or proposal between or among such stockholder, such beneficial owner, and/or any Stockholder Associated Person, including, in the case of a nomination, the nominee, (vi) a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, warrants, convertible securities, stock appreciation or similar rights, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of the stockholder’s notice by, or on behalf of, such stockholder, such beneficial owners, and/or any Stockholder Associated Person, whether or not such instrument or right shall be subject to settlement in underlying shares of capital stock of the Corporation, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of, such stockholder, such beneficial owner, and/or any Stockholder Associated Person, with respect to securities of the Corporation, (vii) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to propose such business or nomination, (viii) a representation that such stockholder, such beneficial owner, and/or any Stockholder Associated Person has complied, and will comply, with all applicable requirements of state law and the Exchange Act with respect to matters set forth in this Section 9 and (ix) any other information relating to such stockholder, beneficial owner, and/or Stockholder Associated Person required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in an election contest pursuant to and in accordance with Section 14(a) of the Exchange Act and the rules and regulations promulgated thereunder. The foregoing notice requirements of this paragraph 2 of Section 9 shall be deemed satisfied by a stockholder with respect to business other than a nomination if the stockholder has notified the Corporation of his, her or its intention to present a proposal at an annual meeting in compliance with applicable rules and regulations promulgated under the Exchange Act and such stockholder’s proposal has been included in a proxy statement that has been prepared by the Corporation to solicit proxies for such annual meeting. The Corporation may require any proposed nominee to furnish such other information as the Corporation may reasonably require, to determine the eligibility of such proposed nominee to serve as a director of the Corporation.
3.Notwithstanding anything in the second sentence of the second paragraph of this Section 9 to the contrary, in the event that the number of directors to be elected to the Board at the annual meeting is increased effective after the time period for which nominations would otherwise be due under the second paragraph of this Section 9 and there is no public announcement naming the nominees for additional directorships at least 70 days prior to the Anniversary, a stockholder’s notice required by this By-law shall also be considered timely, but only with respect to nominees for the additional directorships, if it shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the 10th day following the day on which such public announcement is first made by the Corporation.
8




4.Only persons nominated in accordance with the procedures set forth in this Section 9 or Section 10, as applicable, shall be eligible to serve as directors and only such business shall be conducted at an annual meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section 9. The presiding officer of the meeting (and, in advance of the meeting, the Board of Directors) shall have the power and the duty to determine whether a nomination or any business proposed to be brought before the meeting has been made in accordance with the procedures set forth in these By-laws (including whether the stockholder, beneficial owner and/or any Stockholder Associated Person did or did not solicit, as the case may be, proxies or votes in support of such stockholder’s nominee in compliance with the representations with respect thereto required by this Section 9), and, if any proposed nomination or business is not in compliance with these By-laws, to declare that such defective proposed business or nomination shall not be presented for stockholder action at the meeting and shall be disregarded. Notwithstanding the foregoing provisions of this Section 9, unless otherwise required by law, if the stockholder (or a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a nomination or proposed business, such nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Section 9 and Section 10 of these By-laws, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders.
5.Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation’s notice of meeting. Nominations of persons for election to the Board may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation’s notice of meeting (a) by or at the direction of the Board or stockholders pursuant to Section 2 of this Article I or (b) provided that the Board or stockholders pursuant to Section 2 of this Article I have determined that directors shall be elected at such meeting, by any stockholder of record of the Corporation who is a stockholder of record at the time of giving of notice provided for in this paragraph, who shall be entitled to vote at the meeting and who complies with the procedures set forth in this Section 9, including, without limitation, the procedures regarding Solicitation Notices. The proposal by stockholders of other business to be conducted at a special meeting of stockholders may be made only in accordance with Section 2 of this Article I. The number of nominees a stockholder may nominate for election at the special meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the special meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such special meeting. In the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board, nominations by stockholders of persons for election to such positions as specified in the Corporation’s notice of meeting may be made at such a special meeting of stockholders if the stockholder’s notice required by Section 9 shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the later of the 90th day prior to such special
9



meeting or the 10th day following the day on which the Corporation first makes a public announcement of the date of the special meeting at which directors are to be elected. In no event shall the adjournment or postponement of a special meeting (or the public announcement thereof) commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described above.
6.For purposes of this Section 9 and Section 10 of this Article I, “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or a comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.
7.Notwithstanding the foregoing provisions of this Section 9, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to matters set forth in this Section 9. Nothing in this Section 9 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act.
8.Notwithstanding anything to the contrary in these By-laws, unless otherwise required by law, (1) no stockholder, beneficial owner, and/or any Stockholder Associated Person shall solicit proxies in support of director nominees, other than the Corporation’s nominees, unless such stockholder, beneficial owner, and/or Stockholder Associated Person has complied with Rule 14a-19(b) promulgated under the Exchange Act in connection with the solicitation of such proxies, including the requirement to provide the Corporation with the notices required thereunder in a timely manner and (2) if any stockholder, beneficial owner, and/or Stockholder Associated Person (A) provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act and (B) subsequently fails to comply with the requirements of Rule 14a-19(a)(2) or Rule 14a-19(a)(3) promulgated under the Exchange Act or fails to timely provide reasonable evidence sufficient to satisfy the Corporation that such stockholder, beneficial owner, or Stockholder Associated Person has met the requirements of Rule 14a-19(a)(3) promulgated under the Exchange Act in accordance with the following sentence, then the nomination of each such director nominee shall be disregarded notwithstanding that proxies or votes in respect of the election of such proposed nominees may have been received by the Corporation (which proxies and votes shall be disregarded). If any stockholder, beneficial owner, and/or Stockholder Associated Person provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act, such stockholder, beneficial owner, or Stockholder Associated Person shall deliver to the Corporation, no later than five (5) business days prior to the applicable meeting, reasonable documentary evidence that such person has met the requirements of Rule 14a-19 promulgated under the Exchange Act, including clause (a)(3) thereof, together with a representation that such person has complied with the requirements of Rule 14a-19 promulgated under the Exchange Act.
9.Any person directly or indirectly soliciting proxies from stockholders of the Corporation must use a proxy card color other than white, which shall be reserved for exclusive use by the Board of Directors.
10




10.Unless the Corporation elects otherwise, a stockholder’s notice to the Corporation shall be in writing exclusively (and not in an electronic transmission) and shall be delivered exclusively by hand (including, without limitation, overnight courier service) or by certified or registered mail, return receipt requested, and the Corporation shall not be required to accept delivery of any document not in such written form or so delivered.
Section 10. Proxy Access.
1.Subject to the provisions of this Section 10, the Corporation shall include in its proxy statement (including its form of proxy) for an annual meeting of stockholders the name of any stockholder nominee for election to the Board of Directors submitted pursuant to this Section 10 (each a “Stockholder Nominee”) provided (a) timely written notice of such Stockholder Nominee satisfying this Section 10 (“Notice”) is delivered to the Corporation by or on behalf of a stockholder or stockholders that, at the time the Notice is delivered, satisfy the ownership and other requirements of this Section 10 (such stockholder or stockholders, and any person on whose behalf they are acting, the “Eligible Stockholder”), (b) the Eligible Stockholder expressly elects in writing at the time of providing the Notice to have its nominee included in the Corporation’s proxy statement pursuant to this Section 10, and (c) the Eligible Stockholder and the Stockholder Nominee otherwise satisfy the requirements of this Section 10 and the director qualifications requirements set forth in the Corporation’s Corporate Governance Guidelines and any other document(s) setting forth qualifications for directors.
2.To be timely, an Eligible Stockholder’s notice must be received in writing by the Secretary of the Corporation at the principal executive offices of the Corporation not less than 120 days nor more than 150 days prior to the first anniversary of the preceding year’s annual meeting; provided, however, that in the event that the date of the annual meeting is advanced by more than 30 days, or delayed (other than as a result of adjournment) by more than 60 days, from the first anniversary of the preceding year’s annual meeting, or if no annual meeting was held in the preceding year, a stockholder’s notice must be so received not earlier than the 150th day prior to such annual meeting and not later than the close of business on the later of (a) the 120th day prior to such annual meeting and (b) the tenth day following the day on which notice of the date of such annual meeting was mailed or public announcement (as defined in Section 9 of this Article I) of the date of such annual meeting was made, whichever first occurs. In no event shall the adjournment or postponement of an annual meeting (or the public announcement thereof) commence a new time period (or extend any time period) for the giving of an Eligible Stockholder’s notice as described above.
3.In addition to including the name of the Stockholder Nominee in the Corporation’s proxy statement for the annual meeting, the Corporation also shall include (a) the information concerning the Stockholder Nominee and the Eligible Stockholder that is required to be disclosed in the Corporation’s proxy statement pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder and (b) if the Eligible Stockholder so elects, a Statement (defined below) (collectively, the “Required Information”). Nothing in this Section 10 shall limit the Corporation’s ability to solicit against and include in its proxy statement its own statements relating to any Stockholder Nominee.
11




4.The number of Stockholder Nominees (including Stockholder Nominees that were submitted by an Eligible Stockholder for inclusion in the Corporation’s proxy statement pursuant to this Section 10 but either are subsequently withdrawn or that the Board of Directors decides to nominate (the latter a “Board Nominee”)) appearing in the Corporation’s proxy statement with respect to an annual meeting of stockholders shall not exceed the greater of (a) two or (b) 20% of the number of directors in office as of the last day on which notice of a nomination may be received pursuant to this Section 10 (the “Final Proxy Access Nomination Date”) or, if such amount is not a whole number, the closest whole number below 20% (such greater number the “Permitted Number”); provided, however, that the Permitted Number shall be reduced by (i) the number of director candidates for which the Corporation shall have received one or more valid notices that a stockholder intends to nominate director candidates at the annual meeting of stockholders pursuant to Section 9 of this Article I; provided further, that in no event shall the Permitted Number be less than one, (ii) any number of director candidates who will be included in the Corporation’s proxy materials with respect to the annual meeting as an unopposed (by the Corporation) nominee pursuant to any agreement, arrangement or other understanding with any stockholder or group of stockholders (other than any such agreement, arrangement or understanding entered into in connection with an acquisition of shares of capital stock of the Corporation, by such stockholder or group of stockholders, from the Corporation); provided, that in no event shall the Permitted Number be less than one, and (iii) any number of directors in office as of the nomination deadline who were included in the Corporation’s proxy statement as a Stockholder Nominee for any of the two preceding annual meetings and whom the Board of Directors decides to nominate for election to the Board of Directors. In the event that one or more vacancies for any reason occurs on the Board of Directors at any time after the Final Proxy Access Nomination Date and before the date of the applicable annual meeting of stockholders and the Board of Directors resolves to reduce the size of the Board of Directors in connection therewith, the Permitted Number shall be calculated based on the number of directors in office as so reduced.

5.In the event that the number of Stockholder Nominees submitted by Eligible Stockholders pursuant to this Section 10 exceeds the Permitted Number, each Eligible Stockholder shall select one Stockholder Nominee for inclusion in the Corporation’s proxy statement until the Permitted Number is reached, going in order of the amount (greatest to least) of the Corporation’s capital stock entitled to vote on the election of directors as disclosed in the Notice. If the Permitted Number is not reached after each Eligible Stockholder has selected one Stockholder Nominee, this selection process shall continue as many times as necessary, following the same order each time, until the Permitted Number is reached.

6.An Eligible Stockholder must have owned (as defined below) continuously for at least three years a number of shares that represents 3% or more of the Corporation’s outstanding shares of capital stock entitled to vote in the election of directors (the “Required Shares”) as of both the date the Notice is received by the Corporation in accordance with this Section 10 and the record date for determining stockholders entitled to vote at the annual meeting and must continue to own the Required Shares through the annual meeting date. For purposes of satisfying the ownership requirement under this Section 10, the shares of the Corporation’s capital stock owned by one or more stockholders, or by the person or persons who own shares of the Corporation’s capital stock and on whose behalf any stockholder is acting, may be aggregated, provided that (a) the number of stockholders and other persons whose ownership of shares is aggregated for such purpose shall not exceed 20, (b) each
12



stockholder or other person whose shares are aggregated shall have held such shares continuously for at least three years, and (c) a group of two or more funds that are (i) under common management and investment control, (ii) under common management and funded primarily by the same employer (or by a group of related employers that are under common control), or (iii) a “group of investment companies,” as such term is defined in Section 12(d)(1)(G)(ii) of the Investment Company Act of 1940, as amended, shall be treated as one stockholder or person for this purpose. Whenever an Eligible Stockholder consists of a group of stockholders and/or other persons, any and all requirements and obligations for an Eligible Stockholder set forth in this Section 10 must be satisfied by and as to each such stockholder or other person, except that shares may be aggregated to meet the Required Shares as provided in this Section 10. With respect to any one particular annual meeting, no stockholder or other person may be a member of more than one group of persons constituting an Eligible Stockholder under this Section 10.

7.For purposes of this Section 10, an Eligible Stockholder shall be deemed to “own” only those outstanding shares of the Corporation’s capital stock as to which the person possesses both (a) the full voting and investment rights pertaining to the shares and (b) the full economic interest in (including the opportunity for profit and risk of loss on) such shares; provided that the number of shares calculated in accordance with clauses (a) and (b) shall not include any shares (x) sold by such person or any of its affiliates in any transaction that has not been settled or closed, (y) borrowed by such person or any of its affiliates for any purposes or purchased by such person or any of its affiliates pursuant to an agreement to resell, or (z) subject to any option, warrant, forward contract, swap, contract of sale, other derivative or similar agreement entered into by such person or any of its affiliates, whether any such instrument or agreement is to be settled with shares or with cash based on the notional amount or value of outstanding shares of the Corporation’s capital stock, in any such case which instrument or agreement has, or is intended to have, the purpose or effect of (A) reducing in any manner, to any extent or at any time in the future, such person’s or affiliates’ full right to vote or direct the voting of any such shares, and/or (B) hedging, offsetting or altering to any degree gain or loss arising from the full economic ownership of such shares by such person or affiliate. A person shall “own” shares held in the name of a nominee or other intermediary so long as the person retains the right to instruct how the shares are voted with respect to the election of directors and possesses the full economic interest in the shares.
8.A person’s ownership of shares shall be deemed to continue during any period in which (a) the person has loaned such shares, provided that the person has the power to recall such loaned shares on five business days’ notice and provides a representation that it will promptly recall, and promptly recalls, such loaned shares upon being notified that any of its Stockholder Nominees will be included in the Corporation’s proxy statement, or (b) the person has delegated any voting power by means of a proxy, power of attorney or other instrument or arrangement that is revocable at any time by the person. The terms “owned,” “owning” and other variations of the word “own” shall have correlative meanings. For purposes of this Section 10, the term “affiliate” shall have the meaning ascribed thereto in the regulations promulgated under the Exchange Act.
9.An Eligible Stockholder must provide with its Notice the following in writing to the Secretary: (a) one or more written statements from the record holder of the shares (and from each intermediary through which the shares are or have been held during the requisite three-year holding period) verifying that, as of a date within seven calendar days prior to the date the Notice is received
13



by the Corporation, the Eligible Stockholder owns, and has owned continuously for the preceding three years, the Required Shares, and the Eligible Stockholder’s agreement to provide (i) within five business days after the record date for the annual meeting, written statements from the record holder and intermediaries verifying the Eligible Stockholder’s continuous ownership of the Required Shares through the record date and (ii) immediate notice if the Eligible Stockholder ceases to own any of the Required Shares prior to the date of the applicable annual meeting of stockholders; (b) documentation satisfactory to the Corporation demonstrating that a group of funds qualifies to be treated as one stockholder or person for purposes of this Section 10, if applicable; (c) a representation that the Eligible Stockholder (including each member of any group of stockholders and/or persons that together is an Eligible Stockholder hereunder) (i) intends to continue to own the Required Shares through the date of the annual meeting, (ii) acquired the Required Shares in the ordinary course of business and not with the intent to change or influence control of the Corporation, and does not presently have such intent, (iii) has not nominated and will not nominate for election to the Board of Directors at the annual meeting any person other than the Stockholder Nominee(s) being nominated pursuant to this Section 10, (iv) has not engaged and will not engage in, and has not and will not be, a “participant” in another person’s “solicitation” within the meaning of Rule 14a-1(l) under the Exchange Act in support of the election of any individual as a director at the annual meeting other than its Stockholder Nominee(s) or a Board Nominee, (v) will not distribute to any stockholder any form of proxy for the annual meeting other than the form distributed by the Corporation, and (vi) has provided and will provide facts, statements and other information in all communications with the Corporation and its stockholders that are or will be true and correct in all material respects and do not and will not omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading; (d) the written consent of each Stockholder Nominee to be named in the Corporation’s proxy statement as a nominee and to serve as a director if elected; (e) a copy of the Schedule 14N that has been filed with the Securities and Exchange Commission as required by Rule 14a-18 under the Exchange Act; (f) the information required to be provided by Section 9 of this Article I, as applicable; (g) in the case of a nomination by a group of stockholders that together is an Eligible Stockholder, the designation by all group members of one group member that is authorized to act on behalf of all members of the nominating stockholder group with respect to the nomination and matters related thereto, including withdrawal of the nomination; and (h) an undertaking that the Eligible Stockholder agrees to (i) assume all liability stemming from any legal or regulatory violation arising out of the Eligible Stockholder’s communications with the Corporation’s stockholders or out of the information that the Eligible Stockholder provides to the Corporation, (ii) indemnify and hold harmless the Corporation and each of its directors, officers and employees individually against any liability, loss or damages in connection with any threatened or pending action, suit or proceeding, whether legal, administrative or investigative, against the Corporation or any of its directors, officers or employees in connection with the Eligible Stockholder’s nomination and/or efforts to elect its Stockholder Nominee(s) pursuant to this Section 10, (iii) file with the Securities and Exchange Commission any solicitation or other communication with the Corporation’s stockholders relating to the annual meeting at which the Stockholder Nominee will be nominated, regardless of whether any such filing is required under Section 14 of the Exchange Act and the rules and regulations promulgated thereunder or whether any exemption from filing is available for such solicitation or other communication under Section 14 of the Exchange Act and the rules and regulations promulgated thereunder, and (iv) comply with all other applicable laws, rules, regulations and listing standards with respect to any solicitation in connection with the annual meeting.
14



10.The Eligible Stockholder may include with its Notice, a written statement for inclusion in the Corporation’s proxy statement for the annual meeting, not to exceed 500 words per Stockholder Nominee, in support of each Stockholder Nominee’s candidacy (the “Statement”). Notwithstanding anything to the contrary contained in this Section 10, the Corporation may omit from its proxy statement any information or Statement that it believes would violate any applicable law, rule, regulation or listing standard.
11.Each Stockholder Nominee must (a) provide within five business days of the Corporation’s request an executed agreement, in a form deemed satisfactory to the Corporation, that (i) the Stockholder Nominee has read and agrees to adhere to the Corporation’s Corporate Governance Guidelines and all other Corporation policies and guidelines applicable to directors, including with regard to securities trading, (ii) the Stockholder Nominee is not and will not become a party to (A) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation or (B) any Voting Commitment that could limit or interfere with such person’s ability to comply, if elected as a director of the Corporation, with such person’s fiduciary duties under applicable law, and (iii) the Stockholder Nominee is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification (a “Compensation Arrangement”) in connection with such person’s nomination or candidacy for director and/or service as a director that has not been disclosed to the Corporation; (b) complete, sign and submit all questionnaires required of the Corporation’s Board of Directors within five business days of receipt of each such questionnaire from the Corporation; and (c) provide within five business days of the Corporation’s request such additional information as the Corporation determines may be necessary to permit the Board of Directors to determine whether such Stockholder Nominee meets the requirements of this Section 10 and/or the Corporation’s requirements with regard to director qualifications and policies and guidelines applicable to directors, including whether (i) such Stockholder Nominee is independent under the listing standards of any U.S. exchange upon which the Corporation’s capital stock is listed, any applicable rules of the Securities and Exchange Commission, and any publicly disclosed standards used by the Board of Directors in determining and disclosing the independence of the directors (collectively, the “Independence Standards”), (ii) such Stockholder Nominee has any direct or indirect relationship with the Corporation, and (iii) such Stockholder Nominee has been subject to (A) any event specified in Item 401(f) of Regulation S-K under the Securities Act of 1933, as amended (the “Securities Act”) or (B) any order of the type specified in Rule 506(d) of Regulation D under the Securities Act.
12.In the event that any information or communications provided by the Eligible Stockholder or Stockholder Nominee to the Corporation or its stockholders ceases to be true and correct in any respect or omits a fact necessary to make the statements made, in light of the circumstances under which they were made, not misleading, each Eligible Stockholder or Stockholder Nominee, as the case may be, shall promptly notify the Secretary of any such inaccuracy or omission in such previously provided information and of the information that is required to make such information or communication true and correct; it being understood that
15



providing any such notification shall not be deemed to cure any defect or limit the Corporation’s right to omit a Stockholder Nominee from its proxy materials as provided in this Section 10.
13.The Corporation shall not be required to include, pursuant to this Section 10, a Stockholder Nominee in its proxy statement (or, if the proxy statement has already been filed, to allow the nomination of a Stockholder Nominee, notwithstanding that proxies in respect of such vote may have been received by the Corporation) (a) if the Eligible Stockholder who has nominated such Stockholder Nominee has nominated for election to the Board of Directors at the annual meeting any person other than pursuant to this Section 10, or has or is engaged in, or has been or is a “participant” in another person’s, “solicitation” within the meaning of Rule 14a-1(l) under the Exchange Act in support of the election of any individual as a director at the annual meeting other than its Stockholder Nominee(s) or a Board Nominee, (b) who is not independent under the Independence Standards, (c) whose election as a member of the Board of Directors would violate or cause the Corporation to be in violation of these By-laws, the Corporation’s certificate of incorporation, the Corporation’s Corporate Governance Guidelines or other document setting forth qualifications for directors, the listing standards of any U.S. exchange upon which the Corporation’s capital stock is listed, or any applicable state or federal law, rule or regulation, (d) if the Stockholder Nominee is or becomes a party to any undisclosed or prohibited Voting Commitment, (e) if the Stockholder Nominee is or becomes a party to any undisclosed Compensation Arrangement, (f) who is or has been, within the past three years, an officer or director of a competitor, as defined in Section 8 of the Clayton Antitrust Act of 1914, (g) whose then-current or prior business or personal interests place such Stockholder Nominee in a conflict of interest with the Corporation or any of its subsidiaries that would cause such Stockholder Nominee to violate any fiduciary duties of directors established pursuant to Delaware law, including but not limited to the duty of loyalty and duty of care, (h) who is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses) or has been convicted in such a criminal proceeding within the past ten years, (i) who is subject to any order of the type specified in Rule 506(d) of Regulation D under the Securities Act, or (j) if such Stockholder Nominee or the applicable Eligible Stockholder shall have provided information to the Corporation in respect of such nomination that was untrue in any material respect or omitted to state a material fact necessary in order to make the statement made, in light of the circumstances under which they were made, not misleading or shall have breached any of its or their agreements, representations, undertakings and/or obligations pursuant to this Section 10.
14.Notwithstanding anything to the contrary set forth herein, if (a) the Stockholder Nominee and/or the applicable Eligible Stockholder shall have breached its or their agreements, representations, undertakings and/or obligations pursuant to this Section 10, as determined by the Board of Directors or the person presiding at the annual meeting, or (b) the Eligible Stockholder (or a qualified representative thereof) does not appear at the annual meeting to present any nomination pursuant to this Section 10, (x) the Board of Directors or the person presiding at the annual meeting shall be entitled to declare a nomination by an Eligible Stockholder to be invalid, and such nomination shall be disregarded notwithstanding that proxies in respect of such vote may have been received by the Corporation and (y) the Corporation shall not be required to include in its proxy statement any successor or replacement nominee proposed by the applicable Eligible Stockholder or any other Eligible Stockholder.
16



15.Any Stockholder Nominee who is included in the Corporation’s proxy statement for a particular annual meeting of stockholders but either (a) withdraws from or becomes ineligible or unavailable for election at the annual meeting or (b) does not receive a number of votes cast in favor of his or her election at least equal to 25% of the shares present in person or represented by proxy at the annual meeting and entitled to vote on the Stockholder Nominee’s election, shall be ineligible to be included in the Corporation’s proxy statement as a Stockholder Nominee pursuant to this Section 10 for the next two annual meetings of stockholders following the annual meeting for which the Stockholder Nominee has been nominated for election. This Section 10 shall be the exclusive method for stockholders to include nominees for director election in the Corporation’s proxy materials, except to the extent required by Rule 14a-19 under the Exchange Act.
Section 11. Action Without Meeting. Unless otherwise provided in the Certificate of Incorporation, any action required or permitted to be taken by stockholders for or in connection with any corporate action may be taken without a meeting, without prior notice and without a vote, if a consent or consents, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation in accordance with Section 228 of the Delaware General Corporation Law. No consent shall be effective to take the corporate action referred to therein unless consents signed by a number of stockholders sufficient to take such action are delivered to the Corporation in the manner specified in this paragraph within sixty (60) days of the first date on which a consent is so delivered to the Corporation.
If action is taken by consent of stockholders and in accordance with the foregoing, there shall be filed with the records of the meetings of stockholders such consent or consents.
If action is taken by less than unanimous consent of stockholders, prompt notice of the taking of such action without a meeting shall be given to those who have not consented and a certificate signed and attested to by the Secretary of the Corporation that such notice was given shall be filed with the records of the meetings of stockholders.
In the event that the action consented to is such as would have required the filing of a certificate under any provision of the Delaware General Corporation Law, if such action had been voted upon by the stockholders at a meeting thereof, the certificate filed under such provision shall state, in lieu of any statement required by such provision concerning a vote of stockholders, that consent has been given under Section 228 of the Delaware General Corporation Law.
Section 12. Meetings by Remote Communication. If authorized by the Board of Directors, in its sole discretion, and subject to such guidelines and procedures as the Board of Directors may adopt, stockholders and proxy holders not physically present at a meeting of stockholders may by means of remote communication, to the fullest extent permitted by law: (a) participate in a meeting of stockholders, and (b) be deemed present in person and vote at a meeting of stockholders whether such meeting is to be held at a designated place or solely by means of remote communication.
17




Section 13. Delivery to the Corporation. Whenever Section 2, 9 or 10 of this Article I of these By-laws requires one or more persons (including a record or beneficial owner of stock of the Corporation) to deliver a document or information to the Corporation or any officer, employee or agent thereof (including any notice, request, questionnaire, revocation, representation or other document or agreement), such document or information shall be in writing exclusively (and not in an electronic transmission) and shall be delivered exclusively by hand (including, without limitation, overnight courier service) or by certified or registered mail, return receipt requested and the Corporation shall not be required to accept delivery of any document not in such written form or so delivered. For the avoidance of doubt, with respect to any notice from any stockholder of record or beneficial owner of the Corporation’s capital stock under the Certificate of Incorporation, these By-laws or the Delaware General Corporation Law, to the fullest extent permitted by law, the Corporation expressly opts out of Section 116 of the Delaware General Corporation Law.
ARTICLE II - DIRECTORS
Section 1. General Powers. The business and affairs of the Corporation shall be managed by or under the direction of a Board of Directors, who may exercise all of the powers of the Corporation except as otherwise provided by the Certificate of Incorporation or the Delaware General Corporation Law. In the event of a vacancy in the Board of Directors, the remaining directors, except as otherwise provided by the Certificate of Incorporation or the Delaware General Corporation Law, may exercise the powers of the full Board of Directors until the vacancy is filled. The Board of Directors may appoint a Chairman of the Board. The Chairman of the Board shall preside at all meetings of the Board of Directors and shall perform such duties and possess such powers as are assigned to the Chairman by the Board of Directors.
Section 2. Number and Qualification. Except as otherwise required by the Certificate of Incorporation, the number of directors that shall constitute the whole Board of Directors shall be determined by resolution of the Board of Directors, but in no event shall be less than three (3). The number of directors may be increased at any time by resolution of the Board of Directors. The number of directors may be decreased at any time and from time to time by a majority of the directors then in office (so long as a quorum is present), but only to eliminate vacancies existing by reason of the death, resignation, removal or expiration of the term of one or more directors. The Board of Directors shall be comprised of a majority of directors who are determined by the Board of Directors to be independent directors as such term is defined by Section 303A(2) of the New York Stock Exchange Listed Company Manual.
Section 3. Terms of Office. Each director shall be elected for a term expiring at the next annual meeting of stockholders following such director’s election and shall remain in office until a successor is elected and qualified, or until such director’s earlier death, resignation or removal; provided, however, that the foregoing shall not shorten the term of any incumbent director as of such date.
Section 4. Removal. Except as otherwise provided by the Certificate of Incorporation or the Delaware General Corporation Law, any one or more or all of the directors of the Corporation may be
18



removed, with or without cause, by the holders of a majority of the voting power of the shares entitled to vote thereon.
Section 5. Vacancies. Except as otherwise required by the Certificate of Incorporation or the Delaware General Corporation Law, any vacancy in the Board of Directors, however occurring, or any newly-created directorship resulting from an enlargement of the size of the Board of Directors, shall be filled only by vote of a majority of the directors then in office, even if less than a quorum, or by the sole remaining director and not by the stockholders. A director elected to fill a vacancy or a newly-created directorship shall serve for a term expiring at the next annual meeting of stockholders following such director’s election, and shall remain in office until the election and qualification of the director’s successor or the director’s earlier death, resignation or removal.
Section 6. Resignations. Any director may resign by delivering a resignation to the Corporation at its principal office or to the Chief Executive Officer or Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event.
Section 7. Meetings. Regular meetings of the Board of Directors may be held without notice at such time and place, either within or without the State of Delaware, as shall be determined from time to time by the Board of Directors. A regular meeting of the Board of Directors may be held without notice immediately after and at the same place as the annual meeting of stockholders. Special meetings of the Board of Directors may be called by the Chairman of the Board, the Chief Executive Officer, a majority of the total number of the whole Board of Directors, or by one director in the event that there is only a single director in office and may be held at any time and place, within or without the State of Delaware, as specified by the person(s) calling the meeting.
Section 8. Notice of Meetings. No notice of the annual or other regular meetings of the Board of Directors need be given. Notice of any special meeting of directors shall be given to each director by the Secretary. Notice to each director shall be duly given by mailing the same not later than the second business day before the meeting, or by giving notice in person, by fax, by telephone, or by any other electronic means not later than four hours before the meeting. No notice of a meeting need be given if all directors are present in person. Any business may be transacted at any meeting of the Board of Directors, whether or not specified in a notice of the meeting.
Section 9. Quorum. A majority of the total number of the whole Board of Directors shall constitute a quorum at all meetings of the Board of Directors. In the absence of a quorum at any such meeting, a majority of the directors present may adjourn the meeting from time to time to a different date, place, or time without further notice (or waiver of notice) other than announcement at the meeting, until a quorum shall be present.
Section 10. Action at Meeting. At any meeting of the Board of Directors at which a quorum is present, the vote of a majority of the directors present shall be sufficient to take any action, unless a different vote is specified by the Delaware General Corporation Law, the Certificate of Incorporation or these By-laws.


19



Section 11. Action by Consent. Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee of the Board of Directors may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent to the action in writing or by electronic transmission. After an action is taken, the consent or consents relating thereto shall be filed with the minutes of proceedings of the Board of Directors or committee in the same paper or electronic form as the minutes are maintained.
Section 12. Meetings by Telephone Conference Call. Directors or any members of any committee designated by the directors may participate in a meeting of the Board of Directors or such committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation by such means shall constitute presence in person at such meeting.
Section 13. Compensation of Directors. Directors may be paid such compensation for their services and such reimbursement for expenses of attendance at meetings of the Board of Directors or committees of the Board of Directors as the Board of Directors or any committee to which the Board has delegated responsibility for establishing director compensation may from time to time determine. No such payment shall preclude any director from serving the Corporation or any of its parent, subsidiary, or affiliate corporations in any other capacity and receiving compensation for such service.
Section 14. Committees. The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the Corporation. In addition to other committees that the Board of Directors may designate from time to time, the Board of Directors shall designate a Compensation Committee, an Audit Committee and a Nominating and Corporate Governance Committee each of which shall be comprised only of directors of the Corporation who are determined by the Board of Directors (i) to be “independent directors” as such term is defined by Section 303A(2) of the New York Stock Exchange Listed Company Manual and (ii) with respect to members of the Audit Committee only, to also be “independent” as such term is defined by Rule 10A-3(b)(1) of the Securities and Exchange Commission. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members of the committee present at any meeting and not disqualified from voting, whether or not the member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board of Directors and subject to the provisions of the Delaware General Corporation Law, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it. Each such committee shall keep minutes and make such reports as the Board of Directors may from time to time request. Except as the Board of Directors may otherwise determine, any committee may make rules for the conduct of its business, but unless otherwise provided by the directors or in such rules, its business shall be conducted as nearly as possible in the same manner as is provided in these By-laws for the Board of Directors. A majority of the members of a committee shall constitute a quorum unless the committee consist of one or two members, in which event, one member shall constitute a quorum. All matters shall be determined by a majority vote of the committee members present assuming a quorum is present.
20



Section 15. Emergency Bylaws. In the event of any emergency, disaster, catastrophe or other similar emergency condition of a type described in Section 110(a) of the Delaware General Corporation Law (an “Emergency”), notwithstanding any different or conflicting provisions in Delaware General Corporation Law, the Certificate of Incorporation or these By-laws, during such Emergency:
1.     Notice. A meeting of the Board of Directors or a committee thereof may be called by any director, the Chairman of the Board, the Chief Executive Officer, the President or the Secretary by such means as, in the judgment of the person calling the meeting, may be feasible at the time, and notice of any such meeting of the Board of Directors or any committee may be given, in the judgment of the person calling the meeting, only to such directors as it may be feasible to reach at the time and by such means as may be feasible at the time. Such notice shall be given at such time in advance of the meeting as, in the judgment of the person calling the meeting, circumstances permit.
2.     Quorum. The director or directors in attendance at a meeting called in accordance with Section 15 shall constitute a quorum.
3.     Liability. No officer, director or employee acting in accordance with this Section 15 shall be liable except for willful misconduct. No amendment, repeal or change to this Section 15 shall modify the prior sentence with regard to actions taken prior to the time of such amendment, repeal or change.
ARTICLE III - OFFICERS
Section 1. General Provisions; Qualification. The officers of the Corporation shall be a Chief Executive Officer, a President, a Chief Financial Officer, a General Counsel, a Treasurer and a Secretary, and may include one or more Vice Presidents, one or more Assistant Treasurers and one or more Assistant Secretaries and such other officers as the Board of Directors may deem appropriate. Any two or more offices may be held by the same person.
Section 2. Election. Officers of the Corporation shall be elected annually by the Board of Directors.
Section 3. Tenure. Except as otherwise provided by the Delaware General Corporation Law, by the Certificate of Incorporation or by these By-laws, each officer shall hold office until such officer’s successor is elected and qualified, unless a different term is specified in the vote choosing or appointing such officer, or until such officer’s earlier death, resignation or removal.
Section 4. Resignation and Removal. Any officer may resign by delivering a resignation to the Corporation at its principal office or to the Chief Executive Officer or the Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. Any officer may be removed at any time, with or without cause by vote of the Board of Directors.
Section 5. Vacancies. The Board of Directors may at any time fill any vacancy occurring in any office for any reason. Each such successor shall hold office for the unexpired term of such successor’s predecessor and until such successor’s successor is elected and qualified, or until such successor’s earlier death, resignation or removal.
21



Section 6. The Chief Executive Officer. The Chief Executive Officer shall be the principal executive officer of the Corporation. Subject to the control of the Board of Directors, the Chief Executive Officer shall have general charge of the business and affairs of the Corporation. The Chief Executive Officer shall employ and discharge employees and agents of the Corporation, except such as shall hold their offices by appointment of the Board of Directors, but the Chief Executive Officer may delegate these powers to other officers as to employees under their immediate supervision. The Chief Executive Officer shall have such other powers and perform such other duties as may be prescribed by the Board of Directors.
Section 7. The President. The Board of Directors may appoint an officer of the Corporation to serve as the President of the Corporation. The President shall perform such of the duties of the Chief Executive Officer of the Corporation on behalf of the Corporation as may be assigned to the President from time to time by the Board of Directors or the Chief Executive Officer. In the absence or inability of the Chief Executive Officer to act, the President shall have and possess all of the powers and discharge all of the duties of the Chief Executive Officer, subject to the control of the Board of Directors.
Section 8. Vice Presidents. Each Vice President shall have such powers and perform such duties as the Board of Directors, the Chief Executive Officer, or the President may from time to time prescribe.
Section 9. Chief Financial Officer. The Board of Directors shall appoint an officer to serve as the Chief Financial Officer of the Corporation. The Chief Financial Officer shall be responsible for the Corporation’s public financial reporting obligations and shall have such further powers and duties as are incident to the position of Chief Financial Officer, subject to the direction of the Chief Executive Officer and the Board of Directors.
Section 10. General Counsel. The Board of Directors shall appoint an officer to serve as the General Counsel of the Corporation. The General Counsel shall be the chief legal officer of the Corporation and shall be responsible for all legal affairs of the Corporation, and shall have such further powers and duties as are incident to the position of General Counsel.
Section 11. The Treasurer. The Treasurer shall perform such duties and shall have such powers as may from time to time be assigned to the Treasurer by the Board of Directors, the Chief Executive Officer or the Chief Financial Officer. In addition, subject to the direction of the Board of Directors, the Treasurer shall perform such duties and have such powers as are incident to the office of treasurer, including, without limitation, the duty and power to keep and be responsible for all funds and securities of the Corporation, to deposit funds of the Corporation in depositories, to disburse such funds, to make proper accounts of such funds, and to render statements of all such transactions and of the financial condition of the Corporation.
Section 12. The Secretary. The Secretary shall keep the minutes of all meetings of the Board of Directors and of the stockholders and shall attend to the giving and serving of all notices of the Corporation.
22



The Secretary shall have custody of the seal of the Corporation and shall affix the seal to all certificates of shares of stock of the Corporation and to such other papers or documents as may be proper and, when the seal is so affixed, the Secretary shall attest the same by the Secretary’s signature wherever required. The Secretary shall have charge of the stock certificate book, transfer book, and stock ledger, and such other books and papers as the Board of Directors may direct. The Secretary shall, in general, perform all the duties of secretary, subject to the control of the Board of Directors.
Section 13. Assistant Treasurers. In the absence or inability of the Treasurer to act, any Assistant Treasurer may perform all the duties and exercise all of the powers of the Treasurer, subject to the control of the Board of Directors. An Assistant Treasurer shall also perform such other duties as the Board of Directors, the Chief Executive Officer, or the Treasurer may from time to time prescribe.
Section 14. Assistant Secretaries. In the absence or inability of the Secretary to act, any Assistant Secretary may perform all the duties and exercise all the powers of the Secretary, subject to the control of the Board of Directors. An Assistant Secretary shall also perform such other duties as the Board of Directors, the Chief Executive Officer, or the Secretary may from time to time prescribe.
Section 15. Other Officers. Other officers shall perform such duties and have such powers as may from time to time be assigned to them by the Board of Directors.
Section 16. Delegation of Duties. In case of the absence of any officer of the Corporation, or for any other reason that the Board of Directors may deem sufficient, the Board of Directors may confer, for the time being, the powers or duties, or any of them, of such officer upon any other officer, or upon any director.
Section 17. Salaries. Officers of the Corporation shall be entitled to such salaries, compensation, or reimbursement as shall be fixed or allowed from time to time by the Board of Directors.
ARTICLE IV - CAPITAL STOCK
Section 1. Shares of Stock. The shares of capital stock of the Corporation shall be uncertificated and shall not be represented by certificates, except to the extent as may be required by applicable law or as otherwise authorized by the Board of Directors. The preceding sentence shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. Every holder of capital stock of the Corporation represented by certificates shall be entitled to have a certificate for shares of capital stock of the Corporation signed by, or in the name of the Corporation by two authorized officers of the Corporation (it being understood that each of the Chairman of the Board, the Vice-Chairman of the Board, the Chief Executive Officer, the President, any Vice President, the Secretary, any Assistant Secretary, the Treasurer and any Assistant Treasurer shall be an authorized person for these purposes), certifying the class and number of shares of record owned by such stockholder in the Corporation. Any or all of the signatures may be a facsimile.
Section 2. Transfer of Shares of Stock. Stock of the Corporation shall be transferable in the manner prescribed by applicable law and in these By-Laws. Transfers of stock shall be made on the books of the Corporation, and in the case of certificated shares of stock, only by the person named in the certificate or by such person’s attorney lawfully constituted in writing and upon the surrender of
23



the certificate therefor, properly endorsed for transfer and payment of all necessary transfer taxes; or, in the case of uncertificated shares of stock, upon receipt of proper transfer instructions from the registered holder of the shares or by such person’s attorney lawfully constituted in writing, and upon payment of all necessary transfer taxes and compliance with appropriate procedures for transferring shares in uncertificated form; provided, however, that such surrender and endorsement, compliance or payment of taxes shall not be required in any case in which the officers of the Corporation shall determine to waive such requirement. No transfer of stock shall be valid as against the Corporation for any purpose until it shall have been entered in the books of the Corporation by an entry showing from and to whom transferred.
Section 3. Lost, Stolen or Destroyed Certificates. In the event of the loss, theft or destruction of any certificate of stock, another may be issued in its place pursuant to such regulations as the Board of Directors or transfer agent may establish concerning proof of such loss, theft, or destruction and concerning the giving of a satisfactory bond or bonds of indemnity.
Section 4. Record Date.
(a)    In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders, or to receive payment of any dividend or other distribution or allotment of any rights or to exercise any rights in respect of any change, conversion, or exchange of stock or for the purpose of any other lawful action, the Board of Directors may, except as otherwise required by the Delaware General Corporation Law, fix a record date, which record date shall not precede the date on which the resolution fixing the record date is adopted and which record date shall not be more than sixty (60) nor less than ten (10) days before the date of any meeting of stockholders, nor more than sixty (60) days prior to the time for such other action as hereinbefore described; provided, however, that if no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held, and, for determining stockholders entitled to receive payment of any dividend or other distribution or allotment of rights or to exercise any rights of change, conversion, or exchange of stock or for any other purpose, the record date shall be at the close of business on the day on which the Board of Directors adopts a resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.
(b)    In order that the Corporation may determine the stockholders entitled to consent to corporate action without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which date shall not be more than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. Any stockholder of record seeking to have the stockholders authorize or take corporate action by consent shall, by written notice to the Secretary of the Corporation, request the Board of Directors to fix a record date.
24



The Board of Directors shall promptly, but in all events within ten (10) days after the date on which such a request is received by the Secretary, adopt a resolution fixing the record date. If no record date has been fixed by the Board of Directors within ten (10) days of the date on which such a request is received, the record date for determining stockholders entitled to consent to corporate action without a meeting, when no prior action by the Board of Directors is required by applicable law, shall be the first date on which a consent setting forth the action taken or proposed to be taken is delivered to the Corporation in accordance with Section 228 of the Delaware General Corporation Law. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by applicable law, the record date for determining stockholders entitled to consent to corporate action without a meeting shall be at the close of business on the date on which the Board of Directors adopts the resolution taking such prior action.
Section 5. Regulations. The issue, transfer, conversion and registration of shares of stock shall be governed by such other regulations as the Board of Directors may establish.
ARTICLE V - GENERAL PROVISIONS
Section 1. Fiscal Year. Except as from time to time otherwise designated by the Board of Directors, the fiscal year of the Corporation shall end on December 31.
Section 2. Corporate Seal. The corporate seal shall be in such form as may be approved by the Board of Directors. The corporate seal may be altered from time to time by the Board.
Section 3. Waiver of Notice. Whenever any notice whatsoever is required to be given by the Delaware General Corporation Law, by the Certificate of Incorporation or by these By-laws, a waiver of such notice given by the person entitled to such notice or such person’s duly authorized attorney, whether before or after the time of the event for which notice is to be given shall be deemed equivalent to the notice required to be given to such person. Neither the business nor the purpose of any meeting need be specified in such a waiver. The appearance of such person at such meeting in person or by proxy, shall constitute waiver of notice except attendance for the sole purpose of objecting at the beginning of the meeting to the timeliness or lack of notice.
Section 4. Voting of Securities. Unless otherwise provided by resolution adopted by the Board of Directors, the Chairman of the Board, the President, any Vice President or the Secretary may from time to time appoint an attorney or attorneys or agent or agents of the Corporation, in the name and on behalf of the Corporation, to cast the votes which the Corporation may be entitled to cast as the holder of stock or other securities in any other corporation or other entity, any of whose stock or other securities may be held by the Corporation, at meetings of the holders of the stock or other securities of such other corporation or other entity, or to consent in any manner permitted under applicable law, in the name of the Corporation as such holder, to any action by such other corporation or other entity, and may instruct the person or persons so appointed as to the manner of casting such votes or giving such consents, and may execute or cause to be executed in the name and on behalf of the Corporation and under its corporate seal or otherwise, all such proxies or other instruments as he or she may deem necessary or proper. Any of the rights set forth in this Section 4 which may be delegated to an attorney or agent may also be exercised directly by the Chairman of the Board, the President, any Vice President or the Secretary.
25




Section 5. Evidence of Authority. A certificate by the Secretary, or an Assistant Secretary as to any action taken by the stockholders, directors, a committee or any officer or representative of the Corporation shall as to all persons who rely on the certificate in good faith be conclusive evidence of such action.
Section 6. Certificate of Incorporation. All references in these By-laws to the Certificate of Incorporation shall be deemed to refer to the Third Amended and Restated Certificate of Incorporation of the Corporation, as amended, restated and in effect from time to time.
Section 7. Transactions with Interested Parties. No contract or transaction between the Corporation and one or more of the directors or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of the directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board of Directors or a committee of the Board of Directors that authorizes the contract or transaction or solely because the interested directors’ votes are counted for such purpose, if:
(1) The material facts as to the director’s or officer’s relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum;
(2) The material facts as to the director’s or officer’s relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or
(3) The contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified, by the Board of Directors, a committee of the Board of Directors, or the stockholders.
Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee that authorizes the contract or transaction.
Section 8. Severability. Any determination that any provision of these By-laws is for any reason inapplicable, illegal, or ineffective shall not affect or invalidate any other provision of these By-laws.
Section 9. Limitation on Stock Option Repricing. No stock option granted to an officer or director of the Corporation shall, after issuance, be repriced to a lower exercise price (other than adjustments for stock splits, stock dividends, spinoffs, recapitalizations and like events), without the prior affirmative vote of the holders of a majority in voting power of the shares of capital stock of the Corporation present at a stockholders meeting in person or by proxy and entitled to vote thereon.
26




ARTICLE VI - AMENDMENTS
Section 1. By the Board of Directors. In furtherance and not in limitation of the powers conferred by the Delaware General Corporation Law and the Certificate of Incorporation, the Board of Directors is expressly authorized to alter, amend or repeal any provision of these By-laws or make new by-laws.
Section 2. By the Stockholders. Except as otherwise provided in Section 3 of this Article VI, the stockholders of the Corporation shall have the power to alter, amend or repeal any provision of these By-laws or make new by-laws by affirmative vote of the holders of a majority in voting power of the shares of capital stock of the Corporation issued and outstanding and entitled to vote, voting together as a single class; provided, however, that the power of the stockholders to, alter, amend or repeal any provision of these By-laws or make any new by-laws is further subject to any affirmative vote of the holders of any particular class or series of capital stock of the Corporation as may be required by the Delaware General Corporation Law, the Certificate of Incorporation, or these By-laws.
Section 3. Certain Provisions. Notwithstanding any other provision of the Delaware General Corporation Law, the Certificate of Incorporation, or these By-laws (including Section 2 of this Article VI), the affirmative vote of the holders of at least sixty-six and two-thirds percent (66 2/3%) of the voting power of the shares of capital stock of the Corporation issued and outstanding and entitled to vote shall be required for the stockholders to alter, amend or repeal, or make any new by-laws inconsistent with, Article II or this Article VI of these By-laws. This Section 3 is not intended to abrogate or otherwise affect the power of the Board of Directors to amend Article II or Article VI pursuant to Section 1 of this Article VI.

27


 EX-4.19 3 q4202210-kex419.htm DESCRIPTION OF THE REGISTRANT'S SECURITIES Document

Exhibit 4.19
Description of Registrant’s Securities
The following description of registered securities of Thermo Fisher Scientific Inc. is intended as a summary only and therefore is not a complete description. As used in this “Description of Registrant’s Securities,” the terms “Thermo Fisher,” “Company,” “we,” “our” and “us” refer to Thermo Fisher Scientific Inc. and do not, unless the context otherwise indicates, include our subsidiaries.
Our authorized capital stock consists of 1.2 billion shares of common stock, $1.00 par value per share, and 50,000 shares of preferred stock, $100 par value per share. Our common stock is registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We also have several classes of debt securities registered under Section 12(b) of the Exchange Act.
COMMON STOCK
This description of our common stock is based upon, and qualified by reference to, our Third Amended and Restated Certificate of Incorporation, as amended (our “certificate of incorporation”), our amended and restated by-laws (our “bylaws”), and applicable provisions of Delaware corporate law (the “DGCL”). You should read our certificate of incorporation and bylaws, which are incorporated by reference as Exhibits 3.1 to 3.3 and Exhibit 3.4, respectively, to the Annual Report on Form 10-K for the year ended December 31, 2022, of which this Exhibit 4.19 is a part, for the provisions that are important to you.
General
Annual Meeting. Annual meetings of our stockholders are held on the date designated in accordance with our bylaws. Written notice must be given to each stockholder entitled to vote not less than ten nor more than 60 days before the date of the meeting. The presence in person or by proxy of the holders of record of a majority of our issued and outstanding shares entitled to vote at such meeting constitutes a quorum for the transaction of business at meetings of the stockholders, unless or except to the extent that the presence of a larger number may be required by our certificate of incorporation or the DGCL. Special meetings of the stockholders may only be called by our board of directors, the chairman of the board of directors or the chief executive officer or, solely to the extent required by our bylaws, by our secretary at the written request in proper form of one or more stockholders who have continuously held as stockholders of record not less than 15% of the outstanding shares of our common stock for at least one year prior to the date such request is delivered to our secretary. Except as may be otherwise provided by applicable law, our certificate of incorporation or our bylaws, all matters shall be decided by a majority of the votes cast by stockholders entitled to vote thereon at a duly held meeting of stockholders at which a quorum is present. Except as may be otherwise provided by our certificate of incorporation, a nominee shall be elected to our board of directors if the votes cast for such nominee’s election exceed the votes cast against, provided that if, on the 10th business
1



day before we mail our notice of meeting to the stockholders, the number of nominees exceeds the number of directors to be elected, the election shall be decided by a plurality.
Voting Rights. Each holder of common stock is entitled to one vote for each share held on all matters to be voted upon by stockholders.
Dividends. The holders of common stock, after any preferences of holders of any preferred stock are entitled to receive dividends when and if declared by our board of directors out of legally available funds.
Liquidation, Dissolution and Winding Up. In the event of our liquidation, dissolution or winding up, the holders of the common stock will be entitled to share in our assets available for distribution to stockholders in proportion to the amount of common stock they own. The amount available for common stockholders is calculated after payment of liabilities. Holders of any preferred stock will receive a preferential share of our assets before the holders of the common stock receive any assets.
Other Rights. Holders of the common stock have no right to:
•convert the stock into any other security;
•have the stock redeemed; or
•purchase additional stock or to maintain their proportionate ownership interest.
The common stock does not have cumulative voting rights. Holders of shares of the common stock are not required to make additional capital contributions.
Provisions of Our Certificate of Incorporation and Bylaws and Delaware Law That May Have Anti-Takeover Effects
Certain provisions of our certificate of incorporation and bylaws may have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, control of us. Such provisions could limit the price that certain investors might be willing to pay in the future for shares of our common stock and may limit the ability of stockholders to remove current management or directors or approve transactions that stockholders may deem to be in their best interest and, therefore, could adversely affect the price of our common stock.
Removal of Directors by Stockholders. Our bylaws provide that, except as otherwise provided by our certificate of incorporation or the DGCL, any one or more or all of the members of our board of directors may be removed, with or without cause, by the holders of a majority of the voting power of the shares entitled to vote thereon.
Board Vacancies Filled Only by Majority of Directors Then in Office. Our bylaws provide that, except as otherwise provided by our certificate of incorporation or the DGCL, vacancies and newly created seats on our board may be filled only by our board of directors. Further, only our board of directors may determine the number of directors on our board. The inability of
2



stockholders to determine the number of directors or to fill vacancies or newly created seats on the board makes it more difficult to change the composition of our board of directors.
Stockholder Nomination of Directors and Proposals. Our bylaws provide that a stockholder must notify us in writing of any stockholder nomination of a director or proposal for other business not less than 60 days and not more than 75 days prior to the first anniversary of the date on which we first mailed our proxy materials for the preceding year’s annual meeting; provided, that if the date of the annual meeting is advanced or delayed by more than 30 days from such anniversary date, notice by the stockholder to be timely must be so delivered not later than the close of business on the later of (x) the 90th day prior to the date of such meeting or (y) the 10th day following the day on which public announcement of the date of such annual meeting is first made by us.
Proxy Access. Our bylaws provide for proxy access, which permits a stockholder, or a group of up to 20 stockholders, owning 3% or more of our outstanding common stock continuously for at least three years, to nominate and include in our proxy materials qualifying director nominees constituting up to the greater of (i) 20% of our board of directors or (ii) two directors. To be timely, any proxy access notice must be delivered in writing to our secretary not less than 120 days and not more than 150 days prior to the first anniversary of the preceding year’s annual meeting; provided that in the event that the date of the annual meeting is advanced by more than 30 days or delayed (other than as a result of adjournment) by more than 60 days from the first anniversary of the preceding year’s annual meeting, or if no annual meeting was held in the preceding year, a stockholder’s notice must be received not earlier than 150 days prior to such annual meeting and not later than the close of business on the later of (a) the 120th day prior to such annual meeting and (b) the 10th day following the day on which notice of the date of such annual meeting was mailed or publicly announced. The complete proxy access provisions for director nominations are set forth in our bylaws.
“Blank Check” Preferred Stock. Our board of directors is authorized, without further action by our stockholders, to issue up to 50,000 shares of “blank check” preferred stock of the par value of $100 per share in one or more series possessing such specific terms, including dividend rates, conversion prices, voting rights, redemption prices, maturity dates and other special rights, preferences, qualifications, limitations, and restrictions thereof, as shall be determined in the resolution or resolutions providing for the issue of such preferred stock adopted by our board of directors. The issuance of preferred stock could impede the completion of a merger, tender offer or other takeover attempt.
These provisions of Delaware law, our certificate of incorporation, and our bylaws may have the effect of deterring hostile takeovers or delaying changes in our control or in our management. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and in the policies they implement, and to discourage certain types of transactions that may involve an actual or threatened change of our control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares
3



and, as a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts.
Delaware Business Combination Statute. We are subject to Section 203 of the DGCL (“Section 203”), which prohibits a Delaware corporation from engaging in business combinations with an interested stockholder. An interested stockholder is generally defined as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation or any entity or person affiliated with or controlling or controlled by such entity or person (“interested stockholder”). Section 203 provides that an interested stockholder may not engage in business combinations with the corporation for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:
•before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;
•upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
•on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.
In general, Section 203 defines business combinations to include the following:
•any merger or consolidation involving the corporation and the interested stockholder;
•any sale, lease, transfer, pledge or other disposition of 10% or more of the assets of the corporation to or with the interested stockholder;
•subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;
•any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or
•the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.

DEBT SECURITIES
This description of our registered debt securities is based upon, and qualified by reference to the 2009 Base Indenture, the Eighth Supplemental Indenture, the Thirteenth Supplemental Indenture,
4



the Fifteenth Supplemental Indenture, the Sixteenth Supplemental Indenture, the Eighteenth Supplemental Indenture, the Twenty-First Supplemental Indenture, and the Twenty-Fifth Supplemental Indenture (each as hereinafter defined). You should read the 2009 Base Indenture, the Eighth Supplemental Indenture, the Thirteenth Supplemental Indenture, the Fifteenth Supplemental Indenture, the Sixteenth Supplemental Indenture, the Eighteenth Supplemental Indenture, the Twenty-First Supplemental Indenture, and the Twenty-Fifth Supplemental Indenture, which are incorporated by reference as Exhibits 4.1, 4.3, 4.4, 4.5, 4.6, 4.8, 4.10, and 4.14, respectively, to the Annual Report on Form 10-K of which this Exhibit 4.19 is a part, for the provisions that are important to you.
As used in this description of registered debt securities, the term “Issuer” refers to Thermo Fisher, the term “Fixed Rate Notes” refers collectively to the 2024 Notes, the March 2025 Notes, the April 2025 Notes, the January 2026 3.200% Notes, the January 2026 1.400% Notes, the March 2027 Notes, the April 2027 Notes, the March 2028 Notes, the September 2028 Notes, the 2029 Notes, the 2031 Notes, the 2032 Notes, the 2034 Notes, the 2037 Notes, the 2039 Notes, and the 2049 Notes (each as hereinafter defined), and the term “indenture” means the 2009 Base Indenture as supplemented by the applicable supplemental indenture for the particular series of Fixed Rate Notes being described.
General
We currently have the following series of senior notes issued and outstanding under an Indenture (the “2009 Base Indenture”), dated as of November 20, 2009, by and between Thermo Fisher, as issuer, and The Bank of New York Mellon Trust Company, N.A. (the “Trustee”), as trustee, as supplemented by the Eighth Supplemental Indenture (the “Eighth Supplemental Indenture”), dated as of November 24, 2014, by and among Thermo Fisher, as issuer, the Trustee, as trustee, and The Bank of New York Mellon, London Branch (“BNY London Branch”), as London paying agent: 2.000% Senior Notes due 2025 (the “April 2025 Notes”).
We currently have the following series of senior notes issued and outstanding under the 2009 Base Indenture, as supplemented by the Thirteenth Supplemental Indenture (the “Thirteenth Supplemental Indenture”), dated as of September 12, 2016, by and between Thermo Fisher, as issuer, and the Trustee, as trustee: 0.750% Senior Notes due 2024 (the “2024 Notes”) and 1.375% Senior Notes due 2028 (the “September 2028 Notes”).
We currently have the following series of senior notes issued and outstanding under the 2009 Base Indenture, as supplemented by the Fifteenth Supplemental Indenture (the “Fifteenth Supplemental Indenture”), dated as of March 16, 2017, by and between Thermo Fisher, as issuer, and the Trustee, as trustee: 1.450% Senior Notes due 2027 (the “March 2027 Notes”).
We currently have the following series of senior notes issued and outstanding under the 2009 Base Indenture, as supplemented by the Sixteenth Supplemental Indenture (the “Sixteenth Supplemental Indenture”), dated as of July 24, 2017, by and between Thermo Fisher, as issuer, and the Trustee, as trustee: 1.400% Senior Notes due 2026 (the “January 2026 1.400% Notes”), 1.950% Senior Notes due 2029 (the “2029 Notes”), and 2.875% Senior Notes due 2037 (the “2037 Notes”).
5



We currently have the following series of senior notes issued and outstanding under the 2009 Base Indenture, as supplemented by the Eighteenth Supplemental Indenture (the “Eighteenth Supplemental Indenture”), dated as of September 30, 2019, by and between Thermo Fisher, as issuer, and the Trustee, as trustee: 0.125% Senior Notes due 2025 (the “March 2025 Notes”), 0.500% Senior Notes due 2028 (the “March 2028 Notes”), 0.875% Senior Notes due 2031 (the “2031 Notes”), 1.500% Senior Notes due 2039 (the “2039 Notes”), and 1.875% Senior Notes due 2049 (the “2049 Notes”).
We currently have the following series of senior notes issued and outstanding under the 2009 Base Indenture, as supplemented by the Twenty-First Supplemental Indenture (the “Twenty-First Supplemental Indenture”), dated as of April 2, 2020, by and between Thermo Fisher, as issuer, and the Trustee, as trustee: 1.750% Senior Notes due 2027 (the “April 2027 Notes”) and 2.375% Senior Notes due 2032 (the “2032 Notes”).
We currently have the following series of senior notes issued and outstanding under the 2009 Base Indenture, as supplemented by the Twenty-Fifth Supplemental Indenture (the “Twenty-Fifth Supplemental Indenture”), dated as of November 21, 2022, by and between Thermo Fisher, as issuer, and the Trustee, as trustee: 3.200% Senior Notes due 2026 (the “January 2026 3.200% Notes”) and 3.650% Senior Notes due 2034 (the “2034 Notes”).
The Fixed Rate Notes are general unsecured obligations of the Issuer. Each series of Fixed Rate Notes ranks equally in right of payment with existing and any future unsecured indebtedness of Thermo Fisher, and is junior in right of payment to the Issuer’s senior indebtedness (including senior debt securities). Each series of Fixed Rate Notes is also effectively subordinated to any existing and future secured indebtedness of Thermo Fisher to the extent of the assets securing such indebtedness, and will be structurally subordinated to all existing and any future indebtedness and any other liabilities of their respective subsidiaries. Each series of Fixed Rate Notes is senior in right of payment to any of our existing and future indebtedness that is subordinated to such Fixed Rate Notes.
Aside from the restrictions set forth under “Certain Covenants” below, neither the Fixed Rate Notes nor the indentures restrict our ability or the ability of our subsidiaries to incur additional debt, repurchase securities, recapitalize, or pay dividends or make distributions to shareholders, or require us to maintain interest coverage or other current ratios. We may from time to time, without notice to or the consent of the holders of any series of Fixed Rate Notes, create and issue further notes of any such series ranking equally with the Fixed Rate Notes of such series, and having the same terms as such series (or the same terms other than (1) the payment of interest accruing prior to the issue date of such further notes or (2) the first payment of interest following the issue date of such further notes). Such further notes may be consolidated and form a single series with the notes of such series and have the same terms as to status, redemption, or otherwise as the notes of such series.
Maturity
Each series of Fixed Rate Notes will mature and bear interest as provided in the following table:
6



SeriesMaturityInterest RateInterest Payment DatesRecord DatesAggregate Principal Amount Issued/ Authorized/ Outstanding
2024 NotesSeptember 12, 20240.750%Annually in arrears on September 12 of each year, commencing on September 12, 2017August 28€ 1,000,000,000
March 2025 NotesMarch 1, 20250.125%Annually in arrears on March 1 of each year, commencing on March 1, 2020Fifteenth calendar day prior to the applicable interest payment date€ 800,000,000
April 2025 NotesApril 15, 20252.000%Annually in arrears on April 15 of each year, commencing on April 15, 2015April 1€ 640,000,000
January 2026 3.200% NotesJanuary 21, 20263.200%Annually in arrears on January 21 of each year, commencing on January 21, 2023Business day immediately preceding the applicable interest payment date€ 500,000,000
January 2026 1.400% NotesJanuary 23, 20261.400%Annually in arrears on January 23 of each year, commencing on January 23, 2018January 8€ 700,000,000
March 2027 NotesMarch 16, 20271.450%Annually in arrears on March 16 of each year, commencing on March 16, 2018March 1€ 500,000,000
April 2027 NotesApril 15, 20271.750%Annually in arrears on April 15 of each year, commencing on April 15, 2020Fifteenth calendar day prior to the applicable interest payment date€ 600,000,000
March 2028 NotesMarch 1, 20280.500%Annually in arrears on March 1 of each year, commencing on March 1, 2020Fifteenth calendar day prior to the applicable interest payment date€ 800,000,000
September 2028 NotesSeptember 12, 20281.375%Annually in arrears on September 12 of each year, commencing on September 12, 2017August 28€ 600,000,000
2029 NotesJuly 24, 20291.950%Annually in arrears on July 24 of each year, commencing on July 24, 2018July 9€ 700,000,000
7



SeriesMaturityInterest RateInterest Payment DatesRecord DatesAggregate Principal Amount Issued/ Authorized/ Outstanding
2031 NotesOctober 1, 20310.875%Annually in arrears on October 1 of each year, commencing on October 1, 2020Fifteenth calendar day prior to the applicable interest payment date€ 900,000,000
2032 NotesApril 15, 20322.375%Annually in arrears on April 15 of each year, commencing on April 15, 2020Fifteenth calendar day prior to the applicable interest payment date€ 600,000,000
2034 NotesNovember 21, 20343.650%Annually in arrears on November 21 of each year commencing on November 21, 2023Business day immediately preceding the applicable interest payment date€ 750,000,000
2037 NotesJuly 24, 20372.875%Annually in arrears on July 24 of each year, commencing on July 24, 2018July 9€ 700,000,000
2039 NotesOctober 1, 20391.500%Annually in arrears on October 1 of each year, commencing on October 1, 2020Fifteenth calendar day prior to the applicable interest payment date€ 900,000,000
2049 NotesOctober 1, 20491.875%Annually in arrears on October 1 of each year, commencing on October 1, 2020Fifteenth calendar day prior to the applicable interest payment date€ 1,000,000,000
The Fixed Rate Notes are not subject to any sinking fund.
Interest
The Fixed Rate Notes bear interest, which is paid annually in arrears, at the rates and from the respective dates set forth in the table above.
Interest on an interest payment date is paid to the persons, or “holders” in whose names the Fixed Rate Notes are registered in the security register on the immediately preceding record date noted in the table above, whether or not a business day, as the case may be (each such date being a “regular record date”). Interest on the Fixed Rate Notes will be computed on the basis of an ACTUAL/ACTUAL (ICMA) (as defined in the rulebook of the International Capital Markets Association) day count convention.
8



If any interest payment date, maturity date, or earlier date of redemption falls on a day that is not a business day, the required payment on the Fixed Rate Notes shall be made on the next business day as if it were made on the date the payment was due and no interest shall accrue on the amount so payable for the period from and after that interest payment date, that maturity date, or that date of redemption, as the case may be, until the next business day.
For purposes of the Fixed Rate Notes, “business day” means any day, other than a Saturday or Sunday, (1) which is not a day on which banking institutions in The City of New York or London are authorized or required by law, regulation, or executive order to close and (2) on which the Trans-European Automated Real-Time Gross Settlement Express Transfer system (the TARGET2 system), or any successor thereto, is open.
Optional Redemption
We have the option to redeem the 2024 Notes, the March 2025 Notes, the April 2025 Notes, the January 2026 1.400% Notes, the March 2027 Notes, the April 2027 Notes, the March 2028 Notes, the September 2028 Notes, the 2029 Notes, the 2031 Notes, the 2032 Notes, the 2037 Notes, the 2039 Notes, and the 2049 Notes, in whole at any time or in part from time to time, on at least 15 days but no more than 60 days prior written notice transmitted to the registered holders of such Fixed Rate Notes to be redeemed. We have the option to redeem the January 2026 3.200% Notes and the 2034 Notes, in whole at any time or in part from time to time, on at least 10 days but no more than 60 days prior written notice transmitted to the registered holders of such Fixed Rate Notes to be redeemed. With respect to the March 2025 Notes, the January 2026 3.200% Notes, the April 2027 Notes, the March 2028 Notes, the 2031 Notes, the 2032 Notes, the 2034 Notes, the 2039 Notes, and the 2049 Notes, any notice may, at our discretion, be subject to the satisfaction or waiver of one or more conditions precedent. In such case, the notice shall state the nature of such condition precedent.

Prior to the applicable Par Call Date, upon redemption of the Fixed Rate Notes of any series, we will pay a redemption price equal to the greater of:
(1)    100% of the principal amount of the Fixed Rate Notes to be redeemed, and
(2)    the sum of the present values of the Remaining Scheduled Payments (as defined below) of the Fixed Rate Notes to be redeemed, discounted to the date of redemption on an annual basis (ACTUAL/ACTUAL (ICMA)) using a discount rate equal to the Comparable Bond Rate (as defined below) plus 19 basis points in the case of the April 2025 Notes, 20 basis points in the case of the 2024 Notes, the March 2025 Notes, the January 2026 1.400% Notes, the March 2027 Notes, and the March 2028 Notes, 20 basis points in the case of the January 2026 3.200% Notes, 25 basis points in the case of the September 2028 Notes, the 2029 Notes, the 2031 Notes, and the 2034 Notes, 30 basis points in the case of the 2037 Notes and the 2039 Notes, 35 basis points in the case of the 2049 Notes, 40 basis points in the case of the April 2027 Notes, and 45 basis points in the case of the 2032 Notes,
9



plus, in each case, accrued and unpaid interest thereon, if any, to, but excluding, the redemption date.
On and after the applicable Par Call Date, upon redemption of the Fixed Rate Notes of any series, we will pay a redemption price equal to 100% of the principal amount of the Fixed Rate Notes to be redeemed, plus, in each case, accrued and unpaid interest thereon, if any, to, but excluding, the redemption date.
Notwithstanding the foregoing, installments of interest on the Fixed Rate Notes that are due and payable on an interest payment date falling on or prior to a redemption date will be payable on the interest payment date to the registered holders as of the close of business on the relevant record date in accordance with the Fixed Rate Notes and the applicable indenture.
If less than all of the March 2025 Notes, the January 2026 3.200% Notes, the April 2027 Notes, the March 2028 Notes, the 2031 Notes, the 2032 Notes, the 2034 Notes, the 2039 Notes, or the 2049 Notes are to be redeemed, the Fixed Rate Notes of such series to be redeemed, shall be selected, in the case of global securities, in accordance with applicable depositary procedures and, in the case of definitive securities, in a manner the Trustee deems to be fair and appropriate, unless otherwise required by law or applicable stock exchange requirements. If less than all of the 2024 Notes, the April 2025 Notes, the January 2026 1.400% Notes, the March 2027 Notes, the 2029 Notes, the September 2028 Notes, or the 2037 Notes are to be redeemed, the Fixed Rate Notes of such series to be redeemed shall be selected by the Trustee, in a manner that it deems fair and appropriate in accordance with applicable depositary procedures, unless otherwise required by law or applicable stock exchange requirements. Fixed Rate Notes may be redeemed in part in the minimum authorized denomination for Fixed Rate Notes or in any integral multiple of such amount. Unless we default in payment of the redemption price, on and after the redemption date, interest will cease to accrue on the Fixed Rate Notes or portions thereof called for redemption.
“Comparable Bond Rate” means, for any redemption date, the rate per annum equal to the annual equivalent yield to maturity or interpolated yield to maturity (on a day count basis), computed as of the third business day immediately preceding that redemption date, of the Comparable Government Issue (as defined below), assuming a price for the Comparable Government Issue (expressed as a percentage of its principal amount) equal to the Comparable Price (as defined below) for that redemption date.
“Comparable Government Issue” means the euro-denominated security issued by the German government selected by an Independent Investment Banker (as defined below) as having an actual or interpolated maturity comparable to the remaining term of the Fixed Rate Notes to be redeemed (assuming in the case of the 2024 Notes, the March 2025 Notes, the January 2026 3.200% Notes, the January 2026 1.400% Notes, the March 2027 Notes, the April 2027 Notes, the March 2028 Notes, the September 2028 Notes, the 2029 Notes, the 2031 Notes, the 2032 Notes, the 2034 Notes, the 2037 Notes, the 2039 Notes, or the 2049 Notes to be redeemed matured on their applicable Par Call Date) that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Fixed Rate Notes to be redeemed.
10



“Comparable Price” means, with respect to any redemption date, (a) the average of the Reference Dealer Quotations (as defined below) for such redemption date, after excluding the highest and lowest of the Reference Dealer Quotations, (b) if we obtain fewer than four Reference Dealer Quotations, the arithmetic average of those quotations, or (c) if we obtain only one Reference Dealer Quotation, such Reference Dealer Quotation.
“Independent Investment Banker” means
(a)    with respect to the 2024 Notes, the April 2027 Notes, the September 2028 Notes, and the 2032 Notes, each Reference Dealer appointed by us as Independent Investment Banker (initially, J.P. Morgan Securities plc);
(b)    with respect to the March 2025 Notes, the March 2028 Notes, the 2031 Notes, the 2039 Notes, and the 2049 Notes, any Reference Dealer appointed by us as Independent Investment Banker (initially, Merrill Lynch International);
(c)    with respect to the April 2025 Notes, each Reference Dealer appointed by us as Independent Investment Banker (initially, HSBC Bank plc, Deutsche Bank AG, London Branch and The Royal Bank of Scotland plc);
(d)    with respect to the January 2026 1.400% Notes, the 2029 Notes, and the 2037 Notes, each Reference Dealer appointed by us as Independent Investment Banker (initially, Goldman Sachs & Co. LLC);
(e)    with respect to the March 2027 Notes, each Reference Dealer appointed by us as Independent Investment Banker (initially, HSBC Bank plc); and
(f)    with respect to the January 2026 3.200% Notes and the 2034 Notes, each Reference Dealer appointed by us as Independent Investment Banker (initially, Citigroup Global Markets Limited, Deutsche Bank AG, London Branch and Merrill Lynch International).
“Par Call Date” means June 12, 2024 in the case of the 2024 Notes; January 15, 2025 in the case of the April 2025 Notes; February 1, 2025 in the case of the March 2025 Notes; December 21, 2025 in the case of the January 2026 3.200% Notes; November 23, 2025 in the case of the January 2026 1.400% Notes; December 16, 2026 in the case of the March 2027 Notes; February 15, 2027 in the case of the April 2027 Notes; December 1, 2027 in the case of the March 2028 Notes; June 12, 2028 in the case of the September 2028 Notes; April 24, 2029 in the case of the 2029 Notes; July 1, 2031 in the case of the 2031 Notes; January 15, 2032 in the case of the 2032 Notes; August 21, 2034 in the case of the 2034 Notes; April 24, 2037 in the case of the 2037 Notes; April 1, 2039 in the case of the 2039 Notes; and April 1, 2049 in the case of the 2049 Notes.
“Reference Dealer” means
(a)    with respect to the 2024 Notes and the September 2028 Notes, each of (i) J.P. Morgan Securities plc, Barclays Bank PLC, Mizuho International plc, and Morgan Stanley & Co. International plc and their respective affiliates or successors and (ii) one other nationally recognized investment banking firm (or its respective affiliates) that is a broker or dealer of, and/or a market maker in, German government bonds (each, for purposes of this clause “a”, a “Primary Bond Dealer”) that we select in connection with the particular redemption, and their respective successors;
11



(b)    with respect to the March 2025 Notes, the March 2028 Notes, the 2031 Notes, the 2039 Notes, and the 2049 Notes, each of (i) Merrill Lynch International, Goldman Sachs & Co. LLC, Citigroup Global Markets Limited, and J.P. Morgan Securities plc and their respective affiliates or successors and (ii) one other nationally recognized investment banking firm (or its affiliate) that is a broker or dealer of, and/or market maker in, German government bonds (each, for purposes of this clause “b”, a “Primary Bond Dealer”) that we select in connection with the particular redemption, and its successors;
(c)    with respect to the April 2025 Notes, each of (i) HSBC Bank plc, Deutsche Bank AG, London Branch and The Royal Bank of Scotland plc, and their respective affiliates or successors and (ii) two other nationally recognized investment banking firms (or their respective affiliates) that are brokers or dealers of, and/or market makers in, German government bonds (each, for purposes of this clause “c”, a “Primary Bond Dealer”) that we select in connection with the particular redemption, and their respective successors;
(d)    with respect to the January 2026 1.400% Notes, the 2029 Notes, and the 2037 Notes, each of (i) Goldman Sachs & Co. LLC, Merrill Lynch International, Barclays Bank PLC, and HSBC Bank plc and their respective affiliates or successors and (ii) one other nationally recognized investment banking firm (or its affiliate) that is a broker or dealer of, and/or a market maker in, German government bonds (each, for purposes of this clause “d”, a “Primary Bond Dealer”) that we select in connection with the particular redemption, and its successors;
(e)    with respect to the March 2027 Notes, each of (i) Credit Suisse Securities (Europe) Limited and HSBC Bank plc and their respective affiliates or successors and (ii) three other nationally recognized investment banking firms (or their respective affiliates) that are brokers or dealers of, and/or market makers in, German government bonds (each, for purposes of this clause “e”, a “Primary Bond Dealer”) that we select in connection with the particular redemption, and their respective successors;
(f)    with respect to the April 2027 Notes and the 2032 Notes, each of (i) J.P. Morgan Securities plc, Morgan Stanley & Co. International plc, Merrill Lynch International, and Citigroup Global Markets Limited and their respective affiliates or successors and (ii) one other nationally recognized investment banking firm (or its affiliate) that is a broker or dealer of, and/or market maker in, German government bonds (each, for purposes of this clause “f”, a “Primary Bond Dealer”) that we select in connection with the particular redemption, and its successors; and
(g)    with respect to the January 2026 3.200% Notes and the 2034 Notes, each of (i) Citigroup Global Markets Limited, Deutsche Bank AG, London Branch and Merrill Lynch International and their respective affiliates or successors and (ii) one other nationally recognized investment banking firm (or its affiliate) that is a broker or dealer of, and/or market maker in, German government bonds (each, for purposes of this clause “g”, a “Primary Bond Dealer”) that we select in connection with the particular redemption, and its successors;
provided, in each case, that if at any time any of the above is not a Primary Bond Dealer, we will substitute that entity with another nationally recognized investment banking firm that we select that is a Primary Bond Dealer.
12



“Reference Dealer Quotations” means, with respect to each Reference Dealer and any redemption date, the arithmetic average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Government Issue (expressed, in each case, as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by such Reference Dealer at 11:00 a.m., London time, on the third business day preceding such redemption date.
“Remaining Scheduled Payments” means,
(a)    with respect to each 2024 Note, March 2025 Note, January 2026 3.200% Note, January 2026 1.400% Note, March 2027 Note, April 2027 Note, March 2028 Note, September 2028 Note, 2029 Note, 2031 Note, 2032 Note, 2034 Note, 2037 Note, 2039 Note, and 2049 Note to be redeemed, the remaining scheduled payments of the principal thereof and interest thereon that would be due after the related redemption date but for such redemption (assuming that such notes to be redeemed matured on their applicable Par Call Date); and
(b)    with respect to each April 2025 Note to be redeemed, the remaining scheduled payments of the principal thereof and interest thereon that would be due after the related redemption date for such redemption;
provided, however, that, if any such redemption date is not an interest payment date with respect to such note, the amount of the next succeeding scheduled interest payment thereon will be reduced by the amount of interest accrued thereon to such redemption date.
Redemption Upon Tax Event
2024 Notes, the March 2025 Notes, the April 2025 Notes, the January 2026 1.400% Notes, the March 2027 Notes, the April 2027 Notes, the March 2028 Notes, the September 2028 Notes, the 2029 Notes, the 2031 Notes, the 2032 Notes, the 2037 Notes, the 2039 Notes, and the 2049 Notes
We may redeem at our option the 2024 Notes, the March 2025 Notes, the April 2025 Notes, the January 2026 1.400% Notes, the March 2027 Notes, the April 2027 Notes, the March 2028 Notes, the September 2028 Notes, the 2029 Notes, the 2031 Notes, the 2032 Notes, the 2037 Notes, the 2039 Notes, and the 2049 Notes in whole, but not in part, on at least 15 days’ but not more than 60 days’ notice, at a redemption price equal to 100% of their principal amount (plus any accrued interest and additional amounts then payable with respect to such Fixed Rate Notes to be redeemed), if we determine that (A) as a result of any change or amendment to the laws, treaties, regulations or rulings of the United States or any political subdivision or taxing authority thereof, which change or amendment is announced or becomes effective on or after the date of the applicable prospectus supplement pursuant to which such Fixed Rate Notes of such series were issued, there is a material probability that we have or will become obligated to pay additional amounts as described under “Payment of Additional Amounts” on any Fixed Rate Notes of such series or (B) on or after the date of the applicable prospectus supplement pursuant to which the Fixed Rate Notes of such series were issued, any change in the official application, enforcement or interpretation of those laws, treaties, regulations or rulings, including a holding by a court of competent jurisdiction in the United States or any other action, taken by any taxing
13



authority or a court of competent jurisdiction in the United States, whether or not such action was taken or made with respect to us, results in a material probability that we have or will become obligated to pay additional amounts as described under “Payment of Additional Amounts” on any Fixed Rate Notes of such series; provided that we determine, in our business judgment, that the obligation to pay such additional amounts cannot be avoided by use of reasonable measures available to us, not including substitution of the obligor under the Fixed Rate Notes. Prior to the mailing of any notice of such a redemption, we will deliver to the Trustee (1) an officer’s certificate stating that we are entitled to effect such a redemption and setting forth a statement of facts showing that the conditions precedent to the right of our company to so redeem have occurred and (2) an opinion of counsel to that effect based on that statement of facts.
January 2026 3.200% Notes and 2034 Notes
We may redeem all, but not less than all, of the January 2026 3.200% Notes and 2034 Notes at a redemption price equal to 100% of the principal amount thereof, together with accrued and unpaid interest, if any, to the redemption date under the following conditions:
•if there is an amendment to, or change in, the laws, regulations, rulings or treaties of the United States or any other jurisdiction in which we or any successor (including a continuing corporation, partnership, limited liability company, joint venture, joint-stock company, association, trust or unincorporated organization formed by a consolidation with us, into which we are merged, or that acquires or leases all or substantially all of our property and assets) may be organized, as applicable, or any political subdivision thereof or therein having the power to tax (a “Taxing Jurisdiction”), or any change in the application or official interpretation of such laws, regulations, rulings or treaties, including any action taken by, or a change in published administrative practice of, a taxing authority or a holding by a court of competent jurisdiction, regardless of whether such action, change or holding is with respect to us;
•as a result of such amendment or change, we become, or there is a material probability that we will become, obligated to pay Additional Amounts on the next interest payment date with respect to the notes; and
•the obligation to pay such Additional Amounts cannot be avoided through our commercially reasonable measures, not including substitution of the obligor of the notes;
Prior to effecting any such redemption, we will deliver to the Trustee:
•a certificate stating that we cannot avoid the obligation to pay Additional Amounts after taking commercially reasonable measures available to us;
•a written opinion of our independent tax counsel of recognized standing to the effect that we have or there is a material probability that we will, become obligated, to pay Additional Amounts as a result of a change, amendment, official interpretation or application described above and that we cannot avoid the payment of such Additional Amounts by taking commercially reasonable measures available to us; and
•a notice of redemption to be delivered to the holder of record of the January 2026 3.200% Notes and/or 2034 Notes.
14



Such notice of redemption shall be delivered not less than 10 days, but not more than 90 days, prior to the date of redemption. The notice of redemption cannot be given more than 90 days before the earliest date on which we would otherwise be, or there is a material probability that we would otherwise be, required to pay Additional Amounts.
Payment of Additional Amounts
2024 Notes, the March 2025 Notes, the April 2025 Notes, the January 2026 1.400% Notes, the March 2027 Notes, the April 2027 Notes, the March 2028 Notes, the September 2028 Notes, the 2029 Notes, the 2031 Notes, the 2032 Notes, the 2037 Notes, the 2039 Notes, and the 2049 Notes
We will pay to a holder of the 2024 Notes, the March 2025 Notes, the April 2025 Notes, the January 2026 1.400% Notes, the March 2027 Notes, the April 2027 Notes, the March 2028 Notes, the September 2028 Notes, the 2029 Notes, the 2031 Notes, the 2032 Notes, the 2037 Notes, the 2039 Notes, and the 2049 Notes who is not a United States person (as defined below) additional amounts as may be necessary so that every net payment of the principal of and premium, if any, and interest on such holder’s Fixed Rate Notes, after deduction or withholding for or on account of any present or future tax, assessment or other governmental charge imposed upon that holder by the United States or any taxing authority thereof or therein, will not be less than the amount provided in such holder’s Fixed Rate Notes to be then due and payable. We will not be required, however, to make any payment of additional amounts for or on account of:
(a)    any tax, assessment or other governmental charge that would not have been imposed but for (1) the existence of any present or former connection (other than a connection arising solely from the ownership of those Fixed Rate Notes or the receipt of payments in respect of those Fixed Rate Notes) between that holder (or the beneficial owner for whose benefit such holder holds such Fixed Rate Notes), or between a fiduciary, settlor, beneficiary of, member or shareholder of, or possessor of a power over, that holder or beneficial owner, if that holder or beneficial owner is an estate, trust, partnership or corporation, and the United States, including that holder or beneficial owner, or that fiduciary, settlor, beneficiary, member, shareholder or possessor, being or having been a citizen or resident or treated as a resident of the United States or being or having been engaged in trade or business or present in the United States or having had a permanent establishment in the United States or (2) the presentation of a debt security for payment on a date more than 30 days after the later of the date on which that payment becomes due and payable and the date on which payment is duly provided for;
(b)    any estate, inheritance, gift, sales, transfer, excise, personal property, wealth, capital gains, interest equalization or similar tax, assessment or other governmental charge;
(c)    any tax, assessment, or other governmental charge imposed on foreign personal holding company income or by reason of a holder (or the beneficial owner for whose benefit such holder holds such Fixed Rate Notes), or a fiduciary, settlor, beneficiary of, member or shareholder of, or possessor of a power over, the holder or beneficial owner, if that holder or beneficial owner is an estate, trust, partnership, or corporation, being or having been a passive foreign investment company, a controlled foreign corporation, a foreign tax exempt organization, or a personal holding company with respect to the
15



United States or a corporation that accumulates earnings to avoid U.S. federal income tax;
(d)    any tax, assessment or other governmental charge which is payable otherwise than by withholding from payment of principal of or premium, if any, or interest on such holder’s Fixed Rate Notes;
(e)    any tax, assessment, or other governmental charge required to be withheld by any paying agent from any payment of principal of and premium, if any, or interest on any note if that payment can be made without withholding by any other paying agent;
(f)    any tax, assessment, or other governmental charge which would not have been imposed but for the failure of a holder (or the beneficial owner for whose benefit such holder holds the Fixed Rate Notes), or a fiduciary, settlor, beneficiary of, member or shareholder of, or possessor of power over, the holder or beneficial owner, if that holder or beneficial owner is an estate, trust, partnership or corporation, or any intermediary through which a beneficial owner holds Fixed Rate Notes to comply with our request to comply with certification, information, documentation or other reporting requirements concerning the nationality, residence, identity, or connections with the United States of the beneficial owner or any holder of the Fixed Rate Notes (including, but not limited to, the requirement to provide Internal Revenue Service Forms W-8BEN, Forms W-8BEN-E, Forms W-8ECI, or any subsequent versions thereof or successor thereto, and including, without limitation, any documentation requirement under an applicable income tax treaty);
(g)    any tax, assessment, or other governmental charge imposed as a result of a holder (or the beneficial owner for whose benefit such holder holds such Fixed Rate Notes), or a fiduciary, settlor, beneficiary of, member or shareholder of, or possessor of a power over, the holder or beneficial owner, if that holder or beneficial owner is an estate, trust, partnership or corporation, being or having been (1) a 10% shareholder (as defined in Section 871(h)(3)(B) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”), and the regulations that may be promulgated thereunder) of our company or (2) a controlled foreign corporation that is related to us within the meaning of Section 864(d)(4) of the Code, or (3) a bank receiving interest described in Section 881(c)(3)(A) of the Code;
(h)    any tax, assessment, or other governmental charge that would not have been imposed but for a change in law, regulation, or administrative or judicial interpretation that becomes effective more than 15 days after the payment becomes due or is duly provided for, whichever occurs later;
(i)    any taxes payable under Sections 1471 through 1474 of the Code (or any amended or successor version of such Sections), any current or future regulations or other guidance thereunder, or any agreement (including any intergovernmental agreement) entered into in connection therewith;
(j)    any combination of items (a), (b), (c), (d), (e), (f), (g), (h), and (i); or
(k)    with respect to the April 2025 Notes, any withholding or deduction that is imposed on a payment to an individual and is required to be made pursuant to European Council Directive 2003/48/EC relating to the taxation of savings or any law implementing or complying with, or introduced in order to conform to, such Directive (or any successor
16



version that is substantively comparable) or any combination of items (a), (b), (c), (d), (e), (f), (g), (h), (i), and this item (k);
nor will we pay any additional amounts to any holder that is not the sole beneficial owner of the Fixed Rate Notes, or a portion of the Fixed Rate Notes, or that is a fiduciary, partnership, or limited liability company to the extent that a beneficial owner with respect to the holder, a beneficiary, or settlor with respect to the fiduciary or a member of that partnership, limited liability company, or a beneficial owner thereof would not have been entitled to the payment of those additional amounts had that beneficiary, settlor, member, or beneficial owner received directly its beneficial or distributive share of the payment.
As used in the preceding paragraph, the term “United States person” means any individual who is a citizen or resident of the United States for U.S. federal income tax purposes, a corporation, partnership, or other entity created or organized in or under the laws of the United States, any state of the United States, or the District of Columbia (other than a partnership that is not treated as a United States person under any applicable Treasury Regulations), or any estate or trust the income of which is subject to United States federal income taxation regardless of its source. As used under this heading “Payment of Additional Amounts” and under the heading “Redemption Upon Tax Event”, the term “United States” means the United States of America, the states of the United States, and the District of Columbia.
The Fixed Rate Notes are subject in all cases to any tax, fiscal, or other law or regulation or administrative or judicial interpretation applicable to the Fixed Rate Notes. Except as specifically provided under this heading “Payment of Additional Amounts,” we will not be required to make any payment for any tax, assessment, or other governmental charge imposed by any government or a political subdivision or taxing authority of or in any government or political subdivision.
January 2026 3.200% Notes and 2034 Notes
Unless otherwise required by law, we will not deduct or withhold from payments made under or with respect to the January 2026 3.200% Notes and the 2034 Notes for or on account of any present or future taxes, duties, levies, imposts, assessments or governmental charges of whatever nature imposed or levied by or on behalf of any Taxing Jurisdiction (“Taxes”). In the event that we are required to withhold or deduct any amount for or on account of any Taxes from any payment made under or with respect to the January 2026 3.200% Notes or the 2034 Notes, we will pay such additional amounts so that the net amount received by each holder of the January 2026 3.200% Notes and the 2034 Notes (including additional amounts) after such withholding or deduction will equal the amount that such holder would have received if such Taxes had not been required to be withheld or deducted.
Additional amounts will not be payable with respect to a payment made to a holder of the January 2026 3.200% Notes and the 2034 Notes or a holder of beneficial interests in global securities representing such notes where such holder is subject to taxation on such payment by a relevant Taxing Jurisdiction for any reason other than such holder’s mere ownership of the January 2026 3.200% Notes or the 2034 Notes or for or on account of:
17



•any Taxes that are imposed or withheld solely because such holder (or the beneficial owner for whose benefit such holder holds the January 2026 3.200% Notes or the 2034 Notes) or a fiduciary, settlor, beneficiary, member, shareholder or other equity owner of, or possessor of a power over, such holder (or beneficial owner) if such holder (or beneficial owner) is an estate, trust, partnership, limited liability company, corporation or other entity:
◦is or was present or engaged in, or is or was treated as present or engaged in, a trade or business in the Taxing Jurisdiction or has or had a permanent establishment in the Taxing Jurisdiction (in each cash, other than the mere fact of ownership of such securities, without another presence or business in such Taxing Jurisdiction);
◦has or had any present or former connection (other than the mere fact of ownership of the January 2026 3.200% Notes or the 2034 Notes) with the Taxing Jurisdiction imposing such Taxes, including being or having been a national citizen or resident thereof, being treated as being or having been a resident thereof or being or having been physically present therein;
◦with respect to any withholding Taxes imposed by the United States, is or was with respect to the United States a personal holding company, a passive foreign investment company, a controlled foreign corporation, a foreign private foundation or other foreign tax exempt organization or corporation that has accumulated earnings to avoid United States federal income tax;
◦actually or constructively owns or owned 10% or more of the total combined voting power of all of our classes of stock within the meaning of section 871(h)(3) of the Code; or
◦is or was a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of section 881(c)(3) of the Code;
•any estate, inheritance, gift, sales, transfer, excise, personal property or similar Taxes imposed with respect to the January 2026 3.200% Notes or the 2034 Notes, except as otherwise provided in the indenture;
•any Taxes imposed solely as a result of the presentation of the January 2026 3.200% Notes or the 2034 Notes (where presentation is required) for payment on a date more than 15 days after the date on which such payment became due and payable or the date on which payment thereof is duly provided for, whichever is later, except to the extent that the beneficiary or holder thereof would have been entitled to the payment of additional amounts had the January 2026 3.200% Notes or the 2034 Notes been presented for payment on any date during such 15-day period;
•any Taxes imposed or withheld solely as a result of the failure of such holder or any other person to comply with applicable certification, information, documentation or other reporting requirements concerning the nationality, residence, identity or connection with the Taxing Jurisdiction of such holder, if such compliance is required by statute, regulation, ruling or administrative practice of the relevant Taxing Jurisdiction or by any applicable tax treaty to which the relevant Taxing Jurisdiction is a party as a precondition to relief or exemption from such Taxes;
18



•with respect to withholding Taxes imposed by the United States, any such Taxes imposed by reason of the failure of such holder to fulfill the statement requirements of sections 871(h) or 881(c) of the Code;
•any Taxes that are payable by any method other than withholding or deduction by us or any paying agent from payments in respect of the January 2026 3.200% Notes and the 2034 Notes;
•any Taxes required to be withheld by any paying agent from any payment in respect of the January 2026 3.200% Notes and the 2034 Notes if such payment can be made without such withholding by at least one other paying agent;
•any withholding or deduction for Taxes which would not have been imposed if the January 2026 3.200% Notes or the 2034 Notes had been presented to another paying agent in a member state of the European Union as of the date of the indenture;
•any withholding or deduction required pursuant to sections 1471 through 1474 of the Code, any regulations or agreements thereunder, official interpretations thereof, any intergovernmental agreement, or any law, rule, guidance or administrative practice implementing an intergovernmental agreement entered into in connection with such sections of the Code; or
•any combination of the above conditions.
Additional amounts also will not be payable to any holder of the January 2026 3.200% Notes and the 2034 Notes or the holder of a beneficial interest in a global security representing such notes that is a fiduciary, partnership, limited liability company or other fiscally transparent entity, or to such holder that is not the sole holder of such security or holder of such beneficial interests in such security, as the case may be. The exception, however, will apply only to the extent that a beneficiary or settlor with respect to the fiduciary, or a beneficial owner or member of the partnership, limited liability company or other fiscally transparent entity, would not have been entitled to the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly its beneficial or distributive share of the payment.
We also:
•will make such withholding or deduction of Taxes;
•will remit the full amount of Taxes so deducted or withheld to the relevant Taxing Jurisdiction in accordance with all applicable laws;
•will use our commercially reasonable efforts to obtain from each Taxing Jurisdiction imposing such Taxes certified copies of tax receipts evidencing the payment of any Taxes so deducted or withheld; and
•upon request, will make available to the holders of the January 2026 3.200% Notes and the 2034 Notes, within 90 days after the date the payment of any Taxes deducted or withheld is due pursuant to applicable law, certified copies of tax receipts evidencing such payment by us or if, notwithstanding our efforts to obtain such receipts, the same are not obtainable, other evidence of such payments.
At least 30 days prior to each date on which any payment under or with respect to the January 2026 3.200% Notes or the 2034 Notes is due and payable for which we will be obligated to pay
19



additional amounts, with respect to such payment, we will deliver to the Trustee an officers’ certificate stating the fact that such additional amounts will be payable, the amounts so payable and such other information as is necessary to enable the trustee to pay such Additional Amounts to holders of such series of notes on the payment date.
In addition, we will pay any stamp, issue, registration, documentary or other similar taxes and duties, including interest, penalties and additional amounts with respect thereto, payable in the United States or any political subdivision or taxing authority of or in the United States in respect of the creation, issue, offering, enforcement, redemption or retirement of the January 2026 3.200% Notes or the 2034 Notes.
The foregoing provisions shall survive any termination or the discharge of the indenture governing the January 2026 3.200% Notes and the 2034 Notes and shall apply to any jurisdiction in which we or any successor to us is organized or is engaged in business for tax purposes or any political subdivisions or taxing authority or agency thereof or therein.
Repurchase Upon a Change of Control
If a Change of Control Triggering Event (as defined below) occurs with respect to any series of Fixed Rate Notes, unless the Issuer has redeemed such series of Fixed Rate Notes in full, as described above, has defeased such series of Fixed Rate Notes, or has satisfied and discharged such series of Fixed Rate Notes as described below, the Issuer will make an offer to each holder of the applicable series of Fixed Rate Notes (the “Change of Control Offer”) to repurchase any and all of such holder’s Fixed Rate Notes of such series at a repurchase price in cash equal to 101% of the aggregate principal amount of such Fixed Rate Notes (such principal amount to be equal to €100,000 or an integral multiple of €1,000 in excess thereof), plus accrued and unpaid interest, if any, thereon, to, but excluding, the date of repurchase (the “Change of Control Payment”). Within 30 days following any Change of Control Triggering Event, notice shall be delivered to holders of Fixed Rate Notes of such series describing the transaction or transactions that constitute the Change of Control Triggering Event and offering to repurchase such Fixed Rate Notes on the date specified in the notice, which date will be, (a) for the 2024 Notes, the March 2025 Notes, the April 2025 Notes, the January 2026 1.400% Notes, the March 2027 Notes, the April 2027 Notes, the March 2028 Notes, the September 2028 Notes, the 2029 Notes, the 2031 Notes, the 2032 Notes, the 2037 Notes, the 2039 Notes, and the 2049 Notes, no earlier than 15 days and no later than 60 days from the date such notice is delivered and (b) for the January 2026 3.200% Notes and the 2034 Notes, no earlier than 10 days and no later than 60 days from the date such notice is delivered (as applicable, the “Change of Control Payment Date”), pursuant to the procedures required by the Fixed Rate Notes and described in such notice. Notwithstanding the foregoing, installments of interest on any series of Fixed Rate Notes that are due and payable on interest payment dates falling on or prior to the Change of Control Payment Date will be payable on such interest payment dates to the registered holders as of the close of business on the relevant record dates in accordance with such series of Fixed Rate Notes and the applicable indenture. The Issuer must comply in all material respects with the requirements of Rule 14e-1 under the Exchange Act, and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with
20



the repurchase of the Fixed Rate Notes as a result of a Change of Control Triggering Event. To the extent that the provisions of any such securities laws or regulations conflict with the Change of Control repurchase provisions of the Fixed Rate Notes, the Issuer will be required to comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under the Change of Control repurchase provisions of the Fixed Rate Notes by virtue of such conflicts.
On the Change of Control Payment Date, the Issuer will be required, to the extent lawful, to:

•accept for payment all Fixed Rate Notes or portions of Fixed Rate Notes of the applicable series properly tendered pursuant to the Change of Control Offer;
•deposit with the Trustee or a paying agent an amount equal to the Change of Control Payment in respect of all Fixed Rate Notes or portions of Fixed Rate Notes of the applicable series properly tendered; and
•deliver or cause to be delivered to the Trustee the Fixed Rate Notes properly accepted, together with an officer’s certificate stating the principal amount of Fixed Rate Notes or portions of Fixed Rate Notes of such series being repurchased, and solely for the January 2026 3.200% Notes and the 2034 Notes, that all conditions precedent contained in the indenture to make a Change of Control Offer have been complied with and that the Change of Control Offer has been made in compliance with the indenture.
“Below Investment Grade Rating Event” means, with respect to a series of Fixed Rate Notes, such Fixed Rate Notes are downgraded below Investment Grade Rating (as defined below) by any two of the Rating Agencies (as defined below) on any date during the period (the “Trigger Period”) commencing 60 days prior to the first public announcement by Thermo Fisher of the occurrence of a Change of Control (or pending Change of Control) and ending 60 days following consummation of such Change of Control (which Trigger Period shall be extended so long as the rating of such Fixed Rate Notes is under publicly announced consideration for possible downgrade by at least two of such Rating Agencies on such 60th day, such extension to last with respect to each such Rating Agency until the date on which such Rating Agency considering such possible downgrade either (x) rates such Fixed Rate Notes below Investment Grade or (y) publicly announces that it is no longer considering such Fixed Rate Notes for possible downgrade, provided that no such extension will occur if on such 60th day such Fixed Rate Notes are rated Investment Grade by at least two of such Rating Agencies in question and are not subject to review for possible downgrade by such Rating Agencies).
“Change of Control” means the occurrence of any of the following:
(1)    the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the properties or assets of Thermo Fisher and its subsidiaries taken as a whole to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) other than Thermo Fisher or one of its direct or indirect wholly-owned subsidiaries;
21



(2)    the consummation of any transaction (including, without limitation, any merger or consolidation) as a result of which any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of more than 50% of Thermo Fisher’s outstanding voting stock or other voting stock into which Thermo Fisher’s voting stock is reclassified, consolidated, exchanged, or changed, measured by voting power rather than number of shares;
(3)    Thermo Fisher consolidates with, or merges with or into, any “person” or “group” (as that term is used in Section 13(d)(3) of the Exchange Act), or any “person” or “group” consolidates with, or merges with or into, Thermo Fisher, in any such event pursuant to a transaction in which any of Thermo Fisher’s voting stock or the voting stock of such other person is converted into or exchanged for cash, securities, or other property, other than any such transaction where the shares of Thermo Fisher’s voting stock outstanding immediately prior to such transaction constitute, or are converted into or exchanged for, a majority of the voting stock of the surviving person or any direct or indirect parent company of the surviving person immediately after giving effect to such transaction;
(4)    with respect to the April 2025 Notes, the first day on which a majority of the members of Thermo Fisher’s board of directors are not Continuing Directors (as defined below); or
(5)    the adoption of a plan relating to Thermo Fisher’s liquidation or dissolution.
Notwithstanding the foregoing, a transaction will not be deemed to involve a Change of Control if (a) Thermo Fisher becomes a direct or indirect wholly-owned subsidiary of a holding company (which shall include a parent company) and (b)(i) the holders of the voting stock of such holding company immediately following that transaction are substantially the same as the holders of Thermo Fisher’s voting stock immediately prior to that transaction or (ii) no “person” (as that term is used in Section 13(d)(3) of the Exchange Act) (other than a holding company satisfying the requirements of this sentence) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of more than 50% of the voting power of the voting stock of such holding company immediately following such transaction.
For purposes of this definition, “voting stock” means with respect to any specified person (as that term is used in Section 13(d)(3) of the Exchange Act) capital stock of any class or kind the holders of which are ordinarily, in the absence of contingencies, entitled to vote for the election of directors (or persons performing similar functions) of such person, even if the right to vote has been suspended by the happening of such a contingency.
The definition of Change of Control includes a phrase relating to the direct or indirect sale, lease, transfer, conveyance, or other disposition of “all or substantially all” of the properties or assets of Thermo Fisher and its subsidiaries taken as a whole. Although there is a limited body of case law interpreting the phrase “substantially all,” there is no precise established definition of the phrase under applicable law. Accordingly, the applicability of the requirement that Thermo Fisher offer to repurchase the Fixed Rate Notes as a result of a sale, lease, transfer, conveyance, or other disposition of less than all of the assets of Thermo Fisher and its subsidiaries taken as a whole to another person or group may be uncertain.
22



“Change of Control Triggering Event” means, with respect to any series of Fixed Rate Notes, the occurrence of both a Change of Control and a Below Investment Grade Rating Event.
“Continuing Directors” means, as of any date of determination, any member of the board of directors of Thermo Fisher who (1) was a member of the board of directors of Thermo Fisher on the date of the issuance of the April 2025 Notes; or (2) was nominated for election or elected to the board of directors of Thermo Fisher with the approval of a majority of the Continuing Directors who were members of such board of directors of Thermo Fisher at the time of such nomination or election (either by specific vote or by approval of Thermo Fisher’s proxy statement in which such member was named as a nominee for election as a director, without objection to such nomination).
“Fitch” means Fitch Ratings Limited, and any successor to its rating agency business.
“Investment Grade Rating” means a rating by Moody’s equal to or higher than Baa3 (or the equivalent under a successor rating category of Moody’s) or a rating by S&P equal to or higher than BBB- (or the equivalent under any successor rating category of S&P) or a rating by Fitch equal to or higher than BBB- (or the equivalent under any successor rating category of Fitch).
“Moody’s” means Moody’s Investors Service, Inc., and any successor to its rating agency business.
“Rating Agencies” means (1) Moody’s, S&P and Fitch; and (2) if any of Moody’s, S&P or Fitch ceases to rate the applicable series of Fixed Rate Notes or fails to make a rating of such Fixed Rate Notes publicly available for any reason, a “nationally recognized statistical rating organization” within the meaning of Section 3(a)(62) of the Exchange Act, selected by Thermo Fisher (as certified by a resolution of its board of directors) as a replacement agency for any of Moody’s, S&P or Fitch, or all of them, as the case may be.
“S&P” means S&P Global Ratings, a division of S&P Global, Inc., and any successor to its rating agency business.
Certain Covenants
Limitations on Liens. The Issuer will not, and will not permit any of its subsidiaries to, create, incur, assume, or otherwise cause to become effective any Lien (as defined below) (other than permitted Liens) on any Principal Property (as defined below) or upon shares of stock of any Principal Subsidiary (as defined below) (whether such Principal Property or shares are now existing or owned or hereafter created or acquired), to secure any indebtedness of the Issuer, any of its subsidiaries or any indebtedness of any other Person (as defined below), unless the Issuer or such subsidiary also secures all payments due under the Fixed Rate Notes and all senior debt securities of any series having the benefit of this covenant (together with, if the Issuer shall so determine, any other indebtedness of the Issuer or any subsidiary of the Issuer then existing or thereafter created ranking equally with the Fixed Rate Notes), on an equal and ratable basis with such other indebtedness so secured (or, in the case of indebtedness subordinated to the Fixed Rate Notes, prior or senior thereto, with the same relative priority as the Fixed Rate Notes will
23



have with respect to such subordinated indebtedness) for so long as such other indebtedness shall be so secured. The indentures contain the following exceptions to the foregoing prohibition:
(a)    Liens existing on the date when the Issuer first issued the applicable series of Fixed Rate Notes pursuant to the applicable indenture;
(b)    Liens on property owned or leased by a Person existing at the time such Person is merged with or into or consolidated with the Issuer or any subsidiary of the Issuer or the Issuer or one or more of its subsidiaries acquires directly or indirectly all or substantially all of the stock or assets of such Person; provided that such Liens were in existence prior to the contemplation of such merger, consolidation or acquisition and do not extend to any assets other than those of the Person merged into, consolidated with, or acquired by the Issuer or such subsidiary;
(c)    Liens on property existing at the time of acquisition thereof by the Issuer or any subsidiary of the Issuer, provided that such Liens were in existence prior to the contemplation of such acquisition and do not extend to any property other than the property so acquired by the Issuer or such subsidiary;
(d)    Liens to secure indebtedness incurred prior to, at the time of or within 18 months after the later of the acquisition of any property and the completion of the construction, alteration, repair, or improvement of any property, as the case may be, for the purpose of financing all or a part of the purchase price thereof or cost of the construction, alteration, repair, or improvement thereof and Liens to the extent they secure indebtedness in excess of such purchase price or cost and for the payment of which recourse may be had only against such property;
(e)    Liens in favor of the United States or any state, territory, or possession thereof (or the District of Columbia), or any department, agency, instrumentality, or political subdivision of the United States or any state, territory, or possession thereof (or the District of Columbia), to secure partial, progress, advance or other payments pursuant to any contract or statute or to secure any indebtedness incurred for the purpose of financing all or any part of the purchase price or the cost of constructing or improving the property subject to such Liens;
(f)    any Lien securing indebtedness of a subsidiary owing to the Issuer or to one or more of its subsidiaries;
(g)    Liens incurred or assumed in connection with the issuance of revenue bonds the interest on which is exempt from federal taxation pursuant to Section 103 of the Code;
(h)    Liens created, incurred or assumed in connection with an industrial revenue bond, pollution control bond, or similar financing between the Issuer or any subsidiary of the Issuer and any federal, state, or municipal government or other government body or quasi-governmental agency;
(i)    any extension, renewal, or replacement (or successive extensions, renewals, or replacements) in whole or in part of any Lien referred to in clauses (a) through (h) above, inclusive, so long as (1) the principal amount of the indebtedness secured thereby does not exceed the principal amount of indebtedness so secured at the time of the extension, renewal, or replacement (except that, where an additional principal amount of indebtedness is incurred to provide funds for the completion of a specific project, the additional principal amount, and any related financing costs, may be
24



secured by the Lien as well) and (2) the Lien is limited to the same property subject to the Lien so extended, renewed or replaced (and improvements on the property); and
(j)    any Lien on a Principal Property or the shares of stock of a Principal Subsidiary that would not otherwise be permitted by clauses (a) through (i) above, inclusive, securing indebtedness which, together with:
•the aggregate outstanding principal amount of all other indebtedness of the Issuer and its subsidiaries secured by Liens on a Principal Property or the shares of stock of a Principal Subsidiary that is permitted solely pursuant to this clause (j), and
•the aggregate Value (as defined below) of existing Sale and Leaseback Transactions (as defined below) that are permitted solely pursuant to clause (c) of “Limitation on Sale and Leaseback Transactions” and are still in existence, does not exceed 10% of Consolidated Net Assets (as defined below).
Limitation on Sale and Leaseback Transactions. The Issuer will not, and will not permit any of its subsidiaries to, enter into any Sale and Leaseback Transaction with respect to any Principal Property unless:
(a)    the Issuer or such subsidiary could incur indebtedness, in a principal amount at least equal to the Value of such Sale and Leaseback Transaction, secured by a Lien on the Principal Property to be leased (without equally and ratably securing debt securities of any series having the benefit of this covenant) pursuant to clauses (a) through (i) under “Limitations on Liens” above;
(b)    the Issuer applies, during the six months following the effective date of the Sale and Leaseback Transaction, an amount equal to the Value of the Sale and Leaseback Transaction to either (or a combination of) the voluntary retirement of Funded Debt (as defined below) or to the acquisition of property; or
(c)    the aggregate Value of such Sale and Leaseback Transaction plus the Value of all other Sale and Leaseback Transactions of Principal Properties entered into after the date of the issuance of the Fixed Rate Notes permitted solely by this clause (c) and still in existence, plus the aggregate amount of all indebtedness secured by Liens permitted solely by clause (j) of “Limitations on Liens” does not exceed 10% of Consolidated Net Assets.
Certain Other Covenants. The indentures contain certain other covenants regarding, among other matters, corporate existence and reports to holders of Fixed Rate Notes. The Fixed Rate Notes do not contain any additional financial or restrictive covenants, including covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios. The provisions of the indentures do not afford holders of Fixed Rate Notes issued thereunder protection in the event of a sudden or significant decline in the Issuer’s credit quality or in the event of a takeover, recapitalization or highly leveraged or similar transaction involving the Issuer or any of its affiliates that may adversely affect such holders.
Consolidation, Merger and Sale of Assets. The Issuer will not consolidate with, merge with or into, or sell, convey, transfer, lease or otherwise dispose of all or substantially all of its and its
25



subsidiaries’ property and assets taken as a whole (in one transaction or a series of related transactions) to any Person, or permit any Person to merge with or into the Issuer, unless:
•the Issuer shall be the continuing Person, or the Person (if other than the Issuer) formed by such consolidation or into which the Issuer is merged or that acquired or leased such property and assets (the “Surviving Person”), shall be a Person organized and validly existing under the laws of the United States of America or any jurisdiction thereof, or, subject to certain conditions (including an obligation to pay additional amounts in respect of withholding taxes), a jurisdiction outside the United States, and shall expressly assume, by a supplemental indenture, executed and delivered to the Trustee, all of the Issuer’s obligations under each applicable indenture and the Fixed Rate Notes;
•immediately after giving effect to such transaction, no default or event of default (each as defined in each applicable indenture) shall have occurred and be continuing; and
•the Issuer delivers to the Trustee an officer’s certificate and opinion of counsel, in each case stating that such consolidation, merger, or transfer and such supplemental indenture complies with this provision and that all conditions precedent provided for herein relating to such transaction have been complied with.
The Surviving Person will succeed to, and be substituted for, the Issuer under each applicable indenture and the Fixed Rate Notes and, except in the case of a lease, the Issuer shall be released of all obligations under the indenture and the Fixed Rate Notes.
Definition of Certain Terms. The following are the meanings of terms that are important in understanding the covenants described above with respect to the Fixed Rate Notes.
“Capital Lease Obligation” means, at the time any determination thereof is to be made, the amount of the liability in respect of a capital lease that would at that time be required to be capitalized on a balance sheet in accordance with U.S. GAAP (as defined below) as in effect on the date of the applicable indenture.
“Consolidated Net Assets” means the consolidated total assets of the Issuer and its subsidiaries as reflected in its most recent balance sheet prepared in accordance with U.S. GAAP as in effect at the time of such determination, less (a) all current liabilities (excluding any notes and loans payable, current maturities of long-term debt, the current portion of deferred revenue and obligations under capital leases) and (b) acquisition-related intangible assets in accordance with U.S. GAAP in effect at the time of such determination. Consolidated Net Assets includes goodwill of the Issuer and its subsidiaries.
“Funded Debt” means, as of any date of determination, the Issuer’s indebtedness or the indebtedness of a subsidiary maturing by its terms more than one year after its creation and indebtedness classified as long-term debt under U.S. GAAP as in effect on the date of the applicable indenture, and in each case ranking at least pari passu with the senior debt securities.
26



“indebtedness” means, with respect to any specified Person, any indebtedness of such Person, whether or not contingent:
(1)    in respect of borrowed money;
(2)    evidenced by bonds, notes, debentures, or similar instruments or letters of credit (or reimbursement agreements in respect thereof); and
(3)    in respect of Capital Lease Obligations.
In addition, the term “indebtedness” includes (x) all indebtedness (as defined above) of others secured by a Lien on any asset of the specified Person (whether or not such indebtedness is assumed by the specified Person), provided that the amount of such indebtedness will be the lesser of (A) the fair market value of such asset at such date of determination and (B) the amount of such indebtedness, and (y) to the extent not otherwise included, the guarantee by the specified Person of any indebtedness (as defined above) of any other Person.
“Lien” means, with respect to any asset, any mortgage, lien, pledge, charge, security interest, or encumbrance of any kind in respect of such asset, whether or not filed, recorded, or otherwise perfected under applicable law, including any conditional sale or other title retention agreement.
“Original Issue Discount Security” means any debt security which provides for an amount less than the principal amount thereof to be due and payable upon a declaration of acceleration of maturity thereof pursuant to the applicable indenture.
“Person” means any individual, corporation, partnership, limited liability company, joint venture, joint-stock company, association, trust, unincorporated organization, or government or any agency or political subdivision of a government or governmental agency.
“Principal Property” means any single parcel of real property or any permanent improvement thereon (i) owned by the Issuer or any of its subsidiaries located in the United States, including the Issuer’s principal corporate office, any manufacturing facility or plant, or any portion thereof and (ii) having a book value, as of the date of determination, in excess of 3% of the Issuer’s Consolidated Net Assets, as calculated most recently prior to the applicable issue due of the applicable series of Fixed Rate Notes. Principal Property does not include any property that the Issuer’s board of directors has determined not to be of material importance to the business conducted by the Issuer and its subsidiaries, taken as a whole.
“Principal Subsidiary” means any direct or indirect subsidiary of the Issuer that owns a Principal Property.
“Sale and Leaseback Transaction” means any arrangement with any Person providing for the leasing by the Issuer or any subsidiary of any Principal Property which has been or is to be sold or transferred by the Issuer or such subsidiary to such Person, excluding (1) temporary leases for a term, including renewals at the option of the lessee, of not more than three years, (2) leases between the Issuer and a subsidiary or between subsidiaries of the Issuer, (3) leases of a Principal Property executed by the time of, or within 12 months after the latest of, the acquisition, the completion of construction or improvement, or the commencement of commercial operation of
27



the property, and (4) arrangements pursuant to any provision of law with an effect similar to the former Section 168(f)(8) of the Internal Revenue Code of 1954, as amended.
“U.S. GAAP” means generally accepted accounting principles set forth in the FASB Accounting Standards Codification or in such other statements by such other entity as have been approved by a significant segment of the accounting profession, which are in effect from time to time.
“Value” means, with respect to a Sale and Leaseback Transaction, an amount equal to the net present value of the lease payments (other than amounts required to be paid on account of property taxes, maintenance, repairs, insurance, water rates and other items that do not constitute payments for property rights) with respect to the term of the lease remaining on the date as of which the amount is being determined, without regard to any renewal or extension options contained in the lease, discounted at the weighted average interest rate on the debt securities of all series (including the yield to maturity on any Original Issue Discount Securities) which are outstanding on the effective date of such Sale and Leaseback Transaction.
Events of Default
Each indenture defines an Event of Default with respect to any series of Fixed Rate Notes issued pursuant to the applicable indenture. Events of Default on the Fixed Rate Notes are any of the following:
•Default in the payment of the principal or any premium on Fixed Rate Notes when due (whether at maturity, upon acceleration, redemption or otherwise);
•Default for 30 days in the payment of interest on Fixed Rate Notes when due;
•Failure to comply with the provisions described under the caption “-Repurchase Upon a Change of Control” with respect to any series of Fixed Rate Notes.
•Failure by Thermo Fisher to observe or perform any other term of the applicable indenture for a period of 90 days after it receives a notice of default stating that it is in breach. The notice must be sent by either the Trustee or holders of 25% of the principal amount of the Fixed Rate Notes of the affected series;
•(1) Failure by Thermo Fisher to pay indebtedness for money it borrowed or guaranteed the payment of in an aggregate principal amount of at least $100 million, in the case of the 2024 Notes, the April 2025 Notes, the January 2026 3.200% Notes, the January 2026 1.400% Notes, the March 2027 Notes, the September 2028 Notes, the 2029 Notes, the 2034 Notes, or the 2037 Notes, or $150 million, in the case of the March 2025 Notes, the April 2027 Notes, the March 2028 Notes, the 2031 Notes, the 2032 Notes, the 2039 Notes, or the 2049 Notes, at the later of final maturity and the expiration of any related applicable grace period and such defaulted payment shall not have been made, waived or extended within 30 days or (2) acceleration of the maturity of any indebtedness for money that the Issuer borrowed or guaranteed the payment of in an aggregate principal amount of at least $100 million, in the case of the 2024 Notes, the April 2025 Notes, the
28



January 2026 3.200% Notes, the January 2026 1.400% Notes, the March 2027 Notes, the September 2028 Notes, the 2029 Notes, the 2034 Notes, or the 2037 Notes, or $150 million, in the case of the March 2025 Notes, the April 2027 Notes, the March 2028 Notes, the 2031 Notes, the 2032 Notes, the 2039 Notes, or the 2049 Notes, if such indebtedness has not been discharged in full or such acceleration has not been rescinded or annulled within 30 days; provided, however, that, if the default under the instrument is cured by the Issuer, or waived by the holders of the indebtedness, in each case as permitted by the governing instrument, then the Event of Default under the applicable indenture governing the Fixed Rate Notes caused by such default will be deemed likewise to be cured or waived; and
•Certain events in bankruptcy, insolvency or reorganization with respect to Thermo Fisher.
Each indenture provides that the Trustee may withhold notice to the holders of any series of debt securities issued thereunder of any default if the Trustee’s board of directors, executive committee, or a trust committee of directors or trustees and/or certain officers of the Trustee in good faith determine it in the interest of such holders to do so.
Remedies if an Event of Default Occurs. Each indenture provides that if an Event of Default has occurred with respect to the applicable series of Fixed Rate Notes and has not been cured, the Trustee or the holders of not less than 25% in principal amount of the Fixed Rate Notes of that series then outstanding may declare the entire principal amount of all the Fixed Rate Notes of that series, and accrued interest, if any, to be due and immediately payable. This is called a declaration of acceleration of maturity. If an Event of Default occurs because of certain events in bankruptcy, insolvency, or reorganization with respect to the Issuer, the principal amount of all the Fixed Rate Notes will be automatically accelerated, without any action by the Trustee or any holder. The holders of a majority in aggregate principal amount of the Fixed Rate Notes of the affected series may by written notice to the Issuer and the Trustee, on behalf of the holders of the Fixed Rate Notes of the affected series, rescind an acceleration or waive any existing Default or Event of Default and its consequences under the applicable indenture, if the rescission would not conflict with any judgment or decree, except a continuing Default or Event of Default in the payment of principal of, premium on, if any, or interest, if any, on, such Fixed Rate Notes.
Except as may otherwise be provided in the applicable indenture in cases of default, where the Trustee has some special duties, the Trustee is not required to take any action under such indenture at the request of any holders unless the holders offer the Trustee protection from expenses and liability (called an “indemnity”). If indemnity satisfactory to the Trustee is provided, the holders of a majority in principal amount of the outstanding Fixed Rate Notes of the affected series may direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the Trustee. Subject to certain exceptions contained in the applicable indenture, these majority holders may also direct the Trustee in performing any other action under the applicable indenture.
Before a holder of Fixed Rate Notes bypasses the Trustee and brings its own lawsuit or other formal legal action or takes other steps to enforce its rights or protect its interests relating to the applicable series of Fixed Rate Notes, the following must occur:
29



•The holder must give the Trustee written notice that an Event of Default has occurred and remains uncured.
•The holders of 25% in principal amount of all outstanding Fixed Rate Notes of the affected series must make a written request that the Trustee take action because of the Event of Default and must offer reasonable indemnity to the Trustee against the cost and other liabilities of taking that action.
•The Trustee must have failed to take action for 60 days after receipt of the above notice and offer of indemnity and, during such 60-day period, the Trustee has not received a contrary instruction from holders of a majority in principal amount of all outstanding Fixed Rate Notes of such series.
However, a holder of Fixed Rate Notes is entitled at any time to bring a lawsuit for the payment of money due on its Fixed Rate Notes on or after the due date of that payment.
The Issuer will furnish to the Trustee every year a written statement of one to two of its officers certifying that to their knowledge the Issuer is in compliance with the applicable indenture and the Fixed Rate Notes, or else specifying any default.
Satisfaction and Discharge
The applicable indenture will cease to be of further effect with respect to a series of Fixed Rate Notes and the Trustee, upon the Issuer’s demand and at its expense, will execute appropriate instruments acknowledging the satisfaction and discharge of the applicable indenture upon compliance with certain conditions, including:
•the Issuer having paid all sums payable by it under such indenture, as and when the same shall be due and payable;
•the Issuer having delivered to the Trustee for cancellation all Fixed Rate Notes theretofore authenticated under such indenture;
•all Fixed Rate Notes of any series outstanding under such indenture not theretofore delivered to the Trustee for cancellation shall have become due and payable or are by their terms to become due and payable within one year and the Issuer shall have deposited with the Trustee sufficient cash or U.S. government or U.S. government agency notes or bonds that will generate enough cash to pay, at maturity or upon redemption, all such Fixed Rate Notes of any series outstanding under such indenture; or
•the Issuer having delivered to the Trustee an officer’s certificate and an opinion of counsel, each stating that these conditions have been satisfied.
Defeasance
Full Defeasance. The Issuer can legally release itself from any payment or other obligations on the Fixed Rate Notes of any series (called “full defeasance”) if the following conditions are met:
30



•The Issuer deposits in trust for the benefit of holders of Fixed Rate Notes of the same series a combination of money and U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal, any premium and any other payments on the Fixed Rate Notes of that series on their various due dates.
•There is a change in current U.S. federal tax law or an Internal Revenue Service ruling that lets the Issuer make the above deposit without causing holders of Fixed Rate Notes to be taxed on the Fixed Rate Notes any differently than if the Issuer did not make the deposit and instead repaid the Fixed Rate Notes itself when due. Under current U.S. federal tax law, the deposit and the Issuer’s legal release from the Fixed Rate Notes would be treated as though the Issuer took back a holder’s Fixed Rate Notes and gave such holder its share of the cash and debt securities or bonds deposited in trust. In that event, a holder of Fixed Rate Notes could recognize gain or loss on the Fixed Rate Notes it give back to the Issuer.
•The Issuer delivers to the Trustee a legal opinion of its counsel confirming the tax law change or ruling described above.
If the Issuer ever did accomplish full defeasance, as described above, a holder of Fixed Rate Notes would have to rely solely on the trust deposit for repayment of the Fixed Rate Notes. Such holders could not look to the Issuer for repayment in the event of any shortfall.
However, even if the Issuer makes the deposit in trust and opinion delivery arrangements discussed above, a number of its obligations relating to the Fixed Rate Notes will remain. These include the Issuer’s obligations:
•to register the transfer and exchange of Fixed Rate Notes;
•to replace mutilated, destroyed, lost or stolen Fixed Rate Notes;
•to maintain paying agencies; and
•to hold money for payment in trust.
Covenant Defeasance. Without any change of current U.S. federal tax law, the Issuer can make the same type of deposit described above and be released from some of the covenants on the Fixed Rate Notes of any series. This is called “covenant defeasance.” In that event, holders of Fixed Rate Notes would lose the protection of those covenants but would gain the protection of having money and securities set aside in trust to repay the Fixed Rate Notes. In order to achieve covenant defeasance, the Issuer must do the following:
•The Issuer must deposit in trust for the benefit of holders of Fixed Rate Notes of the same series a combination of money and U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal, any premium and any other payments on the Fixed Rate Notes of that series on their various due dates.
•The Issuer must deliver to the Trustee a legal opinion of its counsel confirming that under current U.S. federal income tax law the Issuer may make the above deposit without causing holders of such series of Fixed Rate Notes to be taxed on the Fixed Rate Notes any differently than if it did not make the deposit and instead repaid the Fixed Rate Notes itself when due.
31



If the Issuer accomplishes covenant defeasance, a holder of such Fixed Rate Notes can still look to it for repayment of the Fixed Rate Notes if there were a shortfall in the trust deposit. In fact, if one of the Events of Default occurred (such as the Issuer’s bankruptcy) and the Fixed Rate Notes become immediately due and payable, there may be such a shortfall. Depending on the event causing the default, a holder of such Fixed Rate Notes may not be able to obtain payment of the shortfall.
Modification and Waiver
There are three types of changes the Issuer can make to the indentures and the Fixed Rate Notes.
Changes Requiring Approval of the Holder. First, there are changes that cannot be made to a series of Fixed Rate Notes without specific approval of each holder of Fixed Rate Notes of such series. The following is a list of those types of changes:
•change the stated maturity of the principal or interest on Fixed Rate Notes of any series;
•reduce any amounts due on any Fixed Rate Notes of such series;
•reduce the amount of principal payable upon acceleration of the maturity of the Fixed Rate Notes following an Event of Default;
•change the place or currency of payment for such series of Fixed Rate Notes;
•impair the holder’s right to sue for the enforcement of any payment on or with respect to the Fixed Rate Notes;
•reduce the percentage in principal amount of the Fixed Rate Notes, the approval of whose holders is needed to modify or amend the applicable indenture or the Fixed Rate Notes;
•reduce the percentage in principal amount of the Fixed Rate Notes, the approval of whose holders is needed to waive compliance with certain provisions of the applicable indenture or to waive certain defaults; and
•modify any other aspect of the provisions dealing with modification and waiver of the applicable indenture, except to increase the percentage required for any modification or to provide that other provisions of such indenture may not be modified or waived without consent of the holder of each Fixed Rate Note of such series affected by the modification.
Changes Not Requiring Approval. The second type of change does not require any vote by holders of the Fixed Rate Notes. The following is a list of those types of changes:
•cure any ambiguity, defect, or inconsistency;
•evidence the succession of another entity to the Issuer’s obligations under the indentures;
•provide for uncertificated Fixed Rate Notes in addition to or in place of certificated Fixed Rate Notes;
•add to the covenants for the benefit of holders of outstanding Fixed Rate Notes or to surrender any right or power the Issuer has under the applicable indenture;
•add additional events of default;
•secure Fixed Rate Notes of any series;
•make any change that does not adversely affect the rights of any holder of Fixed Rate Notes in any material respect;
•issue additional Fixed Rate Notes of any series;
32



•evidence and provide for a successor Trustee and add to or change the provisions of an indenture to provide for or facilitate the administration of the trusts under the applicable indenture; or
•comply with requirements of the SEC in order to effect or maintain the qualification of the applicable indenture under the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”).
Changes Requiring a Majority Vote. Any other change to an indenture and the Fixed Rate Notes would require the following approval:
•If the change affects only Fixed Rate Notes of one series, it must be approved by the holders of a majority in principal amount of the Fixed Rate Notes of that series.
•If the change affects a series of Fixed Rate Notes as well as the senior debt securities of one or more other series issued under the indentures, it must be approved by the holders of a majority in principal amount of the Fixed Rate Notes of such series and each other series of senior debt securities affected by the change.
•In each case, the required approval must be given by written consent.
The same vote would be required for the Issuer to obtain a waiver of a past default. However, the Issuer cannot obtain a waiver of a payment default or a waiver with respect to any other aspect of the applicable indenture and the Fixed Rate Notes listed in the first category described previously under “Changes Requiring Approval of the Holder” unless the Issuer obtains a holder’s individual consent to the waiver.
Further Details Concerning Voting
Any series of Fixed Rate Notes will not be considered outstanding, and therefore not eligible to vote, if the Issuer has deposited or set aside in trust for holders of such series of Fixed Rate Notes money for their payment or redemption. The Fixed Rate Notes of any series will also not be eligible to vote if they have been fully defeased as described above under “Full Defeasance.”
The Issuer generally is entitled to set any day as a record date for the purpose of determining the holders of outstanding Fixed Rate Notes that are entitled to vote or take other action under the applicable indenture. In certain limited circumstances, the Trustee is entitled to set a record date for action by holders. If the Issuer or the Trustee sets a record date for a vote or other action to be taken by holders of Fixed Rate Notes, that vote or action may be taken only by persons who are holders of outstanding Fixed Rate Notes on the record date and must be taken within 180 days following the record date or another period that the Issuer may specify (or as the Trustee may specify, if it set the record date). The Issuer may shorten or lengthen (but not beyond 180 days) this period from time to time.
No Personal Liability of Incorporators, Stockholders, Officers, Directors
The indentures provide that no recourse shall be had under any obligation, covenant, or agreement of the Issuer in the indentures or in any of the Fixed Rate Notes or because of the creation of any indebtedness represented thereby, against any of its incorporators, stockholders,
33



officers, or directors, past, present, or future, or of any predecessor or successor entity thereof under any law, statute, or constitutional provision or by the enforcement of any assessment or by any legal or equitable proceeding or otherwise. Each holder, by accepting the Fixed Rate Notes, waived and released all such liability.
Concerning the Trustee
The Bank of New York Mellon Trust Company, N.A. is the trustee under the indentures. The Bank of New York Mellon, London Branch, has been appointed as paying agent with respect to the April 2025 Notes. The Trustee or its affiliates may from time to time in the future provide banking and other services to the Issuer in the ordinary course of its business.
The indentures provide that, prior to the occurrence of an Event of Default with respect to the Fixed Rate Notes of a series and after the curing or waiving of all such Events of Default with respect to that series, the Trustee will not be liable except for the performance of such duties as are specifically set forth in the applicable indenture. If an Event of Default has occurred and has not been cured or waived, the Trustee will exercise such rights and powers vested in it under the applicable indenture and will use the same degree of care and skill in its exercise as a prudent person would exercise under the circumstances in the conduct of such person’s own affairs.
The indentures and the provisions of the Trust Indenture Act incorporated by reference therein contain limitations on the rights of the Trustee thereunder, should it become a creditor of the Issuer or any of its subsidiaries, to obtain payment of claims in certain cases or to realize on certain property received by the Trustee in respect of any such claims, as security or otherwise. The Trustee is permitted to engage in other transactions, provided that if it acquires any conflicting interest (as defined in the Trust Indenture Act), it must eliminate such conflict or resign.
Unclaimed Funds
All funds deposited with the Trustee or any paying agent for the payment of principal, interest, premium, or additional amounts in respect of Fixed Rate Notes that remain unclaimed for one year after the date upon which the principal of, premium, if any, or interest on such Fixed Rate Notes shall have become due and payable will be repaid to the Issuer. Thereafter, any right of any holder of Fixed Rate Notes to such funds shall be enforceable only against the Issuer, and the Trustee and paying agents will have no liability therefor.
Book-Entry; Delivery and Form
The Fixed Rate Notes are issued in the form of one or more global notes in fully registered form, without coupons, and have been deposited with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary, for, and in respect of interests held through, Euroclear Bank SA/NV (“Euroclear”) and Clearstream Banking, S.A. (“Clearstream”). Except as described herein, certificates will not be issued in exchange for beneficial interests in the global notes. Except as set forth below, the global notes may be
34



transferred, in whole and not in part, only to Euroclear or Clearstream or their respective nominees.
Beneficial interests in the global notes are represented, and transfers of such beneficial interests are effected, through accounts of financial institutions acting on behalf of beneficial owners as direct or indirect participants in Euroclear or Clearstream. Those beneficial interests must be in denominations of €100,000 and integral multiples of €1,000 in excess thereof. Investors may hold Fixed Rate Notes directly through Euroclear or Clearstream, if they are participants in such systems, or indirectly through organizations that are participants in such systems.
For so long as the Fixed Rate Notes are represented by global notes deposited with, and registered in the name of a nominee for, a common depositary for Euroclear and/or Clearstream, each person (other than Euroclear or Clearstream) who is for the time being shown in the records of Euroclear or of Clearstream as the holder of a particular nominal amount of the Fixed Rate Notes (in which regard any certificate or other document issued by Euroclear or Clearstream as to the nominal amount of the Fixed Rate Notes standing to the account of any person shall be conclusive and binding for all purposes save in the case of manifest error) shall upon their receipt of a certificate or other document be treated by Thermo Fisher and the Trustee as the holder of such nominal amount of the Fixed Rate Notes and the registered holder of the global notes shall be deemed not to be the holder for all purposes other than with respect to the payment of principal or interest on such nominal amount of the Fixed Rate Notes, for which purpose the registered holder of the relevant global note shall be treated by Thermo Fisher and the Trustee as the holder of such nominal amount of the Fixed Rate Notes in accordance with and subject to the terms of the global notes and the expressions “noteholder” and “holder of notes” and related expressions shall be construed accordingly.
Certificated Notes
If the depositary for any of the securities represented by a global security is at any time unwilling or unable to continue as depositary or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us within 90 days, we will issue securities in definitive form in exchange for the global security that had been held by the depositary. Any securities issued in definitive form in exchange for a global security will be registered in the name or names that the depositary gives to the Trustee or other relevant agent of ours or theirs. It is expected that the depositary’s instructions will be based upon directions received by the depositary from participants with respect to ownership of beneficial interests in the global security that had been held by the depositary.
Governing Law
The indentures and the Fixed Rate Notes are governed by, and construed in accordance with, the laws of the State of New York.
35


 EX-10.45 4 q4202210-kex1045.htm AMENDMENT TO STOCK OPTION AGREEMENTS FOR MARC CASPER Document
Exhibit 10.45
THERMO FISHER SCIENTIFIC INC.
AMENDMENT TO NONSTATUTORY STOCK OPTION AGREEMENTS
Granted under 2013 Stock Incentive Plan
1.Reference is made to the letter agreement (the “Letter Agreement”) dated as of November 10, 2022 between Thermo Fisher Scientific Inc. (the “Company”) and Marc N. Casper (the “Executive”) providing for the addition of retirement vesting provisions to certain of the Executive’s outstanding equity awards.

2.In accordance with the Letter Agreement, this amendment shall apply to the following nonstatutory stock option agreements granted to the Executive (each, a “Listed Award”):

a.Stock Option Award granted February 23, 2022
b.Stock Option Award granted February 23, 2021
c.Stock Option Award granted February 25, 2020
d.Stock Option Award granted February 26, 2019
e.Stock Option Award granted February 27, 2018
f.Stock Option Award granted February 28, 2017

3.A new paragraph (g) is added to the end of Section 3 of the Listed Awards a. through c. above to read in its entirety as follows:

“(g)    Retirement. If the Participant “retires” from the Company or a Subsidiary prior to the Final Exercise Date then, subject to Section 3(e) above, this Option shall vest and become 100% exercisable upon the date of such retirement and the right to exercise this Option shall terminate on the Final Exercise Date, provided that the retirement date occurs at least two years after the Grant Date. For the purposes of this Agreement, the Participant shall be deemed to have “retired” (i) in the event of a non-employee director of the Company, when the Participant ceases to be a director of the Company or (ii) in the event of an employee of the Company or a Subsidiary, upon the Participant's resignation from employment with the Company or a Subsidiary either (A) after the age of fifty-five (55) and the completion of ten (10) continuous years of service to the Company or a Subsidiary comprising at least twenty (20) hours per week or (B) after the age of sixty (60) and the completion of five (5) continuous years of service to the Company or a Subsidiary comprising at least twenty (20) hours per week. For purposes of this Agreement and for the sake of clarity, subject to execution of a release of claims in a form acceptable to the Company, the Participant may seek to re-characterize any termination of employment initiated by the Company, or a Subsidiary, that is not a termination for “Cause” (as defined in Section 1.2 of the Severance Agreement) as a voluntary termination by reason of retirement, in which case the Participant shall not be entitled to receive any severance or other benefits that would have otherwise been provided by the Company to the Participant pursuant to any agreement between the Company and the Participant or any Company policy. Any such determination shall be made by the Committee in its sole discretion.”
4. A new paragraph (g) is added to the end of Section 3 of the Listed Awards d. through f. above to read in its entirety as follows:


Exhibit 10.45


“(g)    Retirement. If the Participant “retires” from the Company or a Subsidiary prior to the Final Exercise Date then, subject to Section 3(e) above, this Option shall vest and become 100% exercisable upon the date of such retirement and the right to exercise this Option shall terminate on the Final Exercise Date, provided that the retirement date occurs at least two years after the Grant Date. For the purposes of this Agreement, the Participant shall be deemed to have “retired” (i) in the event of a non-employee director of the Company, when the Participant ceases to be a director of the Company or (ii) in the event of an employee of the Company or a Subsidiary, upon the Participant's resignation from employment with the Company or a Subsidiary either (A) after the age of fifty-five (55) and the completion of ten (10) continuous years of service to the Company or a Subsidiary comprising at least twenty (20) hours per week or (B) after the age of sixty (60) and the completion of five (5) continuous years of service to the Company or a Subsidiary comprising at least twenty (20) hours per week.”
5.In each Listed Award, conforming changes are made to Section 2 and Section 3(b) by replacing the words “paragraphs (c) through (f)” with the words “paragraphs (c) through (g)”.

THERMO FISHER SCIENTIFIC INC.
By:/s/ Lisa P. Britt
Name:Lisa P. Britt
Title:Senior Vice President and
Chief Human Resources Officer


Acknowledged and agreed:


/s/ Marc N. Casper        
Marc N. Casper



 EX-10.46 5 q4202210-kex1046.htm AMENDMENT TO RESTRICTED STOCK UNIT AGREEMENTS FOR MARC CASPER Document
Exhibit 10.46
THERMO FISHER SCIENTIFIC INC.
AMENDMENT TO RESTRICTED STOCK UNIT AGREEMENTS
Granted under 2013 Stock Incentive Plan
1.Reference is made to the letter agreement (the “Letter Agreement”) dated as of November 10, 2022 between Thermo Fisher Scientific Inc. (the “Company”) and Marc N. Casper (the “Executive”) providing for the addition of retirement vesting provisions to certain of the Executive’s outstanding equity awards.

2.In accordance with the Letter Agreement, this amendment shall apply to the following restricted stock unit agreements granted to the Executive (each, a “Listed Award”):

a.Time Based Restricted Stock Unit Award granted February 23, 2022
b.Time Based Restricted Stock Unit Award granted February 23, 2021
c.Time Based Restricted Stock Unit Award granted February 25, 2020

3.A new paragraph (g) is added to the end of Section 3 of each Listed Award to read in its entirety as follows:

    “(g)    Retirement. If the Participant Retires from the Company prior to the Final Vesting Date, the RSUs that have not previously vested shall vest 100% upon the effective date of such Retirement, provided that the Retirement date occurs at least two years after the Award Date.”
4.Section 4(a) of each Listed Award is amended in its entirety to read as follows:
“(a)    The Company shall deliver Shares that become issuable pursuant to an RSU within the sixty (60) day period following the date the RSUs vest pursuant to Section 2 or 3 above, except that any RSUs that vest pursuant to Section 3(g) shall be delivered at the time such RSUs would have been delivered under Section 2 had the Participant remained an Eligible Participant.”
5.A new Section 15 is added to read in its entirety as follows:
“15. Retirement. For the purposes of this Agreement, the Participant shall be deemed to have "retired" from the Company (i) in the event of a non-employee director of the Company, when the Participant ceases to be a director of the Company or (ii) in the event of an employee of the Company, upon the Participant's resignation from employment with the Company either (A) after the age of fifty-five (55) and the completion of ten (10) continuous years of service to the Company comprising at least twenty (20) hours per week or (B) after the age of sixty (60) and the completion of five (5) continuous years of service to the Company comprising at least twenty (20) hours per week. For purposes of this Agreement and for the sake of clarity, subject to execution of a release of claims in a form acceptable to the Company, the Participant may seek to re-characterize any termination of employment initiated by the Company, or a subsidiary of the Company, that is not a termination for “Cause” (as defined in Section 1.2 of the


Exhibit 10.46
Severance Agreement) as a voluntary termination by reason of Retirement, in which case the Participant shall not be entitled to receive any severance or other benefits that would have otherwise been provided by the Company to the Participant pursuant to any agreement between the Company and the Participant or any Company policy. Any such determination shall be made by the Committee in its sole discretion.”
6.In each Listed Award, conforming changes are made to Section 2 and Section 3(a) by replacing the words “paragraphs (b) through (f)” with the words “paragraphs (b) through (g)”. Conforming changes are made to Section 5 by replacing the words “paragraphs (b), (c), (e) or (f) of Section 3 above” with the words “paragraphs (b), (c), (e), (f) or (g) of Section 3 above”.

THERMO FISHER SCIENTIFIC INC.
By:/s/ Lisa P. Britt
Name:Lisa P. Britt
Title:Senior Vice President and
Chief Human Resources Officer


Acknowledged and agreed:


/s/ Marc N. Casper        
Marc N. Casper


 EX-10.47 6 q4202210-kex1047.htm AMENDMENT TO PERFORMANCE UNIT AGREEMENTS FOR MARC CASPER Document
Exhibit 10.47
THERMO FISHER SCIENTIFIC INC.
AMENDMENT TO PERFORMANCE RESTRICTED STOCK UNIT AGREEMENTS
Granted under 2013 Stock Incentive Plan
1.Reference is made to the letter agreement (the “Letter Agreement”) dated as of November 10, 2022 between Thermo Fisher Scientific Inc. (the “Company”) and Marc N. Casper (the “Executive”) providing for the addition of retirement vesting provisions to certain of the Executive’s outstanding equity awards.

2.In accordance with the Letter Agreement, this amendment shall apply to the following restricted stock unit agreements granted to the Executive (each, a “Listed Award”):

a.Performance Based Restricted Stock Unit Award granted February 23, 2022
b.Performance Based Restricted Stock Unit Award granted February 23, 2021
c.Performance Based Restricted Stock Unit Award granted February 25, 2020

3.A new paragraph (g) is added to the end of Section 3 of each Listed Award to read in its entirety as follows:

    “(g)    Retirement. If the Participant Retires from the Company after the later of (i) the Performance Certification Date or (ii) the second anniversary of the Award Date, then nevertheless the Participant shall become vested in the remaining RSUs to be delivered (calculated based on the units earned as of the Performance Certification Date, as adjusted pursuant to the provisions of Schedule A).”
4.Section 4 of each Listed Award is amended in its entirety to read as follows:
“4.        Delivery of Shares.
(a)    Except as provided in (b) below, the Company shall deliver the Shares that become issuable upon the vesting of an RSU (i) to the Participant as soon as administratively practicable or (ii) in the event that the Participant’s employment with the Company is terminated by reason of death, to the Participant’s estate as soon as administratively practicable, but in no event later than the last day of the period specified in Treas. Reg. section 1.409A-1(b)(4)(i)(A).
(b)    In the event that the Participant Retires under the conditions of Section 3(g) above, the Company shall deliver the Shares that become issuable pursuant to an RSU, to the extent not previously delivered, within the sixty (60) day period following the date such RSUs would have vested had the Participant remained employed with the Company.
(c)    The Company shall not be obligated to deliver Shares to the Participant unless the issuance and delivery of such Shares shall comply with all relevant provisions of law and other legal requirements including, without limitation, any applicable federal or state securities laws and the requirements of any stock exchange upon which shares of Common Stock may then be listed.”


Exhibit 10.47

5.A new Section 15 is added to read in its entirety as follows:
“15.    Retire or Retirement. For the purposes of this Agreement, the Participant shall be deemed to have "retired" from the Company (i) in the event of a non-employee director of the Company, when the Participant ceases to be a director of the Company or (ii) in the event of an employee of the Company, upon the Participant's resignation from employment with the Company either (A) after the age of fifty-five (55) and the completion of ten (10) continuous years of service to the Company comprising at least twenty (20) hours per week or (B) after the age of sixty (60) and the completion of five (5) continuous years of service to the Company comprising at least twenty (20) hours per week. For purposes of this Agreement and for the sake of clarity, subject to execution of a release of claims in a form acceptable to the Company, the Participant may seek to re-characterize any termination of employment initiated by the Company, or a subsidiary of the Company, that is not a termination for “Cause” (as defined in Section 1.2 of the Severance Agreement) as a voluntary termination by reason of Retirement, in which case the Participant shall not be entitled to receive any severance or other benefits that would have otherwise been provided by the Company to the Participant pursuant to any agreement between the Company and the Participant or any Company policy. Any such determination shall be made by the Committee in its sole discretion
6.In each Listed Award, conforming changes are made to Section 2 and Section 3(a) by replacing the words “paragraphs (b) through (f)” with the words “paragraphs (b) through (g)”. Conforming changes are made to Section 5 by replacing the words “paragraphs (b), (c), (e) or (f) of Section 3 above” with the words “paragraphs (b), (c), (e), (f) or (g) of Section 3 above”. The references in the first sentence of Schedule A, referring to additional vesting conditions, are corrected to “paragraphs (b), (c), (f) or (g) of Section 3”.
7.For the Listed Awards granted February 23, 2021 and February 23, 2022, a new paragraph is added to Schedule A, Vesting Schedule for Performance-Based Restricted Stock Units, immediately below the table relating to the TMO TSR CAGR Performance Adjustment, to read in its entirety as follows:
“In the case of the Participant who Retires pursuant to Section 3(g), the number of Shares deliverable under Section 4(b) pursuant to an RSU that would have vested on the Final Vesting Date had the Participant remained employed with the Company shall be determined taking into account the above long-term performance adjustment based on the TMO TSR CAGR for the full Measurement Period (as if the Participant had remained employed with the Company through the Final Vesting Date).”




Exhibit 10.47

THERMO FISHER SCIENTIFIC INC.
By:/s/ Lisa P. Britt
Name:Lisa P. Britt
Title:Senior Vice President and
Chief Human Resources Officer



Acknowledged and agreed:


/s/ Marc N. Casper        
Marc N. Casper



 EX-21 7 q4202210-kex21sublist.htm SUBSIDIARIES OF THE REGISTRANT Document
Exhibit 21
 THERMO FISHER SCIENTIFIC INC. 


NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Fisher Scientific Operating Company LLCDelaware
100
Thermo Fisher Scientific Senior Financing LLCDelaware
100
Thermo Fisher Scientific (DE) Holding S.a.r.l.Luxembourg
100
Laboratory Management Systems, Inc.Delaware
100
Thermo Fisher Scientific Peru S.R.L.
 [1% by Fisher Clinical Services (Peru) LLC]
Peru
99
Thermo Fisher Scientific Malaysia Sdn. Bhd.Malaysia
100
Fisher Clinical Logistics LLCDelaware
100
Fisher Clinical Services (Suzhou) Co., Ltd.China
100
Fisher Clinical Services Limited Liability Company
[1% by Thermo Fisher Scientific Inc.]
Russia
99
Fisher Clinical Services (Korea) Co., LtdKorea
100
Cohesive Technologies Inc.Delaware
100
Cohesive Technologies (UK) LimitedEngland
100
Thermo Hypersil-Keystone LLCDelaware
100
Thermo Electron A/SDenmark
100
Phitonex, Inc.North Carolina
100
TWX, LLC
[22.5% by Thermo Scientific Portable Analytical Instruments Inc.]
Massachusetts
77.5
Thermo Fisher GP LLCDelaware
100
Thermo Fisher Scientific C.V.
[1% by TFLP LLC]
Netherlands
99
Phadia GmbHGermany
100
Thermo Dutch Holdings Limited Partnership
[1% by Thermo Finland Holdings LLC]
England
99
Fisher Clinical Services Mexico, S. de R.L. de C.V.
 [1% by Fisher Clinical Services (Mexico) LLC]
Mexico
99
Fisher Clinical Services (Mexico) LLCDelaware
100
D-finitive Technologies, Inc.South Carolina
100
Thermo Fisher Scientific Africa Proprietary LtdSouth Africa
100
Thermo Fisher Scientific Middle East Holdings Inc.Delaware
100
Thermo Portable Holdings LLCDelaware
100
TSP Holdings I LLCDelaware
100
Thermo Scientific Portable Analytical Instruments Inc.Delaware
100
1

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Fisher Germany B.V.Netherlands
100
NovaWave Technologies, Inc.California
100
Thermo Fisher RE I Corporation
[20% by Thermo Fisher Insurance Holdings Inc.]
Delaware
80
Thermo Fisher RE II CorporationDelaware
100
Thermo Fisher Scientific Re Ltd.Bermuda
100
Thermo Finland Holdings LLCDelaware
100
Pelican Acquisition CorporationDelaware
100
Priority Air Holdings CorpDelaware
100
Priority Air Express, LLCDelaware
100
Priority Air Express UK LimitedEngland
100
Priority Air Express Pte. Ltd.Singapore
100
PAX – DSI Acquisition LLCDelaware
100
Distribution Solutions International, Inc.Michigan
100
Thermo EGS Gauging LLCDelaware
100
EGS Gauging Technical Services CompanyDelaware
100
EGS Gauging Ltd.England
100
Thermo Asset Management Services Inc.Delaware
100
Thermo CRS Holdings Ltd.Canada
100
Thermo CRS Ltd.
[Series 1 Preferred Shares held by Oxoid Company, Diagnostix Ltd. and Thermo Fisher Scientific (Mississauga) Inc.]
Canada
100
Robocon Labor- und Industrieroboter Gesellschaft m.b.HAustria
100
Thermo Fisher Scientific West Palm Holdings LLCDelaware
100
Thermo Electron North America LLCDelaware
100
picoSpin, LLCColorado
100
Loftus Furnace CompanyPennsylvania
100
NAPCO, Inc.Connecticut
100
Fisher Clinical Services (Colombia) LLCDelaware
100
Fisher Clinical Services Colombia S.A.S.Colombia
100
Fisher Servicios Clinicos (Chile) LLCDelaware
100
Fisher Servicios Clinicos Chile Ltda
[1% by Thermo Fisher Scientific Inc.]
Chile
99
Staten Island Cogeneration CorporationNew York
100
Doe & Ingalls Investors, Inc.Delaware
100
2

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Doe & Ingalls Management, LLC
[47% by Thermo Fisher Scientific Inc.]
Delaware
53
Doe & Ingalls of California Operating LLCNorth Carolina
100
Doe & Ingalls of Florida Operating LLCFlorida
100
Doe & Ingalls of Maryland Operating LLCNorth Carolina
100
Doe & Ingalls of Massachusetts Operating LLCNorth Carolina
100
Doe & Ingalls of North Carolina Operating LLCNorth Carolina
100
Doe & Ingalls Properties II, LLCNorth Carolina
100
Doe & Ingalls Properties, LLCNorth Carolina
100
Thermo Electron Export Inc.Barbados
100
Thermo Fisher Scientific (Mexico City) LLCDelaware
100
Odyssey Luxembourg Holdings S.C.S.
[1% by Odyssey Holdings LLC]
Luxembourg
99
Fisher Worldwide Gene Distribution SPVCayman Islands
100
Thermo Fisher Scientific Odyssey Financing (Barbados) SRLBarbados
100
Thermo Fisher Scientific Odyssey Holdings LimitedEngland
100
Odyssey Venture CorporationDelaware
100
Odyssey Holdings CorporationDelaware
100
One Lambda, IncCalifornia
100
SystemLink, Inc.Virginia
100
Linkage Biosciences, Inc.California
100
Thermo Fisher Scientific TDI S.a.r.l
[.26% by Applied Biosystems International, Inc., .06% by Thermo Fisher Scientific (Finance II) S.a.r.l., and 16.81% by Thermo Fisher Scientific (Finance III) S.a.r.l.]
Luxembourg
82.87
Thermo Fisher (CN) Malta Holdings Limited
[.0000001% by Thermo Fisher Scientific (Finance III) LLC
Malta99.9999999
Thermo Fisher Scientific (Finance III) LLCDelaware
100
Thermo Fisher Scientific TDI 2 S.a.r.l.Luxembourg
100
Thermo Fisher Scientific Remel Luxembourg S.a.r.l.Luxembourg
100
ABII 2 LimitedEngland
100
Remel Europe LimitedEngland100
Odyssey Luxembourg IP Holdings 1 S.à r.l.Luxembourg
100
Odyssey Luxembourg IP Holdings 2 S.à r.l.Luxembourg
100
Thermo Foundation, Inc.Massachusetts
100
Thermo Fisher Financial Services Inc.Delaware
100
3

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Fisher Scientific Chemicals Inc.Delaware
100
Thermo Keytek LLCDelaware
100
Thermo Finland Holdings MT2 B.V.
[10% by Thermo Finland Holdings LLC]
Netherlands
90
Thermo Cayman Holdings Ltd.
[21.26% by Thermo Cambridge Limited]
Cayman Islands
78.73
European Laboratory Holdings LimitedIreland
100
Thermo Fisher Investments (Cayman) Ltd.Cayman Islands
100
Thermo Fisher Scientific Investments (Luxembourg) II S.a.r.l.Luxembourg
100
Thermo Suomi Holding B.V.
[33.33% by Life Sciences International Holdings BV]
Netherlands
66.67
Thermo Fisher (Finland Holdings 2) LLCDelaware
100
Thermo Fisher (Finland Holdings) Limited Partnership
[.5% by Thermo Fisher (Finland Holdings 2) LLC]
England
99.5
Thermo Finland Holdings MT1 B.V.
[.5% by Thermo Fisher (Finland Holdings 2) LLC]
Netherlands
99.5
Thermo Fisher Scientific OyFinland
100
Thermo Electron Manufacturing LimitedEngland
100
G V Instruments LimitedEngland
100
GV Instruments IncDelaware
100
GV Instruments Canada Ltd.Canada
100
Thermo Fisher India Holding B.V.
[6.13% by Thermo Fisher Scientific Inc., .68% by Thermo Gamma-Metrics LLC and 30.74% by Thermo Fisher Scientific (Asheville) LLC]
Netherlands
62.45
Thermo Fisher Scientific India Pvt Ltd
[.00161 % by Thermo Fisher Scientific Inc., .00320% by Thermo Electron LED GmbH, 2.66891% by Phadia Holding AB, .00001% by Phadia AB, and 22.23825% by Dionex Corporation]
India
75.08802
JSC “Thermo Fisher Scientific”Russia
100
Thermedics Detection de Argentina S.R.L
[10% by Thermo Ramsey LLC]
Argentina
90
Fisher Clinical Services Latin America S.R.L.
[10% by Thermo Ramsey LLC]
Argentina
90
Thermo Detection de Mexico S. de R.L. de C.V.
[.00815586%  by Thermo Environmental Instruments LLC and .02975898% by Thermo Fisher Scientific (Mexico City) LLC]
Mexico
99.96208516 
Thermo Fisher Scientific eCommerce Solutions, LLC Delaware
100
Goring Kerr Detection LimitedEngland
100
Thermo Sentron Canada Inc.
[10% by Thermo Fisher Scientific Inc.]
Canada
90
4

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Ramsey S.A.Spain
100
Thermo Ramsey LLCMassachusetts
100
Thermo Fisher Project Cyprus LLCDelaware
100
Thermo Fisher Scientific Brasil Instrumentos de Processo Ltda.
[.01% by Thermo Ramsey LLC]
Brazil
99.99
IntegenX, Inc.California
100
IntegenX LtdEngland
100
Thermo Re, Ltd.Bermuda
100
Thermo Fisher Scientific Clinical Services Ireland LimitedIreland
100
Thermo Electron (Proprietary) LimitedSouth Africa
100
Odyssey Holdings LLCDelaware
100
TFS Group Holding I LLC
[12.51% by Thermo Luxembourg Holding LLC, 4.70% by Molecular BioProducts, Inc., 20.48% by Fisher Scientific Worldwide Inc., .37% by Fisher Clinical Services Inc., .70% by Liberty Lane Investment LLC, .15% by Fisher Scientific International LLC, 7.40% by Thermo Fisher Scientific Life Investments US Financing II LLC, 13.37% by Erie LP Holding LLC, preferred shares held by Thermo Fisher Scientific Life Investments US Financing I LLC, Fisher Scientific Worldwide Holdings I C.V., and Thermo Fisher Scientific Investments (Sweden) S.a.r.l.]
Delaware
40.32
Thermo Fisher Scientific Luxembourg Sweden Holdings I S.à r.lLuxembourg
100
TFS Group Holdings IV LLC
[12.39% by Thermo Fisher Scientific Life Holdings III C.V. LLC and 100% of the preferred shares held by TFS Group Holdings III LLC]
Delaware
87.61
Thermo Fisher Scientific Life UK Holdings LP
[.01% by Thermo Fisher Scientific Life Holdings 2 Limited]
England
99.99
Thermo Fisher Scientific Life Holdings 2 LimitedEngland
100
Thermo Fisher Scientific AU LLCDelaware
100
Thermo Fisher Scientific AU C.V.
[1% by Thermo Fisher Scientific AU LLC]
Netherlands
99
Thermo Fisher Scientific Life Technologies Investment I LLCDelaware
100
Thermo Fisher Scientific Life Technologies Investment II LLCDelaware
100
Thermo Fisher Scientific Life Technologies Investments Holding LP
[.10% by Thermo Fisher Scientific Life Technologies Investment I LLC]
England
99.90
Thermo Electron Australia Pty LimitedAustralia
100
Thermo Trace Pty Ltd.
Australia
100
Thermo Fisher Scientific Australia Pty LtdAustralia
100
Lomb Scientific (Aust) Pty LimitedAustralia
100
Technology Design Solutions Pty LtdAustralia
100
App-Tek International Pty LtdAustralia
100
Thermo Fisher Scientific New Zealand HoldingsNew Zealand
100
5

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Fisher Scientific New Zealand LimitedNew Zealand
100
Thermo Gamma-Metrics Holdings Pty Ltd.Australia
100
Thermo Gamma-Metrics Pty LtdAustralia
100
Thermo Electron (Chile) S.p.A.Chile
100
Thermo Fisher Scientific Life Financing (Cayman)Cayman Islands
100
Thermo Fisher Scientific Life Financing (Barbados) SRLBarbados
100
Thermo Fisher Scientific Life Technologies Investment UK II LimitedEngland
100
Thermo Fisher Scientific Life Holdings LimitedEngland
100
Thermo Fisher Scientific Pakistan (Private) Limited
[50% by Life Technologies Limited]
Pakistan
50
Thermo Fisher Scientific Life Financing LimitedEngland
100
Thermo Fisher Scientific AU LimitedEngland
100
Life Technologies LimitedScotland
100
Thermo Fisher Scientific Life Financing 2 LimitedEngland
100
Thermo Fisher Scientific Life UK Holdings 2 LP
[.01% by Life Technologies Limited]
England
99.99
Matrix MicroScience Ltd.England
100
Thermo Fisher Scientific Matrix Holding LimitedEngland
100
Thermo Fisher Scientific Blade I LimitedEngland
100
Thermo Fisher Scientific Blade II LimitedEngland
100
Thermo Fisher Scientific Blade III LimitedEngland
100
Thermo Fisher Scientific Blade IV LimitedEngalnd
100
Thermo Fisher Scientific Blade V LimitedEngland
100
Thermo Fisher Scientific Blade VI LimitedEngland
100
Thermo Fisher Scientific Blade VII LimitedEngland
100
The Binding Site Corporation LimitedEngland
100
The Nettleton Gate LimitedEngland
100
The Binding Site Group LimitedEngland
100
The Binding Site Pty LimitedAustralia
100
The Binding Site LimitedNew Zealand
100
The Binding Site Ireland LimitedIreland
100
The Binding Site s.r.o.Czech Republic
100
The Binding Site Holding GmbHGermany
100
The Binding Site GmbHGermany
100
6

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
The Binding Site Benelux BVBelgium
100
The Binding Site France SASFrance
100
The Binding Site S.r.l.Italy
100
The Binding Site Denmark ApSDenmark
100
The Binding Site Spain (Specialist Protein Company) S.L.Spain
100
The Binding Site Portugal, Specialist Protein Company, Unip LdaPortugal
100
The Binding Site Group LimitedJordan
100
The Binding Site KKJapan
100
The Binding Site Pte Ltd.Singapore
100
TBS Group (Shanghai) Trade Co. LtdChina
100
The Binding Site S. de R.L. de C.V.Mexico
100
The Binding Site Brazil Comercio De Produtos Para Laboratorio Ltda.Brazil
100
The Binding Site Holding Inc.Delaware
100
The Binding Site Inc.California
100
The Binding Site VT, Inc.Vermont
100
TBS Howard Hill LLCVermont
100
TFS Group Holding II LLCDelaware
100
TFS Life Holding LLC
[6.19% by Thermo Fisher Scientific Life Technologies Investment UK I Limited, .02% by Thermo Fisher Scientific Life Investments US Financing II LLC, preferred shares held by Thermo Fisher Scientific Investments (Sweden) S.a.r.l. , Thermo Fisher Scientific Sweden Holdings LLC, and TFS Group Holding II LLC]
Delaware
93.80
FSWH II LLCDelaware
100
Thermo Patheon Holdings LLCDelaware
100
FSWH I LLCDelaware
100
Thermo CIDTEC Inc.
[2.01% by Thermo Fisher Scientific Inc. and 1.44% by FSWH II LLC]
New York
96.55
Thermo Fisher Scientific Canada Holdings LLCDelaware
100
Thermo Fisher Scientific Canada Financing 1 ULCCanada
100
Thermo Fisher Scientific Senior Holdings US LP
[.01% by Thermo Fisher Scientific Canada Financing 3 ULC]
Delaware
99.99
Thermo Fisher Scientific Canada Financing 2 ULCCanada
100
Thermo Fisher Scientific Senior Holdings LP
[.01% held by Thermo Fisher Scientific Canada Financing 2 ULC]
Canada
99.99
7

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Life Technologies Inc.
[109,472 Class B by Thermo Fisher Scientific Life Canada Holding ULC and 690,000 Class A by Fisher Scientific Company]
Canada
100
Thermo Fisher Scientific Canada Financing 3 ULCCanada
100
Thermo Fisher (CN) Luxembourg Holding S.a.r.l.
[19% by TFS Life Holding LLC]
[Domesticated in the State of Delaware under the name of Thermo Fisher (CN) Luxembourg Holding S.a.r.l. LLC]
Luxembourg
81
TFS Venture Holdings I LLCDelaware
100
Thermo Fisher Scientific Luxembourg Venture Holdings I S.a.r.l.Luxembourg
100
Thermo Fisher Scientific Panama I Cayman LtdCayman Islands
100
Thermo Fisher Senior Canada Holdings LLCDelaware
100
Thermo Fisher (CN-I) Luxembourg LLCDelaware
100
Thermo Fisher (CN-II) Luxembourg LLCDelaware
100
Thermo Fisher Scientific (PN-II) SRLBarbados
100
Thermo Fisher (CN) Luxembourg S.a.r.l.Luxembourg
100
TFS Venture Holdings III S.C.S.
[.01 % by Thermo Fisher Scientific Luxembourg Venture Holdings I S.a.r.l.]
Luxembourg
99.99
Thermo Fisher Scientific PN2 C.V
[1% by Thermo Fisher Scientific PN2 LLC]
Netherlands
99
Thermo Fisher Scientific PN2 LLCDelaware
100
Thermo Fisher Scientific PN2 (Malta) Limited
[.04% by Thermo CN Luxembourg LLC]
Malta
99.96
DPI Newco LLCDelaware
100
Thermo Fisher Scientific FLC LLC
[36.68% by Thermo Fisher Scientific Inc.]
Delaware
63.32
Patheon Manufacturing Services LLCDelaware
100
Patheon Development Services Inc.Delaware
100
REP GBP I-B Blocker, Inc.Delaware
100
Patheon Biologics LLC
[24% by REP GBP I-B Blocker, Inc.]
Delaware
76
Patheon Biologics (NJ) LLCDelaware
100
Patheon API Inc.South Carolina
100
Patheon API Services Inc.South Carolina
100
Patheon API Manufacturing Inc.South Carolina
100
DSM Pharmaceutical Products, Inc.Delaware
100
Percivia LLC
[50% held privately]		Delaware
50
8

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Fisher Scientific (Finance I) S.a.r.l.
[1.26% by Thermo Luxembourg Holding S.a.r.l.]
Luxembourg
98.74
Thermo Fisher Insurance Holdings Inc.Delaware
100
Thermo Fisher Insurance Holdings LLC
[45.62% by Thermo Fisher Scientific Re Ltd.]
Delaware
54.38
Thermo Scientific Microbiology Sdn BhdMalaysia
100
Thermo Scientific Microbiology Pte Ltd.Singapore
100
TFS FEI Holding LLC
[12.07% by Thermo Fisher Scientific (Finance I) S.a.r.l., 5.09% by Thermo Fisher (CN) Luxembourg S.a.r.l., and 21.22% Thermo Fisher (CN) Luxembourg Holding S.a.r.l]
Delaware
61.61
Thermo CN Luxembourg LLCDelaware
100
Thermo Fisher Scientific Luxembourg Venture Holdings II S.a.r.l.
Luxembourg
100
Thermo Fisher Scientific (DPI) Limited Partnership
[.00000001% by Thermo CN Luxembourg LLC]
Canada
99.99999999
Thermo Fisher Scientific (CP1) LimitedEngland
100
Thermo Fisher Scientific PN2 (Luxembourg) S.à.r.lLuxembourg
100
Fisher Canada Holding ULC 1Canada
100
Fisher Canada Holding ULC 2Canada
100
Fisher CLP Holding Limited Partnership
[2.65574447% by Fisher Canada Holding ULC 2]
Canada
97.34425553
Fisher Canada Holding ULC 3Canada
100
Fisher Scientific CompanyCanada
100
Thermo Fisher Scientific (CP2) LimitedEngland
100
Patheon Inc.Canada
100
Patheon KKJapan
100
Patheon U.S. Holdings LLCDelaware
100
Thermo Fisher Scientific PNM Limited Liability Partnership  
[50% by Patheon Inc.]
England
50
Thermo Fisher Scientific (PN-I) SRLBarbados
100
Thermo Fisher Scientific PNM S.a.r.lLuxembourg
100
Patheon I B.V.Netherlands
100
Patheon Softgels B.V.Netherlands
100
Patheon Holdings SASFrance
100
Patheon France SASFrance
100
Patheon Italia S.p.A.Italy
100
Thermo Fisher Scientific (PN1) UK LtdEngland
100
9

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Patheon UK LimitedEngland
100
Patheon Calculus Merger LLCDelaware
100
Patheon Puerto Rico, Inc.Puerto Rico
100
Patheon Puerto Rico Acquisitions CorporationPuerto Rico
100
CEPH International CorporationPuerto Rico
100
Patheon U.S. Holdings Inc.Delaware
100
Patheon Pharmaceuticals Services Inc.Delaware
100
Patheon Pharmaceuticals Inc.Delaware
100
Patheon Banner U.S. Holdings Inc.Delaware
100
Patheon Softgels Inc.Delaware
100
Pharmacaps Mexicana S.A. de C.V.
[.2% by Patheon Banner U.S. Holdings Inc.]		Mexico
99.8
Thermo Fisher Scientific (PN) UK LLCDelaware
100
Patheon UK Pension Trustees LimitedEngland
100
Thermo Fisher Scientific (PN) UK Limited Partnership
[1% by Thermo Fisher Scientific (PN) UK LLC]
England
99
Thermo Fisher Scientific FSUKHCO Financing (Barbados) SRLBarbados
100
Diagnostix Ltd.Canada
100
Fisher Scientific Oxoid Holdings Ltd.England
100
Oxoid CompanyCanada
100
Fisher Scientific Luxembourg S.a.r.l.Luxembourg
100
Thermo Fisher Scientific UK Holding Company Financing LimitedEngland
100
Perbio Science (Canada) CompanyCanada
100
Fisher Scientific UK Holding Company LimitedEngland
100
Fisher Scientific OyFinland
100
Fisher Scientific Norway ASNorway
100
Fisher Scientific A/SNorway
100
Doublecape Holding LimitedEngland
100
I.Q. (BIO) LimitedEngland
100
Oxoid (ELY) LimitedEngland
100
Doublecape LimitedEngland
100
Fisher Scientific Ireland LimitedIreland
100
Doe & Ingalls LimitedIreland
100
10

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Fisher Scientific Holding U.K., LimitedEngland
100
Fisher Scientific U.K., LimitedEngland
100
FSUK Holdings LimitedEngland
100
Sterilin LimitedEngland
100
Fisher Scientific UK Holding Company 2England
100
Fisher Clinical Services U.K. LimitedEngland
100
Fisher Clinical Services Pte Ltd.Singapore
100
Fisher Clinical Services (Beijing) Co., Ltd.China
100
Fisher Scientific Europe Holdings B.V.Netherlands
100
Perbio Science International Netherlands B.V.Netherlands
100
Fisher Scientific The Hague III B.V.
[35.00095% by Fisher Scientific Europe Holdings B.V.]
Netherlands
64.99905
Acros Organics BV
[.3333 by Fisher Scientific The Hague II B.V.]
Belgium
99.6667
Fisher Scientific AG
[17.55% by Fisher Scientific S.A.S.]
Switzerland
82.45
Fisher Scientific The Hague V B.V.Netherlands
100
Fisher Clinical Services GmbHSwitzerland
100
Patheon Logistics Switzerland GmbHSwitzerland
100
Fisher BioPharma Services (India) Private Limited
[.315% by Fisher Clinical Services U.K. Limited]
India
99.685
Fisher Scientific Ireland Investments Unlimited
[.10% by Fisher Scientific Europe Holdings B.V.]
Ireland
99.90
Fisher Emergo B.V.Netherlands
100
Fisher Scientific The Hague II B.V.Netherlands
100
Fisher Scientific Jersey Island LimitedJersey
100
Fisher Maybridge Holdings LimitedEngland
100
Maybridge Chemical Holdings LimitedEngland
100
Maybridge LimitedEngland
100
Fisher Bioblock Holding II SNC
[.99% by Fisher Scientific The Hague II BV]
France
99.01
Thermo Electron Holdings SAS
[22.12% by Fisher Scientific Company]
France
77.88
Inel SASFrance
100
Inel Inc.Delaware
100
Thermo Electron SASFrance
100
11

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Electron LED S.A.S.France
100
Jouan LimitedEngland
100
Thermo Electron IndustriesFrance
100
S.C.I. du 10 rue Dugay Trouin
[2% by Thermo Electron Industries]
France
98
Thermo Fisher Scientific Milano Srl
[.05% by Thermo Electron Industries]
Italy
99.95
Fisher Scientific S.A.S.France
100
Fisher Scientific SRL
 [.1% by Fisher Bioblock Holding II SNC]
Belgium
99.9
SCI Inno 92
[.0004% by Fisher Bioblock Holding II SNC]
France
99.9996
Fisher Scientific S.L.Spain
100
Fisher Scientific, Unipessoal, Lda.Portugal
100
Oxoid Holding SASFrance
100
Thermo Fisher Diagnostics SASFrance
100
Oxoid Senior Holdings LimitedEngland
100
Oxoid UKH LLCDelaware
100
Oxoid 2000 LimitedEngland
100
Oxoid Holdings LimitedEngland
100
Oxoid International LimitedEngland
100
Oxoid Australia Pty. LimitedAustralia
100
OXOID CZ s.r.o.
[1% by Oxoid Limited]
Czech Republic
99
Thermo Fisher Diagnostics ASNorway
100
Thermo Fisher Diagnostics ABSweden
100
Thermo Fisher Diagnostics AGSwitzerland
100
Thermo Fisher Diagnostics B.V.Netherlands
100
Oxoid Inc.Delaware
100
Oxoid NV
[.01% by Oxoid Holdings Limited]
Belgium
99.99
Thermo Fisher Diagnostics S.p.A. Italy
100
Oxoid LimitedEngland
100
Thermo Fisher (Heysham) LimitedEngland
100
Avocado Research Chemicals LimitedEngland
100
12

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
G & M Procter LimitedScotland
100
Oxoid LimitedIreland
100
Oxoid Pension Trustees LimitedEngland
100
Thermo Fisher Scientific Beteiligungsverwaltungs GmbHGermany
100
Thermo Fisher Diagnostics ApsDenmark
100
Phadia s.r.o.
[1% by Phadia AB]
Czech Republic
99
Phadia Taiwan Inc.Taiwan
100
Thermo Fisher Diagnostics LimitedEngland
100
Thermo Fisher Diagnostics K.K.Japan
100
Thermo Fisher Diagnostics Austria GmbHAustria
100
Thermo Fisher Diagnostics NV
[.0016% by Thermo Fisher Diagnostics Limited]
Belgium
99.9984
Thermo Fisher Diagnostics, Sociedade Unipessoal LdaPortugal
100
Thermo Fisher Diagnostics, S.L.U.Spain
100
Thermo Fisher Diagnostics OyFinland
100
Fiberlite Centrifuge LLCDelaware
100
Thermo MF Physics LLC
[3.02% by Thermo Fisher Scientific Spectra-Physics Holdings Luxembourg II S.à r.l.]
Delaware
96.98
Thermo Fisher Investments (Cayman) LLC
[4.37% by Thermo Fisher Scientific Investments (Luxembourg) II S.a.r.l.
 Fisher Biosciences Japan GK owns 100% of the Class A and Class B preferred shares]
Delaware
95.63
Thermo Fisher Scientific CMN LLC
[5.61% by Thermo Fisher Scientific Investments (Luxembourg) S.a.r.l.]
Delaware
94.39
Thermo Fisher Scientific Worldwide Investments LLC
[10.10% by Thermo Fisher Scientific Worldwide Investments (Luxembourg) S.a.r.l.]
Delaware
89.90
Thermo USC I LLC
[5.2589% by Thermo Fisher Scientific Inc. and 9.9573% by Thermo Fisher Scientific (IVGN) Limited]
Delaware
84.7838
Phadia International LLC
[15.28% by Phadia International Holdings LP]
Delaware
84.72
Thermo Fisher Scientific Investments (Sweden) II LLC
[13.19% by Thermo Fisher Scientific Investments (Sweden) S.a.r.l.]
Delaware
86.81
Thermo Fisher Scientific (Cayman) LLC
[14.12% by Thermo Fisher Scientific (Luxembourg) II S.a.r.l.]
Delaware
85.88
Thermo Fisher Scientific Sweden Holdings S.a.r.l
[1% by Thermo Fisher Scientific Sweden Holdings LLC]
Luxembourg
99
FSII Sweden Holdings I ABSweden
100
13

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
FSII Sweden Holdings II ABSweden
100
CB Diagnostics I ABSweden
100
Power Sweden Holdings I ABSweden
100
FSII Sweden Holdings ABSweden
100
Thermo Fisher Scientific Life Canada Holding ULCCanada100
Life Technologies Japan Ltd.Japan100
Pasteur U.S. CorporationDelaware100
Life Technologies GmbHGermany100
Thermo Fisher Scientific GENEART GmbHGermany100
LTC Tech South Africa PTY Ltd.
[25% by The Thermo Fisher Scientific Phambili Trust]
South Africa75
The Thermo Fisher Scientific Phambili TrustSouth Africa100
Power Sweden Holdings II ABSweden100
Perbio Science ABSweden100
Thermo Fisher Scientific PRB S.a.r.l.Luxembourg
100
Thermo Fisher Scientific Investments (Luxembourg) S.a.r.l.
[1% by FSII Sweden Holdings AB]
Luxembourg
99
Thermo Fisher Scientific Life Investments II S.à r.l.Luxembourg
100
Thermo Fisher Scientific Life Investments US Financing II LLC
[1% by Perbio Science Sweden Holdings AB]
Delaware
99
Perbio Science Sweden Holdings ABSweden
100
Fisher Scientific GTF ABSweden
100
Fisher Scientific Biotech Line ApSDenmark
100
CB Diagnostics Holding ABSweden
100
CB Diagnostics ABSweden
100
Phadia Holding ABSweden
100
Phadia Diagnosticos Ltda
[1% by Phadia AB]
Brazil
99
Beijing Phadia Diagnostics Co LtdChina
100
Allergon ABSweden
100
Laboratory Specialties Proprietary Ltd.South Africa
100
Phadia ABSweden
100
Phadia Real Property ABSweden
100
Phadia US Inc.Delaware
100
Life Technologies BPD UK LimitedEngland
100
14

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Perbio Science UK LimitedEngland
100
Thermo Fisher Scientific (Finance III) S.a.r.l.Luxembourg
100
Thermo Fisher Scientific (Finance II) S.a.r.l.Luxembourg
100
Thermo Fisher CM II LLCDelaware
100
Thermo Fisher Scientific Falcon Senior Holdings Inc.Delaware
100
FEI CompanyOregon
100
ASPEX CorporationPennsylvania
100
FEI Korea Ltd.Korea
100
FEI Houston, Inc.Delaware
100
FEI Melbourne Pty Ltd.Australia
100
FEI Saudi Arabia LLC
[10% by FEI Europe B.V.]
Saudi Arabia
90
FEI Technologies, Inc.Oregon
100
FEI EFA, Inc.Delaware
100
Thermo Fisher Scientific FLC Hong Kong LimitedHong Kong
100
Thermo Fisher Scientific Dutch Senior Holdings B.V.Netherlands
100
Thermo Fisher Scientific FLC B.V.Netherlands
100
Thermo Fisher Scientific FLC II B.V.
[Domesticated in the State of Delaware under the name of Thermo Fisher Scientific FLC II B.V.]
Netherlands
100
Thermo Fisher Scientific B.V.Netherlands
100
Thermo Fisher Financial Services B.V.Netherlands
100
Thermo Fisher Scientific (Panama) B.V.Netherlands
100
Thermo Fisher Scientific (Panama) II B.V.Netherlands
100
Thermo Fisher Scientific (Panama) Dutch LLCDelaware
100
Patheon B.V.
Netherlands
100
Patheon Holdings B.V.Netherlands
100
Patheon Holdings I B.V.Netherlands
100
Patheon Holdings II B.V.Netherlands
100
Fisher Bioservices Netherlands B.V.Netherlands
100
Patheon Biologics Australia Pty LtdAustralia
100
Patheon Biologics B.V.Netherlands
100
Patheon Regensburg GmbHGermany
100
Patheon Life Science Products International GmbHAustria
100
15

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Patheon I Holding GmbHAustria
100
Patheon Austria GmbH & Co. KG
[0% by Patheon I Holding GmbH]
Austria
100
Thermo Fisher Scientific Dutch Holdings B.V.Netherlands
100
FEI Electron Optics International B.V.Netherlands
100
Thermo Fisher (FEI) Ireland LtdIreland
100
FEI Microscopy Solutions LtdIsrael
100
FEI CPD B.V.Netherlands
100
FEI EFA International Pte. Ltd.Singapore
100
DCG Systems G.K.Japan
100
FEI Company of USA (S.E.A.) Pte Ltd.Singapore
100
FEI Europe B.V.Netherlands
100
FEI Electron Optics B.V.Netherlands
100
FEI Hong Kong Company LimitedHong Kong
100
Thermo Fisher Electronic Technology Research and Development (Shanghai) Co., LtdChina
100
FEI Trading (Shanghai) Co., Ltd.China
100
Thermo Fisher Scientific Brno s.r.o.Czech Republic
100
FEI Asia Pacific Co., Ltd.China
100
FEI Technology de Mexico S.A. de C.V.
[2% by FEI Company]
Mexico
98
FEI UK LimitedEngland
100
FEI France SASFrance
100
FEI Italia SrlItaly
100
FEI SASFrance
100
FEI Company Japan Ltd.Japan
100
FEI Norway Holding ASNorway
100
FEI Australia Pty LtdAustralia
100
Thermo Fisher Scientific Dutch Holdings II B.V.Netherlands
100
Thermo Fisher Scientific Luxembourg Sweden Holdings II S.à r.l.Luxembourg
100
TFS Breda B.V.
[.25% by Thermo Fisher Scientific C.V.]
Netherlands
99.75
Thermo Fisher Scientific Switzerland B.V.Netherlands
100
SwissAnalytic Group GmbHSwitzerland
100
Thermo Fisher Scientific (Ecublens) SARLSwitzerland
100
16

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Fisher Scientific Holdings Europe LimitedEngland
100
Thermo Fisher Scientific SpAItaly
100
Fisher Luxembourg Danish Holdings SARLLuxembourg
100
Nunc A/SDenmark
100
Proxeon Biosystems ApSDenmark
100
Kendro Laboratory Products LtdEngland
100
Kendro Containment & Services LimitedEngland
100
Thermo Fisher Scientific (Johannesburg) (Proprietary) LimitedSouth Africa
100
Thermo Fisher Scientific (Schweiz) AGSwitzerland
100
Thermo Fisher Scientific Wissenschaftliche Geräte GmbHAustria
100
Thermo Fisher Scientific (Praha) s.r.o.Czech Republic
100
Thermo Electron Sweden Forvaltning AB
[10.08% by Dionex Corporation]
Sweden
89.92
Spectra-Physics ABSweden
100
Thermo Fisher Scientific Spectra S.a.r.l.Luxembourg
100
Thermo Fisher Scientific Spectra-Physics Holdings Luxembourg II S.à r.l.Luxembourg
100
Thermo Fisher Scientific Spectra-Physics Holdings Luxembourg I S.à r.l.Luxembourg
100
Spectra-Physics Holdings LimitedEngland
100
Thermo Fisher Scientific Japan Holdings III B.V.Netherlands
100
Thermo Fisher Scientific K.K.
[0% by TFS Breda B.V. – preferred shares]
Japan
100
Saroph Sweden ABSweden
100
Thermo Electron Sweden ABSweden
100
Thermo Life Sciences ABSweden
100
Thermo Fisher Scientific Norway US Investments LLC
Delaware
100
Thermo Fisher Scientific Norway Holdings ASNorway
100
Thermo Fisher Scientific Life Senior Holdings, Inc.
[15.37% by Thermo Fisher Scientific Norway Holdings AS]
Delaware
84.63
Erie UK 1 LLCDelaware100
Thermo Fisher Scientific Invitrogen Financing (Barbados) SRLBarbados100
Invitrogen Holdings Ltd.Scotland100
Invitrogen Europe LimitedScotland100
Erie N2 LLCDelaware100
17

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Fisher Scientific Powder UK Holdings LimitedEngland100
Erie N10 LLCDelaware100
Erie UK 4 LimitedEngland100
Thermo Fisher Scientific AU II Limited
England
100
Erie Finance LLCDelaware
100
Applied Biosystems International Inc.Delaware100
Erie N2 UK LimitedEngland100
Thermo Fisher Scientific Powder Financing 2 LLCDelaware100
Thermo Fisher Scientific Powder Finance LLCDelaware100
Life Technologies CorporationDelaware100
Combinati IncorporatedDelaware100
Affymetrix, IncDelaware100
Affymetrix Japan K.K.Japan100
Bender MedSystems GmbHAustria100
eBioscience, LtdEngland100
Panomics, L.L.C.California100
USB CorporationOhio100
Thermo Fisher Scientific Life Technologies Israel Investment I LimitedEngland100
Thermo Fisher Scientific Life Technologies Israel Investment II Limited
England100
Thermo Fisher Israel Ltd.Israel100
STC Bio Manufacturing, Inc.Illinois100
Thermo Fisher Scientific Colombia S.A.S.Colombia100
HyClone International Trade (Tianjin) Co., LtdChina100
Invitrogen Argentina SA
[0.18% by Invitrogen Holdings LLC]
Argentina99.82
Invitrogen BioServices India Private Limited
[1% by Invitrogen Holdings LLC]
India99
Invitrogen IP Holdings, Inc.Delaware100
Ion Torrent Systems, Inc.Delaware100
Molecular Probes, Inc.Oregon100
Acoustic Cytometry Systems, Inc.Delaware100
Matrix MicroScience Inc.Delaware100
Gold Cattle Standard Testing Labs, Inc.Texas100
Westover Scientific, Inc.Washington100
18

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Kettlebrook Insurance Co. ltd.
[32.5% by Invitrogen Europe Limited]
Hawaii67.5
Invitrogen Finance CorporationDelaware100
CellzDirect, Inc.Delaware100
Applied Biosystems, LLCDelaware100
NewcoGen PE, LLCDelaware100
BioTrove CorporationDelaware100
BioTrove International, Inc.Delaware100
Life Technologies Clinical Services Lab, Inc.Delaware100
Compendia Bioscience, Inc.Michigan100
Ambion, Inc.Delaware100
CHK Holdings Inc.Delaware100
Thermo Fisher Scientific Norway Senior Holding ASNorway
100
Applied Biosystems de Mexico S. de R.L. de C.V.
[.002% by Applied Biosystems, LLC]
Mexico99.998
Thermo Fisher Scientific (IVGN) Luxembourg S.a.r.l.
[.83% by Ambion, Inc.]
Luxembourg
99.17
Thermo Fisher Scientific (IVGN) LimitedHong Kong
100
Applied Biosystems B.V.Netherlands100
Invitrogen Hong Kong LimitedHong Kong100
Life Technologies Limited
[23.5% by Applied Biosystems BV]
Hong Kong76.5
Life Technologies Holdings PTE Ltd.Singapore100
Affymetrix Biotech Shanghai LtdChina100
Affymetrix UK LtdEngland100
Life Technologies Magyarorszag KftHungary100
Life Technologies Czech Republic s.r.o.Czech Republic100
Life Technologies Polska Sp z.o.o.
[.08% by Invitrogen Holdings LLC]
Poland99.92
Life Technologies Europe B.V.Netherlands100
Bio-Sciences LtdIreland100
Prionics USA Inc.Delaware100
Prionics Lelystad B.V.Netherlands100
Prionics France SASFrance100
Life Technologies SASpain100
19

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Stokes Bio Ltd.Ireland100
Life Technologies s.r.o
[2.1% by Applied Biosystems BV]
Slovakia97.9
Life Technologies ASNorway100
Life Technologies Norway Investments US LLCDelaware100
Nihon Dynal K.K.
[40% held privately]
Japan60
Dynal Biotech Beijing Limited
China100
Life Technologies SASFrance100
Perbio Science France SASFrance100
eBioscience SASFrance100
Laboratoire Service International - L.S.IFrance100
BAC BVNetherlands100
BAC IP BVNetherlands100
Thermo Fisher Scientific (IVGN) B.V.Netherlands100
Thermo Fisher Scientific Life Tech Korea Holdings LLCDelaware100
Life Technologies Brasil Comercio e Industria de Produtos para Biotecnologia Ltda
[3.45% by Thermo Fisher CHK Holding LLC]
Brazil96.55
Thermo Fisher CHK Holding LLCDelaware100
Invitrogen Holdings LLCDelaware100
Thermo Fisher Bioprocessing Research and Development (Shanghai) Co., Ltd.China100
Invitrogen (Shanghai) Investment Co., Ltd.China100
Thermo Fisher Scientific (Guangzhou) Biotechnology Co., Ltd.China100
Thermo Fisher Scientific (Guangzhou) Co., Ltd  China100
Thermo Fisher Scientific Life Technologies Luxembourg Holding LLCDelaware100
Thermo Fisher Scientific Luxembourg Life Technologies UK Holding S.à r.lLuxembourg100
Thermo Fisher Scientific Life Technologies Enterprise Holding LimitedEngland100
Thermo Fisher Scientific Luxembourg Enterprise Holdings S.à r.l.
Luxembourg
100
Thermo Fisher Scientific One LimitedEngland
100
20

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Fisher Scientific Life International Holdings II LP
[.00000004% by Thermo Fisher Scientific One Limited and .55383943% by Thermo Fisher Scientific Life Investments IV S.a.r.l.]
England
99.44616054
Thermo Fisher Scientific Life Technologies Investment UK I LimitedEngland
100
Thermo Fisher Scientific Holdings (Cayman) I
[37.88% by Thermo Fisher Scientific Life Technologies Investment I LLC and 23.42% by Thermo Fisher Scientific Life Technologies Investments Holding LP]
Cayman Islands
38.70
Thermo Fisher Scientific Holdings (Cayman) II Cayman Islands
100
Thermo Fisher Scientific Cayman Investments LLCDelaware100
Thermo Fisher Scientific (Luxembourg) II S.a.r.l.Luxembourg100
Invitrogen Trading (Shanghai) Co., Ltd.China100
Life Technologies DaAn Diagnostic (Guangzhou) Co., Ltd.
[42.5% held privately]
China57.5
Life Technologies Finance Ltd.Scotland100
Thermo Fisher Scientific (Thailand) Co., Ltd.Thailand100
Thermo Fisher Scientific Solutions LLC
[20% by Thermo Fisher Scientific Life Tech Korea Holdings LLC]
Korea80
Applied Biosystems Trading (Shanghai) Company Ltd.China100
Shanghai Life Technologies Biotechnology Co. LimitedChina100
Applied Biosystems Taiwan LLCDelaware100
Life Technologies Co., Ltd.     
[42.6% by Applied Biosystems BV]
Taiwan57.4
Life Technologies Chile SpAChile100
Thermo Fisher Scientific Sweden Holdings LLC
[.2936% by Thermo Fisher Scientific Investments (Sweden) S.a.r.l.]
Delaware
99.7064
Princeton Gamma-Tech Instruments LLCDelaware
100
TPI Real Estate Holdings LLCDelaware
100
Comtest LimitedEngland
100
Thermo Electron Metallurgical Services, Inc.Texas
100
ONIX Systems Inc.Delaware
100
Thermo Process Instruments GP, LLCDelaware
100
21

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Process Instruments, L.P.
[.10% by Thermo Process Instruments GP, LLC]
Texas
99.90
Thermo Measuretech Canada Inc.Canada
100
Onix Holdings LimitedEngland
100
CAC LimitedEngland
100
Thermo Onix LimitedEngland
100
Phadia US Market Holdings LLCDelaware
100
Thermo Electron Scientific Instruments LLCDelaware
100
Thermo Fisher Scientific Japan Holdings I B.V.Netherlands
100
Thermo Fisher Scientific Japan Holdings I LP
[10% by Thermo Fisher Scientific Japan 1 LLC]
Delaware
90
Thermo Fisher Scientific Japan 1 LLCDelaware
100
Fuji Partnership
[17.8184% by Thermo Fisher Scientific Japan Holdings II B.V. and 10.1634% by Thermo Fisher Scientific Japan Holdings III B.V.]
Japan
72.0182
TK Partnership (aka Silent Partnership)
[44.66% by Thermo Fisher Scientific K.K.]
Japan
55.34
Thermo Fisher Scientific (NK) LLCDelaware
100
Thermo Fisher Eurobonds Ltd.Cayman Islands
100
Thermo Fisher Scientific LSI Financing (Barbados) SRLBarbados
100
Thermo Fisher Scientific (Mississauga) Inc.
[Thermo Finnigan LLC owns 100 Series A Preferred shares]
Canada
100
Life Sciences International LimitedEngland
100
Hybaid LimitedEngland
100
Thermo Optek LimitedEngland
100
Thermo Cambridge LimitedEngland
100
VG Systems LimitedEngland
100
Thermo Electron LimitedEngland
100
Thermo Electron Weighing & Inspection LimitedEngland
100
Thermo Electron (Management Services) LimitedEngland
100
Life Sciences International Holdings BVNetherlands
100
Thermo Ramsey Italia S.r.l.Italy
100
Helmet Securities LimitedEngland
100
Life Sciences International LLCDelaware
100
Thermo Fisher Scientific (Asheville) LLCDelaware
100
Thermo Neslab LLCNew Hampshire
100
22

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Fisher Scientific Japan Holdings II B.V.Netherlands
100
Thermo Fisher Scientific Japan Holdings II LP
[10% by Thermo Fisher Scientific Japan 2 LLC]
Delaware
90
Thermo Fisher Scientific Japan 2 LLCDelaware
100
Lab-Line Instruments, Inc.Delaware
100
Thermo Scientific Services, Inc.California
100
Thermo Fisher Scientific (Fuji) LLCDelaware
100
Jouan LLCDelaware
100
Thermo Kevex X-Ray LLCDelaware
100
Thermo Gamma-Metrics LLCDelaware
100
Thermo Fisher Scientific Cork LtdIreland
100
Laser Analytical Systems, Inc.California
100
Thermo Finnigan LLCDelaware
100
TMOI Inc.Delaware
100
Thermo Fisher Scientific (China) Holding LimitedEngland
100
Thermo Fisher Scientific Baltics UAB
[18.24% by Thermo Fisher Scientific (IVGN) Luxembourg S.a.r.l.]
Lithuania
81.70
Fermentas China Co., LtdChina
100
TFS Singapore HK LimitedHong Kong
100
Thermo Fisher Scientific NHK LimitedHong Kong
100
Thermo Fisher Scientific TR LimitedHong Kong
100
Thermo Fisher Scientific BHK (I) LimitedHong Kong
100
Thermo Fisher Scientific BHK (II) LimitedHong Kong
100
Thermo Fisher Scientific (China-HK) Holding LimitedHong Kong
100
Thermo Fisher Scientific (Shanghai) Supply Chain Management Co., LtdChina
100
Thermo Fisher Scientific (Suzhou) Research and Development Co., Ltd.China
100
Alfa Aesar (Hong Kong) LimitedHong Kong
100
Alfa Aesar (China) Chemical Co. Ltd.China
100
Thermo Fisher Scientific (Shanghai) Instruments Co., Ltd.China
100
Thermo Fisher Scientific (Suzhou) Instruments Co., LtdChina
100
Thermo Fisher Scientific (China) Co., Ltd.China
100
Thermo Fisher Biopharma Services (Hangzhou) Ltd.
[49 % held privately]
China
51
Thermo Fisher Scientific (Shanghai) Management Co., Ltd.China
100
23

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Fisher Scientific (Hong Kong) LimitedHong Kong
100
Thermo Life Science International Trading (Tianjin) Co., Ltd.China
100
Thermo Fisher Scientific SLSpain
100
Thermo Fisher (Cayman) Holdings I Ltd.Cayman Islands
100
Thermo Fisher (Gibraltar) Limited
[50% by Thermo Fisher (Cayman) Holdings II Ltd.]
Gibraltar
50
Thermo Fisher (Gibraltar) II LimitedGibraltar
100
Navaho Acquisition Corp.Delaware
100
NanoDrop Technologies LLCDelaware
100
Thermo Fisher (Cayman) Holdings II Ltd.Cayman Islands
100
Thermo BioAnalysis LLC
[5.1% by Life Sciences International Limited and 9.4% by Life Sciences International LLC]
Delaware
85.5
Thermo Fisher Scientific Senior Holdings Australia LLC
Delaware
100
Thermo Fisher German Holdings LLCDelaware
100
Thermo Holding European Operations LLCDelaware
100
Thermo DMA Inc.Texas
100
Thermo BioAnalysis LimitedEngland
100
Thermo Projects LimitedEngland
100
Thermo LabSystems Inc.Massachusetts
100
InnaPhase LimitedEngland
100
Core Informatics, LLCConnecticut
100
Core Informatics UK Ltd.England
100
Thermo Environmental Instruments LLCCalifornia
100
27 Forge Parkway LLCDelaware
100
Thermo Electron (Calgary) LimitedCanada
100
Thermo Orion Inc.Massachusetts
100
Thermo Fisher Scientific Aquasensors LLCDelaware
100
Thermo Electron Puerto Rico, Inc.Puerto Rico
100
Thermo Power CorporationMassachusetts
100
ACI Holdings Inc.New York
100
Thermo Securities CorporationDelaware
100
Thermo Eberline Holdings I LLC
[49% by Thermo Fisher Scientific Inc.]
Delaware
51
Thermo Eberline Holdings II LLCDelaware
100
24

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Eberline LLCDelaware
100
Thermo Instrument Controls de Mexico, S.A. de C.V.
[2% by Thermo Fisher Scientific Inc.]
Mexico
98
ThermoLase LLCDelaware
100
Trex Medical CorporationDelaware
100
Fermentas Inc.Maryland
100
TFS LLCMassachusetts
100
Thermo CorporationDelaware
100
Fisher Scientific GmbHGermany
100
Fisher Scientific Germany Beteiligungs GmbHGermany
100
Fisher Scientific, spol. S.r.o
Czech Republic
100
Fisher Scientific (Austria) GmbHAustria
100
Thermo Fisher Scientific Germany BV & Co. KG
[0% by Thermo Fisher Germany B.V.]
Germany
100
Thermo Fisher Scientific C.F. GmbHGermany
100
Fisher Clinical Services GmbHGermany
100
Fisher Clinical Services Rheinfelden GmbHGermany
100
Thermo Fisher Scientific (Holding II) B.V. & Co. KG
[0% by Thermo Fisher Germany B.V.]
Germany
100
FEI Deutschland GmbHGermany
100
Thermo Fisher Diagnostics GmbHGermany
100
Microgenics Corporation
[100% of the preferred shares held by Thermo Fisher Scientific Vector Holdings 2 LLC]
Delaware
100
AcroMetrix LLC
California
100
Consolidated Technologies, Inc.Wisconsin
100
Remel Inc.Wisconsin
100
Trek Diagnostic Systems LLCDelaware
100
Trek Holding Company Ltd.England
100
Trek Holding Company II Ltd.England
100
Trek Diagnostic Systems Ltd.England
100
Thermo Luxembourg Holding S.a.r.l.
[Domesticated in the State of Delaware under the name of Thermo Luxembourg Holding LLC]
Luxembourg
100
Thermo MT II Limited
[.0000003% by Thermo MT II LLC]
Malta
99.9999997
Thermo MT II LLCDelaware
100
25

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Luxembourg U.S. S.a.r.l.Luxembourg
100
Thermo Fisher Scientific Asset Management 1 GmbHGermany
100
Thermo Fisher Scientific Asset Management 2 GmbHGermany
100
Thermo Fisher Scientific Vector Senior Holdings II UABLithuania
100
Thermo Fisher Scientific Vector Senior Holdings I UABLithuania
100
Thermo Fisher Scientific Vector Holdings UABLithuania
100
Thermo Fisher Scientific Vector Holdings LLCDelaware
100
Thermo Fisher Scientific Vector Holdings 2 LLCDelaware
100
FB2 Blocker, LLCDelaware
100
TFS Brammer Holding Corporation
[43.18% by Thermo Fisher Scientific Vector Holdings LLC]
Delaware
56.82
Brammer Bio Holding Company, LLCDelaware
100
Brammer Bio, LLCDelaware
100
Brammer Bio MA, LLCDelaware
100
Thermo Fisher Scientific Biosciences Corp.Canada
100
Oxoid Investments GmbHGermany
100
B.R.A.H.M.S. GmbH
[5.025% by Phadia GmbH]
Germany
94.975
B.R.A.H.M.S. Biotech GmbH
[6% held privately]
Germany
94
Cezanne S.A.S.France
100
B.R.A.H.M.S. UK LtdEngland
100
Thermo Fisher Scientific Luxembourg German Holdings S.a.r.l.Luxembourg
100
Dionex (UK) Limited
[.10% by Dionex Corporation]
England
99.90
Thermo Fisher Scientific Chromatography Holdings S.à r.l.
[5.28% by Oxoid Investments GmbH]
Luxembourg
94.72
Thermo Fisher Scientific Chromatography Holdings ApsDenmark
100
Dionex CorporationDelaware
100
Thermo Fisher Scientific Pte. Ltd.Singapore
100
Dionex Sweden ABSweden
100
Dionex I, LLCDelaware
100
Dionex (Switzerland) AGSwitzerland
100
Dionex Canada Ltd.Canada
100
Dionex Austria GmbHAustria
100
26

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Dionex Benelux B.V.Netherlands
100
Dionex Holding GmbHGermany
100
Dionex Softron GmbHGermany
100
Dionex Singapore Pte Ltd.Singapore
100
Thermo Fisher Scientific Korea Ltd.Korea
100
Dionex S.A.France
100
Thermo Fisher Diagnostics (Ireland) LimitedIreland
100
Dionex S.p.A.
[.08% held privately]
Italy
99.92
Dionex China LimitedHong Kong
100
Thermo Fisher (China) Analytical Ltd.China
100
Thermo Fisher Scientific Taiwan Co., Ltd.Taiwan
100
Dionex Denmark A/SDenmark
100
Thermo Fisher Scientific (Breda) Holding BVNetherlands
100
Thermo Luxembourg S.a.r.l.Luxembourg
100
Thermo TLH L.P.
[.01% by Thermo TLH (U.K.) Limited]
Delaware
99.99
Thermo TLH (UK) LimitedEngland
100
Thermo TLH (MT) Limited
[.000003% by Thermo TLH L.P.]
Malta
99.999997
Thermo TLH Luxembourg S.a.r.l.Luxembourg
100
Thermo Fisher Scientific IT Services GmbHGermany
100
Thermo Fisher Scientific GmbHGermany
100
BmT GmbH LaborprodukteGermany
100
Thermo Fisher Scientific (Real Estate 1) S.a.r.l.Luxembourg
100
Thermo Fisher Scientific Messtechnik GmbH
[10.04% by Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG]
Germany
89.96
Thermo Electron (Karlsruhe) GmbH
 [10% by Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG]
Germany
90
Thermo Electron Pension Trust GmbHGermany
100
Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG
[0% by Fisher Scientific Germany Beteiligungs GmbH as the General Partner]
Germany
100
Thermo Fisher Scientific (Bremen) GmbH
 [10% by Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG]
Germany
90
La-Pha-Pack GmbHGermany
100
27

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Electron LED GmbH
[10% by Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG]
Germany
90
Oxoid Deutschland GmbHGermany
100
Thermo Fisher (Kandel) GmbHGermany
100
Thermo Fisher Diagnostics sp. z o.oPoland
100
Microgenics B.V. & Co. KG
[.01% by Thermo Fisher Germany B.V.]
Germany
99.9
Advanced Scientifics International, Inc.Pennsylvania
100
Advanced Scientifics, Inc.Pennsylvania
100
Avances Cientificos de Mexico, S. de R.L. de C.V.
[1.005% by Advanced Scientifics International, Inc.]
Mexico98.995
Barnstead Thermolyne LLCDelaware
100
Thermo Fisher Scientific China Holdings I B.V.Netherlands
100
Thermo Fisher Scientific China Holdings II B.V.Netherlands
100
Thermo Fisher Scientific China Holdings III B.V.Netherlands
100
Thermo Fisher China Business Trust
[1% by Thermo Fisher Scientific China Holdings IV B.V.]
China
 99
Thermo Fisher Scientific China Holdings IV B.V.Netherlands
100
Fisher Scientific International LLCDelaware
100
TFS (Barbados) I SrlBarbados
100
Thermo Fisher Scientific Powder Holdings IIICayman Islands
100
Thermo Fisher Scientific Powder Holdings IVCayman Islands
100
NERL Diagnostics LLCWisconsin
100
FHP LLCDelaware
100
Alchematrix, Inc.Delaware
100
Fisher Internet Minority Holdings L.L.C.Delaware
100
Alchematrix LLCDelaware
100
Apogent Technologies Inc.Wisconsin
100
Apogent Holding CompanyDelaware
100
Niton Asia LimitedHong Kong
100
Matrix Technologies LLCDelaware
100
Molecular BioProducts, Inc.California
100
Intrinsic BioProbes, Inc.Arizona
100
Labomex MBP, S. de R. L. De C.V.
[.04% by Apogent Technologies Inc.]
Mexico
99.96
28

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
National Scientific CompanyWisconsin
100
Lab-Chrom-Pack LLCNew York
100
Robbins Scientific LLCCalifornia
100
Apogent Transition Corp.Delaware
100
Erie Scientific LLCDelaware
100
Thermo Fisher TDI Holding LLCDelaware
100
TFLP LLC
[.061140% by Thermo Fisher Scientific Inc., .000001% by Apogent Technologies Inc., .000060% by Fisher Scientific Worldwide Inc., and 9.993898% by Fisher WWD Holding L.L.C.]
Delaware
89.944901
Thermo Fisher Scientific AL-1 LLCDelaware
100
Thermo Fisher Scientific Life Holdings III C.V. LLC
[33.19378799% by Erie Scientific LLC, 22.31855864% by Thermo Fisher Scientific Inc., and .00000002% by Thermo Fisher Scientific AL-1 LLC]
Delaware
44.48765335
TFS Group Holdings III LLCDelaware
100
Metavac LLCDelaware
100
Abgene Inc.Delaware
100
Apogent Finance CompanyDelaware
100
Capitol Vial, Inc.Alabama
100
Capitol Scientific Products, Inc.New York
100
Chase Scientific Glass, Inc.
[50% by Apogent Holding Company]
Wisconsin
50
EP Scientific Products LLCDelaware
100
Erie Scientific Company of Puerto RicoDelaware
100
Erie Scientific Hungary Ipari és Szolgáltató KftHungary
100
Erie UK Holding CompanyDelaware
100
Erie LP Holding LLCDelaware
100
Fisher Scientific Investments (Cayman), Ltd.Cayman Islands
100
Thermo Fisher Scientific Erie Financing (Barbados) SRLBarbados
100
Erie U.K. LimitedEngland
100
Nalge Nunc International CorporationDelaware
100
Epsom Glass Industries LimitedEngland
100
Thermo Fisher Scientific (Monterrey), S. De R.L. De C.V.
[1% by Nalge Nunc International (Monterrey) LLC]
Mexico
99
236 Perinton Parkway, LLCNew York
100
ARG Services LLCDelaware
100
29

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Owl Separation Systems LLCWisconsin
100
Nalge Nunc International (Monterrey) LLCDelaware
100
Erie UK Senior Holding Limited
[1.01% by Erie LP Holding LLC]
England
98.99
LambTrack LimitedEngland
100
Erie UK 2 LimitedEngland
100
Thermo BioSciences Holdings LLCDelaware
100
Pierce Biotechnology, Inc.Delaware
100
Perbio Science, Inc.Delaware
100
Pierce Milwaukee, Inc.Delaware
100
Pierce Milwaukee Holding Corp.Delaware
100
Thermo Fisher Scientific (Milwaukee) LLC
[1% by Pierce Milwaukee, Inc.]
Delaware
99
Advanced Biotechnologies LimitedEngland
100
Abgene LimitedEngland
100
Apogent U.K. LimitedEngland
100
Matrix Technologies Corporation LimitedEngland
100
Chromacol LimitedEngland
100
Ever Ready Thermometer Co., Inc.Wisconsin
100
Samco Scientific LLC
Delaware
100
Samco Scientific (Monterrey) LLCDelaware
100
Seradyn Inc.
Delaware
100
Applied Scientific CorporationCalifornia
100
Cellomics, Inc.Delaware
100
CTPS LLCDelaware
100
Clintrak Pharmaceutical Services, LLCDelaware
100
Fisher Clinical Services (Bristol), LLCDelaware
100
Clintrak Clinical Labeling Services, LLCDelaware
100
Columbia Diagnostics, Inc.Delaware
100
Drakeside Real Estate Holding Company LLCDelaware
100
Duke Scientific CorporationCalifornia
100
Fisher Clinical Services Inc.Pennsylvania
100
Eutech Instruments Pte Ltd.Singapore
100
30

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Fisher Scientific Brasil Serviços de Logística Ltda
[.001% by Fisher BioServices Inc.]
Brazil
99.999
Fisher BioServices Inc.Virginia
100
Southern Trials (Pty) Ltd.South Africa
100
Schantz Road LLCPennsylvania
100
Specialty (SMI) Inc.California
100
Fisher Hamilton China Inc.Delaware
100
Fisher Scientific Brazil Inc.Delaware
100
Systems Manufacturing CorporationDelaware
100
Fisher Scientific Central America Inc.Delaware
100
Fisher Scientific Chile Inc.Delaware
100
Consultores Fisher Scientific Chile Ltd
[50% by Fisher Scientific Worldwide Inc.]
Chile
50
Fisher Scientific Colombia Inc.Delaware
100
Fisher Scientific Company L.L.C.Delaware
100
Fisher Scientific Costa Rica Sociedad de Responsabilidad LimitadaCosta Rica
100
Thermo Fisher Scientific Brahms LLCDelaware
100
Biochemical Sciences LLCDelaware
100
Fisher Scientific de Mexico S.A.Mexico
100
Medical Analysis Systems, Inc.Delaware
100
Medical Analysis Systems International, Inc.California
100
Medical Diagnostics Systems, Inc.California
100
United Diagnostics, Inc.
Delaware
100
Fisher Scientific Latin America Inc.Delaware
100
Fisher Scientific Mexico Inc.Delaware
100
FS Mexicana Holdings LLC
[.01% by Fisher Scientific Mexicana, S. de R.L. de C.V]
Delaware
99.99
Fisher Alder S. de R.L. de C.V.
[.0020% by Fisher Scientific International LLC]
Mexico
99.9980
Fisher Hamilton Mexico LLCDelaware
100
Fisher Scientific Mexicana, S. de R.L. de C.V.
[.01% by Fisher Scientific Worldwide Inc.]
Mexico
99.99
FS Casa Rocas Holdings LLC
[1% by Fisher Mexico, S. de R.L. de C.V]
Delaware
99
Fisher Mexico, S. de R.L. de C.V.
 [.0000269% by FS Casa Rocas Holdings LLC]
Mexico
99.9999731
31

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Fisher Scientific Middle East and Africa Inc.Delaware
100
Fisher Scientific Operating CompanyDelaware
100
Fisher Scientific Venezuela Inc.Delaware
100
Fisher Scientific Worldwide (Shanghai) Co., Ltd.China
100
FRC Holding Inc., VDelaware
100
Golden West Indemnity Company LimitedBermuda
100
Liberty Lane Real Estate Holding Company LLCDelaware
100
New FS Holdings Inc.Delaware
100
Hangar 215, Inc.Delaware
100
Fisher Scientific Worldwide Inc.Delaware
100
Spectra-Physics Holdings USA, LLCDelaware
100
Thermo Fisher Scientific Powder Holdings ICayman Islands
100
Thermo Fisher Scientific Powder Holdings II
[11.76% by Thermo Fisher Scientific Powder Holdings IV]
Cayman Islands
88.24
Thermo Fisher Scientific Powder SRLBarbados
100
Thermo Fisher Scientific Powder US Holdings LimitedEngland
100
Thermo Fisher Scientific Powder US Holdings Corp.Delaware
100
Thermo Fisher Scientific Japan Holdings II LLCDelaware
100
Thermo Fisher Scientific Japan Holdings I LLCDelaware
100
PPD, Inc.Delaware
100
Eagle Holding Company II, LLCDelaware
100
Jaguar Holding Company I, LLCDelaware
100
Jaguar Holding Company IIDelaware
100
Jaguar (Barbados) Finance SRLBarbados
100
Wildcat Acquisition Holdings (UK) LimitedEngland
100
Pharmaceutical Product Development, LLCDelaware
100
Synexus Clinical Research Topco LimitedEngland
100
PPD Vaccines and Biologics, LLCPennsylvania
100
Synexus Compass, Inc. (fmr. Synarc Inc.)Delaware
100
MediciGroup, Inc.Pennsylvania
100
Compass Research, LLCFlorida
100
The Compass Clinic, LLCFlorida
100
Compass NeuroHealth, LLCFlorida
100
NeuroHealth, Inc.Florida
100
32

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Center for Clinical and Basic Research A/SDenmark
100
UAB Center for Clinical and Basic ResearchLithuania
100
UAB DDF Properties LTLithuania
100
CCBR (Beijing) Company LimitedChina
100
PPD Services, Inc.North Carolina
100
PPD Investigator Services, LLCDelaware
100
Synexus Clinical Research US, Inc.Arizona
100
Optimal Research, LLCMaryland
100
PPD Global Central Labs, LLCKentucky
100
Applied Bioscience International, LLCDelaware
100
PPD GP, LLCDelaware
100
PPD Holdings, LLCDelaware
100
PPD Development, L.P.
[.1% by PPD GP, LLC]
Delaware
99.9
PPD Aeronautics CorporationDelaware
100
PPD Aeronautics, LLCNorth Carolina
100
River Ventures, LLCNorth Carolina
100
Pharmaco Investments, Inc.Delaware
100
Acurian, Inc.Delaware
100
Panoply Health LimitedEngland
100
APBI Finance CorporationDelaware
100
PPD CT Investments LLP
[20% by PPD International Holdings, LLC]
England
80
ATP, LLCNorth Carolina
100
Evidera, Inc.Delaware
100
0972792 B.C. LTDCanada
100
Evidera Holdings LtdEngland
100
Evidera Access Consulting LtdEngland
100
Evidera LtdEngland
100
PPD International Holdings, LLCDelaware
100
PPD Scandinavia ABSweden
100
PPD Pharmaceutical Development Japan K.K.Japan
100
PPD-SNBL K.K.
[40% by Shin Nippon Biomedical Laboratories, Ltd.]
Japan
60
33

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
PPD Peru S.A.C.
[.01% by Applied Bioscience International, LLC]
Peru
99.99
PPD Mexico S.A. de C.V.
[.002% by PPD Development, L.P.]
Mexico
99.998
PPD Italy S.r.lItaly
100
PPD International Holdings, Inc. y Compania Limitada
[1 % Applied Bioscience International, LLC]
Chile
99
PPD International Holdings (UK) LtdEngland
100
PPD Switzerland GmbHSwitzerland
100
PPD International Investments Limited
[.4% by AbC.R.O., Inc.]
England
99.6
LLC PPD UkraineUkraine
100
Clinical Technology Centre (International) LimitedEngland
100
Synexus Clinical Research Midco No1 LimitedEngland
100
Synexus Clinical Research Acquisitions LimitedEngland
100
Synexus Clinical Research LimitedEngland
100
Synexus Clinical Research South Africa (Pty) LimitedSouth Africa
100
Synexus Clinical Research GmbHGermany
100
Synexus Czech s.r.o.Czech Republic
100
Synexus LimitedEngland
100
Synexus Magyarorszg Egszsggyi Szolgltat Korltolt Felelssg TrsasgHungary
100
Synexus Polska Sp. Z o.oPoland
100
Synexus Ukraine Limited Liability Company
[1% by Synexus Clinical Research Acquisitions Limited]
Ukraine
99
Synexus Bulgaria EOODBulgaria
100
Medical Centre Synexus Sofia EOODBulgaria
100
PPD UK Holdings LimitedEngland
100
PPD Slovak Republic s.r.o.
[15% by PPD Global Ltd]
Slovak Republic
85
PPD Pharmaceutical Development Vietnam Company LimitedVietnam
100
PPD Pharmaceutical Development India Private Limited
[.01% by PPD Global Ltd.]
India
99.99
34

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
PPD Serbia D.O.O. BeogradSerbia
100
PPD Latvia SIALatvia
100
PPD Global Ltd.England
100
PPD Global Central Labs BVBA
[.1% by PPD Global Ltd]
Belgium
99.9
PPD Laboratories (Suzhou) Co., Ltd.China
100
PPD Global Central Labs (S) Pte. Ltd.Singapore
100
PPD Development Ireland LimitedIreland
100
PPD Development (S) Pte. Ltd.Singapore
100
PPD Pharmaceutical Development (Beijing) Co., Ltd.China
100
PPD Development (HK) Limited.
[50% by Applied Bioscience International, LLC]
Hong Kong
50
PPD Colombia S.A.SColombia
100
PPD Bulgaria EOODBulgaria
100
PPD (Netherlands) B.V.Netherlands
100
PPD Pharmaceutical Development Philippines Corp.
[.0001% held privately]
Philippines
99.9999
Shorecloud Corporation
[.0001% held privately]
Philippines
99.9999
PPD International Holdings GmbHGermany
100
PPD Poland Sp.Z o.o.Poland
100
PPD Hungary Research and Development Ltd.
[3.33% by PPD International Holdings, LLC]
Hungary
96.67
PPD Germany GmbH & Co. KG
[28% by PPD Germany GmbH]
Germany
72
PPD Germany GmbHGermany
100
PPD Czech Republic S.R.O.
[2.22% by PPD International Holdings, LLC]
Czech Republic
97.78
PPD France SASFrance
100
Greenbird LimitedCyprus
100
Limited Liability Company PPD Development (Smolensk)Russia
100
35

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Limited Liability Company Contract Research Organisation InnopharmUkraine
100
Excel PharmaStudies Inc.Cayman Islands
100
Clinical Technology Centre (Ireland) LimitedIreland
100
PPD Guatemala, S.A.
[1.0% by Applied Biosciences International, LLC]
Guatemala
99
PPD do Brasil- Suporte a Pesquisa Clinica Ltd
[.00002% by Pharmaceutical Product Development, LLC]
Brazil
99.99998
Medimix Latam Pesquisa de Mercado LtdaBrazil
100
PPD Development (Thailand) Co., Ltd.
[.0025% by PPD Development (S) Pte. Ltd. and .0025% by PPD UK Holdings Limited]
Thailand
99.995
PPD CanadaCanada
100
PPD Australia Pty LimitedAustralia
100
PPD Argentina S.A.
[5% by Applied Bioscience International, LLC]
Argentina
95
Pharmaceutical Product Development Spain SL
[.763% by PPD Development, L.P.]
Spain
99.237
Pharmaceutical Product Development South Africa (Proprietary) LtdSouth Africa
100
AbC.R.O., Inc.Virginia
100
PPD Romania SRL
[.67% by PPD Bulgaria EOOD]
Romania
99.33
PPD Hrvatska d.o.o.Croatia
100
FSIR Holdings (US) Inc.
[1.265% by Fisher Clinical Services Inc.]
Delaware
98.735
Liberty Lane Investment LLCDelaware
100
Fisher Scientific Holding Company LLCDelaware
100
Fisher Manufacturing (Malaysia) Sdn BhdMalaysia
100
Bumi-Sans Sendirian BerhadMalaysia
100
Fisher Scientific (M) Sdn BhdMalaysia
100
General Scientific Company Sdn Bhd (M)Malaysia
100
Fisher Scientific Holdings (S) Pte LtdSingapore
100
Fisher Scientific Pte. Ltd.
[16.57% by Fisher Scientific International LLC]
Singapore
83.43
Fisher Scientific (SEA) Pte. Ltd.Singapore
100
Fisher Scientific Australia Pty LimitedAustralia
100
36

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
FSIR Holdings (UK) LimitedEngland
100
FSWH Company LLCDelaware
100
FSI Receivables Company LLCDelaware
100
Fisher Bermuda Holdings LimitedBermuda
100
Thermo Fisher Scientific FSIR Financing (Barbados) SRLBarbados
100
Thermo Fisher Scientific FSIR Financing S.a.r.l.Luxembourg
100
Thermo Fisher Scientific FSIR Holdings (UK) Financing LimitedEngland
100
Fisher Scientific Worldwide Holdings I C.V.
[12% by Fisher Scientific Worldwide Inc.]
Netherlands
88
Finesse Solutions, Inc.Delaware
100
Finesse Scientific Equipment (Shanghai) Co., Ltd.China
100
FSWH International Holdings LLCDelaware
100
Thermo Fisher Scientific Life Investments US Financing I LLC
 [1% by FSIR Holdings (US) Inc.]
Delaware
 99
Phadia International Holdings LP
[10% by FSIR Holdings (US) Inc.]
England
90
Thermo Fisher Scientific BVBelgium
100
PharmaFluidics NVBelgium
100
Thermo Fisher Scientific Worldwide Investments (Cayman)Cayman Islands
100
Thermo Fisher Scientific Worldwide Investments (Luxembourg) S.a.r.l.Luxembourg
100
Thermo Fisher Scientific Investments (Sweden) S.a.r.l.
[16.086% by CHK Holdings Inc.]
Luxembourg
83.914
Thermo Fisher Scientific Denmark Senior Holdings ApSDenmark
100
Fisher Scientific Holding HK Limited
[.01% by Fisher Scientific Holding Company LLC]
Hong Kong
99.99
Fisher Scientific (Hong Kong) Limited
[.022% Fisher Scientific Holding Company LLC]
Hong Kong
99.978
Fisher Scientific Japan, Ltd.Japan
100
Fisher Scientific Korea LtdKorea
100
Fisher WWD Holding L.L.C.Delaware
100
Kyle Jordan Investments LLCDelaware
100
Pacific Rim Far East Industries LLCDelaware
100
Pacific Rim Investment, LLCDelaware
100
Marketbase International LimitedHong Kong
100
Thermo-Fisher Biochemical Product (Beijing) Co., Ltd.China
100
37

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
HighChem s.r.o.Slovakia
100
Thermo Fisher Scientific HR Services Mexico, S. de R.L. de C.V.
[1% by Fisher Clinical Services (Mexico) LLC]
Mexico
99
Thermo Fisher Scientific China (C-I) LLCDelaware
100
Shanghai Thermo Fisher (C-I) Trading Co. LtdChina
100
Pasteur Acquisition SRLBarbados
100
Thermo Fisher Scientific China (S) LLCDelaware
100
Shanghai Thermo Fisher (S) Trading Co. LtdChina
100
Molecular Transfer, Inc.Delaware
100
Thermo Fisher Scientific Cyprus I LtdCayman Islands
100
Thermo Fisher Scientific Cyprus II LtdCayman Islands
100
Thermo Fisher Scientific India Holding LLCDelaware
100
Thermo Fisher Scientific Cyprus III LtdCayman Islands
100
Thermo Fisher Scientific PSG CorporationDelaware
100
Fisher BioSciences Japan G.K.Japan
100
Fisher Clinical Services Japan K.K.Japan
100
Thermo Fisher Detection Mexico LLCDelaware
100
Thermo Fisher Costa Rica Sociedad de Responsabilidad Limitada
[1% by Fisher Scientific Company L.L.C.]
Costa Rica
99
Thermo Fisher Scientific South Africa Proprietary Ltd
South Africa
100
Thermo Fisher Biopharma Services Pte. Ltd.Singapore
100
Thermo Services (Hungary) KftHungary
100
Erie UK 1 Limited                           England
100
Erie UK 5 LimitedEngland
100
Erie UK 6 LimitedEngland
100
Erie US II LLCDelaware
100
Erie Finance Holding LimitedEngland
100
Erie Finance LimitedEngland
100
Erie Finance 2 LimitedEngland
100
Erie Finance 1 LimitedEngland
100
Erie (GC) Holding Limited
[1% by Erie US III LLC]
England
99
Erie UK 3 LimitedEngland
100
Erie GC Holding LLCDelaware
100
38

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Erie GC LimitedEngland
100
Erie US III LLCDelaware
100
Quebec Court B.V.
[5.71% by Erie Finance Limited]
Netherlands
94.29
Quebec B.V.Netherlands
100
Thermo Fisher Scientific Powder LLCDelaware
100
Thermo Fisher Scientific (Finance I) B.V.Netherlands
100
Thermo Fisher Scientific Erie Financing S.a r.lLuxembourg
100
Erie Luxembourg LLCDelaware
100
Thermo Fisher Scientific Erie 1 Financing (Barbados) SRLBarbados
100
Thermo Fisher Scientific EMEA LimitedIreland
100
Oncomine Molecular Inc.Delaware
100
Oncomine LLCDelaware
100
Oncomine India Private Limited
[.01% by Oncomine Molecular Inc.
India
99.99
OncomineFrance
100
Oncomine LimitedEngland
100
Oncomine ULCCanada
100
Oncomine Pte. LtdSingapore
100
Oncomine Molecular, S.LSpain
100
Oncomine S.r.lItaly
100
Oncomine K.K.Japan
100
Thermo FLC LP
[42.78% By Thermo Fisher Scientific FLC LLC]
Delaware
57.22
Thermo Fisher Scientific Brussels B.V.Belgium
100
Mesa Biotech, Inc.Delaware
100
Fisher Clinical Services (Peru) LLCDelaware
100
Fisher Clinical Services Peru S.R.L
[1% by Thermo Fisher Scientific Inc.]
Peru
99
Henogen SRLBelgium
100
Ginko Park SABelgium
100
Thermo USC II LLCDelaware
100
Thermo Fisher Scientific Life Sciences COE CorporationDelaware
100
Thermo Fisher Scientific Life Investments IV S.a.r.lLuxembourg
100
39

NAME
STATE OR JURISDICTION OF ORGANIZATION
PERCENT OF OWNERSHIP
Thermo Fisher Scientific PRB Malta Limited
[.03997% by Thermo Fisher Scientific PRB LLC]
Malta
99.96003
Thermo Fisher Scientific PRB LLCDelaware
100
Thermo Fisher Scientific Spectra Malta Limited
[.03997% by Thermo Fisher Scientific Spectra LLC]
Malta
99.96003
Thermo Fisher Scientific Spectra LLC
Delaware
100
Thermo Fisher Scientific Spectra-Physics Investments Malta Limited
[.0000011% by Spectra-Physics Holdings USA, LLC]
Malta
99.9999989
PeproTech, Inc.New Jersey
100
PeproTech EC Ltd.England
100
PeproTech FranceFrance
100
PeproTech GmbHGermany
100
PeproTech Asia LtdIsrael
100
PeproTech BioTech (Suzhou) Co., Ltd.China
100
PeproTech KoreaKorea
100
MLS ACQ, Inc.Delaware
100


40
 EX-22 8 q4202210-kex22.htm SUBSIDIARY ISSUER OF GUARANTEED SECURITIES Document

Exhibit 22


Subsidiary Issuer of Guaranteed Securities

Thermo Fisher Scientific Inc. (the “Registrant”) is the guarantor of the senior secured registered notes listed below issued by Thermo Fisher Scientific (Finance I) B.V., a wholly-owned finance subsidiary of the Registrant.

Thermo Fisher Scientific (Finance I) B.V.
0.800% Senior Notes due 2030
1.125% Senior Notes due 2033
1.625% Senior Notes due 2041
2.000% Senior Notes due 2051
Floating Rate Senior Notes due 2023
0.000% Senior Notes due 2023
0.000% Senior Notes due 2025


 EX-23.1 9 q4202210-kex231pwcconsent.htm CONSENT Document

Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-263034) and Form S-8 (Nos. 33-51189, 33-54347, 333-146068, 333-152344, 333-161939, 333-188846, 333-220231 and 333-261548) of Thermo Fisher Scientific Inc. of our report dated February 23, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.


/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts
February 23, 2023


 EX-31.1 10 q4202210-kex311.htm CERTIFICATION Document

Exhibit 31.1

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Marc N. Casper, certify that:
1.I have reviewed this Annual Report on Form 10-K of Thermo Fisher Scientific Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 23, 2023
/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer


 EX-31.2 11 q4202210-kex312.htm CERTIFICATION Document

Exhibit 31.2

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen Williamson, certify that:
1.I have reviewed this Annual Report on Form 10-K of Thermo Fisher Scientific Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 23, 2023
/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer


 EX-32.1 12 q4202210-kex321.htm CERTIFICATION Document

Exhibit 32.1

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Thermo Fisher Scientific Inc. (the “Company”) for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Marc N. Casper, Chairman, President and Chief Executive Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  February 23, 2023

/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer






























A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-32.2 13 q4202210-kex322.htm CERTIFICATION Document

Exhibit 32.2

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Thermo Fisher Scientific Inc. (the “Company”) for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Stephen Williamson, Senior Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  February 23, 2023

/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer






























A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-101.SCH 14 tmo-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheet link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statement of Income link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statement of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statement of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Consolidated Statement of Redeemable Noncontrolling Interest and Equity link:presentationLink link:calculationLink link:definitionLink 0000010 - Statement - Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Revenue and Contract-related Balances link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Business Segment and Geographical Information link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Other Income/Expense link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Stock-based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Pension and Other Postretirement Benefit Plans link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Debt and Other Financing Arrangements link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Comprehensive Income and Shareholders Equity link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Restructuring and Other Costs link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Revenue and Contract-related Balances (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Business Segment and Geographical Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Stock-based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Debt and Other Financing Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Comprehensive Income and Shareholders Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Restructuring and Other Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Acquisitions - Schedule of Components of Purchase Price (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Acquisitions - Schedule of Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Revenue & Contract-related Balances - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Revenue & Contract-related Balances - Revenue Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Revenue & Contract-related Balances - Revenue Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Revenue & Contract-related Balances - Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Business Segment and Geographical Information - Schedule of Revenue by Geographical Areas (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Other Income/Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Stock-based Compensation Expense - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Stock-based Compensation Expense - Summary of the Company's Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Stock-based Compensation Expense - Summary of the Company's Restricted Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Pensions and Other Postretirement Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - Debt and Other Financing Arrangements - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - Debt and Other Financing Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Leases- Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Leases - Schedule of Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - Leases - Schedule of Future Payments of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - Leases - Schedule of Future Payments of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000079 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000080 - Disclosure - Comprehensive Income and Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000082 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Rollforward of the Fair Value of Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000083 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Aggregate Notional Value and Fair Value of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000084 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Derivative Instruments, Gain (Loss) Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 0000085 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of the Company's Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000086 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 0000087 - Disclosure - Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 0000088 - Disclosure - Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) link:presentationLink link:calculationLink link:definitionLink 0000089 - Disclosure - Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 tmo-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 16 tmo-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 17 tmo-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Non-U.S. Current Foreign Tax Expense (Benefit) Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Total borrowings at par value Total borrowings at par value Long-Term Debt, Gross $5.30% 30-Year Senior Notes, Due 2/1/2044 Senior Notes 5.30% Due 2044 [Member] 5.30% 30-Year Senior Notes, Due 2/1/2044 [Member] 1.450% Notes due 2027 $1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.45% Senior Notes Due 2027 [Member] 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) Deferred income tax provision (benefit) Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Gain (loss) on investments Gain (Loss) on Investments Accumulated Benefit Obligation and Fair Value of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Indefinite-Lived Acquisition-related Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax Finance lease liabilities Finance Lease, Liability Property, plant and equipment, at cost Property, Plant and Equipment, Gross Dividends paid Payments of Ordinary Dividends, Common Stock Fair value Debt Instrument, Fair Value Disclosure Contract liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Currency exchange contracts Foreign Exchange Contract [Member] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Variable rate Debt Instrument, Basis Spread on Variable Rate 2026  Finance Lease, Liability, to be Paid, Year Four Depreciation of property, plant and equipment Depreciation Exercised (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Surety Bonds and Other Guarantees Surety Bonds and Other Guarantees [Member] Surety Bonds and Other Guarantees Discount rate Operating Lease, Weighted Average Discount Rate, Percent Interest rate Debt Instrument, Interest Rate, Stated Percentage Schedule of Revenue by Geographical Areas Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Schedule of Derivative Instruments, Gain (Loss) Recognized Derivative Instruments, Gain (Loss) [Table Text Block] Capital in excess of par value Additional Paid in Capital, Common Stock Other non-cash expenses Other Noncash Income (Expense) Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Income taxes Income Taxes Paid State Current State and Local Tax Expense (Benefit) Recognition upon acquisition Noncontrolling Interest, Increase from Business Combination 2025  Finance Lease, Liability, to be Paid, Year Three Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive stock options excluded from diluted weighted averages shares (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Settlements Defined Benefit Plan, Plan Assets, Payment for Settlement 2028 and thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Ownership [Axis] Ownership [Axis] 1.875% Notes due 2049 $1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) Senior Notes 1.875% Due 2049 [Member] Senior Notes 1.875% Due 2049 [Member] Additions for tax positions of current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Range of probable loss Loss Contingency, Estimate of Possible Loss Reconciliation of Unrecognized Tax Benefits Summary of Income Tax Contingencies [Table Text Block] Cash outlay Payments of Financing Costs Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Letters of Credit / Bank Guarantees Standby Letters of Credit [Member] Hedging Designation [Domain] Hedging Designation [Domain] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Fair value of plan assets at beginning of year Fair value of plan assets at end of year Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Information [Abstract] Valuation Allowance by Deferred Tax Asset [Axis] Valuation Allowance by Deferred Tax Asset [Axis] 1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated) Senior Notes 1.279% Due 2029 [Member] Senior Notes 1.279% Due 2029 Specialty Diagnostics Specialty Diagnostics [Member] Specialty Diagnostics Segment Borrowings outstanding Long-Term Line of Credit Entity Address, State or Province Entity Address, State or Province Options outstanding, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Operating Activities [Domain] Operating Activities [Domain] Award Type [Axis] Award Type [Axis] Actuarial (gains) losses Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 2027  Defined Benefit Plan, Expected Future Benefit Payment, Year Five Operating lease liabilities - current Operating Lease, Liability, Current Entity Listings [Line Items] Entity Listings [Line Items] Costs and operating expenses: Costs and Expenses [Abstract] Multi-asset funds Multi-asset Funds [Member] Multi-asset Funds Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment 0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated) Senior Notes 0.000% Due 2025 [Member] Senior Notes 0.000% Due 2025 Remaining operating lease term Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Option to terminate, term Lessee, Operating Lease, Option to Terminate, Term Term of lessee's operating lease if an option to terminate is available and executed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Finalization of purchase price allocations for 2021 acquisitions Goodwill, Purchase Accounting Adjustments Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Schedule of Estimated Future Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Contract-related Balances Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Revolving Credit Facility Revolving Credit Facility [Member] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Current income tax provision Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Document Type Document Type Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Useful lives Property, Plant and Equipment, Useful Life Components of Net Periodic Benefit Cost (Income) [Abstract] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Canceled/expired (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Assets [Abstract] Assets, Fair Value Disclosure [Abstract] Intra-entity transfers Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Unvested, weighted average grant-date fair value, beginning (in dollars per share) Unvested, weighted average grant-date fair value, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Deferred income tax provision (benefit) Deferred Income Tax Expense (Benefit) Noncurrent assets Assets for Plan Benefits, Defined Benefit Plan Product technology Developed Technology Rights [Member] Contributions from (distributions to) noncontrolling interests Noncontrolling interest, contribution from (distributions to) noncontrolling interests Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders net of decreases in noncontrolling interest balance from payment of dividends or other distributions. Schedule of Contract-related Balances Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] 1.750% Notes due 2027 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) Senior Notes 1.75% Due 2027 [Member] Senior Notes 1.75% Due 2027 1.750% 7-Year Senior Notes, Due 10/15/2028 Senior Notes 1.750% Due 2028 [Member] Senior Notes 1.750% Due 2028 Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] US foreign tax credits generated by repatriation of foreign earnings Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount Debt Disclosure [Abstract] Debt Disclosure [Abstract] 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) Senior Notes 1.625% Due 2041 [Member] Senior Notes 1.625% Due 2041 Income Statement Location [Axis] Income Statement Location [Axis] Employer contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Pension and other postretirement benefit liability adjustments: Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract] Non-recurring Pro Forma Adjustments, Transaction Costs Acquisition-related Costs [Member] Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Variable lease costs Variable Lease, Cost Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Thermo Fisher Scientific Inc. shareholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Net gains on derivative instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Audit Information [Abstract] Audit Information Interest costs Interest cost on benefit obligation Defined Benefit Plan, Interest Cost Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Fair Value of Derivative Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Components of the Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] $3.65% 10-Year Senior Notes, Due 12/15/2025 Senior Notes 3.65% Due 2025 [Member] 3.65% 10-Year Senior Notes, Due 12/15/2025 [Member] Weighted average amortization period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Options exercisable, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Schedule of Acquisition-related Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Other comprehensive items before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Cash paid Payments to Acquire Businesses, Gross Derivative Contract [Domain] Derivative Contract [Domain] Entity Registrant Name Entity Registrant Name 2026  Defined Benefit Plan, Expected Future Benefit Payment, Year Four 1.215% 3-Year Senior Notes, Due 10/18/2024 Senior Notes 1.215% Due 2024 [Member] Senior Notes 1.215% Due 2024 Unrecorded Unconditional Purchase Obligation [Line Items] Unrecorded Unconditional Purchase Obligation [Line Items] Expected annual dividend Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible List] Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other Series of Individually Immaterial Business Acquisitions [Member] Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Pension and Other Postretirement Benefit Plans Retirement Benefits [Text Block] Leases [Abstract] Leases [Abstract] Total equity Balance Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Restructuring Costs Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Minimum Minimum [Member] Entity Emerging Growth Company Entity Emerging Growth Company Common Stock, $1 Par Value - Par Value (in dollars per share) Common Stock, Par or Stated Value Per Share Unrealized losses on hedging instruments (net of tax benefit of $0, $0 and $20) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Analytical Instruments Analytical Instruments [Member] Analytical Instruments Segment Entity Stock Trading Symbol Trading Symbol Entity File Number Entity File Number Operating Activities [Axis] Operating Activities [Axis] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] 2026  Finite-Lived Intangible Asset, Expected Amortization, Year Four Tax provision (benefit) on currency translation adjustment OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax Less: comprehensive income attributable to noncontrolling interests and redeemable noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Non-U.S. Deferred Foreign Income Tax Expense (Benefit) Entity Listings [Table] Entity Listings [Table] Derivatives Contracts Derivatives, Policy [Policy Text Block] Granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Estimated contributions to plan Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Use of Estimates Use of Estimates, Policy [Policy Text Block] Accounts payable Increase (Decrease) in Accounts Payable Total net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Debt settled Business Combination, Consideration Transferred, Liabilities Incurred U.S. equity funds U S Equity Funds [Member] U.S. Equity Funds Net income attributable to Thermo Fisher Scientific Inc. Business Acquisition, Pro Forma Net Income (Loss) Settlements Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Income Taxes Income Tax Disclosure [Text Block] Guarantees [Abstract] Guarantees [Abstract] Acquisitions Defined Benefit Plan, Plan Assets, Business Combination Finished goods Inventory, Finished Goods, Net of Reserves Credit Facility [Domain] Credit Facility [Domain] Cash / money market funds Defined Benefit Plan, Cash and Cash Equivalents [Member] Domestic NOL Expires Domestic NOL Expires [Member] Domestic NOL Expires Acquisition-related intangible assets Intangible Assets, Gross (Excluding Goodwill) Basic (in dollars per share) Basic Earnings Per Share (in dollars per share) Earnings Per Share, Basic Tax benefit on reclassification adjustment for losses on hedging instruments recognized in net income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Net settlement gains on pension plans Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Schedule of Cash, Cash Equivalents and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Laboratory Products and Biopharma Services Laboratory Products and Services [Member] Laboratory Products and Services Segment Ownership [Domain] Ownership [Domain] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in assets and liabilities, excluding the effects of acquisitions and disposition: Increase (Decrease) in Operating Capital [Abstract] Other non-cash restructuring costs Restructuring and Related Costs, Non-Cash Costs Restructuring and other costs which consist principally of gains and losses resulting from changes in estimates for significant litigation-related matters, and, in some periods, may also include gains and losses on the sale of businesses, product lines and real estate, and asset impairment charges. Money market funds Money Market Funds [Member] 2027  Finance Lease, Liability, to be Paid, Year Five Payroll deductions Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Issuance of shares under employees' and directors' stock plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Purchases of company common stock Purchases of company common stock Payments for Repurchase of Common Stock Class of Stock [Axis] Class of Stock [Axis] 2028 and thereafter Long-Term Debt, Maturity, after Year Five Income Taxes Income Tax, Policy [Policy Text Block] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Options to extend, renewal term Lessee, Operating Lease, Renewal Term Cost of revenues adjustments Cost Of Revenues Charges Certain charges to cost of revenues primarily for 1) the sale of inventories revalued at fair value at the date of acquisition and 2) accelerated depreciation at facilities closing due to facility consolidations. Current assets: Assets, Current [Abstract] Discount rate - service cost Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate Service Cost Weighted average rate for present value of future retirement benefits cash flows, used to determine service cost component of net periodic benefit cost of defined benefit plan. 3.200% Notes due 2026 Senior Notes 3.200% Due 2026 [Member] Senior Notes 3.200% Due 2026 Noncurrent contract assets, net Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent Retained earnings Retained Earnings (Accumulated Deficit) Schedule of Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] 2.000% Notes due 2025 $2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) Senior Notes 2.00% Due 2025 [Member] 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro denominated) [Member] Scenario [Domain] Scenario [Domain] Fair Value, Recurring Fair Value, Recurring [Member] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Components of Income From Continuing Operations Before Income Taxes [Abstract] Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Financing costs Debt Related Commitment Fees and Debt Issuance Costs Schedule of Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Foreign Plan Foreign Plan [Member] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] 3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated) Senior Notes 3.20% Due 2026 [Member] Senior Notes 3.20% Due 2026 Research and development and other capitalized costs Deferred Tax Assets, in Process Research and Development Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024 Floating Rate SOFR +0.53% Senior Notes Due 2024 [Member] Floating Rate SOFR +0.53% Senior Notes Due 2024 Loss Contingencies [Table] Loss Contingencies [Table] Current income tax provision Current Income Tax Expense (Benefit) Product revenues Product [Member] 1.950% Notes due 2029 $1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) Senior Notes 1.95% Due 2029 [Member] 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) [Member] Valuation Allowance [Roll Forward] Valuation Allowance [Roll Forward] Valuation Allowance [Roll Forward] Undiscounted product liability accrual Loss Contingency Accrual, Product Liability, Gross, Divested Business The estimated aggregate undiscounted amount of the accrual for damages arising from third-party use of product(s) or process(es) of divested businesses as of the balance sheet date. Vested and unvested expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Inventories Increase (Decrease) in Inventories Unamortized discount Debt Instrument, Unamortized Discount (Premium), Net Cost method investments Equity Securities without Readily Determinable Fair Value, Amount Mesa Biotech Mesa Biotech [Member] Mesa Biotech Balance (in shares) Balance (in shares) Common Stock, Shares, Outstanding Goodwill Beginning balance Ending balance Goodwill Intra-Entity [Axis] Intra-Entity [Axis] Intra-Entity Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Equity funds Equity Funds [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) Senior Notes 0.80% Due 2030 [Member] Senior Notes 0.80% Due 2030 2.80% 20-Year Senior Notes, Due 10/15/2041 Senior Notes 2.800% Due 2041 [Member] Senior Notes 2.800% Due 2041 Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Valuation Allowance Beginning Balance Ending Balance Deferred Tax Assets, Valuation Allowance Deferred income taxes Deferred Income Tax Liabilities, Net Hedging Relationship [Axis] Hedging Relationship [Axis] Entity Public Float Entity Public Float Revenue, Performance Obligation, Description of Timing Revenue, Performance Obligation, Description of Timing Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Cost of revenues Cost of goods and services sold Cost of Goods and Services Sold Deferred Interest Carryforward Deferred Tax Asset, Interest Carryforward [Member] Deferred Tax Asset, Interest Carryforward Derivative contracts Fair value – liabilities Derivative Liability Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Loss Contingencies [Line Items] Loss Contingencies [Line Items] 2023  Defined Benefit Plan, Expected Future Benefit Payment, Year One PPD PPD, Inc [Member] PPD, Inc Common stock, $1 par value, 1,200,000,000 shares authorized; 440,668,112 and 439,154,741 shares issued Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Life Sciences Solutions Life Sciences Solutions [Member] Life Sciences Solutions Segment Senior Notes Senior Notes [Member] Loss Contingencies Commitments and Contingencies, Policy [Policy Text Block] Current liability Liability, Defined Benefit Plan, Current Accumulated benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Machinery, equipment and leasehold improvements Other Capitalized Property Plant and Equipment [Member] U.S. Commercial Paper Program U.S. Commercial Paper Program [Member] Borrowings under the company's U.S. commercial paper program Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023 Floating Rate SOFR +0.35% 18 Month Senior Notes Due 2023 [Member] Floating Rate SOFR +0.35% 18 Month Senior Notes Due 2023 Cash, cash equivalents and restricted cash at beginning of year Cash, cash equivalents and restricted cash at end of year Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Non-U.S. Income (Loss) from Continuing Operations before Income Taxes, Foreign Consumables Consumables [Member] Consumable, single-use products Current liabilities: Liabilities, Current [Abstract] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Change in Accounting Principle, Type [Domain] Change in Accounting Principle, Type [Domain] Other, net Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Options vested and expected to vest, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Contract liabilities Contract with Customer, Liability, Current Total Thermo Fisher Scientific Inc. Shareholders’ Equity Parent [Member] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Income Statement Location [Domain] Income Statement Location [Domain] Amendment Flag Amendment Flag Remaining lease term Lessee, Operating Lease, Remaining Lease Term Estimated useful life Finite-Lived Intangible Asset, Useful Life Fair Value Hedging Fair Value Hedging [Member] Operating lease costs Operating Lease, Cost Total other comprehensive items Other Comprehensive Income (Loss), Net of Tax Portion of Non- U.S. with expiration dates Foreign Country NOL Expires [Member] Portion of Non- U.S. with expiration dates Acquisitions Goodwill, Acquired During Period Revenues Business Acquisition, Pro Forma Revenue Acquisitions Mergers, Acquisitions and Dispositions Disclosures [Text Block] European Viral Vector Business European Viral Vector Manufacturing Business [Member] European Viral Vector Manufacturing Business Construction in progress Construction in Progress [Member] Deferred tax assets (liabilities) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other assets Other Assets, Noncurrent Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Exercisable (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number 2028 and thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accrual for Environmental Loss Contingencies Disclosure [Abstract] Accrual for Environmental Loss Contingencies Disclosure [Abstract] Definite-lived intangible assets: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Supplemental Cash Flow Information Cash Flow, Supplemental Disclosures [Text Block] Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities Operating Lease, Payments Repayment of debt Repayments of Long-Term Debt Options Share-Based Payment Arrangement, Option [Member] Weighted Average Assumptions Used to Determine Benefit Obligation [Abstract] Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Domestic Plan Domestic Plan [Member] Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $9, $11 and $(1)) Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax Expected stock price volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Other Income/Expense Other Income and Other Expense Disclosure [Text Block] Other regions Other Regions [Member] All geographical regions not separately disclosed Contributions to retirement plans Cash contributions to retirement plans Payment for Pension and Other Postretirement Benefits Accounts Receivable Allowances Accounts Receivable, Allowance for Credit Loss, Current Deferred interest Deferred Tax Asset, Interest Carryforward 2.00% 10-Year Senior Notes, Due 10/15/2031 Senior Notes 2.000% Due 2031 [Member] Senior Notes 2.000% Due 2031 Common Stock, $1 Par Value - Shares Authorized (in shares) Common Stock, Shares Authorized Schedule of Guarantor Obligations [Table] Schedule of Guarantor Obligations [Table] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Restricted cash included in other assets Restricted Cash and Cash Equivalents, Noncurrent Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Derivatives designated as hedging instruments Designated as Hedging Instrument [Member] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Business Acquisition [Line Items] Business Acquisition [Line Items] Measurement Frequency [Domain] Measurement Frequency [Domain] Comprehensive Income and Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Schedule of Net Benefit Costs Schedule of Net Benefit Costs [Table Text Block] $2.60% 10-Year Senior Notes, Due 10/1/2029 Senior Notes 2.60% Due 2029 [Member] Senior Notes 2.60% Due 2029 [Member] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Schedule of Carrying Value and Fair Value of the Company's Debt Instruments Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Unrealized (gains) losses on hedging instruments Deferred Tax Assets (Liabilities), Hedging Transactions Amount before allocation of valuation allowances of deferred tax asset (liability) attributable to unrealized losses (gains) from hedging transactions. Schedule of Supplemental Cash Flow Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Outstanding short-term borrowings Short-Term Debt Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Ownership interest, noncontrolling owners Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Pension Obligation Guarantee Financial Guarantee [Member] Schedule of Actuarial Assumptions Defined Benefit Plan, Assumptions [Table Text Block] Business Segment and Geographical Information Segment Reporting Disclosure [Text Block] Other Adjustments to Additional Paid in Capital, Other Excess tax benefits from stock options and restricted stock units Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Intra-Entity [Domain] Intra-Entity [Domain] Intra-Entity [Domain] Alternative investments Alternative Investments [Member] Alternative Investments [Member] Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax Deferred tax liabilities, net Deferred Tax Liabilities, Net Loss Contingency [Abstract] Loss Contingency [Abstract] Unconditional purchase obligations Unrecorded Unconditional Purchase Obligation Liabilities, redeemable noncontrolling interest and equity Liabilities and Equity [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Canceled/expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Inventories Inventories Inventory, Net 3.650% Notes due 2034 Senior Notes 3.650% Due 2034 [Member] Senior Notes 3.650% Due 2034 Accounts payable Accounts Payable, Current Income Tax Authority [Axis] Income Tax Authority [Axis] Options vested and expected to vest, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Basic (in shares) Weighted Average Number of Shares Outstanding, Basic 1.400% Notes due 2026 $1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) Senior Notes 1.40% Due 2026 [Member] 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) [Member] Loss accrual Loss Contingency Accrual Change in fair value of plan assets Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Minimum consolidated net interest coverage ratio Debt, Covenant, Minimum Consolidated Interest Coverage Ratio Minimum permitted Consolidated Interest Coverage Ratio (the ratio of Consolidated EBITDA to Consolidated Interest Expense) as defined in the debt or line of credit facility agreements. Target allocations for investments Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible List] Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Notional amount Derivative, Notional Amount Preferred stock, $100 par value, 50,000 shares authorized; none issued Preferred Stock, Value, Issued Redeemable noncontrolling interest Redeemable noncontrolling interest, balance Redeemable noncontrolling interest, balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Unconditional Purchase Obligations [Abstract] Unconditional Purchase Obligations (Excluding Capital Stock Redemptions) [Abstract] 4.80% 5-Year Senior Notes, Due 11/21/2027 Senior Notes 4.8% Due 2027 [Member] Senior Notes 4.8% Due 2027 Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Schedule of Debt Schedule of Debt [Table Text Block] Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Short-term obligations and current maturities of long-term obligations Less: Short-term obligations and current maturities Debt, Current Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases Lessee, Leases [Policy Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Income before income taxes Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Stock-based Compensation Expense Share-Based Payment Arrangement [Text Block] Backlog Order or Production Backlog [Member] Currency translation and other Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Work in process Inventory, Work in Process, Net of Reserves Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Noncontrolling Interests Noncontrolling Interest [Member] Term Debt Instrument, Term Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Hedged long-term obligations - included in other income/(expense) Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Guarantor Obligations, Nature [Axis] Guarantor Obligations, Nature [Axis] Goodwill [Roll Forward] Goodwill [Roll Forward] Net income Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Land Land [Member] Plus effect of: stock options and restricted stock units (shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements PeproTech PeproTech, Inc. [Member] PeproTech, Inc. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] PPD-SNBL K.K. PPD-SNBL K.K. [Member] PPD-SNBL K.K. (Consolidated subsidiary with a noncontrolling interest) Acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] International equity funds International Equity Funds [Member] International Equity Funds Goodwill recorded Business Acquisition, Goodwill, Expected Tax Deductible Amount Current Fiscal Year End Date Current Fiscal Year End Date Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Acquisition-related intangible assets, net Acquisition-related intangible assets Intangible Assets, Net (Excluding Goodwill) Redeemable Noncontrolling Interest [Roll Forward] Redeemable Noncontrolling Interest [Roll Forward] Redeemable Noncontrolling Interest Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Plan participants' contributions Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Proceeds from interest rate swap Proceeds from Hedge, Financing Activities Total current liabilities Liabilities, Current Net income Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Deferred Tax Implications Deferred Tax Implications [Member] Deferred Tax Implications 2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated) Senior Notes 2.382% Due 2052 [Member] Senior Notes 2.382% Due 2052 Additions due to acquisitions Deferred Tax Assets Valuation Allowance, Increase Resulting from Acquisition Amount of increase in deferred tax valuation allowance resulting from acquisitions. Depreciation and amortization Deferred Tax Liabilities, Depreciation and Amortization The amount as of the balance sheet date of the estimated future tax effects attributable to the difference between the tax basis of long-lived assets, including property, plant and equipment and intangible assets, and the basis of long-lived assets computed in accordance with generally accepted accounting principles. The basis difference, whether due to impairment charges or other reasons, will increase future taxable income when it reverses. Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Summary of the Company's Restricted Unit Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Transaction price allocated to remaining performance obligation Revenue, Remaining Performance Obligation, Amount Fair Value Measurements and Fair Value of Financial Instruments Derivatives and Fair Value [Text Block] Term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Business Acquisition, Pro Forma Information [Abstract] Business Acquisition, Pro Forma Information [Abstract] Foreign-derived intangible income Effective Income Tax Rate Reconciliation, FDII, Amount Income Tax Authority [Domain] Income Tax Authority [Domain] Other financing activities, net Proceeds from (Payments for) Other Financing Activities Europe Europe [Member] Currency translation Restructuring Reserve, Foreign Currency Translation Gain (Loss) Cash acquired Cash Acquired in Excess of Payments to Acquire Business Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Unused lines of credit Line of Credit Facility, Remaining Borrowing Capacity 0.125% Notes due 2025 $0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) Senior Notes 0.125% Due 2025 [Member] Senior Notes 0.125% Due 2025 [Member] Insurance contracts Insurance Contracts [Member] Insurance Contracts Credit Facility [Axis] Credit Facility [Axis] Long-term obligations Long-Term Debt and Lease Obligation Vested (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Purchase price percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Schedule of Short-term Debt [Table] Schedule of Short-Term Debt [Table] 3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated) Senior Notes 3.65% Due 2034 [Member] Senior Notes 3.65% Due 2034 Accrued compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Termination fees Payments for Hedge, Financing Activities Maximum guarantee under lease arrangements Guarantor Obligations, Maximum Exposure, Undiscounted Net actuarial loss Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Settlement/curtailment loss Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect State income taxes, net of federal tax Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Schedule of Restructuring and Other Costs by Segment Restructuring and Related Costs [Table Text Block] Other intangible assets Other Intangible Assets, Net Entity Central Index Key Entity Central Index Key Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Interest income Investment Income, Interest Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Additions due to acquisitions Unrecognized Tax Benefits, Increase Resulting from Acquisition Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Total purchase price Business Combination, Consideration Transferred Withholding taxes Effective Income Tax Rate Reconciliation, Foreign Withholding Taxes Amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign withholding taxes. Derivative funds Defined Benefit Plan, Derivative [Member] City Area Code City Area Code Assets Assets [Abstract] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Plans, Policy [Policy Text Block] Tax return reassessments and settlements Tax return reassessments and settlements Effective Income Tax Rate Reconciliation, Tax Settlement, Amount Unrecorded Unconditional Purchase Obligation [Table] Unrecorded Unconditional Purchase Obligation [Table] Net amount recognized Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Contributions from (distributions to) noncontrolling interests Redeemable Noncontrolling Interest, Contribution From (Distributions To) Redeemable Noncontrolling Interests Redeemable Noncontrolling Interest, Contribution From (Distributions To) Redeemable Noncontrolling Interests Cash compensation charges Charges For Cash Compensation Due To Employees Of Acquired Businesses Charges For Cash Compensation Due To Employees Of Acquired Businesses Earnings per Share Earnings Per Share, Policy [Policy Text Block] 2023  Long-Term Debt, Maturity, Year One Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Other long-term liabilities Other Liabilities, Noncurrent Equity in earnings/(losses) of unconsolidated entities Income (Loss) from Equity Method Investments Contingent Consideration Contingent Consideration [Member] Contingent Consideration [Member] Purchase of property, plant and equipment Capital expenditures Payments to Acquire Property, Plant, and Equipment 2023  Finite-Lived Intangible Asset, Expected Amortization, Year One 2028 and thereafter Finance Lease, Liability, to be Paid, after Year Five Projected benefit obligation at beginning of year Projected benefit obligation at end of year Defined Benefit Plan, Benefit Obligation Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Operating lease ROU assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Global intangible low-taxed income Effective Income Tax Rate Reconciliation, GILTI, Amount Amounts reclassified from accumulated other comprehensive items Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total lease payments Lessee, Operating Lease, Liability, to be Paid Average rate of increase in employee compensation Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Entity Address, Postal Zip Code Entity Address, Postal Zip Code LIFO Method Inventories [Abstract] LIFO Method Related Items [Abstract] 2024  Long-Term Debt, Maturity, Year Two Reconciliation of Unrecognized Tax Benefits [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Investments Investments, Fair Value Disclosure Business Combinations Business Combinations Policy [Policy Text Block] Other Debt Other Debt [Member] Other Debt Revolving credit facility capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Eliminated workforce percentage Restructuring and Related Cost, Percentage of Total Workforce Eliminated The maximum number of positions eliminated in connection with restructuring plans during the period as a percentage of the company's total workforce. Beginning balance Ending balance Restructuring Reserve Currency translation adjustment (net of tax provision (benefit) of $173, $231 and $(221)) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Other investing activities, net Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] 0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated) Senior Notes 0.853% Due 2025 [Member] Senior Notes 0.853% Due 2025 Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Closure of tax years Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Long-lived Assets Long-Lived Assets Net periodic benefit cost (income) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Schedule of Components of Purchase Price Schedule of Business Acquisitions, by Acquisition [Table Text Block] Federal Domestic Tax Authority [Member] Exchange rate effect on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Declared but unpaid dividends Dividends Payable Purchases of company common stock Treasury Stock, Value, Acquired, Cost Method Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) Senior Notes 2.00% Due 2051 [Member] Senior Notes 2.00% Due 2051 Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Schedule of Annual Repayment Requirements for Debt Obligations Schedule of Maturities of Long-Term Debt [Table Text Block] 1.500% Notes due 2039 $1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) Senior Notes 1.500% Due 2039 [Member] Senior Notes 1.500% Due 2039 [Member] Amortization of prior service benefit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Average rate of increase in employee compensation Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Scenario [Axis] Scenario [Axis] Redemption price Debt Instrument, Redemption Price, Percentage Total assets Assets, Fair Value Disclosure Valuation allowances Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Leases Lessee, Operating Leases [Text Block] 0.797% 2-Year Senior Notes, Due 10/18/2023 Senior Notes 0.797% Due 2023 [Member] Senior Notes 0.797% Due 2023 Treasury stock at cost, 50,157,275 and 44,720,112 shares Treasury Stock, Common, Value Insurance contracts Cash Surrender Value, Fair Value Disclosure Derivative Instrument [Axis] Derivative Instrument [Axis] Goodwill [Line Items] Goodwill [Line Items] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Schedule of Aggregate Notional Value of Outstanding Derivative Contracts Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Defined Benefit Plan, Expected Future Benefit Payments [Abstract] Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Acquisitions Defined Benefit Plan, Benefit Obligation, Business Combination Prior service credits Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Derivative contracts Fair value – assets Derivative Asset Pro forma revenues Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual 2.375% Notes due 2032 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) Senior Notes 2.375% Due 2032 [Member] Senior Notes 2.375% Due 2032 Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements The Binding Site Group The Binding Site Group [Member] The Binding Site Group Euro Commercial Paper Program Euro Commercial Paper Program [Member] Borrowings under the company's euro commercial paper program Provision for (reversal of) tax reserves, net Provision for (reversal of) tax reserves, net Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Future restructuring costs Restructuring and Related Cost, Expected Cost Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Undiscounted estimated amounts due from insurers Loss Contingency, Related Receivable, Gross The gross (undiscounted) amount as of the balance sheet date of a recorded receivable related to a loss contingency accrual. For example, an insurance recovery receivable to the extent that the insurance recovery is probable and does not exceed the amount of the loss previously recognized in the financial statements. Document Annual Report Document Annual Report Liability Class [Axis] Liability Class [Axis] Amount reclassified from accumulated other comprehensive items to other income/(expense) Amount reclassified from accumulated other comprehensive items to other income/(expense) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Geographical [Axis] Geographical [Axis] Change in Accounting Principle, Other Change in Accounting Principle, Other [Member] Noncurrent liabilities Liability, Defined Benefit Plan, Noncurrent Cash acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents 1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated) Senior Notes 1.054% Due 2027 [Member] Senior Notes 1.054% Due 2027 Currency translation and other Deferred Tax Assets Valuation Allowance, Increase (Decrease) Resulting From Currency Translation And Other Amount of increase (decrease) in deferred tax valuation allowance resulting from currency translation and other. Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Inventories Inventories [Member] Preferred Stock, $100 Par Value - Shares Issued (in shares) Preferred Stock, Shares Issued 0.500% Notes due 2028 $0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) Senior Notes 0.500% Due 2028 [Member] Senior Notes 0.500% Due 2028 [Member] Unvested Restricted Units [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] 2025  Defined Benefit Plan, Expected Future Benefit Payment, Year Three 2.875% Notes due 2037 $2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) Senior Notes 2.875% Due 2037 [Member] 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) [Member] Current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Segments [Axis] Segments [Axis] Debt and Other Financing Arrangements Debt Disclosure [Text Block] Product and Service [Domain] Product and Service [Domain] $4.10% 30-Year Senior Notes, Due 8/15/2047 Senior Notes 4.10% Due 2047 [Member] 4.10% 30-Year Senior Notes, Due 8/15/2047 [Member] Entity Shell Company Entity Shell Company Reductions for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Foreign currency-denominated debt Foreign currency-denominated debt [Member] Foreign currency-denominated debt [Member] Schedule of Fair Value of the Company's Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023 Floating Rate SOFR +0.39% Senior Notes Due 2023 [Member] Floating Rate SOFR +0.39% Senior Notes Due 2023 2023  Lessee, Operating Lease, Liability, to be Paid, Year One 2025  Long-Term Debt, Maturity, Year Three Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] 0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated) Senior Notes 0.000% Due 2023 [Member] Senior Notes 0.000% Due 2023 Discount rate - interest cost Defined Benefit Plan Assumptions Used Calculating Periodic Benefit Cost Discount Rate Interest Cost Weighted average rate for present value of future retirement benefits cash flows, used to determine interest cost component of net periodic benefit cost of defined benefit plan. Consolidation Items [Domain] Consolidation Items [Domain] Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date Schedule of Change in Each Component of Accumulated Other Comprehensive Items Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Total assets Assets Federal and State Federal and State [Member] Federal and State [Member] Earnings per share attributable to Thermo Fisher Scientific Inc. Earnings Per Share [Abstract] Repayments of commercial paper Repayments of Commercial Paper Interest rate swaps - fair value hedges Interest Rate Swap [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Net Assets Acquired [Abstract] Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] 2027  Lessee, Operating Lease, Liability, to be Paid, Year Five Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Accrued payroll and employee benefits Employee-related Liabilities, Current Segments [Domain] Segments [Domain] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Earnings Per Share Earnings Per Share [Text Block] Goodwill Goodwill, Gross Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Award Type [Domain] Award Type [Domain] Loss on early extinguishment of debt Loss on early extinguishment of debt Gain (Loss) on Extinguishment of Debt Amounts recognized in balance sheet Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] 0.750% Notes due 2024 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) Senior Notes 0.75% Due 2024 [Member] Senior Notes 0.75% Due 2024 [Member] Net Investment Hedging Net Investment Hedging [Member] China CHINA Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Unrecognized tax benefits reclassed to accrued income taxes in connection with IRS settlement Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Currency translation Goodwill, Foreign Currency Translation Gain (Loss) Currency translation adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Customer relationships Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town Unrealized losses on hedging instruments Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Increase (decrease) in UTB Unrecognized Tax Benefits, Period Increase (Decrease) Domestication transaction Effective Income Tax Rate Reconciliation, Domestication Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to domestication actions. Currency translation and other Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Intersegment Eliminations Intersegment Eliminations [Member] 2028-2032 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Government Assistance Government Assistance [Policy Text Block] Restricted cash included in other current assets Restricted Cash and Cash Equivalents, Current Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Defined Benefit Plan, Information about Plan Assets [Abstract] Defined Benefit Plan, Information about Plan Assets [Abstract] Unamortized debt issuance costs Debt Issuance Costs, Net Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Treasury Stock Treasury Stock, Common [Member] Auditor Name Auditor Name Pension Plans, Defined Benefit Pension Plan [Member] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] 1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated) Senior Notes 1.49% Due 2032 [Member] Senior Notes 1.49% Due 2032 NOL carryforwards Operating Loss Carryforwards Finance lease liabilities Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Change in Accounting Principle, Type [Axis] Change in Accounting Principle, Type [Axis] Treasury Stock at Cost (in shares) Balance, treasury stock (in shares) Balance, treasury stock (in shares) Treasury Stock, Common, Shares Noncurrent contract liabilities Contract with Customer, Liability, Noncurrent Research and development expenses Research and Development Expense Additions for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Fair Value Measured at Net Asset Value Per Share Fair Value Measured at Net Asset Value Per Share [Member] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Vested and unvested expected to vest (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Other comprehensive items: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive items Temporary Equity, Foreign Currency Translation Adjustments Nature of Operations and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Capital Loss Capital Loss [Member] Capital Loss State Deferred State and Local Income Tax Expense (Benefit) Percentage of LIFO inventory Percentage of LIFO Inventory Amortization of acquisition-related intangible assets Amortization of acquisition-related intangible assets Amortization of Intangible Assets Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Schedule of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] 2025  Lessee, Operating Lease, Liability, to be Paid, Year Three Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Acquisitions (including assumed balances) Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances, Net Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances, Net Pension and other postretirement benefit liability adjustment Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Fair value of plan assets Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Inventories Inventory, Policy [Policy Text Block] Total Thermo Fisher Scientific Inc. shareholders’ equity Stockholders' Equity Attributable to Parent Finance lease ROU assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Tax credit carryforward Tax Credit Carryforward, Amount Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Other, net Deferred Tax Assets, Other Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] 2025  Finite-Lived Intangible Asset, Expected Amortization, Year Three Rollforward of the Fair Value of Investments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Unrealized gains and losses on hedging instruments: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract] 2027  Long-Term Debt, Maturity, Year Five Retained Earnings Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Dividends declared Dividends, Common Stock, Cash Common Stock, $1.00 par value Common Stock [Member] Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration] Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration] Reportable segments Number of Reportable Segments Schedule of Operating Leases Lease, Cost [Table Text Block] Fair value of contingent consideration Business Combination, Contingent Consideration, Liability Statement [Table] Statement [Table] Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Operating lease liabilities - noncurrent Operating Lease, Liability, Noncurrent Included in currency translation adjustment within other comprehensive items Derivatives used in Net Investment Hedge, Increase (Decrease), Gross of Tax Defined contribution plan expense Defined Contribution Plan, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Purchases of company common stock (in shares) Treasury Stock, Shares, Acquired Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible List] Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Contingent consideration Contingent Consideration Liabilities, Fair Value Disclosures Fair value of contingent consideration liability. Accounts receivable, less allowances of $189 and $150 Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Statement [Line Items] Statement [Line Items] Unvested, beginning balance (shares) Unvested, ending balance (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Projected Benefit Obligation and Fair Value of Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Definite-lived intangible assets, gross Finite-Lived Intangible Assets, Gross Selling, general and administrative expenses Selling, General and Administrative Expense Leased operating facilities Lessee, Operating Lease, Number Of Leases Lessee, Operating Lease, Number Of Leases Pension plans with accumulated benefit obligations in excess of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Lengnau biologics manufacturing facility CSL [Member] CSL ROU assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Items AOCI Attributable to Parent [Member] Auditor Firm ID Auditor Firm ID Document Transition Report Document Transition Report Non- U.S. Foreign Tax Authority [Member] 2024  Defined Benefit Plan, Expected Future Benefit Payment, Year Two Local Phone Number Local Phone Number Summary of the Company's Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating income Subtotal reportable segments Consolidated operating income Operating Income (Loss) Inventory basis difference Deferred Tax Assets, Inventory Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] State State and Local Jurisdiction [Member] Service revenues Service [Member] Total liabilities Liabilities, Fair Value Disclosure Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Interest crediting rate for cash balance plans Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate Net tangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Tangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Tangible Assets Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Preferred Stock, $100 Par Value - Par Value (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2026  Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Federal Deferred Federal Income Tax Expense (Benefit) Capital in Excess of Par Value Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Estimated amounts due from insurers Loss Contingency, Receivable Total intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Diluted (in shares) Diluted weighted average shares (shares) Weighted Average Number of Shares Outstanding, Diluted Acquisition-related Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Guarantor Obligations [Line Items] Guarantor Obligations [Line Items] Schedule of Components of Inventories Schedule of Inventory, Current [Table Text Block] Expected life of options (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Fair value of investments Equity Securities, FV-NI, Noncurrent Buildings and improvements Building and Building Improvements [Member] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Short-term Financing [Line Items] Short-Term Debt [Line Items] Asia-Pacific Asia Pacific [Member] 1.375% Notes due 2028 $1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) Senior Notes 1.375% Due 2028 [Member] Senior Notes 1.375% Due 2028 [Member] Schedule of Financial Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Total Reportable Segments Operating Segments [Member] Options exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Preferred Stock, $100 Par Value - Shares Authorized (in shares) Preferred Stock, Shares Authorized Businesses Sold Businesses Sold [Member] Businesses Sold Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible Enumeration] Restricted Cash and Cash Equivalents, Current, Statement of Financial Position [Extensible Enumeration] Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Net proceeds from issuance of debt Proceeds from Issuance of Long-Term Debt Net income attributable to Thermo Fisher Scientific Inc. Net income Net Income (Loss) Available to Common Stockholders, Basic Common Stock, $1 Par Value - Shares Issued (in shares) Common Stock, Shares, Issued Equity method investments Equity Method Investments Total other comprehensive items Other Comprehensive Income (Loss) Net of Tax Including Redeemable and NonRedeemable NCI Other Comprehensive Income (Loss) Net of Tax Including Redeemable and NonRedeemable NCI Acquired but unpaid property, plant and equipment Capital Expenditures Incurred but Not yet Paid Amounts recognized in accumulated other comprehensive items Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract] Currency transaction gains Foreign Currency Transaction Gain (Loss), before Tax Cash Flow Hedging Cash Flow Hedging [Member] Debt assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities 2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated) Senior Notes 2.069% Due 2042 [Member] Senior Notes 2.069% Due 2042 Investments Investment, Policy [Policy Text Block] Corporate/other Corporate and Other [Member] Instruments Instruments [Member] Instruments (longer-lived products) Comprehensive income attributable to Thermo Fisher Scientific Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Charge for expired tax credits Charge for Expired Tax Credits due to Audit Settlement Charge for Expired Tax Credits due to Audit Settlement Foreign Tax Credit Carryforwards Foreign Tax Credit Carryforwards [Member] Foreign Tax Credit Carryforwards 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) Senior Notes 1.125% Due 2033 [Member] Senior Notes 1.125% Due 2033 Schedule of Segment Reporting Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Product Liability, Workers Compensation and Other Personal Injury Matters Product Liability, Workers Compensation and Other Personal Injury Matters [Member] Amount charged to earnings in the current period for product liability, workers compensation and other personal injury matters. Other accrued expenses Other Liabilities, Current Payments Payments for Restructuring Cross-currency interest rate swaps - designated as net investment hedges Cross Currency Interest Rate Contract [Member] 2023  Finance Lease, Liability, to be Paid, Year One Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statutory federal income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Shares issued under ESPP (shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Outstanding, beginning balance (shares) Outstanding, ending balance (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number 2024  Finance Lease, Liability, to be Paid, Year Two Deferred Tax Assets (Liabilities) [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible List] Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Schedule of Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Changes in fair value included in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Total borrowings at carrying value Carrying value Long-Term Debt Forfeited (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other income/(expense) Other Nonoperating Income (Expense) Restructuring and Other Costs Restructuring and Related Activities Disclosure [Text Block] Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated) Floating Rate 2 Year Senior Notes Due 2023 [Member] Floating Rate 2 Year Senior Notes Due 2023 Guarantor Obligations, Nature [Domain] Guarantor Obligations, Nature [Domain] Performance Guarantee Performance Guarantee [Member] Accumulated other comprehensive items Accumulated Other Comprehensive Income (Loss), Net of Tax Expected long-term rate of return on assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Total current assets Assets, Current Tax benefit on unrealized holding losses on hedging instruments arising during the period Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Entity Small Business Entity Small Business Reconciliation of Benefit Obligations and Plan Assets Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Cash dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Revenues Revenues [Abstract] Estimated future amortization expense of definite-lived intangible assets Finite-Lived Intangible Assets, Net 0.875% Notes due 2031 $0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) Senior Notes 0.875% Due 2031 [Member] Senior Notes 0.875% Due 2031 [Member] Expected timing of satisfaction of remaining performance obligation Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Other liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Cost of product revenues related to an existing supply contract Inventory, Firm Purchase Commitment, Loss Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Options Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Additions (reductions) charged to income tax provision, net Deferred Tax Assets Valuation Allowance, Increase Charged To Income Tax Provision Amount of increase in deferred tax valuation allowance resulting from amounts charged to income tax expense. Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Options outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Other All Other Countries [Member] All Other Countries Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Warrants Other Assets, Fair Value Disclosure Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Total costs and operating expenses Costs and Expenses Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Issuance of shares under employees' and directors' stock plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Total operating lease liability Operating Lease, Liability Stock-based Compensation Expense Share-Based Payment Arrangement [Policy Text Block] Included in other income/(expense) Derivative, Gain (Loss) on Derivative, Net Fixed income funds Fixed Income Funds [Member] 2024  Finite-Lived Intangible Asset, Expected Amortization, Year Two Noncontrolling Interest [Table] Noncontrolling Interest [Table] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Net operating loss and credit carryforwards Deferred Tax Assets, Other Tax Carryforwards Reserves and accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Other Expense Other Expense [Member] Net restructuring charges incurred Restructuring Charges Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Environmental liability Accrual for Environmental Loss Contingencies Purchase Price Business Combination, Consideration Transferred [Abstract] 2026  Long-Term Debt, Maturity, Year Four Hedging Relationship [Domain] Hedging Relationship [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Auditor Location Auditor Location Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Entity Filer Category Entity Filer Category Equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Federal Current Federal Tax Expense (Benefit) United States UNITED STATES Pro forma losses Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Pension plans with projected benefit obligations in excess of plan assets Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract] Selling, general and administrative expenses adjustments Selling General And Administrative Charges Net Certain charges/credits to selling, general and administrative expenses principally associated with acquisition accounting. Liabilities [Abstract] Liabilities, Fair Value Disclosure [Abstract] Investments measured at NAV Alternative Investment Non-cash investing and financing activities Noncash Investing and Financing Items [Abstract] Commitments and Contingencies Commitments and Contingencies Security Exchange Name Security Exchange Name Outstanding, beginning of period (in dollars per share) Outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Restricted Units, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Weighted-average amortization period Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Issuance of stock upon vesting of restricted stock units Stock Issued Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] 4.95% 10-Year Senior Notes, Due 11/21/2032 Senior Notes 4.95% Due 2032 [Member] Senior Notes 4.95% Due 2032 Reclassification adjustment for losses included in net income (net of tax benefit of $1, $17 and $14) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Undiscounted loss accrual Loss Contingency Accrual, Gross The estimated aggregate undiscounted amount of the accrual for loss contingencies as of the balance sheet date. Segment Reconciling Items Segment Reconciling Items [Member] Revenues Revenue from Contract with Customer, Excluding Assessed Tax Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible Enumeration] Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration] Fair value of equity awards exchanged Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Service costs Service cost Defined Benefit Plan, Service Cost Unissued shares of common stock (in shares) Common Stock, Capital Shares Reserved for Future Issuance Cover page. Cover [Abstract] Entity Voluntary Filers Entity Voluntary Filers Undistributed earnings Undistributed Earnings of Foreign Subsidiaries Revenue and Contract-related Balances Revenue from Contract with Customer [Text Block] Maximum period prior to maturity Maximum Period to Maturity Allowed Under Program Maximum maturity period allowed under U.S. commercial paper program Segment Reporting [Abstract] Segment Reporting [Abstract] Change in projected benefit obligations Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Corporate [Member] Corporate Segment [Member] Forecast Forecast [Member] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Risk free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Documents Incorporated by Reference [Text Block] Documents Incorporated by Reference [Text Block] Amortization of actuarial net loss Defined Benefit Plan, Amortization of Gain (Loss) Discount rate for determining benefit obligation Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Total liabilities, redeemable noncontrolling interest and equity Liabilities and Equity Income tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Warranty Obligations Standard Product Warranty, Policy [Policy Text Block] Derivatives not designated as hedging instruments Not Designated as Hedging Instrument [Member] Components of Income Before Provision for Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Foreign Foreign Tax Positions [Member] Foreign Tax Positions [Member] UTB, interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted (in dollars per share) Diluted Earnings Per Share (in dollars per share) Earnings Per Share, Diluted Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Accounting Standards Update 2016-13 Accounting Standards Update 2016-13 [Member] Ownership percentage, parent Noncontrolling Interest, Ownership Percentage by Parent Weighted average shares Weighted Average Shares [Abstract] Weighted Average Shares Consolidation Items [Axis] Consolidation Items [Axis] 2024  Lessee, Operating Lease, Liability, to be Paid, Year Two Other current assets Other Assets, Current Unrecognized tax benefits Beginning balance Ending balance Unrecognized Tax Benefits U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Schedule of Future Payments of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Product and Service [Axis] Product and Service [Axis] Hedge funds Hedge Funds [Member] Class of Stock [Domain] Class of Stock [Domain] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Lease Residual Value Guarantee Guarantee Type, Other [Member] Interest expense Interest Expense Tradenames Trade Names [Member] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Machinery and Equipment Machinery and Equipment [Member] Funded status Defined Benefit Plan, Funded (Unfunded) Status of Plan Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $3, $6 and $4) Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Presentation Reclassification, Comparability Adjustment [Policy Text Block] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Currency translation adjustment: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract] Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible List] Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible Enumeration] Contract assets, net Contract with Customer, Asset, after Allowance for Credit Loss, Current Plan participants' contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Deferred tax liabilities, net before valuation allowance Deferred Tax Assets (Liabilities) Before Valuation Allowance For entities that net deferred tax assets and tax liabilities, represents the unclassified net amount of deferred tax assets, before any related valuation allowance, and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. A temporary difference is a difference between the tax basis of an asset or liability and its carrying amount in the financial statements prepared in accordance with generally accepted accounting principles that will reverse in ensuing periods. Schedule of the Company's Accrued Restructuring Balance Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost (Income) [Abstract] Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Restructuring and other costs Restructuring and other costs Restructuring And Other Costs (Income) Net Amount of restructuring charges, remediation costs and assets impairment loss; and, in some periods, may also include gains and losses on the sale of businesses, product lines and real estate. Commercial Paper Programs Commercial Paper [Member] 2027  Finite-Lived Intangible Asset, Expected Amortization, Year Five Measurement Frequency [Axis] Measurement Frequency [Axis] Research and Development Research and Development Expense, Policy [Policy Text Block] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Type of Adoption [Domain] Accounting Standards Update [Domain] Impairment of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Net amount recognized Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Provision for income taxes at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Remaining performance obligation percentage Revenue, Remaining Performance Obligation, Percentage Redeemable noncontrolling interest Business Combination, Redeemable noncontrolling interest Redeemable noncontrolling interest assumed in a business combination Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] North America North America [Member] Proceeds from issuance of commercial paper Proceeds from Issuance of Commercial Paper Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Cost of Sales Cost of Sales [Member] Projected benefit obligation Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation EX-101.PRE 18 tmo-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 19 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Feb. 04, 2023
Jul. 01, 2022
Entity Listings [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 1-8002    
Entity Registrant Name THERMO FISHER SCIENTIFIC INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 04-2209186    
Entity Address, Address Line One 168 Third Avenue    
Entity Address, City or Town Waltham    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02451    
City Area Code 781    
Local Phone Number 622-1000    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 214,582,365
Entity Common Stock, Shares Outstanding   385,430,077  
Documents Incorporated by Reference [Text Block] Sections of Thermo Fisher’s definitive Proxy Statement for the 2023 Annual Meeting of Shareholders are incorporated by reference into Parts II and III of this report.    
Entity Central Index Key 0000097745    
Amendment Flag false    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Common Stock, $1.00 par value      
Entity Listings [Line Items]      
Title of 12(b) Security Common Stock, $1.00 par value    
Entity Stock Trading Symbol TMO    
Security Exchange Name NYSE    
0.750% Notes due 2024      
Entity Listings [Line Items]      
Title of 12(b) Security 0.750% Notes due 2024    
Entity Stock Trading Symbol TMO 24A    
Security Exchange Name NYSE    
0.125% Notes due 2025      
Entity Listings [Line Items]      
Title of 12(b) Security 0.125% Notes due 2025    
Entity Stock Trading Symbol TMO 25B    
Security Exchange Name NYSE    
2.000% Notes due 2025      
Entity Listings [Line Items]      
Title of 12(b) Security 2.000% Notes due 2025    
Entity Stock Trading Symbol TMO 25    
Security Exchange Name NYSE    
3.200% Notes due 2026      
Entity Listings [Line Items]      
Title of 12(b) Security 3.200% Notes due 2026    
Entity Stock Trading Symbol TMO 26B    
Security Exchange Name NYSE    
1.400% Notes due 2026      
Entity Listings [Line Items]      
Title of 12(b) Security 1.400% Notes due 2026    
Entity Stock Trading Symbol TMO 26A    
Security Exchange Name NYSE    
1.450% Notes due 2027      
Entity Listings [Line Items]      
Title of 12(b) Security 1.450% Notes due 2027    
Entity Stock Trading Symbol TMO 27    
Security Exchange Name NYSE    
1.750% Notes due 2027      
Entity Listings [Line Items]      
Title of 12(b) Security 1.750% Notes due 2027    
Entity Stock Trading Symbol TMO 27B    
Security Exchange Name NYSE    
0.500% Notes due 2028      
Entity Listings [Line Items]      
Title of 12(b) Security 0.500% Notes due 2028    
Entity Stock Trading Symbol TMO 28A    
Security Exchange Name NYSE    
1.375% Notes due 2028      
Entity Listings [Line Items]      
Title of 12(b) Security 1.375% Notes due 2028    
Entity Stock Trading Symbol TMO 28    
Security Exchange Name NYSE    
1.950% Notes due 2029      
Entity Listings [Line Items]      
Title of 12(b) Security 1.950% Notes due 2029    
Entity Stock Trading Symbol TMO 29    
Security Exchange Name NYSE    
0.875% Notes due 2031      
Entity Listings [Line Items]      
Title of 12(b) Security 0.875% Notes due 2031    
Entity Stock Trading Symbol TMO 31    
Security Exchange Name NYSE    
2.375% Notes due 2032      
Entity Listings [Line Items]      
Title of 12(b) Security 2.375% Notes due 2032    
Entity Stock Trading Symbol TMO 32    
Security Exchange Name NYSE    
3.650% Notes due 2034      
Entity Listings [Line Items]      
Title of 12(b) Security 3.650% Notes due 2034    
Entity Stock Trading Symbol TMO 34    
Security Exchange Name NYSE    
2.875% Notes due 2037      
Entity Listings [Line Items]      
Title of 12(b) Security 2.875% Notes due 2037    
Entity Stock Trading Symbol TMO 37    
Security Exchange Name NYSE    
1.500% Notes due 2039      
Entity Listings [Line Items]      
Title of 12(b) Security 1.500% Notes due 2039    
Entity Stock Trading Symbol TMO 39    
Security Exchange Name NYSE    
1.875% Notes due 2049      
Entity Listings [Line Items]      
Title of 12(b) Security 1.875% Notes due 2049    
Entity Stock Trading Symbol TMO 49    
Security Exchange Name NYSE    
XML 20 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Audit Information
 12 Months Ended
Dec. 31, 2022
Audit Information [Abstract]  
Auditor Firm ID 238
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Boston, Massachusetts
XML 21 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheet - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 8,524 $ 4,477
Accounts receivable, less allowances of $189 and $150 8,115 7,977
Inventories 5,634 5,051
Contract assets, net 1,312 968
Other current assets 1,644 1,640
Total current assets 25,229 20,113
Property, plant and equipment, net 9,280 8,333
Acquisition-related intangible assets, net 17,442 20,113
Other assets 4,007 4,640
Goodwill 41,196 41,924
Total assets 97,154 95,123
Current liabilities:    
Short-term obligations and current maturities of long-term obligations 5,579 2,537
Accounts payable 3,381 2,867
Accrued payroll and employee benefits 2,095 2,427
Contract liabilities 2,601 2,655
Other accrued expenses 3,354 2,950
Total current liabilities 17,010 13,436
Deferred income taxes 2,849 3,837
Other long-term liabilities 4,238 4,540
Long-term obligations 28,909 32,333
Commitments and Contingencies
Redeemable noncontrolling interest 116 122
Thermo Fisher Scientific Inc. shareholders’ equity:    
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 440,668,112 and 439,154,741 shares issued 441 439
Capital in excess of par value 16,743 16,174
Retained earnings 41,910 35,431
Treasury stock at cost, 50,157,275 and 44,720,112 shares (12,017) (8,922)
Accumulated other comprehensive items (3,099) (2,329)
Total Thermo Fisher Scientific Inc. shareholders’ equity 43,978 40,793
Noncontrolling interests 54 62
Total equity 44,032 40,855
Total liabilities, redeemable noncontrolling interest and equity $ 97,154 $ 95,123
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheet (Parenthetical) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Accounts Receivable Allowances $ 189 $ 150
Preferred Stock, $100 Par Value - Par Value (in dollars per share) $ 100 $ 100
Preferred Stock, $100 Par Value - Shares Authorized (in shares) 50,000 50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares) 0 0
Common Stock, $1 Par Value - Par Value (in dollars per share) $ 1 $ 1
Common Stock, $1 Par Value - Shares Authorized (in shares) 1,200,000,000 1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares) 440,668,112 439,154,741
Treasury Stock at Cost (in shares) 50,157,275 44,720,112
XML 23 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Income - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues      
Revenues $ 44,915 $ 39,211 $ 32,218
Costs and operating expenses:      
Selling, general and administrative expenses 8,993 8,007 6,930
Research and development expenses 1,471 1,406 1,181
Restructuring and other costs 114 197 99
Total costs and operating expenses 36,522 29,183 24,424
Operating income 8,393 10,028 7,794
Interest income 272 43 65
Interest expense (726) (536) (553)
Other income/(expense) (104) (694) (76)
Income before income taxes 7,835 8,841 7,230
Provision for income taxes (703) (1,109) (850)
Equity in earnings/(losses) of unconsolidated entities (172) (4) (3)
Net income 6,960 7,728 6,377
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest 10 3 2
Net income attributable to Thermo Fisher Scientific Inc. $ 6,950 $ 7,725 $ 6,375
Earnings per share attributable to Thermo Fisher Scientific Inc.      
Basic (in dollars per share) $ 17.75 $ 19.62 $ 16.09
Diluted (in dollars per share) $ 17.63 $ 19.46 $ 15.96
Weighted average shares      
Basic (in shares) 392 394 396
Diluted (in shares) 394 397 399
Product revenues      
Revenues      
Revenues $ 28,548 $ 30,361 $ 25,306
Costs and operating expenses:      
Cost of revenues 14,247 13,594 11,407
Service revenues      
Revenues      
Revenues 16,367 8,850 6,912
Costs and operating expenses:      
Cost of revenues $ 11,697 $ 5,979 $ 4,807
XML 24 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Comprehensive Income - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Comprehensive income      
Net income $ 6,960 $ 7,728 $ 6,377
Currency translation adjustment:      
Currency translation adjustment (net of tax provision (benefit) of $173, $231 and $(221)) (822) 373 (118)
Unrealized gains and losses on hedging instruments:      
Unrealized losses on hedging instruments (net of tax benefit of $0, $0 and $20) 0 0 (65)
Reclassification adjustment for losses included in net income (net of tax benefit of $1, $17 and $14) 2 56 45
Pension and other postretirement benefit liability adjustments:      
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $9, $11 and $(1)) 38 36 (8)
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $3, $6 and $4) 5 13 18
Total other comprehensive items (777) 478 (128)
Comprehensive income 6,183 8,206 6,249
Less: comprehensive income attributable to noncontrolling interests and redeemable noncontrolling interest 3 2 2
Comprehensive income attributable to Thermo Fisher Scientific Inc. $ 6,180 $ 8,204 $ 6,247
XML 25 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Statement of Comprehensive Income [Abstract]      
Tax provision (benefit) on currency translation adjustment $ 173 $ 231 $ (221)
Tax benefit on unrealized holding losses on hedging instruments arising during the period 0 0 20
Tax benefit on reclassification adjustment for losses on hedging instruments recognized in net income 1 17 14
Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period 9 11 (1)
Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost $ 3 $ 6 $ 4
XML 26 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating activities      
Net income $ 6,960 $ 7,728 $ 6,377
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation of property, plant and equipment 986 831 658
Amortization of acquisition-related intangible assets 2,395 1,761 1,667
Change in deferred income taxes (995) (647) (552)
Stock-based compensation 307 230 196
Loss on early extinguishment of debt 26 767 0
Other non-cash expenses 524 190 338
Changes in assets and liabilities, excluding the effects of acquisitions and disposition:      
Accounts receivable (430) (204) (1,302)
Inventories (825) (1,065) (508)
Accounts payable 648 479 59
Contributions to retirement plans (41) (34) (96)
Other (401) (724) 1,452
Net cash provided by operating activities 9,154 9,312 8,289
Investing activities      
Acquisitions, net of cash acquired (39) (19,395) (38)
Purchase of property, plant and equipment (2,243) (2,523) (1,474)
Proceeds from sale of property, plant and equipment 24 20 8
Other investing activities, net 99 (34) (6)
Net cash used in investing activities (2,159) (21,932) (1,510)
Financing activities      
Net proceeds from issuance of debt 3,193 18,137 3,464
Repayment of debt (375) (11,738) (710)
Proceeds from issuance of commercial paper 1,526 2,512 383
Repayments of commercial paper (3,690) 0 (387)
Purchases of company common stock (3,000) (2,000) (1,500)
Dividends paid (455) (395) (337)
Other financing activities, net (9) 65 46
Net cash (used in) provided by financing activities (2,810) 6,581 959
Exchange rate effect on cash (139) 194 176
Increase (decrease) in cash, cash equivalents and restricted cash 4,046 (5,845) 7,914
Cash, cash equivalents and restricted cash at beginning of year 4,491 10,336 2,422
Cash, cash equivalents and restricted cash at end of year $ 8,537 $ 4,491 $ 10,336
XML 27 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Redeemable Noncontrolling Interest and Equity - USD ($)
$ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock, $1.00 par value
Capital in Excess of Par Value
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Treasury Stock
Accumulated Other Comprehensive Items
Accumulated Other Comprehensive Items
Cumulative Effect, Period of Adoption, Adjustment
Total Thermo Fisher Scientific Inc. Shareholders’ Equity
Total Thermo Fisher Scientific Inc. Shareholders’ Equity
Cumulative Effect, Period of Adoption, Adjustment
Noncontrolling Interests
Redeemable noncontrolling interest, balance at Dec. 31, 2019 $ 0                      
Redeemable noncontrolling interest, balance at Dec. 31, 2020 0                      
Balance (in shares) at Dec. 31, 2019     434,000,000                  
Balance at Dec. 31, 2019 29,684 $ (1) $ 434 $ 15,064 $ 22,092 $ (1) $ (5,236) $ (2,679) $ 0 $ 29,675 $ (1) $ 9
Balance, treasury stock (in shares) at Dec. 31, 2019             36,000,000          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of shares under employees' and directors' stock plans (in shares)     3,000,000       0          
Issuance of shares under employees' and directors' stock plans 240   $ 3 319     $ (82)     240    
Stock-based compensation 196     196           196    
Purchases of company common stock (in shares)             4,000,000          
Purchases of company common stock (1,500)           $ (1,500)     (1,500)    
Dividends declared (350)       (350)         (350)    
Net income 6,377       6,375         6,375   2
Total other comprehensive items (128)             (128)   (128)   0
Contributions from (distributions to) noncontrolling interests (1)                     (1)
Balance (in shares) at Dec. 31, 2020     437,000,000                  
Balance at Dec. 31, 2020 34,517   $ 437 15,579 28,116   $ (6,818) (2,807)   34,507   10
Balance, treasury stock (in shares) at Dec. 31, 2020             40,000,000          
Redeemable Noncontrolling Interest [Roll Forward]                        
Recognition upon acquisition 122                      
Net income 1                      
Other comprehensive items (1)                      
Redeemable noncontrolling interest, balance at Dec. 31, 2021 122                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of shares under employees' and directors' stock plans (in shares)     2,000,000       1,000,000          
Issuance of shares under employees' and directors' stock plans 222   $ 2 324     $ (104)     222    
Stock-based compensation 230     230           230    
Purchases of company common stock (in shares)             4,000,000          
Purchases of company common stock (2,000)           $ (2,000)     (2,000)    
Dividends declared (410)       (410)         (410)    
Net income 7,727       7,725         7,725   2
Total other comprehensive items 478             478   478   0
Contributions from (distributions to) noncontrolling interests 50                     50
Other 41     41                
Balance (in shares) at Dec. 31, 2021     439,000,000                  
Balance at Dec. 31, 2021 $ 40,855   $ 439 16,174 35,431   $ (8,922) (2,329)   40,793   62
Balance, treasury stock (in shares) at Dec. 31, 2021 44,720,112           45,000,000          
Redeemable Noncontrolling Interest [Roll Forward]                        
Net income $ 15                      
Other comprehensive items (6)                      
Contributions from (distributions to) noncontrolling interests (15)                      
Redeemable noncontrolling interest, balance at Dec. 31, 2022 116                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of shares under employees' and directors' stock plans (in shares)     2,000,000                  
Issuance of shares under employees' and directors' stock plans 169   $ 2 262     $ (95)     169    
Stock-based compensation 307     307           307    
Purchases of company common stock (in shares)             5,000,000          
Purchases of company common stock (3,000)           $ (3,000)     (3,000)    
Dividends declared (471)       (471)         (471)    
Net income 6,945       6,950         6,950   (5)
Total other comprehensive items (771)             (770)   (770)   (1)
Contributions from (distributions to) noncontrolling interests (2)                     (2)
Balance (in shares) at Dec. 31, 2022     441,000,000                  
Balance at Dec. 31, 2022 $ 44,032   $ 441 $ 16,743 $ 41,910   $ (12,017) $ (3,099)   $ 43,978   $ 54
Balance, treasury stock (in shares) at Dec. 31, 2022 50,157,275           50,000,000          
XML 28 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]      
Cash dividends declared per common share (in dollars per share) $ 1.20 $ 1.04 $ 0.88
XML 29 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of Operations and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations and Summary of Significant Accounting Policies Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.
Principles of Consolidation
The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At December 31, 2022 and 2021, the company had such investments with carrying amounts of $369 million and $576 million, respectively. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method. At December 31, 2022 and 2021, the fair value of such investments was $7 million and $217 million, respectively.
Redeemable Noncontrolling Interest
The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events.
Presentation
Certain reclassifications of prior year amounts have been made to conform to the current year presentation.
Revenue Recognition
Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year.
Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date.
Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.
Contract-related Balances
Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.
Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional.
Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract.
Warranty Obligations
The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred.
Leases
Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations.
Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense.
Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.
As a lessee, the company accounts for the lease and non-lease components as a single lease component.
Research and Development
The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.
Restructuring Costs
Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment
contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.
From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to generate revenues. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period.
Income Taxes
The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused.
The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.
Earnings per Share
Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units.
Cash and Cash Equivalents
Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value.
Inventories
Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income. The components of inventories are as follows:
December 31,December 31,
(In millions)20222021
Raw materials$2,405 $1,922 
Work in process660 676 
Finished goods2,569 2,453 
Inventories$5,634 $5,051 
Prior to the third quarter of 2021, certain of the company’s businesses utilized the LIFO method of accounting for inventories. During the third quarter of 2021, these businesses, which comprised approximately 5% of consolidated inventories, changed from the LIFO method to the FIFO method. The company believes this change is preferable as it will provide a consistent, uniform costing method for all inventories across the company, better reflect the current value of inventories, and improve comparability with peers. Prior financial statements have not been retrospectively adjusted due to immateriality. The cumulative pre-tax effect of this change in accounting principle of $33 million was recorded as an increase to inventories and a decrease to cost of product revenues in the third quarter of 2021. This change was recorded in the Laboratory Products and
Biopharma Services ($20 million) and Specialty Diagnostics ($13 million) segments. Reductions to cost of revenues as a result of the liquidation of LIFO inventories were nominal during 2020 and the first half of 2021.
Property, Plant and Equipment
Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income. Property, plant and equipment consists of the following:
December 31,December 31,
(In millions)20222021
Land$454 $431 
Buildings and improvements3,153 2,575 
Machinery, equipment and leasehold improvements7,967 7,020 
Construction in progress2,695 2,567 
Property, plant and equipment, at cost14,269 12,593 
Less: Accumulated depreciation and amortization4,989 4,260 
Property, plant and equipment, net$9,280 $8,333 
Acquisition-related Intangible Assets
Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.
In addition, the company has tradenames and in-process research and development that have indefinite lives and which are not amortized. Intangible assets with indefinite lives are reviewed for impairment annually or whenever events or changes in circumstances indicate they may be impaired. The company may perform an optional qualitative assessment. If the company determines that the fair value of the indefinite-lived intangible asset is more likely than not greater than its carrying amount, no additional testing is necessary. If not, or if the company bypasses the optional qualitative assessment, it writes the carrying value down to the fair value, if applicable.
Acquisition-related intangible assets are as follows:
Balance at December 31, 2022Balance at December 31, 2021
(In millions)GrossAccumulated AmortizationNetGrossAccumulated AmortizationNet
Definite lived:
Customer relationships
$21,792 $(8,330)$13,462 $22,802 $(7,792)$15,010 
Product technology
5,882 (4,360)1,522 6,041 (3,977)2,064 
Tradenames
1,635 (1,008)627 1,722 (919)803 
Backlog
1,038 (442)596 1,060 (59)1,001 
30,347 (14,140)16,207 31,625 (12,747)18,878 
Indefinite lived:
Tradenames
1,235 N/A1,235 1,235 N/A1,235 
Acquisition-related intangible assets
$31,582 $(14,140)$17,442 $32,860 $(12,747)$20,113 
The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2022 is as follows:
(In millions)
2023 $2,279 
2024 1,863 
2025 1,582 
2026 1,322 
2027 1,296 
2028 and thereafter7,865 
Estimated future amortization expense of definite-lived intangible assets$16,207 
Other Assets
Other assets in the accompanying balance sheet include operating lease right-of-use assets, investments, deferred tax assets, pension assets, cash surrender value of life insurance, insurance recovery receivables related to product liability matters, certain intangible assets and other assets.
At December 31, 2022 and 2021, the company had $36 million and $33 million, respectively, of intangible assets not derived from acquisitions, net of accumulated amortization, which are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years.
Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments. At December 31, 2022 and 2021, the company had such investments with carrying amounts of $55 million and $22 million, respectively, and investments measured at NAV of $22 million and $16 million, respectively, which are included in other assets.
Goodwill
The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2022, 2021 or 2020.
The changes in the carrying amount of goodwill by segment are as follows:
(In millions)Life Sciences
Solutions		Analytical
Instruments		Specialty
Diagnostics		Laboratory
Products and
Biopharma Services		Total
Balance at December 31, 2020
$8,590 $5,079 $3,370 $9,002 $26,041 
Acquisitions
1,560 56 8 14,400 16,024 
Currency translation
(7)(92)(101)59 (141)
Balance at December 31, 2021
10,143 5,043 3,277 23,461 41,924 
Acquisitions
— 24 — — 24 
Finalization of purchase price allocations for 2021 acquisitions
9 — — 168 177 
Currency translation
(6)(102)(186)(635)(929)
Balance at December 31, 2022
$10,146 $4,965 $3,091 $22,994 $41,196 
Loss Contingencies
Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.
Currency Translation
All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period. Currency transaction gains are included in the accompanying statement of income and in aggregate were $62 million, $25 million and $24 million in 2022, 2021 and 2020, respectively.
Derivative Contracts
The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.
The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Singapore dollars, Japanese yen, Hong Kong dollars, Czech koruna and Swedish krona. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management.
Cash flow hedges. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item.
Fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings.
Net investment hedges. The company uses foreign currency-denominated debt, certain foreign-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
Government Assistance
From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement. Such amounts were not material to the consolidated financial statements as of and for the year ended December 31, 2022.
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic materially adversely affected certain of the company’s businesses in 2020, particularly in the Analytical Instruments segment and, to a lesser extent, some businesses within the other three segments. The negative impacts significantly lessened in 2021 and 2022. The extent and duration of negative impacts in the future, which may include inflationary pressures and supply chain disruptions, are uncertain and may require changes to estimates. Actual results could differ from those estimates.
Recent Accounting Pronouncements
In September 2022, the FASB issued new guidance to require entities to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under these programs for each period presented. The company will adopt some aspects of this guidance in 2023 using a retrospective method and other aspects in 2024 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures; however, the impact in future periods will be dependent on the extent of arrangements of this nature entered into by the company
In November 2021, the FASB issued new guidance to require entities to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. The company adopted this guidance in the fourth quarter of 2022 using a prospective method. The adoption of this guidance did not have a material impact on the company’s disclosures; however, the impact in future periods will be dependent on the extent of future transactions of this nature entered into by the company.
In October 2021, the FASB amended guidance to recognize and measure contract assets and contract liabilities acquired in a business combination. Generally, this new guidance will result in the company recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The company adopted this guidance in the fourth quarter of 2021 retrospectively to all business combinations completed in the first three quarters of 2021 and prospectively to all future business combinations. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements for acquisitions that closed in 2021 and 2022; however, the impact in future periods will be dependent on the contract assets and contract liabilities acquired in future business combinations.
In July 2021, the FASB amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. The company adopted the guidance in the third quarter of 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements.
In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company adopted this guidance in 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates.
In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. The company adopted the guidance in 2020 using a modified retrospective method. The adoption of this guidance reduced accounts receivable and retained earnings by $1 million on January 1, 2020.
XML 30 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions
 12 Months Ended
Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Acquisitions AcquisitionsThe company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining
the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.
Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.
2023
On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not expected to be tax deductible.
The components of the purchase price and net assets acquired are as follows:
(In billions)The Binding Site
Purchase price
Cash paid
$2.42 
Debt settled
0.31 
Cash acquired
(0.02)
$2.71 
Net assets acquired
Definite-lived intangible assets
$1.07 
Goodwill
1.77 
Net tangible assets
0.15 
Deferred tax assets (liabilities)
(0.28)
$2.71 
The weighted-average amortization period for definite-lived intangible assets is 17 years.
The preliminary allocation of the purchase price for the acquisition of The Binding Site is based on estimates of the fair value of the net assets acquired and is subject to adjustment upon finalization, largely with respect to acquired intangible assets and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions.
2022
In 2022, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Fourier-transform infrared gas analysis technologies.
2021
On January 15, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, the Belgium-based European viral vector manufacturing business of Groupe Novasep SAS. The European viral vector manufacturing business provides manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities for cell and gene vaccines and therapies. The goodwill recorded as a result of this business combination is not tax deductible.
On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company. Mesa Biotech has developed and commercialized a polymerase chain reaction (PCR) based rapid point-of-care testing platform available for detecting infectious diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care. The goodwill recorded as a result of this business combination is not tax deductible.
On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Biopharma Services segment, of a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers as well. The goodwill recorded as a result of this business combination is not tax deductible.
On December 8, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, PPD, Inc., a U.S.-based global provider of clinical research services to the pharma and biotech industry. The addition of PPD’s clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their productivity within the drug development process. The goodwill recorded as a result of this business combination is not tax deductible.
On December 30, 2021, the company acquired, within the Life Sciences Solutions segment, PeproTech, Inc., a U.S.-based developer and manufacturer of recombinant proteins. PeproTech provides bioscience reagents known as recombinant proteins, including cytokines and growth factors. The acquisition expands the segment’s bioscience offerings. The goodwill recorded as a result of this business combination is not tax deductible.
In addition, in 2021, the company acquired, within the Life Sciences Solutions segment, cell sorting technology assets, an Ireland-based life sciences distributor and a developer of a digital PCR platform; within the Analytical Instruments segment, a Belgium-based developer of micro-chip based technology for liquid chromatography columns; and within the Specialty Diagnostics segment, a transplant diagnostics information system provider.
The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:
(In millions)PPDPeproTechEuropean Viral Vector BusinessMesa BiotechLengnau biologics manufacturing facilityOther
Purchase price
Cash paid
$17,237 $1,946 $848 $421 $17 $298 
Fair value of equity awards exchanged
43 — — — — — 
Fair value of contingent consideration
— — — 65 1 117 
Cash acquired
(1,244)(83)(18)(14)— (12)
$16,036 $1,863 $830 $472 $18 $403 
Net assets acquired
Current assets
$2,477 $58 $39 $54 $— $12 
Property, plant and equipment
527 18 59 2 93 2 
Definite-lived intangible assets:
Customer relationships
6,257 510 302 — — 2 
Product technology
— 282 25 279 — 224 
Tradenames
594 — — 2 — 2 
Backlog1,038 — — — — — 
Goodwill
13,949 1,198 600 237 18 198 
Other assets
1,060 11 3 3 364 2 
Contract liabilities(1,539)— (59)— — (1)
Deferred tax assets (liabilities)
(1,782)(192)(80)(72)— (27)
Finance lease liabilities
(90)— (24)— (82)— 
Debt assumed
(4,299)— — — — — 
Other liabilities assumed
(2,034)(22)(35)(33)(375)(11)
Redeemable noncontrolling interest(122)— — — — — 
$16,036 $1,863 $830 $472 $18 $403 
During 2022, we finalized the allocations of the purchase price for the Lengnau biologics manufacturing facility, PPD, Inc. and PeproTech, Inc., largely with respect to definite-lived intangible assets, property, plant and equipment, contract liabilities,
equity method investments, asset retirement obligations, defined benefit pension plans, assumed contingent consideration and the related deferred taxes. The adjustments to the income statement recorded during 2022 were not material.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2021 are 17 years for customer relationships, 11 years for product technology, 7 years for tradenames and 3 years for backlog. The weighted average amortization period for all definite-lived intangible assets acquired in 2021 is 14 years.
Unaudited Pro Forma Information
The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020:
 Year Ended
 December 31,December 31,
(In millions)20212020
Revenues$44,886 $36,887 
Net income attributable to Thermo Fisher Scientific Inc.$7,369 $5,361 
The historical consolidated financial information of the company and PPD has been adjusted in the pro forma information to give effect to pro forma events that are directly attributable to the acquisitions and related financing arrangements and are factually supportable.
To reflect the acquisition of PPD as if it had occurred on January 1, 2020, the unaudited pro forma results include adjustments to reflect, among other things, the incremental intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset and the interest expense from debt financings obtained to partially fund the cash consideration transferred. Pro forma adjustments were tax effected at the company's historical statutory rates in effect for the respective periods. The unaudited pro forma amounts are not necessarily indicative of the combined results of operations that would have been realized had the acquisitions and related financings occurred on the aforementioned dates, nor are they meant to be indicative of any anticipated combined results of operations that the company will experience after the transaction. In addition, the amounts do not include any adjustments for actions that may be taken following the completion of the transaction, such as expected cost savings, operating synergies, or revenue enhancements that may be realized subsequent to the transaction.
Pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2021, excludes $312 million of transaction costs, initial restructuring costs, and debt extinguishment costs directly attributable to the PPD acquisition that were included in the determination of net income attributable to Thermo Fisher Scientific Inc. for that period. These items have reduced pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2020, by $197 million.
The company’s results would not have been materially different from its pro forma results had the company’s other 2021 acquisitions occurred at the beginning of 2020.
PPD’s revenues and losses attributable to Thermo Fisher Scientific Inc. in 2021, subsequent to the acquisition date, were $378 million and $(60) million, respectively. The loss includes non-recurring transaction and compensation costs.
2020
In 2020, the company acquired, within the Life Sciences Solutions segment, a U.S.-based provider of a spectral dye platform for high-resolution biology applications which will extend the company’s existing tools for protein and cell analysis applications.
XML 31 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue and Contract-related Balances
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue and Contract-related Balances Revenues and Contract-related Balances
Disaggregated Revenues
Revenues by type are as follows:
(In millions)202220212020
Revenues
Consumables
$20,624 $22,608 $18,527 
Instruments
7,924 7,753 6,779 
Services
16,367 8,850 6,912 
Consolidated revenues
$44,915 $39,211 $32,218 
Revenues by geographic region based on customer location are as follows:
(In millions)202220212020
Revenues
North America
$24,594 $19,659 $17,081 
Europe
10,762 11,134 8,284 
Asia-Pacific
8,115 7,218 5,822 
Other regions
1,444 1,200 1,031 
Consolidated revenues
$44,915 $39,211 $32,218 
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data.
Remaining Performance Obligations
The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2022 was $26.97 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 55% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.
Contract-related Balances
Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows:
December 31,December 31,
(In millions)20222021
Current contract assets, net$1,312 $968 
Noncurrent contract assets, net7 9 
Current contract liabilities2,601 2,655 
Noncurrent contract liabilities1,179 1,238 
Substantially all of the current contract liabilities balance at December 31, 2021 and 2020 was recognized in revenues during 2022 and 2021, respectively.
XML 32 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Business Segment and Geographical Information
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Business Segment and Geographical Information Business Segment and Geographical Information
The company’s financial performance is reported in four segments. A description of each segment follows.
Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Analytical Instruments: provides a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. These products and services are used by customers in
pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory.
Specialty Diagnostics: offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which improves patient care in a more cost-efficient manner.
Laboratory Products and Biopharma Services: offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more efficient, productive and cost-effective. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing.
The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation.
Business Segment Information
(In millions)202220212020
Revenues
Life Sciences Solutions
$13,532 $15,631 $12,168 
Analytical Instruments
6,624 6,069 5,124 
Specialty Diagnostics
4,763 5,659 5,343 
Laboratory Products and Biopharma Services
22,511 14,862 12,245 
Eliminations
(2,515)(3,010)(2,662)
Consolidated revenues
44,915 39,211 32,218 
Segment Income
Life Sciences Solutions
5,582 7,817 6,109 
Analytical Instruments
1,507 1,197 808 
Specialty Diagnostics
1,024 1,280 1,368 
Laboratory Products and Biopharma Services
2,872 1,844 1,271 
Subtotal reportable segments
10,985 12,138 9,556 
Cost of revenues adjustments
(46)(8)(6)
Selling, general and administrative expenses adjustments
(37)(144)10 
Restructuring and other costs
(114)(197)(99)
Amortization of acquisition-related intangible assets
(2,395)(1,761)(1,667)
Consolidated operating income
8,393 10,028 7,794 
Interest income272 43 65 
Interest expense(726)(536)(553)
Other income/(expense)
(104)(694)(76)
Consolidated income before taxes
$7,835 $8,841 $7,230 
Depreciation
Life Sciences Solutions
$214 $197 $140 
Analytical Instruments
83 83 76 
Specialty Diagnostics
75 128 100 
Laboratory Products and Biopharma Services
614 423 342 
Consolidated depreciation
$986 $831 $658 
Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of significant transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges/credits related to product liability litigation.
(In millions)202220212020
Total assets
Life Sciences Solutions
$21,848 $22,751 $20,209 
Analytical Instruments
10,019 9,692 9,773 
Specialty Diagnostics
5,542 6,010 6,534 
Laboratory Products and Biopharma Services
51,281 52,639 22,711 
Corporate/other (a)
8,464 4,031 9,825 
Consolidated total assets
$97,154 $95,123 $69,052 
Capital expenditures
Life Sciences Solutions
$490 $810 $392 
Analytical Instruments
140 79 74 
Specialty Diagnostics
112 167 175 
Laboratory Products and Biopharma Services
1,403 1,327 772 
Corporate/other
98 140 61 
Consolidated capital expenditures
$2,243 $2,523 $1,474 
(a)Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
Geographical Information
(In millions)202220212020
Revenues (b)
United States
$23,820 $18,907 $16,435 
China
3,793 3,444 2,797 
Other
17,302 16,860 12,986 
Consolidated revenues
$44,915 $39,211 $32,218 
Long-lived Assets (c)
United States
$6,308 $5,578 $3,686 
Other
4,565 4,286 3,001 
Consolidated long-lived assets
$10,873 $9,864 $6,687 
(b)Revenues are attributed to countries based on customer location.
(c)Includes property, plant and equipment, net, and operating lease ROU assets.
XML 33 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Other Income/Expense
 12 Months Ended
Dec. 31, 2022
Other Income and Expenses [Abstract]  
Other Income/Expense Other Income/(Expense)
In all periods, other income/(expense) includes currency transaction gains and losses on non-operating monetary assets and liabilities and net periodic pension benefit cost/income, excluding the service cost component which is included in operating expenses on the accompanying statement of income. In 2022, other income/(expense) includes $161 million of net losses on investments, $67 million of net gains on derivative instruments to address certain foreign currency risks, $26 million of losses on the early extinguishment of debt (Note 10), and $2 million of net settlement gains on pension plans.
In 2021, other income/(expense) includes $767 million of losses on the early extinguishment of debt (Note 10), $36 million of financing costs associated with obtaining bridge financing commitments in connection with the agreement to acquire PPD (Note 2), offset in part by $66 million of net gains on investments. The company had a cash outlay of $36 million in 2021 associated with obtaining the bridge financing commitments, included in other financing activities, net, in the accompanying statement of cash flows.
In 2020, other income/(expense) includes $81 million of financing costs for a terminated acquisition, primarily for loan commitment fees and entering into hedging contracts and $42 million reclassified from accumulated other comprehensive items related to a hedge arrangement (Note 14), offset in part by $10 million of net gains on investments. The company had a cash outlay of $51 million in 2020 associated with obtaining the loan commitments included in other financing activities, net, in the accompanying statement of cash flows.
XML 34 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-based Compensation Expense
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Expense Stock-based Compensation Expense
The company has stock-based compensation plans for its key employees, directors and others. These plans permit the grant of a variety of stock and stock-based awards, including restricted stock units, stock options or performance-based shares, as determined by the compensation committee of the company’s Board of Directors or, for certain non-officer grants, by the company’s employee equity committee, which consists of its chief executive officer. The company generally issues new shares of its common stock to satisfy option exercises and restricted unit vesting. Grants of stock options and restricted units generally provide that in the event of both a change in control of the company and a qualifying termination of an option or unit holder’s employment, all options and service-based restricted unit awards held by the recipient become immediately vested (unless an employment or other agreement with the employee provides for different treatment).
Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses.
Stock Options
The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate was calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.
The weighted average assumptions used in the Black-Scholes option pricing model are as follows: 
202220212020
Expected stock price volatility
26 %26 %22 %
Risk free interest rate
2.0 %0.8 %1.1 %
Expected life of options (years)
4.74.34.3
Expected annual dividend
0.2 %0.2 %0.3 %
The weighted average per share grant-date fair values of options granted during 2022, 2021 and 2020 were $135.07, $123.97 and $61.19, respectively. The total intrinsic value of options exercised during the same periods was $336 million, $501 million and $457 million, respectively. The intrinsic value is the difference between the market value of the shares on the exercise date and the exercise price of the option.
A summary of the company’s option activity for the year ended December 31, 2022 is presented below:
Shares
(in millions)		Weighted average exercise priceWeighted average remaining contractual term
(in years)		Aggregate intrinsic
value
(in millions)
Outstanding at December 31, 2021
6.0 $319.95 
Granted
0.8 530.48 
Exercised
(0.9)199.85 
Canceled/expired
(0.3)503.76 
Outstanding at December 31, 2022
5.6 $359.27 4.2$1,125 
Vested and unvested expected to vest at December 31, 2022
5.3 $351.97 4.7$1,114 
Exercisable at December 31, 2022
2.9 $251.44 2.8$891 
As of December 31, 2022, there was $228 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be recognized through 2026 with a weighted average amortization period of 2.4 years.
Restricted Share/Unit Awards
Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.
A summary of the company’s restricted unit activity for the year ended December 31, 2022 is presented below:
 Units
(in millions)		Weighted
average
grant-date
fair value
Unvested at December 31, 2021
0.8 $425.39 
Granted
0.4 520.83 
Vested
(0.4)375.77 
Forfeited
(0.1)510.37 
Unvested at December 31, 2022
0.7 $495.39 
The total fair value of shares vested during 2022, 2021 and 2020 was $163 million, $151 million and $126 million, respectively.
As of December 31, 2022, there was $200 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is expected to be recognized through 2026 with a weighted average amortization period of 1.9 years.
Employee Stock Purchase Plans
Qualifying employees are eligible to participate in an employee stock purchase plan sponsored by the company. Shares may be purchased under the program at 95% of the fair market value at the end of the purchase period and the shares purchased are not subject to a holding period. Shares are purchased through payroll deductions of up to 10% of each participating employee’s qualifying gross wages. The company issued 0.2 million, 0.1 million and 0.2 million shares, respectively, of its common stock in 2022, 2021 and 2020 under the employee stock purchase plan.
XML 35 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans
 12 Months Ended
Dec. 31, 2022
Retirement Benefits [Abstract]  
Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans
401(k) Savings Plan and Other Defined Contribution Plans
The company’s 401(k) savings and other defined contribution plans cover the majority of the company’s eligible U.S. and certain non-U.S. employees. Contributions to the plans are made by both the employee and the company. Company contributions are based on the level of employee contributions. Company contributions to these plans are based on formulas determined by the company. In 2022, 2021 and 2020, the company charged to expense $402 million, $299 million and $254 million, respectively, related to its defined contribution plans.
Defined Benefit Pension Plans
Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented.
The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.
When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.
The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined. During 2022, 2021 and 2020, the company made cash contributions of approximately $41 million, $34 million and $96 million, respectively. Contributions to the plans included in the following table are estimated at between $30 and $50 million for 2023.
The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans:
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)2022202120222021
Accumulated benefit obligation
$995 $1,260 $1,016 $1,475 
Change in projected benefit obligations
Projected benefit obligation at beginning of year
$1,260 $1,302 $1,552 $1,486 
Acquisitions
— — 51 170 
Service costs
— — 34 27 
Interest costs
27 23 20 11 
Settlements
— — (31)(7)
Plan participants' contributions
— — 9 6 
Actuarial (gains) losses
(210)20 (447)(57)
Benefits paid
(82)(85)(19)(30)
Currency translation and other
— — (100)(54)
Projected benefit obligation at end of year
$995 $1,260 $1,069 $1,552 
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)2022202120222021
Change in fair value of plan assets
Fair value of plan assets at beginning of year
$1,226 $1,267 $1,302 $1,160 
Acquisitions— — 14 158 
Actual return on plan assets
(212)37 (347)14 
Employer contributions
5 7 36 27 
Settlements
— — (31)(7)
Plan participants' contributions
— — 9 6 
Benefits paid
(82)(85)(19)(30)
Currency translation and other
— — (96)(26)
Fair value of plan assets at end of year$937 $1,226 $868 $1,302 
Funded status
$(58)$(34)$(201)$(250)
Amounts recognized in balance sheet
Noncurrent assets
$— $32 $81 $205 
Current liability
(6)(7)(11)(10)
Noncurrent liabilities
(52)(59)(271)(445)
Net amount recognized
$(58)$(34)$(201)$(250)
Amounts recognized in accumulated other comprehensive items
Net actuarial loss
$200 $157 $74 $167 
Prior service credits
— — (4)(3)
Net amount recognized
$200 $157 $70 $164 
For domestic pension plans, actuarial gains experienced in 2022 were driven by increases in the weighted average discount rates used to determine the projected benefit obligation, as well as differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns. For non-U.S. pension plans, actuarial gains experienced in 2022 were principally driven by increases in the weighted average discount rates used to determine the projected benefit obligation.
For domestic pension plans, actuarial losses experienced in 2021 were driven by differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns, which were partially offset by actuarial gains due to increases in the weighted average discount rates used to determine the projected benefit obligation differences. For non-U.S. pension plans, actuarial gains experienced in 2021 were principally driven by increases in the weighted average discount rates used to determine the projected benefit obligation.
The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2022 and 2021 and are as follows:
 Domestic pension benefitsNon-U.S. pension benefits
 2022202120222021
Weighted average assumptions used to determine projected benefit obligations
Discount rate for determining benefit obligation
5.01 %2.70 %3.91 %1.45 %
Interest crediting rate for cash balance plans
4.96 %2.58 %2.19 %1.25 %
Average rate of increase in employee compensation
N/AN/A2.78 %2.73 %
The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year, as presented in the following table:
 Domestic pension benefitsNon-U.S. pension benefits
 202220212020202220212020
Weighted average assumptions used to determine net benefit cost (income)
Discount rate - service cost
N/AN/AN/A1.00 %0.65 %1.21 %
Discount rate - interest cost
2.70 %2.33 %3.13 %1.36 %0.80 %1.44 %
Average rate of increase in employee compensation
N/AN/AN/A2.73 %2.30 %2.27 %
Expected long-term rate of return on assets
4.75 %4.25 %5.00 %2.33 %2.02 %2.33 %
The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.
The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows.
The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.
Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements.
The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases.
The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows:
 Pension plans
(In millions)20222021
Pension plans with projected benefit obligations in excess of plan assets
Projected benefit obligation
$1,636 $2,010 
Fair value of plan assets
1,296 1,521 
The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows:
 Pension plans
(In millions)20222021
Pension plans with accumulated benefit obligations in excess of plan assets
Accumulated benefit obligation
$1,583 $1,937 
Fair value of plan assets
1,294 1,521 
The measurement date used to determine benefit information is December 31 for all plan assets and benefit obligations.
The net periodic pension benefit cost (income) includes the following components:
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)202220212020202220212020
Components of net benefit cost (income)
Service cost
$— $— $— $34 $27 $24 
Interest cost on benefit obligation
27 23 35 20 11 18 
Expected return on plan assets
(45)(40)(47)(26)(19)(19)
Amortization of actuarial net loss
4 7 6 7 12 10 
Amortization of prior service benefit
— — — (1)— (1)
Settlement/curtailment loss
— — — (2)— 8 
Net periodic benefit cost (income)
$(14)$(10)$(6)$32 $31 $40 
Expected benefit payments are estimated using the same assumptions used in determining the company’s benefit obligation at December 31, 2022. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows:
(In millions)Domestic pension benefitsNon-U.S. pension benefits
Expected benefit payments
2023 $85 $47 
2024 81 48 
2025 81 51 
2026 80 55 
2027 79 55 
2028-2032373 313 
Domestic Pension Plan Assets
The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.
Non-U.S. Pension Plan Assets
The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds, multi-asset funds, alternative investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% - 90% for fixed income funds, 0% - 35% for multi-asset funds, and 0% - 45% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.
The fair values of the company’s plan assets at December 31, 2022 and 2021, by asset category are as follows:
 December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs		Not subject to leveling (a)
(In millions)2022(Level 1)(Level 2)(Level 3)
Domestic pension plan assets
U.S. equity funds
$89 $— $— $— $89 
International equity funds
91 — — — 91 
Fixed income funds
739 — — — 739 
Money market funds
18 — — — 18 
Total domestic pension plans
$937 $— $— $— $937 
Non-U.S. pension plan assets
Equity funds
$8 $— $— $— $8 
Fixed income funds
299 — — — 299 
Multi-asset funds
56 — — — 56 
Derivative funds
190 — — — 190 
Insurance contracts
306 — 306 — — 
Cash / money market funds
9 4 — — 5 
Total non-U.S. pension plans
$868 $4 $306 $— $558 
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
 December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs		Not subject to leveling (a)
(In millions)2021(Level 1)(Level 2)(Level 3)
Domestic pension plan assets
U.S. equity funds
$124 $— $— $— $124 
International equity funds
117 — — — 117 
Fixed income funds
966 — — — 966 
Money market funds
19 — — — 19 
Total domestic pension plans$1,226 $— $— $— $1,226 
Non-U.S. pension plan assets
Equity funds
$17 $— $— $— $17 
Fixed income funds
651 — — — 651 
Hedge funds
3 — — — 3 
Multi-asset funds
73 — — — 73 
Derivative funds
253 — — — 253 
Alternative investments
1 — — — 1 
Insurance contracts
295 — 295 — — 
Cash / money market funds
9 5 — — 4 
Total non-U.S. pension plans$1,302 $5 $295 $— $1,002 
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
The tables above present the fair value of the company’s plan assets in accordance with the fair value hierarchy (Note 14). Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. The fair value amounts of these investments presented in the above tables are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension plan assets. These investments were also redeemable at the balance sheet date or within limited time restrictions.
XML 36 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The components of income before provision for income taxes are as follows:
(In millions)202220212020
U.S.$3,859 $3,340 $4,762 
Non-U.S.3,976 5,501 2,468 
Income before income taxes
$7,835 $8,841 $7,230 
The components of the provision for income taxes are as follows:
(In millions)202220212020
Current income tax provision
Federal$813 $446 $521 
Non-U.S.633 1,148 423 
State254 160 175 
1,700 1,754 1,119 
Deferred income tax provision (benefit)
Federal$(611)$(227)$(237)
Non-U.S.(314)(399)(18)
State(72)(19)(14)
 (997)(645)(269)
Provision for income taxes
$703 $1,109 $850 
The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following:
(In millions)202220212020
Statutory federal income tax rate
21 %21 %21 %
Provision for income taxes at statutory rate
$1,645 $1,857 $1,518 
Increases (decreases) resulting from:
Foreign rate differential
(329)(255)(223)
Income tax credits
(202)(315)(335)
Global intangible low-taxed income
96 76 86 
Foreign-derived intangible income
(149)(119)(156)
Excess tax benefits from stock options and restricted stock units
(80)(124)(114)
Provision for (reversal of) tax reserves, net
(544)(17)(26)
Intra-entity transfers
(18)(284)— 
Domestication transaction— — (263)
Valuation allowances
344 36 379 
Withholding taxes
84 164 115 
Tax return reassessments and settlements
(210)1 (196)
State income taxes, net of federal tax111 82 147 
Other, net
(45)7 (82)
Provision for income taxes
$703 $1,109 $850 
The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate.
During 2022, the company settled an IRS audit relating to the 2017 and 2018 tax years. The company recorded a $208 million net tax benefit primarily from this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $658 million. The company recorded $49 million of charges for expired tax credits and other related components of the settlement. The company recorded a charge of $395 million to establish a valuation allowance against
certain U.S. foreign tax credits which the company believes will more likely than not expire unutilized. The company also recorded $101 million of additional net unrecognized tax benefit liabilities related to other tax audits.
During 2021, the company recorded a $188 million income tax benefit related to the deferred tax implications of an intra-entity transfer of assets. Also in 2021, the company recorded a $96 million income tax benefit related to a capital loss resulting from certain intra-entity transactions.
During 2020, the company settled an IRS audit relating to the 2014, 2015, and 2016 tax years. The company recorded a $25 million net tax benefit primarily from this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $378 million, of which $144 million was reclassified to income taxes payable. The company recorded $53 million of charges for expired tax credits and other related components of the settlement. The company recorded a charge of $156 million to establish a valuation allowance against certain U.S. foreign tax credits which the company believes will more likely than not expire unutilized.
In 2020, the company recorded a $263 million income tax benefit related to a domestication transaction involving the transfer of certain non-U.S. subsidiaries to the U.S., including interest expense of those subsidiaries. The company also recorded a valuation allowance of $212 million against the amount of interest expense that the company believes will more likely than not go unused.
The foreign tax credits discussed below are the result of foreign earnings and profits remitted or deemed remitted to the U.S. during the reporting year and the U.S. treatment of taxes paid in the foreign jurisdictions in the years those profits were originally earned.
In 2020, the company implemented foreign tax credit planning in Sweden which resulted in $96 million of foreign tax credits, with no related incremental U.S. income tax expense.
The company generally receives a tax deduction upon the exercise of non-qualified stock options by employees, or the vesting of restricted stock units held by employees, for the difference between the exercise price and the market price of the underlying common stock on the date of exercise. The company uses the incremental tax benefit approach for utilization of tax attributes. These excess tax benefits reduce the tax provision. In 2022, 2021 and 2020, the company's tax provision was reduced by $80 million, $124 million and $114 million, respectively, of such benefits.
Net deferred tax asset (liability) in the accompanying balance sheet consists of the following:
(In millions)20222021
Deferred tax asset (liability)
Depreciation and amortization
$(4,277)$(4,687)
Net operating loss and credit carryforwards
1,951 1,652 
Reserves and accruals
140 162 
Accrued compensation
259 318 
Inventory basis difference
364 181 
Deferred interest445 295 
Research and development and other capitalized costs
220 — 
Unrealized (gains) losses on hedging instruments
(199)(33)
Other, net
435 251 
Deferred tax liabilities, net before valuation allowance
(662)(1,861)
Less: Valuation allowance
1,322 968 
Deferred tax liabilities, net
$(1,984)$(2,829)
The company estimates the degree to which tax assets and loss and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2022, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense.
The changes in the valuation allowance are as follows:
 Year Ended December 31,
(In millions)202220212020
Beginning balance
$968 $933 $408 
Additions (reductions) charged to income tax provision, net
344 24 514 
Additions due to acquisitions
14 30 — 
Currency translation and other
(4)(19)11 
Ending balance$1,322 $968 $933 
At December 31, 2022, the company had net federal, state and non-U.S. net operating loss carryforwards of $68 million, $97 million and $1.16 billion, respectively. Use of the carryforwards is limited based on the future income of certain subsidiaries. Of the federal net operating loss carryforwards, $33 million expire in the years 2023 through 2037, and the remainder do not expire. The state net operating loss carryforwards expire in the years 2023 through 2042. Of the net non-U.S. net operating loss carryforwards, $422 million expire in the years 2025 through 2042, and the remainder do not expire.
At December 31, 2022, the company had foreign tax credit carryforwards of $551 million and deferred interest carryforwards of $445 million. The foreign tax credit carryforwards will expire in the years 2025 through 2032 while deferred interest carryforwards do not expire.
U.S. federal taxes have been recorded on approximately $29 billion of undistributed foreign earnings as of December 31, 2022. A provision has not been made for certain U.S. state income taxes or additional non-U.S. taxes that would be due when cash is repatriated to the U.S. as the company’s undistributed foreign earnings are intended to be reinvested outside of the U.S. indefinitely. The determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed. The company’s intent is to only make distributions from non-U.S. subsidiaries in the future when they can be made at no net tax cost.
Unrecognized Tax Benefits
As of December 31, 2022, the company had $0.57 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate.
A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:
(In millions)202220212020
Beginning balance
$1,124 $1,091 $1,552 
Additions due to acquisitions
15 26 — 
Additions for tax positions of current year
104 32 8 
Additions for tax positions of prior years
24 60 — 
Reductions for tax positions of prior years
(659)(5)(296)
Closure of tax years
(4)(27)— 
Settlements
(32)(53)(173)
Ending balance
$572 $1,124 $1,091 
Substantially all of the unrecognized tax benefits are classified as long-term liabilities. The company does not expect its unrecognized tax benefits to change significantly over the next twelve months.
During 2022, the company’s unrecognized tax benefits increased by $143 million as a result of uncertain tax positions relating to foreign tax positions and decreased $610 million relating to U.S. federal and state tax positions which included $658 million from the settlement of the IRS audit of the 2017 and 2018 tax years. The company also assumed $15 million of uncertain tax benefits as part of the acquisition of PPD.
During 2021, the company’s unrecognized tax benefits increased by $80 million as a result of uncertain tax positions relating to foreign tax positions and decreased $75 million relating to U.S. federal and state tax positions. The company also assumed $26 million of uncertain tax benefits as part of the acquisition of PPD.
During 2020, the company’s unrecognized tax benefits decreased $51 million as a result of uncertain tax positions relating to foreign tax positions and $410 million relating to U.S. federal and state tax positions which included $378 million from the settlement of the IRS audit of the 2014, 2015 and 2016 tax years.
The company classified interest and penalties related to unrecognized tax benefits as income tax expense. The total amount of interest and penalties related to uncertain tax positions and recognized in the balance sheet as of December 31, 2022 and 2021 was $74 million and $59 million, respectively.
The company conducts business globally and, as a result, Thermo Fisher or one or more of its subsidiaries files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the company is subject to examination by taxing authorities throughout the world, including such major jurisdictions as Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, the United Kingdom and the United States. With few exceptions, the company is no longer subject to U.S. state and local or non-U.S. income tax examinations for years before 2012 and no longer subject to U.S. federal income tax examinations for years before 2019.
XML 37 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Earnings Per Share
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Earnings Per Share Earnings per Share
(In millions except per share amounts)202220212020
Net income attributable to Thermo Fisher Scientific Inc.
$6,950 $7,725 $6,375 
Basic weighted average shares
392 394 396 
Plus effect of: stock options and restricted stock units
2 3 3 
Diluted weighted average shares
394 397 399 
Basic earnings per share
$17.75 $19.62 $16.09 
Diluted earnings per share
$17.63 $19.46 $15.96 
Antidilutive stock options excluded from diluted weighted average shares
2 1 1 
XML 38 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Debt and Other Financing Arrangements
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Debt and Other Financing Arrangements
Note 10.    Debt and Other Financing Arrangements
Effective interest rate at December 31,December 31,December 31,
(Dollars in millions)202220222021
Commercial Paper2.60 %$310 $2,522 
Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023
1,000 1,000 
Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023
500 500 
0.797% 2-Year Senior Notes, Due 10/18/2023
1.03 %1,350 1,350 
Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
1.85 %1,819 1,933 
0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
0.06 %589 625 
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
0.93 %1,071 1,137 
Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024
500 500 
1.215% 3-Year Senior Notes, Due 10/18/2024
1.42 %2,500 2,500 
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
0.40 %857 910 
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
2.09 %686 728 
0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated)
1.05 %170 — 
0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)
0.15 %589 625 
3.65% 10-Year Senior Notes, Due 12/15/2025
— 350 
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)
3.38 %535 — 
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
1.52 %749 796 
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
1.65 %535 568 
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
1.96 %642 682 
1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)
1.18 %221 — 
4.80% 5-Year Senior Notes, Due 11/21/2027
5.00 %600 — 
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
0.77 %857 910 
Effective interest rate at December 31,December 31,December 31,
(Dollars in millions)202220222021
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
1.46 %642 682 
1.750% 7-Year Senior Notes, Due 10/15/2028
1.89 %700 700 
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
2.07 %749 796 
2.60% 10-Year Senior Notes, Due 10/1/2029
2.74 %900 900 
1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)
1.44 %36 — 
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)
0.88 %1,873 1,990 
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
1.13 %963 1,023 
2.00% 10-Year Senior Notes, Due 10/15/2031
2.23 %1,200 1,200 
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
2.54 %642 682 
1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)
1.60 %48 — 
4.95% 10-Year Senior Notes, Due 11/21/2032
5.09 %600 — 
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)
1.20 %1,606 1,706 
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)
3.76 %803 — 
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
2.94 %749 796 
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
1.73 %963 1,023 
2.80% 20-Year Senior Notes, Due 10/15/2041
2.90 %1,200 1,200 
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)
1.77 %1,339 1,421 
2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)
2.13 %111 — 
5.30% 30-Year Senior Notes, Due 2/1/2044
5.37 %400 400 
4.10% 30-Year Senior Notes, Due 8/15/2047
4.23 %750 750 
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
1.98 %1,071 1,137 
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)
2.06 %803 853 
2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)
2.43 %254 — 
Other 79 76 
Total borrowings at par value
34,561 34,971 
Unamortized discount
(112)(117)
Unamortized debt issuance costs
(171)(184)
Total borrowings at carrying value
34,278 34,670 
Finance lease liabilities
210 200 
Less: Short-term obligations and current maturities
5,579 2,537 
Long-term obligations$28,909 $32,333 
SOFR - Secured Overnight Financing Rate
EURIBOR - Euro Interbank Offered Rate
The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs.
See Note 14 for fair value information pertaining to the company’s long-term borrowings.
As of December 31, 2022, the annual repayment requirements for debt obligations are as follows:
(In millions)BorrowingsFinance Lease Liabilities
2023 $5,583 $11 
2024 4,071 16 
2025 2,298 12 
2026 1,285 11 
2027 1,999 10 
2028 and thereafter19,325 150 
$34,561 $210 
In addition to available borrowings under the company’s revolving credit agreements, discussed below, the company had unused lines of credit of $72 million as of December 31, 2022. These unused lines of credit generally provide for short-term unsecured borrowings at various interest rates.
Credit Facilities
The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term SOFR, a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of December 31, 2022, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit.
Commercial Paper Programs
The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of December 31, 2022, there were $0.31 billion of outstanding borrowings under these programs.
Senior Notes
Interest is payable quarterly on the floating rate senior notes, annually on the euro-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the fixed rate senior notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. Except for the euro-denominated floating rate senior notes, which may not be redeemed early, the floating rate senior notes may be redeemed in whole or in part on or after their applicable call dates at a redemption price of 100% of the principal amount plus accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements. The company was in compliance with all covenants at December 31, 2022.
In 2022 the company completed the full allocation of an amount equal to the net proceeds from the 0.000% senior notes due 2025 to finance or refinance, in whole or in part, certain COVID-19 response projects.
In 2022, the company redeemed all of its 3.650% Senior Notes due 2025. In connection with the redemption, the company incurred $26 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income.
In 2021, the company redeemed some of its existing senior notes. In connection with these redemptions, the company incurred $767 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income. Upon redemption of the senior notes, the company terminated the related fixed to floating rate interest rate
swap arrangements and received $22 million, included in other financing activities, net, in the accompanying statement of cash flows.
Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the Floating Rate Senior Notes due 2023, the 0.00% Senior Notes due 2023, the 0.00% Senior Notes due 2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051 included in the table above (collectively, the “Euronotes”) in registered public offerings. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company.
XML 39 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Leases
 12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Leases Leases
As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally for 1 to 10 years) or have options to terminate the arrangement within 1 year.
The company has guaranteed the residual value of three leased operating facilities with lease terms ending in 2023, 2024 and 2025. The company has agreed with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 10). The aggregate maximum guarantee under these three lease arrangements is $147 million. Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated balance sheet as of December 31, 2022, but exclude any amounts for residual value guarantees.
As a lessee, the consolidated financial statements include the following relating to operating leases:
(Dollars in millions)202220212020
Statement of income
Operating lease costs
$351 $254 $224 
Variable lease costs
109 66 49 
Statement of cash flows
Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities$289 $288 $222 
Operating lease ROU assets obtained in exchange for new operating lease liabilities430 293 202 
Balance sheet
ROU assets$1,593 $1,531 
Operating lease liabilities - current272 266 
Operating lease liabilities - noncurrent1,313 1,203 
Weighted average at end of year
Remaining operating lease term9.4 years9.9 years
Discount rate3.2 %2.6 %
ROU assets are classified in other assets in the consolidated balance sheet. Operating lease liabilities are classified in other accrued expenses and other long-term liabilities, respectively, in the consolidated balance sheet.
Lease costs arising from finance leases, short-term leases, and sublease income are not material. See Note 10 for additional information relating to finance leases.
As of December 31, 2022, future payments of operating lease liabilities are as follows:
(In millions)
2023 $321 
2024 293 
2025 220 
2026 172 
2027 136 
2028 and thereafter730 
Total lease payments1,872 
Less: imputed interest
287 
Total operating lease liability$1,585 
As a lessor, operating leases, sales-type leases and direct financing leases are not material.
XML 40 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Purchase Obligations
The company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or fixed assets and to pay royalties that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable at any time without penalty. The aggregate amount of the company’s unconditional purchase obligations totaled $2.40 billion at December 31, 2022 and the majority of these obligations are expected to be settled during 2023.
The Analytical Instruments segment recorded a charge to cost of product revenues for $108 million in 2020 related to an existing supply contract for components of electron microscopy instruments. The agreement requires the company to make future minimum purchases through 2025. The company developed and launched an alternative product beginning in 2020 and based on the expected demand for the internally developed product vs. the third-party product, the company does not expect to use all of the product it will be required to buy, resulting in a loss on the purchase commitment.
Letters of Credit, Guarantees and Other Commitments
Outstanding letters of credit and bank guarantees totaled $297 million at December 31, 2022. Substantially all of these letters of credit and guarantees expire before 2040.
Outstanding surety bonds and other guarantees totaled $84 million at December 31, 2022. The expiration of these bonds and guarantees ranges through 2024.
The letters of credit, bank guarantees and surety bonds principally secure performance obligations, and allow the holder to draw funds up to the face amount of the letter of credit, bank guarantee or surety bond if the applicable business unit does not perform as contractually required.
The company is a guarantor of pension plan obligations of a divested business. The purchaser of the divested business has agreed to pay for the pension benefits, however the company was required to guarantee payment of these pension benefits should the purchaser fail to do so. The amount of the guarantee at December 31, 2022 was $28 million.
In connection with the sale of businesses of the company, the buyers have assumed certain contractual obligations of such businesses and have agreed to indemnify the company with respect to those assumed liabilities. In the event a third-party to a transferred contract does not recognize the transfer of obligations or a buyer defaults on its obligations under the transferred contract, the company could be liable to the third-party for such obligations. However, in such event, the company would be entitled to seek indemnification from the buyer.
Indemnifications
In conjunction with certain transactions, primarily divestitures, the company has agreed to indemnify the other parties with respect to certain liabilities related to the businesses that were sold or leased properties that were abandoned (e.g., retention of certain environmental, tax, employee and product liabilities). The scope and duration of such indemnity obligations vary from transaction to transaction. Where probable, an obligation for such indemnifications is recorded as a liability. Generally, a
maximum obligation cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, historically the company has not made significant payments for these indemnifications.
In connection with the company’s efforts to reduce the number of facilities that it occupies, the company has vacated some of its leased facilities or sublet them to third parties. When the company sublets a facility to a third-party, it remains the primary obligor under the master lease agreement with the owner of the facility. As a result, if a third-party vacates the sublet facility, the company would be obligated to make lease or other payments under the master lease agreement. The company believes that the financial risk of default by sublessors is individually and in the aggregate not material to the company’s financial position or results of operations.
In connection with the sale of products in the ordinary course of business, the company often makes representations affirming, among other things, that its products do not infringe on the intellectual property rights of others and agrees to indemnify customers against third-party claims for such infringement. The company has not been required to make material payments under such provisions.
Environmental Matters
The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At December 31, 2022, the company’s total environmental liability was approximately $75 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows.
Litigation and Related Contingencies
The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows.
Product Liability, Workers Compensation and Other Personal Injury Matters
The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. The range of probable loss for product liability, workers compensation and other personal injury matters of the company’s continuing operations at December 31, 2022, was
approximately $223 million to $384 million on an undiscounted basis. The portion of these liabilities assumed in the 2006 merger with Fisher was recorded at its fair (present) value at the date of merger. The company’s accrual for all such matters in total, including the discounted liabilities, was $229 million at December 31, 2022 (or $232 million undiscounted). The accrual includes estimated defense costs and is gross of estimated amounts due from insurers of $95 million at December 31, 2022 (or $98 million undiscounted) that are included in other assets in the accompanying balance sheet. The portion of these insurance assets assumed in the merger with Fisher was also recorded at its fair value at the date of merger. In addition to the above accrual, as of December 31, 2022, the company had a product liability accrual of $17 million (undiscounted) relating to divested businesses.Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis.
XML 41 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Comprehensive Income and Shareholders Equity
 12 Months Ended
Dec. 31, 2022
Stockholders' Equity Note [Abstract]  
Comprehensive Income and Shareholders' Equity Comprehensive Income and Shareholders' Equity
Comprehensive Income (Loss)
Changes in each component of accumulated other comprehensive items, net of tax are as follows:
(In millions)Currency
translation
adjustment		Unrealized
losses on
hedging
instruments		Pension and
other
postretirement
benefit
liability
adjustment		Total
Balance at December 31, 2021$(2,065)$(35)$(229)$(2,329)
Other comprehensive items before reclassifications
(822)— 38 (784)
Amounts reclassified from accumulated other comprehensive items
7 2 5 14 
Net other comprehensive items
(815)2 43 (770)
Balance at December 31, 2022$(2,880)$(33)$(186)$(3,099)
Shareholders’ Equity
At December 31, 2022, the company had reserved 22 million unissued shares of its common stock for possible issuance under stock-based compensation plans.
Early in the first quarter of 2023, the company repurchased $3.00 billion of the company's common stock (5.2 million shares).
XML 42 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements and Fair Value of Financial Instruments
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements and Fair Value of Financial Instruments Fair Value Measurements and Fair Value of Financial Instruments
Fair Value Measurements
The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2022. The company’s financial assets and liabilities carried at fair value are primarily comprised of investments in publicly traded securities, insurance contracts, investments in derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration.
Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access.
Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves.
Level 3: Inputs are unobservable data points that are not corroborated by market data.
The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:
December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs
(In millions)2022(Level 1)(Level 2)(Level 3)
Assets
Cash equivalents
$5,804 $5,804 $— $— 
Investments
25 25 — — 
Warrants
12 — 12 — 
Insurance contracts
162 — 162 — 
Derivative contracts
79 — 79 — 
Total assets
$6,082 $5,829 $253 $— 
Liabilities
Derivative contracts
$101 $— $101 $— 
Contingent consideration
174 — — 174 
Total liabilities
$275 $— $101 $174 
December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs
(In millions)2021(Level 1)(Level 2)(Level 3)
Assets
Cash equivalents
$2,210 $2,210 $— $— 
Investments
298 298 — — 
Warrants
15 — 15 — 
Insurance contracts
181 — 181 — 
Derivative contracts
36 — 36 — 
Total assets
$2,740 $2,508 $232 $— 
Liabilities
Derivative contracts
$1 $— $1 $— 
Contingent consideration
317 — — 317 
Total liabilities
$318 $— $1 $317 
The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense.
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration.
(In millions)20222021
Contingent consideration
Beginning balance
$317 $70 
Acquisitions (including assumed balances)
(18)403 
Payments
(66)(109)
Changes in fair value included in earnings
(59)(47)
Ending balance
$174 $317 
Derivative Contracts
The following table provides the aggregate notional value of outstanding derivative contracts.
December 31,December 31,
(In millions)20222021
Notional amount
Cross-currency interest rate swaps - designated as net investment hedges
$2,100 $900 
Currency exchange contracts
2,434 2,149 
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheet and statement of income.
 Fair value – assetsFair value – liabilities
 December 31,December 31,December 31,December 31,
(In millions)2022202120222021
Derivatives designated as hedging instruments
Cross-currency interest rate swaps (a)
$77 $25 $85 $— 
Derivatives not designated as hedging instruments
Currency exchange contracts (b)
2 11 16 1 
Total derivatives
$79 $36 $101 $1 
(a)The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities.
(b)The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.
 Gain (loss) recognized
(In millions)20222021
Fair value hedging relationships
Cross-currency interest rate swaps
Hedged long-term obligations - included in other income/(expense)
$77 $— 
Derivatives designated as hedging instruments - included in other income/(expense)
(81)— 
Interest rate swaps
Hedged long-term obligations - included in other income/(expense)
— 25 
Derivatives designated as hedging instruments - included in other income/(expense)
— (3)
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to other income/(expense)
(3)(73)
 Gain (loss) recognized
(In millions)20222021
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in currency translation adjustment within other comprehensive items
695 922 
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive items
52 71 
Included in other income/(expense)
19 8 
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues
6 12 
Included in other income/(expense)
102 162 
Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions.
The company uses foreign currency-denominated debt, certain foreign-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
See Note 1 and Note 10 for additional information on the company’s risk management objectives and strategies.
Cash Flow Hedge Arrangements
In 2020 the company entered into interest rate swap arrangements to mitigate the risk of interest rates rising prior to completion of debt offerings. Based on the company's conclusion that the debt offerings were probable, the swaps hedged the cash flow risk for each of the interest payments on the planned fixed-rate debt issues. The aggregate fair value of the terminated hedges, net of tax, has been classified as a reduction to accumulated other comprehensive items and will be amortized to interest expense over the term of the related debt issuances. The company had cash outlays aggregating $85 million in 2020 associated with termination of the arrangements, included in other financing activities, net, in the accompanying statement of cash flows.
In late 2020, the company determined that the previously anticipated debt offerings were probable of not occurring and reclassified $42 million from accumulated other comprehensive items to other income/(expense). During 2021, in connection with the extinguishment of debt (Note 10), the company reclassified $65 million from accumulated other comprehensive items to other income/(expense).
Fair Value of Other Financial Instruments
The carrying value and fair value of the company’s debt instruments are as follows:
December 31, 2022December 31, 2021
CarryingFairCarryingFair
(In millions)valuevaluevaluevalue
Senior notes
$33,889 $29,901 $32,072 $33,449 
Commercial paper
310 310 2,522 2,522 
Other
79 79 76 76 
$34,278 $30,290 $34,670 $36,047 
The fair value of debt instruments was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.
XML 43 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Supplemental Cash Flow Information
 12 Months Ended
Dec. 31, 2022
Supplemental Cash Flow Information [Abstract]  
Supplemental Cash Flow Information Supplemental Cash Flow Information
(In millions)202220212020
Cash paid for:
Interest
$667 $555 $471 
Income taxes
1,234 2,182 1,324 
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment
393 379 347 
Fair value of equity awards exchanged— 43 — 
Fair value of acquisition contingent consideration— 183 — 
Finance lease ROU assets obtained in exchange for new finance lease liabilities33 15 5 
Declared but unpaid dividends
119 104 89 
Issuance of stock upon vesting of restricted stock units
241 265 217 
Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:
 December 31,December 31,
(In millions)20222021
Cash and cash equivalents$8,524 $4,477 
Restricted cash included in other current assets12 13 
Restricted cash included in other assets1 1 
Cash, cash equivalents and restricted cash$8,537 $4,491 
Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring and Other Costs
 12 Months Ended
Dec. 31, 2022
Restructuring and Related Activities [Abstract]  
Restructuring and Other Costs Restructuring and Other Costs
Restructuring and other costs in 2022 primarily included impairment of long-lived assets and continuing charges for headcount reductions and facility consolidations in an effort to streamline operations. In 2022, severance actions associated with facility consolidations and cost reduction measures affected less than 2% of the company’s workforce.
Restructuring and other costs in 2021 primarily included charges for impairments of an acquired technology asset and a tradename asset, and, to a lesser extent, compensation due to employees at acquired businesses on the date of acquisition. In 2021, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.
Restructuring and other costs in 2020 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, and charges for the write-off of acquired technology. In 2020, severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce.
As of February 23, 2023, the company has identified restructuring actions that will result in additional charges of approximately $60 million, primarily in 2023, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred.
Restructuring and other costs by segment are as follows:
(In millions)202220212020
Life Sciences Solutions
$30 $129 $34 
Analytical Instruments
1 6 26 
Specialty Diagnostics
68 18 9 
Laboratory Products and Biopharma Services
12 35 23 
Corporate
3 9 7 
$114 $197 $99 
The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.
(In millions)Total (a)
Balance at December 31, 2019$34 
Net restructuring charges incurred in 2020 (b)
51 
Payments
(57)
Currency translation
(7)
Balance at December 31, 202021 
Net restructuring charges incurred in 2021 (c)
37 
Payments
(40)
Currency translation
(1)
Balance at December 31, 202117 
Net restructuring charges incurred in 2022 (d)
68 
Payments
(44)
Balance at December 31, 2022$41 
(a)The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.
(b)Excludes $48 million of charges, principally $32 million for impairment of acquired technology in the Life Sciences Solutions segment resulting from a reduction in expected cash flows and, to a lesser extent, charges across the company’s segments for fixed asset writedowns and costs associated with environmental remediation at abandoned/previously owned facilities.
(c)Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segment, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
(d)Excludes $46 million of net charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.
The company expects to pay accrued restructuring costs primarily through 2023.
XML 45 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of Operations and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principles of Consolidation
Principles of Consolidation
The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At December 31, 2022 and 2021, the company had such investments with carrying amounts of $369 million and $576 million, respectively. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method. At December 31, 2022 and 2021, the fair value of such investments was $7 million and $217 million, respectively.
Redeemable Noncontrolling Interest
The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events.
Presentation
Presentation
Certain reclassifications of prior year amounts have been made to conform to the current year presentation.
Revenue Recognition
Revenue Recognition
Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year.
Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date.
Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.
Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional.
Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract.
Contract-related Balances
Contract-related Balances
Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.
Warranty Obligations Warranty ObligationsThe company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred.
Leases
Leases
Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations.
Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense.
Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.
As a lessee, the company accounts for the lease and non-lease components as a single lease component.
Research and Development
Research and Development
The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.
Restructuring Costs
Restructuring Costs
Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment
contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.
From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to generate revenues. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period.
Income Taxes
Income Taxes
The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused.
The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.
Earnings per Share
Earnings per Share
Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units.
Cash and Cash Equivalents
Cash and Cash Equivalents
Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value.
Inventories InventoriesInventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income.
Property, Plant and Equipment Property, Plant and EquipmentProperty, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income.
Acquisition-related Intangible Assets
Acquisition-related Intangible Assets
Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.
Investments Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments.
Goodwill
Goodwill
The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2022, 2021 or 2020.
Loss Contingencies
Loss Contingencies
Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.
Currency Translation Currency TranslationAll assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period.
Derivatives Contracts
Derivative Contracts
The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.
The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Singapore dollars, Japanese yen, Hong Kong dollars, Czech koruna and Swedish krona. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management.
Cash flow hedges. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item.
Fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings.
Net investment hedges. The company uses foreign currency-denominated debt, certain foreign-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
Government Assistance
Government Assistance
From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement. Such amounts were not material to the consolidated financial statements as of and for the year ended December 31, 2022.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic materially adversely affected certain of the company’s businesses in 2020, particularly in the Analytical Instruments segment and, to a lesser extent, some businesses within the other three segments. The negative impacts significantly lessened in 2021 and 2022. The extent and duration of negative impacts in the future, which may include inflationary pressures and supply chain disruptions, are uncertain and may require changes to estimates. Actual results could differ from those estimates.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In September 2022, the FASB issued new guidance to require entities to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under these programs for each period presented. The company will adopt some aspects of this guidance in 2023 using a retrospective method and other aspects in 2024 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures; however, the impact in future periods will be dependent on the extent of arrangements of this nature entered into by the company
In November 2021, the FASB issued new guidance to require entities to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. The company adopted this guidance in the fourth quarter of 2022 using a prospective method. The adoption of this guidance did not have a material impact on the company’s disclosures; however, the impact in future periods will be dependent on the extent of future transactions of this nature entered into by the company.
In October 2021, the FASB amended guidance to recognize and measure contract assets and contract liabilities acquired in a business combination. Generally, this new guidance will result in the company recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The company adopted this guidance in the fourth quarter of 2021 retrospectively to all business combinations completed in the first three quarters of 2021 and prospectively to all future business combinations. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements for acquisitions that closed in 2021 and 2022; however, the impact in future periods will be dependent on the contract assets and contract liabilities acquired in future business combinations.
In July 2021, the FASB amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. The company adopted the guidance in the third quarter of 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements.
In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company adopted this guidance in 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates.
In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. The company adopted the guidance in 2020 using a modified retrospective method. The adoption of this guidance reduced accounts receivable and retained earnings by $1 million on January 1, 2020.
Business Combinations The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining
the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.
Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.
2023
On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not expected to be tax deductible.
Stock-based Compensation Expense
Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses.
Stock Options
The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate was calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.
Restricted Share/Unit Awards
Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.
Pension and Other Postretirement Benefit Plans
Defined Benefit Pension Plans
Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented.
The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.
When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.
The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined.
The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.
The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows.
The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.
Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements.
The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases.
Domestic Pension Plan Assets
The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.
Non-U.S. Pension Plan Assets
The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds, multi-asset funds, alternative investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% - 90% for fixed income funds, 0% - 35% for multi-asset funds, and 0% - 45% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.
XML 46 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of Operations and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Components of Inventories The components of inventories are as follows:
December 31,December 31,
(In millions)20222021
Raw materials$2,405 $1,922 
Work in process660 676 
Finished goods2,569 2,453 
Inventories$5,634 $5,051 
Schedule of Property, Plant and Equipment Property, plant and equipment consists of the following:
December 31,December 31,
(In millions)20222021
Land$454 $431 
Buildings and improvements3,153 2,575 
Machinery, equipment and leasehold improvements7,967 7,020 
Construction in progress2,695 2,567 
Property, plant and equipment, at cost14,269 12,593 
Less: Accumulated depreciation and amortization4,989 4,260 
Property, plant and equipment, net$9,280 $8,333 
Schedule of Acquisition-related Intangible Assets
Acquisition-related intangible assets are as follows:
Balance at December 31, 2022Balance at December 31, 2021
(In millions)GrossAccumulated AmortizationNetGrossAccumulated AmortizationNet
Definite lived:
Customer relationships
$21,792 $(8,330)$13,462 $22,802 $(7,792)$15,010 
Product technology
5,882 (4,360)1,522 6,041 (3,977)2,064 
Tradenames
1,635 (1,008)627 1,722 (919)803 
Backlog
1,038 (442)596 1,060 (59)1,001 
30,347 (14,140)16,207 31,625 (12,747)18,878 
Indefinite lived:
Tradenames
1,235 N/A1,235 1,235 N/A1,235 
Acquisition-related intangible assets
$31,582 $(14,140)$17,442 $32,860 $(12,747)$20,113 
Schedule of Indefinite-Lived Acquisition-related Intangible Assets
Acquisition-related intangible assets are as follows:
Balance at December 31, 2022Balance at December 31, 2021
(In millions)GrossAccumulated AmortizationNetGrossAccumulated AmortizationNet
Definite lived:
Customer relationships
$21,792 $(8,330)$13,462 $22,802 $(7,792)$15,010 
Product technology
5,882 (4,360)1,522 6,041 (3,977)2,064 
Tradenames
1,635 (1,008)627 1,722 (919)803 
Backlog
1,038 (442)596 1,060 (59)1,001 
30,347 (14,140)16,207 31,625 (12,747)18,878 
Indefinite lived:
Tradenames
1,235 N/A1,235 1,235 N/A1,235 
Acquisition-related intangible assets
$31,582 $(14,140)$17,442 $32,860 $(12,747)$20,113 
Schedule of Future Amortization Expense The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2022 is as follows:
(In millions)
2023 $2,279 
2024 1,863 
2025 1,582 
2026 1,322 
2027 1,296 
2028 and thereafter7,865 
Estimated future amortization expense of definite-lived intangible assets$16,207 
Schedule of Changes in Carrying Amount of Goodwill The changes in the carrying amount of goodwill by segment are as follows:
(In millions)Life Sciences
Solutions		Analytical
Instruments		Specialty
Diagnostics		Laboratory
Products and
Biopharma Services		Total
Balance at December 31, 2020
$8,590 $5,079 $3,370 $9,002 $26,041 
Acquisitions
1,560 56 8 14,400 16,024 
Currency translation
(7)(92)(101)59 (141)
Balance at December 31, 2021
10,143 5,043 3,277 23,461 41,924 
Acquisitions
— 24 — — 24 
Finalization of purchase price allocations for 2021 acquisitions
9 — — 168 177 
Currency translation
(6)(102)(186)(635)(929)
Balance at December 31, 2022
$10,146 $4,965 $3,091 $22,994 $41,196 
XML 47 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions (Tables)
 12 Months Ended
Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of Components of Purchase Price The components of the purchase price and net assets acquired are as follows:
(In billions)The Binding Site
Purchase price
Cash paid
$2.42 
Debt settled
0.31 
Cash acquired
(0.02)
$2.71 
Net assets acquired
Definite-lived intangible assets
$1.07 
Goodwill
1.77 
Net tangible assets
0.15 
Deferred tax assets (liabilities)
(0.28)
$2.71 
The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:
(In millions)PPDPeproTechEuropean Viral Vector BusinessMesa BiotechLengnau biologics manufacturing facilityOther
Purchase price
Cash paid
$17,237 $1,946 $848 $421 $17 $298 
Fair value of equity awards exchanged
43 — — — — — 
Fair value of contingent consideration
— — — 65 1 117 
Cash acquired
(1,244)(83)(18)(14)— (12)
$16,036 $1,863 $830 $472 $18 $403 
Net assets acquired
Current assets
$2,477 $58 $39 $54 $— $12 
Property, plant and equipment
527 18 59 2 93 2 
Definite-lived intangible assets:
Customer relationships
6,257 510 302 — — 2 
Product technology
— 282 25 279 — 224 
Tradenames
594 — — 2 — 2 
Backlog1,038 — — — — — 
Goodwill
13,949 1,198 600 237 18 198 
Other assets
1,060 11 3 3 364 2 
Contract liabilities(1,539)— (59)— — (1)
Deferred tax assets (liabilities)
(1,782)(192)(80)(72)— (27)
Finance lease liabilities
(90)— (24)— (82)— 
Debt assumed
(4,299)— — — — — 
Other liabilities assumed
(2,034)(22)(35)(33)(375)(11)
Redeemable noncontrolling interest(122)— — — — — 
$16,036 $1,863 $830 $472 $18 $403 
During 2022, we finalized the allocations of the purchase price for the Lengnau biologics manufacturing facility, PPD, Inc. and PeproTech, Inc., largely with respect to definite-lived intangible assets, property, plant and equipment, contract liabilities,
equity method investments, asset retirement obligations, defined benefit pension plans, assumed contingent consideration and the related deferred taxes. The adjustments to the income statement recorded during 2022 were not material.
Schedule of Pro Forma Information
The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020:
 Year Ended
 December 31,December 31,
(In millions)20212020
Revenues$44,886 $36,887 
Net income attributable to Thermo Fisher Scientific Inc.$7,369 $5,361 
XML 48 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue and Contract-related Balances (Tables)
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
Disaggregated Revenues
Revenues by type are as follows:
(In millions)202220212020
Revenues
Consumables
$20,624 $22,608 $18,527 
Instruments
7,924 7,753 6,779 
Services
16,367 8,850 6,912 
Consolidated revenues
$44,915 $39,211 $32,218 
Revenues by geographic region based on customer location are as follows:
(In millions)202220212020
Revenues
North America
$24,594 $19,659 $17,081 
Europe
10,762 11,134 8,284 
Asia-Pacific
8,115 7,218 5,822 
Other regions
1,444 1,200 1,031 
Consolidated revenues
$44,915 $39,211 $32,218 
Schedule of Contract-related Balances Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows:
December 31,December 31,
(In millions)20222021
Current contract assets, net$1,312 $968 
Noncurrent contract assets, net7 9 
Current contract liabilities2,601 2,655 
Noncurrent contract liabilities1,179 1,238 
XML 49 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Business Segment and Geographical Information (Tables)
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information Business Segment Information
(In millions)202220212020
Revenues
Life Sciences Solutions
$13,532 $15,631 $12,168 
Analytical Instruments
6,624 6,069 5,124 
Specialty Diagnostics
4,763 5,659 5,343 
Laboratory Products and Biopharma Services
22,511 14,862 12,245 
Eliminations
(2,515)(3,010)(2,662)
Consolidated revenues
44,915 39,211 32,218 
Segment Income
Life Sciences Solutions
5,582 7,817 6,109 
Analytical Instruments
1,507 1,197 808 
Specialty Diagnostics
1,024 1,280 1,368 
Laboratory Products and Biopharma Services
2,872 1,844 1,271 
Subtotal reportable segments
10,985 12,138 9,556 
Cost of revenues adjustments
(46)(8)(6)
Selling, general and administrative expenses adjustments
(37)(144)10 
Restructuring and other costs
(114)(197)(99)
Amortization of acquisition-related intangible assets
(2,395)(1,761)(1,667)
Consolidated operating income
8,393 10,028 7,794 
Interest income272 43 65 
Interest expense(726)(536)(553)
Other income/(expense)
(104)(694)(76)
Consolidated income before taxes
$7,835 $8,841 $7,230 
Depreciation
Life Sciences Solutions
$214 $197 $140 
Analytical Instruments
83 83 76 
Specialty Diagnostics
75 128 100 
Laboratory Products and Biopharma Services
614 423 342 
Consolidated depreciation
$986 $831 $658 
Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of significant transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges/credits related to product liability litigation.
(In millions)202220212020
Total assets
Life Sciences Solutions
$21,848 $22,751 $20,209 
Analytical Instruments
10,019 9,692 9,773 
Specialty Diagnostics
5,542 6,010 6,534 
Laboratory Products and Biopharma Services
51,281 52,639 22,711 
Corporate/other (a)
8,464 4,031 9,825 
Consolidated total assets
$97,154 $95,123 $69,052 
Capital expenditures
Life Sciences Solutions
$490 $810 $392 
Analytical Instruments
140 79 74 
Specialty Diagnostics
112 167 175 
Laboratory Products and Biopharma Services
1,403 1,327 772 
Corporate/other
98 140 61 
Consolidated capital expenditures
$2,243 $2,523 $1,474 
(a)Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
Schedule of Revenue by Geographical Areas
Geographical Information
(In millions)202220212020
Revenues (b)
United States
$23,820 $18,907 $16,435 
China
3,793 3,444 2,797 
Other
17,302 16,860 12,986 
Consolidated revenues
$44,915 $39,211 $32,218 
Long-lived Assets (c)
United States
$6,308 $5,578 $3,686 
Other
4,565 4,286 3,001 
Consolidated long-lived assets
$10,873 $9,864 $6,687 
(b)Revenues are attributed to countries based on customer location.
(c)Includes property, plant and equipment, net, and operating lease ROU assets.
XML 50 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-based Compensation Expense (Tables)
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model
The weighted average assumptions used in the Black-Scholes option pricing model are as follows: 
202220212020
Expected stock price volatility
26 %26 %22 %
Risk free interest rate
2.0 %0.8 %1.1 %
Expected life of options (years)
4.74.34.3
Expected annual dividend
0.2 %0.2 %0.3 %
Summary of the Company's Option Activity A summary of the company’s option activity for the year ended December 31, 2022 is presented below:
Shares
(in millions)		Weighted average exercise priceWeighted average remaining contractual term
(in years)		Aggregate intrinsic
value
(in millions)
Outstanding at December 31, 2021
6.0 $319.95 
Granted
0.8 530.48 
Exercised
(0.9)199.85 
Canceled/expired
(0.3)503.76 
Outstanding at December 31, 2022
5.6 $359.27 4.2$1,125 
Vested and unvested expected to vest at December 31, 2022
5.3 $351.97 4.7$1,114 
Exercisable at December 31, 2022
2.9 $251.44 2.8$891 
Summary of the Company's Restricted Unit Activity A summary of the company’s restricted unit activity for the year ended December 31, 2022 is presented below:
 Units
(in millions)		Weighted
average
grant-date
fair value
Unvested at December 31, 2021
0.8 $425.39 
Granted
0.4 520.83 
Vested
(0.4)375.77 
Forfeited
(0.1)510.37 
Unvested at December 31, 2022
0.7 $495.39 
XML 51 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans (Tables)
 12 Months Ended
Dec. 31, 2022
Retirement Benefits [Abstract]  
Reconciliation of Benefit Obligations and Plan Assets The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans:
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)2022202120222021
Accumulated benefit obligation
$995 $1,260 $1,016 $1,475 
Change in projected benefit obligations
Projected benefit obligation at beginning of year
$1,260 $1,302 $1,552 $1,486 
Acquisitions
— — 51 170 
Service costs
— — 34 27 
Interest costs
27 23 20 11 
Settlements
— — (31)(7)
Plan participants' contributions
— — 9 6 
Actuarial (gains) losses
(210)20 (447)(57)
Benefits paid
(82)(85)(19)(30)
Currency translation and other
— — (100)(54)
Projected benefit obligation at end of year
$995 $1,260 $1,069 $1,552 
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)2022202120222021
Change in fair value of plan assets
Fair value of plan assets at beginning of year
$1,226 $1,267 $1,302 $1,160 
Acquisitions— — 14 158 
Actual return on plan assets
(212)37 (347)14 
Employer contributions
5 7 36 27 
Settlements
— — (31)(7)
Plan participants' contributions
— — 9 6 
Benefits paid
(82)(85)(19)(30)
Currency translation and other
— — (96)(26)
Fair value of plan assets at end of year$937 $1,226 $868 $1,302 
Funded status
$(58)$(34)$(201)$(250)
Amounts recognized in balance sheet
Noncurrent assets
$— $32 $81 $205 
Current liability
(6)(7)(11)(10)
Noncurrent liabilities
(52)(59)(271)(445)
Net amount recognized
$(58)$(34)$(201)$(250)
Amounts recognized in accumulated other comprehensive items
Net actuarial loss
$200 $157 $74 $167 
Prior service credits
— — (4)(3)
Net amount recognized
$200 $157 $70 $164 
Schedule of Actuarial Assumptions The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2022 and 2021 and are as follows:
 Domestic pension benefitsNon-U.S. pension benefits
 2022202120222021
Weighted average assumptions used to determine projected benefit obligations
Discount rate for determining benefit obligation
5.01 %2.70 %3.91 %1.45 %
Interest crediting rate for cash balance plans
4.96 %2.58 %2.19 %1.25 %
Average rate of increase in employee compensation
N/AN/A2.78 %2.73 %
The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year, as presented in the following table:
 Domestic pension benefitsNon-U.S. pension benefits
 202220212020202220212020
Weighted average assumptions used to determine net benefit cost (income)
Discount rate - service cost
N/AN/AN/A1.00 %0.65 %1.21 %
Discount rate - interest cost
2.70 %2.33 %3.13 %1.36 %0.80 %1.44 %
Average rate of increase in employee compensation
N/AN/AN/A2.73 %2.30 %2.27 %
Expected long-term rate of return on assets
4.75 %4.25 %5.00 %2.33 %2.02 %2.33 %
Projected Benefit Obligation and Fair Value of Plan Assets The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows:
 Pension plans
(In millions)20222021
Pension plans with projected benefit obligations in excess of plan assets
Projected benefit obligation
$1,636 $2,010 
Fair value of plan assets
1,296 1,521 
Accumulated Benefit Obligation and Fair Value of Plan Assets The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows:
 Pension plans
(In millions)20222021
Pension plans with accumulated benefit obligations in excess of plan assets
Accumulated benefit obligation
$1,583 $1,937 
Fair value of plan assets
1,294 1,521 
Schedule of Net Benefit Costs The net periodic pension benefit cost (income) includes the following components:
 Domestic pension benefitsNon-U.S. pension benefits
(In millions)202220212020202220212020
Components of net benefit cost (income)
Service cost
$— $— $— $34 $27 $24 
Interest cost on benefit obligation
27 23 35 20 11 18 
Expected return on plan assets
(45)(40)(47)(26)(19)(19)
Amortization of actuarial net loss
4 7 6 7 12 10 
Amortization of prior service benefit
— — — (1)— (1)
Settlement/curtailment loss
— — — (2)— 8 
Net periodic benefit cost (income)
$(14)$(10)$(6)$32 $31 $40 
Schedule of Estimated Future Benefit Payments Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows:
(In millions)Domestic pension benefitsNon-U.S. pension benefits
Expected benefit payments
2023 $85 $47 
2024 81 48 
2025 81 51 
2026 80 55 
2027 79 55 
2028-2032373 313 
Schedule of Fair Value of the Company's Plan Assets
The fair values of the company’s plan assets at December 31, 2022 and 2021, by asset category are as follows:
 December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs		Not subject to leveling (a)
(In millions)2022(Level 1)(Level 2)(Level 3)
Domestic pension plan assets
U.S. equity funds
$89 $— $— $— $89 
International equity funds
91 — — — 91 
Fixed income funds
739 — — — 739 
Money market funds
18 — — — 18 
Total domestic pension plans
$937 $— $— $— $937 
Non-U.S. pension plan assets
Equity funds
$8 $— $— $— $8 
Fixed income funds
299 — — — 299 
Multi-asset funds
56 — — — 56 
Derivative funds
190 — — — 190 
Insurance contracts
306 — 306 — — 
Cash / money market funds
9 4 — — 5 
Total non-U.S. pension plans
$868 $4 $306 $— $558 
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
 December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs		Not subject to leveling (a)
(In millions)2021(Level 1)(Level 2)(Level 3)
Domestic pension plan assets
U.S. equity funds
$124 $— $— $— $124 
International equity funds
117 — — — 117 
Fixed income funds
966 — — — 966 
Money market funds
19 — — — 19 
Total domestic pension plans$1,226 $— $— $— $1,226 
Non-U.S. pension plan assets
Equity funds
$17 $— $— $— $17 
Fixed income funds
651 — — — 651 
Hedge funds
3 — — — 3 
Multi-asset funds
73 — — — 73 
Derivative funds
253 — — — 253 
Alternative investments
1 — — — 1 
Insurance contracts
295 — 295 — — 
Cash / money market funds
9 5 — — 4 
Total non-U.S. pension plans$1,302 $5 $295 $— $1,002 
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
XML 52 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Components of Income Before Provision for Income Taxes The components of income before provision for income taxes are as follows:
(In millions)202220212020
U.S.$3,859 $3,340 $4,762 
Non-U.S.3,976 5,501 2,468 
Income before income taxes
$7,835 $8,841 $7,230 
Components of the Provision for Income Taxes The components of the provision for income taxes are as follows:
(In millions)202220212020
Current income tax provision
Federal$813 $446 $521 
Non-U.S.633 1,148 423 
State254 160 175 
1,700 1,754 1,119 
Deferred income tax provision (benefit)
Federal$(611)$(227)$(237)
Non-U.S.(314)(399)(18)
State(72)(19)(14)
 (997)(645)(269)
Provision for income taxes
$703 $1,109 $850 
Schedule of Effective Income Tax Rate Reconciliation The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following:
(In millions)202220212020
Statutory federal income tax rate
21 %21 %21 %
Provision for income taxes at statutory rate
$1,645 $1,857 $1,518 
Increases (decreases) resulting from:
Foreign rate differential
(329)(255)(223)
Income tax credits
(202)(315)(335)
Global intangible low-taxed income
96 76 86 
Foreign-derived intangible income
(149)(119)(156)
Excess tax benefits from stock options and restricted stock units
(80)(124)(114)
Provision for (reversal of) tax reserves, net
(544)(17)(26)
Intra-entity transfers
(18)(284)— 
Domestication transaction— — (263)
Valuation allowances
344 36 379 
Withholding taxes
84 164 115 
Tax return reassessments and settlements
(210)1 (196)
State income taxes, net of federal tax111 82 147 
Other, net
(45)7 (82)
Provision for income taxes
$703 $1,109 $850 
Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance
Net deferred tax asset (liability) in the accompanying balance sheet consists of the following:
(In millions)20222021
Deferred tax asset (liability)
Depreciation and amortization
$(4,277)$(4,687)
Net operating loss and credit carryforwards
1,951 1,652 
Reserves and accruals
140 162 
Accrued compensation
259 318 
Inventory basis difference
364 181 
Deferred interest445 295 
Research and development and other capitalized costs
220 — 
Unrealized (gains) losses on hedging instruments
(199)(33)
Other, net
435 251 
Deferred tax liabilities, net before valuation allowance
(662)(1,861)
Less: Valuation allowance
1,322 968 
Deferred tax liabilities, net
$(1,984)$(2,829)
The company estimates the degree to which tax assets and loss and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2022, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense.
The changes in the valuation allowance are as follows:
 Year Ended December 31,
(In millions)202220212020
Beginning balance
$968 $933 $408 
Additions (reductions) charged to income tax provision, net
344 24 514 
Additions due to acquisitions
14 30 — 
Currency translation and other
(4)(19)11 
Ending balance$1,322 $968 $933 
Reconciliation of Unrecognized Tax Benefits A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:
(In millions)202220212020
Beginning balance
$1,124 $1,091 $1,552 
Additions due to acquisitions
15 26 — 
Additions for tax positions of current year
104 32 8 
Additions for tax positions of prior years
24 60 — 
Reductions for tax positions of prior years
(659)(5)(296)
Closure of tax years
(4)(27)— 
Settlements
(32)(53)(173)
Ending balance
$572 $1,124 $1,091 
XML 53 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Earnings Per Share (Tables)
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
(In millions except per share amounts)202220212020
Net income attributable to Thermo Fisher Scientific Inc.
$6,950 $7,725 $6,375 
Basic weighted average shares
392 394 396 
Plus effect of: stock options and restricted stock units
2 3 3 
Diluted weighted average shares
394 397 399 
Basic earnings per share
$17.75 $19.62 $16.09 
Diluted earnings per share
$17.63 $19.46 $15.96 
Antidilutive stock options excluded from diluted weighted average shares
2 1 1 
XML 54 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Debt and Other Financing Arrangements (Tables)
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Schedule of Debt
Effective interest rate at December 31,December 31,December 31,
(Dollars in millions)202220222021
Commercial Paper2.60 %$310 $2,522 
Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023
1,000 1,000 
Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023
500 500 
0.797% 2-Year Senior Notes, Due 10/18/2023
1.03 %1,350 1,350 
Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
1.85 %1,819 1,933 
0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)
0.06 %589 625 
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
0.93 %1,071 1,137 
Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024
500 500 
1.215% 3-Year Senior Notes, Due 10/18/2024
1.42 %2,500 2,500 
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
0.40 %857 910 
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
2.09 %686 728 
0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated)
1.05 %170 — 
0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)
0.15 %589 625 
3.65% 10-Year Senior Notes, Due 12/15/2025
— 350 
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)
3.38 %535 — 
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
1.52 %749 796 
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
1.65 %535 568 
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
1.96 %642 682 
1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)
1.18 %221 — 
4.80% 5-Year Senior Notes, Due 11/21/2027
5.00 %600 — 
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
0.77 %857 910 
Effective interest rate at December 31,December 31,December 31,
(Dollars in millions)202220222021
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
1.46 %642 682 
1.750% 7-Year Senior Notes, Due 10/15/2028
1.89 %700 700 
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
2.07 %749 796 
2.60% 10-Year Senior Notes, Due 10/1/2029
2.74 %900 900 
1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)
1.44 %36 — 
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)
0.88 %1,873 1,990 
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
1.13 %963 1,023 
2.00% 10-Year Senior Notes, Due 10/15/2031
2.23 %1,200 1,200 
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
2.54 %642 682 
1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)
1.60 %48 — 
4.95% 10-Year Senior Notes, Due 11/21/2032
5.09 %600 — 
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)
1.20 %1,606 1,706 
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)
3.76 %803 — 
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
2.94 %749 796 
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
1.73 %963 1,023 
2.80% 20-Year Senior Notes, Due 10/15/2041
2.90 %1,200 1,200 
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)
1.77 %1,339 1,421 
2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)
2.13 %111 — 
5.30% 30-Year Senior Notes, Due 2/1/2044
5.37 %400 400 
4.10% 30-Year Senior Notes, Due 8/15/2047
4.23 %750 750 
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
1.98 %1,071 1,137 
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)
2.06 %803 853 
2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)
2.43 %254 — 
Other 79 76 
Total borrowings at par value
34,561 34,971 
Unamortized discount
(112)(117)
Unamortized debt issuance costs
(171)(184)
Total borrowings at carrying value
34,278 34,670 
Finance lease liabilities
210 200 
Less: Short-term obligations and current maturities
5,579 2,537 
Long-term obligations$28,909 $32,333 
SOFR - Secured Overnight Financing Rate
EURIBOR - Euro Interbank Offered Rate
Schedule of Annual Repayment Requirements for Debt Obligations As of December 31, 2022, the annual repayment requirements for debt obligations are as follows:
(In millions)BorrowingsFinance Lease Liabilities
2023 $5,583 $11 
2024 4,071 16 
2025 2,298 12 
2026 1,285 11 
2027 1,999 10 
2028 and thereafter19,325 150 
$34,561 $210 
XML 55 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Leases (Tables)
 12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Schedule of Operating Leases
As a lessee, the consolidated financial statements include the following relating to operating leases:
(Dollars in millions)202220212020
Statement of income
Operating lease costs
$351 $254 $224 
Variable lease costs
109 66 49 
Statement of cash flows
Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities$289 $288 $222 
Operating lease ROU assets obtained in exchange for new operating lease liabilities430 293 202 
Balance sheet
ROU assets$1,593 $1,531 
Operating lease liabilities - current272 266 
Operating lease liabilities - noncurrent1,313 1,203 
Weighted average at end of year
Remaining operating lease term9.4 years9.9 years
Discount rate3.2 %2.6 %
ROU assets are classified in other assets in the consolidated balance sheet. Operating lease liabilities are classified in other accrued expenses and other long-term liabilities, respectively, in the consolidated balance sheet.
Schedule of Future Payments of Operating Lease Liabilities As of December 31, 2022, future payments of operating lease liabilities are as follows:
(In millions)
2023 $321 
2024 293 
2025 220 
2026 172 
2027 136 
2028 and thereafter730 
Total lease payments1,872 
Less: imputed interest
287 
Total operating lease liability$1,585 
XML 56 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Comprehensive Income and Shareholders Equity (Tables)
 12 Months Ended
Dec. 31, 2022
Stockholders' Equity Note [Abstract]  
Schedule of Change in Each Component of Accumulated Other Comprehensive Items Changes in each component of accumulated other comprehensive items, net of tax are as follows:
(In millions)Currency
translation
adjustment		Unrealized
losses on
hedging
instruments		Pension and
other
postretirement
benefit
liability
adjustment		Total
Balance at December 31, 2021$(2,065)$(35)$(229)$(2,329)
Other comprehensive items before reclassifications
(822)— 38 (784)
Amounts reclassified from accumulated other comprehensive items
7 2 5 14 
Net other comprehensive items
(815)2 43 (770)
Balance at December 31, 2022$(2,880)$(33)$(186)$(3,099)
XML 57 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements and Fair Value of Financial Instruments (Tables)
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Measured at Fair Value
The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:
December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs
(In millions)2022(Level 1)(Level 2)(Level 3)
Assets
Cash equivalents
$5,804 $5,804 $— $— 
Investments
25 25 — — 
Warrants
12 — 12 — 
Insurance contracts
162 — 162 — 
Derivative contracts
79 — 79 — 
Total assets
$6,082 $5,829 $253 $— 
Liabilities
Derivative contracts
$101 $— $101 $— 
Contingent consideration
174 — — 174 
Total liabilities
$275 $— $101 $174 
December 31,Quoted
prices in
active
markets		Significant
other
observable
inputs		Significant
unobservable
inputs
(In millions)2021(Level 1)(Level 2)(Level 3)
Assets
Cash equivalents
$2,210 $2,210 $— $— 
Investments
298 298 — — 
Warrants
15 — 15 — 
Insurance contracts
181 — 181 — 
Derivative contracts
36 — 36 — 
Total assets
$2,740 $2,508 $232 $— 
Liabilities
Derivative contracts
$1 $— $1 $— 
Contingent consideration
317 — — 317 
Total liabilities
$318 $— $1 $317 
Rollforward of the Fair Value of Investments The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration.
(In millions)20222021
Contingent consideration
Beginning balance
$317 $70 
Acquisitions (including assumed balances)
(18)403 
Payments
(66)(109)
Changes in fair value included in earnings
(59)(47)
Ending balance
$174 $317 
Schedule of Aggregate Notional Value of Outstanding Derivative Contracts The following table provides the aggregate notional value of outstanding derivative contracts.
December 31,December 31,
(In millions)20222021
Notional amount
Cross-currency interest rate swaps - designated as net investment hedges
$2,100 $900 
Currency exchange contracts
2,434 2,149 
Schedule of Fair Value of Derivative Instruments
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheet and statement of income.
 Fair value – assetsFair value – liabilities
 December 31,December 31,December 31,December 31,
(In millions)2022202120222021
Derivatives designated as hedging instruments
Cross-currency interest rate swaps (a)
$77 $25 $85 $— 
Derivatives not designated as hedging instruments
Currency exchange contracts (b)
2 11 16 1 
Total derivatives
$79 $36 $101 $1 
(a)The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities.
(b)The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.
Schedule of Derivative Instruments, Gain (Loss) Recognized
 Gain (loss) recognized
(In millions)20222021
Fair value hedging relationships
Cross-currency interest rate swaps
Hedged long-term obligations - included in other income/(expense)
$77 $— 
Derivatives designated as hedging instruments - included in other income/(expense)
(81)— 
Interest rate swaps
Hedged long-term obligations - included in other income/(expense)
— 25 
Derivatives designated as hedging instruments - included in other income/(expense)
— (3)
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to other income/(expense)
(3)(73)
 Gain (loss) recognized
(In millions)20222021
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in currency translation adjustment within other comprehensive items
695 922 
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive items
52 71 
Included in other income/(expense)
19 8 
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues
6 12 
Included in other income/(expense)
102 162 
Schedule of Carrying Value and Fair Value of the Company's Debt Instruments The carrying value and fair value of the company’s debt instruments are as follows:
December 31, 2022December 31, 2021
CarryingFairCarryingFair
(In millions)valuevaluevaluevalue
Senior notes
$33,889 $29,901 $32,072 $33,449 
Commercial paper
310 310 2,522 2,522 
Other
79 79 76 76 
$34,278 $30,290 $34,670 $36,047 
The fair value of debt instruments was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.
XML 58 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Supplemental Cash Flow Information (Tables)
 12 Months Ended
Dec. 31, 2022
Supplemental Cash Flow Information [Abstract]  
Schedule of Supplemental Cash Flow Disclosures
(In millions)202220212020
Cash paid for:
Interest
$667 $555 $471 
Income taxes
1,234 2,182 1,324 
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment
393 379 347 
Fair value of equity awards exchanged— 43 — 
Fair value of acquisition contingent consideration— 183 — 
Finance lease ROU assets obtained in exchange for new finance lease liabilities33 15 5 
Declared but unpaid dividends
119 104 89 
Issuance of stock upon vesting of restricted stock units
241 265 217 
Schedule of Cash, Cash Equivalents and Restricted Cash Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:
 December 31,December 31,
(In millions)20222021
Cash and cash equivalents$8,524 $4,477 
Restricted cash included in other current assets12 13 
Restricted cash included in other assets1 1 
Cash, cash equivalents and restricted cash$8,537 $4,491 
XML 59 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring and Other Costs (Tables)
 12 Months Ended
Dec. 31, 2022
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring and Other Costs by Segment Restructuring and other costs by segment are as follows:
(In millions)202220212020
Life Sciences Solutions
$30 $129 $34 
Analytical Instruments
1 6 26 
Specialty Diagnostics
68 18 9 
Laboratory Products and Biopharma Services
12 35 23 
Corporate
3 9 7 
$114 $197 $99 
Schedule of the Company's Accrued Restructuring Balance
The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.
(In millions)Total (a)
Balance at December 31, 2019$34 
Net restructuring charges incurred in 2020 (b)
51 
Payments
(57)
Currency translation
(7)
Balance at December 31, 202021 
Net restructuring charges incurred in 2021 (c)
37 
Payments
(40)
Currency translation
(1)
Balance at December 31, 202117 
Net restructuring charges incurred in 2022 (d)
68 
Payments
(44)
Balance at December 31, 2022$41 
(a)The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.
(b)Excludes $48 million of charges, principally $32 million for impairment of acquired technology in the Life Sciences Solutions segment resulting from a reduction in expected cash flows and, to a lesser extent, charges across the company’s segments for fixed asset writedowns and costs associated with environmental remediation at abandoned/previously owned facilities.
(c)Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segment, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
(d)Excludes $46 million of net charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.
XML 60 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Noncontrolling Interest [Line Items]      
Equity method investments $ 369 $ 576  
Fair value of investments 7 217  
Cost method investments 55 22  
Investments measured at NAV 22 16  
Currency transaction gains $ 62 $ 25 $ 24
PPD-SNBL K.K.      
Noncontrolling Interest [Line Items]      
Ownership percentage, parent 60.00%    
Ownership interest, noncontrolling owners 40.00%    
XML 61 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of Operations and Summary of Significant Accounting Policies - Inventories (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Oct. 02, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Raw materials   $ 2,405 $ 1,922    
Work in process   660 676    
Finished goods   2,569 2,453    
Inventories   5,634 5,051    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Inventories   5,634 5,051    
Product revenues          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cost of goods and services sold   $ (14,247) $ (13,594) $ (11,407)  
Change in Accounting Principle, Other          
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Inventories $ 33        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Percentage of LIFO inventory         5.00%
Inventories 33        
Change in Accounting Principle, Other | Product revenues          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cost of goods and services sold 33        
Change in Accounting Principle, Other | Laboratory Products and Biopharma Services          
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Inventories 20        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Inventories 20        
Change in Accounting Principle, Other | Laboratory Products and Biopharma Services | Product revenues          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cost of goods and services sold 20        
Change in Accounting Principle, Other | Specialty Diagnostics          
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Inventories 13        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Inventories 13        
Change in Accounting Principle, Other | Specialty Diagnostics | Product revenues          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cost of goods and services sold $ 13        
XML 62 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, at cost $ 14,269 $ 12,593
Less: Accumulated depreciation and amortization 4,989 4,260
Property, plant and equipment, net 9,280 8,333
Land    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, at cost 454 431
Buildings and improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, at cost $ 3,153 2,575
Buildings and improvements | Minimum    
Property, Plant and Equipment [Line Items]    
Useful lives 25 years  
Buildings and improvements | Maximum    
Property, Plant and Equipment [Line Items]    
Useful lives 40 years  
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, at cost $ 2,695 2,567
Machinery, equipment and leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, at cost $ 7,967 $ 7,020
Machinery and Equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Useful lives 3 years  
Machinery and Equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Useful lives 10 years  
XML 63 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Intangible Assets [Line Items]    
Definite-lived intangible assets, gross $ 30,347 $ 31,625
Accumulated Amortization (14,140) (12,747)
Estimated future amortization expense of definite-lived intangible assets 16,207 18,878
Acquisition-related intangible assets 31,582 32,860
Acquisition-related intangible assets 17,442 20,113
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]    
2023  2,279  
2024  1,863  
2025  1,582  
2026  1,322  
2027  1,296  
2028 and thereafter 7,865  
Estimated future amortization expense of definite-lived intangible assets 16,207 18,878
Other intangible assets $ 36 33
Maximum    
Intangible Assets [Line Items]    
Estimated useful life 20 years  
Tradenames    
Intangible Assets [Line Items]    
Indefinite-lived intangible assets $ 1,235 1,235
Customer relationships    
Intangible Assets [Line Items]    
Definite-lived intangible assets, gross 21,792 22,802
Accumulated Amortization (8,330) (7,792)
Estimated future amortization expense of definite-lived intangible assets 13,462 15,010
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]    
Estimated future amortization expense of definite-lived intangible assets 13,462 15,010
Product technology    
Intangible Assets [Line Items]    
Definite-lived intangible assets, gross 5,882 6,041
Accumulated Amortization (4,360) (3,977)
Estimated future amortization expense of definite-lived intangible assets 1,522 2,064
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]    
Estimated future amortization expense of definite-lived intangible assets 1,522 2,064
Tradenames    
Intangible Assets [Line Items]    
Definite-lived intangible assets, gross 1,635 1,722
Accumulated Amortization (1,008) (919)
Estimated future amortization expense of definite-lived intangible assets 627 803
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]    
Estimated future amortization expense of definite-lived intangible assets 627 803
Backlog    
Intangible Assets [Line Items]    
Definite-lived intangible assets, gross 1,038 1,060
Accumulated Amortization (442) (59)
Estimated future amortization expense of definite-lived intangible assets 596 1,001
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]    
Estimated future amortization expense of definite-lived intangible assets $ 596 $ 1,001
XML 64 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of Operations and Summary of Significant Accounting Policies - Goodwill (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Goodwill [Roll Forward]    
Beginning balance $ 41,924 $ 26,041
Acquisitions 24 16,024
Finalization of purchase price allocations for 2021 acquisitions 177  
Currency translation (929) (141)
Ending balance 41,196 41,924
Life Sciences Solutions    
Goodwill [Roll Forward]    
Beginning balance 10,143 8,590
Acquisitions 0 1,560
Finalization of purchase price allocations for 2021 acquisitions 9  
Currency translation (6) (7)
Ending balance 10,146 10,143
Analytical Instruments    
Goodwill [Roll Forward]    
Beginning balance 5,043 5,079
Acquisitions 24 56
Finalization of purchase price allocations for 2021 acquisitions 0  
Currency translation (102) (92)
Ending balance 4,965 5,043
Specialty Diagnostics    
Goodwill [Roll Forward]    
Beginning balance 3,277 3,370
Acquisitions 0 8
Finalization of purchase price allocations for 2021 acquisitions 0  
Currency translation (186) (101)
Ending balance 3,091 3,277
Laboratory Products and Biopharma Services    
Goodwill [Roll Forward]    
Beginning balance 23,461 9,002
Acquisitions 0 14,400
Finalization of purchase price allocations for 2021 acquisitions 168  
Currency translation (635) 59
Ending balance $ 22,994 $ 23,461
XML 65 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of Operations and Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Jan. 01, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Accounts receivable $ 8,115 $ 7,977  
Retained earnings $ 41,910 $ 35,431  
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2016-13      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Accounts receivable     $ (1)
Retained earnings     $ (1)
XML 66 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 03, 2023
Dec. 31, 2021
Dec. 31, 2020
Dec. 30, 2021
Dec. 08, 2021
Sep. 30, 2021
Feb. 25, 2021
Jan. 15, 2021
Business Acquisition [Line Items]                
Weighted-average amortization period   14 years            
The Binding Site Group | Subsequent Event                
Business Acquisition [Line Items]                
Weighted-average amortization period 17 years              
European Viral Vector Business                
Business Acquisition [Line Items]                
Goodwill recorded               $ 0
Mesa Biotech                
Business Acquisition [Line Items]                
Goodwill recorded             $ 0  
Lengnau biologics manufacturing facility                
Business Acquisition [Line Items]                
Goodwill recorded           $ 0    
PPD                
Business Acquisition [Line Items]                
Goodwill recorded         $ 0      
Net income attributable to Thermo Fisher Scientific Inc.   $ 7,369 $ 5,361          
Pro forma revenues   378            
Pro forma losses   (60)            
PPD | Non-recurring Pro Forma Adjustments, Transaction Costs                
Business Acquisition [Line Items]                
Net income attributable to Thermo Fisher Scientific Inc.   $ 312 $ (197)          
PeproTech                
Business Acquisition [Line Items]                
Goodwill recorded       $ 0        
Customer relationships                
Business Acquisition [Line Items]                
Weighted-average amortization period   17 years            
Product technology                
Business Acquisition [Line Items]                
Weighted-average amortization period   11 years            
Tradenames                
Business Acquisition [Line Items]                
Weighted-average amortization period   7 years            
Backlog                
Business Acquisition [Line Items]                
Weighted-average amortization period   3 years            
XML 67 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions - Schedule of Components of Purchase Price (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 03, 2023
Dec. 30, 2021
Dec. 08, 2021
Sep. 30, 2021
Feb. 25, 2021
Jan. 15, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Purchase Price                  
Fair value of equity awards exchanged             $ 0 $ 43,000 $ 0
Fair value of contingent consideration             $ 0 183,000 $ 0
The Binding Site Group | Subsequent Event                  
Purchase Price                  
Cash paid $ 2,420,000                
Debt settled 310,000                
Cash acquired 20,000                
Total purchase price 2,710,000                
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets: 1,070,000                
Goodwill 1,770,000                
Net tangible assets 150,000                
Deferred tax assets (liabilities) (280,000)                
Total net assets acquired $ 2,710,000                
PPD                  
Purchase Price                  
Cash paid     $ 17,237,000            
Fair value of equity awards exchanged     43,000            
Fair value of contingent consideration     0            
Cash acquired     (1,244,000)            
Total purchase price     16,036,000            
Net Assets Acquired [Abstract]                  
Current assets     2,477,000            
Property, plant and equipment     527,000            
Goodwill     13,949,000            
Other assets     1,060,000            
Contract liabilities     (1,539,000)            
Deferred tax assets (liabilities)     (1,782,000)            
Finance lease liabilities     (90,000)            
Debt assumed     (4,299,000)            
Other liabilities assumed     (2,034,000)            
Redeemable noncontrolling interest     (122,000)            
Total net assets acquired     16,036,000            
PPD | Customer relationships                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:     6,257,000            
PPD | Product technology                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:     0            
PPD | Tradenames                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:     594,000            
PPD | Backlog                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:     $ 1,038,000            
PeproTech                  
Purchase Price                  
Cash paid   $ 1,946,000              
Fair value of contingent consideration   0              
Cash acquired   (83,000)              
Total purchase price   1,863,000              
Net Assets Acquired [Abstract]                  
Current assets   58,000              
Property, plant and equipment   18,000              
Goodwill   1,198,000              
Other assets   11,000              
Contract liabilities   0              
Deferred tax assets (liabilities)   (192,000)              
Finance lease liabilities   0              
Debt assumed   0              
Other liabilities assumed   (22,000)              
Total net assets acquired   1,863,000              
PeproTech | Customer relationships                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:   510,000              
PeproTech | Product technology                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:   282,000              
PeproTech | Tradenames                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:   $ 0              
European Viral Vector Business                  
Purchase Price                  
Cash paid           $ 848,000      
Fair value of contingent consideration           0      
Cash acquired           (18,000)      
Total purchase price           830,000      
Net Assets Acquired [Abstract]                  
Current assets           39,000      
Property, plant and equipment           59,000      
Goodwill           600,000      
Other assets           3,000      
Contract liabilities           (59,000)      
Deferred tax assets (liabilities)           (80,000)      
Finance lease liabilities           (24,000)      
Debt assumed           0      
Other liabilities assumed           (35,000)      
Total net assets acquired           830,000      
European Viral Vector Business | Customer relationships                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:           302,000      
European Viral Vector Business | Product technology                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:           25,000      
European Viral Vector Business | Tradenames                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:           $ 0      
Mesa Biotech                  
Purchase Price                  
Cash paid         $ 421,000        
Fair value of contingent consideration         65,000        
Cash acquired         (14,000)        
Total purchase price         472,000        
Net Assets Acquired [Abstract]                  
Current assets         54,000        
Property, plant and equipment         2,000        
Goodwill         237,000        
Other assets         3,000        
Contract liabilities         0        
Deferred tax assets (liabilities)         (72,000)        
Finance lease liabilities         0        
Debt assumed         0        
Other liabilities assumed         (33,000)        
Total net assets acquired         472,000        
Mesa Biotech | Customer relationships                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:         0        
Mesa Biotech | Product technology                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:         279,000        
Mesa Biotech | Tradenames                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:         $ 2,000        
Lengnau biologics manufacturing facility                  
Purchase Price                  
Cash paid       $ 17,000          
Fair value of contingent consideration       1,000          
Cash acquired       0          
Total purchase price       18,000          
Net Assets Acquired [Abstract]                  
Current assets       0          
Property, plant and equipment       93,000          
Goodwill       18,000          
Other assets       364,000          
Contract liabilities       0          
Deferred tax assets (liabilities)       0          
Finance lease liabilities       (82,000)          
Debt assumed       0          
Other liabilities assumed       (375,000)          
Total net assets acquired       18,000          
Lengnau biologics manufacturing facility | Customer relationships                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:       0          
Lengnau biologics manufacturing facility | Product technology                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:       0          
Lengnau biologics manufacturing facility | Tradenames                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:       $ 0          
Other                  
Purchase Price                  
Cash paid               298,000  
Fair value of contingent consideration               117,000  
Cash acquired               (12,000)  
Total purchase price               403,000  
Net Assets Acquired [Abstract]                  
Current assets               12,000  
Property, plant and equipment               2,000  
Goodwill               198,000  
Other assets               2,000  
Contract liabilities               (1,000)  
Deferred tax assets (liabilities)               (27,000)  
Finance lease liabilities               0  
Debt assumed               0  
Other liabilities assumed               (11,000)  
Total net assets acquired               403,000  
Other | Customer relationships                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:               2,000  
Other | Product technology                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:               224,000  
Other | Tradenames                  
Net Assets Acquired [Abstract]                  
Definite-lived intangible assets:               $ 2,000  
XML 68 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions - Schedule of Pro Forma Information (Details) - PPD - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Business Acquisition, Pro Forma Information [Abstract]    
Revenues $ 44,886 $ 36,887
Net income attributable to Thermo Fisher Scientific Inc. $ 7,369 $ 5,361
XML 69 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue & Contract-related Balances - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]      
Revenues $ 44,915 $ 39,211 $ 32,218
North America      
Disaggregation of Revenue [Line Items]      
Revenues 24,594 19,659 17,081
Europe      
Disaggregation of Revenue [Line Items]      
Revenues 10,762 11,134 8,284
Asia-Pacific      
Disaggregation of Revenue [Line Items]      
Revenues 8,115 7,218 5,822
Other regions      
Disaggregation of Revenue [Line Items]      
Revenues 1,444 1,200 1,031
Consumables      
Disaggregation of Revenue [Line Items]      
Revenues 20,624 22,608 18,527
Instruments      
Disaggregation of Revenue [Line Items]      
Revenues 7,924 7,753 6,779
Service revenues      
Disaggregation of Revenue [Line Items]      
Revenues $ 16,367 $ 8,850 $ 6,912
XML 70 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue & Contract-related Balances - Revenue Performance Obligations (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2022
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Transaction price allocated to remaining performance obligation $ 26,970
Revenue, Performance Obligation, Description of Timing Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligation percentage 55.00%
Expected timing of satisfaction of remaining performance obligation 12 months
XML 71 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue & Contract-related Balances - Contract Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]    
Contract assets, net $ 1,312 $ 968
Noncurrent contract assets, net 7 9
Contract liabilities 2,601 2,655
Noncurrent contract liabilities $ 1,179 $ 1,238
XML 72 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2022
USD ($)
Segment
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Segment Reporting Information [Line Items]      
Reportable segments | Segment 4    
Revenues $ 44,915 $ 39,211 $ 32,218
Subtotal reportable segments 8,393 10,028 7,794
Restructuring and other costs (114) (197) (99)
Amortization of acquisition-related intangible assets (2,395) (1,761) (1,667)
Consolidated operating income 8,393 10,028 7,794
Interest income 272 43 65
Interest expense (726) (536) (553)
Other income/(expense) (104) (694) (76)
Income before income taxes 7,835 8,841 7,230
Depreciation of property, plant and equipment 986 831 658
Total assets 97,154 95,123 69,052
Capital expenditures 2,243 2,523 1,474
Life Sciences Solutions      
Segment Reporting Information [Line Items]      
Restructuring and other costs (30) (129) (34)
Total assets 21,848 22,751 20,209
Capital expenditures 490 810 392
Analytical Instruments      
Segment Reporting Information [Line Items]      
Restructuring and other costs (1) (6) (26)
Total assets 10,019 9,692 9,773
Capital expenditures 140 79 74
Specialty Diagnostics      
Segment Reporting Information [Line Items]      
Restructuring and other costs (68) (18) (9)
Total assets 5,542 6,010 6,534
Capital expenditures 112 167 175
Laboratory Products and Biopharma Services      
Segment Reporting Information [Line Items]      
Restructuring and other costs (12) (35) (23)
Total assets 51,281 52,639 22,711
Capital expenditures 1,403 1,327 772
Corporate/other      
Segment Reporting Information [Line Items]      
Total assets [1] 8,464 4,031 9,825
Capital expenditures 98 140 61
Total Reportable Segments      
Segment Reporting Information [Line Items]      
Subtotal reportable segments 10,985 12,138 9,556
Consolidated operating income 10,985 12,138 9,556
Total Reportable Segments | Life Sciences Solutions      
Segment Reporting Information [Line Items]      
Revenues 13,532 15,631 12,168
Subtotal reportable segments 5,582 7,817 6,109
Consolidated operating income 5,582 7,817 6,109
Depreciation of property, plant and equipment 214 197 140
Total Reportable Segments | Analytical Instruments      
Segment Reporting Information [Line Items]      
Revenues 6,624 6,069 5,124
Subtotal reportable segments 1,507 1,197 808
Consolidated operating income 1,507 1,197 808
Depreciation of property, plant and equipment 83 83 76
Total Reportable Segments | Specialty Diagnostics      
Segment Reporting Information [Line Items]      
Revenues 4,763 5,659 5,343
Subtotal reportable segments 1,024 1,280 1,368
Consolidated operating income 1,024 1,280 1,368
Depreciation of property, plant and equipment 75 128 100
Total Reportable Segments | Laboratory Products and Biopharma Services      
Segment Reporting Information [Line Items]      
Revenues 22,511 14,862 12,245
Subtotal reportable segments 2,872 1,844 1,271
Consolidated operating income 2,872 1,844 1,271
Depreciation of property, plant and equipment 614 423 342
Intersegment Eliminations      
Segment Reporting Information [Line Items]      
Revenues (2,515) (3,010) (2,662)
Segment Reconciling Items      
Segment Reporting Information [Line Items]      
Cost of revenues adjustments (46) (8) (6)
Selling, general and administrative expenses adjustments (37) (144) 10
Restructuring and other costs (114) (197) (99)
Amortization of acquisition-related intangible assets $ (2,395) $ (1,761) $ (1,667)
[1] Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
XML 73 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Business Segment and Geographical Information - Schedule of Revenue by Geographical Areas (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenues $ 44,915 $ 39,211 $ 32,218
Long-lived Assets [1] 10,873 9,864 6,687
United States      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenues [2] 23,820 18,907 16,435
Long-lived Assets [1] 6,308 5,578 3,686
China      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenues [2] 3,793 3,444 2,797
Other      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenues [2] 17,302 16,860 12,986
Long-lived Assets [1] $ 4,565 $ 4,286 $ 3,001
[1] Includes property, plant and equipment, net, and operating lease ROU assets.
[2] Revenues are attributed to countries based on customer location.
XML 74 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Other Income/Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]      
Gain (loss) on investments $ (161) $ 66 $ 10
Net gains on derivative instruments 67    
Loss on early extinguishment of debt (26) (767) 0
Net settlement gains on pension plans $ 2    
Cash outlay   36 51
Financing costs     81
Interest rate swaps - fair value hedges | Cash Flow Hedging | Other Expense      
Schedule of Equity Method Investments [Line Items]      
Amount reclassified from accumulated other comprehensive items to other income/(expense)   $ 65 $ (42)
XML 75 R57.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-based Compensation Expense - Narrative (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted average grant date fair value (in dollars per share) $ 135.07 $ 123.97 $ 61.19
Total intrinsic value $ 336 $ 501 $ 457
Fair value of shares vested $ 163 $ 151 $ 126
Purchase price percentage 95.00%    
Payroll deductions 10.00%    
Shares issued under ESPP (shares) 0.2 0.1 0.2
Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation cost $ 228    
Weighted average amortization period 2 years 4 months 24 days    
Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation cost $ 200    
Weighted average amortization period 1 year 10 months 24 days    
Minimum | Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
Term 7 years    
Minimum | Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
Maximum | Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 5 years    
Term 10 years    
Maximum | Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 4 years    
XML 76 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]      
Expected stock price volatility 26.00% 26.00% 22.00%
Risk free interest rate 2.00% 0.80% 1.10%
Expected life of options (years) 4 years 8 months 12 days 4 years 3 months 18 days 4 years 3 months 18 days
Expected annual dividend 0.20% 0.20% 0.30%
XML 77 R59.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-based Compensation Expense - Summary of the Company's Option Activity (Details)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2022
USD ($)
$ / shares
shares
Options Outstanding [Roll Forward]  
Outstanding, beginning balance (shares) | shares 6.0
Granted (shares) | shares 0.8
Exercised (shares) | shares (0.9)
Canceled/expired (shares) | shares (0.3)
Outstanding, ending balance (shares) | shares 5.6
Vested and unvested expected to vest (shares) | shares 5.3
Exercisable (shares) | shares 2.9
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Outstanding, beginning of period (in dollars per share) | $ / shares $ 319.95
Granted (in dollars per share) | $ / shares 530.48
Exercised (in dollars per share) | $ / shares 199.85
Canceled/expired (in dollars per share) | $ / shares 503.76
Outstanding, end of period (in dollars per share) | $ / shares 359.27
Vested and unvested expected to vest (in dollars per share) | $ / shares 351.97
Exercisable (in dollars per share) | $ / shares $ 251.44
Options, Additional Disclosures [Abstract]  
Options outstanding, weighted average remaining contractual term 4 years 2 months 12 days
Options vested and expected to vest, weighted average remaining contractual term 4 years 8 months 12 days
Options exercisable, weighted average remaining contractual term 2 years 9 months 18 days
Options outstanding, aggregate intrinsic value | $ $ 1,125
Options vested and expected to vest, aggregate intrinsic value | $ 1,114
Options exercisable, aggregate intrinsic value | $ $ 891
XML 78 R60.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-based Compensation Expense - Summary of the Company's Restricted Unit Activity (Details)
shares in Millions
 12 Months Ended
Dec. 31, 2022
$ / shares
shares
Unvested Restricted Units [Roll Forward]  
Unvested, beginning balance (shares) | shares 0.8
Granted (shares) | shares 0.4
Vested (shares) | shares (0.4)
Forfeited (shares) | shares (0.1)
Unvested, ending balance (shares) | shares 0.7
Restricted Units, Additional Disclosures [Abstract]  
Unvested, weighted average grant-date fair value, beginning (in dollars per share) | $ / shares $ 425.39
Granted (in dollars per share) | $ / shares 520.83
Vested (in dollars per share) | $ / shares 375.77
Forfeited (in dollars per share) | $ / shares 510.37
Unvested, weighted average grant-date fair value, ending (in dollars per share) | $ / shares $ 495.39
Restricted Stock Units (RSUs) | Minimum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting period 3 years
Restricted Stock Units (RSUs) | Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting period 4 years
XML 79 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Pensions and Other Postretirement Benefit Plans - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]      
Defined contribution plan expense $ 402 $ 299 $ 254
Cash contributions to retirement plans $ 41 $ 34 $ 96
U.S. equity funds | United States | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 10.00%    
International equity funds | United States | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 10.00%    
Fixed income funds | United States | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 80.00%    
Minimum      
Defined Benefit Plan Disclosure [Line Items]      
Estimated contributions to plan $ 30    
Minimum | Fixed income funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 30.00%    
Minimum | Equity funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 0.00%    
Minimum | Multi-asset funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 0.00%    
Minimum | Derivative funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 0.00%    
Maximum      
Defined Benefit Plan Disclosure [Line Items]      
Estimated contributions to plan $ 50    
Maximum | Fixed income funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 90.00%    
Maximum | Equity funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 25.00%    
Maximum | Multi-asset funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 35.00%    
Maximum | Derivative funds | Foreign Plan | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Target allocations for investments 45.00%    
XML 80 R62.htm IDEA: XBRL DOCUMENT v3.22.4
Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
United States      
Defined Benefit Plan Disclosure [Line Items]      
Accumulated benefit obligation $ 995 $ 1,260  
Change in projected benefit obligations      
Projected benefit obligation at beginning of year 1,260 1,302  
Acquisitions 0 0  
Service costs 0 0 $ 0
Interest costs 27 23 35
Settlements 0 0  
Plan participants' contributions 0 0  
Actuarial (gains) losses (210) 20  
Benefits paid (82) (85)  
Currency translation and other 0 0  
Projected benefit obligation at end of year 995 1,260 1,302
Change in fair value of plan assets      
Fair value of plan assets at beginning of year 1,226 1,267  
Acquisitions 0 0  
Actual return on plan assets (212) 37  
Employer contributions 5 7  
Settlements 0 0  
Plan participants' contributions 0 0  
Benefits paid (82) (85)  
Currency translation and other 0 0  
Fair value of plan assets at end of year 937 1,226 1,267
Funded status (58) (34)  
Amounts recognized in balance sheet      
Noncurrent assets 0 32  
Current liability (6) (7)  
Noncurrent liabilities (52) (59)  
Net amount recognized (58) (34)  
Amounts recognized in accumulated other comprehensive items      
Net actuarial loss 200 157  
Prior service credits 0 0  
Net amount recognized 200 157  
Foreign Plan      
Defined Benefit Plan Disclosure [Line Items]      
Accumulated benefit obligation 1,016 1,475  
Change in projected benefit obligations      
Projected benefit obligation at beginning of year 1,552 1,486  
Acquisitions 51 170  
Service costs 34 27 24
Interest costs 20 11 18
Settlements (31) (7)  
Plan participants' contributions 9 6  
Actuarial (gains) losses (447) (57)  
Benefits paid (19) (30)  
Currency translation and other (100) (54)  
Projected benefit obligation at end of year 1,069 1,552 1,486
Change in fair value of plan assets      
Fair value of plan assets at beginning of year 1,302 1,160  
Acquisitions 14 158  
Actual return on plan assets (347) 14  
Employer contributions 36 27  
Settlements (31) (7)  
Plan participants' contributions 9 6  
Benefits paid (19) (30)  
Currency translation and other (96) (26)  
Fair value of plan assets at end of year 868 1,302 $ 1,160
Funded status (201) (250)  
Amounts recognized in balance sheet      
Noncurrent assets 81 205  
Current liability (11) (10)  
Noncurrent liabilities (271) (445)  
Net amount recognized (201) (250)  
Amounts recognized in accumulated other comprehensive items      
Net actuarial loss 74 167  
Prior service credits (4) (3)  
Net amount recognized $ 70 $ 164  
XML 81 R63.htm IDEA: XBRL DOCUMENT v3.22.4
Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Components of Net Periodic Benefit Cost (Income) [Abstract]      
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible List] Other income/(expense)    
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible List] Other income/(expense)    
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible List] Other income/(expense)    
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible List] Other income/(expense)    
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible List] Other income/(expense)    
Pension Plans, Defined Benefit | United States      
Weighted Average Assumptions Used to Determine Benefit Obligation [Abstract]      
Discount rate for determining benefit obligation 5.01% 2.70%  
Interest crediting rate for cash balance plans 4.96% 2.58%  
Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost (Income) [Abstract]      
Discount rate - interest cost 2.70% 2.33% 3.13%
Expected long-term rate of return on assets 4.75% 4.25% 5.00%
Components of Net Periodic Benefit Cost (Income) [Abstract]      
Service cost $ 0 $ 0 $ 0
Interest cost on benefit obligation 27 23 35
Expected return on plan assets (45) (40) (47)
Amortization of actuarial net loss 4 7 6
Amortization of prior service benefit 0 0 0
Settlement/curtailment loss 0 0 0
Net periodic benefit cost (income) $ (14) $ (10) $ (6)
Pension Plans, Defined Benefit | Foreign Plan      
Weighted Average Assumptions Used to Determine Benefit Obligation [Abstract]      
Discount rate for determining benefit obligation 3.91% 1.45%  
Interest crediting rate for cash balance plans 2.19% 1.25%  
Average rate of increase in employee compensation 2.78% 2.73%  
Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost (Income) [Abstract]      
Discount rate - service cost 1.00% 0.65% 1.21%
Discount rate - interest cost 1.36% 0.80% 1.44%
Average rate of increase in employee compensation 2.73% 2.30% 2.27%
Expected long-term rate of return on assets 2.33% 2.02% 2.33%
Components of Net Periodic Benefit Cost (Income) [Abstract]      
Service cost $ 34 $ 27 $ 24
Interest cost on benefit obligation 20 11 18
Expected return on plan assets (26) (19) (19)
Amortization of actuarial net loss 7 12 10
Amortization of prior service benefit (1) 0 (1)
Settlement/curtailment loss (2) 0 8
Net periodic benefit cost (income) $ 32 $ 31 $ 40
XML 82 R64.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Pension plans with projected benefit obligations in excess of plan assets    
Projected benefit obligation $ 1,636 $ 2,010
Fair value of plan assets 1,296 1,521
Pension Plans, Defined Benefit    
Defined Benefit Plan Disclosure [Line Items]    
Accumulated benefit obligation 1,583 1,937
Fair value of plan assets $ 1,294 $ 1,521
XML 83 R65.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details) - Pension Plans, Defined Benefit
$ in Millions
Dec. 31, 2022
USD ($)
United States  
Defined Benefit Plan, Expected Future Benefit Payments [Abstract]  
2023  $ 85
2024  81
2025  81
2026  80
2027  79
2028-2032 373
Foreign Plan  
Defined Benefit Plan, Expected Future Benefit Payments [Abstract]  
2023  47
2024  48
2025  51
2026  55
2027  55
2028-2032 $ 313
XML 84 R66.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
United States      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 937 $ 1,226 $ 1,267
United States | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 937 1,226 [1]  
United States | U.S. equity funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 89 124  
United States | U.S. equity funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | U.S. equity funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | U.S. equity funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | U.S. equity funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 89 124 [1]  
United States | International equity funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 91 117  
United States | International equity funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | International equity funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | International equity funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | International equity funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 91 117 [1]  
United States | Fixed income funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 739 966  
United States | Fixed income funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Fixed income funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Fixed income funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Fixed income funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 739 966 [1]  
United States | Money market funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 18 19  
United States | Money market funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Money market funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Money market funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Money market funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 18 19 [1]  
Foreign Plan      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 868 1,302 $ 1,160
Foreign Plan | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4 5  
Foreign Plan | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 306 295  
Foreign Plan | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 558 1,002 [1]  
Foreign Plan | Fixed income funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 299 651  
Foreign Plan | Fixed income funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Fixed income funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Fixed income funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Fixed income funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 299 651 [1]  
Foreign Plan | Equity funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 8 17  
Foreign Plan | Equity funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Equity funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Equity funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Equity funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 8 17 [1]  
Foreign Plan | Hedge funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   3  
Foreign Plan | Hedge funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Foreign Plan | Hedge funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Foreign Plan | Hedge funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Foreign Plan | Hedge funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1]   3  
Foreign Plan | Multi-asset funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 56 73  
Foreign Plan | Multi-asset funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Multi-asset funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Multi-asset funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Multi-asset funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 56 73 [1]  
Foreign Plan | Derivative funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 190 253  
Foreign Plan | Derivative funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Derivative funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Derivative funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Derivative funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 190 253 [1]  
Foreign Plan | Alternative investments      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   1  
Foreign Plan | Alternative investments | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Foreign Plan | Alternative investments | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Foreign Plan | Alternative investments | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Foreign Plan | Alternative investments | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets [1]   1  
Foreign Plan | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 306 295  
Foreign Plan | Insurance contracts | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Insurance contracts | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 306 295  
Foreign Plan | Insurance contracts | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Insurance contracts | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0 [1]  
Foreign Plan | Cash / money market funds      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 9 9  
Foreign Plan | Cash / money market funds | Quoted Prices in Active Markets (Level 1)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4 5  
Foreign Plan | Cash / money market funds | Significant Other Observable Inputs (Level 2)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Cash / money market funds | Significant Unobservable Inputs (Level 3)      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan | Cash / money market funds | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 5 $ 4 [1]  
[1] Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
XML 85 R67.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Components of Income From Continuing Operations Before Income Taxes [Abstract]      
U.S. $ 3,859 $ 3,340 $ 4,762
Non-U.S. 3,976 5,501 2,468
Income before income taxes 7,835 8,841 7,230
Current income tax provision      
Federal 813 446 521
Non-U.S. 633 1,148 423
State 254 160 175
Current income tax provision 1,700 1,754 1,119
Deferred income tax provision (benefit)      
Federal (611) (227) (237)
Non-U.S. (314) (399) (18)
State (72) (19) (14)
Deferred income tax provision (benefit) (997) (645) (269)
Provision for income taxes $ 703 $ 1,109 $ 850
XML 86 R68.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]      
Statutory federal income tax rate 21.00% 21.00% 21.00%
Provision for income taxes at statutory rate $ 1,645 $ 1,857 $ 1,518
Foreign rate differential (329) (255) (223)
Income tax credits (202) (315) (335)
Global intangible low-taxed income 96 76 86
Foreign-derived intangible income (149) (119) (156)
Excess tax benefits from stock options and restricted stock units (80) (124) (114)
Provision for (reversal of) tax reserves, net (544) (17) (26)
Intra-entity transfers (18) (284) 0
Domestication transaction 0 0 (263)
Valuation allowances 344 36 379
Withholding taxes 84 164 115
Tax return reassessments and settlements (210) 1 (196)
State income taxes, net of federal tax 111 82 147
Other, net (45) 7 (82)
Provision for income taxes $ 703 $ 1,109 $ 850
XML 87 R69.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating Loss Carryforwards [Line Items]        
Tax return reassessments and settlements $ 210 $ (1) $ 196  
Provision for (reversal of) tax reserves, net 544 17 26  
Valuation allowances 344 36 379  
Intra-entity transfers (18) (284) 0  
Domestication transaction 0 0 (263)  
US foreign tax credits generated by repatriation of foreign earnings     96  
Excess tax benefits from stock options and restricted stock units (80) (124) (114)  
Undistributed earnings 29,000      
Unrecognized tax benefits 572 1,124 1,091 $ 1,552
Additions due to acquisitions 15 26 0  
UTB, interest and penalties 74 59    
Foreign Tax Credit Carryforwards        
Operating Loss Carryforwards [Line Items]        
Tax credit carryforward 551      
Deferred Interest Carryforward        
Operating Loss Carryforwards [Line Items]        
Tax credit carryforward 445      
Federal        
Operating Loss Carryforwards [Line Items]        
NOL carryforwards 68      
State        
Operating Loss Carryforwards [Line Items]        
NOL carryforwards 97      
Non- U.S.        
Operating Loss Carryforwards [Line Items]        
NOL carryforwards 1,160      
Portion of Non- U.S. with expiration dates        
Operating Loss Carryforwards [Line Items]        
NOL carryforwards 422      
Deferred Interest Carryforward        
Operating Loss Carryforwards [Line Items]        
Valuation allowances     212  
Federal        
Operating Loss Carryforwards [Line Items]        
Tax return reassessments and settlements 208   25  
Provision for (reversal of) tax reserves, net 658   378  
Charge for expired tax credits 49   53  
Valuation allowances 395   156  
Unrecognized tax benefits reclassed to accrued income taxes in connection with IRS settlement 101   144  
Foreign        
Operating Loss Carryforwards [Line Items]        
Increase (decrease) in UTB 143 80 (51)  
Federal and State        
Operating Loss Carryforwards [Line Items]        
Increase (decrease) in UTB $ (610) (75) $ (410)  
Deferred Tax Implications        
Operating Loss Carryforwards [Line Items]        
Intra-entity transfers   188    
Capital Loss        
Operating Loss Carryforwards [Line Items]        
Intra-entity transfers   $ 96    
XML 88 R70.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Deferred Tax Assets (Liabilities) [Abstract]      
Depreciation and amortization $ (4,277) $ (4,687)  
Net operating loss and credit carryforwards 1,951 1,652  
Reserves and accruals 140 162  
Accrued compensation 259 318  
Inventory basis difference 364 181  
Deferred interest 445 295  
Research and development and other capitalized costs 220 0  
Unrealized (gains) losses on hedging instruments (199) (33)  
Other, net 435 251  
Deferred tax liabilities, net before valuation allowance (662) (1,861)  
Valuation Allowance 1,322 968 $ 933
Deferred tax liabilities, net (1,984) (2,829)  
Valuation Allowance [Roll Forward]      
Beginning Balance 968 933 408
Additions (reductions) charged to income tax provision, net 344 24 514
Additions due to acquisitions 14 30 0
Currency translation and other (4) (19) 11
Ending Balance $ 1,322 $ 968 $ 933
XML 89 R71.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits [Roll Forward]      
Beginning balance $ 1,124 $ 1,091 $ 1,552
Additions due to acquisitions 15 26 0
Additions for tax positions of current year 104 32 8
Additions for tax positions of prior years 24 60 0
Reductions for tax positions of prior years (659) (5) (296)
Closure of tax years (4) (27) 0
Settlements (32) (53) (173)
Ending balance $ 572 $ 1,124 $ 1,091
XML 90 R72.htm IDEA: XBRL DOCUMENT v3.22.4
Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Earnings Per Share [Abstract]      
Net income $ 6,950 $ 7,725 $ 6,375
Basic (in shares) 392 394 396
Plus effect of: stock options and restricted stock units (shares) 2 3 3
Diluted weighted average shares (shares) 394 397 399
Basic Earnings Per Share (in dollars per share) $ 17.75 $ 19.62 $ 16.09
Diluted Earnings Per Share (in dollars per share) $ 17.63 $ 19.46 $ 15.96
Antidilutive stock options excluded from diluted weighted averages shares (shares) 2 1 1
XML 91 R73.htm IDEA: XBRL DOCUMENT v3.22.4
Debt and Other Financing Arrangements - Schedule of Debt (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Total borrowings at par value $ 34,561 $ 34,971
Unamortized discount (112) (117)
Unamortized debt issuance costs (171) (184)
Total borrowings at carrying value 34,278 34,670
Finance lease liabilities 210 200
Less: Short-term obligations and current maturities 5,579 2,537
Long-term obligations $ 28,909 $ 32,333
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Long-term obligations Long-term obligations
Commercial Paper Programs    
Debt Instrument [Line Items]    
Effective interest rate 2.60%  
Total borrowings at par value $ 310 $ 2,522
Total borrowings at carrying value 310 2,522
Senior Notes    
Debt Instrument [Line Items]    
Total borrowings at carrying value $ 33,889 32,072
Senior Notes | Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023    
Debt Instrument [Line Items]    
Variable rate 0.35%  
Term 1 year 6 months  
Total borrowings at par value $ 1,000 1,000
Senior Notes | Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023    
Debt Instrument [Line Items]    
Variable rate 0.39%  
Term 2 years  
Total borrowings at par value $ 500 500
Senior Notes | 0.797% 2-Year Senior Notes, Due 10/18/2023    
Debt Instrument [Line Items]    
Interest rate 0.797%  
Term 2 years  
Effective interest rate 1.03%  
Total borrowings at par value $ 1,350 1,350
Senior Notes | Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)    
Debt Instrument [Line Items]    
Variable rate 0.20%  
Term 2 years  
Effective interest rate 1.85%  
Total borrowings at par value $ 1,819 1,933
Senior Notes | 0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.00%  
Term 2 years  
Effective interest rate 0.06%  
Total borrowings at par value $ 589 625
Senior Notes | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.75%  
Term 8 years  
Effective interest rate 0.93%  
Total borrowings at par value $ 1,071 1,137
Senior Notes | Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024    
Debt Instrument [Line Items]    
Variable rate 0.53%  
Term 3 years  
Total borrowings at par value $ 500 500
Senior Notes | 1.215% 3-Year Senior Notes, Due 10/18/2024    
Debt Instrument [Line Items]    
Interest rate 1.215%  
Term 3 years  
Effective interest rate 1.42%  
Total borrowings at par value $ 2,500 2,500
Senior Notes | $0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.125%  
Term 5 years 6 months  
Effective interest rate 0.40%  
Total borrowings at par value $ 857 910
Senior Notes | $2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.00%  
Term 10 years  
Effective interest rate 2.09%  
Total borrowings at par value $ 686 728
Senior Notes | 0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.853%  
Term 3 years  
Effective interest rate 1.05%  
Total borrowings at par value $ 170 0
Senior Notes | 0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.00%  
Term 4 years  
Effective interest rate 0.15%  
Total borrowings at par value $ 589 625
Senior Notes | $3.65% 10-Year Senior Notes, Due 12/15/2025    
Debt Instrument [Line Items]    
Interest rate 3.65%  
Term 10 years  
Total borrowings at par value $ 0 350
Senior Notes | 3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 3.20%  
Term 3 years  
Effective interest rate 3.38%  
Total borrowings at par value $ 535 0
Senior Notes | $1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.40%  
Term 8 years 6 months  
Effective interest rate 1.52%  
Total borrowings at par value $ 749 796
Senior Notes | $1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.45%  
Term 10 years  
Effective interest rate 1.65%  
Total borrowings at par value $ 535 568
Senior Notes | 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.75%  
Term 7 years  
Effective interest rate 1.96%  
Total borrowings at par value $ 642 682
Senior Notes | 1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.054%  
Term 5 years  
Effective interest rate 1.18%  
Total borrowings at par value $ 221 0
Senior Notes | 4.80% 5-Year Senior Notes, Due 11/21/2027    
Debt Instrument [Line Items]    
Interest rate 4.80%  
Term 5 years  
Effective interest rate 5.00%  
Total borrowings at par value $ 600 0
Senior Notes | $0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.50%  
Term 8 years 6 months  
Effective interest rate 0.77%  
Total borrowings at par value $ 857 910
Senior Notes | $1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.375%  
Term 12 years  
Effective interest rate 1.46%  
Total borrowings at par value $ 642 682
Senior Notes | 1.750% 7-Year Senior Notes, Due 10/15/2028    
Debt Instrument [Line Items]    
Interest rate 1.75%  
Term 7 years  
Effective interest rate 1.89%  
Total borrowings at par value $ 700 700
Senior Notes | $1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.95%  
Term 12 years  
Effective interest rate 2.07%  
Total borrowings at par value $ 749 796
Senior Notes | $2.60% 10-Year Senior Notes, Due 10/1/2029    
Debt Instrument [Line Items]    
Interest rate 2.60%  
Term 10 years  
Effective interest rate 2.74%  
Total borrowings at par value $ 900 900
Senior Notes | 1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.279%  
Term 7 years  
Effective interest rate 1.44%  
Total borrowings at par value $ 36 0
Senior Notes | 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.80%  
Term 9 years  
Effective interest rate 0.88%  
Total borrowings at par value $ 1,873 1,990
Senior Notes | $0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 0.875%  
Term 12 years  
Effective interest rate 1.13%  
Total borrowings at par value $ 963 1,023
Senior Notes | 2.00% 10-Year Senior Notes, Due 10/15/2031    
Debt Instrument [Line Items]    
Interest rate 2.00%  
Term 10 years  
Effective interest rate 2.23%  
Total borrowings at par value $ 1,200 1,200
Senior Notes | 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.375%  
Term 12 years  
Effective interest rate 2.54%  
Total borrowings at par value $ 642 682
Senior Notes | 1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.49%  
Term 10 years  
Effective interest rate 1.60%  
Total borrowings at par value $ 48 0
Senior Notes | 4.95% 10-Year Senior Notes, Due 11/21/2032    
Debt Instrument [Line Items]    
Interest rate 4.95%  
Term 10 years  
Effective interest rate 5.09%  
Total borrowings at par value $ 600 0
Senior Notes | 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.125%  
Term 12 years  
Effective interest rate 1.20%  
Total borrowings at par value $ 1,606 1,706
Senior Notes | 3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 3.65%  
Term 12 years  
Effective interest rate 3.76%  
Total borrowings at par value $ 803 0
Senior Notes | $2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.875%  
Term 20 years  
Effective interest rate 2.94%  
Total borrowings at par value $ 749 796
Senior Notes | $1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.50%  
Term 20 years  
Effective interest rate 1.73%  
Total borrowings at par value $ 963 1,023
Senior Notes | 2.80% 20-Year Senior Notes, Due 10/15/2041    
Debt Instrument [Line Items]    
Interest rate 2.80%  
Term 20 years  
Effective interest rate 2.90%  
Total borrowings at par value $ 1,200 1,200
Senior Notes | 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.625%  
Term 20 years  
Effective interest rate 1.77%  
Total borrowings at par value $ 1,339 1,421
Senior Notes | 2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.069%  
Term 20 years  
Effective interest rate 2.13%  
Total borrowings at par value $ 111 0
Senior Notes | $5.30% 30-Year Senior Notes, Due 2/1/2044    
Debt Instrument [Line Items]    
Interest rate 5.30%  
Term 30 years  
Effective interest rate 5.37%  
Total borrowings at par value $ 400 400
Senior Notes | $4.10% 30-Year Senior Notes, Due 8/15/2047    
Debt Instrument [Line Items]    
Interest rate 4.10%  
Term 30 years  
Effective interest rate 4.23%  
Total borrowings at par value $ 750 750
Senior Notes | $1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 1.875%  
Term 30 years  
Effective interest rate 1.98%  
Total borrowings at par value $ 1,071 1,137
Senior Notes | 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.00%  
Term 30 years  
Effective interest rate 2.06%  
Total borrowings at par value $ 803 853
Senior Notes | 2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)    
Debt Instrument [Line Items]    
Interest rate 2.382%  
Term 30 years  
Effective interest rate 2.43%  
Total borrowings at par value $ 254 0
Other Debt    
Debt Instrument [Line Items]    
Total borrowings at par value 79 76
Total borrowings at carrying value $ 79 $ 76
XML 92 R74.htm IDEA: XBRL DOCUMENT v3.22.4
Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Debt Disclosure [Abstract]    
2023  $ 5,583  
2024  4,071  
2025  2,298  
2026  1,285  
2027  1,999  
2028 and thereafter 19,325  
Total borrowings at par value 34,561 $ 34,971
2023  11  
2024  16  
2025  12  
2026  11  
2027  10  
2028 and thereafter 150  
Finance lease liabilities $ 210 $ 200
XML 93 R75.htm IDEA: XBRL DOCUMENT v3.22.4
Debt and Other Financing Arrangements - Narrative (Details)
 12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Short-term Financing [Line Items]      
Unused lines of credit $ 72,000,000    
Loss on early extinguishment of debt $ 26,000,000 $ 767,000,000 $ 0
Senior Notes      
Short-term Financing [Line Items]      
Redemption price 100.00%    
Interest rate swaps - fair value hedges      
Short-term Financing [Line Items]      
Proceeds from interest rate swap $ 22,000,000    
Commercial Paper Programs      
Short-term Financing [Line Items]      
Outstanding short-term borrowings $ 310,000,000    
U.S. Commercial Paper Program | Commercial Paper Programs      
Short-term Financing [Line Items]      
Maximum period prior to maturity 397 days    
Euro Commercial Paper Program | Commercial Paper Programs      
Short-term Financing [Line Items]      
Maximum period prior to maturity 183 days    
$3.65% 10-Year Senior Notes, Due 12/15/2025 | Senior Notes      
Short-term Financing [Line Items]      
Interest rate 3.65%    
0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated) | Senior Notes      
Short-term Financing [Line Items]      
Interest rate 0.00%    
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) | Senior Notes      
Short-term Financing [Line Items]      
Interest rate 0.80%    
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) | Senior Notes      
Short-term Financing [Line Items]      
Interest rate 1.125%    
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) | Senior Notes      
Short-term Financing [Line Items]      
Interest rate 1.625%    
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) | Senior Notes      
Short-term Financing [Line Items]      
Interest rate 2.00%    
Revolving Credit Facility      
Short-term Financing [Line Items]      
Revolving credit facility capacity $ 5,000,000,000    
Minimum consolidated net interest coverage ratio 3.5    
Borrowings outstanding $ 0    
XML 94 R76.htm IDEA: XBRL DOCUMENT v3.22.4
Leases- Narrative (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2022
USD ($)
lease
Lessee, Lease, Description [Line Items]  
Leased operating facilities | lease 3
Lease Residual Value Guarantee  
Lessee, Lease, Description [Line Items]  
Maximum guarantee under lease arrangements | $ $ 147
Minimum  
Lessee, Lease, Description [Line Items]  
Remaining lease term 1 month
Options to extend, renewal term 1 year
Maximum  
Lessee, Lease, Description [Line Items]  
Remaining lease term 30 years
Options to extend, renewal term 10 years
Option to terminate, term 1 year
XML 95 R77.htm IDEA: XBRL DOCUMENT v3.22.4
Leases - Schedule of Operating Leases (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Leases [Abstract]      
Operating lease costs $ 351 $ 254 $ 224
Variable lease costs 109 66 49
Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities 289 288 222
Operating lease ROU assets obtained in exchange for new operating lease liabilities 430 293 $ 202
ROU assets 1,593 1,531  
Operating lease liabilities - current 272 266  
Operating lease liabilities - noncurrent $ 1,313 $ 1,203  
Remaining operating lease term 9 years 4 months 24 days 9 years 10 months 24 days  
Discount rate 3.20% 2.60%  
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other assets Other assets  
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other accrued expenses Other accrued expenses  
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other long-term liabilities Other long-term liabilities  
XML 96 R78.htm IDEA: XBRL DOCUMENT v3.22.4
Leases - Schedule of Future Payments of Operating Lease Liabilities (Details)
$ in Millions
Dec. 31, 2022
USD ($)
Leases [Abstract]  
2023  $ 321
2024  293
2025  220
2026  172
2027  136
2028 and thereafter 730
Total lease payments 1,872
Less: imputed interest 287
Total operating lease liability $ 1,585
XML 97 R79.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2022
Unrecorded Unconditional Purchase Obligation [Line Items]    
Unconditional purchase obligations   $ 2,400
Accrual for Environmental Loss Contingencies Disclosure [Abstract]    
Environmental liability   $ 75
Loss Contingency [Abstract]    
Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]   Other accrued expenses, Other long-term liabilities
Letters of Credit / Bank Guarantees    
Guarantor Obligations [Line Items]    
Maximum guarantee under lease arrangements   $ 297
Surety Bonds and Other Guarantees    
Guarantor Obligations [Line Items]    
Maximum guarantee under lease arrangements   84
Inventories | Analytical Instruments | Cost of Sales    
Unrecorded Unconditional Purchase Obligation [Line Items]    
Cost of product revenues related to an existing supply contract $ 108  
Businesses Sold | Pension Obligation Guarantee    
Guarantor Obligations [Line Items]    
Maximum guarantee under lease arrangements   28
Product Liability, Workers Compensation and Other Personal Injury Matters    
Loss Contingency [Abstract]    
Loss accrual   229
Undiscounted loss accrual   232
Estimated amounts due from insurers   95
Undiscounted estimated amounts due from insurers   98
Undiscounted product liability accrual   17
Product Liability, Workers Compensation and Other Personal Injury Matters | Minimum    
Loss Contingency [Abstract]    
Range of probable loss   223
Product Liability, Workers Compensation and Other Personal Injury Matters | Maximum    
Loss Contingency [Abstract]    
Range of probable loss   $ 384
XML 98 R80.htm IDEA: XBRL DOCUMENT v3.22.4
Comprehensive Income and Shareholders' Equity (Details) - USD ($)
shares in Millions, $ in Millions
 2 Months Ended 12 Months Ended
Feb. 23, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Balance $ 44,032 $ 40,855 $ 34,517 $ 29,684
Total other comprehensive items   (777) 478 (128)
Balance   $ 44,032 40,855 34,517
Unissued shares of common stock (in shares)   22.0    
Purchases of company common stock   $ 3,000 2,000 1,500
Subsequent Event        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Purchases of company common stock $ 3,000      
Purchases of company common stock (in shares) 5.2      
Currency translation adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Balance $ (2,880) (2,065)    
Other comprehensive items before reclassifications   (822)    
Amounts reclassified from accumulated other comprehensive items   7    
Total other comprehensive items   (815)    
Balance   (2,880) (2,065)  
Unrealized losses on hedging instruments        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Balance (33) (35)    
Other comprehensive items before reclassifications   0    
Amounts reclassified from accumulated other comprehensive items   2    
Total other comprehensive items   2    
Balance   (33) (35)  
Pension and other postretirement benefit liability adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Balance (186) (229)    
Other comprehensive items before reclassifications   38    
Amounts reclassified from accumulated other comprehensive items   5    
Total other comprehensive items   43    
Balance   (186) (229)  
Accumulated Other Comprehensive Items        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Balance $ (3,099) (2,329) (2,807) (2,679)
Other comprehensive items before reclassifications   (784)    
Amounts reclassified from accumulated other comprehensive items   14    
Total other comprehensive items   (770)    
Balance   $ (3,099) $ (2,329) $ (2,807)
XML 99 R81.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Liabilities [Abstract]    
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other long-term liabilities  
Fair Value, Recurring    
Assets [Abstract]    
Cash equivalents $ 5,804 $ 2,210
Investments 25 298
Warrants 12 15
Insurance contracts 162 181
Derivative contracts 79 36
Total assets 6,082 2,740
Liabilities [Abstract]    
Derivative contracts 101 1
Contingent consideration 174 317
Total liabilities 275 318
Fair Value, Recurring | Quoted Prices in Active Markets (Level 1)    
Assets [Abstract]    
Cash equivalents 5,804 2,210
Investments 25 298
Warrants 0 0
Insurance contracts 0 0
Derivative contracts 0 0
Total assets 5,829 2,508
Liabilities [Abstract]    
Derivative contracts 0 0
Contingent consideration 0 0
Total liabilities 0 0
Fair Value, Recurring | Significant Other Observable Inputs (Level 2)    
Assets [Abstract]    
Cash equivalents 0 0
Investments 0 0
Warrants 12 15
Insurance contracts 162 181
Derivative contracts 79 36
Total assets 253 232
Liabilities [Abstract]    
Derivative contracts 101 1
Contingent consideration 0 0
Total liabilities 101 1
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)    
Assets [Abstract]    
Cash equivalents 0 0
Investments 0 0
Warrants 0 0
Insurance contracts 0 0
Derivative contracts 0 0
Total assets 0 0
Liabilities [Abstract]    
Derivative contracts 0 0
Contingent consideration 174 317
Total liabilities $ 174 $ 317
XML 100 R82.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements and Fair Value of Financial Instruments - Rollforward of the Fair Value of Investments (Details) - Contingent Consideration - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance $ 317 $ 70
Acquisitions (including assumed balances) (18) 403
Payments (66) (109)
Changes in fair value included in earnings (59) (47)
Ending balance $ 174 $ 317
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative expenses Selling, general and administrative expenses
XML 101 R83.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Aggregate Notional Value and Fair Value of Derivative Instruments (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Derivatives, Fair Value [Line Items]    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets, Other assets  
Cross-currency interest rate swaps - designated as net investment hedges | Derivatives designated as hedging instruments    
Derivatives, Fair Value [Line Items]    
Fair value – assets $ 77 $ 25
Fair value – liabilities 85 0
Cross-currency interest rate swaps - designated as net investment hedges | Net Investment Hedging    
Derivatives, Fair Value [Line Items]    
Notional amount 2,100 900
Currency exchange contracts    
Derivatives, Fair Value [Line Items]    
Notional amount 2,434 2,149
Currency exchange contracts | Derivatives not designated as hedging instruments    
Derivatives, Fair Value [Line Items]    
Fair value – assets 2 11
Fair value – liabilities 16 1
Fair Value, Recurring    
Derivatives, Fair Value [Line Items]    
Fair value – assets 79 36
Fair value – liabilities $ 101 $ 1
XML 102 R84.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Derivative Instruments, Gain (Loss) Recognized (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Currency exchange contracts | Other Expense | Derivatives not designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Included in other income/(expense) $ 102 $ 162  
Currency exchange contracts | Cost of Sales | Derivatives not designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Included in other income/(expense) 6 12  
Fair Value Hedging | Interest rate swaps - fair value hedges | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Included in other income/(expense) 0 (3)  
Fair Value Hedging | Interest rate swaps - fair value hedges | Other Expense | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Hedged long-term obligations - included in other income/(expense) 0 25  
Fair Value Hedging | Cross-currency interest rate swaps - designated as net investment hedges | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Included in other income/(expense) (81) 0  
Fair Value Hedging | Cross-currency interest rate swaps - designated as net investment hedges | Other Expense | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Hedged long-term obligations - included in other income/(expense) 77 0  
Cash Flow Hedging | Interest rate swaps - fair value hedges | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Termination fees     $ 85
Cash Flow Hedging | Interest rate swaps - fair value hedges | Other Expense      
Derivative Instruments, Gain (Loss) [Line Items]      
Amount reclassified from accumulated other comprehensive items to other income/(expense)   (65) $ 42
Cash Flow Hedging | Interest rate swaps - fair value hedges | Other Expense | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Amount reclassified from accumulated other comprehensive items to other income/(expense) 3 73  
Net Investment Hedging | Foreign currency-denominated debt | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Included in currency translation adjustment within other comprehensive items 695 922  
Net Investment Hedging | Cross-currency interest rate swaps - designated as net investment hedges | Derivatives designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Included in other income/(expense) 19 8  
Included in currency translation adjustment within other comprehensive items $ 52 $ 71  
XML 103 R85.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of the Company's Debt Instruments (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Carrying value $ 34,278 $ 34,670
Fair value 30,290 36,047
Senior Notes    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Carrying value 33,889 32,072
Fair value 29,901 33,449
Commercial Paper Programs    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Carrying value 310 2,522
Fair value 310 2,522
Other Debt    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Carrying value 79 76
Fair value $ 79 $ 76
XML 104 R86.htm IDEA: XBRL DOCUMENT v3.22.4
Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Supplemental Cash Flow Information [Abstract]      
Interest $ 667 $ 555 $ 471
Income taxes 1,234 2,182 1,324
Non-cash investing and financing activities      
Acquired but unpaid property, plant and equipment 393 379 347
Fair value of equity awards exchanged 0 43 0
Fair value of contingent consideration 0 183 0
Finance lease ROU assets obtained in exchange for new finance lease liabilities 33 15 5
Declared but unpaid dividends 119 104 89
Issuance of stock upon vesting of restricted stock units $ 241 $ 265 $ 217
XML 105 R87.htm IDEA: XBRL DOCUMENT v3.22.4
Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Supplemental Cash Flow Information [Abstract]        
Cash and cash equivalents $ 8,524 $ 4,477    
Restricted cash included in other current assets 12 13    
Restricted cash included in other assets 1 1    
Cash, cash equivalents and restricted cash $ 8,537 $ 4,491 $ 10,336 $ 2,422
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible Enumeration] Other current assets      
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible Enumeration] Other assets      
XML 106 R88.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Feb. 23, 2023
Restructuring Cost and Reserve [Line Items]        
Eliminated workforce percentage 2.00% 1.00% 1.00%  
Restructuring and other costs $ 114 $ 197 $ 99  
Life Sciences Solutions        
Restructuring Cost and Reserve [Line Items]        
Restructuring and other costs 30 129 34  
Analytical Instruments        
Restructuring Cost and Reserve [Line Items]        
Restructuring and other costs 1 6 26  
Specialty Diagnostics        
Restructuring Cost and Reserve [Line Items]        
Restructuring and other costs 68 18 9  
Laboratory Products and Biopharma Services        
Restructuring Cost and Reserve [Line Items]        
Restructuring and other costs 12 35 23  
Corporate [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring and other costs $ 3 $ 9 $ 7  
Forecast        
Restructuring Cost and Reserve [Line Items]        
Future restructuring costs       $ 60
XML 107 R89.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Restructuring Reserve [Roll Forward]      
Beginning balance $ 17 $ 21 $ 34
Net restructuring charges incurred 68 37 51
Payments (44) (40) (57)
Currency translation   (1) (7)
Ending balance 41 17 21
Other non-cash restructuring costs $ 46 160 48
Impairment of intangible assets   122 $ 32
Cash compensation charges   $ 35  
XML 108 R9999.htm IDEA: XBRL DOCUMENT v3.22.4
Label Element Value
Domestic NOL Expires [Member]  
Operating Loss Carryforwards us-gaap_OperatingLossCarryforwards $ 33,000,000
XML 109 tmo-20221231_htm.xml IDEA: XBRL DOCUMENT 0000097745 2022-01-01 2022-12-31 0000097745 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes0.75Due2024Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes0.125Due2025Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes200Due2025Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes3200Due2026Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1.40Due2026Member 2022-01-01 2022-12-31 0000097745 tmo:A1.45SeniorNotesDue2027Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes175Due2027Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes0.500Due2028Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1.375Due2028Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1.95Due2029Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes0.875Due2031Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes2375Due2032Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes3650Due2034Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes2.875Due2037Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1.500Due2039Member 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1.875Due2049Member 2022-01-01 2022-12-31 0000097745 2022-07-01 0000097745 2023-02-04 0000097745 2022-12-31 0000097745 2021-12-31 0000097745 us-gaap:ProductMember 2022-01-01 2022-12-31 0000097745 us-gaap:ProductMember 2021-01-01 2021-12-31 0000097745 us-gaap:ProductMember 2020-01-01 2020-12-31 0000097745 us-gaap:ServiceMember 2022-01-01 2022-12-31 0000097745 us-gaap:ServiceMember 2021-01-01 2021-12-31 0000097745 us-gaap:ServiceMember 2020-01-01 2020-12-31 0000097745 2021-01-01 2021-12-31 0000097745 2020-01-01 2020-12-31 0000097745 2020-12-31 0000097745 2019-12-31 0000097745 us-gaap:CommonStockMember 2019-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000097745 us-gaap:RetainedEarningsMember 2019-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2019-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000097745 us-gaap:ParentMember 2019-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2019-12-31 0000097745 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0000097745 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000097745 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:ParentMember 2019-12-31 0000097745 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000097745 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2020-01-01 2020-12-31 0000097745 us-gaap:ParentMember 2020-01-01 2020-12-31 0000097745 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000097745 us-gaap:CommonStockMember 2020-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000097745 us-gaap:RetainedEarningsMember 2020-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2020-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000097745 us-gaap:ParentMember 2020-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2020-12-31 0000097745 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0000097745 us-gaap:ParentMember 2021-01-01 2021-12-31 0000097745 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000097745 us-gaap:CommonStockMember 2021-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000097745 us-gaap:RetainedEarningsMember 2021-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2021-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000097745 us-gaap:ParentMember 2021-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2021-12-31 0000097745 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0000097745 us-gaap:ParentMember 2022-01-01 2022-12-31 0000097745 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000097745 us-gaap:CommonStockMember 2022-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000097745 us-gaap:RetainedEarningsMember 2022-12-31 0000097745 us-gaap:TreasuryStockCommonMember 2022-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000097745 us-gaap:ParentMember 2022-12-31 0000097745 us-gaap:NoncontrollingInterestMember 2022-12-31 0000097745 tmo:PPDSNBLKKMember 2022-12-31 0000097745 us-gaap:ChangeInAccountingPrincipleOtherMember 2021-09-30 0000097745 us-gaap:ChangeInAccountingPrincipleOtherMember 2021-10-02 0000097745 us-gaap:ProductMember us-gaap:ChangeInAccountingPrincipleOtherMember 2021-07-04 2021-10-02 0000097745 us-gaap:ChangeInAccountingPrincipleOtherMember tmo:LaboratoryProductsandServicesMember 2021-10-02 0000097745 us-gaap:ProductMember us-gaap:ChangeInAccountingPrincipleOtherMember tmo:LaboratoryProductsandServicesMember 2021-07-04 2021-10-02 0000097745 us-gaap:ChangeInAccountingPrincipleOtherMember tmo:SpecialtyDiagnosticsMember 2021-10-02 0000097745 us-gaap:ProductMember us-gaap:ChangeInAccountingPrincipleOtherMember tmo:SpecialtyDiagnosticsMember 2021-07-04 2021-10-02 0000097745 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2022-01-01 2022-12-31 0000097745 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2022-01-01 2022-12-31 0000097745 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-12-31 0000097745 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-12-31 0000097745 us-gaap:LandMember 2022-12-31 0000097745 us-gaap:LandMember 2021-12-31 0000097745 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0000097745 us-gaap:BuildingAndBuildingImprovementsMember 2021-12-31 0000097745 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2022-12-31 0000097745 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2021-12-31 0000097745 us-gaap:ConstructionInProgressMember 2022-12-31 0000097745 us-gaap:ConstructionInProgressMember 2021-12-31 0000097745 srt:MaximumMember 2022-01-01 2022-12-31 0000097745 us-gaap:CustomerRelationshipsMember 2022-12-31 0000097745 us-gaap:CustomerRelationshipsMember 2021-12-31 0000097745 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000097745 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0000097745 us-gaap:TradeNamesMember 2022-12-31 0000097745 us-gaap:TradeNamesMember 2021-12-31 0000097745 us-gaap:OrderOrProductionBacklogMember 2022-12-31 0000097745 us-gaap:OrderOrProductionBacklogMember 2021-12-31 0000097745 us-gaap:TradeNamesMember 2022-12-31 0000097745 us-gaap:TradeNamesMember 2021-12-31 0000097745 tmo:LifeSciencesSolutionsMember 2020-12-31 0000097745 tmo:AnalyticalInstrumentsMember 2020-12-31 0000097745 tmo:SpecialtyDiagnosticsMember 2020-12-31 0000097745 tmo:LaboratoryProductsandServicesMember 2020-12-31 0000097745 tmo:LifeSciencesSolutionsMember 2021-01-01 2021-12-31 0000097745 tmo:AnalyticalInstrumentsMember 2021-01-01 2021-12-31 0000097745 tmo:SpecialtyDiagnosticsMember 2021-01-01 2021-12-31 0000097745 tmo:LaboratoryProductsandServicesMember 2021-01-01 2021-12-31 0000097745 tmo:LifeSciencesSolutionsMember 2021-12-31 0000097745 tmo:AnalyticalInstrumentsMember 2021-12-31 0000097745 tmo:SpecialtyDiagnosticsMember 2021-12-31 0000097745 tmo:LaboratoryProductsandServicesMember 2021-12-31 0000097745 tmo:LifeSciencesSolutionsMember 2022-01-01 2022-12-31 0000097745 tmo:AnalyticalInstrumentsMember 2022-01-01 2022-12-31 0000097745 tmo:SpecialtyDiagnosticsMember 2022-01-01 2022-12-31 0000097745 tmo:LaboratoryProductsandServicesMember 2022-01-01 2022-12-31 0000097745 tmo:LifeSciencesSolutionsMember 2022-12-31 0000097745 tmo:AnalyticalInstrumentsMember 2022-12-31 0000097745 tmo:SpecialtyDiagnosticsMember 2022-12-31 0000097745 tmo:LaboratoryProductsandServicesMember 2022-12-31 0000097745 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201613Member 2020-01-01 0000097745 tmo:TheBindingSiteGroupMember us-gaap:SubsequentEventMember 2023-01-03 2023-01-03 0000097745 tmo:TheBindingSiteGroupMember us-gaap:SubsequentEventMember 2023-01-03 0000097745 tmo:EuropeanViralVectorManufacturingBusinessMember 2021-01-15 0000097745 tmo:MesaBiotechMember 2021-02-25 0000097745 tmo:CSLMember 2021-09-30 0000097745 tmo:PPDIncMember 2021-12-08 0000097745 tmo:PeproTechIncMember 2021-12-30 0000097745 tmo:PPDIncMember 2021-12-08 2021-12-08 0000097745 tmo:PeproTechIncMember 2021-12-30 2021-12-30 0000097745 tmo:EuropeanViralVectorManufacturingBusinessMember 2021-01-15 2021-01-15 0000097745 tmo:MesaBiotechMember 2021-02-25 2021-02-25 0000097745 tmo:CSLMember 2021-09-30 2021-09-30 0000097745 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-01-01 2021-12-31 0000097745 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-12-31 0000097745 tmo:PPDIncMember us-gaap:CustomerRelationshipsMember 2021-12-08 0000097745 tmo:PeproTechIncMember us-gaap:CustomerRelationshipsMember 2021-12-30 0000097745 tmo:EuropeanViralVectorManufacturingBusinessMember us-gaap:CustomerRelationshipsMember 2021-01-15 0000097745 tmo:MesaBiotechMember us-gaap:CustomerRelationshipsMember 2021-02-25 0000097745 tmo:CSLMember us-gaap:CustomerRelationshipsMember 2021-09-30 0000097745 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:CustomerRelationshipsMember 2021-12-31 0000097745 tmo:PPDIncMember us-gaap:DevelopedTechnologyRightsMember 2021-12-08 0000097745 tmo:PeproTechIncMember us-gaap:DevelopedTechnologyRightsMember 2021-12-30 0000097745 tmo:EuropeanViralVectorManufacturingBusinessMember us-gaap:DevelopedTechnologyRightsMember 2021-01-15 0000097745 tmo:MesaBiotechMember us-gaap:DevelopedTechnologyRightsMember 2021-02-25 0000097745 tmo:CSLMember us-gaap:DevelopedTechnologyRightsMember 2021-09-30 0000097745 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0000097745 tmo:PPDIncMember us-gaap:TradeNamesMember 2021-12-08 0000097745 tmo:PeproTechIncMember us-gaap:TradeNamesMember 2021-12-30 0000097745 tmo:EuropeanViralVectorManufacturingBusinessMember us-gaap:TradeNamesMember 2021-01-15 0000097745 tmo:MesaBiotechMember us-gaap:TradeNamesMember 2021-02-25 0000097745 tmo:CSLMember us-gaap:TradeNamesMember 2021-09-30 0000097745 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:TradeNamesMember 2021-12-31 0000097745 tmo:PPDIncMember us-gaap:OrderOrProductionBacklogMember 2021-12-08 0000097745 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0000097745 us-gaap:DevelopedTechnologyRightsMember 2021-01-01 2021-12-31 0000097745 us-gaap:TradeNamesMember 2021-01-01 2021-12-31 0000097745 us-gaap:OrderOrProductionBacklogMember 2021-01-01 2021-12-31 0000097745 tmo:PPDIncMember 2021-01-01 2021-12-31 0000097745 tmo:PPDIncMember 2020-01-01 2020-12-31 0000097745 tmo:PPDIncMember us-gaap:AcquisitionRelatedCostsMember 2021-01-01 2021-12-31 0000097745 tmo:PPDIncMember us-gaap:AcquisitionRelatedCostsMember 2020-01-01 2020-12-31 0000097745 tmo:ConsumablesMember 2022-01-01 2022-12-31 0000097745 tmo:ConsumablesMember 2021-01-01 2021-12-31 0000097745 tmo:ConsumablesMember 2020-01-01 2020-12-31 0000097745 tmo:InstrumentsMember 2022-01-01 2022-12-31 0000097745 tmo:InstrumentsMember 2021-01-01 2021-12-31 0000097745 tmo:InstrumentsMember 2020-01-01 2020-12-31 0000097745 srt:NorthAmericaMember 2022-01-01 2022-12-31 0000097745 srt:NorthAmericaMember 2021-01-01 2021-12-31 0000097745 srt:NorthAmericaMember 2020-01-01 2020-12-31 0000097745 srt:EuropeMember 2022-01-01 2022-12-31 0000097745 srt:EuropeMember 2021-01-01 2021-12-31 0000097745 srt:EuropeMember 2020-01-01 2020-12-31 0000097745 srt:AsiaPacificMember 2022-01-01 2022-12-31 0000097745 srt:AsiaPacificMember 2021-01-01 2021-12-31 0000097745 srt:AsiaPacificMember 2020-01-01 2020-12-31 0000097745 tmo:OtherRegionsMember 2022-01-01 2022-12-31 0000097745 tmo:OtherRegionsMember 2021-01-01 2021-12-31 0000097745 tmo:OtherRegionsMember 2020-01-01 2020-12-31 0000097745 2023-01-01 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2022-01-01 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2021-01-01 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2020-01-01 2020-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2022-01-01 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2021-01-01 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2020-01-01 2020-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2022-01-01 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2021-01-01 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2020-01-01 2020-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2022-01-01 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2021-01-01 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2020-01-01 2020-12-31 0000097745 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-12-31 0000097745 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-12-31 0000097745 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-12-31 0000097745 us-gaap:OperatingSegmentsMember 2022-01-01 2022-12-31 0000097745 us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0000097745 us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0000097745 us-gaap:MaterialReconcilingItemsMember 2022-01-01 2022-12-31 0000097745 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-12-31 0000097745 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-12-31 0000097745 us-gaap:CorporateAndOtherMember 2022-12-31 0000097745 us-gaap:CorporateAndOtherMember 2021-12-31 0000097745 us-gaap:CorporateAndOtherMember 2020-12-31 0000097745 tmo:LifeSciencesSolutionsMember 2020-01-01 2020-12-31 0000097745 tmo:AnalyticalInstrumentsMember 2020-01-01 2020-12-31 0000097745 tmo:SpecialtyDiagnosticsMember 2020-01-01 2020-12-31 0000097745 tmo:LaboratoryProductsandServicesMember 2020-01-01 2020-12-31 0000097745 us-gaap:CorporateAndOtherMember 2022-01-01 2022-12-31 0000097745 us-gaap:CorporateAndOtherMember 2021-01-01 2021-12-31 0000097745 us-gaap:CorporateAndOtherMember 2020-01-01 2020-12-31 0000097745 country:US 2022-01-01 2022-12-31 0000097745 country:US 2021-01-01 2021-12-31 0000097745 country:US 2020-01-01 2020-12-31 0000097745 country:CN 2022-01-01 2022-12-31 0000097745 country:CN 2021-01-01 2021-12-31 0000097745 country:CN 2020-01-01 2020-12-31 0000097745 tmo:AllOtherCountriesMember 2022-01-01 2022-12-31 0000097745 tmo:AllOtherCountriesMember 2021-01-01 2021-12-31 0000097745 tmo:AllOtherCountriesMember 2020-01-01 2020-12-31 0000097745 country:US 2022-12-31 0000097745 country:US 2021-12-31 0000097745 country:US 2020-12-31 0000097745 tmo:AllOtherCountriesMember 2022-12-31 0000097745 tmo:AllOtherCountriesMember 2021-12-31 0000097745 tmo:AllOtherCountriesMember 2020-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:OtherExpenseMember 2020-01-01 2020-12-31 0000097745 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000097745 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000097745 us-gaap:EmployeeStockOptionMember 2022-12-31 0000097745 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000097745 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000097745 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000097745 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0000097745 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000097745 srt:MinimumMember 2022-12-31 0000097745 srt:MaximumMember 2022-12-31 0000097745 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000097745 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000097745 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000097745 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000097745 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000097745 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000097745 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000097745 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000097745 us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:USEquityFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InternationalEquityFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 srt:MinimumMember us-gaap:EquityFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 srt:MaximumMember us-gaap:EquityFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 srt:MinimumMember us-gaap:FixedIncomeFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 srt:MaximumMember us-gaap:FixedIncomeFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 srt:MinimumMember tmo:MultiassetFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 srt:MaximumMember tmo:MultiassetFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 srt:MinimumMember us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 srt:MaximumMember us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:MoneyMarketFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000097745 tmo:USEquityFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:USEquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:InternationalEquityFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:InternationalEquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FixedIncomeFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:MoneyMarketFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:EquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FixedIncomeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:HedgeFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:HedgeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:MultiassetFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:AlternativeInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:AlternativeInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:AlternativeInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:AlternativeInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:AlternativeInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 tmo:InsuranceContractsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000097745 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0000097745 us-gaap:DomesticCountryMember 2022-12-31 0000097745 tmo:DeferredTaxImplicationsMember 2021-01-01 2021-12-31 0000097745 tmo:CapitalLossMember 2021-01-01 2021-12-31 0000097745 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0000097745 us-gaap:DomesticCountryMember 2020-12-31 0000097745 tmo:DeferredTaxAssetInterestCarryforwardMember 2020-01-01 2020-12-31 0000097745 us-gaap:DomesticCountryMember 2022-12-31 0000097745 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0000097745 us-gaap:ForeignCountryMember 2022-12-31 0000097745 tmo:DomesticNOLExpiresMember 2022-12-31 0000097745 tmo:ForeignCountryNolExpiresMember 2022-12-31 0000097745 tmo:ForeignTaxCreditCarryforwardsMember 2022-12-31 0000097745 tmo:DeferredTaxAssetInterestCarryforwardMember 2022-12-31 0000097745 tmo:ForeignTaxPositionsMember 2022-01-01 2022-12-31 0000097745 tmo:FederalAndStateMember 2022-01-01 2022-12-31 0000097745 tmo:ForeignTaxPositionsMember 2021-01-01 2021-12-31 0000097745 tmo:FederalAndStateMember 2021-01-01 2021-12-31 0000097745 tmo:ForeignTaxPositionsMember 2020-01-01 2020-12-31 0000097745 tmo:FederalAndStateMember 2020-01-01 2020-12-31 0000097745 us-gaap:CommercialPaperMember 2022-12-31 0000097745 us-gaap:CommercialPaperMember 2021-12-31 0000097745 tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:FloatingRateSOFR039SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:FloatingRateSOFR039SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:FloatingRateSOFR039SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes0797Due2023Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0797Due2023Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes0797Due2023Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:FloatingRate2YearSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:FloatingRate2YearSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:FloatingRate2YearSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes0000Due2023Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0000Due2023Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes0000Due2023Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes0.75Due2024Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0.75Due2024Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes0.75Due2024Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:FloatingRateSOFR053SeniorNotesDue2024Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:FloatingRateSOFR053SeniorNotesDue2024Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:FloatingRateSOFR053SeniorNotesDue2024Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes1215Due2024Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1215Due2024Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1215Due2024Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes0.125Due2025Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0.125Due2025Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes0.125Due2025Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes200Due2025Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes200Due2025Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes200Due2025Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes0853Due2025Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0853Due2025Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes0853Due2025Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes0000Due2025Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0000Due2025Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes0000Due2025Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes3.65Due2025Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes3.65Due2025Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes3.65Due2025Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes320Due2026Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes320Due2026Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes320Due2026Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes1.40Due2026Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1.40Due2026Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1.40Due2026Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:A1.45SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:A1.45SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:A1.45SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes175Due2027Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes175Due2027Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes175Due2027Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes1054Due2027Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1054Due2027Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1054Due2027Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes48Due2027Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes48Due2027Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes48Due2027Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes0.500Due2028Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0.500Due2028Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes0.500Due2028Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes1.375Due2028Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1.375Due2028Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1.375Due2028Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes1750Due2028Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1750Due2028Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1750Due2028Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes1.95Due2029Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1.95Due2029Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1.95Due2029Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes2.60Due2029Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2.60Due2029Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes2.60Due2029Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes1279Due2029Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1279Due2029Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1279Due2029Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes080Due2030Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes080Due2030Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes080Due2030Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes0.875Due2031Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes0.875Due2031Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes0.875Due2031Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes2000Due2031Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2000Due2031Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes2000Due2031Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes2375Due2032Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2375Due2032Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes2375Due2032Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes149Due2032Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes149Due2032Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes149Due2032Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes495Due2032Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes495Due2032Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes495Due2032Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes1125Due2033Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1125Due2033Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1125Due2033Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes365Due2034Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes365Due2034Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes365Due2034Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes2.875Due2037Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2.875Due2037Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes2.875Due2037Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes1.500Due2039Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1.500Due2039Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1.500Due2039Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes2800Due2041Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2800Due2041Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes2800Due2041Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes1625Due2041Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1625Due2041Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1625Due2041Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes2069Due2042Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2069Due2042Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes2069Due2042Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes530Due2044Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes530Due2044Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes530Due2044Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes4.10Due2047Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes4.10Due2047Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes4.10Due2047Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes1.875Due2049Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes1.875Due2049Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes1.875Due2049Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes200Due2051Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes200Due2051Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes200Due2051Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:SeniorNotes2382Due2052Member us-gaap:SeniorNotesMember 2022-12-31 0000097745 tmo:SeniorNotes2382Due2052Member us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 tmo:SeniorNotes2382Due2052Member us-gaap:SeniorNotesMember 2021-12-31 0000097745 tmo:OtherDebtMember 2022-12-31 0000097745 tmo:OtherDebtMember 2021-12-31 0000097745 us-gaap:RevolvingCreditFacilityMember 2022-12-31 0000097745 us-gaap:RevolvingCreditFacilityMember 2022-01-01 2022-12-31 0000097745 tmo:U.S.CommercialPaperProgramMember us-gaap:CommercialPaperMember 2022-01-01 2022-12-31 0000097745 tmo:EuroCommercialPaperProgramMember us-gaap:CommercialPaperMember 2022-01-01 2022-12-31 0000097745 us-gaap:CommercialPaperMember 2022-12-31 0000097745 us-gaap:SeniorNotesMember 2022-01-01 2022-12-31 0000097745 us-gaap:InterestRateSwapMember 2022-01-01 2022-12-31 0000097745 us-gaap:GuaranteeTypeOtherMember 2022-12-31 0000097745 us-gaap:CostOfSalesMember tmo:AnalyticalInstrumentsMember us-gaap:InventoriesMember 2020-01-01 2020-12-31 0000097745 us-gaap:StandbyLettersOfCreditMember 2022-12-31 0000097745 tmo:SuretyBondsAndOtherGuaranteesMember 2022-12-31 0000097745 us-gaap:FinancialGuaranteeMember tmo:BusinessesSoldMember 2022-12-31 0000097745 srt:MinimumMember tmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember 2022-12-31 0000097745 srt:MaximumMember tmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember 2022-12-31 0000097745 tmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember 2022-12-31 0000097745 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000097745 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000097745 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000097745 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-12-31 0000097745 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0000097745 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-12-31 0000097745 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000097745 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000097745 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000097745 us-gaap:SubsequentEventMember 2023-01-01 2023-02-23 0000097745 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000097745 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000097745 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000097745 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000097745 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000097745 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000097745 tmo:ContingentConsiderationMember 2021-12-31 0000097745 tmo:ContingentConsiderationMember 2020-12-31 0000097745 tmo:ContingentConsiderationMember 2022-01-01 2022-12-31 0000097745 tmo:ContingentConsiderationMember 2021-01-01 2021-12-31 0000097745 tmo:ContingentConsiderationMember 2022-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2022-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2021-12-31 0000097745 us-gaap:ForeignExchangeContractMember 2022-12-31 0000097745 us-gaap:ForeignExchangeContractMember 2021-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2022-01-01 2022-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2021-01-01 2021-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2022-01-01 2022-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2021-01-01 2021-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2022-01-01 2022-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2021-01-01 2021-12-31 0000097745 tmo:ForeigncurrencydenominateddebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000097745 tmo:ForeigncurrencydenominateddebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherExpenseMember 2022-01-01 2022-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherExpenseMember 2021-01-01 2021-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-12-31 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:OtherExpenseMember 2021-01-01 2021-12-31 0000097745 us-gaap:SeniorNotesMember 2022-12-31 0000097745 us-gaap:SeniorNotesMember 2021-12-31 0000097745 srt:ScenarioForecastMember 2023-02-23 0000097745 us-gaap:CorporateMember 2022-01-01 2022-12-31 0000097745 us-gaap:CorporateMember 2021-01-01 2021-12-31 0000097745 us-gaap:CorporateMember 2020-01-01 2020-12-31 iso4217:USD shares iso4217:USD shares pure tmo:Segment tmo:lease 0000097745 false 2022 FY http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent 10-K true 2022-12-31 --12-31 false 1-8002 THERMO FISHER SCIENTIFIC INC. DE 04-2209186 168 Third Avenue Waltham MA 02451 781 622-1000 Common Stock, $1.00 par value TMO NYSE 0.750% Notes due 2024 TMO 24A NYSE 0.125% Notes due 2025 TMO 25B NYSE 2.000% Notes due 2025 TMO 25 NYSE 3.200% Notes due 2026 TMO 26B NYSE 1.400% Notes due 2026 TMO 26A NYSE 1.450% Notes due 2027 TMO 27 NYSE 1.750% Notes due 2027 TMO 27B NYSE 0.500% Notes due 2028 TMO 28A NYSE 1.375% Notes due 2028 TMO 28 NYSE 1.950% Notes due 2029 TMO 29 NYSE 0.875% Notes due 2031 TMO 31 NYSE 2.375% Notes due 2032 TMO 32 NYSE 3.650% Notes due 2034 TMO 34 NYSE 2.875% Notes due 2037 TMO 37 NYSE 1.500% Notes due 2039 TMO 39 NYSE 1.875% Notes due 2049 TMO 49 NYSE Yes No Yes Yes Large Accelerated Filer false false true false 214582365000 385430077 Sections of Thermo Fisher’s definitive Proxy Statement for the 2023 Annual Meeting of Shareholders are incorporated by reference into Parts II and III of this report. 238 PricewaterhouseCoopers LLP Boston, Massachusetts 8524000000 4477000000 189000000 150000000 8115000000 7977000000 5634000000 5051000000 1312000000 968000000 1644000000 1640000000 25229000000 20113000000 9280000000 8333000000 17442000000 20113000000 4007000000 4640000000 41196000000 41924000000 97154000000 95123000000 5579000000 2537000000 3381000000 2867000000 2095000000 2427000000 2601000000 2655000000 3354000000 2950000000 17010000000 13436000000 2849000000 3837000000 4238000000 4540000000 28909000000 32333000000 116000000 122000000 100 100 50000 50000 0 0 1 1 1200000000 1200000000 440668112 439154741 441000000 439000000 16743000000 16174000000 41910000000 35431000000 50157275 44720112 12017000000 8922000000 -3099000000 -2329000000 43978000000 40793000000 54000000 62000000 44032000000 40855000000 97154000000 95123000000 28548000000 30361000000 25306000000 16367000000 8850000000 6912000000 44915000000 39211000000 32218000000 14247000000 13594000000 11407000000 11697000000 5979000000 4807000000 8993000000 8007000000 6930000000 1471000000 1406000000 1181000000 114000000 197000000 99000000 36522000000 29183000000 24424000000 8393000000 10028000000 7794000000 272000000 43000000 65000000 726000000 536000000 553000000 -104000000 -694000000 -76000000 7835000000 8841000000 7230000000 703000000 1109000000 850000000 -172000000 -4000000 -3000000 6960000000 7728000000 6377000000 10000000 3000000 2000000 6950000000 7725000000 6375000000 17.75 19.62 16.09 17.63 19.46 15.96 392000000 394000000 396000000 394000000 397000000 399000000 6960000000 7728000000 6377000000 173000000 231000000 -221000000 -822000000 373000000 -118000000 0 0 -20000000 0 0 -65000000 -1000000 -17000000 -14000000 -2000000 -56000000 -45000000 9000000 11000000 -1000000 -38000000 -36000000 8000000 -3000000 -6000000 -4000000 5000000 13000000 18000000 -777000000 478000000 -128000000 6183000000 8206000000 6249000000 3000000 2000000 2000000 6180000000 8204000000 6247000000 6960000000 7728000000 6377000000 986000000 831000000 658000000 2395000000 1761000000 1667000000 995000000 647000000 552000000 307000000 230000000 196000000 -26000000 -767000000 0 -524000000 -190000000 -338000000 430000000 204000000 1302000000 825000000 1065000000 508000000 648000000 479000000 59000000 41000000 34000000 96000000 401000000 724000000 -1452000000 9154000000 9312000000 8289000000 39000000 19395000000 38000000 2243000000 2523000000 1474000000 24000000 20000000 8000000 -99000000 34000000 6000000 -2159000000 -21932000000 -1510000000 3193000000 18137000000 3464000000 375000000 11738000000 710000000 1526000000 2512000000 383000000 3690000000 0 387000000 3000000000 2000000000 1500000000 455000000 395000000 337000000 -9000000 65000000 46000000 -2810000000 6581000000 959000000 -139000000 194000000 176000000 4046000000 -5845000000 7914000000 4491000000 10336000000 2422000000 8537000000 4491000000 10336000000 0 434000000 434000000 15064000000 22092000000 36000000 -5236000000 -2679000000 29675000000 9000000 29684000000 -1000000 0 -1000000 -1000000 3000000 3000000 319000000 0 -82000000 240000000 240000000 196000000 196000000 196000000 4000000 1500000000 1500000000 1500000000 0.88 350000000 350000000 350000000 6375000000 6375000000 2000000 6377000000 -128000000 -128000000 0 -128000000 -1000000 -1000000 0 437000000 437000000 15579000000 28116000000 40000000 -6818000000 -2807000000 34507000000 10000000 34517000000 2000000 2000000 324000000 1000000 -104000000 222000000 222000000 230000000 230000000 230000000 4000000 2000000000 2000000000 2000000000 1.04 410000000 410000000 410000000 122000000 1000000 7725000000 7725000000 2000000 7727000000 -1000000 478000000 478000000 0 478000000 50000000 50000000 41000000 41000000 122000000 439000000 439000000 16174000000 35431000000 45000000 -8922000000 -2329000000 40793000000 62000000 40855000000 2000000 2000000 262000000 -95000000 169000000 169000000 307000000 307000000 307000000 5000000 3000000000 3000000000 3000000000 1.20 471000000 471000000 471000000 15000000 6950000000 6950000000 -5000000 6945000000 -6000000 -770000000 -770000000 -1000000 -771000000 -15000000 -2000000 -2000000 116000000 441000000 441000000 16743000000 41910000000 50000000 -12017000000 -3099000000 43978000000 54000000 44032000000 Nature of Operations and Summary of Significant Accounting Policies <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At December 31, 2022 and 2021, the company had such investments with carrying amounts of $369 million and $576 million, respectively. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method. At December 31, 2022 and 2021, the fair value of such investments was $7 million and $217 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interest</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications of prior year amounts have been made to conform to the current year presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract-related Balances</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warranty Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessee, the company accounts for the lease and non-lease components as a single lease component. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to generate revenues. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income. The components of inventories are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,922 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,569 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,634 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,051 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the third quarter of 2021, certain of the company’s businesses utilized the LIFO method of accounting for inventories. During the third quarter of 2021, these businesses, which comprised approximately 5% of consolidated inventories, changed from the LIFO method to the FIFO method. The company believes this change is preferable as it will provide a consistent, uniform costing method for all inventories across the company, better reflect the current value of inventories, and improve comparability with peers. Prior financial statements have not been retrospectively adjusted due to immateriality. The cumulative pre-tax effect of this change in accounting principle of $33 million was recorded as an increase to inventories and a decrease to cost of product revenues in the third quarter of 2021. This change was recorded in the Laboratory Products and </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biopharma Services ($20 million) and Specialty Diagnostics ($13 million) segments. Reductions to cost of revenues as a result of the liquidation of LIFO inventories were nominal during 2020 and the first half of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income. Property, plant and equipment consists of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery, equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,593 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,280 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,333 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-related Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the company has tradenames and in-process research and development that have indefinite lives and which are not amortized. Intangible assets with indefinite lives are reviewed for impairment annually or whenever events or changes in circumstances indicate they may be impaired. The company may perform an optional qualitative assessment. If the company determines that the fair value of the indefinite-lived intangible asset is more likely than not greater than its carrying amount, no additional testing is necessary. If not, or if the company bypasses the optional qualitative assessment, it writes the carrying value down to the fair value, if applicable. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related intangible assets are as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:23.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Definite lived:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product technology</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,977)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backlog</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,347 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,140)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,207 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,625 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,747)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,878 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Indefinite lived:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related intangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,582 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,442 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,860 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,747)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2022 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,279 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated future amortization expense of definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,207 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets in the accompanying balance sheet include operating lease right-of-use assets, investments, deferred tax assets, pension assets, cash surrender value of life insurance, insurance recovery receivables related to product liability matters, certain intangible assets and other assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, the company had $36 million and $33 million, respectively, of intangible assets not derived from acquisitions, net of accumulated amortization, which are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments. At December 31, 2022 and 2021, the company had such investments with carrying amounts of $55 million and $22 million, respectively, and investments measured at NAV of $22 million and $16 million, respectively, which are included in other assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2022, 2021 or 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill by segment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.658%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.584%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences<br/>Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical<br/>Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory<br/>Products and<br/>Biopharma Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,590 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,041 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,143 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,043 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,277 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,461 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,924 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finalization of purchase price allocations for 2021 acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,146 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,965 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,091 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,994 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,196 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Currency Translation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period. Currency transaction gains are included in the accompanying statement of income and in aggregate were $62 million, $25 million and $24 million in 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Singapore dollars, Japanese yen, Hong Kong dollars, Czech koruna and Swedish krona. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment hedges. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses foreign currency-denominated debt, certain foreign-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement. Such amounts were not material to the consolidated financial statements as of and for the year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic materially adversely affected certain of the company’s businesses in 2020, particularly in the Analytical Instruments segment and, to a lesser extent, some businesses within the other three segments. The negative impacts significantly lessened in 2021 and 2022. The extent and duration of negative impacts in the future, which may include inflationary pressures and supply chain disruptions, are uncertain and may require changes to estimates. Actual results could differ from those estimates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the FASB issued new guidance to require entities to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under these programs for each period presented. The company will adopt some aspects of this guidance in 2023 using a retrospective method and other aspects in 2024 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures; however, the impact in future periods will be dependent on the extent of arrangements of this nature entered into by the company</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to require entities to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. The company adopted this guidance in the fourth quarter of 2022 using a prospective method. The adoption of this guidance did not have a material impact on the company’s disclosures; however, the impact in future periods will be dependent on the extent of future transactions of this nature entered into by the company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB amended guidance to recognize and measure contract assets and contract liabilities acquired in a business combination. Generally, this new guidance will result in the company recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The company adopted this guidance in the fourth quarter of 2021 retrospectively to all business combinations completed in the first three quarters of 2021 and prospectively to all future business combinations. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements for acquisitions that closed in 2021 and 2022; however, the impact in future periods will be dependent on the contract assets and contract liabilities acquired in future business combinations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FASB amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. The company adopted the guidance in the third quarter of 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company adopted this guidance in 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates.</span></div>In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. The company adopted the guidance in 2020 using a modified retrospective method. The adoption of this guidance reduced accounts receivable and retained earnings by $1 million on January 1, 2020. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At December 31, 2022 and 2021, the company had such investments with carrying amounts of $369 million and $576 million, respectively. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method. At December 31, 2022 and 2021, the fair value of such investments was $7 million and $217 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interest</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events.</span></div> 369000000 576000000 7000000 217000000 0.60 0.40 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications of prior year amounts have been made to conform to the current year presentation.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract-related Balances</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.</span></div> Warranty ObligationsThe company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.</span></div>As a lessee, the company accounts for the lease and non-lease components as a single lease component. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to generate revenues. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value.</span></div> InventoriesInventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income. The components of inventories are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,922 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,569 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,634 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,051 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2405000000 1922000000 660000000 676000000 2569000000 2453000000 5634000000 5051000000 0.05 33000000 -33000000 20000000 -20000000 13000000 -13000000 Property, Plant and EquipmentProperty, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income. P25Y P40Y P3Y P10Y Property, plant and equipment consists of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Machinery, equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,593 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,280 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,333 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 454000000 431000000 3153000000 2575000000 7967000000 7020000000 2695000000 2567000000 14269000000 12593000000 4989000000 4260000000 9280000000 8333000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-related Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.</span></div> P20Y <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related intangible assets are as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:23.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Definite lived:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product technology</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,977)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backlog</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,347 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,140)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,207 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,625 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,747)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,878 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Indefinite lived:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related intangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,582 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,442 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,860 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,747)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related intangible assets are as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:23.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Definite lived:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product technology</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,977)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backlog</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,347 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,140)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,207 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,625 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,747)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,878 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Indefinite lived:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related intangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,582 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,442 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,860 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,747)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 21792000000 8330000000 13462000000 22802000000 7792000000 15010000000 5882000000 4360000000 1522000000 6041000000 3977000000 2064000000 1635000000 1008000000 627000000 1722000000 919000000 803000000 1038000000 442000000 596000000 1060000000 59000000 1001000000 30347000000 14140000000 16207000000 31625000000 12747000000 18878000000 1235000000 1235000000 1235000000 1235000000 31582000000 14140000000 17442000000 32860000000 12747000000 20113000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2022 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,279 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated future amortization expense of definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,207 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2279000000 1863000000 1582000000 1322000000 1296000000 7865000000 16207000000 36000000 33000000 P20Y Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments. 55000000 22000000 22000000 16000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2022, 2021 or 2020.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill by segment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.658%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.584%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences<br/>Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical<br/>Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory<br/>Products and<br/>Biopharma Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,590 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,041 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,143 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,043 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,277 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,461 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,924 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finalization of purchase price allocations for 2021 acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,146 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,965 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,091 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,994 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,196 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 8590000000 5079000000 3370000000 9002000000 26041000000 1560000000 56000000 8000000 14400000000 16024000000 -7000000 -92000000 -101000000 59000000 -141000000 10143000000 5043000000 3277000000 23461000000 41924000000 0 24000000 0 0 24000000 9000000 0 0 168000000 177000000 -6000000 -102000000 -186000000 -635000000 -929000000 10146000000 4965000000 3091000000 22994000000 41196000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.</span></div> Currency TranslationAll assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period. 62000000 25000000 24000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Singapore dollars, Japanese yen, Hong Kong dollars, Czech koruna and Swedish krona. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment hedges. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses foreign currency-denominated debt, certain foreign-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.</span> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement. Such amounts were not material to the consolidated financial statements as of and for the year ended December 31, 2022.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div> The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic materially adversely affected certain of the company’s businesses in 2020, particularly in the Analytical Instruments segment and, to a lesser extent, some businesses within the other three segments. The negative impacts significantly lessened in 2021 and 2022. The extent and duration of negative impacts in the future, which may include inflationary pressures and supply chain disruptions, are uncertain and may require changes to estimates. Actual results could differ from those estimates. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the FASB issued new guidance to require entities to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under these programs for each period presented. The company will adopt some aspects of this guidance in 2023 using a retrospective method and other aspects in 2024 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures; however, the impact in future periods will be dependent on the extent of arrangements of this nature entered into by the company</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to require entities to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. The company adopted this guidance in the fourth quarter of 2022 using a prospective method. The adoption of this guidance did not have a material impact on the company’s disclosures; however, the impact in future periods will be dependent on the extent of future transactions of this nature entered into by the company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB amended guidance to recognize and measure contract assets and contract liabilities acquired in a business combination. Generally, this new guidance will result in the company recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The company adopted this guidance in the fourth quarter of 2021 retrospectively to all business combinations completed in the first three quarters of 2021 and prospectively to all future business combinations. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements for acquisitions that closed in 2021 and 2022; however, the impact in future periods will be dependent on the contract assets and contract liabilities acquired in future business combinations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FASB amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. The company adopted the guidance in the third quarter of 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company adopted this guidance in 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates.</span></div>In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. The company adopted the guidance in 2020 using a modified retrospective method. The adoption of this guidance reduced accounts receivable and retained earnings by $1 million on January 1, 2020. -1000000 -1000000 AcquisitionsThe company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not expected to be tax deductible.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the purchase price and net assets acquired are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.913%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In billions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Binding Site</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt settled</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash acquired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net tangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.71 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average amortization period for definite-lived intangible assets is 17 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary allocation of the purchase price for the acquisition of The Binding Site is based on estimates of the fair value of the net assets acquired and is subject to adjustment upon finalization, largely with respect to acquired intangible assets and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Fourier-transform infrared gas analysis technologies. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 15, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, the Belgium-based European viral vector manufacturing business of Groupe Novasep SAS. The European viral vector manufacturing business provides manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities for cell and gene vaccines and therapies. The goodwill recorded as a result of this business combination is not tax deductible.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company. Mesa Biotech has developed and commercialized a polymerase chain reaction (PCR) based rapid point-of-care testing platform available for detecting infectious diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care. The goodwill recorded as a result of this business combination is not tax deductible.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Biopharma Services segment, of a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers as well. The goodwill recorded as a result of this business combination is not tax deductible.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, PPD, Inc., a U.S.-based global provider of clinical research services to the pharma and biotech industry. The addition of PPD’s clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their productivity within the drug development process. The goodwill recorded as a result of this business combination is not tax deductible.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2021, the company acquired, within the Life Sciences Solutions segment, PeproTech, Inc., a U.S.-based developer and manufacturer of recombinant proteins. PeproTech provides bioscience reagents known as recombinant proteins, including cytokines and growth factors. The acquisition expands the segment’s bioscience offerings. The goodwill recorded as a result of this business combination is not tax deductible. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2021, the company acquired, within the Life Sciences Solutions segment, cell sorting technology assets, an Ireland-based life sciences distributor and a developer of a digital PCR platform; within the Analytical Instruments segment, a Belgium-based developer of micro-chip based technology for liquid chromatography columns; and within the Specialty Diagnostics segment, a transplant diagnostics information system provider. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PPD</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PeproTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Viral Vector Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mesa Biotech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lengnau biologics manufacturing facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of equity awards exchanged</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash acquired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,036 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product technology</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt assumed</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities assumed</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,034)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redeemable noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,036 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we finalized the allocations of the purchase price for the Lengnau biologics manufacturing facility, PPD, Inc. and PeproTech, Inc., largely with respect to definite-lived intangible assets, property, plant and equipment, contract liabilities, </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity method investments, asset retirement obligations, defined benefit pension plans, assumed contingent consideration and the related deferred taxes. The adjustments to the income statement recorded during 2022 were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average amortization periods for definite-lived intangible assets acquired in 2021 are 17 years for customer relationships, 11 years for product technology, 7 years for tradenames and 3 years for backlog. The weighted average amortization period for all definite-lived intangible assets acquired in 2021 is 14 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Unaudited Pro Forma Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Thermo Fisher Scientific Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The historical consolidated financial information of the company and PPD has been adjusted in the pro forma information to give effect to pro forma events that are directly attributable to the acquisitions and related financing arrangements and are factually supportable. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reflect the acquisition of PPD as if it had occurred on January 1, 2020, the unaudited pro forma results include adjustments to reflect, among other things, the incremental intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset and the interest expense from debt financings obtained to partially fund the cash consideration transferred. Pro forma adjustments were tax effected at the company's historical statutory rates in effect for the respective periods. The unaudited pro forma amounts are not necessarily indicative of the combined results of operations that would have been realized had the acquisitions and related financings occurred on the aforementioned dates, nor are they meant to be indicative of any anticipated combined results of operations that the company will experience after the transaction. In addition, the amounts do not include any adjustments for actions that may be taken following the completion of the transaction, such as expected cost savings, operating synergies, or revenue enhancements that may be realized subsequent to the transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2021, excludes $312 million of transaction costs, initial restructuring costs, and debt extinguishment costs directly attributable to the PPD acquisition that were included in the determination of net income attributable to Thermo Fisher Scientific Inc. for that period. These items have reduced pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2020, by $197 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s results would not have been materially different from its pro forma results had the company’s other 2021 acquisitions occurred at the beginning of 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PPD’s revenues and losses attributable to Thermo Fisher Scientific Inc. in 2021, subsequent to the acquisition date, were $378 million and $(60) million, respectively. The loss includes non-recurring transaction and compensation costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the company acquired, within the Life Sciences Solutions segment, a U.S.-based provider of a spectral dye platform for high-resolution biology applications which will extend the company’s existing tools for protein and cell analysis applications.</span></div> The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not expected to be tax deductible.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the purchase price and net assets acquired are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.913%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In billions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Binding Site</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt settled</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash acquired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net tangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.71 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PPD</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PeproTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Viral Vector Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mesa Biotech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lengnau biologics manufacturing facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of equity awards exchanged</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash acquired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,036 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product technology</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradenames</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backlog</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt assumed</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities assumed</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,034)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redeemable noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,036 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we finalized the allocations of the purchase price for the Lengnau biologics manufacturing facility, PPD, Inc. and PeproTech, Inc., largely with respect to definite-lived intangible assets, property, plant and equipment, contract liabilities, </span></div>equity method investments, asset retirement obligations, defined benefit pension plans, assumed contingent consideration and the related deferred taxes. The adjustments to the income statement recorded during 2022 were not material. 2420000000 310000000 20000000.00 2710000000 1070000000.00 1770000000 150000000 280000000 2710000000 P17Y 0 0 0 0 0 17237000000 1946000000 848000000 421000000 17000000 298000000 43000000 0 0 0 65000000 1000000 117000000 1244000000 83000000 18000000 14000000 0 12000000 16036000000 1863000000 830000000 472000000 18000000 403000000 2477000000 58000000 39000000 54000000 0 12000000 527000000 18000000 59000000 2000000 93000000 2000000 6257000000 510000000 302000000 0 0 2000000 0 282000000 25000000 279000000 0 224000000 594000000 0 0 2000000 0 2000000 1038000000 13949000000 1198000000 600000000 237000000 18000000 198000000 1060000000 11000000 3000000 3000000 364000000 2000000 1539000000 0 59000000 0 0 1000000 1782000000 192000000 80000000 72000000 0 27000000 90000000 0 24000000 0 82000000 0 4299000000 0 0 0 0 0 2034000000 22000000 35000000 33000000 375000000 11000000 122000000 16036000000 1863000000 830000000 472000000 18000000 403000000 P17Y P11Y P7Y P3Y P14Y <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1, 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Thermo Fisher Scientific Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 44886000000 36887000000 7369000000 5361000000 312000000 -197000000 378000000 -60000000 Revenues and Contract-related Balances <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by type are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumables</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,218 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region based on customer location are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North America</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia-Pacific</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other regions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,218 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2022 was $26.97 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 55% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract-related Balances</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:70.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current contract assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,312 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent contract assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the current contract liabilities balance at December 31, 2021 and 2020 was recognized in revenues during 2022 and 2021, respectively.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by type are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumables</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,218 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region based on customer location are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North America</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia-Pacific</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other regions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,218 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 20624000000 22608000000 18527000000 7924000000 7753000000 6779000000 16367000000 8850000000 6912000000 44915000000 39211000000 32218000000 24594000000 19659000000 17081000000 10762000000 11134000000 8284000000 8115000000 7218000000 5822000000 1444000000 1200000000 1031000000 44915000000 39211000000 32218000000 26970000000 0.55 P12M Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:70.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current contract assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,312 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent contract assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1312000000 968000000 7000000 9000000 2601000000 2655000000 1179000000 1238000000 Business Segment and Geographical Information <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s financial performance is reported in four segments. A description of each segment follows. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analytical Instruments: provides a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. These products and services are used by customers in </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specialty Diagnostics: offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which improves patient care in a more cost-efficient manner. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory Products and Biopharma Services: offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more efficient, productive and cost-effective. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segment Information</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment Income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal reportable segments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,985 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,556 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues adjustments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring and other costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated operating income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,794 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated income before taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,841 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated depreciation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of significant transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges/credits related to product liability litigation. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,534 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,711 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate/other (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,154 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate/other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated capital expenditures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,243 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,523 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,474 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geographical Information</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,793 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated long-lived assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,873 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,864 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,687 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Revenues are attributed to countries based on customer location.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Includes property, plant and equipment, net, and operating lease ROU assets.</span></div> 4 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segment Information</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment Income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal reportable segments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,985 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,556 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues adjustments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring and other costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated operating income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,794 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated income before taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,841 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated depreciation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of significant transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges/credits related to product liability litigation. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,534 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,711 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate/other (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,154 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate/other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated capital expenditures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,243 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,523 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,474 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.</span></div> 13532000000 15631000000 12168000000 6624000000 6069000000 5124000000 4763000000 5659000000 5343000000 22511000000 14862000000 12245000000 -2515000000 -3010000000 -2662000000 44915000000 39211000000 32218000000 5582000000 7817000000 6109000000 1507000000 1197000000 808000000 1024000000 1280000000 1368000000 2872000000 1844000000 1271000000 10985000000 12138000000 9556000000 46000000 8000000 6000000 37000000 144000000 -10000000 114000000 197000000 99000000 2395000000 1761000000 1667000000 8393000000 10028000000 7794000000 272000000 43000000 65000000 726000000 536000000 553000000 -104000000 -694000000 -76000000 7835000000 8841000000 7230000000 214000000 197000000 140000000 83000000 83000000 76000000 75000000 128000000 100000000 614000000 423000000 342000000 986000000 831000000 658000000 21848000000 22751000000 20209000000 10019000000 9692000000 9773000000 5542000000 6010000000 6534000000 51281000000 52639000000 22711000000 8464000000 4031000000 9825000000 97154000000 95123000000 69052000000 490000000 810000000 392000000 140000000 79000000 74000000 112000000 167000000 175000000 1403000000 1327000000 772000000 98000000 140000000 61000000 2243000000 2523000000 1474000000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geographical Information</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,793 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated long-lived assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,873 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,864 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,687 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Revenues are attributed to countries based on customer location.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Includes property, plant and equipment, net, and operating lease ROU assets.</span></div> 23820000000 18907000000 16435000000 3793000000 3444000000 2797000000 17302000000 16860000000 12986000000 44915000000 39211000000 32218000000 6308000000 5578000000 3686000000 4565000000 4286000000 3001000000 10873000000 9864000000 6687000000 Other Income/(Expense) <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In all periods, other income/(expense) includes currency transaction gains and losses on non-operating monetary assets and liabilities and net periodic pension benefit cost/income, excluding the service cost component which is included in operating expenses on the accompanying statement of income. In 2022, other income/(expense) includes $161 million of net losses on investments, $67 million of net gains on derivative instruments to address certain foreign currency risks, $26 million of losses on the early extinguishment of debt (Note 10), and $2 million of net settlement gains on pension plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, other income/(expense) includes $767 million of losses on the early extinguishment of debt (Note 10), $36 million of financing costs associated with obtaining bridge financing commitments in connection with the agreement to acquire PPD (Note 2), offset in part by $66 million of net gains on investments. The company had a cash outlay of $36 million in 2021 associated with obtaining the bridge financing commitments, included in other financing activities, net, in the accompanying statement of cash flows.</span></div>In 2020, other income/(expense) includes $81 million of financing costs for a terminated acquisition, primarily for loan commitment fees and entering into hedging contracts and $42 million reclassified from accumulated other comprehensive items related to a hedge arrangement (Note 14), offset in part by $10 million of net gains on investments. The company had a cash outlay of $51 million in 2020 associated with obtaining the loan commitments included in other financing activities, net, in the accompanying statement of cash flows. -161000000 67000000 -26000000 2000000 -767000000 36000000 66000000 36000000 81000000 -42000000 10000000 51000000 Stock-based Compensation Expense <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has stock-based compensation plans for its key employees, directors and others. These plans permit the grant of a variety of stock and stock-based awards, including restricted stock units, stock options or performance-based shares, as determined by the compensation committee of the company’s Board of Directors or, for certain non-officer grants, by the company’s employee equity committee, which consists of its chief executive officer. The company generally issues new shares of its common stock to satisfy option exercises and restricted unit vesting. Grants of stock options and restricted units generally provide that in the event of both a change in control of the company and a qualifying termination of an option or unit holder’s employment, all options and service-based restricted unit awards held by the recipient become immediately vested (unless an employment or other agreement with the employee provides for different treatment).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate was calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes option pricing model are as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected stock price volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected annual dividend</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average per share grant-date fair values of options granted during 2022, 2021 and 2020 were $135.07, $123.97 and $61.19, respectively. The total intrinsic value of options exercised during the same periods was $336 million, $501 million and $457 million, respectively. The intrinsic value is the difference between the market value of the shares on the exercise date and the exercise price of the option.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the company’s option activity for the year ended December 31, 2022 is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining contractual term <br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate intrinsic <br/>value <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319.95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">530.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199.85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/expired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and unvested expected to vest at December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,114 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercisable at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">891 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, there was $228 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be recognized through 2026 with a weighted average amortization period of 2.4 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share/Unit Awards</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the company’s restricted unit activity for the year ended December 31, 2022 is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Units<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>average<br/>grant-date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unvested at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">520.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">510.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of shares vested during 2022, 2021 and 2020 was $163 million, $151 million and $126 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, there was $200 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is expected to be recognized through 2026 with a weighted average amortization period of 1.9 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qualifying employees are eligible to participate in an employee stock purchase plan sponsored by the company. Shares may be purchased under the program at 95% of the fair market value at the end of the purchase period and the shares purchased are not subject to a holding period. Shares are purchased through payroll deductions of up to 10% of each participating employee’s qualifying gross wages. The company issued 0.2 million, 0.1 million and 0.2 million shares, respectively, of its common stock in 2022, 2021 and 2020 under the employee stock purchase plan.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate was calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share/Unit Awards</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.</span></div> P3Y P5Y P7Y P10Y <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes option pricing model are as follows: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected stock price volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected annual dividend</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.26 0.26 0.22 0.020 0.008 0.011 P4Y8M12D P4Y3M18D P4Y3M18D 0.002 0.002 0.003 135.07 123.97 61.19 336000000 501000000 457000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the company’s option activity for the year ended December 31, 2022 is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining contractual term <br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate intrinsic <br/>value <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319.95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">530.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199.85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/expired</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and unvested expected to vest at December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,114 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercisable at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">891 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 6000000.0 319.95 800000 530.48 900000 199.85 300000 503.76 5600000 359.27 P4Y2M12D 1125000000 5300000 351.97 P4Y8M12D 1114000000 2900000 251.44 P2Y9M18D 891000000 228000000 P2Y4M24D P3Y P4Y <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the company’s restricted unit activity for the year ended December 31, 2022 is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Units<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>average<br/>grant-date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unvested at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">520.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">510.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 800000 425.39 400000 520.83 400000 375.77 100000 510.37 700000 495.39 163000000 151000000 126000000 200000000 P1Y10M24D 0.95 0.10 200000 100000 200000 Pension and Other Postretirement Benefit Plans <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">401(k) Savings Plan and Other Defined Contribution Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s 401(k) savings and other defined contribution plans cover the majority of the company’s eligible U.S. and certain non-U.S. employees. Contributions to the plans are made by both the employee and the company. Company contributions are based on the level of employee contributions. Company contributions to these plans are based on formulas determined by the company. In 2022, 2021 and 2020, the company charged to expense $402 million, $299 million and $254 million, respectively, related to its defined contribution plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Benefit Pension Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined. During 2022, 2021 and 2020, the company made cash contributions of approximately $41 million, $34 million and $96 million, respectively. Contributions to the plans included in the following table are estimated at between $30 and $50 million for 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated benefit obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,475 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in projected benefit obligations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation at beginning of year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan participants' contributions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(447)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation at end of year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,260 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,069 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in fair value of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employer contributions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan participants' contributions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts recognized in balance sheet</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liability</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amount recognized</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts recognized in accumulated other comprehensive items</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net actuarial loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amount recognized</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For domestic pension plans, actuarial gains experienced in 2022 were driven by increases in the weighted average discount rates used to determine the projected benefit obligation, as well as differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns. For non-U.S. pension plans, actuarial gains experienced in 2022 were principally driven by increases in the weighted average discount rates used to determine the projected benefit obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For domestic pension plans, actuarial losses experienced in 2021 were driven by differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns, which were partially offset by actuarial gains due to increases in the weighted average discount rates used to determine the projected benefit obligation differences. For non-U.S. pension plans, actuarial gains experienced in 2021 were principally driven by increases in the weighted average discount rates used to determine the projected benefit obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2022 and 2021 and are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average assumptions used to determine projected benefit obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate for determining benefit obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate for cash balance plans</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average rate of increase in employee compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year, as presented in the following table:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.646%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average assumptions used to determine net benefit cost (income)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate - service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate - interest cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average rate of increase in employee compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected long-term rate of return on assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with projected benefit obligations in excess of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with accumulated benefit obligations in excess of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement date used to determine benefit information is December 31 for all plan assets and benefit obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic pension benefit cost (income) includes the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.646%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Components of net benefit cost (income)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xNzgvZnJhZzowNjljMThkNjJkY2I0ZjdmODU0ODhlNWUyODFiN2MxYy90YWJsZTplMTQwMTQ2NmY5NDQ0NmMzYTA5Mjg0MzQzN2U2NmM4My90YWJsZXJhbmdlOmUxNDAxNDY2Zjk0NDQ2YzNhMDkyODQzNDM3ZTY2YzgzXzQtMC0xLTEtOTU5MTU_943e2ce2-6752-488a-95ca-d929567e9236">Interest cost on benefit obligation</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xNzgvZnJhZzowNjljMThkNjJkY2I0ZjdmODU0ODhlNWUyODFiN2MxYy90YWJsZTplMTQwMTQ2NmY5NDQ0NmMzYTA5Mjg0MzQzN2U2NmM4My90YWJsZXJhbmdlOmUxNDAxNDY2Zjk0NDQ2YzNhMDkyODQzNDM3ZTY2YzgzXzUtMC0xLTEtOTU5MTU_a396288c-ac21-4bb0-aa31-00a8ce1da07c">Expected return on plan assets</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xNzgvZnJhZzowNjljMThkNjJkY2I0ZjdmODU0ODhlNWUyODFiN2MxYy90YWJsZTplMTQwMTQ2NmY5NDQ0NmMzYTA5Mjg0MzQzN2U2NmM4My90YWJsZXJhbmdlOmUxNDAxNDY2Zjk0NDQ2YzNhMDkyODQzNDM3ZTY2YzgzXzYtMC0xLTEtOTU5MTU_9e956cce-dd35-4d65-afc3-9aee23c5a2af">Amortization of actuarial net loss</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xNzgvZnJhZzowNjljMThkNjJkY2I0ZjdmODU0ODhlNWUyODFiN2MxYy90YWJsZTplMTQwMTQ2NmY5NDQ0NmMzYTA5Mjg0MzQzN2U2NmM4My90YWJsZXJhbmdlOmUxNDAxNDY2Zjk0NDQ2YzNhMDkyODQzNDM3ZTY2YzgzXzctMC0xLTEtOTU5MTU_c423f7e2-71b4-4a77-8379-5f020aa5873b">Amortization of prior service benefit</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xNzgvZnJhZzowNjljMThkNjJkY2I0ZjdmODU0ODhlNWUyODFiN2MxYy90YWJsZTplMTQwMTQ2NmY5NDQ0NmMzYTA5Mjg0MzQzN2U2NmM4My90YWJsZXJhbmdlOmUxNDAxNDY2Zjk0NDQ2YzNhMDkyODQzNDM3ZTY2YzgzXzgtMC0xLTEtOTU5MTU_678fac42-c2c1-4192-a183-f1a529e9d055">Settlement/curtailment loss</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are estimated using the same assumptions used in determining the company’s benefit obligation at December 31, 2022. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Domestic Pension Plan Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-U.S. Pension Plan Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds, multi-asset funds, alternative investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% - 90% for fixed income funds, 0% - 35% for multi-asset funds, and 0% - 45% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the company’s plan assets at December 31, 2022 and 2021, by asset category are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.420%"/><td style="width:0.1%"/></tr><tr style="height:41pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not subject to leveling (a)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Domestic pension plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International equity funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total domestic pension plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. pension plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Multi-asset funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash / money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-U.S. pension plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. </span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.420%"/><td style="width:0.1%"/></tr><tr style="height:41pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not subject to leveling (a)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Domestic pension plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International equity funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total domestic pension plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. pension plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedge funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Multi-asset funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alternative investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash / money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-U.S. pension plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,002 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. </span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables above present the fair value of the company’s plan assets in accordance with the fair value hierarchy (Note 14). Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. The fair value amounts of these investments presented in the above tables are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension plan assets. These investments were also redeemable at the balance sheet date or within limited time restrictions.</span></div> 402000000 299000000 254000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Benefit Pension Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.</span></div>The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined.<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Domestic Pension Plan Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-U.S. Pension Plan Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds, multi-asset funds, alternative investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% - 90% for fixed income funds, 0% - 35% for multi-asset funds, and 0% - 45% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.</span></div> 41000000 34000000 96000000 30000000 50000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated benefit obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,475 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in projected benefit obligations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation at beginning of year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan participants' contributions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(447)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation at end of year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,260 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,069 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in fair value of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employer contributions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan participants' contributions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts recognized in balance sheet</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liability</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amount recognized</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts recognized in accumulated other comprehensive items</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net actuarial loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amount recognized</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 995000000 1260000000 1016000000 1475000000 1260000000 1302000000 1552000000 1486000000 0 0 51000000 170000000 0 0 34000000 27000000 27000000 23000000 20000000 11000000 0 0 31000000 7000000 0 0 9000000 6000000 210000000 -20000000 447000000 57000000 82000000 85000000 19000000 30000000 0 0 100000000 54000000 995000000 1260000000 1069000000 1552000000 1226000000 1267000000 1302000000 1160000000 0 0 14000000 158000000 -212000000 37000000 -347000000 14000000 5000000 7000000 36000000 27000000 0 0 31000000 7000000 0 0 9000000 6000000 82000000 85000000 19000000 30000000 0 0 -96000000 -26000000 937000000 1226000000 868000000 1302000000 -58000000 -34000000 -201000000 -250000000 0 32000000 81000000 205000000 6000000 7000000 11000000 10000000 52000000 59000000 271000000 445000000 -58000000 -34000000 -201000000 -250000000 -200000000 -157000000 -74000000 -167000000 0 0 -4000000 -3000000 200000000 157000000 70000000 164000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2022 and 2021 and are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average assumptions used to determine projected benefit obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate for determining benefit obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate for cash balance plans</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average rate of increase in employee compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year, as presented in the following table:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.646%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average assumptions used to determine net benefit cost (income)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate - service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate - interest cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average rate of increase in employee compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected long-term rate of return on assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.0501 0.0270 0.0391 0.0145 0.0496 0.0258 0.0219 0.0125 0.0278 0.0273 0.0100 0.0065 0.0121 0.0270 0.0233 0.0313 0.0136 0.0080 0.0144 0.0273 0.0230 0.0227 0.0475 0.0425 0.0500 0.0233 0.0202 0.0233 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with projected benefit obligations in excess of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1636000000 2010000000 1296000000 1521000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with accumulated benefit obligations in excess of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1583000000 1937000000 1294000000 1521000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic pension benefit cost (income) includes the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.646%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Components of net benefit cost (income)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xNzgvZnJhZzowNjljMThkNjJkY2I0ZjdmODU0ODhlNWUyODFiN2MxYy90YWJsZTplMTQwMTQ2NmY5NDQ0NmMzYTA5Mjg0MzQzN2U2NmM4My90YWJsZXJhbmdlOmUxNDAxNDY2Zjk0NDQ2YzNhMDkyODQzNDM3ZTY2YzgzXzQtMC0xLTEtOTU5MTU_943e2ce2-6752-488a-95ca-d929567e9236">Interest cost on benefit obligation</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xNzgvZnJhZzowNjljMThkNjJkY2I0ZjdmODU0ODhlNWUyODFiN2MxYy90YWJsZTplMTQwMTQ2NmY5NDQ0NmMzYTA5Mjg0MzQzN2U2NmM4My90YWJsZXJhbmdlOmUxNDAxNDY2Zjk0NDQ2YzNhMDkyODQzNDM3ZTY2YzgzXzUtMC0xLTEtOTU5MTU_a396288c-ac21-4bb0-aa31-00a8ce1da07c">Expected return on plan assets</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xNzgvZnJhZzowNjljMThkNjJkY2I0ZjdmODU0ODhlNWUyODFiN2MxYy90YWJsZTplMTQwMTQ2NmY5NDQ0NmMzYTA5Mjg0MzQzN2U2NmM4My90YWJsZXJhbmdlOmUxNDAxNDY2Zjk0NDQ2YzNhMDkyODQzNDM3ZTY2YzgzXzYtMC0xLTEtOTU5MTU_9e956cce-dd35-4d65-afc3-9aee23c5a2af">Amortization of actuarial net loss</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xNzgvZnJhZzowNjljMThkNjJkY2I0ZjdmODU0ODhlNWUyODFiN2MxYy90YWJsZTplMTQwMTQ2NmY5NDQ0NmMzYTA5Mjg0MzQzN2U2NmM4My90YWJsZXJhbmdlOmUxNDAxNDY2Zjk0NDQ2YzNhMDkyODQzNDM3ZTY2YzgzXzctMC0xLTEtOTU5MTU_c423f7e2-71b4-4a77-8379-5f020aa5873b">Amortization of prior service benefit</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xNzgvZnJhZzowNjljMThkNjJkY2I0ZjdmODU0ODhlNWUyODFiN2MxYy90YWJsZTplMTQwMTQ2NmY5NDQ0NmMzYTA5Mjg0MzQzN2U2NmM4My90YWJsZXJhbmdlOmUxNDAxNDY2Zjk0NDQ2YzNhMDkyODQzNDM3ZTY2YzgzXzgtMC0xLTEtOTU5MTU_678fac42-c2c1-4192-a183-f1a529e9d055">Settlement/curtailment loss</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 0 0 34000000 27000000 24000000 27000000 23000000 35000000 20000000 11000000 18000000 45000000 40000000 47000000 26000000 19000000 19000000 -4000000 -7000000 -6000000 -7000000 -12000000 -10000000 0 0 0 -1000000 0 -1000000 0 0 0 2000000 0 -8000000 -14000000 -10000000 -6000000 32000000 31000000 40000000 Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. pension benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 85000000 47000000 81000000 48000000 81000000 51000000 80000000 55000000 79000000 55000000 373000000 313000000 0.10 0.10 0.80 0 0.25 0.30 0.90 0 0.35 0 0.45 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the company’s plan assets at December 31, 2022 and 2021, by asset category are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.420%"/><td style="width:0.1%"/></tr><tr style="height:41pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not subject to leveling (a)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Domestic pension plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International equity funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total domestic pension plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. pension plan assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Multi-asset funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash / money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-U.S. pension plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. </span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.420%"/><td style="width:0.1%"/></tr><tr style="height:41pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not subject to leveling (a)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Domestic pension plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International equity funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total domestic pension plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. pension plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedge funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Multi-asset funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative funds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alternative investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash / money market funds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-U.S. pension plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,002 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. </span></td></tr></table></div> 89000000 0 0 0 89000000 91000000 0 0 0 91000000 739000000 0 0 0 739000000 18000000 0 0 0 18000000 937000000 0 0 0 937000000 8000000 0 0 0 8000000 299000000 0 0 0 299000000 56000000 0 0 0 56000000 190000000 0 0 0 190000000 306000000 0 306000000 0 0 9000000 4000000 0 0 5000000 868000000 4000000 306000000 0 558000000 124000000 0 0 0 124000000 117000000 0 0 0 117000000 966000000 0 0 0 966000000 19000000 0 0 0 19000000 1226000000 0 0 0 1226000000 17000000 0 0 0 17000000 651000000 0 0 0 651000000 3000000 0 0 0 3000000 73000000 0 0 0 73000000 253000000 0 0 0 253000000 1000000 0 0 0 1000000 295000000 0 295000000 0 0 9000000 5000000 0 0 4000000 1302000000 5000000 295000000 0 1002000000 Income Taxes<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income before provision for income taxes are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,340 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,835 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,841 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,230 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the provision for income taxes are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred income tax provision (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(997)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory federal income tax rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes at statutory rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,645 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases (decreases) resulting from:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign rate differential</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Excess tax benefits from stock options and restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (reversal of) tax reserves, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intra-entity transfers</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestication transaction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowances</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Withholding taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax return reassessments and settlements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the company settled an IRS audit relating to the 2017 and 2018 tax years. The company recorded a $208 million net tax benefit primarily from this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $658 million. The company recorded $49 million of charges for expired tax credits and other related components of the settlement. The company recorded a charge of $395 million to establish a valuation allowance against </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain U.S. foreign tax credits which the company believes will more likely than not expire unutilized. The company also recorded $101 million of additional net unrecognized tax benefit liabilities related to other tax audits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the company recorded a $188 million income tax benefit related to the deferred tax implications of an intra-entity transfer of assets. Also in 2021, the company recorded a $96 million income tax benefit related to a capital loss resulting from certain intra-entity transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the company settled an IRS audit relating to the 2014, 2015, and 2016 tax years. The company recorded a $25 million net tax benefit primarily from this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $378 million, of which $144 million was reclassified to income taxes payable. The company recorded $53 million of charges for expired tax credits and other related components of the settlement. The company recorded a charge of $156 million to establish a valuation allowance against certain U.S. foreign tax credits which the company believes will more likely than not expire unutilized. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the company recorded a $263 million income tax benefit related to a domestication transaction involving the transfer of certain non-U.S. subsidiaries to the U.S., including interest expense of those subsidiaries. The company also recorded a valuation allowance of $212 million against the amount of interest expense that the company believes will more likely than not go unused. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign tax credits discussed below are the result of foreign earnings and profits remitted or deemed remitted to the U.S. during the reporting year and the U.S. treatment of taxes paid in the foreign jurisdictions in the years those profits were originally earned.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the company implemented foreign tax credit planning in Sweden which resulted in $96 million of foreign tax credits, with no related incremental U.S. income tax expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company generally receives a tax deduction upon the exercise of non-qualified stock options by employees, or the vesting of restricted stock units held by employees, for the difference between the exercise price and the market price of the underlying common stock on the date of exercise. The company uses the incremental tax benefit approach for utilization of tax attributes. These excess tax benefits reduce the tax provision. In 2022, 2021 and 2020, the company's tax provision was reduced by $80 million, $124 million and $114 million, respectively, of such benefits. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax asset (liability) in the accompanying balance sheet consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax asset (liability)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss and credit carryforwards</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,951 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserves and accruals</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory basis difference</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development and other capitalized costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (gains) losses on hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net before valuation allowance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(662)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,861)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,984)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,829)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company estimates the degree to which tax assets and loss and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2022, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the valuation allowance are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions (reductions) charged to income tax provision, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions due to acquisitions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation and other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the company had net federal, state and non-U.S. net operating loss carryforwards of $68 million, $97 million and $1.16 billion, respectively. Use of the carryforwards is limited based on the future income of certain subsidiaries. Of the federal net operating loss carryforwards, $33 million expire in the years 2023 through 2037, and the remainder do not expire. The state net operating loss carryforwards expire in the years 2023 through 2042. Of the net non-U.S. net operating loss carryforwards, $422 million expire in the years 2025 through 2042, and the remainder do not expire.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the company had foreign tax credit carryforwards of $551 million and deferred interest carryforwards of $445 million. The foreign tax credit carryforwards will expire in the years 2025 through 2032 while deferred interest carryforwards do not expire.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal taxes have been recorded on approximately $29 billion of undistributed foreign earnings as of December 31, 2022. A provision has not been made for certain U.S. state income taxes or additional non-U.S. taxes that would be due when cash is repatriated to the U.S. as the company’s undistributed foreign earnings are intended to be reinvested outside of the U.S. indefinitely. The determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed. The company’s intent is to only make distributions from non-U.S. subsidiaries in the future when they can be made at no net tax cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the company had $0.57 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions due to acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions of current year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Closure of tax years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the unrecognized tax benefits are classified as long-term liabilities. The company does not expect its unrecognized tax benefits to change significantly over the next twelve months.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the company’s unrecognized tax benefits increased by $143 million as a result of uncertain tax positions relating to foreign tax positions and decreased $610 million relating to U.S. federal and state tax positions which included $658 million from the settlement of the IRS audit of the 2017 and 2018 tax years. The company also assumed $15 million of uncertain tax benefits as part of the acquisition of PPD.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the company’s unrecognized tax benefits increased by $80 million as a result of uncertain tax positions relating to foreign tax positions and decreased $75 million relating to U.S. federal and state tax positions. The company also assumed $26 million of uncertain tax benefits as part of the acquisition of PPD.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the company’s unrecognized tax benefits decreased $51 million as a result of uncertain tax positions relating to foreign tax positions and $410 million relating to U.S. federal and state tax positions which included $378 million from the settlement of the IRS audit of the 2014, 2015 and 2016 tax years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company classified interest and penalties related to unrecognized tax benefits as income tax expense. The total amount of interest and penalties related to uncertain tax positions and recognized in the balance sheet as of December 31, 2022 and 2021 was $74 million and $59 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company conducts business globally and, as a result, Thermo Fisher or one or more of its subsidiaries files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the company is subject to examination by taxing authorities throughout the world, including such major jurisdictions as Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, the United Kingdom and the United States. With few exceptions, the company is no longer subject to U.S. state and local or non-U.S. income tax examinations for years before 2012 and no longer subject to U.S. federal income tax examinations for years before 2019.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income before provision for income taxes are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,340 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,835 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,841 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,230 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3859000000 3340000000 4762000000 3976000000 5501000000 2468000000 7835000000 8841000000 7230000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the provision for income taxes are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred income tax provision (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(997)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 813000000 446000000 521000000 633000000 1148000000 423000000 254000000 160000000 175000000 1700000000 1754000000 1119000000 -611000000 -227000000 -237000000 -314000000 -399000000 -18000000 -72000000 -19000000 -14000000 -997000000 -645000000 -269000000 703000000 1109000000 850000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory federal income tax rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes at statutory rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,645 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases (decreases) resulting from:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign rate differential</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Excess tax benefits from stock options and restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (reversal of) tax reserves, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intra-entity transfers</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestication transaction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowances</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Withholding taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax return reassessments and settlements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0.21 0.21 0.21 1645000000 1857000000 1518000000 -329000000 -255000000 -223000000 202000000 315000000 335000000 96000000 76000000 86000000 149000000 119000000 156000000 -80000000 -124000000 -114000000 -544000000 -17000000 -26000000 -18000000 -284000000 0 0 0 263000000 344000000 344000000 36000000 36000000 379000000 379000000 84000000 164000000 115000000 -210000000 1000000 -196000000 111000000 82000000 147000000 -45000000 7000000 -82000000 703000000 1109000000 850000000 -208000000 -658000000 49000000 395000000 101000000 188000000 96000000 -25000000 -378000000 144000000 53000000 156000000 263000000 212000000 96000000 -80000000 -124000000 -114000000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax asset (liability) in the accompanying balance sheet consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax asset (liability)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss and credit carryforwards</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,951 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserves and accruals</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory basis difference</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development and other capitalized costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (gains) losses on hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net before valuation allowance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(662)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,861)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,984)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,829)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company estimates the degree to which tax assets and loss and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2022, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the valuation allowance are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions (reductions) charged to income tax provision, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions due to acquisitions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation and other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 4277000000 4687000000 1951000000 1652000000 140000000 162000000 259000000 318000000 364000000 181000000 445000000 295000000 220000000 0 -199000000 -33000000 435000000 251000000 -662000000 -1861000000 1322000000 968000000 1984000000 2829000000 968000000 933000000 408000000 344000000 24000000 514000000 14000000 30000000 0 -4000000 -19000000 11000000 1322000000 968000000 933000000 68000000 97000000 1160000000 33000000 422000000 551000000 445000000 29000000000 570000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions due to acquisitions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions of current year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Closure of tax years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1124000000 1091000000 1552000000 15000000 26000000 0 104000000 32000000 8000000 24000000 60000000 0 659000000 5000000 296000000 4000000 27000000 0 32000000 53000000 173000000 572000000 1124000000 1091000000 143000000 -610000000 -658000000 15000000 80000000 -75000000 26000000 -51000000 -410000000 -378000000 74000000 59000000 Earnings per Share <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Thermo Fisher Scientific Inc.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,375 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted average shares</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plus effect of: stock options and restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.63 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.46 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.96 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Antidilutive stock options excluded from diluted weighted average shares</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Thermo Fisher Scientific Inc.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,375 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted average shares</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plus effect of: stock options and restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.63 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.46 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.96 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Antidilutive stock options excluded from diluted weighted average shares</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 6950000000 7725000000 6375000000 392000000 394000000 396000000 2000000 3000000 3000000 394000000 397000000 399000000 17.75 19.62 16.09 17.63 19.46 15.96 2000000 1000000 1000000 <div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10.    Debt and Other Financing Arrangements </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective interest rate at December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.797% 2-Year Senior Notes, Due 10/18/2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,933 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.215% 3-Year Senior Notes, Due 10/18/2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.65% 10-Year Senior Notes, Due 12/15/2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.80% 5-Year Senior Notes, Due 11/21/2027 </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective interest rate at December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.750% 7-Year Senior Notes, Due 10/15/2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60% 10-Year Senior Notes, Due 10/1/2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.00% 10-Year Senior Notes, Due 10/15/2031</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.95% 10-Year Senior Notes, Due 11/21/2032 </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80% 20-Year Senior Notes, Due 10/15/2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.30% 30-Year Senior Notes, Due 2/1/2044</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.10% 30-Year Senior Notes, Due 8/15/2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total borrowings at par value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,561 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,971 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total borrowings at carrying value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Short-term obligations and current maturities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTAvZnJhZzo5Njg4ZDg3N2Q4Yjg0MDk2OTUxZjhjZDNjZDE2ODY2ZC90YWJsZTozM2Y4ZDBiZjNlOTA0OGQxYWQxNmRmMjk2MDhiOTI4Ny90YWJsZXJhbmdlOjMzZjhkMGJmM2U5MDQ4ZDFhZDE2ZGYyOTYwOGI5Mjg3XzQ1LTAtMS0xLTk1OTE1_604487c3-8ee2-4b5e-9844-f85677001b08"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTAvZnJhZzo5Njg4ZDg3N2Q4Yjg0MDk2OTUxZjhjZDNjZDE2ODY2ZC90YWJsZTozM2Y4ZDBiZjNlOTA0OGQxYWQxNmRmMjk2MDhiOTI4Ny90YWJsZXJhbmdlOjMzZjhkMGJmM2U5MDQ4ZDFhZDE2ZGYyOTYwOGI5Mjg3XzQ1LTAtMS0xLTk1OTE1_f48e0ed6-f6bf-4012-a946-cb2740bf1122">Long-term obligations</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,909 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,333 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SOFR - Secured Overnight Financing Rate</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EURIBOR - Euro Interbank Offered Rate</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 14 for fair value information pertaining to the company’s long-term borrowings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the annual repayment requirements for debt obligations are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance Lease Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,583 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,561 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to available borrowings under the company’s revolving credit agreements, discussed below, the company had unused lines of credit of $72 million as of December 31, 2022. These unused lines of credit generally provide for short-term unsecured borrowings at various interest rates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Facilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term SOFR, a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of December 31, 2022, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of December 31, 2022, there were $0.31 billion of outstanding borrowings under these programs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest is payable quarterly on the floating rate senior notes, annually on the euro-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the fixed rate senior notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. Except for the euro-denominated floating rate senior notes, which may not be redeemed early, the floating rate senior notes may be redeemed in whole or in part on or after their applicable call dates at a redemption price of 100% of the principal amount plus accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements. The company was in compliance with all covenants at December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 the company completed the full allocation of an amount equal to the net proceeds from the 0.000% senior notes due 2025 to finance or refinance, in whole or in part, certain COVID-19 response projects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the company redeemed all of its 3.650% Senior Notes due 2025. In connection with the redemption, the company incurred $26 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the company redeemed some of its existing senior notes. In connection with these redemptions, the company incurred $767 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income. Upon redemption of the senior notes, the company terminated the related fixed to floating rate interest rate </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">swap arrangements and received $22 million, included in other financing activities, net, in the accompanying statement of cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the Floating Rate Senior Notes due 2023, the 0.00% Senior Notes due 2023, the 0.00% Senior Notes due 2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051 included in the table above (collectively, the “Euronotes”) in registered public offerings. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company.</span></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective interest rate at December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.797% 2-Year Senior Notes, Due 10/18/2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,933 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.215% 3-Year Senior Notes, Due 10/18/2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.65% 10-Year Senior Notes, Due 12/15/2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.80% 5-Year Senior Notes, Due 11/21/2027 </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective interest rate at December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.750% 7-Year Senior Notes, Due 10/15/2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60% 10-Year Senior Notes, Due 10/1/2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.00% 10-Year Senior Notes, Due 10/15/2031</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.95% 10-Year Senior Notes, Due 11/21/2032 </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80% 20-Year Senior Notes, Due 10/15/2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.30% 30-Year Senior Notes, Due 2/1/2044</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.10% 30-Year Senior Notes, Due 8/15/2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total borrowings at par value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,561 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,971 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total borrowings at carrying value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Short-term obligations and current maturities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTAvZnJhZzo5Njg4ZDg3N2Q4Yjg0MDk2OTUxZjhjZDNjZDE2ODY2ZC90YWJsZTozM2Y4ZDBiZjNlOTA0OGQxYWQxNmRmMjk2MDhiOTI4Ny90YWJsZXJhbmdlOjMzZjhkMGJmM2U5MDQ4ZDFhZDE2ZGYyOTYwOGI5Mjg3XzQ1LTAtMS0xLTk1OTE1_604487c3-8ee2-4b5e-9844-f85677001b08"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTAvZnJhZzo5Njg4ZDg3N2Q4Yjg0MDk2OTUxZjhjZDNjZDE2ODY2ZC90YWJsZTozM2Y4ZDBiZjNlOTA0OGQxYWQxNmRmMjk2MDhiOTI4Ny90YWJsZXJhbmdlOjMzZjhkMGJmM2U5MDQ4ZDFhZDE2ZGYyOTYwOGI5Mjg3XzQ1LTAtMS0xLTk1OTE1_f48e0ed6-f6bf-4012-a946-cb2740bf1122">Long-term obligations</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,909 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,333 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SOFR - Secured Overnight Financing Rate</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EURIBOR - Euro Interbank Offered Rate</span></div> 0.0260 310000000 2522000000 0.0035 P1Y6M 1000000000 1000000000 0.0039 P2Y 500000000 500000000 0.00797 P2Y 0.0103 1350000000 1350000000 0.0020 P2Y 0.0185 1819000000 1933000000 0.00000 P2Y 0.0006 589000000 625000000 0.0075 P8Y 0.0093 1071000000 1137000000 0.0053 P3Y 500000000 500000000 0.01215 P3Y 0.0142 2500000000 2500000000 0.00125 P5Y6M 0.0040 857000000 910000000 0.0200 P10Y 0.0209 686000000 728000000 0.00853 P3Y 0.0105 170000000 0 0.00000 P4Y 0.0015 589000000 625000000 0.0365 P10Y 0 350000000 0.0320 P3Y 0.0338 535000000 0 0.0140 P8Y6M 0.0152 749000000 796000000 0.0145 P10Y 0.0165 535000000 568000000 0.0175 P7Y 0.0196 642000000 682000000 0.01054 P5Y 0.0118 221000000 0 0.0480 P5Y 0.0500 600000000 0 0.0050 P8Y6M 0.0077 857000000 910000000 0.01375 P12Y 0.0146 642000000 682000000 0.01750 P7Y 0.0189 700000000 700000000 0.0195 P12Y 0.0207 749000000 796000000 0.0260 P10Y 0.0274 900000000 900000000 0.01279 P7Y 0.0144 36000000 0 0.0080 P9Y 0.0088 1873000000 1990000000 0.00875 P12Y 0.0113 963000000 1023000000 0.0200 P10Y 0.0223 1200000000 1200000000 0.02375 P12Y 0.0254 642000000 682000000 0.0149 P10Y 0.0160 48000000 0 0.0495 P10Y 0.0509 600000000 0 0.01125 P12Y 0.0120 1606000000 1706000000 0.0365 P12Y 0.0376 803000000 0 0.02875 P20Y 0.0294 749000000 796000000 0.0150 P20Y 0.0173 963000000 1023000000 0.0280 P20Y 0.0290 1200000000 1200000000 0.01625 P20Y 0.0177 1339000000 1421000000 0.02069 P20Y 0.0213 111000000 0 0.0530 P30Y 0.0537 400000000 400000000 0.0410 P30Y 0.0423 750000000 750000000 0.01875 P30Y 0.0198 1071000000 1137000000 0.0200 P30Y 0.0206 803000000 853000000 0.02382 P30Y 0.0243 254000000 0 79000000 76000000 34561000000 34971000000 112000000 117000000 171000000 184000000 34278000000 34670000000 210000000 200000000 5579000000 2537000000 28909000000 32333000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the annual repayment requirements for debt obligations are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance Lease Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,583 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,561 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5583000000 11000000 4071000000 16000000 2298000000 12000000 1285000000 11000000 1999000000 10000000 19325000000 150000000 34561000000 210000000 72000000 5000000000 3.5 0 P397D P183D 310000000 1 1 0.00000 0.03650 -26000000 -767000000 22000000 0.0000 0.0000 0.0080 0.01125 0.01625 0.0200 Leases <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally for 1 to 10 years) or have options to terminate the arrangement within 1 year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has guaranteed the residual value of three leased operating facilities with lease terms ending in 2023, 2024 and 2025. The company has agreed with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 10). The aggregate maximum guarantee under these three lease arrangements is $147 million. Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated balance sheet as of December 31, 2022, but exclude any amounts for residual value guarantees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessee, the consolidated financial statements include the following relating to operating leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statement of income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statement of cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance sheet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities - noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remaining operating lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets are classified in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTYvZnJhZzpkNjliMGJkNmFkYTc0MzU4YjVmZGM1YWEzOWY0N2E4Yi90ZXh0cmVnaW9uOmQ2OWIwYmQ2YWRhNzQzNThiNWZkYzVhYTM5ZjQ3YThiXzE1NjM_8c395164-5c6c-4c6a-be5c-ef34bbc212ec"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTYvZnJhZzpkNjliMGJkNmFkYTc0MzU4YjVmZGM1YWEzOWY0N2E4Yi90ZXh0cmVnaW9uOmQ2OWIwYmQ2YWRhNzQzNThiNWZkYzVhYTM5ZjQ3YThiXzE1NjM_fec7d49e-14a8-4d73-800f-d3b67528e44c">other assets</span></span> in the consolidated balance sheet. Operating lease liabilities are classified in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTYvZnJhZzpkNjliMGJkNmFkYTc0MzU4YjVmZGM1YWEzOWY0N2E4Yi90ZXh0cmVnaW9uOmQ2OWIwYmQ2YWRhNzQzNThiNWZkYzVhYTM5ZjQ3YThiXzE1NTg_3daafd3c-8ee6-4bd7-a206-9697de6930b5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTYvZnJhZzpkNjliMGJkNmFkYTc0MzU4YjVmZGM1YWEzOWY0N2E4Yi90ZXh0cmVnaW9uOmQ2OWIwYmQ2YWRhNzQzNThiNWZkYzVhYTM5ZjQ3YThiXzE1NTg_5438f477-bcaf-48ac-8f58-7f9620a94d80">other accrued expenses</span></span> and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTYvZnJhZzpkNjliMGJkNmFkYTc0MzU4YjVmZGM1YWEzOWY0N2E4Yi90ZXh0cmVnaW9uOmQ2OWIwYmQ2YWRhNzQzNThiNWZkYzVhYTM5ZjQ3YThiXzE1NTk_784d8ebf-54e0-4686-bf9c-0b38ca41c885"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTYvZnJhZzpkNjliMGJkNmFkYTc0MzU4YjVmZGM1YWEzOWY0N2E4Yi90ZXh0cmVnaW9uOmQ2OWIwYmQ2YWRhNzQzNThiNWZkYzVhYTM5ZjQ3YThiXzE1NTk_da4e772e-bdce-4292-a132-1757aa42751f">other long-term liabilities</span></span>, respectively, in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs arising from finance leases, short-term leases, and sublease income are not material. See Note 10 for additional information relating to finance leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, future payments of operating lease liabilities are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:84.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.676%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,872 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,585 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessor, operating leases, sales-type leases and direct financing leases are not material.</span></div> P1M P30Y P1Y P10Y P1Y 3 3 147000000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessee, the consolidated financial statements include the following relating to operating leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statement of income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statement of cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance sheet</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities - noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remaining operating lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets are classified in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTYvZnJhZzpkNjliMGJkNmFkYTc0MzU4YjVmZGM1YWEzOWY0N2E4Yi90ZXh0cmVnaW9uOmQ2OWIwYmQ2YWRhNzQzNThiNWZkYzVhYTM5ZjQ3YThiXzE1NjM_8c395164-5c6c-4c6a-be5c-ef34bbc212ec"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTYvZnJhZzpkNjliMGJkNmFkYTc0MzU4YjVmZGM1YWEzOWY0N2E4Yi90ZXh0cmVnaW9uOmQ2OWIwYmQ2YWRhNzQzNThiNWZkYzVhYTM5ZjQ3YThiXzE1NjM_fec7d49e-14a8-4d73-800f-d3b67528e44c">other assets</span></span> in the consolidated balance sheet. Operating lease liabilities are classified in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTYvZnJhZzpkNjliMGJkNmFkYTc0MzU4YjVmZGM1YWEzOWY0N2E4Yi90ZXh0cmVnaW9uOmQ2OWIwYmQ2YWRhNzQzNThiNWZkYzVhYTM5ZjQ3YThiXzE1NTg_3daafd3c-8ee6-4bd7-a206-9697de6930b5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTYvZnJhZzpkNjliMGJkNmFkYTc0MzU4YjVmZGM1YWEzOWY0N2E4Yi90ZXh0cmVnaW9uOmQ2OWIwYmQ2YWRhNzQzNThiNWZkYzVhYTM5ZjQ3YThiXzE1NTg_5438f477-bcaf-48ac-8f58-7f9620a94d80">other accrued expenses</span></span> and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTYvZnJhZzpkNjliMGJkNmFkYTc0MzU4YjVmZGM1YWEzOWY0N2E4Yi90ZXh0cmVnaW9uOmQ2OWIwYmQ2YWRhNzQzNThiNWZkYzVhYTM5ZjQ3YThiXzE1NTk_784d8ebf-54e0-4686-bf9c-0b38ca41c885"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTYvZnJhZzpkNjliMGJkNmFkYTc0MzU4YjVmZGM1YWEzOWY0N2E4Yi90ZXh0cmVnaW9uOmQ2OWIwYmQ2YWRhNzQzNThiNWZkYzVhYTM5ZjQ3YThiXzE1NTk_da4e772e-bdce-4292-a132-1757aa42751f">other long-term liabilities</span></span>, respectively, in the consolidated balance sheet.</span></div> 351000000 254000000 224000000 109000000 66000000 49000000 289000000 288000000 222000000 430000000 293000000 202000000 1593000000 1531000000 272000000 266000000 1313000000 1203000000 P9Y4M24D P9Y10M24D 0.032 0.026 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, future payments of operating lease liabilities are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:84.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.676%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,872 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,585 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 321000000 293000000 220000000 172000000 136000000 730000000 1872000000 287000000 1585000000 Commitments and Contingencies<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or fixed assets and to pay royalties that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable at any time without penalty. The aggregate amount of the company’s unconditional purchase obligations totaled $2.40 billion at December 31, 2022 and the majority of these obligations are expected to be settled during 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Analytical Instruments segment recorded a charge to cost of product revenues for $108 million in 2020 related to an existing supply contract for components of electron microscopy instruments. The agreement requires the company to make future minimum purchases through 2025. The company developed and launched an alternative product beginning in 2020 and based on the expected demand for the internally developed product vs. the third-party product, the company does not expect to use all of the product it will be required to buy, resulting in a loss on the purchase commitment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit, Guarantees and Other Commitments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding letters of credit and bank guarantees totaled $297 million at December 31, 2022. Substantially all of these letters of credit and guarantees expire before 2040. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding surety bonds and other guarantees totaled $84 million at December 31, 2022. The expiration of these bonds and guarantees ranges through 2024. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The letters of credit, bank guarantees and surety bonds principally secure performance obligations, and allow the holder to draw funds up to the face amount of the letter of credit, bank guarantee or surety bond if the applicable business unit does not perform as contractually required.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is a guarantor of pension plan obligations of a divested business. The purchaser of the divested business has agreed to pay for the pension benefits, however the company was required to guarantee payment of these pension benefits should the purchaser fail to do so. The amount of the guarantee at December 31, 2022 was $28 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of businesses of the company, the buyers have assumed certain contractual obligations of such businesses and have agreed to indemnify the company with respect to those assumed liabilities. In the event a third-party to a transferred contract does not recognize the transfer of obligations or a buyer defaults on its obligations under the transferred contract, the company could be liable to the third-party for such obligations. However, in such event, the company would be entitled to seek indemnification from the buyer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with certain transactions, primarily divestitures, the company has agreed to indemnify the other parties with respect to certain liabilities related to the businesses that were sold or leased properties that were abandoned (e.g., retention of certain environmental, tax, employee and product liabilities). The scope and duration of such indemnity obligations vary from transaction to transaction. Where probable, an obligation for such indemnifications is recorded as a liability. Generally, a </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maximum obligation cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, historically the company has not made significant payments for these indemnifications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the company’s efforts to reduce the number of facilities that it occupies, the company has vacated some of its leased facilities or sublet them to third parties. When the company sublets a facility to a third-party, it remains the primary obligor under the master lease agreement with the owner of the facility. As a result, if a third-party vacates the sublet facility, the company would be obligated to make lease or other payments under the master lease agreement. The company believes that the financial risk of default by sublessors is individually and in the aggregate not material to the company’s financial position or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of products in the ordinary course of business, the company often makes representations affirming, among other things, that its products do not infringe on the intellectual property rights of others and agrees to indemnify customers against third-party claims for such infringement. The company has not been required to make material payments under such provisions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At December 31, 2022<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8xOTkvZnJhZzo3YjYwOTNiMTliZTM0Nzk4YWRiMTgzYTVmMTFkZjJjZC90ZXh0cmVnaW9uOjdiNjA5M2IxOWJlMzQ3OThhZGIxODNhNWYxMWRmMmNkXzEwNTcw_2221297f-89d9-40ee-a156-ab18c978309e">, the company’s total environmental liability was approximately</span> $75 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation and Related Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability, Workers Compensation and Other Personal Injury Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. The range of probable loss for product liability, workers compensation and other personal injury matters of the company’s continuing operations at December 31, 2022, was </span></div>approximately $223 million to $384 million on an undiscounted basis. The portion of these liabilities assumed in the 2006 merger with Fisher was recorded at its fair (present) value at the date of merger. The company’s accrual for all such matters in total, including the discounted liabilities, was $229 million at December 31, 2022 (or $232 million undiscounted). The accrual includes estimated defense costs and is gross of estimated amounts due from insurers of $95 million at December 31, 2022 (or $98 million undiscounted) that are included in other assets in the accompanying balance sheet. The portion of these insurance assets assumed in the merger with Fisher was also recorded at its fair value at the date of merger. In addition to the above accrual, as of December 31, 2022, the company had a product liability accrual of $17 million (undiscounted) relating to divested businesses.Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis. 2400000000 108000000 297000000 84000000 28000000 75000000 223000000 384000000 229000000 232000000 95000000 98000000 17000000 Comprehensive Income and Shareholders' Equity <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of accumulated other comprehensive items, net of tax are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency<br/>translation<br/>adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized<br/>losses on<br/>hedging<br/>instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension and<br/>other<br/>postretirement<br/>benefit<br/>liability<br/>adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,065)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,329)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive items before reclassifications</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive items</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net other comprehensive items</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(815)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,880)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,099)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholders’ Equity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the company had reserved 22 million unissued shares of its common stock for possible issuance under stock-based compensation plans.</span></div>Early in the first quarter of 2023, the company repurchased $3.00 billion of the company's common stock (5.2 million shares). <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of accumulated other comprehensive items, net of tax are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency<br/>translation<br/>adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized<br/>losses on<br/>hedging<br/>instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension and<br/>other<br/>postretirement<br/>benefit<br/>liability<br/>adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,065)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,329)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive items before reclassifications</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive items</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net other comprehensive items</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(815)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,880)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,099)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -2065000000 -35000000 -229000000 -2329000000 -822000000 0 38000000 -784000000 -7000000 -2000000 -5000000 -14000000 -815000000 2000000 43000000 -770000000 -2880000000 -33000000 -186000000 -3099000000 22000000 3000000000 5200000 Fair Value Measurements and Fair Value of Financial Instruments<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2022. The company’s financial assets and liabilities carried at fair value are primarily comprised of investments in publicly traded securities, insurance contracts, investments in derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Inputs are unobservable data points that are not corroborated by market data. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.713%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.419%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,082 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8yMDUvZnJhZzo5YmM1MDRhMmFiODQ0YjEyYWMwNWE2ZTI5MjhjZDMzMC90YWJsZTpjY2M3MjA4YzkwMWY0MjI5YjgwOGFiNzVlNTc2M2ZiMy90YWJsZXJhbmdlOmNjYzcyMDhjOTAxZjQyMjliODA4YWI3NWU1NzYzZmIzXzExLTAtMS0xLTk1OTE1_78ce8f46-685d-47dd-b078-0a1c291bdffb">Derivative contracts</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.713%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.419%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent consideration</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions (including assumed balances)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8yMDUvZnJhZzo5YmM1MDRhMmFiODQ0YjEyYWMwNWE2ZTI5MjhjZDMzMC90YWJsZTpiM2Y3YmY4OTkyM2E0Zjg5ODhhN2VhYmNkNTNiOWYzZC90YWJsZXJhbmdlOmIzZjdiZjg5OTIzYTRmODk4OGE3ZWFiY2Q1M2I5ZjNkXzUtMC0xLTEtOTU5MTU_5d56fe23-c44b-484e-a565-d3926a4d9bb9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8yMDUvZnJhZzo5YmM1MDRhMmFiODQ0YjEyYWMwNWE2ZTI5MjhjZDMzMC90YWJsZTpiM2Y3YmY4OTkyM2E0Zjg5ODhhN2VhYmNkNTNiOWYzZC90YWJsZXJhbmdlOmIzZjdiZjg5OTIzYTRmODk4OGE3ZWFiY2Q1M2I5ZjNkXzUtMC0xLTEtOTU5MTU_de91fb5b-ee26-4a46-aa68-deabcb5c2bb1">Changes in fair value included in earnings</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the aggregate notional value of outstanding derivative contracts. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps - designated as net investment hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheet and statement of income. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8yMDUvZnJhZzo5YmM1MDRhMmFiODQ0YjEyYWMwNWE2ZTI5MjhjZDMzMC90YWJsZToyMmMwZmUwZjBkOGY0MDY2YWJiZjQ3ODdiMzZjZGM0OC90YWJsZXJhbmdlOjIyYzBmZTBmMGQ4ZjQwNjZhYmJmNDc4N2IzNmNkYzQ4XzAtMi0xLTEtOTU5MTU_030aac4a-a16a-4c69-a212-a0fb572ad2f9">Fair value – assets</span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value – liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency exchange contracts (b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) recognized</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value hedging relationships</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedged long-term obligations - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedged long-term obligations - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount reclassified from accumulated other comprehensive items to other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) recognized</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial instruments designated as net investment hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency-denominated debt and other payables</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in currency translation adjustment within other comprehensive items</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in currency translation adjustment within other comprehensive items</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cost of product revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company uses foreign currency-denominated debt, certain foreign-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 and Note 10 for additional information on the company’s risk management objectives and strategies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedge Arrangements </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 the company entered into interest rate swap arrangements to mitigate the risk of interest rates rising prior to completion of debt offerings. Based on the company's conclusion that the debt offerings were probable, the swaps hedged the cash flow risk for each of the interest payments on the planned fixed-rate debt issues. The aggregate fair value of the terminated hedges, net of tax, has been classified as a reduction to accumulated other comprehensive items and will be amortized to interest expense over the term of the related debt issuances. The company had cash outlays aggregating $85 million in 2020 associated with termination of the arrangements, included in other financing activities, net, in the accompanying statement of cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2020, the company determined that the previously anticipated debt offerings were probable of not occurring and reclassified $42 million from accumulated other comprehensive items to other income/(expense). During 2021, in connection with the extinguishment of debt (Note 10), the company reclassified $65 million from accumulated other comprehensive items to other income/(expense).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Other Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and fair value of the company’s debt instruments are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,889 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,278 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,290 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,670 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,047 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The fair value of debt instruments was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.713%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.419%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,082 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8yMDUvZnJhZzo5YmM1MDRhMmFiODQ0YjEyYWMwNWE2ZTI5MjhjZDMzMC90YWJsZTpjY2M3MjA4YzkwMWY0MjI5YjgwOGFiNzVlNTc2M2ZiMy90YWJsZXJhbmdlOmNjYzcyMDhjOTAxZjQyMjliODA4YWI3NWU1NzYzZmIzXzExLTAtMS0xLTk1OTE1_78ce8f46-685d-47dd-b078-0a1c291bdffb">Derivative contracts</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.713%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.419%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>other<br/>observable<br/>inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Significant<br/>unobservable<br/>inputs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Level 3)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 5804000000 5804000000 0 0 25000000 25000000 0 0 12000000 0 12000000 0 162000000 0 162000000 0 79000000 0 79000000 0 6082000000 5829000000 253000000 0 101000000 0 101000000 0 174000000 0 0 174000000 275000000 0 101000000 174000000 2210000000 2210000000 0 0 298000000 298000000 0 0 15000000 0 15000000 0 181000000 0 181000000 0 36000000 0 36000000 0 2740000000 2508000000 232000000 0 1000000 0 1000000 0 317000000 0 0 317000000 318000000 0 1000000 317000000 The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent consideration</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions (including assumed balances)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8yMDUvZnJhZzo5YmM1MDRhMmFiODQ0YjEyYWMwNWE2ZTI5MjhjZDMzMC90YWJsZTpiM2Y3YmY4OTkyM2E0Zjg5ODhhN2VhYmNkNTNiOWYzZC90YWJsZXJhbmdlOmIzZjdiZjg5OTIzYTRmODk4OGE3ZWFiY2Q1M2I5ZjNkXzUtMC0xLTEtOTU5MTU_5d56fe23-c44b-484e-a565-d3926a4d9bb9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8yMDUvZnJhZzo5YmM1MDRhMmFiODQ0YjEyYWMwNWE2ZTI5MjhjZDMzMC90YWJsZTpiM2Y3YmY4OTkyM2E0Zjg5ODhhN2VhYmNkNTNiOWYzZC90YWJsZXJhbmdlOmIzZjdiZjg5OTIzYTRmODk4OGE3ZWFiY2Q1M2I5ZjNkXzUtMC0xLTEtOTU5MTU_de91fb5b-ee26-4a46-aa68-deabcb5c2bb1">Changes in fair value included in earnings</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 317000000 70000000 -18000000 403000000 66000000 109000000 59000000 47000000 174000000 317000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the aggregate notional value of outstanding derivative contracts. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps - designated as net investment hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2100000000 900000000 2434000000 2149000000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheet and statement of income. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8yMDUvZnJhZzo5YmM1MDRhMmFiODQ0YjEyYWMwNWE2ZTI5MjhjZDMzMC90YWJsZToyMmMwZmUwZjBkOGY0MDY2YWJiZjQ3ODdiMzZjZGM0OC90YWJsZXJhbmdlOjIyYzBmZTBmMGQ4ZjQwNjZhYmJmNDc4N2IzNmNkYzQ4XzAtMi0xLTEtOTU5MTU_030aac4a-a16a-4c69-a212-a0fb572ad2f9">Fair value – assets</span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value – liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency exchange contracts (b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities. </span></div>(b)The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses. 77000000 25000000 85000000 0 2000000 11000000 16000000 1000000 79000000 36000000 101000000 1000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) recognized</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value hedging relationships</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedged long-term obligations - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedged long-term obligations - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments - included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount reclassified from accumulated other comprehensive items to other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) recognized</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial instruments designated as net investment hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency-denominated debt and other payables</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in currency translation adjustment within other comprehensive items</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in currency translation adjustment within other comprehensive items</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cost of product revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 77000000 0 -81000000 0 0 25000000 0 -3000000 -3000000 -73000000 695000000 922000000 52000000 71000000 19000000 8000000 6000000 12000000 102000000 162000000 85000000 -42000000 65000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and fair value of the company’s debt instruments are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,889 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,278 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,290 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,670 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,047 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The fair value of debt instruments was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. 33889000000 29901000000 32072000000 33449000000 310000000 310000000 2522000000 2522000000 79000000 79000000 76000000 76000000 34278000000 30290000000 34670000000 36047000000 Supplemental Cash Flow Information <div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash paid for:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash investing and financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired but unpaid property, plant and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of equity awards exchanged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of acquisition contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease ROU assets obtained in exchange for new finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Declared but unpaid dividends</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of stock upon vesting of restricted stock units</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8yMDgvZnJhZzpiYjU1ZGY4MzYxMTQ0NzdiYmVlMjIwNzVkMTA2M2U2Zi90YWJsZTo2NWQxMWNhMTI5YTQ0YjVmOGFkYjkwYzVjMTliM2JlOS90YWJsZXJhbmdlOjY1ZDExY2ExMjlhNDRiNWY4YWRiOTBjNWMxOWIzYmU5XzMtMC0xLTEtOTU5MTU_0dec5d65-1e41-48cb-8c32-76351eb5deb6">Restricted cash included in other current assets</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8yMDgvZnJhZzpiYjU1ZGY4MzYxMTQ0NzdiYmVlMjIwNzVkMTA2M2U2Zi90YWJsZTo2NWQxMWNhMTI5YTQ0YjVmOGFkYjkwYzVjMTliM2JlOS90YWJsZXJhbmdlOjY1ZDExY2ExMjlhNDRiNWY4YWRiOTBjNWMxOWIzYmU5XzQtMC0xLTEtOTU5MTU_01401c74-fe9b-4ee0-88a1-7843acf0a6d3">Restricted cash included in other assets</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,537 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,491 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash paid for:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash investing and financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired but unpaid property, plant and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of equity awards exchanged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of acquisition contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease ROU assets obtained in exchange for new finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Declared but unpaid dividends</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of stock upon vesting of restricted stock units</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 667000000 555000000 471000000 1234000000 2182000000 1324000000 393000000 379000000 347000000 0 43000000 0 0 183000000 0 33000000 15000000 5000000 119000000 104000000 89000000 241000000 265000000 217000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8yMDgvZnJhZzpiYjU1ZGY4MzYxMTQ0NzdiYmVlMjIwNzVkMTA2M2U2Zi90YWJsZTo2NWQxMWNhMTI5YTQ0YjVmOGFkYjkwYzVjMTliM2JlOS90YWJsZXJhbmdlOjY1ZDExY2ExMjlhNDRiNWY4YWRiOTBjNWMxOWIzYmU5XzMtMC0xLTEtOTU5MTU_0dec5d65-1e41-48cb-8c32-76351eb5deb6">Restricted cash included in other current assets</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4ZGY2NjE1Yjg3ZjRlMTViYzZjZWVkNmEzZjJhMzlmL3NlYzoyOGRmNjYxNWI4N2Y0ZTE1YmM2Y2VlZDZhM2YyYTM5Zl8yMDgvZnJhZzpiYjU1ZGY4MzYxMTQ0NzdiYmVlMjIwNzVkMTA2M2U2Zi90YWJsZTo2NWQxMWNhMTI5YTQ0YjVmOGFkYjkwYzVjMTliM2JlOS90YWJsZXJhbmdlOjY1ZDExY2ExMjlhNDRiNWY4YWRiOTBjNWMxOWIzYmU5XzQtMC0xLTEtOTU5MTU_01401c74-fe9b-4ee0-88a1-7843acf0a6d3">Restricted cash included in other assets</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,537 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,491 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 8524000000 4477000000 12000000 13000000 1000000 1000000 8537000000 4491000000 Restructuring and Other Costs <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and other costs in 2022 primarily included impairment of long-lived assets and continuing charges for headcount reductions and facility consolidations in an effort to streamline operations. In 2022, severance actions associated with facility consolidations and cost reduction measures affected less than 2% of the company’s workforce.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and other costs in 2021 primarily included charges for impairments of an acquired technology asset and a tradename asset, and, to a lesser extent, compensation due to employees at acquired businesses on the date of acquisition. In 2021, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and other costs in 2020 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, and charges for the write-off of acquired technology. In 2020, severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 23, 2023, the company has identified restructuring actions that will result in additional charges of approximately $60 million, primarily in 2023, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and other costs by segment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net restructuring charges incurred in 2020 (b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net restructuring charges incurred in 2021 (c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net restructuring charges incurred in 2022 (d)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.</span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes $48 million of charges, principally $32 million for impairment of acquired technology in the Life Sciences Solutions segment resulting from a reduction in expected cash flows and, to a lesser extent, charges across the company’s segments for fixed asset writedowns and costs associated with environmental remediation at abandoned/previously owned facilities. </span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segment, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.</span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes $46 million of net charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company expects to pay accrued restructuring costs primarily through 2023.</span></div> 0.02 0.01 0.01 60000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and other costs by segment are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life Sciences Solutions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Analytical Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Diagnostics</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory Products and Biopharma Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 30000000 129000000 34000000 1000000 6000000 26000000 68000000 18000000 9000000 12000000 35000000 23000000 3000000 9000000 7000000 114000000 197000000 99000000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net restructuring charges incurred in 2020 (b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net restructuring charges incurred in 2021 (c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net restructuring charges incurred in 2022 (d)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.</span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes $48 million of charges, principally $32 million for impairment of acquired technology in the Life Sciences Solutions segment resulting from a reduction in expected cash flows and, to a lesser extent, charges across the company’s segments for fixed asset writedowns and costs associated with environmental remediation at abandoned/previously owned facilities. </span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and Laboratory Products and Biopharma Services segment, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.</span></div><div style="padding-left:20.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes $46 million of net charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.</span></div> 34000000 51000000 57000000 -7000000 21000000 37000000 40000000 -1000000 17000000 68000000 44000000 41000000 48000000 32000000 160000000 122000000 35000000 46000000 Includes property, plant and equipment, net, and operating lease ROU assets. Revenues are attributed to countries based on customer location. Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices. Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. EXCEL 110 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

]C*>17OAG]X940J2#-+ MNE)\;,OZT0@4%6QJRG4DJL+8]C,*3)06VY8?))1EFM]-[Q^E6-"CC=L2<,]> M/7MQ9PQ\6H+]NYP-;>W@$.3GJ:/&9BKM:P3SPKK M"YVHMNE5S\56V608(S4Q#/*OG/C/RI]'VFJD[*=JP3 BWBI)K-:1DH!(F-I#UF1#LN:)D M(Q9FL5I350T!6'INDV4:KCM]U$(5UE3&J&Z8L9-D@T/J\ON<6N@!@;V\#;8;PBY%ZE(3*S#?EZ(MHV M!/UL'5/R;#H]A\GGR\#-\80;9@B^H CMSLOT;U(;*IHX,"(3 0DL)K\G6%'O M4?]J^TNN<<"XMT-\B.;%%+*7H<;$+IB:S,&X%*C-!;>Q#"%3A#M$O=NY=,CG M$00GYNK>XZ!PLZ@;&>](2N,HK(N+6A>(%%5"-8[B8# )3=P-X-=?[S^\Y[E6 M8A*KW/) K[*U-X\WO?ZP$7Q-3[ "N::-]"EBQI%DLY(H^,Y+$JH=X?IE4$]5 MU=SE36R\B9)#.(TK]X%)R_0R3Y0B@3:KRKRBHC]B"/+Y"8QWN0QQ[D\HC:3)?4$%=>HSWD::VFE0R8!.E=,)"-C1&;K M7GN CF-D<- $%#@& MW[9?QS9'BIE3IJM,15C!*(2I?L]QD^VENK3+!>)P&H'6HM-"+$^:;\ M\X=>TN."C4%2Y= GA*0 MI5,VQ3QR*U4@R?>!GD9NF?<"AVG)SB()@E;/:!? M_+M'/Y(-*VS&PO)+S%\?I)V0M"WQ!%Y%DP_\F9=+49LJS/Z8"%BTY,[I\Z=W M35L'>Y1PVRNXP)L3V BYX1\478QW-\9_2 M5"7$Y-TVU(W:%94F<8Z4LLRBV9Y10)N43DDS-1>VG2>[94UAMSN"37+ )[3H MR5L/_'N![0*.[AW\3VI@L&^%XME\_[]I\E1$8_SMXX/_8;Z>TO892IF@W ?9 MN/I*R:-Q)K ) RBIMN;0XFK:YL@F;0Y4:EW#%9J&XWI%6I[U%P4:J$0T7CY: M!"*Q\BQ5N"2I&0T2E,Q3R8;6%_),E >N3X\4#+7O1 MEI882?7-HYL)-N!\'#.FM0C#LB2S!-7 -:TSZ5"$QA6XD'LH(8"/SI$^. M'CU&>&Y;)"=TQJ7);^@UH'_X"ES=+%\,V*RC2^X=/WAX="MUNM'DDCO!P]I8 M:#1I[4>Y)6^84F>Z$BE+@E M&JH'A/5<=>X'_<>3HNP08?U#25G\ _K1DU@<,%IWCJ2"L,DDB$:3Q%^'0-[A M/0[F]2W\?Z%/EJ\/Z:MO^V+BNX>'Q]\]V/KUO<.CS_SNX?WM#[WLEY<-]O[A M=\<[,]9'A_>/'_WQMWU\^/CH:K?]EF2!Y0%$#@7S;]_<_R;$CDFK_'"\^I < MQ6%:5#1CJ6.!^Z,WY/=5B+SV)6]T#]_GFRM=.O'R$J.^0:]_ M9IU8$Q?0?RW3LK#![LZD3=*-I\NLA*GFF\H[N7-\[][1553X[9ZV MJT_6]P?8.NXNG9)\W6M?H6NO>WR %_-UX4[_1/(!WXIM<:?;A M-ADX($T-]N4_#^D>>#[@@N ]7F$- E[^C- !#5S_W[_\0F3/-8;']. Y>O1) MY\E'S:J;OI(_E5E=#7F6O,'&S7UYW:;D#BG3:S>[=T7&+M,6QU]F0N_*%%Q) M#YYR ]5^#4HJ.ZL;;J$S5JGF!S^639<+2R)>]GA*:::H,>N,+GAXL'E$_2<8 MBQE8BR>'R8_-A\^,.OQ'FHN/CF[P7-TH&=N^O15U]13>K@,II&WZ'V$C3LY) MNC$A.$FGV-ZKPQ.V"(_^ M"/VW:T=/[U;(@_L;5D=ER\Z@FFZ>W7+#-.##1S=XKFZ6E&W5@.ROA7ZEUEM^ M^!]A_(U5H)F+ /3U#NC#_RSS[+^;#O13\A8[*5=PVQML%)(+WU+F+!]!>WGH/B^ MCU&'XT+.LOC;-U?KH[UK6VC\UH/&I2*H%*!V)QS(G4#7?9T"W!Z+'P^JIB'"LE"8 M<)C\WV9(NH4T@Y8>HUR:@Q6:F391ES*CBNC= NU152[+7EO+U)<\""N"]CU+ M_[B>I?=UEQQZAM[K[EMJ"FKRC$K5M5GMBY%8G'JQD%ZG.\5LNPW?+WR85'0$ M6P^+S!/45+NDHJ;?[75@Y[H@3=$-Q!10LEY@?JZ.^^APO3]QDV.'*-MHF[D4 M);$*&P ?E&*S4JR%Y'KQSK"(47&.X=!#AEJT"*FJ\CH%W4Q'X9#B@;0;5L8H MKZY2F<7S8Z:&:-M/L$*+IR$A,JX+VC[(/?0!V8)A!N1&2J6%ORO"_6@MBI): M:2^$'\V3"$].N_(Q\$^S HD-D;,H(^XD)F_U$0%[3#P%1P&KRD8,;DY;&U#) MOG#">@X\+$,R"XC_:(HR3_U2PN)?U/W0?E$=YPW:))Z3#1E4:4JYIO5,XL). M]0*VT2S#,:K=P >DJ\!YYO)%)K3"IA%^AP4A&G-.7(O*_\R73A-83A3KC@@6 MJ"M"3__VQ=\_X@5%L\1>][GENE=2)9F2(%_%B']6*+&8MP3&1YT@I$.-UFKR M)0G3PDK1,CX^:DJ#8D]X\D %,K$0::B6!M%WE3NG)67F3U^JC=T7J4O)8?*2 MM8/04_$L\?$1MJ"\)54&3@G/J'TCS9S6CQ.#K[]!Q(2,72V(4HU_AX30D_J MV&1]&3^7JS.+8P@6Q@/V8QMS=C#[7V=Y]'V?2VKUH3-KNCY4.20?D M!-#CY0>Q'54::4NK%;AL"7-?GVN;WTP3($- MQSX0B1$=*LZYJ\),^#6%YBIRF0?!D#?HOM M+_SV)D.M%1(1?B/A'1/8NF)>K]GU:R4$" MCS)CVD[6'%A5G2LE(1'(G/$TO.,P.?/586>("E3,$,C2_"(YI8UA/[//WCL* MEVN;,4H +#LD>;$OIX,59L].&"KA]?Y%SED3K P*MXR?/WKLI>O,/ MFY>]:M0+:F".K00Y5D'1/G(X"R3I:/GH#)X@WY-.VJ&%27*=[4C>$Z'&=3NQ 5()\:# H03]@!&.+T09([/F[@TRU9)V1I M3'2& Q;)N7N8O&K.0P:%&R_1&(L@7IK+5HF8N-'&XBL-);)[9MT"UJ01G<.Z([^,CR$D?STZO/\PF2D_>QUDOAC\%&+CGOH,_D6M8B24880]FG,) M#@71L'+@ R 8#^^F97B7#JLM24R,#("2PEK">1P(U8ACC6_N&G^[J+<8 M4[-J0P!B>HVE7%D(J;$ M:V@@4O EH/E219:PGQ+ 1/8;W1@%VXF5&]R]N"4 MB- CA3\QPQ%%LU+)J['+;]AF0S%08Q"O281IS*G.$S9)3P<63 /?3I>2"-KS M4TEZJ>]UM'*\8)B5F7D.7NKTRP8;I21LR+1STS^D1KBXPKLOX!']VI(:#;%% MH93=$F+%-3$,JA3*-%%-; KF&P>E%/76EG/4HL@VO;$LK/ O%.I2^K HM=I& MU!S!4M1\L5JGIA6?5^BL;&=(_=HNA6_3TAMO-E[>QUR_9G0B^+AT$E'C9K"B M^%CC,WK.H;V2>N;!DJ%2)7K#PK]DYY"6S+ 9 M0([)*3D6U_^'@K3L3,"_S2'G$ST^DQ,R/OOENY;E*TK0\LC>F&OCVL(%\X&; ME@9S@X(1H%3G<[0LZ%IAP<=M+,V-\!=+YD EF /^*U IV[9I>@^WG,&*-G) M!(LD'/1\'5S5EI=N]3TD]J,R>71OWU7FSPYQ?0*\]0\P&:>F<:]%_W0M*HJ0 MO:L1PS]H0[92N$/K"&3!W74V?CV^#&Y"-Z,[C6FT]?<4*QX]_0R]LYK["]2^ M:RLK91D2EZM31T[^(7Z _D[\6W4"PSCVY_17E+"HK8HPH4OG)K<"_PC;_7R+ M05WZEP?I1<";E FY)1;W]/4_7SX[./H^T5_MU_/KK6>,@@,+.6L-+3XEAC0H MC>T5I;<6MGMTY3D10^\7ZVMO/A,X"ZJ1\6#8AV6O#[_BDA34KUP:-Z]:V!.2 M*#1.B/4O]FOS]=;FCT4S[!?N:R.'.!R@%5C8LK%V[1E8#U4VPW"-1FRB\.V! MXKLYB0L72K\P7].A]05]YC@Q((;(&M]#5+_JXD2( MD!!Z6%-_NZ%=-F45!17!;F_:LELR@C!K=PG;L!&&/WJ(77"'FY MP @Q3(0R55BYH[.N8SK-U*0&O*X"9^12N21.ND)-A$!%68>LC/!B9%/SN%* M=L_+R/@1%%( MLL;4+J*)G-IH\R_QVIK"A)WU(S7 M?VN611Y4N+SL##2U0KL2V^8:5#&75G'^'N=/@6%Z5YV0(.$[JQQ^"[^TI::CN[[GJW#!#W417^4(.K5)1Y+_K RJ_L)A M)JLJPU ;_DI>7#1M5: GS%W 3>30SJQ!)H9U+#N*1R%0G4YZ26J. I#:#IGQ MT;PN.!01=Q$./I_6 1;)91(F7Q.!)O'&,/+WBA VT^!!ZB%KNZ$HN&$NO MO%#.UF2<.K"UFE8UBVQ78NWB+0P>9D;%=7QIB20T-X1(QZ/2Q1#O1F0>R'!& M)T*I^Y9,K)X4KBD.TNG':ZF7^28-$9YS<%%+Y0(Q80WN7>R1C5JGA10U%-H%3=NGB3OP)QD8 M_ZS5/53'Z'D\+YSC"JZ.6TE$00XJ<5"SGT\L*\!X&O".638M$L^5^?N*[CJN M\Q0/S0=5_$TQVG#TW9/XJ52M=8&.2PW" 38;]N$VGH1=G/$F2T/)V7C5TDMX MKBY*D+^J?(^WGX&+M1PM$YX%2@J =A(-)0TE1#E8,%'IHBW?)* H(_LM,=3S,9I@6#LTQXERSNQYID\<3;#NA',G;$LD$M%V1K)#K/5* MX6;X>1K?%!\HIW0F$F.?D8I!E*JV3:.]'R<#J909-A S XGP>Q=XH&*:\/;^ MI4'X94@IC65T9RH"*<%1N*C];Z+"H)1\@8%^J!1K0<-@O9M45^L!9A4F^">9 M5"9)31L,%G=U^6]/$1F%?W3[A:&\G., YEE)O)59 8L (R"C<_0\TN;DHDS? ML_:%X&*SA=*95!T>/C'0.#TO20)"5,6\XU)LO^FM2T>"T-/Y*("1&=V1V[?; M'F?]<9SU43Q[>YSU'F=]@ZSZE[VZICX33>8FQX%"H,)45I9BD<*7&/XE.XY* M22LQ=F^,T7VM[)7YG\)>^4D<=8?).SR)"F0"PIK_CBMTZ1"A\/W0=@.=^4D] M+&?P?G!;L\HL ;#(SM;%ZS+OBRBO!V$7E^Z/*#Q 7D0V77,&GAW(DTKD/B/^ M]19)LSGLP$S;99HN].!'5$(89Q?PG&@7^ X]S/WZ?56H":^3%CMF6."NV3E5 MX=9-WZ_-UUN;F+](0SZ-8(/V2_$U*X@Y]8)K@62\/IX&)D]?DA.X7XZONAS+ M65D'4CF.H.#A3[LEV(L8\5@A4J[%]*XW62F9AE%*QW%)1D/ *E9[.-U77$:P MY'V9O2[-V&_8H^BN3=,Q:UL47POQ0MA#3=4I_7J;@;4^2/BR\1E[SP6.G @Y MV'.X92_@()0/<'G9(]7XK#\7=S]H_INS]$O* MK!7XFSBC+@$+AEX%9S;5'$[TJ;^AD$M)^G_LX8^Z0NS25$ZCGGY$O G,Q(7S M&K^@WG0PA^2#C# QPEL7HQ]5Q S_T_80A6=F&H6S83?<;@!"$V:V*ZWIA/-A0=@ MKDT6W#:B($+)*%P?$HR'<=\*"? ))=;D9#04'Z I;[T M\D29=)I2N=3.A;\=_9Z8-T')V!]'L_W)@FZ283R%DT.<%/DNT7/#IM&&W590 M/HJ+W'H&Y86JG7!WL"4$:IOEOP]E5_J6 !O'00UJOLWD5VA/<>[MG)@PHE]' M-)V^ YWB%F/"3G\.7'N@VTO=)KZ$X KA#6G'C8$%!G7G]Y,&_-LD&\Y\['\Z M21W0D=H_*9K3CT:&W<&2VC$?Z1&\HXCIIC5A>,*4X,?^L+42U5)KHT MYU2U:C!FL%U6 R*N,8@/ SO+.#2.\7T[/Y)8]>.3P2^1<0JA,S'M? ZY=F!.X#8"_4RV"D*S>X6.\Z-;JIDE_M3#Y,70XAOY%._( MSC&RK#\URS<6^R9>M7 ELCN^=XQ3-K]7+F3LF$.P;TQ]NZA;&5;M@F.)&1\^ MC==8&DRF%6NQ5#4LL7,:08@+P"?S&KMH6FV!=H#GC&)!Z\CZ1->+< ^^RF*T M [>QG,;SB$E$<([ :E)G&IU M!C-PU^NWK"(T1+=PKM?%RY9(0T+8!MQG'\HEPQO^^N#H\/B>)QS& ?P5/GF@ MGS#,3^,(M#7AY9ZYW.'.YX:G]X]2XCO>//MI C_Z.GV#H$R0\[\>/3H\/@J# MN?19O_'O.]:5+/(&R/NI<\IU&2C60?D@J3AB\1*$4C#TPX*YRC8?EJA4&$4I(\._:-C_;/&Q4AQ<]/H3IS7E+YIE3^K#-JK:IBT MO!W9MIJ(12[?K*U)!8W+$R*M&@#I+0]V S:N*@Y_%BGNT;IO3!U^Q9EE32@+ M3,<0C?OM:_4U3<6 !VQ]C,<,U],1-(#+9VS-C&<*H=T.1UM3T][GHYZ# M#*N .1WQPDB=&'DNIIB<.>/"S=FRZ@3B MKLCU#/LTX0)$Q.\Q0RH97SX>S_T*I>I1M'Z+99J(S2:M-Q>(:6S<+)7IND$."!4K,=Q=WYX WCE.'9*B@!54 MTD3/LOH]7IROF;>V[$V'!'^JS(W_(6X+'%%2CC5>EU"H1:L(]\)D69M=;.P> M#%CQ'&L=H=+O:"T/X6_D?-5K(J*_,@]-9R4!E+>-_XYQL&E29W %5GJ67=;U M%+OS14=2\21-!?0I6@F48E%XZNO$>^T)D,;$:'O,Z!=@1H_WF-$]9O0KFD&7 M2J/I^8']2J$).V'G M#;"3V,_ADXKGA4Y:W.!$E9!T#@QP=O!2P6-B6RV.I_O0WEKKH_''YV53^7A[ M1)>(/%]7BL=8 M7DV/5@?EE'TJRM2'TTM?T.P,<0RXKKH9M"Y'WSC+\X&"J5@YJ(QK M9)[Q@RZ%6AL7_I)LSR[IIJT)=S*A6\<5W5=0.CS%.?DGU-X%7"%.%?2$*$)T MJ=;V4B% M[6H4,_K0[@X]J$#W@$1W=QD]X+=WXVM&X_Y">2M$2Z:+%#%,1JB^,29S0Y!X[0M$MO=J0=UQ'0]/>492SN M'VK[/6Z-TJ$3V@O8A649[@X_XLPP M0@ 8-B3J1E(B@)DW^G"P[^A'J=++0N)3( MT47DLPZBK9^Y;E5J+C=PG^BA@,>0N,"C<\Q;D"GF(U#DM7^0IS5--P\3@Q,> MY:+\A+0.5B(^<:LNG\%&!'+=XBA>M 1'14 M&OLSE?%H7,(R.6_0])"E;BUY)I(I5Z)9(DC5W)MP*D<;9:^3-(ZF'9&7;7D7 MO4&ZL20<+=&=$K4Q,BU _8(WK1EKX23&%M7K!NFA#HU)7F7ETJ.@L',SIB3@ MVU*M*SZ.X"PB9<]UW)'QS- !>C*N=3+)#D,M*PE M^ACW-O1;&-=OO2+M&E* M/.I(]L9AN!ZG1##'C,2?3IJK= :%:6_TBMWWW(* M&9FAUE/*,Y90O!T__(@M14K$P+25WXFM!,FJ4IM+#@!N\.'[)8A((EAH21_S M3\("Q4:Y]>XM;W09;&U\ND$^A8LDFZT\8^U95DLIO:\^-)1KVT>.6\6'Q5GO MD 4N>_] ^^;XN8'!U0-\@P"??\$]NJ+4^$6<7E\0DL$"3D9DJP"[8E(@6&L-%DQ<42L[0TTOU6NREDU)R%8PM5'E$*];INSJ[-A]9 M38])BR*P,W!U':5)'9JI;%F@F8I;-^.:,CU.8D)=_[*R)(?)\P'U,>PC4EU* M,#&(44&\$P*_H8@-JLBE0Y# @=:V'-\"Z80CJ=^2<(< M25R+!<\(N>,Z+?$[CA*D)2;%>U E'"X@A!'K!::#9$HYJB464Y[?TV\YO:^? M4LOR=IC\% @?':H72:1H$ ]F"9^)QXT0X84#GJ$$.+_FH!\+,Z]2I#>B2%.W M)=24U>:0G3.E73B#Z:7H5*?=#5NBHM\-)1NSZW#P,7?.)<=>NMV8HRU&$K%+ M1\QV/BYEUS,L\G"ZJC/)%@2*%M=X"PD>Y]E*A$TT[7L2D>L',@I^#5T( L%& M9'V4EQZ%KN0]S4MNOE]'%@SJAI3/5^:R02B)9[]EAY[VB)\.CFG)[2P4V-7@ MY34UDV_]KW].4.+L.O(MXB8!6U<8 MO1-0_.IW?01<:5YT+)V_K5*(LMG :6&3>8_,A]^(T0M- MHC^$HK'Y-47>/S0*GHF2SZ,:E >(W6NC%Q'/\(B@+(TI M?&TI'P8DR?RI'.8^X#_>DW+N/?E^H*&7"L8SO1Q;IDQ4 >D7X+><>08(%HLH MX"I4J=S*$Z?@@!'9INOR)1)SE>(4=@S[F/*73S43%? Q *X-/>5,N2CE I5VD/#/H5@-U-I[%%&E7C5ATVP[S$&++HX[G"DVWB M.$JDQ"><#'IXH+AX0FY>$4^&:WM\:$SCA31U>/YAU4I"W[>0QKEZ]O,O^!D' M:4*EI#7>EV!BPPF#C+@PS','9@SR3Q2.*P<\F[@?QB35/KY[_(KR1I+DR=J6 MLZ+!B:DU>L FYAG_@:<_Y23G98M8 PJ)$ Y5[A$G-OW;O@'Y@)^?\I<$G6V8 M_8WH,#RJZ5*9]SU18+=PV;]I3H!F\[_@?L0)#PNW0I6>:CAV(]-+]N/,,7DZ MW9_/:0^XF,/1+BD,W*%XH3#WD4%J8D8^S\N;@")A: N@18^1K(2#N9%(I6;7 M\-61V3-& '>39<%!0"_#2FP"./Z B?>C5?M:'''ZWI9*(.,&;PW.*6<5(6V) MP(9&P5P+_QJ8I-LG%?VS:]?CDJ:;*N6V($2F#X9?)[+K49>0'-%*E'/7%E3Z M24C_@(I GHR&R.I"[1!_J7\/?8>X'14J#O=O' 3S+%?*[D8+,\,G+W 25YGJ$KGOJ ZGL*Y7=#ESLXE&5/F.LQITT-ALQG?H'& L+YB%_@H2= M&=$K*AKT6# Y@#J7,5DT/@BT84%:OT_19VD*0D]0N/X2@LV52):C/ZAC9LBC'R MQ.E%%,8G_@M,L!%"C//#6!8'O@"[W8&,L0)LI3#W/G;K MD;RZ2380 W]#45446$[S"F:CQVW$0<@P3R$7MH'_0&%J\O<2>VHL$N;:W1_* M=I1A/KJ\'6"UUU)?A[BP15,5S"[CD284\+K*9-UY?OK377AQS".H\8]L*K:E MEC8=W':1?7!\GL'!)6T2-;$*-^LTM&B&8;J=O"0:?TS6%.=-CMG2,SC\5AAL M%"O:]$@D7O)5S0I$-!/ MM(@4'VC<@6DY5&>9B953U(!@QVR%T::SJ*.DM"Z&P4IQ6I.1'63.X@D/2H3: M;@0\A[S%N,6/+79AZ8Z+L0S"FN%6ZMX2[X@B8DT1[;B)8IPME?+PV= 63DL@ M-&OMVR!M?;PYV#F*N!']XS)?,O1C._5C.1DIF;D4##*5D&RN9EQ3:+%H5OIH MU&E2$,>,NDB%"8Y2>LC$9-W0S5KG[= J_H.BF M#*200_-MD*+;0;#P--"J1.@\JVA8EU*Z=UN;"%-&+LQ.*_1^KSD'_%N@CR0= M4J\]8:U5?!N0;^[31!M&./NDL[ T5TT%!N?Q:3[.&Q^$OD@^,O[$Z2/K(O3Q MG(.3R JE'<[L?2BD[5M/$>SS;)!B/SF4QH%W4GK>"^)^3;@XOI=GT[GX$1A7 MB% _' (A!1$$(PRA^U'C<-]8 MBYO%T)L0,>&Y"YH[D.CCG&.U2=@,_OA\H>OR#-?EI*!^*3TK9"D-Z)([>/F+ M9R=WS70I=I764Y^]MD]>P1^_9>.Z^'-OM<^RH$*X&L MHW#)C*6MQ5L2M8WL1FTN@[,U>4>I4=*-/G7;<3&.MY)@+V'YMZ!GL]#-F3>. M-@S<)(*RS+'7KB)9YLY:)U; F#()R=JGTGMG%LK;^T:4J46R3Z'IU8] 54K, MA^,EX5Z@9/T)(R,;AD5C*^\"JU88"'M$M,Z72PIA%M%+$D; \6\('*PU#9F: M1_:>9=G9(]U^0*LRX,]UF6/=;DI["97/_Q&(1-[J/&),V7):8"D&S!6W@6SI7/V M6,U;[!-'X'2J?6"_-IA"&%WSQ8045)]E1+*W^X8)X4C)N#00(&U:0"K: /$K M]X%MD'*BP"ZP601_4G 2X8;3&(<1>[>T&;Y^?.U5Y@4L_E -X">I&)R'W2,L MBD)*T=1L"88RSG^S 3/9[*5AH0\M,D1-XF'HV DL@QT@I@A!QO%$UN/MQN<#'']"+%&\1E MVQ&?$9>ILS/+Z=/U*/&\:AT"3#0"1>*J&L'T$:ZYTA<;8T\7P3,##)=X&.Z) MB1H/7%;V@I99I8PIJ=5B\Z:JFHL0 ,>\8Y-K"Q/RG0K.C<2ON,%>%_G@GO>) M:\6HL*MO4NZC26'A<:3/QN"F"&PDM&?PVEB@P$B.G"K69EF?+Z166Q+7]%'< M1B4560^-7 )6G$@&\T7D:6=@O7.]J%]4BQFO^N;,8=1WI_*06VJ6QZ%/(R84 M\/!LL+HK0APTS@:,?BPZ6,!2VQ&,&BM66EP!<@BY1URS/V_:2)EUBMFC0 NN MH@Z [A+31?0+J=:7IM=Q&7Y'I$.A_36*3+F<867O4J'O/I U9Y'N.0HAKT;Y MFA+Q#4[B5US&S_?RW\#T<6+&;Z0TD,1,1%S.L&DXC8!A"-+-*:5DE!D.%E:9I5SB#ASBLWS/Q@_6 )GMKZ!$GS9-SG='#I>J MXE.">P*Y\M^:4_^7'#Q2+5[UT62,N)3UJZ(VH,\+XRM#5TD_,8+(Q B#(I[Q#%O9O^UFD2KD%3J M2)%XLI8K*0+[[10MB)V9"@XTH>4-$3"9)@SSUH+&CUR0DDXD ML5!$(/W[4WX>)J@1!1B:#I#L*9?C3 ?H_*)[ \SJ0C7S-K<.*^O18;""=1&0 M/Z)@>*I)E2MO0&C#R/:!T-:%8?@K;2+*_\KVINB9CX_R8X%!14PH6-.R"VT4 MY&F\CY'9G*P0SS8B&TRIJ828:6 44VNBW;6C29IQ=4U$ 2=P/'$ M&= J 4!B]BO)#!/X2TC+QI1??*JKZL)+R)47/!3=W%]R"SPL[YMLDT184H*^ MF]6;/,\%^.2)4&@?!!L_]L;T(261N9M$AQY]"&7.,8XD>$5J#]/:P_'"EPJA MZ4Z20J G^(ET&Y 4\L9A>E*![&(-%Q8<96UH9SBB2IL\P?P-4_YY+>QDBJTA M$8V)?_V(A1EAJF19HJ\\XVI.E[URX\1\/,@/M6*53DDGAMPCOT6U4Q)YJ5EE M^[S8N'8&_RF<#3)-I7C%:XW-,Y.G!Z6H*-UYJ,KT5&F(@PT'5'DAU!J9' 9DQMKSQ;.3-, F""WQ MW# \G>#\K1DI\>SYR=TTR@/#8=+HS<2?6.LJ"%ZF0'^U7P:_@I_C/\6?_AR@ M-3\/,-M:*RD(C6<__WQZEW_L&<->81$HGG?1")^_.M$+_P%F%_'4" &:*0PS M%7DB'1QL*&W?)>:'4@X;;@&YF,8B;"%-E*:C(4(PE57?39,SF!?VB_IA(# MW[C#*%>U!:@QYP4!X4EC@<-E33<&*VJ*^SQ<^?36S^J(MO P$)I#< M]YW,T2EFZF FOILH/&$BRPT^;]S:GOM.CJY":0K"'((T XF,F MEEJ5XY%DXKXX9Y*J29U.E]9-?4#ZS\:_A$*1^E.-&Q6.1@J6R,I)"(L'-HJE MV7N]D% U7#B01:)N1*CMW]S#$;#8>UW3CTCW@)4O :P\W -6]H"5FP)8"?H5 M50$RJ%*_N4QCY\(83>8SH)>KD7'P[X)YII+* M]5+]'R<$.+:HJ8"IZ/R?E1YHVA#T-X_#D#!,6]%F%S@A)AG6*#4_,^!*@_'0 M4MI:.PSO#BA.&TH-8;2I)$,6YR69+TV9=*,F">W6*$$:7;@UX3"5E9A,07QR MVB%IVG'8*:)G"X>SIR_7BLC-JB))N9)AT:);_9%4AKIH7#=41>9+RZFUP'LY M1KW/.1/G;9A1*9FO=;8;@ G1-HIQ-H)9$WUU;*I;N'\]*GGG3<^1)_?I!#I[:DEBS/NX72BS4S-&CH!F MR@J?1HHK9FN="?%NNC$]K$UZ:5N79Z;+G2V]A)OP$"G'@&H&] U#6**"6G$, M."07<.W;RBV8P2-@=R2>B2B*>\\"'::(*(:0P/NP_":0:>'0^B^1D MA[3C98V5%:^4VM/!U@%3!'2"GWS<6AU%@*"3*R87(<-@MD[,669Z6F&DA)K9 M;O2J\00B$1/2M2>]?8]SZF_KFSEX1"MO@[C)6.^8+#O1%DB:-)&2HB5(M.3D M-J:&G.RP_Y5/6=K'R]\DO4QL'^CP,#+E@P.LO>,XV+C013IMC0IZ&DI+D&$Y MPX8\:$'-VVPHTN1]F;^?^0XI<[C&><-/ZE]2"C]UH_B,#S.FGGZ&]A7-J[ . M>>KK5"9%:N1L@#*0<,\<=LEH6G^:D#)B?VISX\O_3!, %$4E ME8U6U_;UVNP]0PO-]A=WD2(;^@*IPN<#@7DV K>FKI##E4\;UKMO_#N>8(*8 MK_N?P^1'GG[\-#F^=W2/AR6H-3 XRP-9(%[9LIXH\X<%YWX5E3E!0UV5)#?+ MUH !*=A+1KNT9/.[^V,2$\B+AY:"X"<"9.?XOY2&PJX00,IZ)W;R6 MZ/^>.A49=RG(]*005A# MU38KP\#X:=M AA[RA!5<",;#?A5GL.3,TA2% #KBMB$D$%._DCEKL&FG-=W' M5/2Q:?%I#4'B6:7S)!97S_&"!@NQBVIMX[+LAFZSA%.0QZB_,&F,S60&S%9- M\56,1CCI8%YP+\5:^A7!]L\7F47:T("&SNQ"^PJ;/@E]L@\;H5UE[$0J/V">,BIAK;34OPM)$<6D&, MMKYELZ0Z6;03O#E3UG,BE3&'S\8X_-%@*Y]B713@KC[A2,4E @XWU,C=$;>D^]T-92.HVC68NT(.S=Q?83V??8HF.FN3#=V_S%FGCFAP5C MAAA "^;OK2(J'=N4F\OE0QN]E-/H?*_$$U;8,1\F;^1K8Y:2^F<8)S=&D6J' M5F (7J1L0W!X(4$%^E0]#5AC2^2^"& /"['@6VX52;%[?N)JYX1V@GP:C.ZU?5SJ>,+14J'D.H);G&=5R2Q'C89UT"IW17B-%G>B=KH4 M".AHY!H6U5B&;:U$=&W$ZSE2 %4"+D:')]1YL#IGCF'KJI#75@I( V7HX5OGU%EJ\M M]X8=* T&"U7XTS4+;0>GSD28IQULG-0XX=&"E2^ M2'K%@+Q-;[0]O.(+X!6/]O"*/;SBQFMMH3L8F<^D4O#<#B4,7=]ZBU^TL]=X MLQ:N\I;"17!5/%5N/TY/467-%-<%JUJJ?Z)VL9+ZJ@8?B9AV/.545VW)M %C MOOC(F1478CY4I ?)WO"-O]'\<>W8X4ES ?LV M9#Z )U,9%QC>@\*6QK\:^2[2:YFR,K)7+/XF> .AGSG:3#ZMJ0CQZ<%3E9ZX M/H+TD0,?"A*;L_'+NVVRG"3(,P^1WPW@T_R=:@#>4)EF4C"D.W5+&?EO/ MU,M#6]-$O7^"-W!CV&^)WS9Y:[;3"S\#;Y#IMW([I+VFW_%%->#^\FD9RE,K M[6GM[332W(.0EM4*^U8.@$HY_=7! M1($#22B*%N) V.8"I]CVF56GJ#!IP-=JJU.B-;<)1VU?G"&W"O=<]?,F5:O6 M9LD,HRZG9#X8-67:<5$N@]]5V"_IGZDO(.)B$OR4CI4<4GH02Q4G3.GL$"Y72<,<67]KV '$L['($D$W3?<)N MWUF=^)HXFP5U;)8?1S8#D?!6;(1(,UT^FA6Z"D/M^YQ1:%)P:["@GBEVHG4/ M=[W"2JF$C1_>>W#]*D^-[Q\O_!X8/ODQEF0UFA8DLES!IS)Z(PBYM5.BR)'-;U[LVL:=OF0@/OR/LD MS2]DHCSSE])F8!";':AAA3?XZ\/#>_?\@!I,]5(9)X9T,5=\P%LD7V_>FXFM MY0%W*>+K8]":;PEYC:JISP[0;D0"R%[0>C4SG,D-E4)(A$J."4HI.>-YAGUI M7 ;""OGF+:2^&L1[8'.VF!ME!S;?=E9%?1VKG3SP&QUR]_O@ZE$QVVABSH<* M 3^F[8CJ-L78W"FMNGUAS:10^J7#X/%0D>^X%@L)?)22VS!1W4CH5&)PL9-+0(P" M,>>E[+& 9X!_@%989GS"TG4J#\:_2>/$E[>RMI-QL'D5A3C0=V;061]!YOQ) MZ37!Z#VGXTG:R(_8U4"WC"?*'UBD>"Z?*NL?4YJXX#Q5A:[XI/@A:\T*'2?. MC,,MB7R+V[2XK,VYY-PFO^V%NR^],<\1V>XA&Q+ I+HZ"J#W01[3C-DT?,,% MUXZF\O4<6R)G7O",VCL'B]2$5R(PO#AO/,DJ'B>EW#?2]=-N!1KI;V7&'D8OKK:>I)%K+D:;AS 4O64Q(8WQ&^ MD;/@+;Y%Z\OF/+]\].\%7V'Z#YPSEN$LP XHK"3=]BV"-.=&(C 9VF)P* MW6I8;L4P+Q"L@$O/0$SL9$>G/H$8ZK5T?>/+ZK5@^&A#^,2[?TXJO\#2/&,A ME%UD,$W]3D+#59/5(6(4=,A5;@$/(HUI)!,K!9;#\NJK 6.^?_CPAZ/#>U15 M)G :\@BSM>:;YV6'-46_#UG;WPH>UM%)MLDS'K5TC%N%FTD/<1\,X8):BG+&J5^R=P#*MP'<>5;'X50 M!#M_M!'RC"AKK"L,;.WD*@ J_-!:ALD.IXKX!55;M[_\/#!:!L? MX"?7U=>U=\ODZ,=#=FHW__9.>SB8L92-IG#G-=BO3>T^6PZ.CV^C M'!QO%8,WG'D" V?GU_V=,62:"R7706Q;Q^4K<-XX3$,ZPERFB<<>!7)/S?J$ M_N3P)MA2D?W7ALN(N%9E#[OY$MC-=]MA-Y^P6Q]^\[6Q.IM3ND?O?";,9@<4 MY_VMBI.ZAV*F%"42(]FW07\*3ZLG'912-.'*BA ?UFUDJEK+R.Y)0])M=1^F M_E/J; 6F()5.X*8ZE_S:@+M]=*Q(B\AW"_GJTU"X3-5*1T\^EE68S_^TB>3E M+# /2J;P#V2VXE6PKMF-&4NR:-W\;]_\Y2JF,=C&3[VKS]( *]%3Q^B<3(?L M[]>9QOE\:^_Q;;3V'FQ56J_@!\DI=Z5]5G9YU2#A^.ZKKE^CEHN?+0[WCSY9 M'"ZS"+[VXK\Y>?LN>?GRL]_^P6W<# ^W;P:N=]%Z]K?$<]IF=?]_.G*&P15X M_OM 9]A;J=,^[9O\O=1IO\J(=(RTX4L\LMKDC=3$4K20?PNG&#'J?HF#=0V8 ML>EM)C/VIBV955UFB69EYW7(:RZJP!?J\(4P*DGX:D^(CP_ZOTW[GE\X>:Z1 MPA"KZ];+65,E[UZ]_H)(\(U9[I])T+M;M]*,^GCA9NV0M6M6!@\(]'%_G XI MDN/_G[UW86X;2=)%_PJBC^>LO$%1!/CN/M,WU+(]HYEN6VMY9O?&B1L3(% D MT08!-AZ2.;_^9F95 040I$A*,@&R-G;KW094%HHF""'*NE*%,Q(+_@8D^:93,980)GX#9 M26)T8ORC)$XB6E4+5Q+.7+FD^KIES'Z4?_G)]>*E;Z]^] ):)7WIIR(9T16" M71@P/BBT&B(C_W7N)6EWN*!_KGRS^'6;?G65N.N_ZXW:L/Z-O^ZTS8-^ M9[9-LW_@-S*?' M7I$T<(G .:8@FG_^H?N#_((4OR D;X!\G/[D"W[RB2,0YLJ/UO*;81:--[1@ MRM#'4>^E[XWQ4]<&0>L=93IGM]]F,L@]=7!'VRFV9?M4DU.G_7^A],^\G2[= MFG'6>>B,*7,M$E669(DM;8_"_YQ YTN5I_@%DSYX]>P4?C@!#96:1@5A2C4? M@"1R4G8XB^Q%;%R8;\^7FK_9WRA?RD7=,5*J>019*4$$$UE6C+K"Y&3.[>%* MDAH4*+O )H \9STN4ED >"F8:EI$W&JZ8L/*&;5DN134F=+__2048;0'@-X& M!0\,2;H]#F[C"U[B&7J1>I%;%_F$2K/^)L=A3%EM W2=#SR/\I.3A(C>%Y^P MN:IE7!H?PX>VT=\%AY\DP\9#L_8C9<=H GZ;K?%HW!IU+>[@*A-P3]ZA+7=V MW_!+GM.SSZ9NS/[F.8>QQR$<86O]CM7N]QO/ MVUN-*BE]#6 ?H4:!TL2'FEZ0^C0 />H=<]I&]S ]:E?E=QM85M"R&6!Y&-M6 ML\ZK0J4^)7U*^I3T*3W[E'HM>/SQSNA\O!VR\8AQ0;=S+[NF=_([:Z.F7NJE M/B5]2OJ4]"G5^I[6YO3^$>5B!MZQ+6@1/A+9>ETX/#=,,?=/4F.G^%)SN/Q0 M9^6+D^O(-L>S[8RZ"=?NKLZJ'=::9P^*@C3;S-6PI&%)PU*]8:D.CITKJCFH M*.8HU!%BL4:QCO URC>>I!I5;V#*VJ? N&?+A'MKL$S(ZE@F+Q;Z);1Y.= [ M+V*\^Y0R58+W:\[J/+ [*V_:VBTU;56*/L3$S7)QD7'M^X4"$C&C5"E9R]]$ M;=-)V]6%'RB&7_Z]E[V*N;9^VUL)>7+Z:9P?=Q[]D>;3XK#"F4 M19W,CFRA^PP"]?8FT'L[PE;#O%AOZD5Q4JJ:*95WJ=3:^SR,BW[;DAF,XCS> MMHWK)"LLDWP"?[XQU:<_8ON\;+C;-)_AER\HWFD)RE&5CN/0]Q1K@ <; M:X _\^$U;N-+S%ZH KXW.,7S'VZI 0_L&;4.R20,^R*D<2P[05T'MK^B :Y3 MI>/(36%&R.>\<_RGK'-\XUGJ,Z/^^PX.'S46.+NNT 4+?OB*U,,K )N_9'.% M=$.7EVOHTNUB0YKJ\?'QW;,G/8L?+CR MOOT_;NC\^>H:]"'O@<57S)W9T16PJWTU'@Y[_2OB/_JK9>%?3?,J68272'G3 MZIKM>0*&QW408-NIS\0IR$0?PF@!^NGEWX_-WC0UVLT:ZRKE[L2,67,):KQ$ MC'P"S86_%+3O*>.CB&6[,5YB1/5""V939R(QN!E'#W&QP^$XD4N-X8ETO D] M#?9U'+307'5^SA)L'L<#VR4V+H(PN/S+]?5=]NRWT*3<>.O^/[X;&)9,Y7M1VT5(B:6(V18N3VN ML>+9U]NP2SU@^9'^)H[TV.).QVS^9& ?H8C;J*^K0!UN NS?"7E0:Q/@TP-. MEV"/IX">T0+G],6(2_Z;>;M=M]$(,"7.S$'H4/-&R2)HGPI6:#8W2O MW6?TVAT=<<3U"]!KM\ZZ-3J&[]Q']U4;.FWE+->S9P%H/YZ3#Z!6Q^3@SY19 MKGA#(91^7-Y6*#.^2RYEE+'*5L.RSEP()/G'@X?1K@QW9P M_+68=L7GU/"Y"&+RE2>^0(XQ&M<<&X_,]_&_'%\4+?:WML?C5\1+^\E7MXCL/ A-=*U?O)"3!BP'&IX4/\<^J._M7?!3"$UG1RCXH4%=L096 M>SP:ODI#I)?O-&5VVOWAZ[2:.O/%#MJ#WFZ]T4ZGS='%.^HP0NT194<0',,# MUGS>U48Z!\ZX(0M&5,]Z]^;Y[OZ&G(%5;7+VSI7>)[%H9]C8E,CWK$5_7@)I2UL27\EU44:TLII3)U)0 M*"P?%.X%3KC8I5&HS@8_X6SP4:L[[C:^1D5S7',XSNRT.M:H\2RW3UE4\U2' M"W.PYF1[Y<-IGG*PI8SZ-)0#@X<_=!N2O3%NU!X>I2;_Z$*DV6,7-W:_/=#L MH=ECT^4[:(]WOWT;RQE< I;):UCH)Q2SN'9_3V/,>UB[G5\EE35;%#UPIR%N MG&G+"=1OGQ%DT>;>*9E[XU'SNV!HEFL0RUDMLZL]##57QT&^YY M.&$5YZPM'*O7/LYXD*-C@&:/79(2S/9Q6EIJ]F@">UP,VNNSP$Z/,U[3/]+@ M((7K886>:S ["F!'L9H>GB21-TEYO4<2&EMK)77FPYE;B<8HMS7^$L4/B;S$VP8,AJW^[WNJ[2U.*Q9QE-M+<8OT=;B%(8_2M:<%5E3 MWV6O7-MXXA?:*)P6J>2+2O-LC M%Q$GC; ]_\I((GB<3\WI]&VRMV74U9;1ZR?:'V77TA:("@K7?YZP'_<%+[U3 MZH9QX,RS$V^&L8>Q7]O9;/^Y9; 3]41?V"N:(1"G"\--*36$CAIVLW._U&[1 MW=$M;?^(G9WO/1R$@.-)^&2S#7UGJ6%L=8O9K'FMTAH7G[3>JSLV)FD,*XAC M8VX_,*#H$H=J,->X^?3/VW>7YEAIHFLD+,:N^+=KQ*AV*E%SLGZZKRL>%C8"B+ "*E"[XW>LG,#R>V;SS8C@.+4_HIXS8C M!G92Q"?VM(UKEX\%P($8+0.;$XM%Q:)'L'J&--_OP<-U*)^L7GXVIB1[$.T& M]\XG88BNS_S,:"],KCAK#"-V((Y'"BZ?P0&$ M8D["WP < !R59E.HE(%^;LI;,W,F^Y9@ZVDXD&RJ'N_\9TRC< %L"QN+;5], M^4B!$Z+$]OAW7;9D)-0X.01$'B06A\9(.DBN+@D+[&M%7Y='!/P&_VP;]_0: M9 TI0M28GN\G8U#Y4)K#^*;;-LUL4B ^],VP;0VRG\!"L0\H_8;/H$3^QUDB M0/_5"4#:.\[7M$E.1WYNV]D3#@(NVQ4L-@H1==P(Z!'@2 -D;=>;TBBSQ"/B M9\?Y8/O 3W X<@H Y]2(9P L[2C!"0EQ8B;@&;OR\H5_TS (5UWAFBA(>6D;"CNTY-ZX].9'\#'$<:;7L"S88-:'_CKV M;.,.\'I*)L ,R-T27>7I?IA[@=TB(N)!>S1#*)Q.8U@TD-&6*\<7K*U/"OAM M8+Q/@7U82YR$6!N)\B*,$*SL0#[655F;D\,/X:.;GW\#XD)IK7(D7E@R:=1' MTDMS1B!]8.?F\?FPF;7N])F.0/WSML'\\',8+JGJW3*Y7 M4=7W&8$T>&K2U2LNH63&]'!\"5PX7'-!,9K#1R^Y_H%0$80/-$4&(/DQ@Z26 M/IKO=C2_PM%$]BR[H0"8"(_IG(1(D/ M*V\74 \RW>@!/BWO;J$793:5ET42<$W1,A0KC)A#LWN4"!QJ>UZ\45D2N@\L MV^$/ )/_W\(BDRN#C MLJ?G(\/:QE;22UK2H'5\%-\J[!EGG/%7VJ">)7*52), C%#\/!I4J9^(D?%F MB0Z-Y]G*X4:1'/5,A[.-CY2!F_0E!A#SU "[UG MF4[6RP7;"%Y#/L0+>^YU) MY3FDL:#$,JZ7T+Q05/IHNWS87F;+X809H$' 9R7>R]PON@L MX(!)5%PL_7#%V(:I5.K!E89SN_D@25B>GI_WC/EY8ST_3\_/>PW.4N\T.0%S M(\R*WV,8+TX,-IUZ9'=[TK.)YN9=!/<<&?!@[SMXP][F3S4N[NYNW^8NX'@5 MXQ#S'(4CAGY;_H)8W(,$Y_1X'/*)C^&03DH'3FU6EFTL6#(/72#>C/!=>*YC M4/N<-72VA69#N\E &$#/AY_SU.YY<+*9<>)& MF=I.=NG@!^ -_+W<+U3TJ1^NE]8F"_9CR/-8/W-5[KHJF:JI"LRGP/@;')<= MK0RSWQ).\$3QQ9#"%N&X1XQ:"!?M'IXPH:?RA_["_)F7+BXGI*1S9Q_L^<&+ M,"3#R%5:C,ADX@5\]Q>XDI?,^!@^P->7QOWU/;_&]WJ.B-+$I=]GD1A4$S:$ M6@ UA+,\0*$4P\D#.63>1\6-0F"3B_)CY^YY(6Z M;=@/MN<3NN!1NZ#X.T+UGM)(^Y143S1J8]7=+NS7"LX2&$CS:!%D9CM.2I^TW0=4PJLI! S(([:T0!A_>LR5[D M%5KKO[)@%MAIR[B'9?R;17X6]KNY_Q4$9N&)H"DLGYBP'-:F*!)\E.+4:IB> MI@D+DZT0C4=;[#3._AU<\G3THU>]#>_NWE6"D5#RQ"T5D5S!.DD)S0SJ/&V M9VE41'-%L',E$$)D,N#CX,WY7;/YT<("C\G+&&+$EU)-LBN0YR:4;CKT"!$" M>7+L?1%[9!1 F.?9+'N>N5'0WQ7ZNE$Z*SL04!L_,8;;@#4'77IW#&CT9=.- M)Z\P&9?.1HI'_#* =T^\P.:43IB'KKKLB;D&E6?_H$]I1I;6UP#S;^RX\BFJ MN>&LDO!KIL@(UQ@N(]Q785*6(?GT!+SABF+>;2G9.5OY8FN0N$54_<7C3L5[ MN 2X1LV9X^^2.53HB;/G*:H1W'[V*A8"G,>U+\P3K%3@6V**"(-7*G@X'9GXR&TQZ#_SH# MAS%W8'>GEMT=3__5MWXXA"7K.T_^GA_!KJ/D:R]U55YAA7<9QN'@(LMD2E$! MA3)%;FLT-F?K 94)FV(6B\R1<^9H,<97< FZ'D\:==F4\GLH#P<$M-@DF(R-.Y3TH=6VQH>5Z7[_ M$EZST^Z/#QMX?Z3%[O;8)XIA&E09=O$NI.0A%,4%3Q>-UVJ;MFSQQ$:F8P3X MK'=OZG'QN]!O34WX3N/B7_P0GO."XRRR+A-_UBN:CM9_;H.=K ?JZ"ZB/_QL M=EO]KM7X-J*:Y1K$C^7JTJ&T1E=$=96&GD=R'K<$)],L\]3/J M#,;'.R.MIJZ=2*7;OAZ-*YK'WKW6\ 3&$9SV&8$:U-\7@K0:]*J6\LXY#%HU M.M"':+7ZYKZZO]:-OK.!UFN-!OOZ!+1R])I'\M[W%EY@O[+C[K3OVPO$GCU& MO6E]Z#N?3[?5,3M'.1^M"ZV=QDU6\()9W*\>NMHQ$I17V!MNF&)2!C7/>T9G MP>8Z?E^2,K4&AEZO-3ZT0_=+4*?F@VNT:)RO:'3'+>M0>^J8HG'"DU3TUNJS M8+TUO;5:+5AO36^M5@O66]-;J]6"]=;TUFJU8+TUO;5:+5AO36YM?=S(CA6H M_1]^?JII&7RB,55_EMD>=H8'E;SIJC^]V*,L=MP>FH<]5:_UB;5:O9V>*FX' M^0'I5^YS[%.CS>8N]8J[!CP;T_'NN753!Y2!UOJC4?A8SCYX 78HQPU>^OCW MFNO7Q$%^U6)L==?$>*>JX[K%_'0%NJY WUR!?E:[_Q(";E#?Y9NY'V6\PW;("6\D?RA-:M7O6L)E^KY71\S0- M3SIM9X?MUUHF#RJM/T"*&I";ICFYV9Q\2,5^PS@Y]W8\XXYK8M:]V=T]Y7ZO M_3=QBGF=F*FA_/2"[*0YZNSAZ:5O'_ M^E^:,?0S7N89W[L5P=%5,C%A^]A&3O-0JV>VC].DIS'8==;LT>^T.YH]-'ML MTGE&[='>GI#F<0:7@&7R.JDAC?WHAO*)'5-TZS2HRF5B?*(7&"'/XLS:%>'/ M,&/.>+1QYK$'NX!%&&[*<% ;GQ4N/FN(X7$X7ACGN\4R[U?.3&X9;N3!1W&Z MXR)T::@5GYPFQ]FZ;$'CB$,Y2XUE(VI;QM(&D:#AZ^%T&K,$'R/F_8DWX\QD M,?L1GBM?RX>_J9N,J[0G,5F=)M?);=*PTVSD\\+[1KTLXP2'4,Y@B]GK,5F( M&GY7+W/C1/G-([7$*?6P\&49\KRD'R/FTZ#VO-[E3\548,%OG?PK]B3&M.O- M7]F-4SD,X=QR%M6%=ZU.*9=7^7./2J915LDTCW*)G['+"3#,UTM["EO^T?8? M[57\PU61=$ EL:+^J(TG]?I$_IDR]IZ:Q%:CLZL>^/?EK^\___;)^'![#W\Q M[F]NWW_\9O4B5V3-'K]33O-!% M9KK(K$$.:5UDIHO,=)&9+C+316:ZR.R[4E07F>G2G*/-&FQ*98YFY/-@Y(,' M,C:%D<\UY_ZEC[6!8>BC)RB<6I79'G.<=)691J@GB'E@HI1&*,U/U56++ZV2 M-YZA=*69KL)X2FA:_8ZNE*G[&9EC?4;U/B-K<)0#.OH54Y<*'OT,7=&D*YH. MFP[?'NF2%FY2/<7M?W4.SQ]Y0_C3ZUHY8W;9IZ!*?DRWQ@5MUMQ(?4=@C M/^_*DAS;B<(X-FS?ITH;44'SO__7R#*'/^4E/BQN&8]>,N=5,$[JVYCP%K%@ MEE?I,)\Y211BGA@^U F7*RJK<>81;#8)9Y&]G/,?+6QX9[RDSR]8$JV4%_&R M'G5C^Y7U+*-PZB4&K&,.Q&*P3MO'Y6^LU:$5J<5 +5GA V_!_6*ES[;:H+91 M3 O+??7%-JRVH$EKK6$=1#TJ&^[AZO-L'RZB=[P> M%M9Z<*9@@S^J2QJ>O8;=.4^7-.B2!EW2H$L:=$F#+FG0)0VZI$%G@E=MO]8R MV6L-!]W3S@37C'P.C-QO#?JZI.$D$SPOS($>(U#+;.&&\I.>FE-;CFH@.^EZ M!LU/>DBC++,QE#/T/7 M,>@ZAN\:;S7;?9VHKMECSA@A:>1>K$13O<:K>(M%FD0NGD6*E5#))@ L_1MT'?4 M7Y6+-)Z>O;)ENHQ<938DYB'TTP5K&3Y\E>TV9H46RT>B/+!"#4?;J%38!'%- M6ICMQR$^SG:PC 3>8QMOS*[,"31@;ZZ7X((=V#\25JPC&XR#SQ!U*/AK!W.H M<"=(V 5+YJ&+/[8=!U")MC@-(RH<"9(P\EC5E)@=ZT9Z3]2-F)8N'-'E#7JQ MNABCD6O5A2,;E(=?;4!Q&VZ/E7&7J0%P!_[BAJA8UY3HFA(-41O+<@],:=(0I1FJ M6I_154JZL$07ENQISK9&PWUM %VT\)V!K37JZ>*?>I]17P_):'Q!QBD]0Q>7 MZ/3P'6\7/21#L\=6]CAP^*!FCY=$W]H1J]/NZ2$9IUMML?.0C+5*!76"A!R5 MP6QGCFG]SQV7(?(U8Y&OF5!S@"4766K<( ,*%GY4^2S6_#9((F\28H5#V^&;=,T)J+< ;8DZQK< M-,)J!:3+KM,X*LF'BYNP@-$\#GR\@U^TE520UL9Q'539L:GN8_\)'8=5@UB= MXU:#%.7S$M56$J:"=%V^AG@]"9PD7?_)K]/U/S\3&6*@\\H(PL2(TX5D"KHL M8#<'U[X,M]2^5..1R BO1PKWQS"X#)<,F!5YX#9ABWCCP3=W$LS0:EOCPZH* M=-G)TXO=[;%/6,X-,I!UEK7.LMZ<95VK5-!-]_:X?&V/CW!K$_T^DN*4,-!5 M$H-]6[(@9L4K2&?@Z0R\?5,@#G2M-"7]3K/Q6;#QN*[M]5\H 8(S7Z>"^\IW M4YV.A4H,PP3= ]R O[H0]]8N2J".[Y::Z'1ZW[MSH#Z=G4]G,#[.Z7SO,&O] M]>1K]_J +42%D][0/J'B?(K]4P@I?$_F9@I$4K M7ON2;]P^3D_MQJ0?G#5WF-;>G7%/A#VTYKE1\Y1@JW7-TU1ES.[>=X).23LC M]NB=:SOL[=EG:PDQ8LD_4\.=I](I:I^T5A6@,R[6?N)CMECV4^Z>>)LUY74I MX2;/R6-T<-A$5,OP&_1[Y54,,R-NKM[1Z_'Q*@9"^#E/@AXM SI"ERF\#?J/7S/ M_IN_!1UPO=M(XQH> (,"Z*2G.7M)C,2O.ZOSTJP=O/(4/[FU-X"K67H? M M*ABLDW_%GL2AGR:;O[(;:W* MPNI_M/U'>Q7_<%6D FQ8/+P_:B/17Y]>N]TZ-3J&876J]%_??_[MD_'A]A[^ M8MS?W+[_^.7VP^V-P([B0@+Z '7#1S2@$&V:6[Z.)C M"+>*V7E;?7^]&0S+Z$"XQR_*R'L@"0:9;"@ M(,?1R(N_[P)Q9AKEA<2-%W-I*(5IE=Z!^ MF]_>",8(P#%"?.AX-EXEE/ >3G#;^/M)Y+F@.ZA?6"P\CJBX5"<, L;O$_HF MZ0.SB/'](RE1.8@8:07\K*RW58G?;P:#C0=5R %O_*W^I2+9GQBB<*5+GT&L MJ(+R!J1O1_BAD//*6LX^7$WX%1HD\6#[*?6M!)8"O8B4/?SYFU'.4?+)\-_? M4V!NN,XIL]]X!![E6I[+IBR*Q,JD3@"_"\)'TF4IX1Y>/6'P=D#&?S.7EQV4 M]THO*CBAJS/W*?6>UW;DQ%#UVD4(\OYOOC6I39?2][DD%4H5X!./S/?Y)Y'- ME-J&-U9GE-&$/X52_*-PP;>=8O5 +N"Q<1&#%DML/7K;-C;MU]QZP(](XK7M MBQH'_)A8H9 %T.$NX=VH!2OJ'.(6>GY@N6^L44_N8G,Y0I/$!6QA!)D'EK,, M< 4L?2Y40B!LL03$IF]P2DH]#<0C!A3WIF K S@!:"+$$8-QFPH?7F#_MO&N M;'VA**"B[#(J:B%U&"\B:,H6+"0*RJBN" N)\ >/<\^9 MJYR"]RV?%U H-,OPE]O;TA*7:@LNG5<^B9$_%;L"D8";(BJ("*X;H8];>,C] MXF\EE$73/6)$FHP7IP!+8226]\"O[DV47L/$C+;V$HCT#<0O0>DUS3])ZCF-4$X7!5*#"H666 &(SA;8>Y$@PX["+V&:Q)[++^M_M._;QCV> M!:]QC%7&FMMP\#GB<7XD/,F^6G6/248%-N#Z(2Q1WIW$)N5'KBW(0V4&(,HE M]93#EP1GPP:9,'#\L:=O8N M&$2/=<''W.^58X/XDR,9ZD_X,AN/;U400K6_@2SM%;6^'/U8@%@'-@YQF;C' MD#$9XVK1%."EH+P[#EY_PDM,Q..UU:6+!A#'#U?\HI$?S#6Z!\\V%BR:,7%5 MJ;8"+]MF>.7F'X[G:/1,TA4&;?A'2%P!U;;4_N[@66E.46BG;8T&KU)G>5CU MYM8Z2[,]Z&S^=0T7N]?0K.-TF&A"T/4=<]AB OI(UVR=;Y'E1BJ<4%'QK2XF MUL7$KUY,?!JYOS>H2:'.0BH5 UWGP?;1.-?S9W2QY6'['K7ZEJX:UHS<>$;N MM7K#84T9^0P:I]/<08I8ZZJ#O6NI@'='^]93Z9K@[WY(H^%Q:H=.J!7D=2$ M,K?]Z2;_?2&[-5=ZT8\8W&G&)A!-\+="@^A)3#)ZB(S&+#?!'DD^=N7F8 M0BQ)A@]$YF,Q$<&QE[:#_E_V#1Z.OOF6Z!HI(L#\*5[D7F*2S"H+YU%6SR3_ M=YQ.X*6>S:,<8 [+K-IB/(+BXI0Q,$5O)ZU<./1IG1A0G-'.9. I8DD:!123 MD9Y3Q0&;N3V5)!&*YC"7/U!^@%I&>@^8R\R#YCP*L1Z=1(,$5DF!"/HI9H?" MMN(\"8,B-]+=:EP7XY!\!W'JS+&DA2]<;IAZ89;W7"20&S(>9^&Q25J&#+0 M34&X,%T[<]OS(*I@)60*-;F@R" 9%U(:P)PB]"QFC*@\37&"ZHD%THO!+Z0. M^^;%278(538H_1 _RBFBN/W+TIJ$,T;9)4->",1%7PX5$C!+9>&H&1BG5/>4M8[<< M<4N%@L3 #"W^_ #.S[!ZF'*=S$\AQ>V:*"2=C_S*ZYHM2B2ISGR)YV&47(*L M+62)@RUF;J^?ZA3.G>+4G#= ]H*O&'%*EYP7*1***97X@Q!? MT.FH[7/3(&9.BM',!49"+_.G"VKA1$N+,5 MX,1J#H;1>/A@9#]B_!<#RVF0*')! 7>X5Q*;.JY2!B:+*+5G:2_Q^:'<%&R7 MAP\I^R/%5XAP,Z5@< *L?5^$S40V7Y++$P'LEH,,PESB1':2NE"EC*-TVAL/ M#6Y /YF'Z4R5ZDR6,;LKPBM$9,@M,G167^NS),$+#F\M>OKFL)Q.ZW\ZK=_2 M:?TGE=8_UL%G'7S^+L'G!CB==/!0!P_KWXGX:/V%>3XZURU)YB+W5AG'<&Z ML "JQ[KK<'W/QVR-N]:Y-!X^+L!<"(1Y6U"0\T+Y[Z$@GW;?+(";D=G9G9MU M!]_O>SZ#5G]D-KZ);^T1YT.Q!.IT>TB>]=T]@)O[.)UC]1GM?D:CSKBI"5RO M%[C:'3,HE/4I\R%>;U"1&ICQ\"X?MMM:=YN*0FR,7Z]W/E*Z&U'/AS#Z*C)8 MD*28T,7[_]!OQ>#96.144=B.TF;R";3<]*4U8$N;3KM7:N_1:8^RGQ2[>;2* MO4[B=(FM0_)1O'RL;]NX#@I-(;-%+>V5Z%@@]JZL8M#/TSAN=NAS4NQ+4AAF M?$+<8M:.6ZQ.D5O,=F?X_;FEIR3]W.2-H'C/-*4C)?^!TI=R;3]#*]M/Y6CK MQ%M0NX,I[_!$U,'8/_:DP+P5%L2\H8KDUQW9M]!$)V=?\P385\W"\F*:1@Z[ MXXUN\"A\QI.O!+/0N&W12<]G,ZJ_#[&[ Z4-\917GC:ZL"EUAU@F#:;V0QC1 MT\(TX?3%_"77FU("J](#@_(#1;,=Y*\(FV>@VP\_$[<,;XK)G"TZJC!@F'VZ M"*,L35>\UG!9[$3>!!:2IR[-F4U91:(#[:MHWP=?I7=B>/FO@O]AB_\-@(![ MN5%9%VG\B23E#GY'[79O@]_3:&7\QK?>>N5];=V%;-L+[,$SZK##7>J[O%&- MO9Z#RS-O92>7I6J=,=9CPQP[(9[ AAHR:%%I/,NT\B9XPW&&W^RV^)] %T/<\ZY>K*5-"WJ!\7;N %B M5; M&_JO '*?4IA].-V:!AW5*(;9'RU3N-]VV.59[/:+4 MM@WCLUJ$5/BJ;/N^ED8N)'>U!L3=T5I[R4&U15$-#E4QE0IPB%@!'KJEO/[* M$C'80XA'%#I?C8M^NYLU?Z4V3S%OLT_(DU,#K9-!F61J5=*GP+AGRX0W7D%Y MY B)C_DEM".74NH],,EX@\0TF8,E]N_*78@:A7WW @=XS0&!6LW17B@?7MUO M_B973GK(*J$X$_$REC0"5?Z/%.Q/V ['&$O\:]D7,?-4K$%<./&]F3 7UKT6H)"8N9I3 M0%"J:2II169[V,MA,"\- R;NY@=+713A2:('-_9SAQTN>')+]?25ET11:P\. M[[7-7?&SLP4_&\^/2@6N=#*IC"/,5E$3"I3",D-0XS956?$FP.*06L8D3;)* M+=];>+SM>FMM&D(: '"&LX #IMI%_$+T*V\IZ;RB7;SXOHG3%,3( G7I_-=# M?JRYVP?_BF7/HO.P>$CO;1$Y>9='G$&$O N$20-LK2CG_^1LE[^P)9D\C$ T ML#NQ ]<19TU9+G0="B M<&7[)!UB(];;*I#!ED3M$LB%[Q M7JIFQTA -+,#S\'221:D3'C9,W2(19MW["]>^D1Q\A(?,4"J@?B@J& 7@SI< M/$=&W;B5HF8)X[+F'2_-PDPI7ZAT_\W$0C8L&%#(L7'O<$5%B]#XX,5S*D$- M[!FOQ2Y5CF.K )<7N9*2266>3Y40TZRJ$.2'_I53-8GPAFD)=T-(3F0L%.9= M 22**73"C:J>#4$<85J+*6?%T3 *.1#J=>WI,VI/N\>H/=6EI8V?&"61K;T9 M9JB5RP:,POF&8EZ#F%] (W1XBY,L8H Z"XO@@PMI;Q2ZK>0A!X(6FMB30VX& MH')^'E=7(K17Q ^:KPCGET$^J3#3.+,&])M^9?!-M9X:<]A:GQ_1*H[:>7]W M3S>3N%KXS8*'E<;*@(0MMS#IH:J2L/%S<^8O8^5^P5[FK VR4V&?8/PFH)]4=\2X-9Y^*@R=J8YR-L)V3C>X '[7BP9 MW*8AQGSO1=\>L7HY$RD5_BEEB]PH\-0A-Y0+D.W$A:6C\7*YL"D[0HXC+<;S MLTFD7T! ;=])?2'CP S9.D!5XPH4S4I A[CO.1B4_O%P\2QH]]VRP%X>46(I M%#MX[2CWEB44:6/V\*;^X><;H2@KJMBES!F@"7:J_P0,OFBF-.+!+!0^5B1/ M>HD(TE%/YT#@XLD7=;U6H9^3,FGK:M=5R*25+!&!NV SJ[GZ.8HEW5)27)X: MU*=HO]7#^B@.Q AVKC =J+B F !2<'HV,09?*15V$ 0W)*]##J-L17**$TL< M/L5%"': @NXK$DG/>L:-ID5F7Y%!@HOINVML@V.@H]1)N.-4]0>BX83B 3GPPFAS5=R7'GDZY\U"P%S $#42$ MT_^)#'QDZH,\;-BE[O/,8& %+[#_E)%ER5GX]T!NO-@RJ5F^MW G3*DL? MSYSCF6ZD]*H7%HH:]Z)>EK+K6FAYP.9]>MN5.LT2Q4.=5-O*'3\4)HM 6>,M M\&10HT*6O80M:Z>(G\JZLP(E5;GHYCT[[QZYCUYSG8Z+%@G2'5 M>7("#3T4RK(PH)X1VM+"NJ>PTEC!; AK\;JA,)4Z#;.H:64,6AZAF7.17>!M MFF>9QZ,R)S^8SPZ??EG(1D(?'^:R^'[HR-MC_54D\GPT'OKX\J"RU3%6P/[ M3N^1S]61<=4C:'WJ,"L,IC@,U$1#Q;K+,$8QZ/#^-&CJ&NZ"!IR2L+!'.!9WVC@JC];,A8)FQ!O92TLWU58T%>A...)G2;A M@\1/";RY'[I@CLAAQ!3)XO,UC0NICBFVASJ:3WKZ6<"'#$MOR95O/\KOB)B= M3U<%OI7'%W(K^#!@/PB^3\C_51QCIT1M%/4RJ_#, S:49R4Z+ZM)?:UBS\\' M#]:;^1_1ODQ)&<^.0'A\U!&>V82]K(-U*LLS2A/PI-*-(WE':AN!Q2W8QSKU1!<\4MJW%L*%L7810PYQV]<$.]LC:DYLDVU6&#SN?C+ M?*MO=%.2T2Y)]GGJ";GTX' _ 'H89N?R[QEEL9-W(@;+2^\(?"%."28H,(@7 M/G5!Q\!CPN7_CC9O44[8_;/>MU>HJ.7KQ-Y[C='UHOOE9,TMVM]^=>A&T/ MAX>N1]-U.UUW:P#[5(\,+I5"SK8/O*MSQ[F+=P@G$6F\LITKJE%L2>%5,;27 M=U9_F3ZOXV?34"0!U(B*+]4%]D1IHP=,;D\F(3H5525R]&R,[Q=B]!NB_Z\Q ME_)EC^MP3Z8(Y;H9")6Y,\E^7"?DXOTK-N[-O;5\)TY^7O>T"=]G'Z M+A\= S5W[&)8:>FM]?ETVOM.@3\1Z3U"Q_:::S#WS(X,5) MQ//115YA2;N9Z$[K!]*\>QR/ACZ@U]-N3L3"T]RQBY>FM^^P0"V_WUM^CW-" M1Y=?[:%93P]:92M>'E*EJ(V[O*&ZK.];3[NI]1OV]%9@3,>,T=^RB MP+2&@^.XZ?09[1S'WUN%.1$)UHZ8-;UF8YW%Z9E*G1-+VMQO[[6& M!+/3&H\.M.'VJ])J@/W]#&:NW<%:^]]KKWVL1[_Q-"9J3-P%$ZV6V3TP/TQC M8HT/MFL>FE1VNI@HK "Y!O%)WI7^P-+V@SZJ4+@+9'3#%%V'^Q:BZA<^XX4O M9!#6W:>]?TU^94?]8Q?=ZVTO)T1/N"N?[:)LKA)>M<-:ZR(7 M9J>WQ@1-=(T?^1F:YQO$\X/Q>?/\F>B9VV(,HC[%?5TM\B13CDSSA)+"ZO*, MD^248=?2G*++"3='>2M-DA..]3Y3B3S+N,9^>Z\U'IH'IJK5(Z9Q(I:8%J)F M"]'>@<&S$J*SC2:=\C;H4*]HZ,#/>D3[(2/:>WI$>[-'M/^TBRVC9WGHF1-Z MEH>>Y?$]8@AZEH>>Y?':M'F961X-B]KLG1TD!T3J?"#]#)T/M',^T+/$YJP+ M%L=[)S&?2,%B79Q%OU5"9)Q\?[N_JUA)TGD35)>7)6$QI/!UKRIYQBW@=-^#;_\/F=QFG7;S:G.-H?MP7$&\M0J$J0Y__PX M?]SN'1B9/27./^NDUYLP3E [C=@#"U)XK*UFP=HZ"W9OBG;:INXAIEEE-U;I M:%8Y;X/FGOGPPUG+F+& 1;9/L]QM=^$%7IQ$U!#%$&WF2M@\>95.V#L)7&,K MC$#@QEKAT:RR$ZMTM6Y\WKKQ9P80G#I)&L%6")AY^T\'=&8 8$/1TK.6^M^)/: E^X)HJ>"3VB MY"!S4VL[FE5V"MNU1SW-*F>M&-]%X0,HPJ 53T.)Q=@\H.PC?IUIB:>MXER8 M[6'GK(>M:3;9C4UZX[-FD[/6@M__D7K)"GLIRRS$*S^,,4@73HT4 #F@;@7D MHL!LP\1CAWDFSEK5Z;1[6M71K+)C:/Q<@ANPA,O.$B,1+IA7DY41+AEFK&.NI)-X#X?[ MO)ZIA)V^JM4[N$=@3]/9K/MF-3_K6>?/) M6=LK=U$(I'%C,/C#A1';/GL=,#[K;)A#@P^GI.EH1MF%48XSB+16A_R]W:T4 M33["67\H>%A/./C^Q/W]U/>*$^#+<8"S#"F^)&5JC8>#UKB[[]#;%R1.TS5; M+:%:0E]=0D=[-XW1$EI4=JZH%:N\6Y6DP84=S;Q 4LB" Q$_0:K@/PM9A>:H MG%:(/_GN;&&1 F&_-0PCRRZ,6)SZ26RP;XZ?NJ#VS&$?\#*LSTGF++,[O> ! M%AY&'OPN8@^VG\*7[80^@]GBI3+W]OH;O,"P.I9EV'X<9J][8PT-V*,O8MOR M+2OC,?(2=NF&CT&,]?&AXU%*^J.7S T?EW@9.[@T>P(6+JM%I'-]D^_&!:-E Z63N1>[ETHZ25=:&JP74\0+'6]J^OS*2"!:!\)+(1'2T MP"M\D;XQ26,46NH7%R -X&>P;\26O"H%O[@SMI@]%5MF*!=A4$*UA/D^ \K" MRZ1K;>/SS?+SX8W*"U3H+)&;^#ZJZOI!>WW3[6]ZD!,ND(Q<-MV4VH*SQ=(/ M5PP)E0CQA//.WJ$2 +AQ9=8HGD?\&Z<;LR$?\ M1-D"PLWE+>.R2;(S%PX*-URV"'P'H)_WP'LEPD] Q/E"X(B!Q/#4.,-S8 78 M*8!F&D4L<%9&Y,5?!?-8Y><#7R4^H\7R5R$C(1?A9]!MO%F$RBS>'6QB3+O4 MXV82>>Z, 0%MA/;%PB.J&E/&"K>)C0MQ>:[-:3,C*S#C MH!SB?N7;C]EEC@_%=Q?6@P$).X5;0F&UV+B ]\!&Z&R![?NCC'4F+&!3^#3_ M8K#V72DY;W<5*GA^S^IFS^=\F=&)KY,+ZI1%D1Q0#S<*,*S0(!!^XUA(?I$0 M:UNKX$_/_?,/GC5RIX.!V9^,AM,>@_\Z PS9#.SNU+*[X^F_AH,?GF3J09&I MQV6F[O?*3(T_>6FFIO#8UG14XNH;4,O1=#.N';K/\;#OX&IV/,$K[Z7FMZ-( MEW8_*.WU->1W;:O5 OQESNCVM8/5__Y?(\L<_A0;KA<[:4QB3-(6V/X*="]2 M)5 PO "T+0_( X+J^3WD.\US(> MYYXS-^8VW!(3%/9EQ$"Q)V4"0-0!:QQ5/*XIV_FQ"%W0!XJ('KVD)#ALR=N/ MD:C\(_#P7_>)5-:O%T MQV[C[!'QI@SBX0LQJUPD[)"4CQATP\"><:$&M%_8 M7YEB#!#-XCA=+#D%DCDH*/9T"@J8 +@E7"JHDRYP%UQU$NJIU/T]-&3RKN\8 M_LS:#!.I^56#)P67>1JQD@FB/*=M?,+S@9OX X/'BZL@>R=&GM>#[9 M3@A3!=8E\S!FA2NNHMN;<-;GBH9Z [2-W_(W3ICOP>YB(L@"N]PC$_KL&WTM MQEN<%(;?4W$XN=K%BB*QQW**"VKA0N"#B M,$"/#V=_16PYZ^?+@ZN&4X98AFZ>[$ 4LCAV%*V02)1V$N4^4# %>FR>:O['9=<$\B6D(LJLL%8O5+H3GESWE6B;0$5KR^H4 /W&4!JF7(,4V*'5K*H3T]Y5U"7JT, \R9R"^79*3:S?R):IZ7WK3 MFK=2&B,YF-B*L@FJ(_J$\JJWD;\O&53'"D%D4^%&AW:JO MDNH6MWLB-K,C4E$OO+?EG2"!+CSX.6A97'%*80_YYKBV)1U:N%O0@C#/1OT1 M/ 2T?D$ET/Y8U.)[!(8(WHD>.GP*F75>&AHYN']Q'+'>%SVC!OWC!D?PX09%O=T MNEP=ABO."_#HN<1P+1]41CI M-N>0ZV(_\U/ [-P/,%.IX)6IL"XGQ6@0?"M(N2<&O@YX%!CHRD!YXG MC5+N96D;[\4*RN_FQC)21*(Q/@YC9I&WD"3Q*(K"I3T-T% G.;7=!Q8!E"A" M(:W*5FZO3VT'3'SX20I*)"BD %DDRA(12$65KF@9#4NX R2OU6U1V 9W^Y6M M$)#!B@^8&$F%7@E XUD(ZPER_PN@1H3W&= *$'V-&#-7_8\W"0$#0U^\Z9G MMJV.,1'^: K+P$]Z\B?D6T'*P'/\50OAYQV QF+"(IZATS5;W,U]$4OP,;> MS]MV[F@E/W<.@],T0:>7@I/9V2DJ1R&^3[XT[C#)*J&%?VH6A8]XO7*GEWP- M_[?B8A'GV#8^"!=\)B4*Z\-7D.+*U<^=^C(1(*:[>\E85/+OR7')2623QVV1 M^@EW;-)%Q1_F288E1VGF9A63R13/[!P,& =9& CH*&ZJV ,,L2/I+\L/3+@E M\%?I;Q$.&G0A+FR724-K M33>2GF:'8X"-&^ XPMVGU3>D4$K*3U-$%P/CST*TPR^XNN#\^V_H$\<@D NJ M1^1-4*-!M"SR*G 4Z7VA(#*$.*XY)O!$H**'>6=P">,_X#<(VJU"DD6U^.*M7V8/( .IM[ GVA@N M7ERNS]N$B)G*AX.]A-8&/!Z11R0$S<-'3+QI"0 4US7+58'>$5]5?62-363YVVZUXF1H&X>J0>I\)Z>5[%Z$#\47@ M0'A1*,9#N*!SX%U&,IN= GVD%"96\MWH_$L"49T.1,YY/ RX_N/8CE;-Q\__ M1@-<'J?/5 ? W=V[0LX?D$KJ/91M4D18S/::^%X\1XQ]#(%&CVLL0=R*1B( MDDA\DR_SVJ7QJ9ZRJ[@(E'4"9 M9^-Q'"?Q)@6NZBY0<@TVW2FX!'F=J*D)F7!5W1V9O>MFZ"<$>&Z[W**0#B+X M55&YQT]P#G;+UL4EMRXNT;JXW&A=9*0IKXQ;&IR8)5L#8U6Y$!5IX7HN@8R@ MR>ZW;)8@LTXET.CAFP'?X([+)RA. VEAA2BM<3I!NB5V9F12G/;HET M"R.D7%&_(K#ZQARWNXH)1CO(P$;:5R?DCGEWZOZ7=SM;W^:@;>5\\P+&]8U( MNWQ2]R!CD^H1"!=XQ.W,-$:VQT!G>YQXML>1."M# M7O3&ILM8Z*04%^5F\E2F<93O"]7+H%Q!F#/*W+*3X4VG;5K9+2KK 90[<_"V MCNK3GHD=M]RQ_043+VNXFP.5P7\$>*IPJ_\;SA7V9OS"4^Z;KP7RZ\L CO4" MU!DP<,.=/%EH*2$OEQ=GF:9YGBD?=<3-R.E*YE.4;^\\&=>05U5);>.6&ZO^ MJ$@\1JF*Z3>BWB'._+_HO8S1BOR=4IVQD,'.4B^4)/ \,W6#KY[;L [5ZQ7, M>>Y*5J+3#[;G\\2%I&3F0?(RV[#3[@^?-@U;_'5BR6],]294OB3]"&9+ MB8N4JX^8:@IEKUPG7(O<&Y M24FJ)($N"*ZWD-7D64R@) XVBS/=I/'+.L$L7Y0 MKE_4**R_1I"0/@??$57G;>-&B:H(XK14RK0V'6,K+XYEWT3:#!7.>S(F&E5> M_@#PS"^59H44 P4@D9!#\Q(Y/B'1"B?.48\\078@BP\)(G-R\_0W7KC"/?=* M8>+$]O-+?$ZY;U4+S4LZZZB&'ZBX_C/3;JXQ4YWH<%( 64SF=!DR+^*!2 ]% M6.(>(KK]\R8'CT%!3[94C]A-_F#UR. C;CD1*&HPTHTHD_%J,.$&US M7=*6U.:W:;X,T@H\I3**UE6IPLQ"$'QT:I&3*7(VE<[<#7[*@MI5K6?A1ZKX)/>VM[N5RM%6C:K3'E>J894:E1M1U&ZR MRKS.(FJ&7)_[[!4FX7*3>Z K=#"7QVOQB93D4M#)U$2%];QT\G97\@.M$991 MN!!RW[92,*JL.Z,I733Y>9(=2Q643Z8([%A^/MZ[_'Q0Z_+SSSS36BT^C\(@ M1'._4)73V)OC6N2@+:409^U=0 VCEEOYUM'T=VWT.9#K@[*@7$45PZ8[^#ED M9"MO E>/BJ5=3_(8AT $,W_":XP[/@\6P)%U8@)X"Q>G,;QN9?5Y,?&-55/_,83L3Y[\=?&BZZJ]'F82 BZF:R:IUUBRQZ1L9S; M.&06HB\L3ZFN,&/X%:(&+$7:+SD9I9Y3U62BE/PLD_J*WDWN=A0E^+ANNNA" MF5-#K8:2.1C?L[G(8YU1;%<9G)6_IC!&J_@>5 %YO10F]@.HS='7YA:)(-Z' M2:[>-^9>TL_4]D@\9#J=XMW.4]75;\>/]I+Z&\GK%O/M596+RN_B>1@EEZA! MHO[[:$>N"*C*UG1)1)4#N4Z"F:_D&90MF835!H]BK!".I3M>DG%--5'.?L-! M@S*">E[Y"2):+B>SM*B)&5J]G[E_8C]PE]F%2DMM!.$)2ED4$FK^9%&6* M/9/N2FY$$9A&9E$^)%.ELISXG,7$$8N]7&9[*1 QJT;C-%2:#\;EM;$T"EO& M+^C&P3EMV*\3SBLA@W'6,N[A3WN):K<;^L"$0(&_V;!EY-05"UK&7]&9\W?\ M(_O S;\9$/1K&*6!3:2Z?V0N/OTKW#DV6B^9+T(T "OD,\A9NDF=X'&M\$TFI_WQJW89*M\?FRP+N Y^8D8P^X)@ 0Q1Y)\7"/5!T M4H-XA!P['WB(>"."9^GY>9N>]>272:*Z6S-$HK^@/Q3L22:S/Y6TO++%N/'A M&+J:AF [&H\VU5!97A?\$IB$441M#P0Z4=JGN(8+Y:#EM_%G%&\4 M6D'1/[U^8;6-OT@71"O/-"V_5ZK2,M$&NI4G&>DX@R/F(I3=+3NEE53 M:QJ?39Y-"5VGMBB)DXG5*):ESR *<80A[YA2$%BLPMV,FAMS51'HWG0[;6N< MN]LV/BAY[)2PKI0"< ]8%O\7&$0M&+";"\*[#$546!_XF)A;+=AO M&-OAWD[7;AX6"1>N(,UD98!$B&Y82[A:9*7#\^G 4T"#_$7VME;U$:^Z5I4HI;6:[6$_6VOC=9;;(/-JMDJ7FE1:'DO9M;8L:-]0 MYYH]133UDT6'#W#+(S=?*C>R8A+FW?C0_ .M/,*7B"CN;2#4"[M\[CE/K"M7 MLE-T^7DD)!7+> MGDK/D_X]8E79<3ICND Z#;#,R',]FU(G1,;2ND&^*MOLE/_ C5V#>UA@[5B: M71G?V7D!J/)F[29!!J<^MJ#/0WP;W1=?GO(C5$I]]2+0P%;]!WLZ"U0[OV7< MV($-#PYRS\#','ID,_P1?@23\$&ZW]F!_!*+^'9X?TN*/Y403/3_$4VM-]!$ MHDEU2'_W\XC8U.?12?%VX=NW'2==I#QZ*$<#@(W$YGA^B$C8+5JZM?%782 + M'.9 X7GH8_Z_6!99;'CO%Q(@L3J;7&?E5N27ZI$0% *O4 &(XO!!SB]NEE>X MB6>IABJU+,\KDA?A \L^7^:T:T#T/\%+8:M8JR+REC&\=XF5VW0I5W)B7GHG MTXT4(6I57%N%R.IFHA&'E._\W@G=^5_6]"3I/]WF 2Q#R2Y.T(/?1'7[F2(N M\F_6DAWY$2_M%8_!.@R7QK-VUMNBR>>#GFA_%3[G,$NZIT]DH+!Q0[LP*Z:S M52%^"4Z4]BU5L)*38XV1 S40C>F3(G&6=] )=J(QU@J,,Y5$[ NY_JC[4C8C M1WT.Q1E9A;M :-KH9GQOQR#H4@JRBNRSD:@&E1>^+8M5"KV;['"0HP!Z^QSF% MDH*(!%D>X?KUE:6&Y;,1WEAF/MMCFWJR(>-PQPAX_\0F(% $?+0Q /XAB[7> MY]WQ*>24PI'Q[/=H!2IF8C=>/K_,X;9U82?".[[PDD1FHL6\43!*#%>;"-(] MV>.%-UE\(LEC.CU*2NK_L6NS%F,.&O^??_A?3\N9:9F"-\V^M K>?YM[$]DK MI((QC7L'KHK4ITEY]L\U2+DY&&5&IX@RXXTHHR3)D\'JQ4I2/#D.1&*53;6= M@9IG562&/">G\7#T,4SXO>C0"(=#>6ELGB0O;<[9ND&U-?0Y3-Q%H0.8$-6R M.';/',/?UJLIWQ>J*7/F-UZ:"'41BBH/8%YEVLI[>_"6'=A4:$OZN#/WV!1T M4>:D/ L(._$)KQG_79YK)G[7HJPOV3^7N\2Y-PUSO/,F2I6SEL3A..KA++/# M,2[L6)0-8B*7)]IP<(7_,]YKG,'-KGUI]G$@&W[?[+OB7WFJ;.9YOG:2MTKS M)J7]G_#S.5@?QER>FZZH,\HXFRP?2.9?\1X;53N@ D\^, <;\O$,"I=A)1=S ME9PR+!O +GZBE ,0G2H=Y+B:O*\?[P4 )_$@ _M/)PSV6Y5E M=>CC"RG'I$+&2ZSM1;6!AJ[+'G;26E]@(QN;CP.R7>Q62Q41W^&:F19KYMLY M+SSY5@^]@*0QQ7&NTF)H6.BPEAE*:H5LQ+K1RL6IU@H>C7(C>;=/E2'>O.=M#N!VUO2:[.>[/C MZ#>\R0N]$H$(]:H/7 .=2^*]&1E#QH?(7K#',/IZ3)^E<6%US.Y;69DIJI5O M:/9YPL@4NT?!#DE5^Q3-[$#,2\_.^@N.]X0[F7^+#Q:^N/ET_^FM8BF1G9DS M3[7-4F2Z"@-HGYS[W5D.LU0S+GZ&D5/G&T!MZPKXA/,!T .P3$%X'!48IEZT M:!EWF&C[B-KR/$QC=A.B"1\;O_YZQUTA5)B^CR/D90" ^(# 4"8/>9'XJG!3 M+)?4I0S'-V ;Z ^7%E^15Z$3?, .W6;G\N^'NUE[)^EF_66CF_43A9UO\SYB MC1>63\ ';!*E&-!$!@,VZW) ^27$# GRL$;,D>,4U/0;P&\R5,5X]"3S#9:Y M_Y?5Y:_4 RCWMGB+!7,]RHQHB1$@6<=X^#CU4Q(9)/>@C$5B+").IY>Z3XZW MV8O2P..-&%!#^;8R(E*-4.9LU:=HF#U0EL:*\U!Y1T&W@AV;XVZ/.]UDU2CO M X^;YSJ)6*9]Q$:/EC!2.2/S&9.O2LH),TB>C1#1G%:,P>$TI "B-=YAZG(VHS!JN MC(B!7CM!1Z[H0",?3KT(4,^T"LG!W'8G7*[RF1:H,B2)[R]WR+EI;Q&4%I/Q0RYMO&/#(ZJ]B&+.$G_X-$2D; ,>X.?/:!;D,@=H<_*G#.DT50^'- Q=YPY.6GR=F5FRV8AKNOG@^OS8TT+@AN.2MZ(AXRN=S/@E; M(L#$)R.&Z_R5C:M#_N+ 3$^>XU! !C@5KAB3,Y_P!78^>";O\QBI7Y>37/FW M?(^M?^-PQ7!XDHKA3=O8I!DJ8>C/V:WZ0:3&_TWI+"6X[HY:,2:@2_)V# WA!.F>8@LBL[/1SLI,CI9R/8N[ MEUL!4LD&M9NZO:+CK_'Z#EY;:@-P,1:=$()*=3-++&O.+',8B**R1V'!X,'I MUF*T"5*1&T:91U7HNE//5X?$W+^_(878S[MWPPH-UU[%HI,EW1)^6.KB+KN; M\W F;]&'2IOQ+E_ '2T@2V!\JWCDN3TF,A_S$YYE)]R2]4]")2^HP%Z@IG,4 M-.+FJ\)/L<9:R&(3CZA]YI[V&.OTW3W2=[L2V% .[FS@P=MCY^1FWC^1XW02 M2Z*JU M?01NW[_];1.XW=K([<(3O3(^/09PBXND3%E&QT<"4T1K:_D[U_E(I&XP,3\?Q[$0;1/'T03U_3C Q>?Q0?@9GW MK]JM]UOZ5ITUPU?>W6.>[%JB_4-\[9(XB=8XH\Q?V6\,0N26;N@0++KC?GPADG3+*'A4DIA DAO,F?4I,ZB2*V(^ MN@=UFF]*MJ)9(M#;7699=ZO(L7GSVJ6]CTM[@&->>,;H5%%!$XQRRRS:.YY% MJ_0G^.!%"]7UK8_O2,W./ "WU"QS^AGE4ZH?SB)('#QDWZ MG&IP3OUMYW13Z-2I3ZTNI]8WMYX:-ES[ %I;K,^J!F?5VW96GYG+V((J#3^& M@:BBP0;!1C9$AHH#J(/K+L=9K5KK W[% QY2BB EO#YM(!Q^AC4WCRPPCZXQ M)UO:Q60FAJ+QWH0Y-LX+3^9L1;\("DF5F*N+/Y&^I1;^0/E.[G12/5%JS@_S M1/9$EKZ<'4-EP6V8?38(Q03DB"7A2W6QKYAH/&Z/ M^EV,'B41_,^5+Q:!I38%EJX2=_UWXU%[W-G\ZT[;S'YW1<_FSX<=X#[__$/W MASSX12?TH[7\9IA%;QT>6GD3?/W%>)?RE=_3./&FJQJX:8DZV+22]XOBY31% M'T0EM+[B>M:@-0CW-/$Z/_S<-1$MRX&U[*"OB!D/<6;N7]_9!&?F8'/G5UD2 M:]RG"]C5JO%!"5"6=)+!<2"(TMSW^, M.<__U(3#>G;>0<.8LWJ_[__GK[>_W'Z![;U[_S_?87]5W+073^7,^=VUJF%G M>(A6-6P/QL.=E*K]?M?O=@_ZYK:UCL;M[O!%-,")[7R=13B*YU+PL@. !B:F M."E!>U .J9[0-9#7?]JB-PJ^VJ0YOJCPC'?2 Z7^]S'%1AL93PO"[4,3N>T. M;OJ'PYYQ*%VWZN-'H.J[8N&]('*!NGNSWI3^3Y(((>2Y? ?/. YYK+9Y$*<) M$CR+TYY#QBHVXT0D]']1]]B3E#1W]8X5;B+&6?&G8Z]/V';S)%G^>'7U^/C8 MAE6V9^'#U77DS+'%[Q5S9W9TA5,9KL;#8:]_A8L=]SMF?V@!'W5ZUNB*?;,N MS?8\ 3F_SBO=L?&U;Y/H_<:B&7:GX[X=WE;H>AEYOF'VJ56 V:(YA0'-5PIF MF,40+4+C W83B]2N +>!TVX9=^$CIAU=.W^D'E?[J0BSS5]Z]ZY%GWNU@J== MJ([]O+)\"XGO('*RTP*/64>VTBGQ1DQ1+;5%&H$)R)\D2#;@)#/^[P>/7-!M MP[P<=3K6_[?>BD/F6 DVKMM1:C*OFVB*3YZJF1_3ZJVWMPYNM//L4M\^X@ M5M)GF@!@UK$5-PU@=08P5,^L+@"8V3-[O:N5-30MDWU[Z#Y*+4WV'T-9WZIK M9:+_9>Y%H('L"WR-A+EJ18Q_,]?&/N(DV0S9S!XAVZ!.R-9 U:RK53.-;!N1 MS33'7=/JF_WN<#@RQU?N:#3LCUW0S 2PE:#HO>^51^_>,QI^_8OQMS3P0%VY MR^<4@=UY1Q(8R8)E^:4;V?N,&[!2\@VSBT)O]L\'Y09\PW5"N0;J;SVMO^WH M2.G7&^6VKT^@W!\];!,+!M)7 *J>HH&5%2G1FWC=6%QKU*J,BJ*/K[4F74]9 M>Q$5XB5NUN]^.[^.B-,#=QI \,15_:5PU+QU9]S"!L!Q:G,5'7-%.-""3G\Q M>7O1>WOA>=[;B^NW/"%UEO(J;N/^\N_4PWJ:1@$H]!+^\_[4+3Z47G1&51O] M,AO[_ :PC#3O5:NT]?+#8'9)_49=-DG6F932\Y*XF,<7IY/8 MFH/SO>,'6)J"\V>IS4H[?=P9](;#P=4$=-K>&.ST\5@:ZK>4]H"=7-7025$G MLSID>8Z-"4L><::6RO0*/=];?9N;S#N6=TK=]#K]+H# M,-K'8XNCW+WW#52-^W0IAD78OI$!7S%H7(PFF!1-0"/\Y*'/>C;T59.N3M#7 M0 7O,'>E5O#."_IZ@'N@YEVY(VO0'YH ?3V!?._Q[;M!7TEUH7 #!AUXPDS! M2[DGZI%W(<&?,]9Z"C9;QJ]AX,*#?L$)B_,6;R>RXD,G6&WCVKT70-#J$Z@3 M@C90>3S,%:J5Q_-"T,&P,Q@- 4'-H=GO#14$Q;@TX%:P(XK>X_A5'KLA3RD& M-%Y(>51AM'8H:!P"@$KJX3K=:I)^V$"EL:^51@UY3T+>L#/J=6U;]R>^:X M-[84I$/'X.Y(][?47Q5LL[-&N__8 >>08H8D5DU@KH$*W5 K=!KF=H"Y_M : M#@#F>M:HKWH![VG^YNY =YW.$*%,C7+[%,\5B583M&N@4C?22IU&NR?1;FSU M1V9O>.6..D.SVRW'/ [QV'4I7<,<5^+=DX&+LP.\=<+5!/,:J.&-&Z;AJ6WP M-.Q]5]@;]'I]A#W3Z@UZ"NQ]A*?O 7N?G"1$V1T]B7F)QKP,\TI4JPG@-5#) M,SM:R]-P]Q3<8?)L?]SO MSU.U:WH\9E'X&E5YCEIJ;\/*5CE;Q M=D]+*1"N3MDH#=3S3%VQ<6ZP%Q^">_"_[GAH7;EFKS/LF>NX=P]OQ8&"NWOS MK&[6"4M#W\[N/$DUK>D=#'FZ?$-#WCKD$=^MXUZWT^]U0-^S>OU.I[N.>[Q- MS#X&KJA8UKBWGX4KR583X&NBKJ>+-\X-^/93]0#H!J9E=;K#<7]P%:S V@7T M&X^_]?X%N'=9,G3#--K3MP&ZGL,4LB8ZFG0MZ+F96(=D5IB#P; _[G:N7,OJ M#;I]C#"6>V%6ID^,93>/J@%BMR@,O ^\[1?,J;*9-4MMM#_"T[2T#I@^MIYR M,=;]/YX)A;I>5$/A'AD79F> &1$8KY,..O$*Y-LP]NCB@Q?8@$_&[5OCE_8_V\;%ELOD[>G1<%\^/./[]$6" MV%(J:W*A-M&VT"7)^D)]UF6P1_9./ORI=)N^T(6BX?19">':.GDNF#:MUEF# MZ7/ 5!U.U3/'' Y+/LL-(GG/G#3R$H_%KS1MJO[B8G;T,/&S$I=#AXD/X6^6 M.<9AXG]T.T/VS>S\ZRE#%.?O&N_D0$J\R5D0\S%?=SZ<'$[;?N=%#.R(:)>A M<9&<,Y=/C\N5&3X*9U [M4!.%]^J'/P7J$4 "_YJTVCR_\I&D__!/RJFDV<] M4D3?0-(>.L.U*EI\4V?\TV&*Q'^>I2:!1Z8U"0V-3T(CYM*!QH[0^+5C(C)> MFMUV\BW)H/&]#W 5@4S?Y(/%MP!CJP+@A!R3>)OU!3ES6R[<=1"D8)=N@+B_ M9Q W]6+@:6/%; ESQ=D_ N7,E^H5\"+XUD35[_2&E;\FPQX!MU>A;=+8L M CZZ&^7X&J>@0 -]2\YZ=*T M.OWA>-SI]*R>I?SH_)'?+XML@OQ10'_[B][QP;U_POK;.=@ MVNUV+\>=P<#4^N+.>*K'HI\;B.P?CQ1_M4AK[(Q0:QQ]1:519 G=\^QLO&BV M&]9"F_H8!I>_V8$]XZ@B[>F"5GEL:-FB+SZ[>U0^.;Y7KI]XIE9HG*M:>%@Q M69W50@UC+QB-% AF=G($^XJ-]+A/L"\#DEQ9!GAR$(D2;W>U&!3@Q ;I_,I6 M!ELL_7#%&%>/V3?FI&072T59M97%% T[(#S@MO*XOMAG]5_ 5MYH)'?-EYT- M?K9*W6%YW\=6ZHY J\\@Y!$7[LR]C]K)>R'"15]_E5:CI!%P'6>+XD!F\"X/ M>5F1,L?C"@W#[(RMSG-DZFQTB\-2A[5NT5S=8@?58C3J]+H=[E7I=\QNO].' M.VHX&%Q-^KU1ISN-V;<'L_/8Z7$G"V_*2WXXDBIQC>X$*;NC5'TUATYO;_ [ M.,+(1PD*;:+_"M!W9NK$8:F>QU8G- !^9P <=#HFSF&8],< @1D BI2+ O2] MO-Y58^3;7^W;S8U$,,=_..29)/6"NB;J>H1DEUA=>J+?MN\Y0']+ V98PY<=OW"V MZMV!T?G^.H MU8B*<3)7>MYS#948XV/;N+'C)U?Y-D_Y;OI=:-2JXE3*QAL MI'*GD_\+BB," MQ2%EMI@@>".1V=*M@$7#JD1$;R=$Y#FZV#P>W])D)#2P*\4Z!O['YOP68\?< M97/T BT5-R*>GJSUTI.UK!*I]62MER6[GJRE)VOIR5IZLM9.%[6>K*4G:[VB M.:6+0K4Y=;@Y914[3NQI0Y'I\"EKNQ8F6&:0P#=+UM/;6MI*%>'$VMM*)^\= MTB6>&LYV=)E;70YG)O6-_9=9A+*MM4]*?T$0?,]!D;Q/0N>K\8\ P*$(< TH M:G^5XJ;K9>3Y(A)+R*:;QCX;WG19IX:WI^>@=CO#<6]H7KF]L=4=X1Q4L[/> M&PQ3(E+ I96 KD_+#6W"MI>!KB<^*#6>>8= [B#OUA<#GU_G5,H.&_(=UPKT MFJC36;JL4X/>#J!G=;N#X?C*[??,8:_C[ES'3D+*(1#^C;\"X,)B]?IBU?-; MM_YF2YCJUA"FFJB;6;H<4\/4&DP-A_V^R6'*ZELC"YL+#8:CX=6D9_;['?-? M-+.D*_M/*R,DMJ9?/1_N813OQ;?.:A (%1W2E-F?&'./(#US#QX;Q7<[:;E%6\&/G1X MO6P3MGMI];OF4&M[NR.QK3 MAO1WR@4!B1N8'1JAU.L=$C_=)0RA)HG4$M5ZO.IQ5A&.;2^":>[2@D*-6;2\:N:D(H%'8*?SW;ZF?!6X5.#* 3)?= MX:A[+'NQD;J5+EO48+0MB-GI#?ICT*WZO6ZG?V6;PTO+[ RZ_[+8MYZ[UN," MI'I77"H6*O*DA&']P*I7E8#Q'T]-\#7N+T<"P'@\P^ #RLUA70S!1FI.NBA M@]7!8+76>>( L)+"W*TO7%6TBS@!N&JD;J63_L\-KO8:FBOP"L=^6]; NDH6 MEF7";UUAZ F'_$W$7#5Y7V*1'&K+QW18+<->A,%LNX.KE0W2O4\GL>=Z=H21 MO"<'BT^C<&$D0$P"%_SOTHZ2%>),Q)*P9?QB!U\I>V,!M'7L%B#J=9M2/:[= MA1<(['G ?F9,! V8#7J?CUZFZ*GGUP]G#TIV4\S:TN&] ,R>K5*H:P_.#64/ M'BG5&8OHP%A$![ICCK&_L@2C=[L%.SUGSGSC5QM>YK*28CBJJV*(N6KC?3N) M[1P5J%?+[28JBUU=3:!A[% 8ZW4XC*W%*/]!VA4*[ZZ6;H9\A2]LQ#WNB^>Y M'?5+TZ4H:.=,4*^)REM7%R=HU#L8]:QCH1Z/6=37"XBPMVVJP"G!7B.5/5V' MH&'OZ8RV,?ZUVY=CD!'X=A^#7#5,X"[T/6=52[QZZ119=BVC"FU6_DE&R//>>XM10R[.1 MVIPN/M"(=S#B#5ZA%R5AV#D24UP?347YO<=2-13E&ZG7ZJH.C?(' ]/PNU7, MGB-U&P[[PP;#OI[(]=(3N;HE4NN)7"]+=CV12T_DTA.Y]$2NG6YL/9%+3^1Z M19M2%]_N2#&S7V^;/>ZB%B7D,8@L3L\86)E!EHX4Y M:K"%>?*.15W2K!V+!^/2N'@)G#;P']&WN GX15/]HZ/_-O_BN=0H-M($T*76 M&OT/!:=^Y_M->COW"Z"AP:7^N91J-E'U[^D"=>W_>1J8:(2Q:7)@PK$FE3D% MKZ7ZU].C\6HQ#=J>P+0C^+1KJ;:]GL?V9?#M M;#4V766NX>UP>!N_\J\=0O^ MUAM8_2MW9 Y&_1[-6^\*5>WN[EU+#E<'>6S0P)0NZ5BP_B+VEU^Z-!1^M0N^..KA#?U0%BU1MWMJ_OF5XOJZ!"F: 2%'2HFS"( M4S^!8WSF/,WJ/'F)$AD95XYIV M",/&![NKVD?6I?&&WS#B=^&!&8+6->4HVJ1PF [VK); MQLW<8U-E%(7H_F9$[(_40SF:K."WSMP.9@R$"40L]5DL*C2Z]J79N[#?DA%J M]EW^+QHJ:[OA$DW;91K%J D#_N5NQY+*\;T=3>R Q9>?OOEL16^! MW^#0W1<3U\;=AR"N.CGP?,75VBJN'[S #AS/]D]57)MWNUKZ=CU?<;5>\7:= M%,1ULJ.XCCN#/<7U&([B\_04 U;HJ_U\L>(5KW:-%:>F5^ HP=N/]XU4+8Y MKO_YY?.OQBWF2V&$]9W,+KPDYO;DS[.L0S>$-P=A8MC+)68T>CS7\Q99P.;= M&=[9B6U00N.$.78:PV.2V*#W)/8,I"MB!N8_NI@+^>@E\^P9N#K^0?F^=N$8 M3_^B0^:]O_EK(^^Z8S'O%_M;&(0+A/J$!3'>#??.G"WLC)N?R46-A,";ZU\U M!!["13>V[Z0^US'^?_;>O*FM)'D7_BH*?A/W[;Y!T;6?.NZY1- &>^AK"2^X M/?"/HU8CK(4K"=OPZ=^L[>Z\2'MU'DG9]:'::2Q&DE82D-SM_)4BZCR"]T<:W$AA%&7K[?B^! MT7UDZ&W/Q^CP(?N7,0[]#&5IW"QEA[+J[2]T0!G!NU_6']V-4P?>?6@'&#\ M=^_Z8F__S-MBA*W6Q?A@^K7FY W5FP4C]2F[9Y\R/N7>G6KIU'3_9Z-)E0M2 M$F%4%KB'OZV$T\=)S0+5+ ^?"W:S8O5]T-_O%&C^L956E-W!^![ / M^Z\;.X2E^>/&^Q,0^;#6\$!&SN!)THELA8E%\4(&" MY1N*)_?\><3)XH'Z?'#2[<&LW158/6[[,]"<+5QJSUW[G_$MB>_7X^RG3^5; MN: +?RS;(BQ?_&#I5H[5(MJJK8IE#B:X?W$+&K,J\[DN!,**NA@WE\>2*S>W MV[6W'!/.*?.(E$3SYQM\"SKZB&]=MXD\S4BJ+MA_7:P3!/W1_V.F.NWM'6-/ M+KY#$R5:AY/-*>.BKK/#ZK\H2OSS1S7BG?K-P"S>+BT#167=#\N4"/76K MPEAN24V >_1*[A%YB8FU!X;TP_A6]_N(=@2@"MWOT0T3[V%U._W(3H;,9.:Z M\[#V5_%;J\^T+8?0''KIW.;\#EA#FVGUN O=4OQ^O9M_2C+$%A&+?RQ16SR_ M7?/FBJS![9C6VAAKS]% 7;PM>]9\.N]BG^ M"V/U::R9) Q/)PSOMVH[+?\#[(>>KOU?WQR<+,EZ7CS/6 6QN4'7;BM!B>K- MK.BC">RJ+,A#B%DBNG-]9L+O9CNV>ZCKSF5S96C( M$ZS58RG.,[BH./S7H)==]YJ^4XB M%#\Q@!]%&[[5[W9J?V_58H ]48EJ",//BJ,N6R+>Z%X_FLA7=V^7,X[B@2^: YBV MO<7(_M?_4*[^?,*:H3T?>XC3 M/9KLT>=E@!S"%_9J>UNUO[7]6@5K](GW=O5G4_@[FV6@_9-O]EM+JP>Y%F;0 M8RC :,TUS7H&)I#G_>LX/;= VKZ//4[2"6H6F M03=T?1(+Z?K$V,;VP[L^R6SK%GV?[B0"J[ S\]LYW:[#Q[HUL=IO[.[]MW;P MJO;RH/'AX,W^[L[AWBXL0F.G\7)_YTWMPR'\H@Y+L?I-KLHZZY5I<'C+41]. ME)]_V>T4=*SH%WA=NN/# 'XQ4?M^NAP]O-(_-_VF:^I>K$:O>U5ZX7$2\>LF2/6\4^S[D_[YUK^_"GIY6_5F,\!WSN190?K0?S+><4>PK?QZ_R+#:K\C-:4O3D MT>='8H/#80-)./SVPRU:[^]?;ES\%=M M?[?V[^:/"#R-\S:,P-9B?V28\7L?P!X/EM-,TYQ:(7@PTO@L8U3J3#&JK!:? M=RFF%!-,4/R!4$8V:AW=CICFFR]VSEUST.W%+]QW&Z6)[]@_%V:W^^T-??_M MB-7/W>G>M^/7^>G!Z3X_?GU$&Z=[Y.CT"SL^?=^J'_[3/+H\/CW^],_71GL/ M?OK[I'[9:K]AC=;19??BX/7[=N/TZ$?CTSYOT"-\? B?;=?I$?VG=;Q[? (_ M71P=UL5Q2_VH7]:_'7?^/CF^['ZOT[V+QNMWI''Y]]?&Y3ZN[WYA1X?[HOYI M_^*XW3@YV#VZ/#K\NW7T(<='G_[N'Q^>->NG.Q>-RZ.+QNZ^./ATA!OM=_RH M_?ZT?OFJ>42/R-'EQ^^-W1W<&'WFOW^?F+9K';3W+^J[^ZQQ"M]S^E4/7,*)/?Y\>G_YSVCC<@3&\(_^]_#BHO\0_WASN#0X./XKZX<=O[O4_ MW/WG[]8Q;7TSIUV8A_O:.-SC!Y_V83V.\,'A_H^#W;T?QX=?Q,'A7EP#>GP( M8_E'L?J[SY0JG#M!$&R<0YQKAHRC%#$=@F74$.;5QC9EZM]_3,C!]N_+BK25 M=LLDX9K!^B="BW_KQ_W&]_;D.'Y<;V*T3__8?> MOCF?>5270EM6<>@BZ?DR]?S*F5":4[;;CAZ(7N%6N/#QGG+094* 1T. E]WV6<^?^$X_-AU)>+">>"!6%P]@ MZ%G"@\?# ]T_J;UJ=;_W$PJL&0H(LK(H$(>NUAH%GC8S_<&P\=X[[]M%-+#1 M[43W:J_;BE=]P*2(+MI^&:C<^W_GS<'%PY!E624C$KX\5$GYZN(+##U?:WQY M"@EN= ?PL$'WUWD-R6RHL&YDJZO6,'2"?Z;7]TZ9O'W.5\JJ?&B2U"M$%I-6 M*1\OK?+.^7+SQ&1&6!X?Q&;R"HFX?T!^1@E^JB%/DVMPV"U,T[^ZNN>*&-CP MRDB_L$0_G.B>/^FVG.\5$;+#$]]K=V%R??BA]L$V81V: 6:^W[%;M5^EUA5W ML/ R]:IXXKR*JO/S10_.FAT $YA:IUB%N3F(<1T*J[X#OW]9FOJU+IR_8V\O M!63\JO^3+<%/H>63KYWH;[ZF8Q)'S)6$26L0VC:,Y2**K1TW7_X7_^C*,5_OBR_J/@7^?/W7X9=-XN?X@.*$\*[R?'U)Q)%FX4S M=S/^:">\O&,O]*YY6V>2MS7'>9LO>5O\,3XM^HC"E8_(:WLR2DP=P.$\XG7- M4H;.8&>Z[F:65R:FQJ\GL!U_BSFDH'XPZM8%O!9\;YC1"BLUMHX3JQ"N MI/!Z/48K'&\,UG2KWYW=]N%>_'_]:_?YY5,6+T::UFX,!R!SLPX>S* :]N#$'O2^ZT[PLS,:KK.E# M..4='.[EI_K]>(?TMY<''PY^WZHX3.UW:MWS7JU;PO-F,9M?RORDOA@0XAJ M0#^>U$$W>ZV+J'N@#*U:6Q M]V>#4COC-WSL-*_<7,6X=XJ<,;U5VXGXT9RS):-E:6N $/C/NY\ML0^AA+8$ M."L$. 7%4"+.]IU?^E^LU2KD87W]%/XY;V8ZP,9'@ P\WBS2/5C,IT#P4L 2T^*$*6[O=]OS_R@4?QN'ID!UXHC;!;/WG\ MAD[]:L;1K M=@ (=K6XAYW[UK(EI ?_SR(2,=0?1X,S/X[GZ4O2'I^VT"^7\? M9I'_7LQD[L6J:P9/+XX="/ C@2WNNH!!7X_JX]6&K%L ,[\5U\_8< M\#O2A);^WK\Z/6$#8?"%F=X[C\=6? %F>=Z:M' ^7'^^"+?\L">Z\\6/&SRC M1Q:3J@"2_8J>@82X:_X;K"KSN$9)WX0&>#M M[+(H1*%7VJQ7=D'Z,Y]H8Z]'D ._#_T8%@E"(W>/@VN)&&[XKQ?_"F6'>UW:@UWKW7FOC%:4J%Y:K>S-5W/S/V"Y.\6I$E6^-HA$WD0C ,S. M;[$[J(TX]@6T842\=3OB88D;KMFWK6Y_^,S;S;$\3(:[H4L+>32:;[IUK@=7 MWS37$#^/.!^_'*"X$WTH\7(K#+O9+NSOMG8^VF#7IL!F-(:_>Y!;^'OJ*Z+@ M1XD>\AT]SEWN,I,[G>#7$RX!HSAY.^616V!/_,7=3()2%*]\([#KI4#H:X'\ M[O77PMCP/^#,ZP\95URXXNMG5M_YN,#EL5R2L'%+Z$:SY>H<+G:P&!;\.X[H M)QL_)M+]**K=0@?&!+;8P6)'0";CD=H!9M/OZ][%E=PU>_:\'9,K%4!U^YHP.]ZD(^2@L>=>],$7GM]]*^+ M-W:G9J?LRSLH7S_:@U&T0()+(2]-M)%X6;\B"\6X$\88QSDSW:WF,KD M5Q3V>QQY7./^&-Y$2?'1772KK7W )HY\8L6Y;GWS;'CH N4"%M$<%)LP.==B MV,;'YQ3G8+?3FLLG]#EL;6_<[3G&G,O5'06SIA!@1+I^^?F=,P3S7UTH'2 M'P847',X[\+MJ =#B_K+D,Q',0$+8L(G<77,=B'DHRN57 MV:OHYY5)$0VW,H9>^C)*"Z0_Q+4K5E^RR)Z_!JSA@V_GT"U,KV;G6[?U;>B8 M*SQ&S<+\ 95IM7SG2\%@ARH(>EHH3:$A_D?M]-Q]&>K[XXMW#(#_=5WHAVH:]]/NBT_]*R5[F7XGLWH M>0F VA_93P15J_=*2]#-#F_N R%([XRZ2V6WKPCB;P*2;@]$N M5QDY;HK]%7@[T#]\U<-0.P65A-TRI9K)!Q=NSYF=2Q,-R)\\!$&WS[\2!D..>]$,O6E4QA3\@ZX[II7%N+5TQUL3'\0XTN=F)#4 M046L)DYS:$*6:SKFAHQ/C"]'@^ :+0=@K9'!E=ASO4W2P_?,"VK="9O1EHXU=J,=+IP&Y62N?#%] '\['/;$ MUPQ7KW@??,:"2A3QP_H8*RY=F?TQ/:Q=.R#*U1HZ.L;%.RIJ=#"7.2EC E5Z MWLM]+'VFYV=Q$K/QW$ESMF )NL@+F7!YENDQ12;+4">_Z6:K9.6C+1Z9V!&( MMFJO"@R)'I[)N7R/]GL\.$ #VEWXL=7\&CD[F *=XDP=>I;'Y@E6+,S11$.Z M/\IG&9.V"#57SI0XE!: =I$R6&S_4([''A9=%+4O41N*G83O%3CNORUY!0RG M>=+M%CF&I;<#WMHJL*581-#?0D#A6!T,6N48A@^%[RD$;:B7%^5DX@##.4SA M:Z?[O>7=EP+(XKZ!7L#ZQWR"ZZ7=JHVMW5QQ&%_"N&(/6,9.=^(=<:3&^TYM M#$^;/^&.XR)\K;=C;.3*4BCPJ*2KQ3!*'"P09?3M &&A-']+/_R54!8AE&+V MWTHMZ@ 0%/\8!9$V1][#^._^#8='<:I=#Z-8()CST)$_'-?.P#EG\<1).;Y,QE\)WV;Y<3>! MT=?>ON@T]D6"Q! 0(XCU^KK5'P=RV#A0T^AH=$U@KCU_I=S1[U?$MX:6\SA:@IQZ294MAS;4%1&A\.#1N3Z= M1U3BRM@H#J\A.[KYM.Z/6?[C(CYZW,VVY>9<68]?,&$@3F9CSY&,S>G/%-]T MHR&X67)%73N!O1MSE>BR:N+58HTQ18#O\DM\"#'5"71]_J9-13?+S1D+;[?& M&7,%5^;:YWY-Z:_F/.36\96A*PIF$'R1Q!.QI3CXAJ2[>';_:U3Z^,RKTPZT MN/)ZO.-<;RS&/=2MJ_G?9^=+7UUGZ/,M%FKTC,)-,$P.N*N[H.!9?3\WX6(4 M<)^; WCE;1Q'F4K*Y)PI3D3T-X<4I@CD]TOT&YMY&>^S%R.#]F?SF[KV$%PZQ./D2_^$4ZP^N[-HKB2X32LH)E$D4.H;GK@*D4?XWAU@R MMA!S6,=LRFIIYHR%O>?-ML@B&J>?NC7*)_JM^>WW%/A[4."/I<#?4E9V*O4I M*E-Q/>^*X-Q>7Z_OL8RBXB-T+TZM>5;YI/%9'DJ3_,K"<13?9PO@ 5UJQ<3E M4C=J>N0@B2?0^? .RD3PK8CH@T'?ZIY=927$08_Y(/K1"!W76]#7;Y.@/0:& MH^E<9\'\?%%FGGT-ZM>D=(115SZ!,6H]HK]7'*B,>(SQY,)&^C8):\7CBEC= M]5$S0^RNO>9;M;=WMIQ*?"YR$LN,4(#EN+Q3HYB5ACF0>Q7K*,V6JX69,E"' M.=Y7:2<@4J-$O2M'Y$W$8!Y=NT7DK5)AN3_Z?RR_2GL#?O'D-=J/1C7:1>.P M3@]>?[PX/MVYK!^^P_7#_C/^7G!Z=?"3R''Q_^W:[OUG\T=M_]J)_"^W:_LOJGCY?U]JO3^NL]5J=[ M/_Y[N0?O_<(_Y]HP$9A%F?$6<9P'E"OC$,\T_/F[73Q](K(S?*%YDVW5,MG*3A?OW^VC&&990:1X'/$&1=(2Z5A MR7Q&@U4N(R X?W7[@W@&U $MM3TYCT[:?D5EYI4WO7/@$67C#,J*8!2[%X8^ M5<4"^/BW,H=QWO$W_.HJS7\\R2:M MPLPJK(^@_[;?&>57Q>M_\=))K7]2W(PO7>>C?Y57.W]_OL(0R=VSGCVYBPH8 M;;]^Z8',.#0-* MW$%2'K::#_F"IQGDG84K%/^KIOS<4 =]F/=?!L=>W$N0IF9]KSU:A6?<%VNF MQ*%6_)W/D8N)XOCY+%5Y4D&)-.JU?]OW9=QU!B6[?Z_V<#R9$C^[R/OFA]]B+*XD['Q;_VK@5Q9_!2]WJQ MU.D_NG7N-VIE.BQ\[X_!B\YY&[EN48([/A9$$U8/'BF?W!/^=>@)/VL=[-;I M\>X_K<;AUQ^-RQU\L+M##C[]W3P^W,?'GX[XT>57WH@M;)M7;6Z_'IU:^!G& MT8#Y-"[?49B?^._ENT&].='F]G,PUC*'*0J&98CGE")E MG$.8<,V(U5RRV.AD4U ^(2\618L*@G&'#B<@\ M[._&-M_D658A>'ILOG'[3DWYXH,#MU/?G='UT:+ R+?HTH^Y1?W^=6)H>4/O M"2+ MU-]])E[G4E"#L,(YXA@.&Z6"1H[GSN9YYBCU(%\"S\C7K=O!W=_C0>]VALRU M65?9LEL8XL]H7\,/KA0P&70+U,XIOLF9E"X'JFGSS"">686,-@9E(GBJC"62 MTL@W"1$/->CF&U5+Y9M)CQ_Y9$UZ_$AZ/$W,G&/!*T9 CZT'8N8%RJFS(%A8 M$\RMT1C,L&PS?S@Q6Z >/VO/_WXGEL7HQMHD2XTS_@S<;NM86V5P6Y21,MJO M"\"T!&:+ [.C6:.$TT!A2Q#-VT$6(S2X17 >5,.#!")$6:9#ER3GL 7>9XR*/>8D$JI+<+\@ZO MIA%2E(.'+1@FJA3EWY::K/+ M26.GS1,M,J>)D\ADF4)<2P:T(O=(<2NSW&26$[6QG4M5(7W]A7$RNIH%@_4_ M5_'JO?-9.W\.BA(]=B)+.'F!5L#N*C:NO!V0S*R%@_;7&3,K,T;G) 2428,1 M5QD87)H99)D'Z\OF@?$LFEF2)U_0^FKOHLRLI+W+U=YIDPM3YE3(&*)Y )/+ M.XYRX3QR@68R:,VIRDOMG>QN2<#'E [=PPHIG/XAW\34+8JBC]0KTW>,6\-V][L>1A+$)_UM+# MRM/QZNY96:?^OC&T!;+!YPN0B[**1GO\-N[P3L?MC?8WI1$L%B]_S!A)&CL) M?%$A);4 UN@-,MX(E%&#N72PJS8ZZC>I6A1KK(R-E""@0C92@H#'@X IDXDQ MZH*00(P,"[&@+$$:,XMR 1N9*V>Q-_%> F,/MI@>"P(6FF>T:A;3SG4;;32J M:M[L#'3G2W/8/CYE'ZV0<;1_M74ECP1 W/LQ+.S_NMMUL;M80L@%(N3%'"-) M6C%YYQQYIK1EHM)1(YT(B2U@ H(X8;1;L)DJ>H(7D\:3\G96Q7,8R !K=CDW^ M[X4#V^6,J>(,RUBN,\1HP(A+S&(6@$%&".NERH*.B9=\$^,J50U*&EQ-2R5I M\"-H\)1I(DG(G=0!94P%Q/.<(R,501*HAO1>A&!"U."US.-93URM'8Z%D04Q=AG*"A+05>90PI;BT@F/7&>4.YHH;7YPXLB5\\O\N L MXJNK48^81#R_J4:91/S@Y.$'5I%^6%Q\Y4M,WW[ZZP+WB\V33F"_0+ G,R:: MD8X;$%Y$1*PP+01&*E<=]ZW MBX;(H'D19WO=%GSF2\Q3\SW?OT[S'UPLC[VLS3.J=9V8#R?=W@ !_K1K70.CT8.BE6_1,' H3F"RG?<*:8H-6UI=$/SI M]Z=>@JE9UR,[2W:]274(ET LQ.R5V5]*ZH MNBJR!]\HKUYV34*AM42A17DV$@HM#86FW!M&9-KA$)"V)&8(\1SE7'$4C'&Y MR@"D.-O8IIN"52G'[UG7?K[J 7BF+R+O39E"*V!7C3;M;;EG"=P6#F[[LU5[ MN)& 85H!N$D2FQPZ^"DH6&"L+=A9(HM-Z-@F4P\N;)_2ABJKPHONDI54>)DJ M/&6?6-@\IKQ#3I@<<4HSE M.$,MN7?1/(FN M^-+]WCYK=2^\KQG?\:&9+EVMA-&R-]RU]^7-_[&X2P*_Q8/?;$$=)J4UA"ED M%/&(&\.0DS8^LS5.FC,\ B96F MR..,@RGC8\,M4&[&,,XD\YG5*FHSI\G54A$MO6JS-1;[3>Z6%;! M18*[Q4_+!>*9DT@;^*?,@(UD&/:UJ(&^*<6#V4ARQ2RTS,W0 M(>-_G/E./[4M7PD+IMBZQ-&6BG&S)6\$G%>64V!F.&*54M6R&/S?#5_4991TOQE:_ZT4<0QR3,,1I'!8!19 MH9!F8!FYW#JM,%.&&=!\MLG9HDIH5:\SPSI5,-[UP8/BQ'8,MMOVM8'^\?2> MG><+C(N[?U5NZWZQJX?ZQQA2IO8UBT7)V2HV'C90.T,0U00#=:0"F2 P(LR( MG$OC3#!%MB%?U)VLRIA'"04J9!XE%'A4%)BQE4#SZ]<;KOC^XWLJ$> M$/#9CN%#M%'52H9PZC3@. M&FEB,3(RIRRWFF62;VQ3M9GC-2RNDW1ZT=&JI--/H-/35HS+*&4F0UB#)G-2 MQ*X]6#$AM]Z"LG.6;6PSNL#>XA7RO*Q3/O/ERM5P2?\=5*6'(;+.$S M]D'(<,AX,,AI&Q#GTB&##4$A%]0K1C(GLR@P4RBR@E)XER,P2>&2I7#Z0@T3 M@G@B468-0]R#**J,&\2\H-+$6S5!W2B%SYH>O_]ET>_$E5> *U]O8V-B%_>' MF[A7%&U_J7N]"_CM3CN67TJ&]-U@9[;P;,BI\"X- $CS EHL!$,&4DP< M9#YJ,*45TN#$@Z?5M=2-U$HBM9+X^2VH$]]K=VNOFOV8Q?(!"!=0K]"TM?V. MW:KU3W3/GW1;SO?Z_^M_%"79G\->-R^6:@*O^C.J D<5NF[WMC=**>\/NO;K M9NU?/S,HWOK>ARA["S$L]ANOIBV+J]%\B(-YJWL'O0^#6+?L']TZ]]??/K0E M<+(E;F%+U"_>'.Y,V!)OV/N6_\_[B^-/[LQ0+H]W=RZ.3EM?&Z?OOMA_KIWF=!%!,**Y09H1 0B(",MSD(*.:Y M9((*P7]NF=X@2/?CF$F05E60[5OL7=W:S=*'G%P=E_'/0J)*R_0-E>PEH1F2;!62;""-QS'*P6* MJEC.-\,H9SQ'U(*,<6+RG)J-;8$W\:U0KA2TFK[:_3^KA';[_?[YM$"&Y@_O MT*7O=9,L/J$L-@[M9VR%RC)"$( %D4AT*VI*D M_)92/A7[,MP0[#*&+(_MSC"6*->QYYF@F&56N"S/4^)'DKX%2=_TQ5*CM(@M M/YVG&>(!3E[8GPR97!/#O+-6TF4G?*R3QS+F)'4[E7!7ED-)+J8%ZL_EKVR4 M^BX\Y]*"#?)/JWX:;93W7X]?[\?YT:/3KZ1^^N[B>+?1A.\+]<,OGXGS08<@ M$&/Q7K?$"BDXHI$D@BF"B;)8/:VO,DE1]:6( V?7N>#(L M,P<"I:C;V)ZM:5]%-^68O"57TLH(X>7^9T$-#2981*2V8$D8$$<9/ H!9T(S MK[S!3T;?DU2MJ%1I[< 2I11E0<1FT"1#VG&&/!!XXZG%)MJG9)/BPD?Y6'[* MY0GF/*=2$LKJ"&7C\-WG++:.X0$C&R1#7"N/5 :2F>=*4I=GW.1V8YMSO"FE MVH13;U8"XRVCJIRP2>0J+G*G>Y^UH0(3@Q&@#$<\DW"ZYCQ#RH8L\!QK;&/= M$Y9O$L$W,SYK[(U [\&>S)30_-B-PZ[T=>CJ2LG*=]3%Z9J*6LD\9QAYKB68 MJEC$6TX:&4:PP SL#2XB?C^X"UBZ;E!9[5Q<%["DG0_4SFF7-.4L<*T1-X3 M4<2&+HZY"VKG(8H94K5@Z^+#X1*W9J?D?UO?[M6ZX]B2E M>H8K8&/LP!K%[]*MM[KI]CO#+1T#MU1*9(&@-]L&@SDGB*(6.:H,XCPX9 S- MD<[ PA=6,>& 4A()IOV#2XFDPH:5U>=%625)GQ];GZ>,&$=SEP>/D> ^($XP M15JS@)@PDAFO?*94H<\D>W#;OHI6.%PY.^:]'VCXI:MYW>O ;%)UPU4P74:[ MMC?IUA M:2S%P-?(9O[P#E[)H5)9?5Y<_8:DSX^KSU.F2Q:LU8HK%&(?/NXQ0A<6Z1\,I M^,>0B@R_,(4>%Z;0]%>AQZ-/[YM'ISNL<;EW :_SQNX./FK#WZ__^7J\^U>S M?AC7QM+&[E^A?OKEL^!.ARP8Q'*B@'Z"12E6 MU6C+O'IVWV]/0.3FJ.HPHI;,O45JZA1]T\8&X7.+@B,2<:8M(+OW"(<@&>>! M*)/'REV;F,SV%OL].9W70(,71=V2!C^.!D\1MN"UQ+G+$+7>(IZ;@#3).1(9 M,Q0;3XP0&]MJ,Y]3?>])%/A9>YG'_!FU;M$&T';;9SU_XCO]YC=?:PY\.WF> M*VJQ]&&:\--,N.UZ3XN68B_'=[3LF/JFVX]]4@_"H?Z1\'"!>#C;:BY!(LFRWA0N394&Q^;I>)\-H7H]GB87-'55?#[&S1)P:NHX-/% MAC,IC#8@TR*SL7M@0'FL]0=4QC@O&,X%BSW1&:V(@B\R/9!E*V;P''9CMIO)NF'5*Y MQ$A;:?* ?6YPO)O&-O-L41V2;Z:8ZOR@W4-+Y9>O\E#WD798IDV>( M!I8A3K% N3<$2>T) STG.,] Y_%FEB\J>7BY.O^LJ^LWYK>/2CZA5;!WZLU. MMP>(-^HVD\#M;N VVQM*JB"(E@R13.6(6^&1R;U".$AO%E 6I9= (L-,BKJA"!NL,V> E-SKC/OB-;9FZ/E4[ M3[#PT$SY6YXT8^:9,K#E>5WV.[9U'A?N;;<71[$S&/2:YGP0^^0==N=WRDNL M;7'8^>[[C&&3&6\YMA2YS&C$F6UU%G*A* MV>BGZ+N9_<0 :S6U:;::@Z;O;]9ZO^PG7J35/]AH^P4'_=7GAI)2KO4+!A+A MNN=QT*,U>P!"_W13GP"@_W57NK*HQ5F78VM1YNV;:T79Z;@4;ECJ@?1CME:) M,"1HFP'I-PQQD>/8K,(BHFB&98B5#\3&=I[%4H0+(OX+TJ0G=N@E,$U@6CD. MD,#T<<%T^K8UU4SA0!$VL?T/!3M?4<>0R +&7N?:<;#N<[$).[D>8%J8_W\4 MC')DL8Y9Z&W=^]+LC 8G06N&OXFCD9.89GTTA2=L>**N;/CM?YO>']N3IO%2 MOFAA&$'PKT""#MNOU[2-MP9TYR(R@DYW$*N9]^#7G8(>?.D!G3C3O4&LQ#06AV=,M#\YO_\WG2#DQ&"C7UPN+;X^B/:P"#.!S=_9'5WY1424S1L[,\XPP(?J7)! M2B*,R@+W\+>5H)1.:A8 "/+PF?"BWU+QJ9/>-6_]XI'I>?T5Z0"3?J%;W_5% M?^./R<6#=1IM5MRI7RSR<$G71UUFR'6I+O_9>U\_J+W:_P _U#Z\W-]K'.Z_ MVG]9VV^\W)JW96LQZY<'C0\';_9W=P[W=FL?#N&O.LR[=O J3ON@OC>:>('# MUPI; #^,L:7/^O[%Z(<_7;-_UM(7+YJ=XIN*#_TYN3AB-HNF6(KRY6M9W,*E M/ X=0,-O'KZ\5;PT=9"5KPFYA3F]\66\1>[U&MGBF-WSDS%]WXA/0@OEVWD_F=&-,A8C;S'\(915:@2.O>[4]0%4WL0IIBW_J MH+C)CI]CRE>:%N]ZZ]O&]VJ,;-XF#?(V\T[KE];OP>NW/OCSVWZG!D]M 4OK M%V7<8[@R( M*Q[>?N^_^<[Y@ZIQW395>E&;\) O2(.\<9!52;XEZ@F48SZXO.UUW;D=U'H/ M5Y)?)-;=99'7+(8X;X:5/G+N$ B4.>6*<6ICK"B6.&%*9)HR(365RNC/N]%V MP003=-N*ZH4DONIUVR]CWA$,X5-S-'8 MW1\&";OP/75RL+MSV6A_Q,>G[^!S]L=1^TC4=X^^'UU^@7\WX//O3ZZ#A-W+ MXT]U^'T=QX!>_/OXU'T]:G\D]?9'?KS[SVG]=(\?PS,:TT'"TSA6F,OE.];8 M/8:_8')U\:G^D7]\*1]?/J5_/?RW:#>C '"O<'!X4=1/_SX MF669R;RQR%*G$1>QTW?. H+-#"IXPDCNP$I1FX(OZDYWA?*!$VRM)6QA$J'* MDB"XX9DDBE-'!,6!^8P[R0O8(B/8NE7A^ 1;3PI;C9>3L*5TYJ1D#E$3%.)& MJ=@17J$,4Y[I7&FKR,8VPYM,/KB0?(*M!%N/ EN9D9EE 8-Q13@G*I?*.B]9 MYK B+,@"MO (MG""K>K#UI2UE5$,_Y<,>6("XE)ZI+4GB#ELJ)4,-AF#M24V M&985@JVJW*JH$+7^X'O?FM8O@EJGJ_JW@\? B+! 0*F@GEOFC1949EH+)YUF MA"U \Y@ 3 M ' 2;F./=P>FDN"< B<24A4%?'*R],(<RUGCEB$>64@G (#E2L;F>$B1PK8/(<-C89ODF M[&Z"B 01L[?\=I8 MG.1L<=GOR:/_1/GB<2\/PNMNUQ45I,JDB_Z';LLERW%QEN/7&?^3S!@02AT0 MSS/X0^<9TM9(I"RV'F,6=WACF_!-RE,D?GWU>>&)U$F?'T>?IYU%.7-4.$V1 M,D&"4G-096,LDEK+3)B<&\]!G]FFR%.WF_75YX5G&"=]?B1]GCJ?C1%6&FFB M*@O$B1?(Z#QFT5!%;88-T?%\)IL<5^E\KDIDO8)LI;^XA.(%>L?7&@T7GE"< MT/ QT'!OMM]-R)22S@=$G2NZM@,<$N.!LX2@%"&^J'0+<"CS!\-A]:Z#)85> M5N)P4NC'4NBITM4ZQT1XC%'N#!@Y2CED/-6(RCS'6ELI,=G8%INPKTF?UU:? M%YX@G/3YL?3Y:%*?73"9"\HCPRT%TA+;B&,6VXCKG&-IF QB8YMOJH?3E73O M<;GW'HM.49NU+[[C8RGX&#S4KMWL-/N#7E&S_2J"F (NJY<)/-S?U^7N DCN M3.SM7KFU"2T7B):S79!HE@47;1[A+ 8ZH\ ."CE#E!/N!6>YQ#1>C\KS1?7M M2,[:ZNGVPE-XDVX_A6Y/-^5Q#L192P3$%)B--A[E2A-$),M8EE,!&QIU&U?* M<9MTN^*YMTFWGT*WIUB.\HX01C(4F-*(8Z&1TE(AFRFPT;1UTKOBNB.KTK7F M%)294U6X[W7/GA3LQOEOOM4]BYVL%D%MDO/GR2XYEIL*X+A[O:4)&1>/C!9<2DTH_FDI/ M$1FE@-+$3%^D#$ TY[&0BRE4NE*E[))*5YS())5^1)6>XB\& M&^P!>.%L)G!*DQ#S1:U!P@4-^ZI2_>Z"KN M=PU.? ^6IS](89D5XBZ#=O?%Q&8"+![$K2QN[NUW;+?M&WZ0H.]NT'FR<3DK+CUU=K%T9/DM8N2VNG. @8*P84 M,P70K/#SI,VEM9;5V80PD:>VRM':*9ECBC79" M(L=,AKBW.3(>:^0=R97GF;-YV-C.'YS9N88QDLJ5A+0_J2!1C2#)\RWPM/ ( M2@&$@(I#;TP_N6,6B)-XAI-D.#<:.\!)GKOHC@E(,<91;BAWQFFC,K.QS>2F MH \NG_M8Y9L2 *PBH4D \#@ ,$5OF.:8** W&;5@*%E/D:&4(Q; H)7<6EPT M9\PWB7IP(F@"@#4$@(5'9Q( +!< 9A+*K,3,.\2,)XA+C)$.3"&7"66:\0SQI 2SJ-8W28X;[ 4)J;2LX5=DZF,=90@ MH(KT*$' TB%@BB$%[[BPG",3)$5<*XFT(QI9;YWVDN L^(UM@CF,[V\P65MJP M>ASI)^ET*\>1]D$]>[X_> A%2NF[3\2"]CO?8.MBRFZ)?Z/-3#!W-YBC,VP' MFUSDN68H$S*R':N1H4(B19V@.1BQG,?>\=FB0D$KZNQ=:W5=.&-)ZKHP=9V^ M'H,=,) 0?;4&K!*;:Z2\ )WEQ 4JC.0A;&SS1<5MDK963UL7SBV2MBY,6Z>AD$H@XK!'C*D58<*$6NI,WR@*4S&]MR4;TV4QQE41QAF&OVU'&4U<.Q MWYZ6)93;=W6M+^'77?"+S9 #ZW"F1 ;X!4B&>+ &:6?AG[DP5E"%)0;\RNCL M5=S?4P[\&FCH$HA!TM"':>@4'[ 9)\PSC&06-=2Z+-Z4IT@RE;N 2> Q6"E8 MTM#UU- ED(&DH0_3T"D.X/,H]QAFBF>4:X]:*B8I>Q/ MHJ%5N9*25^9&2G%9:Q@U^..W(3/XO1JW4-8;W!9 $/HP7_AI)IP:][31[70G MPZH)].X%>GR&.!B92Z&M1,8I #VK.=(<]!++LKJ M:NX"B$/2W,?1W"E"(:0TF J..",!19,2J:BY@,09MT)2K/G&MIR3]) T=QTT M=P&$(FGNXVCN%-$0&=, M1QYV!/$B1-(2\,1S3QQ&?8VCTF+V4,\ =6+,ZP1 MSRC5H69\Z/;\D&_4!OI'53J>/-]LSB4$*D9)G*]ZW?9+^*YFYQR6;YCEV>WT M_RJDH'S?892!>K/3[34'%R/_S$['33YE[_^=P\MU/SCINNN(;LH2723HBMG+ M(I1+XK,\]LGUB,?&*KFD 8$113*;>[!M0\P25>S!0=Z4*+Z&T+*$"$N"EA6% MEFDF%AC-3<@18V#4<6PDRHV7R-&,@0%NN)(BWD-3_,%E4Q.TK"&T+"$TE*!E M1:%EBBI2CK7(,$-$8[!:3*S^DX/]8CTS\2#B>>:BU4(7UE%F5>ZVK!&??-OK M?FOV(TB +BV*3R8_VM-R1D#5HNQS5U@!HNBRP2>K0";%'D=%'E)A"<=N0_7U2G^@845/O= M.(B()4B-0KE0(*UY;J4B6;PNL[&MQ"S[6.58U6K>B2D9.O"'FM>]#DRG_\=O M+6#OOO][K1M 'T$'"SJG!][58 ;-07.,8J2LWVJ2BQN"]+?TSB0 O L _ICA M' QCS83(8V4Q@WA&#=+>8>28-41Y $3"P5B9<^L^I>VO@P(O+S\N*?!R%'B* M;>! 1!Z=IYH'CW@N+3*P;TARRW&F>28QV]A^2))<4M_JJN_RDN22^BY'?:";&ROUY6I@N&"0>YBMK07"P(D4\*^6(RX90YIZCGRVFJLB8A]L3:V MY68N'QSEO9.*K)##])GJ_,)#(DGGEZ7STZTKG3*]=3T8-!KFO.!-BU?&W1KL'M1 M;WO=5JML^%)F5I;=,GN _[Y=O/6&]Z7 S"IQ)6"_UQZAG3%)..PV)O8WU6R\ M'YI>SK FPBP.5DCDG52(*^!/6N(,2:T-B6DE8$?%T@45:B.I\?+5 M>/KVC)+,9SQ'3G(&1,@)9#!3R"HN,':!:8+G>7B3%J^+%B^62D5\P306,?N!!72XA2LF4];#D]\K]VMO6KV8S6U M#[89,\5"T]9 I;:6$=I9HIOGIQ>#G@ 4_[4<_GX'T:_V2;!D6O9--UOE,?"R MVVYW.Q\&7?OUI-N")>[_I?M-F_Q?"SPD\ QC!&5.!.L0D*[(>,-(B M9 BVEA"F\J -*2.@JP& 0R?":!0CJ><%O"W:3_A(SQA;,0;+XKKGT3,P70(D MC7))HWS6?JF]XH3!"4(^C4$/=!UF"!H21 T MY0*T!G8@8(5TP!9QJ7.D\U@\.VC-?9X3,(D @N36G/)O*Y\MM$Z<=;?9.A]X MM[P:M7=P[?[$N;:&:'[W^:\;UB^;\0YE.Z']W=!^MK\DUYZP''M$0^Q-YRE% MB@,%5D$PSK1U/"<%YY4/SO"^LU:L3M0[P=OS@K=EL^D$;_>%MRD^K7*>,\4T MT@XL6AX+&JO%LV4T_P=E]X.YI)V*;2 MNX"T(@3@#6-D,B\0SS"V% O*.0-X$UOYZL!;2ME)HTPI.XM+V?E4_,.[FH9! MZ2^^3-NY7UWQ56:=GI$R&< !<25B$6DJD5-<,OB=HMQ' M-7ZPIR9E5:QT5L6M,&_2&U>NWSQWR .=^"L.F8]%8(8R,8.<"33O!IJSE?=9 MKO) E4)62(DXPQ;E6 8D-.9Y3H2Q\4+^ FR?Q2O4ZA7J3C#RM 0JP&8=04%RL+TRJY"V6,2$ (YSZBPS,L+(@LMZ)QA),/+X!"[!R,)@9(K" M*:Z]MYE U,;;.=0RI!W)$&PJ&)><*ZD*&'EP8GQU8*1@@'\4E_M'9&>,I+5U M[TNS,QJ@!*49_B:.2$YJK_6QF.L$BXNT;JBYV_\VO3^V)UG54KYH81!1!()_ MBA$T8L3AB:]I:[MM^.Z+V#^@TQW TXO*"9VBF<"7GF[5SG1O$+M #TY\W]!)H\\$7CPJT'KM2=-V X)R[@"6?=?C-*]8N>;^E!\YO_\WO3 M#4Y&H#CVJ>$H\/5'M(&) 3S=^)'5W>E72$YY!<;^C#,L0)EY_13K I%_HUG=]T=_X8W+Q8)W& M=^H7BSQ[7_ 7ZH?7BYO]=#X'M3?OM_[SU[C MP_X_>W$;#NI[HY&6A62N *0XX&#$+7W6]R]&/_SIFOVSEKYXT>P4WUM\Z,_) MS1*S>3C%UI0O7^O&%B[U8^CG''[S\.6MXJ6I [M\3<@MS.F-+^,M9_Q!:*[0" M1U[W:GN \FYB%=(6_]3]<%.QOSETI=+,?]=;']EVC9'-VV12WF;>:?W2^CUX M_=8'?W[;[]3@J2U@C?V9;O$/@Z%5VND8F'S6LR?/>O;X+MI]FSL3=\*]>R5K MY$^0JS'_ZL/+;ONLYT]\I]_\YH?]=!XA=7Q1&U*AFS;K-,B4U/23=E-/5RUF M_6\4K\>=X67G6*U>M_./HV@F.SK=NZS'*.+I7^WCW7>X?KE/#UX?D8-/?W^M M?]J#]WXE]=-][@^N%'7-_]R \^[7\_AN^O?SKZ M7F]_Q$>G)R?'+Z>BF>TC N\1QX=_G=9WW_UH'+[[WCC\(H[@NV&N/XY/=RZ. M#]\W#UZ_^OK?RW>#>C-&,O<&!XQ)+JK94X72&A(8K248+3Q3*X'1*Q,ZDA MQB+8+ ^;YWC K&R\I!(8)3!:"3!:>+Y7 J,E@=&4942=$8%G&'$49$IX@2.O9)C$Z1%Y8L^R5V=]:\5<#"(+6CLI!=HX-O]%]7P J5GW.(9 M57'7T*PRS*7S9?>\!W^^A<7KND/](]ES=[+G[* ^22Z_ MN=?_?OUO'M/7-G':_'WUZ=7)\V&@?M?R\/#O>_'YT>?ZV? M?OU^<-AJ-UXI5G_WF7BK;:9S9(7)P!Q4.=)<&Z0]%BQDGAFA8HGDV0+)FW<2 MQ(4[+Y(@KI$@-MY]9D)GUG%@(X8".:'&()6KV!R&JB!SX2PF&]L@%C."6-,= M5_O7;X]+7OL@8_!3DLKUE4I>__*9^\ LTPX!9\:QRA0!JRCWE"\K!(49 MP0&1G"G$G0@H%]8@F5$F>= JLV)C6]'9&G S.7=WI"2I;E0%?-!/:E,FG7\< MG9\.IC%**>QY0)ID#O'<"&2((TC2#$Q%1Q33L6C*',*2"L956O%7SX!/$/!( M$#!U[!O- P[&HUQRCKAF.3+6"V2#RYVBDHL,;VP3,AM-?Y)C_Q=>T-%E3QBG M_SE@/(]WII#(##1^[/0\C/K2N]H7P)=^X?%H Z?O&IUO_\'YN)'ML)?/H!U M\=[;EN[WFP'V+(XY60IWM13VOK\YW)DH:O2&O6_Y_[R_./[DS@SE\N#3'FL< MPM@O+8;OQ0WX',R?'AQ^N6@<[GP_HG^WXAS@^T+C].MGG\D@F+2(\A"K4PN& M3#0WP,SDF0H.9 '.K=D4XHK&1I($KI8$7M8_"R,,IU:C6)P+<1>;8'%G$!$6 M!X^-9XK.D\ R*%)I2I6D<:6D\6!WY[.DBAJO/2).*Q0;IB.M-8\EXQ3.92:) ME?%FYT^(5PJ&K,QEI04I[DXLZ55H[WA>;VC^\ Y=^EXW:?6=M7JJD+3$@C!C M6)!T_HXZ/U6P67#IK%4. M"2\SQ//@D/%YAES(SFG5&,\#!]49N3Z;'=LZ M=][!#[7.52V+BK@^%P46B>T_&"%^_(KM-S[]&Z"N&[S\P%[+$1R',/0LBD1%H)@;+@)+<9\7#8Q0L* M:^4!38)8+4&L'^[\^,PHEBPW8* \@$+ "Y=)AQ 7C,GC-50S'/KCC M=_6*J"0UK[ZQF-3\WFH^Y67UO,*V>-+S>^OYE /3@MTL37#("2H0Z'J.E/0ETNUO4)#KK]@<]/VCVBG9N5\[)5E.;9JLYN!CS^=C]O*7.7^OW]'&;OWB>/?C]^-/>Q<8%7"4>,0P=XAGPB,MG46:"ND(S2W'/EX(7,G2,4E> MUTQ>Q6=/ [8D'/&@1D%KH)UQ%*P.UD*5*P8+#PR(4AP ML*)P,!7/@-T%'! 62:LXXH1D2%MBD7,JLU0$$!"SL?V0JC1K&,FHD#-WI]V% ML5^6N=C=4"1;QQSLPDMPUFMV>S5X\+>F]5=NW>G<[-)[V[3P0^D8MJ"BJYNJ M?3-LO.IUVSL'+_=OC4@)8>Z,,/A7CH"P_N/H\/@4YG5Q=/GE M^]'A2:O1AM^_;GQMO*Y36*=0/]QCG\%*9+BZ*6L2X,B!%&#B. M!(/EZ5VY25:?MZSN__A,C0S MCV2&(Y4;G! .M ,!8F!;WN6.P:R.FM;KTC> M=Q+7=1)7_EE;(SG\!_))&1A_5" C"4;2:>7A0"8F$9DPB06.ZJ28>Y5IHQ /A1A#ILA!;':7"X>L+ H_JK$T@ M4 40F/+12J]X9AA8Z"(HQ%FF4&Y\0$+8+),T9(88 ($'1W+7L'(&%Y7QU!YV M![HU3+B=TP&W&EDRIMMSOH<&W;,7<>O[W5;3U>+2K"#&5KLG4T3;!)'W@T@R MRY4<6$7<$H1C4P4NK$:*<8<$-E09GN7&T8WM;$Y_\#L'LFZG(BL4ZUXGG:\J MN4J:?F]-GV)$-H"J4U.XV#'BRCNDN#2(6U)W2NL[M7/ M@D^*?V_%G\Y443ES(:-("VP1#P%^"HJA8#46&>/:25!\0A>0J[)319D[YVWDN@,T'$""VKM!+9UA4T:&D#O* MD" 9 1LK5RCWF4$S [V,:VVJ3XP?<+$G"L%7 L/,J5@*/2P#%% M[C0)6NO@$!%4(4ZT1B8'LX.Y3+LL$YK+F#BY2?ELS88J D=5XE]/P?'F8\$; MW^^_F Y\E57A]9C^U0;=6F=" ^%=I0J6=QIZWGG?+MYZP_NJ$4E;:[1^3'YX M.W1. 'P7 &8SE$]A:AW/,L14%C/7/45:,8>\Q"K75#H7W>H/IGOI5FAE=?HQ MJ5O2Z:7H]'3R8,9#)@U!#D>/N<.R6M+E<[1<,9,)US^.01ZMV(Z^^E0OKISO[ M!%C[KWNZ%1:Q/NMR"#TF64QNN@6>/GR&)6I@!\0*CGR\@<^5LTC%VJK$,96+ MW&>8\3(P.-M._4%NN@7HTQ/' !*P)F!=8<:>@'6QP#I=E;2E('3V=OX"5@3L"9@756W20+6Q0+KE+\D#\[D."C$3/ Q M(\4@0PQ%PF4Z\["W/.=E8'GV:M"J FOA2>^[R."%%NI!][50K.C.[8) M;^H/X!=%TF&YR,L''L4\-1 MX.N/: ,3.Q_<_)'5W>E7*)ORI8W]&6=8H"Y5+DA)A%%9X![^MA)TW4G- M4L M#Y^)(!NC3YWTKMV/7SPR/:^_(AT;L+W0K>_ZHK_QQ^3BP3J-[]0O%GFXI.NC M@C,^TE(%_[/WOGY0>[7_ 7ZH?7BYO]OY7$+ES(Y].4/OWGX\E;Q MTM096;XFY!;F],:7\1:YUVMDBV-VST_>/%A"MH1*@UW68,6M'ON+D-$=FL7] M\JU$S+QW#LD;HD2%V,R1U[W:'@"6F[!/'W'EQBC['0S:2E/$76]]V_A>C9'- M:;/_OO-.ZY?6[\'K=TNU7@'WU&_[G1H\M06\HC]S+WDU5%9_?]DG6**@(XFUT! M')NL;/M+JB^CC6PAL21A&__ZTRW ABEL(S.!*3%2%5L6$ZGG'/T\/>[C[GT1 MOI,U>^=,V:[I&KKY>)3[T]K<9DEB5X<[E[&KL_V__N"O M#Z-\]=>K3_N?=NC^;[OE]UZ\V_]KAQ\?(O_\.Y>QJ[?_/BK7 M?7C]-KU[_=?^N_VWY7,_I:/7A__S;O_3T=N]P]T/K_B+M_N?7K'__?3'=*]? MXU8[TX/#/]7>X9]_4Y%5V9"ZB"52(J-(Q'.0!'STU#.5F+,U=.7TG9.MNI?" MCV2TDF34>LH2DM']D-'^UG4R@@3!L00D\Y2)=$X3+W0D6<3LO(W<^[BV8=;- M#?VWD(R0C+I(1JVG^2 9W1,9-32C3*4/P1F2)>J,;O$:_/$#70/R,=CZC*UX>;CH#AVTX*1#H?Q[F6K9[V>33L_7>R< /I[/^ M)_"?T_Y)10RV.5D^U\E5 :,6L) 6\&K./^*E%$ZE0"@UADB9(@E69 M]];YM0UG<93]ZB*T=7\"(O0.")US&D3FD[2:).,HD<'[HJ>K6M^D8V;9>(8 MSFY\) /BJJ /\NYGD6[.)(I>Q_:X,L[9&Z!",,)+0ATK5@;GFEA%)3'&%"K, M116E=FV#KQ>CI$.3&!'2';?EX\8&G M(E\GQMUA'(.?P#:<_[T[W+Z0[7E3E,,J6:3 A2CPS9RAHFAP22I-($(B,B9% M/ V,&.4XETJ94)TZ[@8S9>%)B>AQ[2!L6S=1$+;W =NF,:)Y$"'20!B-ADCP M@;CH$PG>.)%4+@IJS?>^H5$1PG858-NZ&8*PO1?8-D[;F#TXFC/)P".1/FA2 M%"9&;' AL"+!P(O!H=1\3_9'@>UW+(W+?C%EG?!MI#^-*S'8-,=I+Z>C^*Z< M2A-(LWE>,)S,/!T83UJ^>-++(S^&7ZLHMZY($L^$A4"M$*3_W:AJ!=\D$A6#L>*4*PM@361O/MQ"'0:('(F*N_ M1/ ZM3@2;4(P7J:B?<>U#2[:FFF 8.T>6%LWOA"L+8&UT="9\L1KQ@617-ER ML@8@Q?X*I @LJ6Q29$ZO;90_.@36EJ([L^_F]@9KHFD8= F$M1RR5\ '?CPX MZY6%ECLZ[4^.:@U+S55+$*8_U.WG23N6'M9HF)3;+:^:'/>;[P\G5;XP.1CN M7)/L0=XN5;$%>I@'W/W9!0$<&8;SLZK9-UBWC(K+<$?*Q6^IT2R]#9\M@6R4RF=?9X MD>AYD'OG7*S(?(LQW]F<)4*%3LQF38)TFDAA);&<*^*T<%:Q8+Q):QN*MS6@ M$+VDW0/N_9DB"-SV@-LT02 Z#3P17<1!I"[:BO5>D\QB\B*IJ.G,8XKAC=4% M;@LF" +WWH';G%WI)60C N$B1R*C220D5F<$*S# E3.,KFT(<>?B_.Z%.E;) MSC@O9)G42I;SPOM9'Z]!WX?^8-:U;KW8'G%P6A=?9TGVBBP@ELNN%_*?_UK- M4;NU\1E?,;]&<)OJ(/2MB+#=FCIERO&KZ'S@KXLM)9YT<./$GV%D8UF2"F_K:GE^+E0DNL6(CL_;&3ID MG0,C3@I/I(N&% F*HIJXQ"(O1Y/(M>55ES(<$+>=RRE$W-XW;N?"&IERQ6M3 M$U84%!X,*82;B$K41AY .[!K&](XQ.W*XO8!0QN(VQ_%;;-Y@@6AD]+$QU3. M6Z%E,2P8(YE17_YC2J10#(LNP1:#%_,)A>6*<3^\#Q#+0/"V!MZ&*5%41I&$]$3%5+T!@A6-I&!9"LU8 MU*Q@NN@AYH8&)PC>KH*W$RT2%@$Q9D*VB?"&I2%\%-H77!M?FZE2E8B#&K8L M:E2&+ V%6>6&O&%8#T9 I.I,!*1 I3=KVG8R'KWO)TB]<-8;7>*I5T7V?M9: MH1N1D# :)QB3Z>CDE[H))J-!/_7J0UIM1FW=E"EBWRI2?WXA]%_/_IS466:? MB73SL]R12%LD4C5OYY13,CE(Q+H$1#*;B$^%4K4R7AM&'6^J! M>3L(+9%?]HER0NL6$G+"8W%"PWPR,<@0J"':,DZD$X:XH#6Q-(2" IE]XI43 M!+NS3024LS)P]J& M7>?VSBEG#\()%Z;8Y2HN-[R<(;YMA\P#?<;WGQBNL.45=L6B=X]@T)NO]F.8 M/+SM?K=GWKDS]V;*Q">&3^Q>GUA7ZC^9[8R#%K(?=^8D3 M5C'F)=4DJLB(#"&>-]I**D?O.)A ^=J&F#<=,!Z["NAM/SU[(?2B8Z!-:#>= MA46V47%.G*6>R%1;VQNMJK/0@) "5&UGR]RZ<'=I2H/P[BZ\VT_=QL/Y/A'< MS-JFBF5?[J1.>!:#D$$%[](LM=YT MI!0?@U;S)LYX5.XQ37IY/#KN30H@[M/8>=*.LD>U=2[$_*Q(^641\D'^!FDB M+R["B_.3%"1+E@9&"0?E:LD1)YYR1:BV40BMH[:YZ#PX-'UU =R^08, OD< M-ZN"3:;,N#J$F6E2J9C8J(! 4CFK3)T.HDYP0P"O+(#;MUH0P/<(X(9EXE71 MCI)7Q3*I(Q@U,R0(E@B3QC(CH_19K6UTJ<,X1E]N;CS4Z]^0)3S+KL.8RS*8 M(5]ICW#IPWDV&E\EQIG(/^>%7RW9049)4MX M,%8R%87F:6W#M562@Y[8#GIB[RW*@BB^+Q0W#!,90U%$6280I",R9B"..DJ\ MURQDR;U)$3N?KBR [RV4@@"^+P W#)/H?&3)"Z*27LAL$V"V$B[V6173'\N].KZ%E_Z(?QP1[DWT?#-X

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

\YQ M9F_ VN&$:?2*.:**^?TR)'O._(Y64!9E0I:EB#(!!S*1$^23$X0)CZ7!:QMJ M634-7Y/U75,KJ:3&OQ;;IYSE7#+\D07#QGKO'8T)*1X9b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
  •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�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�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end

    •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end XML 111 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 112 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 113 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 627 574 1 true 177 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://thermofisher.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://thermofisher.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheet Sheet http://thermofisher.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheet Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheet (Parenthetical) Sheet http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical Consolidated Balance Sheet (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statement of Income Sheet http://thermofisher.com/role/ConsolidatedStatementofIncome Consolidated Statement of Income Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statement of Comprehensive Income Sheet http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome Consolidated Statement of Comprehensive Income Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statement of Comprehensive Income (Parenthetical) Sheet http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical Consolidated Statement of Comprehensive Income (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statement of Cash Flows Sheet http://thermofisher.com/role/ConsolidatedStatementofCashFlows Consolidated Statement of Cash Flows Statements 8 false false R9.htm 0000009 - Statement - Consolidated Statement of Redeemable Noncontrolling Interest and Equity Sheet http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity Consolidated Statement of Redeemable Noncontrolling Interest and Equity Statements 9 false false R10.htm 0000010 - Statement - Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical) Sheet http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquityParenthetical Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical) Statements 10 false false R11.htm 0000011 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies Nature of Operations and Summary of Significant Accounting Policies Notes 11 false false R12.htm 0000012 - Disclosure - Acquisitions Sheet http://thermofisher.com/role/Acquisitions Acquisitions Notes 12 false false R13.htm 0000013 - Disclosure - Revenue and Contract-related Balances Sheet http://thermofisher.com/role/RevenueandContractrelatedBalances Revenue and Contract-related Balances Notes 13 false false R14.htm 0000014 - Disclosure - Business Segment and Geographical Information Sheet http://thermofisher.com/role/BusinessSegmentandGeographicalInformation Business Segment and Geographical Information Notes 14 false false R15.htm 0000015 - Disclosure - Other Income/Expense Sheet http://thermofisher.com/role/OtherIncomeExpense Other Income/Expense Notes 15 false false R16.htm 0000016 - Disclosure - Stock-based Compensation Expense Sheet http://thermofisher.com/role/StockbasedCompensationExpense Stock-based Compensation Expense Notes 16 false false R17.htm 0000017 - Disclosure - Pension and Other Postretirement Benefit Plans Sheet http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlans Pension and Other Postretirement Benefit Plans Notes 17 false false R18.htm 0000018 - Disclosure - Income Taxes Sheet http://thermofisher.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 0000019 - Disclosure - Earnings Per Share Sheet http://thermofisher.com/role/EarningsPerShare Earnings Per Share Notes 19 false false R20.htm 0000020 - Disclosure - Debt and Other Financing Arrangements Sheet http://thermofisher.com/role/DebtandOtherFinancingArrangements Debt and Other Financing Arrangements Notes 20 false false R21.htm 0000021 - Disclosure - Leases Sheet http://thermofisher.com/role/Leases Leases Notes 21 false false R22.htm 0000022 - Disclosure - Commitments and Contingencies Sheet http://thermofisher.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 22 false false R23.htm 0000023 - Disclosure - Comprehensive Income and Shareholders Equity Sheet http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquity Comprehensive Income and Shareholders Equity Notes 23 false false R24.htm 0000024 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstruments Fair Value Measurements and Fair Value of Financial Instruments Notes 24 false false R25.htm 0000025 - Disclosure - Supplemental Cash Flow Information Sheet http://thermofisher.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 25 false false R26.htm 0000026 - Disclosure - Restructuring and Other Costs Sheet http://thermofisher.com/role/RestructuringandOtherCosts Restructuring and Other Costs Notes 26 false false R27.htm 0000027 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies Nature of Operations and Summary of Significant Accounting Policies (Policies) Policies http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies 27 false false R28.htm 0000028 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Tables) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables Nature of Operations and Summary of Significant Accounting Policies (Tables) Tables http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies 28 false false R29.htm 0000029 - Disclosure - Acquisitions (Tables) Sheet http://thermofisher.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://thermofisher.com/role/Acquisitions 29 false false R30.htm 0000030 - Disclosure - Revenue and Contract-related Balances (Tables) Sheet http://thermofisher.com/role/RevenueandContractrelatedBalancesTables Revenue and Contract-related Balances (Tables) Tables http://thermofisher.com/role/RevenueandContractrelatedBalances 30 false false R31.htm 0000031 - Disclosure - Business Segment and Geographical Information (Tables) Sheet http://thermofisher.com/role/BusinessSegmentandGeographicalInformationTables Business Segment and Geographical Information (Tables) Tables http://thermofisher.com/role/BusinessSegmentandGeographicalInformation 31 false false R32.htm 0000032 - Disclosure - Stock-based Compensation Expense (Tables) Sheet http://thermofisher.com/role/StockbasedCompensationExpenseTables Stock-based Compensation Expense (Tables) Tables http://thermofisher.com/role/StockbasedCompensationExpense 32 false false R33.htm 0000033 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) Sheet http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables Pension and Other Postretirement Benefit Plans (Tables) Tables http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlans 33 false false R34.htm 0000034 - Disclosure - Income Taxes (Tables) Sheet http://thermofisher.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://thermofisher.com/role/IncomeTaxes 34 false false R35.htm 0000035 - Disclosure - Earnings Per Share (Tables) Sheet http://thermofisher.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://thermofisher.com/role/EarningsPerShare 35 false false R36.htm 0000036 - Disclosure - Debt and Other Financing Arrangements (Tables) Sheet http://thermofisher.com/role/DebtandOtherFinancingArrangementsTables Debt and Other Financing Arrangements (Tables) Tables http://thermofisher.com/role/DebtandOtherFinancingArrangements 36 false false R37.htm 0000037 - Disclosure - Leases (Tables) Sheet http://thermofisher.com/role/LeasesTables Leases (Tables) Tables http://thermofisher.com/role/Leases 37 false false R38.htm 0000038 - Disclosure - Comprehensive Income and Shareholders Equity (Tables) Sheet http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityTables Comprehensive Income and Shareholders Equity (Tables) Tables http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquity 38 false false R39.htm 0000039 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables) Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables Fair Value Measurements and Fair Value of Financial Instruments (Tables) Tables http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstruments 39 false false R40.htm 0000040 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://thermofisher.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://thermofisher.com/role/SupplementalCashFlowInformation 40 false false R41.htm 0000041 - Disclosure - Restructuring and Other Costs (Tables) Sheet http://thermofisher.com/role/RestructuringandOtherCostsTables Restructuring and Other Costs (Tables) Tables http://thermofisher.com/role/RestructuringandOtherCosts 41 false false R42.htm 0000042 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details) Details 42 false false R43.htm 0000043 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Inventories (Details) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails Nature of Operations and Summary of Significant Accounting Policies - Inventories (Details) Details http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables 43 false false R44.htm 0000044 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details) Details 44 false false R45.htm 0000045 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details) Details 45 false false R46.htm 0000046 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Goodwill (Details) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails Nature of Operations and Summary of Significant Accounting Policies - Goodwill (Details) Details http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables 46 false false R47.htm 0000047 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) Sheet http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails Nature of Operations and Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) Details 47 false false R48.htm 0000048 - Disclosure - Acquisitions - Narrative (Details) Sheet http://thermofisher.com/role/AcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 48 false false R49.htm 0000049 - Disclosure - Acquisitions - Schedule of Components of Purchase Price (Details) Sheet http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails Acquisitions - Schedule of Components of Purchase Price (Details) Details 49 false false R50.htm 0000050 - Disclosure - Acquisitions - Schedule of Pro Forma Information (Details) Sheet http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails Acquisitions - Schedule of Pro Forma Information (Details) Details 50 false false R51.htm 0000051 - Disclosure - Revenue & Contract-related Balances - Disaggregation of Revenue (Details) Sheet http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails Revenue & Contract-related Balances - Disaggregation of Revenue (Details) Details 51 false false R52.htm 0000052 - Disclosure - Revenue & Contract-related Balances - Revenue Performance Obligations (Details) Sheet http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails Revenue & Contract-related Balances - Revenue Performance Obligations (Details) Details 52 false false R53.htm 0000053 - Disclosure - Revenue & Contract-related Balances - Contract Assets and Liabilities (Details) Sheet http://thermofisher.com/role/RevenueContractrelatedBalancesContractAssetsandLiabilitiesDetails Revenue & Contract-related Balances - Contract Assets and Liabilities (Details) Details 53 false false R54.htm 0000054 - Disclosure - Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details) Sheet http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details) Details 54 false false R55.htm 0000055 - Disclosure - Business Segment and Geographical Information - Schedule of Revenue by Geographical Areas (Details) Sheet http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails Business Segment and Geographical Information - Schedule of Revenue by Geographical Areas (Details) Details 55 false false R56.htm 0000056 - Disclosure - Other Income/Expense (Details) Sheet http://thermofisher.com/role/OtherIncomeExpenseDetails Other Income/Expense (Details) Details http://thermofisher.com/role/OtherIncomeExpense 56 false false R57.htm 0000057 - Disclosure - Stock-based Compensation Expense - Narrative (Details) Sheet http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails Stock-based Compensation Expense - Narrative (Details) Details 57 false false R58.htm 0000058 - Disclosure - Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details) Sheet http://thermofisher.com/role/StockbasedCompensationExpenseScheduleofWeightedAverageAssumptionsusedintheBlackScholesOptionPricingModelDetails Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details) Details 58 false false R59.htm 0000059 - Disclosure - Stock-based Compensation Expense - Summary of the Company's Option Activity (Details) Sheet http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails Stock-based Compensation Expense - Summary of the Company's Option Activity (Details) Details 59 false false R60.htm 0000060 - Disclosure - Stock-based Compensation Expense - Summary of the Company's Restricted Unit Activity (Details) Sheet http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails Stock-based Compensation Expense - Summary of the Company's Restricted Unit Activity (Details) Details 60 false false R61.htm 0000061 - Disclosure - Pensions and Other Postretirement Benefit Plans - Narrative (Details) Sheet http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails Pensions and Other Postretirement Benefit Plans - Narrative (Details) Details 61 false false R62.htm 0000062 - Disclosure - Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details) Sheet http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details) Details 62 false false R63.htm 0000063 - Disclosure - Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details) Sheet http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details) Details 63 false false R64.htm 0000064 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details) Sheet http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details) Details 64 false false R65.htm 0000065 - Disclosure - Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details) Sheet http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details) Details 65 false false R66.htm 0000066 - Disclosure - Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details) Sheet http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details) Details 66 false false R67.htm 0000067 - Disclosure - Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details) Sheet http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details) Details 67 false false R68.htm 0000068 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Details 68 false false R69.htm 0000069 - Disclosure - Income Taxes - Narrative (Details) Sheet http://thermofisher.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 69 false false R70.htm 0000070 - Disclosure - Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details) Sheet http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details) Details 70 false false R71.htm 0000071 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Sheet http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Details 71 false false R72.htm 0000072 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) Sheet http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) Details 72 false false R73.htm 0000073 - Disclosure - Debt and Other Financing Arrangements - Schedule of Debt (Details) Sheet http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails Debt and Other Financing Arrangements - Schedule of Debt (Details) Details 73 false false R74.htm 0000074 - Disclosure - Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details) Sheet http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details) Details 74 false false R75.htm 0000075 - Disclosure - Debt and Other Financing Arrangements - Narrative (Details) Sheet http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails Debt and Other Financing Arrangements - Narrative (Details) Details 75 false false R76.htm 0000076 - Disclosure - Leases- Narrative (Details) Sheet http://thermofisher.com/role/LeasesNarrativeDetails Leases- Narrative (Details) Details 76 false false R77.htm 0000077 - Disclosure - Leases - Schedule of Operating Leases (Details) Sheet http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails Leases - Schedule of Operating Leases (Details) Details 77 false false R78.htm 0000078 - Disclosure - Leases - Schedule of Future Payments of Operating Lease Liabilities (Details) Sheet http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails Leases - Schedule of Future Payments of Operating Lease Liabilities (Details) Details 78 false false R79.htm 0000079 - Disclosure - Commitments and Contingencies (Details) Sheet http://thermofisher.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://thermofisher.com/role/CommitmentsandContingencies 79 false false R80.htm 0000080 - Disclosure - Comprehensive Income and Shareholders' Equity (Details) Sheet http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails Comprehensive Income and Shareholders' Equity (Details) Details http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityTables 80 false false R81.htm 0000081 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) Details 81 false false R82.htm 0000082 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Rollforward of the Fair Value of Investments (Details) Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails Fair Value Measurements and Fair Value of Financial Instruments - Rollforward of the Fair Value of Investments (Details) Details 82 false false R83.htm 0000083 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Aggregate Notional Value and Fair Value of Derivative Instruments (Details) Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Aggregate Notional Value and Fair Value of Derivative Instruments (Details) Details 83 false false R84.htm 0000084 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Derivative Instruments, Gain (Loss) Recognized (Details) Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Derivative Instruments, Gain (Loss) Recognized (Details) Details 84 false false R85.htm 0000085 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of the Company's Debt Instruments (Details) Sheet http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of the Company's Debt Instruments (Details) Details 85 false false R86.htm 0000086 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details) Sheet http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details) Details 86 false false R87.htm 0000087 - Disclosure - Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Details 87 false false R88.htm 0000088 - Disclosure - Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) Sheet http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) Details 88 false false R89.htm 0000089 - Disclosure - Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) Sheet http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1 Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details) Details 89 false false R9999.htm Uncategorized Items - tmo-20221231.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - tmo-20221231.htm Cover 90 false false All Reports Book All Reports tmo-20221231.htm q4202210-kex1045.htm q4202210-kex1046.htm q4202210-kex1047.htm q4202210-kex21sublist.htm q4202210-kex22.htm q4202210-kex231pwcconsent.htm q4202210-kex311.htm q4202210-kex312.htm q4202210-kex321.htm q4202210-kex322.htm q4202210-kex34.htm q4202210-kex419.htm tmo-20221231.xsd tmo-20221231_cal.xml tmo-20221231_def.xml tmo-20221231_lab.xml tmo-20221231_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 115 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tmo-20221231.htm": { "axisCustom": 1, "axisStandard": 42, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 2048, "http://xbrl.sec.gov/dei/2022": 85 }, "contextCount": 627, "dts": { "calculationLink": { "local": [ "tmo-20221231_cal.xml" ] }, "definitionLink": { "local": [ "tmo-20221231_def.xml" ] }, "inline": { "local": [ "tmo-20221231.htm" ] }, "labelLink": { "local": [ "tmo-20221231_lab.xml" ] }, "presentationLink": { "local": [ "tmo-20221231_pre.xml" ] }, "schema": { "local": [ "tmo-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 959, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 20, "http://xbrl.sec.gov/dei/2022": 4, "total": 24 }, "keyCustom": 31, "keyStandard": 543, "memberCustom": 81, "memberStandard": 76, "nsprefix": "tmo", "nsuri": "http://thermofisher.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://thermofisher.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000010 - Statement - Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical)", "menuCat": "Statements", "order": "10", "role": "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquityParenthetical", "shortName": "Consolidated Statement of Redeemable Noncontrolling Interest and Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "11", "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies", "shortName": "Nature of Operations and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Acquisitions", "menuCat": "Notes", "order": "12", "role": "http://thermofisher.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Revenue and Contract-related Balances", "menuCat": "Notes", "order": "13", "role": "http://thermofisher.com/role/RevenueandContractrelatedBalances", "shortName": "Revenue and Contract-related Balances", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Business Segment and Geographical Information", "menuCat": "Notes", "order": "14", "role": "http://thermofisher.com/role/BusinessSegmentandGeographicalInformation", "shortName": "Business Segment and Geographical Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Other Income/Expense", "menuCat": "Notes", "order": "15", "role": "http://thermofisher.com/role/OtherIncomeExpense", "shortName": "Other Income/Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Stock-based Compensation Expense", "menuCat": "Notes", "order": "16", "role": "http://thermofisher.com/role/StockbasedCompensationExpense", "shortName": "Stock-based Compensation Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Pension and Other Postretirement Benefit Plans", "menuCat": "Notes", "order": "17", "role": "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlans", "shortName": "Pension and Other Postretirement Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "18", "role": "http://thermofisher.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Earnings Per Share", "menuCat": "Notes", "order": "19", "role": "http://thermofisher.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorFirmId", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "menuCat": "Cover", "order": "2", "role": "http://thermofisher.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorFirmId", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Debt and Other Financing Arrangements", "menuCat": "Notes", "order": "20", "role": "http://thermofisher.com/role/DebtandOtherFinancingArrangements", "shortName": "Debt and Other Financing Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Leases", "menuCat": "Notes", "order": "21", "role": "http://thermofisher.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "22", "role": "http://thermofisher.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Comprehensive Income and Shareholders Equity", "menuCat": "Notes", "order": "23", "role": "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquity", "shortName": "Comprehensive Income and Shareholders Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments", "menuCat": "Notes", "order": "24", "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstruments", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Supplemental Cash Flow Information", "menuCat": "Notes", "order": "25", "role": "http://thermofisher.com/role/SupplementalCashFlowInformation", "shortName": "Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Restructuring and Other Costs", "menuCat": "Notes", "order": "26", "role": "http://thermofisher.com/role/RestructuringandOtherCosts", "shortName": "Restructuring and Other Costs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "27", "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Nature of Operations and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "28", "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables", "shortName": "Nature of Operations and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Acquisitions (Tables)", "menuCat": "Tables", "order": "29", "role": "http://thermofisher.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Balance Sheet", "menuCat": "Statements", "order": "3", "role": "http://thermofisher.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Balance Sheet", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Revenue and Contract-related Balances (Tables)", "menuCat": "Tables", "order": "30", "role": "http://thermofisher.com/role/RevenueandContractrelatedBalancesTables", "shortName": "Revenue and Contract-related Balances (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Business Segment and Geographical Information (Tables)", "menuCat": "Tables", "order": "31", "role": "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationTables", "shortName": "Business Segment and Geographical Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Stock-based Compensation Expense (Tables)", "menuCat": "Tables", "order": "32", "role": "http://thermofisher.com/role/StockbasedCompensationExpenseTables", "shortName": "Stock-based Compensation Expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)", "menuCat": "Tables", "order": "33", "role": "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables", "shortName": "Pension and Other Postretirement Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "34", "role": "http://thermofisher.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Earnings Per Share (Tables)", "menuCat": "Tables", "order": "35", "role": "http://thermofisher.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Debt and Other Financing Arrangements (Tables)", "menuCat": "Tables", "order": "36", "role": "http://thermofisher.com/role/DebtandOtherFinancingArrangementsTables", "shortName": "Debt and Other Financing Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "37", "role": "http://thermofisher.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Comprehensive Income and Shareholders Equity (Tables)", "menuCat": "Tables", "order": "38", "role": "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityTables", "shortName": "Comprehensive Income and Shareholders Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)", "menuCat": "Tables", "order": "39", "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Balance Sheet (Parenthetical)", "menuCat": "Statements", "order": "4", "role": "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical", "shortName": "Consolidated Balance Sheet (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Supplemental Cash Flow Information (Tables)", "menuCat": "Tables", "order": "40", "role": "http://thermofisher.com/role/SupplementalCashFlowInformationTables", "shortName": "Supplemental Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Restructuring and Other Costs (Tables)", "menuCat": "Tables", "order": "41", "role": "http://thermofisher.com/role/RestructuringandOtherCostsTables", "shortName": "Restructuring and Other Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details)", "menuCat": "Details", "order": "42", "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Inventories (Details)", "menuCat": "Details", "order": "43", "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)", "menuCat": "Details", "order": "44", "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details)", "menuCat": "Details", "order": "45", "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i8c962c6a83d2480dbd542bf36386c64e_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Goodwill (Details)", "menuCat": "Details", "order": "46", "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i8dce6ce3dc154a3bae24754db79c5420_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)", "menuCat": "Details", "order": "47", "role": "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "iee155bd21b9443918e390431e57402c5_I20200101", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i1541b8bd3da747fc8af992a42bfb265f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Acquisitions - Narrative (Details)", "menuCat": "Details", "order": "48", "role": "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "shortName": "Acquisitions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i1541b8bd3da747fc8af992a42bfb265f_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Acquisitions - Schedule of Components of Purchase Price (Details)", "menuCat": "Details", "order": "49", "role": "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "shortName": "Acquisitions - Schedule of Components of Purchase Price (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ia9d0070e0b064bac9890203c7be6586d_D20230103-20230103", "decimals": "-4", "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Statement of Income", "menuCat": "Statements", "order": "5", "role": "http://thermofisher.com/role/ConsolidatedStatementofIncome", "shortName": "Consolidated Statement of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i4f49283643044f478b9a3f8bb54fe477_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Acquisitions - Schedule of Pro Forma Information (Details)", "menuCat": "Details", "order": "50", "role": "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails", "shortName": "Acquisitions - Schedule of Pro Forma Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i4f49283643044f478b9a3f8bb54fe477_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Revenue & Contract-related Balances - Disaggregation of Revenue (Details)", "menuCat": "Details", "order": "51", "role": "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails", "shortName": "Revenue & Contract-related Balances - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "id16c9b8e607c4a26833da777609197e1_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-7", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Revenue & Contract-related Balances - Revenue Performance Obligations (Details)", "menuCat": "Details", "order": "52", "role": "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails", "shortName": "Revenue & Contract-related Balances - Revenue Performance Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-7", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Revenue & Contract-related Balances - Contract Assets and Liabilities (Details)", "menuCat": "Details", "order": "53", "role": "http://thermofisher.com/role/RevenueContractrelatedBalancesContractAssetsandLiabilitiesDetails", "shortName": "Revenue & Contract-related Balances - Contract Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details)", "menuCat": "Details", "order": "54", "role": "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "shortName": "Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Business Segment and Geographical Information - Schedule of Revenue by Geographical Areas (Details)", "menuCat": "Details", "order": "55", "role": "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails", "shortName": "Business Segment and Geographical Information - Schedule of Revenue by Geographical Areas (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Other Income/Expense (Details)", "menuCat": "Details", "order": "56", "role": "http://thermofisher.com/role/OtherIncomeExpenseDetails", "shortName": "Other Income/Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Stock-based Compensation Expense - Narrative (Details)", "menuCat": "Details", "order": "57", "role": "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "shortName": "Stock-based Compensation Expense - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details)", "menuCat": "Details", "order": "58", "role": "http://thermofisher.com/role/StockbasedCompensationExpenseScheduleofWeightedAverageAssumptionsusedintheBlackScholesOptionPricingModelDetails", "shortName": "Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i8c962c6a83d2480dbd542bf36386c64e_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Stock-based Compensation Expense - Summary of the Company's Option Activity (Details)", "menuCat": "Details", "order": "59", "role": "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails", "shortName": "Stock-based Compensation Expense - Summary of the Company's Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i8c962c6a83d2480dbd542bf36386c64e_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statement of Comprehensive Income", "menuCat": "Statements", "order": "6", "role": "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome", "shortName": "Consolidated Statement of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i8c962c6a83d2480dbd542bf36386c64e_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Stock-based Compensation Expense - Summary of the Company's Restricted Unit Activity (Details)", "menuCat": "Details", "order": "60", "role": "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails", "shortName": "Stock-based Compensation Expense - Summary of the Company's Restricted Unit Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i8c962c6a83d2480dbd542bf36386c64e_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Pensions and Other Postretirement Benefit Plans - Narrative (Details)", "menuCat": "Details", "order": "61", "role": "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "shortName": "Pensions and Other Postretirement Benefit Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ia5ed56f32e6142188e6f03b61235331e_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details)", "menuCat": "Details", "order": "62", "role": "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails", "shortName": "Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ia5ed56f32e6142188e6f03b61235331e_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ia5ed56f32e6142188e6f03b61235331e_I20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details)", "menuCat": "Details", "order": "63", "role": "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "shortName": "Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ia5ed56f32e6142188e6f03b61235331e_I20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details)", "menuCat": "Details", "order": "64", "role": "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ia5ed56f32e6142188e6f03b61235331e_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details)", "menuCat": "Details", "order": "65", "role": "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ia5ed56f32e6142188e6f03b61235331e_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ia5ed56f32e6142188e6f03b61235331e_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details)", "menuCat": "Details", "order": "66", "role": "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc53032087cf4554aa9632adeeb1387a_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details)", "menuCat": "Details", "order": "67", "role": "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails", "shortName": "Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "menuCat": "Details", "order": "68", "role": "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails", "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationTaxSettlements", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Income Taxes - Narrative (Details)", "menuCat": "Details", "order": "69", "role": "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i8af74da454294f4c98429fe4339e93aa_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationTaxCreditsForeign", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statement of Comprehensive Income (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical", "shortName": "Consolidated Statement of Comprehensive Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "tmo:DeferredTaxLiabilitiesDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details)", "menuCat": "Details", "order": "70", "role": "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails", "shortName": "Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "tmo:DeferredTaxLiabilitiesDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i8c962c6a83d2480dbd542bf36386c64e_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "menuCat": "Details", "order": "71", "role": "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "menuCat": "Details", "order": "72", "role": "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails", "shortName": "Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Debt and Other Financing Arrangements - Schedule of Debt (Details)", "menuCat": "Details", "order": "73", "role": "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "shortName": "Debt and Other Financing Arrangements - Schedule of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details)", "menuCat": "Details", "order": "74", "role": "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails", "shortName": "Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Debt and Other Financing Arrangements - Narrative (Details)", "menuCat": "Details", "order": "75", "role": "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "shortName": "Debt and Other Financing Arrangements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "tmo:LesseeOperatingLeaseNumberOfLeases", "reportCount": 1, "unique": true, "unitRef": "lease", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Leases- Narrative (Details)", "menuCat": "Details", "order": "76", "role": "http://thermofisher.com/role/LeasesNarrativeDetails", "shortName": "Leases- Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "tmo:LesseeOperatingLeaseNumberOfLeases", "reportCount": 1, "unique": true, "unitRef": "lease", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Leases - Schedule of Operating Leases (Details)", "menuCat": "Details", "order": "77", "role": "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails", "shortName": "Leases - Schedule of Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Leases - Schedule of Future Payments of Operating Lease Liabilities (Details)", "menuCat": "Details", "order": "78", "role": "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails", "shortName": "Leases - Schedule of Future Payments of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-7", "first": true, "lang": "en-US", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "79", "role": "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-7", "first": true, "lang": "en-US", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Consolidated Statement of Cash Flows", "menuCat": "Statements", "order": "8", "role": "http://thermofisher.com/role/ConsolidatedStatementofCashFlows", "shortName": "Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncreaseDecreaseInDeferredIncomeTaxes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Comprehensive Income and Shareholders' Equity (Details)", "menuCat": "Details", "order": "80", "role": "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "shortName": "Comprehensive Income and Shareholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ie80e4a72376d4198ae17cc476ce8e38b_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)", "menuCat": "Details", "order": "81", "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ie80e4a72376d4198ae17cc476ce8e38b_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i60878a44917b49138cb7a9902f57a5b5_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Rollforward of the Fair Value of Investments (Details)", "menuCat": "Details", "order": "82", "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Rollforward of the Fair Value of Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i5ed01dfd6bb74828a316a09cf87444f5_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ide442f74ffc54605a83463133db72b7c_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Aggregate Notional Value and Fair Value of Derivative Instruments (Details)", "menuCat": "Details", "order": "83", "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Aggregate Notional Value and Fair Value of Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ide442f74ffc54605a83463133db72b7c_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ieb44d9fd492c413db15685843b1fa6a8_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000084 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Derivative Instruments, Gain (Loss) Recognized (Details)", "menuCat": "Details", "order": "84", "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Derivative Instruments, Gain (Loss) Recognized (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ieb44d9fd492c413db15685843b1fa6a8_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000085 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of the Company's Debt Instruments (Details)", "menuCat": "Details", "order": "85", "role": "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails", "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Carrying Value and Fair Value of the Company's Debt Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000086 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details)", "menuCat": "Details", "order": "86", "role": "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails", "shortName": "Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000087 - Disclosure - Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "menuCat": "Details", "order": "87", "role": "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails", "shortName": "Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i55336b273de0454a9e99fb0286361259_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "tmo:RestructuringAndRelatedCostPercentageOfTotalWorkforceEliminated", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000088 - Disclosure - Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details)", "menuCat": "Details", "order": "88", "role": "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails", "shortName": "Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "ifc427a292c554fb6be77326a78328ca5_D20220101-20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "tmo:RestructuringAndRelatedCostPercentageOfTotalWorkforceEliminated", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i8c962c6a83d2480dbd542bf36386c64e_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000089 - Disclosure - Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details)", "menuCat": "Details", "order": "89", "role": "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1", "shortName": "Restructuring and Other Costs - Schedule of the Company's Accrued Restructuring Balance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i543675df6cd846f1bcf2c783b1f03656_I20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i543675df6cd846f1bcf2c783b1f03656_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000009 - Statement - Consolidated Statement of Redeemable Noncontrolling Interest and Equity", "menuCat": "Statements", "order": "9", "role": "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity", "shortName": "Consolidated Statement of Redeemable Noncontrolling Interest and Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i543675df6cd846f1bcf2c783b1f03656_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "tmo-20221231.htm", "contextRef": "i27599cd46074414ab65551bbfc72d38e_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - tmo-20221231.htm", "menuCat": "Cover", "order": "90", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - tmo-20221231.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 177, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r968", "r969", "r970" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r968", "r969", "r970" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r968", "r969", "r970" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r968", "r969", "r970" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r966" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r965" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r965" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r965" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r972" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]", "terseLabel": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]", "terseLabel": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r965" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r965" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r965" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r965" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r973" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r968", "r969", "r970" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r964" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r967" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Entity Stock Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia-Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r361", "r408", "r420", "r421", "r422", "r423", "r424", "r426", "r430", "r506", "r507", "r508", "r509", "r511", "r512", "r514", "r516", "r517", "r1030", "r1031" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r361", "r408", "r420", "r421", "r422", "r423", "r424", "r426", "r430", "r506", "r507", "r508", "r509", "r511", "r512", "r514", "r516", "r517", "r1030", "r1031" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r300", "r365", "r372", "r378", "r450", "r710", "r711", "r712", "r740", "r741", "r778", "r781", "r783", "r784", "r853" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r300", "r365", "r372", "r378", "r450", "r710", "r711", "r712", "r740", "r741", "r778", "r781", "r783", "r784", "r853" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r300", "r365", "r372", "r378", "r450", "r710", "r711", "r712", "r740", "r741", "r778", "r781", "r783", "r784", "r853" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r498", "r499", "r502", "r503", "r668", "r861", "r884", "r912", "r913", "r934", "r952", "r963", "r1032", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r498", "r499", "r502", "r503", "r668", "r861", "r884", "r912", "r913", "r934", "r952", "r963", "r1032", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "domainItemType" }, "srt_NorthAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "North America [Member]", "terseLabel": "North America" } } }, "localname": "NorthAmericaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r432", "r863", "r935", "r961", "r1027", "r1028", "r1037", "r1087" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r432", "r863", "r935", "r961", "r1027", "r1028", "r1037", "r1087" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r498", "r499", "r502", "r503", "r614", "r668", "r702", "r703", "r704", "r860", "r861", "r884", "r912", "r913", "r934", "r952", "r963", "r1019", "r1032", "r1080", "r1081", "r1082", "r1083", "r1084" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r498", "r499", "r502", "r503", "r614", "r668", "r702", "r703", "r704", "r860", "r861", "r884", "r912", "r913", "r934", "r952", "r963", "r1019", "r1032", "r1080", "r1081", "r1082", "r1083", "r1084" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r669", "r1002" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r378", "r669", "r978", "r1002" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r433", "r434", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r936", "r962", "r1037" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails", "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r433", "r434", "r897", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r936", "r962", "r1037" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails", "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r378", "r669", "r978", "r979", "r1002" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "xbrltype": "stringItemType" }, "tmo_A1.45SeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)", "label": "1.45% Senior Notes Due 2027 [Member]", "terseLabel": "1.450% Notes due 2027", "verboseLabel": "$1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)" } } }, "localname": "A1.45SeniorNotesDue2027Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_AllOtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All Other Countries", "label": "All Other Countries [Member]", "terseLabel": "Other" } } }, "localname": "AllOtherCountriesMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails" ], "xbrltype": "domainItemType" }, "tmo_AlternativeInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alternative Investments [Member]", "label": "Alternative Investments [Member]", "terseLabel": "Alternative investments" } } }, "localname": "AlternativeInvestmentsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "tmo_AnalyticalInstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Analytical Instruments Segment", "label": "Analytical Instruments [Member]", "terseLabel": "Analytical Instruments" } } }, "localname": "AnalyticalInstrumentsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "xbrltype": "domainItemType" }, "tmo_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://thermofisher.com/20221231", "xbrltype": "stringItemType" }, "tmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetTangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Tangible Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Tangible Assets", "terseLabel": "Net tangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetTangibleAssets", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "tmo_BusinessCombinationRedeemableNoncontrollingInterest": { "auth_ref": [], "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "order": 10.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redeemable noncontrolling interest assumed in a business combination", "label": "Business Combination, Redeemable noncontrolling interest", "negatedLabel": "Redeemable noncontrolling interest" } } }, "localname": "BusinessCombinationRedeemableNoncontrollingInterest", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "tmo_BusinessesSoldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Businesses Sold", "label": "Businesses Sold [Member]", "terseLabel": "Businesses Sold" } } }, "localname": "BusinessesSoldMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "tmo_CSLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CSL", "label": "CSL [Member]", "terseLabel": "Lengnau biologics manufacturing facility" } } }, "localname": "CSLMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "domainItemType" }, "tmo_CapitalLossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital Loss", "label": "Capital Loss [Member]", "terseLabel": "Capital Loss" } } }, "localname": "CapitalLossMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_ChargeForExpiredTaxCreditsDueToAuditSettlement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Charge for Expired Tax Credits due to Audit Settlement", "label": "Charge for Expired Tax Credits due to Audit Settlement", "terseLabel": "Charge for expired tax credits" } } }, "localname": "ChargeForExpiredTaxCreditsDueToAuditSettlement", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "tmo_ChargesForCashCompensationDueToEmployeesOfAcquiredBusinesses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Charges For Cash Compensation Due To Employees Of Acquired Businesses", "label": "Charges For Cash Compensation Due To Employees Of Acquired Businesses", "terseLabel": "Cash compensation charges" } } }, "localname": "ChargesForCashCompensationDueToEmployeesOfAcquiredBusinesses", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "monetaryItemType" }, "tmo_ConsumablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consumable, single-use products", "label": "Consumables [Member]", "terseLabel": "Consumables" } } }, "localname": "ConsumablesMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "tmo_ContingentConsiderationLiabilitiesFairValueDisclosures": { "auth_ref": [], "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent consideration liability.", "label": "Contingent Consideration Liabilities, Fair Value Disclosures", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationLiabilitiesFairValueDisclosures", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "tmo_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration [Member]", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "tmo_CostOfRevenuesCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Certain charges to cost of revenues primarily for 1) the sale of inventories revalued at fair value at the date of acquisition and 2) accelerated depreciation at facilities closing due to facility consolidations.", "label": "Cost Of Revenues Charges", "negatedLabel": "Cost of revenues adjustments" } } }, "localname": "CostOfRevenuesCharges", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "xbrltype": "monetaryItemType" }, "tmo_DebtCovenantMinimumConsolidatedInterestCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum permitted Consolidated Interest Coverage Ratio (the ratio of Consolidated EBITDA to Consolidated Interest Expense) as defined in the debt or line of credit facility agreements.", "label": "Debt, Covenant, Minimum Consolidated Interest Coverage Ratio", "terseLabel": "Minimum consolidated net interest coverage ratio" } } }, "localname": "DebtCovenantMinimumConsolidatedInterestCoverageRatio", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "pureItemType" }, "tmo_DeferredTaxAssetInterestCarryforwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Asset, Interest Carryforward", "label": "Deferred Tax Asset, Interest Carryforward [Member]", "terseLabel": "Deferred Interest Carryforward" } } }, "localname": "DeferredTaxAssetInterestCarryforwardMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance": { "auth_ref": [], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For entities that net deferred tax assets and tax liabilities, represents the unclassified net amount of deferred tax assets, before any related valuation allowance, and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. A temporary difference is a difference between the tax basis of an asset or liability and its carrying amount in the financial statements prepared in accordance with generally accepted accounting principles that will reverse in ensuing periods.", "label": "Deferred Tax Assets (Liabilities) Before Valuation Allowance", "totalLabel": "Deferred tax liabilities, net before valuation allowance" } } }, "localname": "DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "tmo_DeferredTaxAssetsLiabilitiesHedgingTransactions": { "auth_ref": [], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "order": 6.0, "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset (liability) attributable to unrealized losses (gains) from hedging transactions.", "label": "Deferred Tax Assets (Liabilities), Hedging Transactions", "terseLabel": "Unrealized (gains) losses on hedging instruments" } } }, "localname": "DeferredTaxAssetsLiabilitiesHedgingTransactions", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "tmo_DeferredTaxAssetsValuationAllowanceIncreaseChargedToIncomeTaxProvision": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in deferred tax valuation allowance resulting from amounts charged to income tax expense.", "label": "Deferred Tax Assets Valuation Allowance, Increase Charged To Income Tax Provision", "terseLabel": "Additions (reductions) charged to income tax provision, net" } } }, "localname": "DeferredTaxAssetsValuationAllowanceIncreaseChargedToIncomeTaxProvision", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "tmo_DeferredTaxAssetsValuationAllowanceIncreaseDecreaseResultingFromCurrencyTranslationAndOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred tax valuation allowance resulting from currency translation and other.", "label": "Deferred Tax Assets Valuation Allowance, Increase (Decrease) Resulting From Currency Translation And Other", "terseLabel": "Currency translation and other" } } }, "localname": "DeferredTaxAssetsValuationAllowanceIncreaseDecreaseResultingFromCurrencyTranslationAndOther", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "tmo_DeferredTaxAssetsValuationAllowanceIncreaseResultingfromAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in deferred tax valuation allowance resulting from acquisitions.", "label": "Deferred Tax Assets Valuation Allowance, Increase Resulting from Acquisition", "terseLabel": "Additions due to acquisitions" } } }, "localname": "DeferredTaxAssetsValuationAllowanceIncreaseResultingfromAcquisition", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "tmo_DeferredTaxImplicationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Implications", "label": "Deferred Tax Implications [Member]", "terseLabel": "Deferred Tax Implications" } } }, "localname": "DeferredTaxImplicationsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_DeferredTaxLiabilitiesDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "order": 1.0, "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount as of the balance sheet date of the estimated future tax effects attributable to the difference between the tax basis of long-lived assets, including property, plant and equipment and intangible assets, and the basis of long-lived assets computed in accordance with generally accepted accounting principles. The basis difference, whether due to impairment charges or other reasons, will increase future taxable income when it reverses.", "label": "Deferred Tax Liabilities, Depreciation and Amortization", "negatedLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "tmo_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRateServiceCost": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine service cost component of net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate Service Cost", "terseLabel": "Discount rate - service cost" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRateServiceCost", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "percentItemType" }, "tmo_DefinedBenefitPlanAssumptionsUsedCalculatingPeriodicBenefitCostDiscountRateInterestCost": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine interest cost component of net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan Assumptions Used Calculating Periodic Benefit Cost Discount Rate Interest Cost", "terseLabel": "Discount rate - interest cost" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingPeriodicBenefitCostDiscountRateInterestCost", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "percentItemType" }, "tmo_DomesticNOLExpiresMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Domestic NOL Expires", "label": "Domestic NOL Expires [Member]", "terseLabel": "Domestic NOL Expires" } } }, "localname": "DomesticNOLExpiresMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_EffectiveIncomeTaxRateReconciliationDomestication": { "auth_ref": [], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 13.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to domestication actions.", "label": "Effective Income Tax Rate Reconciliation, Domestication", "negatedTerseLabel": "Domestication transaction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDomestication", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "tmo_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesAmount": { "auth_ref": [], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign withholding taxes.", "label": "Effective Income Tax Rate Reconciliation, Foreign Withholding Taxes Amount", "terseLabel": "Withholding taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesAmount", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "tmo_EuroCommercialPaperProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings under the company's euro commercial paper program", "label": "Euro Commercial Paper Program [Member]", "terseLabel": "Euro Commercial Paper Program" } } }, "localname": "EuroCommercialPaperProgramMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_EuropeanViralVectorManufacturingBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "European Viral Vector Manufacturing Business", "label": "European Viral Vector Manufacturing Business [Member]", "terseLabel": "European Viral Vector Business" } } }, "localname": "EuropeanViralVectorManufacturingBusinessMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "domainItemType" }, "tmo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuancesNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances, Net", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances, Net", "terseLabel": "Acquisitions (including assumed balances)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuancesNet", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "tmo_FederalAndStateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal and State [Member]", "label": "Federal and State [Member]", "terseLabel": "Federal and State" } } }, "localname": "FederalAndStateMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_FloatingRate2YearSeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Floating Rate 2 Year Senior Notes Due 2023", "label": "Floating Rate 2 Year Senior Notes Due 2023 [Member]", "terseLabel": "Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated)" } } }, "localname": "FloatingRate2YearSeniorNotesDue2023Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_FloatingRateSOFR03518MonthSeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Floating Rate SOFR +0.35% 18 Month Senior Notes Due 2023", "label": "Floating Rate SOFR +0.35% 18 Month Senior Notes Due 2023 [Member]", "terseLabel": "Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023" } } }, "localname": "FloatingRateSOFR03518MonthSeniorNotesDue2023Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_FloatingRateSOFR039SeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Floating Rate SOFR +0.39% Senior Notes Due 2023", "label": "Floating Rate SOFR +0.39% Senior Notes Due 2023 [Member]", "terseLabel": "Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023" } } }, "localname": "FloatingRateSOFR039SeniorNotesDue2023Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_FloatingRateSOFR053SeniorNotesDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Floating Rate SOFR +0.53% Senior Notes Due 2024", "label": "Floating Rate SOFR +0.53% Senior Notes Due 2024 [Member]", "terseLabel": "Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024" } } }, "localname": "FloatingRateSOFR053SeniorNotesDue2024Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_ForeignCountryNolExpiresMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of Non- U.S. with expiration dates", "label": "Foreign Country NOL Expires [Member]", "terseLabel": "Portion of Non- U.S. with expiration dates" } } }, "localname": "ForeignCountryNolExpiresMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_ForeignTaxCreditCarryforwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Tax Credit Carryforwards", "label": "Foreign Tax Credit Carryforwards [Member]", "terseLabel": "Foreign Tax Credit Carryforwards" } } }, "localname": "ForeignTaxCreditCarryforwardsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_ForeignTaxPositionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Tax Positions [Member]", "label": "Foreign Tax Positions [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignTaxPositionsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_ForeigncurrencydenominateddebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign currency-denominated debt [Member]", "label": "Foreign currency-denominated debt [Member]", "terseLabel": "Foreign currency-denominated debt" } } }, "localname": "ForeigncurrencydenominateddebtMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "domainItemType" }, "tmo_InstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Instruments (longer-lived products)", "label": "Instruments [Member]", "terseLabel": "Instruments" } } }, "localname": "InstrumentsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "tmo_InsuranceContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance Contracts", "label": "Insurance Contracts [Member]", "terseLabel": "Insurance contracts" } } }, "localname": "InsuranceContractsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "tmo_InternationalEquityFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International Equity Funds", "label": "International Equity Funds [Member]", "terseLabel": "International equity funds" } } }, "localname": "InternationalEquityFundsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_IntraEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intra-Entity", "label": "Intra-Entity [Axis]", "terseLabel": "Intra-Entity [Axis]" } } }, "localname": "IntraEntityAxis", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "tmo_IntraEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intra-Entity [Domain]", "label": "Intra-Entity [Domain]", "terseLabel": "Intra-Entity [Domain]" } } }, "localname": "IntraEntityDomain", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_LaboratoryProductsandServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory Products and Services Segment", "label": "Laboratory Products and Services [Member]", "terseLabel": "Laboratory Products and Biopharma Services" } } }, "localname": "LaboratoryProductsandServicesMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "xbrltype": "domainItemType" }, "tmo_LesseeOperatingLeaseNumberOfLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Leases", "label": "Lessee, Operating Lease, Number Of Leases", "terseLabel": "Leased operating facilities" } } }, "localname": "LesseeOperatingLeaseNumberOfLeases", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "tmo_LesseeOperatingLeaseOptiontoTerminateTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease if an option to terminate is available and executed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Option to Terminate, Term", "terseLabel": "Option to terminate, term" } } }, "localname": "LesseeOperatingLeaseOptiontoTerminateTerm", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "tmo_LifeSciencesSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Sciences Solutions Segment", "label": "Life Sciences Solutions [Member]", "terseLabel": "Life Sciences Solutions" } } }, "localname": "LifeSciencesSolutionsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "xbrltype": "domainItemType" }, "tmo_LossContingencyAccrualGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated aggregate undiscounted amount of the accrual for loss contingencies as of the balance sheet date.", "label": "Loss Contingency Accrual, Gross", "terseLabel": "Undiscounted loss accrual" } } }, "localname": "LossContingencyAccrualGross", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "tmo_LossContingencyAccrualProductLiabilityGrossDivestedBusiness": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated aggregate undiscounted amount of the accrual for damages arising from third-party use of product(s) or process(es) of divested businesses as of the balance sheet date.", "label": "Loss Contingency Accrual, Product Liability, Gross, Divested Business", "terseLabel": "Undiscounted product liability accrual" } } }, "localname": "LossContingencyAccrualProductLiabilityGrossDivestedBusiness", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "tmo_LossContingencyRelatedReceivableGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The gross (undiscounted) amount as of the balance sheet date of a recorded receivable related to a loss contingency accrual. For example, an insurance recovery receivable to the extent that the insurance recovery is probable and does not exceed the amount of the loss previously recognized in the financial statements.", "label": "Loss Contingency, Related Receivable, Gross", "terseLabel": "Undiscounted estimated amounts due from insurers" } } }, "localname": "LossContingencyRelatedReceivableGross", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "tmo_MaximumPeriodToMaturityAllowedUnderProgram": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum maturity period allowed under U.S. commercial paper program", "label": "Maximum Period to Maturity Allowed Under Program", "terseLabel": "Maximum period prior to maturity" } } }, "localname": "MaximumPeriodToMaturityAllowedUnderProgram", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "durationItemType" }, "tmo_MesaBiotechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mesa Biotech", "label": "Mesa Biotech [Member]", "terseLabel": "Mesa Biotech" } } }, "localname": "MesaBiotechMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "domainItemType" }, "tmo_MultiassetFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multi-asset Funds", "label": "Multi-asset Funds [Member]", "terseLabel": "Multi-asset funds" } } }, "localname": "MultiassetFundsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_NoncontrollingInterestContributionFromDistributionsToNoncontrollingInterests": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders net of decreases in noncontrolling interest balance from payment of dividends or other distributions.", "label": "Noncontrolling interest, contribution from (distributions to) noncontrolling interests", "terseLabel": "Contributions from (distributions to) noncontrolling interests" } } }, "localname": "NoncontrollingInterestContributionFromDistributionsToNoncontrollingInterests", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "tmo_OtherComprehensiveIncomeLossNetOfTaxIncludingRedeemableAndNonRedeemableNCI": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss) Net of Tax Including Redeemable and NonRedeemable NCI", "label": "Other Comprehensive Income (Loss) Net of Tax Including Redeemable and NonRedeemable NCI", "terseLabel": "Total other comprehensive items" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxIncludingRedeemableAndNonRedeemableNCI", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "tmo_OtherDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Debt", "label": "Other Debt [Member]", "terseLabel": "Other Debt" } } }, "localname": "OtherDebtMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "tmo_OtherRegionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All geographical regions not separately disclosed", "label": "Other Regions [Member]", "terseLabel": "Other regions" } } }, "localname": "OtherRegionsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "tmo_PPDIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PPD, Inc", "label": "PPD, Inc [Member]", "terseLabel": "PPD" } } }, "localname": "PPDIncMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "xbrltype": "domainItemType" }, "tmo_PPDSNBLKKMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PPD-SNBL K.K. (Consolidated subsidiary with a noncontrolling interest)", "label": "PPD-SNBL K.K. [Member]", "terseLabel": "PPD-SNBL K.K." } } }, "localname": "PPDSNBLKKMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "xbrltype": "domainItemType" }, "tmo_PeproTechIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PeproTech, Inc.", "label": "PeproTech, Inc. [Member]", "terseLabel": "PeproTech" } } }, "localname": "PeproTechIncMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "domainItemType" }, "tmo_ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount charged to earnings in the current period for product liability, workers compensation and other personal injury matters.", "label": "Product Liability, Workers Compensation and Other Personal Injury Matters [Member]", "terseLabel": "Product Liability, Workers Compensation and Other Personal Injury Matters" } } }, "localname": "ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "tmo_RedeemableNoncontrollingInterestContributionFromDistributionsToRedeemableNoncontrollingInterests": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redeemable Noncontrolling Interest, Contribution From (Distributions To) Redeemable Noncontrolling Interests", "label": "Redeemable Noncontrolling Interest, Contribution From (Distributions To) Redeemable Noncontrolling Interests", "terseLabel": "Contributions from (distributions to) noncontrolling interests" } } }, "localname": "RedeemableNoncontrollingInterestContributionFromDistributionsToRedeemableNoncontrollingInterests", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "tmo_RedeemableNoncontrollingInterestRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable Noncontrolling Interest", "label": "Redeemable Noncontrolling Interest [Roll Forward]", "terseLabel": "Redeemable Noncontrolling Interest [Roll Forward]" } } }, "localname": "RedeemableNoncontrollingInterestRollForward", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "stringItemType" }, "tmo_RestructuringAndOtherCostsIncomeNet": { "auth_ref": [], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of restructuring charges, remediation costs and assets impairment loss; and, in some periods, may also include gains and losses on the sale of businesses, product lines and real estate.", "label": "Restructuring And Other Costs (Income) Net", "negatedLabel": "Restructuring and other costs", "terseLabel": "Restructuring and other costs" } } }, "localname": "RestructuringAndOtherCostsIncomeNet", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "xbrltype": "monetaryItemType" }, "tmo_RestructuringAndRelatedCostPercentageOfTotalWorkforceEliminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum number of positions eliminated in connection with restructuring plans during the period as a percentage of the company's total workforce.", "label": "Restructuring and Related Cost, Percentage of Total Workforce Eliminated", "terseLabel": "Eliminated workforce percentage" } } }, "localname": "RestructuringAndRelatedCostPercentageOfTotalWorkforceEliminated", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "xbrltype": "percentItemType" }, "tmo_RestructuringAndRelatedCostsNonCashCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restructuring and other costs which consist principally of gains and losses resulting from changes in estimates for significant litigation-related matters, and, in some periods, may also include gains and losses on the sale of businesses, product lines and real estate, and asset impairment charges.", "label": "Restructuring and Related Costs, Non-Cash Costs", "terseLabel": "Other non-cash restructuring costs" } } }, "localname": "RestructuringAndRelatedCostsNonCashCosts", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "monetaryItemType" }, "tmo_SellingGeneralAndAdministrativeChargesNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Certain charges/credits to selling, general and administrative expenses principally associated with acquisition accounting.", "label": "Selling General And Administrative Charges Net", "negatedLabel": "Selling, general and administrative expenses adjustments" } } }, "localname": "SellingGeneralAndAdministrativeChargesNet", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "xbrltype": "monetaryItemType" }, "tmo_SeniorNotes0.125Due2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 0.125% Due 2025 [Member]", "label": "Senior Notes 0.125% Due 2025 [Member]", "terseLabel": "0.125% Notes due 2025", "verboseLabel": "$0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)" } } }, "localname": "SeniorNotes0.125Due2025Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes0.500Due2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 0.500% Due 2028 [Member]", "label": "Senior Notes 0.500% Due 2028 [Member]", "terseLabel": "0.500% Notes due 2028", "verboseLabel": "$0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)" } } }, "localname": "SeniorNotes0.500Due2028Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes0.75Due2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 0.75% Due 2024 [Member]", "label": "Senior Notes 0.75% Due 2024 [Member]", "terseLabel": "0.750% Notes due 2024", "verboseLabel": "0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)" } } }, "localname": "SeniorNotes0.75Due2024Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes0.875Due2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 0.875% Due 2031 [Member]", "label": "Senior Notes 0.875% Due 2031 [Member]", "terseLabel": "0.875% Notes due 2031", "verboseLabel": "$0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)" } } }, "localname": "SeniorNotes0.875Due2031Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes0000Due2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 0.000% Due 2023", "label": "Senior Notes 0.000% Due 2023 [Member]", "terseLabel": "0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated)" } } }, "localname": "SeniorNotes0000Due2023Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes0000Due2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 0.000% Due 2025", "label": "Senior Notes 0.000% Due 2025 [Member]", "terseLabel": "0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)" } } }, "localname": "SeniorNotes0000Due2025Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes0797Due2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 0.797% Due 2023", "label": "Senior Notes 0.797% Due 2023 [Member]", "terseLabel": "0.797% 2-Year Senior Notes, Due 10/18/2023" } } }, "localname": "SeniorNotes0797Due2023Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes080Due2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 0.80% Due 2030", "label": "Senior Notes 0.80% Due 2030 [Member]", "terseLabel": "0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)" } } }, "localname": "SeniorNotes080Due2030Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes0853Due2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 0.853% Due 2025", "label": "Senior Notes 0.853% Due 2025 [Member]", "terseLabel": "0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated)" } } }, "localname": "SeniorNotes0853Due2025Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes1.375Due2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.375% Due 2028 [Member]", "label": "Senior Notes 1.375% Due 2028 [Member]", "terseLabel": "1.375% Notes due 2028", "verboseLabel": "$1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)" } } }, "localname": "SeniorNotes1.375Due2028Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes1.40Due2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) [Member]", "label": "Senior Notes 1.40% Due 2026 [Member]", "terseLabel": "1.400% Notes due 2026", "verboseLabel": "$1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)" } } }, "localname": "SeniorNotes1.40Due2026Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes1.500Due2039Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.500% Due 2039 [Member]", "label": "Senior Notes 1.500% Due 2039 [Member]", "terseLabel": "1.500% Notes due 2039", "verboseLabel": "$1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)" } } }, "localname": "SeniorNotes1.500Due2039Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes1.875Due2049Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.875% Due 2049 [Member]", "label": "Senior Notes 1.875% Due 2049 [Member]", "terseLabel": "1.875% Notes due 2049", "verboseLabel": "$1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)" } } }, "localname": "SeniorNotes1.875Due2049Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes1.95Due2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) [Member]", "label": "Senior Notes 1.95% Due 2029 [Member]", "terseLabel": "1.950% Notes due 2029", "verboseLabel": "$1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)" } } }, "localname": "SeniorNotes1.95Due2029Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes1054Due2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.054% Due 2027", "label": "Senior Notes 1.054% Due 2027 [Member]", "terseLabel": "1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated)" } } }, "localname": "SeniorNotes1054Due2027Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes1125Due2033Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.125% Due 2033", "label": "Senior Notes 1.125% Due 2033 [Member]", "terseLabel": "1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)" } } }, "localname": "SeniorNotes1125Due2033Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes1215Due2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.215% Due 2024", "label": "Senior Notes 1.215% Due 2024 [Member]", "terseLabel": "1.215% 3-Year Senior Notes, Due 10/18/2024" } } }, "localname": "SeniorNotes1215Due2024Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes1279Due2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.279% Due 2029", "label": "Senior Notes 1.279% Due 2029 [Member]", "terseLabel": "1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated)" } } }, "localname": "SeniorNotes1279Due2029Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes149Due2032Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.49% Due 2032", "label": "Senior Notes 1.49% Due 2032 [Member]", "terseLabel": "1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated)" } } }, "localname": "SeniorNotes149Due2032Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes1625Due2041Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.625% Due 2041", "label": "Senior Notes 1.625% Due 2041 [Member]", "terseLabel": "1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)" } } }, "localname": "SeniorNotes1625Due2041Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes1750Due2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.750% Due 2028", "label": "Senior Notes 1.750% Due 2028 [Member]", "terseLabel": "1.750% 7-Year Senior Notes, Due 10/15/2028" } } }, "localname": "SeniorNotes1750Due2028Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes175Due2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 1.75% Due 2027", "label": "Senior Notes 1.75% Due 2027 [Member]", "terseLabel": "1.750% Notes due 2027", "verboseLabel": "1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)" } } }, "localname": "SeniorNotes175Due2027Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes2.60Due2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2.60% Due 2029 [Member]", "label": "Senior Notes 2.60% Due 2029 [Member]", "terseLabel": "$2.60% 10-Year Senior Notes, Due 10/1/2029" } } }, "localname": "SeniorNotes2.60Due2029Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes2.875Due2037Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) [Member]", "label": "Senior Notes 2.875% Due 2037 [Member]", "terseLabel": "2.875% Notes due 2037", "verboseLabel": "$2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)" } } }, "localname": "SeniorNotes2.875Due2037Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes2000Due2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2.000% Due 2031", "label": "Senior Notes 2.000% Due 2031 [Member]", "terseLabel": "2.00% 10-Year Senior Notes, Due 10/15/2031" } } }, "localname": "SeniorNotes2000Due2031Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes200Due2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.00% 10-Year Senior Notes, Due 4/15/2025 (euro denominated) [Member]", "label": "Senior Notes 2.00% Due 2025 [Member]", "terseLabel": "2.000% Notes due 2025", "verboseLabel": "$2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)" } } }, "localname": "SeniorNotes200Due2025Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes200Due2051Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2.00% Due 2051", "label": "Senior Notes 2.00% Due 2051 [Member]", "terseLabel": "2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)" } } }, "localname": "SeniorNotes200Due2051Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes2069Due2042Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2.069% Due 2042", "label": "Senior Notes 2.069% Due 2042 [Member]", "terseLabel": "2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated)" } } }, "localname": "SeniorNotes2069Due2042Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes2375Due2032Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2.375% Due 2032", "label": "Senior Notes 2.375% Due 2032 [Member]", "terseLabel": "2.375% Notes due 2032", "verboseLabel": "2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)" } } }, "localname": "SeniorNotes2375Due2032Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes2382Due2052Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2.382% Due 2052", "label": "Senior Notes 2.382% Due 2052 [Member]", "terseLabel": "2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated)" } } }, "localname": "SeniorNotes2382Due2052Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes2800Due2041Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2.800% Due 2041", "label": "Senior Notes 2.800% Due 2041 [Member]", "terseLabel": "2.80% 20-Year Senior Notes, Due 10/15/2041" } } }, "localname": "SeniorNotes2800Due2041Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes3.65Due2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.65% 10-Year Senior Notes, Due 12/15/2025 [Member]", "label": "Senior Notes 3.65% Due 2025 [Member]", "terseLabel": "$3.65% 10-Year Senior Notes, Due 12/15/2025" } } }, "localname": "SeniorNotes3.65Due2025Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes3200Due2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 3.200% Due 2026", "label": "Senior Notes 3.200% Due 2026 [Member]", "terseLabel": "3.200% Notes due 2026" } } }, "localname": "SeniorNotes3200Due2026Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes320Due2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 3.20% Due 2026", "label": "Senior Notes 3.20% Due 2026 [Member]", "terseLabel": "3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)" } } }, "localname": "SeniorNotes320Due2026Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes3650Due2034Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 3.650% Due 2034", "label": "Senior Notes 3.650% Due 2034 [Member]", "terseLabel": "3.650% Notes due 2034" } } }, "localname": "SeniorNotes3650Due2034Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes365Due2034Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 3.65% Due 2034", "label": "Senior Notes 3.65% Due 2034 [Member]", "terseLabel": "3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)" } } }, "localname": "SeniorNotes365Due2034Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes4.10Due2047Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.10% 30-Year Senior Notes, Due 8/15/2047 [Member]", "label": "Senior Notes 4.10% Due 2047 [Member]", "terseLabel": "$4.10% 30-Year Senior Notes, Due 8/15/2047" } } }, "localname": "SeniorNotes4.10Due2047Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes48Due2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 4.8% Due 2027", "label": "Senior Notes 4.8% Due 2027 [Member]", "terseLabel": "4.80% 5-Year Senior Notes, Due 11/21/2027" } } }, "localname": "SeniorNotes48Due2027Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes495Due2032Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 4.95% Due 2032", "label": "Senior Notes 4.95% Due 2032 [Member]", "terseLabel": "4.95% 10-Year Senior Notes, Due 11/21/2032" } } }, "localname": "SeniorNotes495Due2032Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SeniorNotes530Due2044Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.30% 30-Year Senior Notes, Due 2/1/2044 [Member]", "label": "Senior Notes 5.30% Due 2044 [Member]", "terseLabel": "$5.30% 30-Year Senior Notes, Due 2/1/2044" } } }, "localname": "SeniorNotes530Due2044Member", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "tmo_SpecialtyDiagnosticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specialty Diagnostics Segment", "label": "Specialty Diagnostics [Member]", "terseLabel": "Specialty Diagnostics" } } }, "localname": "SpecialtyDiagnosticsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "domainItemType" }, "tmo_SuretyBondsAndOtherGuaranteesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Surety Bonds and Other Guarantees", "label": "Surety Bonds and Other Guarantees [Member]", "terseLabel": "Surety Bonds and Other Guarantees" } } }, "localname": "SuretyBondsAndOtherGuaranteesMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "tmo_TheBindingSiteGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Binding Site Group", "label": "The Binding Site Group [Member]", "terseLabel": "The Binding Site Group" } } }, "localname": "TheBindingSiteGroupMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "domainItemType" }, "tmo_U.S.CommercialPaperProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings under the company's U.S. commercial paper program", "label": "U.S. Commercial Paper Program [Member]", "terseLabel": "U.S. Commercial Paper Program" } } }, "localname": "U.S.CommercialPaperProgramMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_USEquityFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. Equity Funds", "label": "U S Equity Funds [Member]", "terseLabel": "U.S. equity funds" } } }, "localname": "USEquityFundsMember", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "tmo_ValuationAllowanceRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Valuation Allowance [Roll Forward]", "label": "Valuation Allowance [Roll Forward]", "terseLabel": "Valuation Allowance [Roll Forward]" } } }, "localname": "ValuationAllowanceRollForward", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "stringItemType" }, "tmo_WeightedAverageSharesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Shares", "label": "Weighted Average Shares [Abstract]", "terseLabel": "Weighted average shares" } } }, "localname": "WeightedAverageSharesAbstract", "nsuri": "http://thermofisher.com/20221231", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "Accounting Standards Update 2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r18", "r960" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r438", "r439" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, less allowances of $189 and $150", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "auth_ref": [ "r501", "r928", "r976", "r977", "r1020", "r1024" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies.", "label": "Accrual for Environmental Loss Contingencies", "terseLabel": "Environmental liability" } } }, "localname": "AccrualForEnvironmentalLossContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForEnvironmentalLossContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrual for Environmental Loss Contingencies Disclosure [Abstract]", "terseLabel": "Accrual for Environmental Loss Contingencies Disclosure [Abstract]" } } }, "localname": "AccrualForEnvironmentalLossContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r34", "r40", "r227", "r982", "r983", "r984" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Pension and other postretirement benefit liability adjustment" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r113", "r310" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r330", "r340", "r341", "r768", "r921", "r982" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Unrealized losses on hedging instruments" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r37", "r39", "r40", "r319", "r877", "r892", "r896" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive items" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r339", "r340", "r816", "r817", "r818", "r819", "r820", "r823" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r36", "r40", "r227", "r855", "r887", "r888", "r982", "r983", "r984", "r994", "r995", "r996" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Items" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r32", "r40", "r227", "r340", "r341", "r817", "r818", "r819", "r820", "r823", "r982" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Currency translation adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted-average amortization period" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AcquisitionRelatedCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information).", "label": "Acquisition-related Costs [Member]", "terseLabel": "Non-recurring Pro Forma Adjustments, Transaction Costs" } } }, "localname": "AcquisitionRelatedCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r10" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Capital in excess of par value" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r710", "r711", "r712", "r994", "r995", "r996", "r1066" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Capital in Excess of Par Value" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis": { "auth_ref": [ "r366", "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by type of change in accounting principle. Excludes change from amendment to accounting standards.", "label": "Change in Accounting Principle, Type [Axis]", "terseLabel": "Change in Accounting Principle, Type [Axis]" } } }, "localname": "AdjustmentsForChangeInAccountingPrincipleAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r298", "r299", "r300", "r301", "r302", "r366", "r367", "r368", "r369", "r378", "r441", "r442", "r447", "r448", "r449", "r450", "r451", "r452", "r710", "r711", "r712", "r738", "r739", "r740", "r741", "r757", "r758", "r759", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r828", "r829", "r832", "r833", "r834", "r835", "r850", "r851", "r852", "r853", "r854", "r855", "r865", "r866", "r867", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "terseLabel": "Other" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r179", "r180", "r673" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r320", "r440", "r453" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts Receivable Allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestment": { "auth_ref": [ "r787", "r795" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.", "label": "Alternative Investment", "terseLabel": "Investments measured at NAV" } } }, "localname": "AlternativeInvestment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r67", "r98", "r106" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization of acquisition-related intangible assets", "verboseLabel": "Amortization of acquisition-related intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive stock options excluded from diluted weighted averages shares (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r270", "r284", "r314", "r356", "r416", "r422", "r428", "r445", "r506", "r507", "r509", "r510", "r511", "r513", "r515", "r517", "r518", "r764", "r769", "r799", "r960", "r1030", "r1031", "r1077" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r305", "r324", "r356", "r445", "r506", "r507", "r509", "r510", "r511", "r513", "r515", "r517", "r518", "r764", "r769", "r799", "r960", "r1030", "r1031", "r1077" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r254" ], "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets [Abstract]" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r677", "r678", "r679", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r701", "r702", "r703", "r704", "r705" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r756", "r946", "r949" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r200", "r201", "r756", "r946", "r949" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information [Abstract]", "terseLabel": "Business Acquisition, Pro Forma Information [Abstract]" } } }, "localname": "BusinessAcquisitionProFormaInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Schedule of the nature and amount of any material, nonrecurring adjustments directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]", "terseLabel": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]" } } }, "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r1060", "r1061" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Schedule of Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Goodwill recorded" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r754", "r755" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "verboseLabel": "Net income attributable to Thermo Fisher Scientific Inc." } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r754", "r755" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenues" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r211", "r212", "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred [Abstract]", "terseLabel": "Purchase Price" } } }, "localname": "BusinessCombinationConsiderationTransferredAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r211", "r212" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Fair value of equity awards exchanged" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r209", "r211", "r212", "r761" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Debt settled" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r210", "r213", "r762" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "terseLabel": "Pro forma losses" } } }, "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Pro forma revenues" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "auth_ref": [ "r203" ], "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease obligation assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "negatedLabel": "Finance lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "negatedTerseLabel": "Cash acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "auth_ref": [ "r203" ], "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "terseLabel": "Current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r203" ], "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "order": 11.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "negatedLabel": "Contract liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r203" ], "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "negatedLabel": "Other liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r203" ], "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Deferred tax assets (liabilities)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r202", "r203" ], "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Definite-lived intangible assets:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r203" ], "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt", "negatedTerseLabel": "Debt assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r203" ], "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r202", "r203" ], "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r203" ], "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Net Assets Acquired [Abstract]" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r72", "r73", "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Acquired but unpaid property, plant and equipment" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business.", "label": "Cash Acquired in Excess of Payments to Acquire Business", "terseLabel": "Cash acquired" } } }, "localname": "CashAcquiredInExcessOfPaymentsToAcquireBusiness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r69", "r308", "r915" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r62", "r69", "r75" ], "calculation": { "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year", "totalLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows", "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r62", "r262" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashSurrenderValueFairValueDisclosure": { "auth_ref": [], "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI).", "label": "Cash Surrender Value, Fair Value Disclosure", "terseLabel": "Insurance contracts" } } }, "localname": "CashSurrenderValueFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInAccountingPrincipleMember": { "auth_ref": [ "r366", "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Change in accounting principle. Excludes change from amendment to accounting standards.", "label": "Change in Accounting Principle, Type [Domain]", "terseLabel": "Change in Accounting Principle, Type [Domain]" } } }, "localname": "ChangeInAccountingPrincipleMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingPrincipleOtherMember": { "auth_ref": [ "r997", "r998", "r999", "r1000", "r1001" ], "lang": { "en-us": { "role": { "documentation": "Change in accounting principle, classified as other. Excludes change from amendment to accounting standards.", "label": "Change in Accounting Principle, Other [Member]", "terseLabel": "Change in Accounting Principle, Other" } } }, "localname": "ChangeInAccountingPrincipleOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "terseLabel": "Hedged long-term obligations - included in other income/(expense)" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "terseLabel": "Reconciliation of Benefit Obligations and Plan Assets" } } }, "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r316", "r317", "r318", "r356", "r382", "r386", "r388", "r390", "r398", "r399", "r445", "r506", "r509", "r510", "r511", "r517", "r518", "r549", "r550", "r552", "r556", "r562", "r799", "r914", "r975", "r990", "r1003" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper Programs" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r26", "r276", "r293" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r123", "r492", "r494", "r899", "r1029" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r130", "r900" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Loss Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Unissued shares of common stock (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared per common share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r994", "r995", "r1066" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock, $1.00 par value" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity", "http://thermofisher.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, $1 Par Value - Par Value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, $1 Par Value - Shares Authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, $1 Par Value - Shares Issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r9", "r143" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r9", "r960" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $1 par value, 1,200,000,000 shares authorized; 440,668,112 and 439,154,741 shares issued" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]", "terseLabel": "Deferred Tax Assets (Liabilities) [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r42", "r335", "r337", "r346", "r873", "r881" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to Thermo Fisher Scientific Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r221", "r222", "r231", "r335", "r337", "r345", "r872", "r880" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: comprehensive income attributable to noncontrolling interests and redeemable noncontrolling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r220", "r231", "r335", "r337", "r344", "r871", "r879" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r223", "r922" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r1035" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Contract-related Balances" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueandContractrelatedBalancesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r564", "r566", "r587" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Contract assets, net" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/RevenueContractrelatedBalancesContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetNoncurrent": { "auth_ref": [ "r564", "r566", "r587" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Noncurrent contract assets, net" } } }, "localname": "ContractWithCustomerAssetNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r564", "r565", "r587" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/RevenueContractrelatedBalancesContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r564", "r565", "r587" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Noncurrent contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateAndOtherMember": { "auth_ref": [ "r1005" ], "lang": { "en-us": { "role": { "documentation": "Component of an entity that provides financial and operational oversight and administrative support for other segments and other segments not separately reported due to size or nature of business activities. Excludes intersegment elimination and reconciling items.", "label": "Corporate and Other [Member]", "terseLabel": "Corporate/other" } } }, "localname": "CorporateAndOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateMember": { "auth_ref": [ "r1005" ], "lang": { "en-us": { "role": { "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.", "label": "Corporate Segment [Member]", "terseLabel": "Corporate [Member]" } } }, "localname": "CorporateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r49", "r863" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "negatedTerseLabel": "Cost of goods and services sold", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r46" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "stringItemType" }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": { "auth_ref": [ "r118", "r119", "r122" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.", "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]", "terseLabel": "Restructuring Costs" } } }, "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r1040", "r1065" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross-currency interest rate swaps - designated as net investment hedges" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r993", "r1057", "r1059" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r993", "r1057" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Non-U.S." } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r195", "r735", "r745", "r993" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Current income tax provision" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current income tax provision" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r993", "r1057", "r1059" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r315" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt and lease obligation, classified as current.", "label": "Debt, Current", "terseLabel": "Short-term obligations and current maturities of long-term obligations", "verboseLabel": "Less: Short-term obligations and current maturities" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r137", "r354", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r535", "r542", "r543", "r545" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt and Other Financing Arrangements" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r4", "r5", "r6", "r271", "r273", "r282", "r361", "r519", "r520", "r521", "r522", "r523", "r525", "r531", "r532", "r533", "r534", "r536", "r537", "r538", "r539", "r540", "r541", "r831", "r929", "r930", "r931", "r932", "r933", "r991" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r6", "r273", "r282", "r546" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Total borrowings at par value", "totalLabel": "Total borrowings at par value" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r533", "r798", "r930", "r931" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r23", "r264", "r548", "r831" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r23", "r520" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r24", "r361", "r519", "r520", "r521", "r522", "r523", "r525", "r531", "r532", "r533", "r534", "r536", "r537", "r538", "r539", "r540", "r541", "r831", "r929", "r930", "r931", "r932", "r933", "r991" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r24", "r144", "r145", "r146", "r147", "r263", "r264", "r267", "r280", "r361", "r519", "r520", "r521", "r522", "r523", "r525", "r531", "r532", "r533", "r534", "r536", "r537", "r538", "r539", "r540", "r541", "r544", "r831", "r929", "r930", "r931", "r932", "r933", "r991" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r1033" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedLabel": "Unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.", "label": "Debt Related Commitment Fees and Debt Issuance Costs", "terseLabel": "Financing costs" } } }, "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r993", "r1058", "r1059" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r265", "r1033" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r195", "r993", "r1058" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Non-U.S." } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r67", "r195", "r736", "r744", "r745", "r993" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Deferred income tax provision (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred income tax provision (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r719", "r720" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r993", "r1058", "r1059" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]", "terseLabel": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetInterestCarryforward": { "auth_ref": [ "r1056" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "order": 8.0, "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.", "label": "Deferred Tax Asset, Interest Carryforward", "terseLabel": "Deferred interest" } } }, "localname": "DeferredTaxAssetInterestCarryforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r193", "r1056" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "order": 9.0, "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets, in Process Research and Development", "terseLabel": "Research and development and other capitalized costs" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r193", "r1056" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "order": 5.0, "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventory basis difference" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r193", "r1056" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "order": 7.0, "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other, net" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOtherTaxCarryforwards": { "auth_ref": [ "r193", "r1056" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "order": 2.0, "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.", "label": "Deferred Tax Assets, Other Tax Carryforwards", "terseLabel": "Net operating loss and credit carryforwards" } } }, "localname": "DeferredTaxAssetsOtherTaxCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r193", "r1056" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "order": 4.0, "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "terseLabel": "Accrued compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r193", "r1056" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "order": 3.0, "parentTag": "tmo_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Reserves and accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r732" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r183", "r1055" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Deferred tax liabilities, net" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofDeferredTaxAssetLiabilityandChangesinValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "auth_ref": [ "r623" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "terseLabel": "Accumulated benefit obligation" } } }, "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": { "auth_ref": [ "r35", "r40", "r1042" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax", "totalLabel": "Net amount recognized" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract]", "terseLabel": "Amounts recognized in accumulated other comprehensive items" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "auth_ref": [ "r40", "r635" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "negatedLabel": "Net actuarial loss" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r40", "r635" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "terseLabel": "Prior service credits" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r605", "r944" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r598" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedLabel": "Actuarial (gains) losses" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r592", "r630", "r656", "r944", "r945" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Amortization of actuarial net loss" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r592", "r631", "r657", "r944", "r945" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of prior service benefit" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "auth_ref": [ "r156", "r158" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "totalLabel": "Net amount recognized" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]", "terseLabel": "Amounts recognized in balance sheet" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r269", "r283", "r590", "r591", "r613", "r944" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Noncurrent assets" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Discount rate for determining benefit obligation" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Average rate of increase in employee compensation" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate", "terseLabel": "Interest crediting rate for cash balance plans" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r639", "r661" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "terseLabel": "Expected long-term rate of return on assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "terseLabel": "Average rate of increase in employee compensation" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r593" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Projected benefit obligation at end of year", "periodStartLabel": "Projected benefit obligation at beginning of year" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r600", "r664" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "auth_ref": [ "r597" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "terseLabel": "Plan participants' contributions" } } }, "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBusinessCombinationsAndAcquisitionsBenefitObligation": { "auth_ref": [ "r602" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in benefit obligation of defined benefit plan from business combination.", "label": "Defined Benefit Plan, Benefit Obligation, Business Combination", "terseLabel": "Acquisitions" } } }, "localname": "DefinedBenefitPlanBusinessCombinationsAndAcquisitionsBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBusinessCombinationsAndAcquisitionsPlanAssets": { "auth_ref": [ "r610" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in plan assets of defined benefit plan from business combination.", "label": "Defined Benefit Plan, Plan Assets, Business Combination", "terseLabel": "Acquisitions" } } }, "localname": "DefinedBenefitPlanBusinessCombinationsAndAcquisitionsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r642", "r942", "r943", "r944" ], "lang": { "en-us": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "auth_ref": [ "r942" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "terseLabel": "Cash / money market funds" } } }, "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Change in projected benefit obligations" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Change in fair value of plan assets" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r607", "r617", "r660", "r942", "r943", "r944", "r945" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Employer contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDerivativeMember": { "auth_ref": [ "r942" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or other contract with one or more underlyings, notional amount or payment provision or both; can be settled net by means outside contract or delivery of asset; and with minimal or no initial net investment, in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Derivative [Member]", "terseLabel": "Derivative funds" } } }, "localname": "DefinedBenefitPlanDerivativeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payments [Abstract]" } } }, "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r624" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "terseLabel": "2028-2032" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r624" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "terseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r624" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "2027" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r624" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2026" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r624" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2025" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r624" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2024" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "auth_ref": [ "r625", "r945" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "terseLabel": "Estimated contributions to plan" } } }, "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r592", "r629", "r655", "r944", "r945" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r604", "r615", "r617", "r618", "r942", "r943", "r944" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Fair value of plan assets at end of year", "periodStartLabel": "Fair value of plan assets at beginning of year", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r599" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "negatedLabel": "Currency translation and other" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r590", "r613", "r944" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "totalLabel": "Funded status" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInformationAboutPlanAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Information about Plan Assets [Abstract]", "terseLabel": "Defined Benefit Plan, Information about Plan Assets [Abstract]" } } }, "localname": "DefinedBenefitPlanInformationAboutPlanAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r592", "r596", "r628", "r654", "r944", "r945" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest costs", "verboseLabel": "Interest cost on benefit obligation" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r626", "r652", "r944", "r945" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost (income)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "terseLabel": "Components of Net Periodic Benefit Cost (Income) [Abstract]" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "auth_ref": [ "r626", "r652" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes amortization of gain (loss) component of net periodic benefit (cost) credit for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible List]" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "auth_ref": [ "r626", "r652" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes amortization of prior service cost (credit) component of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible List]" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "auth_ref": [ "r626", "r652" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes expected return (loss) on plan asset component of net periodic benefit (cost) credit for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible List]" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "auth_ref": [ "r626", "r652" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes interest cost component of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible List]" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementAndCurtailmentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "auth_ref": [ "r626", "r1045" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes settlement and curtailment gain (loss) component of net periodic benefit (cost) credit for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible List]" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementAndCurtailmentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": { "auth_ref": [ "r649", "r944" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": { "auth_ref": [ "r649", "r944" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "terseLabel": "Projected benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]", "terseLabel": "Pension plans with accumulated benefit obligations in excess of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "auth_ref": [ "r649", "r650", "r944" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "terseLabel": "Accumulated benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "auth_ref": [ "r649", "r650", "r944" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r609", "r1047" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "auth_ref": [ "r608" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Plan participants' contributions" } } }, "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r606" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency translation and other" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "auth_ref": [ "r614", "r944" ], "lang": { "en-us": { "role": { "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "terseLabel": "Target allocations for investments" } } }, "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]", "terseLabel": "Pension plans with projected benefit obligations in excess of plan assets" } } }, "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": { "auth_ref": [ "r1039", "r1041", "r1046" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment", "negatedTerseLabel": "Settlement/curtailment loss" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r594", "r627", "r653", "r944", "r945" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service costs", "verboseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "auth_ref": [ "r595" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "negatedLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]", "terseLabel": "Weighted Average Assumptions Used to Determine Benefit Obligation [Abstract]" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]", "terseLabel": "Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost (Income) [Abstract]" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r665" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plan expense" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r67", "r111" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation of property, plant and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r771" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes derivative asset.", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r325", "r326", "r798", "r920" ], "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative contracts", "verboseLabel": "Fair value \u2013 assets" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r1064" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Included in other income/(expense)" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r242", "r243", "r246", "r248", "r920" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r239", "r242", "r246" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r239", "r242", "r246", "r248", "r250", "r252", "r773" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r325", "r326", "r798", "r920" ], "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative contracts", "verboseLabel": "Fair value \u2013 liabilities" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r771" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes derivative liability.", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r1062", "r1063" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesAndFairValueTextBlock": { "auth_ref": [ "r253", "r259" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.", "label": "Derivatives and Fair Value [Text Block]", "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments" } } }, "localname": "DerivativesAndFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r233", "r235", "r239", "r240", "r249", "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives Contracts" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives designated as hedging instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Product technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r586", "r935", "r936", "r937", "r938", "r939", "r940", "r941" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r1037" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueandContractrelatedBalancesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r676", "r706", "r707", "r709", "r714", "r953" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation Expense" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r5", "r7", "r272", "r285" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "terseLabel": "Declared but unpaid dividends" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticPlanMember": { "auth_ref": [ "r1048", "r1049", "r1050" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Domestic Plan [Member]", "terseLabel": "Domestic Plan" } } }, "localname": "DomesticPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings per share attributable to Thermo Fisher Scientific Inc." } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r347", "r370", "r371", "r372", "r373", "r374", "r379", "r382", "r388", "r389", "r390", "r394", "r784", "r785", "r874", "r882", "r925" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic Earnings Per Share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r347", "r370", "r371", "r372", "r373", "r374", "r382", "r388", "r389", "r390", "r394", "r784", "r785", "r874", "r882", "r925" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted Earnings Per Share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r391", "r392", "r393", "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r1069" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Exchange rate effect on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r358", "r722", "r747" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount": { "auth_ref": [ "r1053" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).", "label": "Effective Income Tax Rate Reconciliation, FDII, Amount", "negatedLabel": "Foreign-derived intangible income" } } }, "localname": "EffectiveIncomeTaxRateReconciliationFdiiAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": { "auth_ref": [ "r1053" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).", "label": "Effective Income Tax Rate Reconciliation, GILTI, Amount", "terseLabel": "Global intangible low-taxed income" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r1052", "r1053" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "terseLabel": "Excess tax benefits from stock options and restricted stock units" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and employee benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r708" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average amortization period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes accrual for environmental loss contingency.", "label": "Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r143", "r300", "r339", "r340", "r341", "r362", "r363", "r364", "r367", "r375", "r377", "r397", "r450", "r563", "r710", "r711", "r712", "r740", "r741", "r783", "r816", "r817", "r818", "r819", "r820", "r823", "r855", "r887", "r888", "r889" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityFundsMember": { "auth_ref": [ "r1040" ], "lang": { "en-us": { "role": { "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments.", "label": "Equity Funds [Member]", "terseLabel": "Equity funds" } } }, "localname": "EquityFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r93", "r417", "r981" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "auth_ref": [ "r797" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.", "label": "Equity Securities, FV-NI, Noncurrent", "terseLabel": "Fair value of investments" } } }, "localname": "EquitySecuritiesFVNINoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r443" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Cost method investments" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r788", "r789", "r794" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r254", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r533", "r617", "r618", "r619", "r620", "r621", "r622", "r789", "r857", "r858", "r859", "r930", "r931", "r942", "r943", "r944" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r257", "r258" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r788", "r789", "r790", "r791", "r796" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedging" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r533", "r617", "r622", "r789", "r857", "r942", "r943", "r944" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r533", "r617", "r622", "r789", "r858", "r930", "r931", "r942", "r943", "r944" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r533", "r617", "r618", "r619", "r620", "r621", "r622", "r789", "r859", "r930", "r931", "r942", "r943", "r944" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r255", "r258" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r255", "r258" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Rollforward of the Fair Value of Investments" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "auth_ref": [ "r617", "r787", "r796" ], "lang": { "en-us": { "role": { "documentation": "Fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "terseLabel": "Fair Value Measured at Net Asset Value Per Share" } } }, "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r792" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedLabel": "Changes in fair value included in earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r255" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r533", "r617", "r618", "r619", "r620", "r621", "r622", "r857", "r858", "r859", "r930", "r931", "r942", "r943", "r944" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r793", "r796" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "auth_ref": [ "r792" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).", "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsRollforwardoftheFairValueofInvestmentsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r241", "r244", "r250" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r837", "r848" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "totalLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "2028 and thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease liability.", "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinancialGuaranteeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An agreement (contract) that requires the guarantor to make payments to the guaranteed party based on another entity's failure to pay specified obligations, such as debt, to a lender.", "label": "Financial Guarantee [Member]", "terseLabel": "Pension Obligation Guarantee" } } }, "localname": "FinancialGuaranteeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Estimated useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r312", "r474" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails_1": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "2028 and thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r107" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r107" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r107" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r107" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r107" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r471", "r473", "r474", "r476", "r864", "r868" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r105", "r868" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 }, "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails_1": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Definite-lived intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r99", "r104" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r105", "r864" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 }, "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Estimated future amortization expense of definite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixedIncomeFundsMember": { "auth_ref": [ "r1040" ], "lang": { "en-us": { "role": { "documentation": "Investment that pools funds from investors to invest in a combination of underlying investments, primarily fixed income investments.", "label": "Fixed Income Funds [Member]", "terseLabel": "Fixed income funds" } } }, "localname": "FixedIncomeFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Non- U.S." } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r808", "r810", "r812", "r814" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Currency transaction gains" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r825" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r920", "r942", "r958" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Currency exchange contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r1048", "r1049", "r1050" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "Foreign Plan" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r242", "r245" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "terseLabel": "Net gains on derivative instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r52", "r92", "r974" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "terseLabel": "Gain (loss) on investments" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r67", "r135", "r136" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on early extinguishment of debt", "verboseLabel": "Loss on early extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r311", "r458", "r869", "r927", "r960", "r1008", "r1015" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r460", "r927" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Acquisitions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r469", "r470", "r927" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Acquisition-related Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r464" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r459", "r466", "r927" ], "calculation": { "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Goodwill" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r197", "r1014" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Finalization of purchase price allocations for 2021 acquisitions" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GovernmentAssistancePolicyTextBlock": { "auth_ref": [ "r826", "r827" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for government assistance.", "label": "Government Assistance [Policy Text Block]", "terseLabel": "Government Assistance" } } }, "localname": "GovernmentAssistancePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GuaranteeObligationsByNatureAxis": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Information by nature of guarantee.", "label": "Guarantor Obligations, Nature [Axis]", "terseLabel": "Guarantor Obligations, Nature [Axis]" } } }, "localname": "GuaranteeObligationsByNatureAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GuaranteeObligationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Guarantor Obligations [Line Items]", "terseLabel": "Guarantor Obligations [Line Items]" } } }, "localname": "GuaranteeObligationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GuaranteeObligationsMaximumExposure": { "auth_ref": [ "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.", "label": "Guarantor Obligations, Maximum Exposure, Undiscounted", "terseLabel": "Maximum guarantee under lease arrangements" } } }, "localname": "GuaranteeObligationsMaximumExposure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteeObligationsNatureDomain": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees.", "label": "Guarantor Obligations, Nature [Domain]", "terseLabel": "Guarantor Obligations, Nature [Domain]" } } }, "localname": "GuaranteeObligationsNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GuaranteeTypeOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement that requires the guarantor to make payments to a guaranteed party in compensation for that party's or parties' loss or injury, classified as other.", "label": "Guarantee Type, Other [Member]", "terseLabel": "Lease Residual Value Guarantee" } } }, "localname": "GuaranteeTypeOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GuaranteesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Guarantees [Abstract]", "terseLabel": "Guarantees [Abstract]" } } }, "localname": "GuaranteesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgeFundsMember": { "auth_ref": [ "r1040" ], "lang": { "en-us": { "role": { "documentation": "Investments in registered hedge funds.", "label": "Hedge Funds [Member]", "terseLabel": "Hedge funds" } } }, "localname": "HedgeFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r239", "r773" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r67", "r109" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r357", "r746" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S." } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r357", "r746" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Non-U.S." } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r416", "r421", "r427", "r430", "r926" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]", "terseLabel": "Components of Income From Continuing Operations Before Income Taxes [Abstract]" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r45", "r67", "r93", "r277", "r294", "r413" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 3.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "terseLabel": "Equity in earnings/(losses) of unconsolidated entities" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r477", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r358", "r723", "r730", "r734", "r742", "r748", "r750", "r751", "r753" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the additional liability or refund received or expected based on a final settlement with a taxing authority.", "label": "Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority", "terseLabel": "Unrecognized tax benefits reclassed to accrued income taxes in connection with IRS settlement" } } }, "localname": "IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r359", "r376", "r377", "r414", "r721", "r743", "r749", "r883" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes", "totalLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/IncomeTaxesComponentsofIncomeBeforeProvisionforIncomeTaxesandProvisionforIncomeTaxesDetails", "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r338", "r717", "r718", "r730", "r731", "r733", "r737" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r1053" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Valuation allowances" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationDispositionOfAssets": { "auth_ref": [ "r1053" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.", "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount", "terseLabel": "Intra-entity transfers" } } }, "localname": "IncomeTaxReconciliationDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r1053" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r722" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Provision for income taxes at statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r1053" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 12.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other, net" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r1053" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 11.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State income taxes, net of federal tax" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "auth_ref": [ "r1053" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount", "negatedTerseLabel": "Provision for (reversal of) tax reserves, net", "terseLabel": "Provision for (reversal of) tax reserves, net" } } }, "localname": "IncomeTaxReconciliationTaxContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "auth_ref": [ "r1053" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "negatedLabel": "Income tax credits" } } }, "localname": "IncomeTaxReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": { "auth_ref": [ "r1053" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount", "terseLabel": "US foreign tax credits generated by repatriation of foreign earnings" } } }, "localname": "IncomeTaxReconciliationTaxCreditsForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxSettlements": { "auth_ref": [ "r1053" ], "calculation": { "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 14.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount", "negatedTerseLabel": "Tax return reassessments and settlements", "terseLabel": "Tax return reassessments and settlements" } } }, "localname": "IncomeTaxReconciliationTaxSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r63", "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r66" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r66" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r66" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Change in deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r66" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities, excluding the effects of acquisitions and disposition:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r66" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r383", "r384", "r385", "r390", "r675" ], "calculation": { "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Plus effect of: stock options and restricted stock units (shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r472", "r475" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r108" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r101", "r108" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [ "r311" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Acquisition-related intangible assets" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r97", "r103" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Acquisition-related intangible assets, net", "totalLabel": "Acquisition-related intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r265", "r278", "r342", "r410", "r830" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r348", "r351", "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r957" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swaps - fair value hedges" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r408", "r420", "r421", "r422", "r423", "r424", "r426", "r430" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment Eliminations" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.", "label": "Inventories [Member]", "terseLabel": "Inventories" } } }, "localname": "InventoriesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r95", "r917" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFirmPurchaseCommitmentLoss": { "auth_ref": [ "r456" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss recognized on firm purchase commitment for inventory.", "label": "Inventory, Firm Purchase Commitment, Loss", "terseLabel": "Cost of product revenues related to an existing supply contract" } } }, "localname": "InventoryFirmPurchaseCommitmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r322", "r916", "r960" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r307", "r321", "r396", "r454", "r455", "r457", "r862", "r923" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r95", "r919" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r95", "r918" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r51", "r409" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r444", "r1086" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r788" ], "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LIFOMethodRelatedItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIFO Method Related Items [Abstract]", "terseLabel": "LIFO Method Inventories [Abstract]" } } }, "localname": "LIFOMethodRelatedItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r1038" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r1075" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Operating Leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r841" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r840" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r1076" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Payments of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "2028 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r848" ], "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r1073" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r1074" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Options to extend, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r849" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r14", "r275", "r291", "r960", "r992", "r1007", "r1067" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, redeemable noncontrolling interest and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, redeemable noncontrolling interest and equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r22", "r306", "r356", "r445", "r506", "r507", "r509", "r510", "r511", "r513", "r515", "r517", "r518", "r765", "r769", "r770", "r799", "r960", "r1030", "r1077", "r1078" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r254" ], "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities [Abstract]" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r6", "r273", "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit", "terseLabel": "Borrowings outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r19" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Revolving credit facility capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r19" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Unused lines of credit" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r6", "r273", "r287", "r532", "r547", "r930", "r931" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Total borrowings at carrying value", "verboseLabel": "Carrying value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r6" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-Term Debt and Lease Obligation", "terseLabel": "Long-term obligations" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r133", "r361", "r1034" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "2028 and thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r133", "r361", "r537" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r133", "r361", "r537" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r133", "r361", "r537" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r133", "r361", "r537" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r133", "r361", "r537" ], "calculation": { "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofAnnualRepaymentRequirementsforDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r24", "r134" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r125", "r126", "r497", "r498", "r499", "r1025", "r1026" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r125", "r126", "r497", "r498", "r499", "r1025", "r1026" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss Contingency [Abstract]", "terseLabel": "Loss Contingency [Abstract]" } } }, "localname": "LossContingencyAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r497", "r978" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r498", "r499", "r505" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Range of probable loss" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r125", "r126", "r497", "r498", "r499", "r1025", "r1026" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyReceivable": { "auth_ref": [ "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable.", "label": "Loss Contingency, Receivable", "terseLabel": "Estimated amounts due from insurers" } } }, "localname": "LossContingencyReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and Equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r0", "r216" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r30", "r274", "r290", "r356", "r445", "r506", "r509", "r510", "r511", "r517", "r518", "r799" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Noncontrolling Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Ownership interest, noncontrolling owners" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership percentage, parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r30", "r48", "r219", "r228" ], "lang": { "en-us": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest [Table]", "terseLabel": "Noncontrolling Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAdditionalAccountingPolicyandBalanceSheetDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r1040" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r350" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r350" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r62", "r65", "r68" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r224", "r230", "r333", "r336", "r376", "r377", "r984" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "terseLabel": "Net income" } } }, "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r370", "r371", "r372", "r373", "r379", "r380", "r387", "r390", "r416", "r421", "r427", "r430", "r926" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income", "totalLabel": "Net income attributable to Thermo Fisher Scientific Inc." } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "auth_ref": [ "r140", "r224", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "terseLabel": "Net income" } } }, "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r78", "r298", "r299", "r300", "r301", "r302", "r365", "r366", "r367", "r368", "r369", "r372", "r378", "r394", "r441", "r442", "r447", "r448", "r449", "r450", "r451", "r452", "r710", "r711", "r712", "r738", "r739", "r740", "r741", "r757", "r758", "r759", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r828", "r829", "r832", "r833", "r834", "r835", "r850", "r851", "r852", "r853", "r854", "r855", "r865", "r866", "r867", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "auth_ref": [ "r149", "r204", "r226" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from a business combination.", "label": "Noncontrolling Interest, Increase from Business Combination", "terseLabel": "Recognition upon acquisition" } } }, "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r218", "r563", "r994", "r995", "r996" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r434" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-lived Assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives not designated as hedging instruments" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofAggregateNotionalValueandFairValueofDerivativeInstrumentsDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonrecurringAdjustmentAxis": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Axis]", "terseLabel": "Nonrecurring Adjustment [Axis]" } } }, "localname": "NonrecurringAdjustmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NonrecurringAdjustmentDomain": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Domain]", "terseLabel": "Nonrecurring Adjustment [Domain]" } } }, "localname": "NonrecurringAdjustmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r1006" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r416", "r421", "r427", "r430", "r926" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Consolidated operating income", "totalLabel": "Operating income", "verboseLabel": "Subtotal reportable segments" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r842", "r959" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r837" ], "calculation": { "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofFuturePaymentsofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r837" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities - current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r837" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities - noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r839", "r844" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r836" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "ROU assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r847", "r959" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r846", "r959" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Remaining operating lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r191" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "NOL carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r420", "r421", "r422", "r423", "r424", "r430" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Total Reportable Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrderOrProductionBacklogMember": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Orders, production or production backlog arising from contracts such as purchase or sales orders acquired in a business combination.", "label": "Order or Production Backlog [Member]", "terseLabel": "Backlog" } } }, "localname": "OrderOrProductionBacklogMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r77", "r84", "r232" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Nature of Operations and Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r323", "r960" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of other assets.", "label": "Other Assets, Fair Value Disclosure", "terseLabel": "Warrants" } } }, "localname": "OtherAssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r313" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized.", "label": "Other Capitalized Property Plant and Equipment [Member]", "terseLabel": "Machinery, equipment and leasehold improvements" } } }, "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]", "terseLabel": "Pension and other postretirement benefit liability adjustments:" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]", "terseLabel": "Unrealized gains and losses on hedging instruments:" } } }, "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]", "terseLabel": "Currency translation adjustment:" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r33", "r37", "r809", "r811", "r815" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Currency translation adjustment (net of tax provision (benefit) of $173, $231 and $(221))" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax": { "auth_ref": [ "r31", "r38", "r809", "r813", "r822" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax", "terseLabel": "Tax provision (benefit) on currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r40", "r43", "r340", "r816", "r818", "r823", "r982" ], "calculation": { "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive items before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r327", "r328" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Unrealized losses on hedging instruments (net of tax benefit of $0, $0 and $20)" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "auth_ref": [ "r329" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "negatedLabel": "Tax benefit on unrealized holding losses on hedging instruments arising during the period" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r328", "r331" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedLabel": "Reclassification adjustment for losses included in net income (net of tax benefit of $1, $17 and $14)" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r328", "r331", "r772" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "negatedLabel": "Amount reclassified from accumulated other comprehensive items to other income/(expense)", "terseLabel": "Amount reclassified from accumulated other comprehensive items to other income/(expense)" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "auth_ref": [ "r329" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "negatedLabel": "Tax benefit on reclassification adjustment for losses on hedging instruments recognized in net income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax": { "auth_ref": [ "r37", "r41", "r162" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax", "terseLabel": "Net settlement gains on pension plans" } } }, "localname": "OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r43", "r143", "r334", "r337", "r343", "r816", "r821", "r823", "r870", "r878", "r982", "r983" ], "calculation": { "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive items" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive items:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "auth_ref": [ "r35", "r37" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax", "negatedLabel": "Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $9, $11 and $(1))" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax": { "auth_ref": [ "r35", "r38", "r220" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax", "terseLabel": "Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBeforeReclassificationAdjustmentsTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax": { "auth_ref": [ "r37", "r41", "r162", "r332" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $3, $6 and $4)" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax": { "auth_ref": [ "r38", "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax (expense) benefit for reclassification adjustment from accumulated other comprehensive (income) loss of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax", "negatedLabel": "Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other Expense" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails", "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r153", "r181" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income/Expense" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Other Intangible Assets, Net", "terseLabel": "Other intangible assets" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r21", "r960" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r25" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash expenses" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income/(expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Thermo Fisher Scientific Inc. Shareholders\u2019 Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForHedgeFinancingActivities": { "auth_ref": [ "r352", "r988" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.", "label": "Payments for Hedge, Financing Activities", "terseLabel": "Termination fees" } } }, "localname": "PaymentsForHedgeFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r985", "r986" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other investing activities, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r59" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of company common stock", "terseLabel": "Purchases of company common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r481", "r989" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r59" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "terseLabel": "Cash outlay" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r56", "r760" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r56" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r57" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property, plant and equipment", "terseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitContributions": { "auth_ref": [ "r64" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.", "label": "Payment for Pension and Other Postretirement Benefits", "negatedLabel": "Contributions to retirement plans", "terseLabel": "Cash contributions to retirement plans" } } }, "localname": "PensionAndOtherPostretirementBenefitContributions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r614", "r616", "r622", "r641", "r643", "r644", "r645", "r646", "r647", "r662", "r663", "r665", "r671", "r944" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Pension and Other Postretirement Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r5", "r590", "r591", "r613", "r944" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "negatedLabel": "Current liability" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r7", "r590", "r591", "r613", "r944" ], "calculation": { "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "negatedLabel": "Noncurrent liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "auth_ref": [ "r163", "r168", "r169", "r170", "r171" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "terseLabel": "Pension and Other Postretirement Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r154", "r590", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r639", "r640", "r642", "r645", "r648", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r665", "r666", "r670", "r944", "r945", "r949", "r950", "r951" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plans, Defined Benefit" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PercentageOfLIFOInventory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of LIFO (last in first out) inventory to total inventory as of the balance sheet date if other than 100 percent.", "label": "Percentage of LIFO Inventory", "terseLabel": "Percentage of LIFO inventory" } } }, "localname": "PercentageOfLIFOInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PerformanceGuaranteeMember": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "An agreement (contract) that requires the guarantor to make payments to a guaranteed party based on another entity's failure to perform under an obligating agreement. This may include the issuance of a performance standby letter of credit which requires the guarantor to make payments if a specified party fails to perform under a nonfinancial contractual obligation.", "label": "Performance Guarantee [Member]", "terseLabel": "Performance Guarantee" } } }, "localname": "PerformanceGuaranteeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [ "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r642", "r942", "r943", "r944" ], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r8", "r549" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, $100 Par Value - Par Value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, $100 Par Value - Shares Authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r8", "r549" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, $100 Par Value - Shares Issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r8", "r960" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $100 par value, 50,000 shares authorized; none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r980" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Presentation" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromHedgeFinancingActivities": { "auth_ref": [ "r352", "r987" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.", "label": "Proceeds from Hedge, Financing Activities", "terseLabel": "Proceeds from interest rate swap" } } }, "localname": "ProceedsFromHedgeFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommercialPaper": { "auth_ref": [ "r58" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from borrowing by issuing commercial paper.", "label": "Proceeds from Issuance of Commercial Paper", "terseLabel": "Proceeds from issuance of commercial paper" } } }, "localname": "ProceedsFromIssuanceOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r58" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Net proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r987", "r988" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r55" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r935" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product revenues" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r304", "r333", "r336", "r349", "r356", "r366", "r376", "r377", "r416", "r421", "r427", "r430", "r445", "r506", "r507", "r509", "r510", "r511", "r513", "r515", "r517", "r518", "r763", "r766", "r767", "r785", "r799", "r875", "r926", "r955", "r956", "r984", "r1030" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows", "http://thermofisher.com/role/ConsolidatedStatementofComprehensiveIncome", "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r112", "r309" ], "calculation": { "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r114", "r292", "r876", "r960" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r114", "r901", "r902" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Contract-related Balances" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r40", "r43", "r340", "r816", "r820", "r823", "r982" ], "calculation": { "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedLabel": "Amounts reclassified from accumulated other comprehensive items" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r138", "r139", "r141", "r142" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "periodEndLabel": "Redeemable noncontrolling interest, balance", "periodStartLabel": "Redeemable noncontrolling interest, balance", "terseLabel": "Redeemable noncontrolling interest" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfCommercialPaper": { "auth_ref": [ "r60" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow due to repaying amounts borrowed by issuing commercial paper.", "label": "Repayments of Commercial Paper", "negatedLabel": "Repayments of commercial paper" } } }, "localname": "RepaymentsOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r60" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Repayment of debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r182", "r297", "r1085" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r69", "r75", "r308" ], "calculation": { "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash included in other current assets" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage, classified as current.", "label": "Restricted Cash and Cash Equivalents, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r69", "r75", "r898" ], "calculation": { "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash included in other assets" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage, classified as noncurrent.", "label": "Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r479", "r481", "r484", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Other Costs" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCosts" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r480", "r483", "r487", "r489" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Future restructuring costs" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r67", "r485", "r487", "r1021" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Net restructuring charges incurred" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r481", "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveTranslationAdjustment": { "auth_ref": [ "r1022", "r1023" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "verboseLabel": "Currency translation" } } }, "localname": "RestructuringReserveTranslationAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r11", "r148", "r289", "r891", "r896", "r960" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r300", "r362", "r363", "r364", "r367", "r375", "r377", "r450", "r710", "r711", "r712", "r740", "r741", "r783", "r887", "r889" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r638", "r639", "r640", "r642", "r645", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r1048", "r1049", "r1050" ], "lang": { "en-us": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r638", "r639", "r640", "r642", "r645", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r1048", "r1049", "r1050" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r154", "r155", "r590", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r639", "r640", "r642", "r645", "r648", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r665", "r666", "r667", "r670", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r154", "r155", "r590", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r639", "r640", "r642", "r645", "r648", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r665", "r666", "r667", "r670", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r407", "r408", "r420", "r425", "r426", "r432", "r433", "r436", "r585", "r586", "r863" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails", "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r589", "r924" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r567", "r568", "r569", "r570", "r571", "r572", "r575", "r576", "r588", "r589" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue and Contract-related Balances" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueandContractrelatedBalances" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.", "label": "Revenue, Performance Obligation, Description of Timing", "terseLabel": "Revenue, Performance Obligation, Description of Timing" } } }, "localname": "RevenuePerformanceObligationDescriptionOfTiming", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r573" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Transaction price allocated to remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Expected timing of satisfaction of remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r1036" ], "lang": { "en-us": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Percentage", "terseLabel": "Remaining performance obligation percentage" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RevenueContractrelatedBalancesRevenuePerformanceObligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r845", "r959" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance lease ROU assets obtained in exchange for new finance lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r845", "r959" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease ROU assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r944", "r1043", "r1044" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]", "terseLabel": "Accumulated Benefit Obligation and Fair Value of Plan Assets" } } }, "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r40", "r1071", "r1072" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Change in Each Component of Accumulated Other Comprehensive Items" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Fair Value of the Company's Plan Assets" } } }, "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Schedule of Actuarial Assumptions" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r944", "r1043" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]", "terseLabel": "Projected Benefit Obligation and Fair Value of Plan Assets" } } }, "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r200", "r201", "r756" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Components of Purchase Price" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Carrying Value and Fair Value of the Company's Debt Instruments" } } }, "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Disclosures" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Components of the Provision for Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r163", "r164", "r165", "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationandFairValueofPlanAssetsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofEstimatedFutureBenefitPaymentsDetails", "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansScheduleofFairValueoftheCompanysPlanAssetsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansActuarialAssumptionsDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansNarrativeDetails", "http://thermofisher.com/role/PensionsandOtherPostretirementBenefitPlansReconciliationofBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r242", "r246", "r773" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments, Gain (Loss) Recognized" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Fair Value of Derivative Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r1004" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r94", "r304", "r356", "r445", "r799" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/OtherIncomeExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of Estimated Future Benefit Payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r788", "r789" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r99", "r104", "r864" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r99", "r104" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Acquisition-related Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r927" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r927", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGuaranteeObligationsTable": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure about the type or nature of guarantees, for example performance, indemnification, payment and other guarantees, and related information such as term, origin and purpose, triggering event, maximum exposure, and carrying value. Represents the guarantor's disclosures which include the information about each guarantee, or each group of similar guarantees, even if the likelihood of the guarantor's need to make any payments under the guarantee is remote. This excludes disclosures for product warranties.", "label": "Schedule of Guarantor Obligations [Table]", "terseLabel": "Schedule of Guarantor Obligations [Table]" } } }, "localname": "ScheduleOfGuaranteeObligationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r993" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Components of Income Before Provision for Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r108", "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Indefinite-Lived Acquisition-related Intangible Assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r2", "r15", "r16", "r17" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Components of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Annual Repayment Requirements for Debt Obligations" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Net Benefit Costs" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "terseLabel": "Schedule of Aggregate Notional Value of Outstanding Derivative Contracts" } } }, "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r75", "r268", "r288" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r480", "r481", "r482", "r483", "r487", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r116", "r117", "r120" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Schedule of Restructuring and Other Costs by Segment" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r115", "r121" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of the Company's Accrued Restructuring Balance" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/RestructuringandOtherCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r47", "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of Revenue by Geographical Areas" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r44", "r89" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofRevenuebyGeographicalAreasDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r85", "r86", "r87", "r96" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r85", "r86", "r87", "r96" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r672", "r674", "r677", "r678", "r679", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r701", "r702", "r703", "r704", "r705" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of the Company's Restricted Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r172", "r173", "r175" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of the Company's Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]", "terseLabel": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r404", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r436", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r483", "r489", "r927", "r1087" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentOperatingActivitiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations.", "label": "Operating Activities [Domain]", "terseLabel": "Operating Activities [Domain]" } } }, "localname": "SegmentOperatingActivitiesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r404", "r405", "r406", "r416", "r419", "r424", "r428", "r429", "r430", "r431", "r432", "r435", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Business Segment and Geographical Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r50" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofIncome": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails", "http://thermofisher.com/role/DebtandOtherFinancingArrangementsScheduleofDebtDetails", "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCarryingValueandFairValueoftheCompanysDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Other" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/AcquisitionsScheduleofProFormaInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r935" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service revenues" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/RevenueContractrelatedBalancesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r66" ], "calculation": { "http://thermofisher.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r953" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Purchase price percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Restricted Units, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r692" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r692" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r689", "r690" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested, ending balance (shares)", "periodStartLabel": "Unvested, beginning balance (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Unvested Restricted Units [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r689", "r690" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested, weighted average grant-date fair value, ending (in dollars per share)", "periodStartLabel": "Unvested, weighted average grant-date fair value, beginning (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r696" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of shares vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected annual dividend" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseScheduleofWeightedAverageAssumptionsusedintheBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r702" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseScheduleofWeightedAverageAssumptionsusedintheBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseScheduleofWeightedAverageAssumptionsusedintheBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Payroll deductions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r696" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r1051" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Canceled/expired (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r1051" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Canceled/expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r178" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r681", "r682" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (shares)", "periodStartLabel": "Outstanding, beginning balance (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r681", "r682" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of period (in dollars per share)", "periodStartLabel": "Outstanding, beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r697" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Options vested and expected to vest, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r697" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and unvested expected to vest (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r697" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and unvested expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r677", "r678", "r679", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r701", "r702", "r703", "r704", "r705" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails", "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysRestrictedUnitActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r680", "r699", "r700", "r701", "r702", "r705", "r713", "r714" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based Compensation Expense" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r954" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseScheduleofWeightedAverageAssumptionsusedintheBlackScholesOptionPricingModelDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r178" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options exercisable, weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r697" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options vested and expected to vest, weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r3", "r271", "r286", "r960" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-Term Debt", "terseLabel": "Outstanding short-term borrowings" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]", "terseLabel": "Short-term Financing [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/DebtandOtherFinancingArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Warranty Obligations" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r131", "r217", "r296", "r504" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Letters of Credit / Bank Guarantees" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r303", "r404", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r436", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r478", "r483", "r489", "r927", "r1087" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/BusinessSegmentandGeographicalInformationScheduleofSegmentReportingInformationDetails", "http://thermofisher.com/role/CommitmentsandContingenciesDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesGoodwillDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesInventoriesDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails", "http://thermofisher.com/role/RestructuringandOtherCostsScheduleoftheCompanysAccruedRestructuringBalanceDetails_1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r316", "r317", "r318", "r356", "r382", "r386", "r388", "r390", "r398", "r399", "r445", "r506", "r509", "r510", "r511", "r517", "r518", "r549", "r550", "r552", "r556", "r562", "r799", "r914", "r975", "r990", "r1003" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r28", "r143", "r300", "r339", "r340", "r341", "r362", "r363", "r364", "r367", "r375", "r377", "r397", "r450", "r563", "r710", "r711", "r712", "r740", "r741", "r783", "r816", "r817", "r818", "r819", "r820", "r823", "r855", "r887", "r888", "r889" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by continuing and discontinuing operations.", "label": "Operating Activities [Axis]", "terseLabel": "Operating Activities [Axis]" } } }, "localname": "StatementOperatingActivitiesSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r362", "r363", "r364", "r397", "r863" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r72", "r73", "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of stock upon vesting of restricted stock units" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r8", "r9", "r143", "r148" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares issued under ESPP (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r8", "r9", "r143", "r148" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of shares under employees' and directors' stock plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r8", "r9", "r143", "r148", "r686" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/StockbasedCompensationExpenseSummaryoftheCompanysOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r8", "r9", "r148", "r174" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of shares under employees' and directors' stock plans" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r9", "r12", "r13", "r91", "r960", "r992", "r1007", "r1067" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Thermo Fisher Scientific Inc. shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Thermo Fisher Scientific Inc. shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r218", "r219", "r229", "r300", "r301", "r340", "r362", "r363", "r364", "r367", "r375", "r450", "r563", "r710", "r711", "r712", "r740", "r741", "r783", "r816", "r817", "r823", "r855", "r888", "r889", "r992", "r1007", "r1067" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedBalanceSheet", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r152", "r355", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r563", "r774" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Comprehensive Income and Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r824", "r856" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r824", "r856" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r824", "r856" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r185", "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Cash Flow Information [Abstract]" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r191" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments.", "label": "Temporary Equity, Foreign Currency Translation Adjustments", "terseLabel": "Other comprehensive items" } } }, "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Tradenames" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/AcquisitionsNarrativeDetails", "http://thermofisher.com/role/AcquisitionsScheduleofComponentsofPurchasePriceDetails", "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesAcquisitionrelatedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseGrossOfTax": { "auth_ref": [ "r1068", "r1070" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of increase (decrease) in the cumulative translation adjustment from gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.", "label": "Derivatives used in Net Investment Hedge, Increase (Decrease), Gross of Tax", "terseLabel": "Included in currency translation adjustment within other comprehensive items" } } }, "localname": "TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseGrossOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofDerivativeInstrumentsGainLossRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "periodEndLabel": "Balance, treasury stock (in shares)", "periodStartLabel": "Balance, treasury stock (in shares)", "terseLabel": "Treasury Stock at Cost (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheetParenthetical", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r29", "r150", "r151" ], "calculation": { "http://thermofisher.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "negatedLabel": "Treasury stock at cost, 50,157,275 and 44,720,112 shares" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r9", "r143", "r148" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Purchases of company common stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ComprehensiveIncomeandShareholdersEquityDetails", "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r143", "r148", "r150" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Purchases of company common stock" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofRedeemableNoncontrollingInterestandEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r298", "r299", "r300", "r301", "r302", "r366", "r367", "r368", "r369", "r378", "r441", "r442", "r447", "r448", "r449", "r450", "r451", "r452", "r710", "r711", "r712", "r738", "r739", "r740", "r741", "r757", "r758", "r759", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r828", "r829", "r832", "r833", "r834", "r835", "r850", "r851", "r852", "r853", "r854", "r855", "r865", "r866", "r867", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": { "auth_ref": [ "r492", "r493", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement.", "label": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]", "terseLabel": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]" } } }, "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unconditional Purchase Obligations (Excluding Capital Stock Redemptions) [Abstract]", "terseLabel": "Unconditional Purchase Obligations [Abstract]" } } }, "localname": "UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r281", "r295", "r715", "r752" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.", "label": "Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Undistributed earnings" } } }, "localname": "UndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r716", "r725" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r726" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Reductions for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r728" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedLabel": "Settlements" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r724" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "UTB, interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.", "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition", "terseLabel": "Additions due to acquisitions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails", "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r727" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions for tax positions of current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r726" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "auth_ref": [ "r1054" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "terseLabel": "Increase (decrease) in UTB" } } }, "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r729" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Closure of tax years" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "auth_ref": [ "r493" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Unrecorded Unconditional Purchase Obligation", "terseLabel": "Unconditional purchase obligations" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": { "auth_ref": [ "r492", "r493", "r495" ], "lang": { "en-us": { "role": { "documentation": "Pertinent information about unrecorded unconditional purchase arrangements to acquire goods or services, by category of goods or services. arrangements to acquire goods or services, by category of goods or services.", "label": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]", "terseLabel": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Unrecorded Unconditional Purchase Obligation [Line Items]", "terseLabel": "Unrecorded Unconditional Purchase Obligation [Line Items]" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationTable": { "auth_ref": [ "r492", "r493", "r495" ], "lang": { "en-us": { "role": { "documentation": "Describes each unrecorded unconditional purchase obligation arrangement to purchase goods and services that extend over multiple periods, any assets pledged to secure payment, and the fixed or determinable amount of payments due in each of the next five years and thereafter.", "label": "Unrecorded Unconditional Purchase Obligation [Table]", "terseLabel": "Unrecorded Unconditional Purchase Obligation [Table]" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r81", "r82", "r83", "r400", "r401", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.", "label": "Valuation Allowance by Deferred Tax Asset [Axis]", "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]" } } }, "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r843", "r959" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/LeasesScheduleofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r381", "r390" ], "calculation": { "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted average shares (shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r379", "r390" ], "calculation": { "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://thermofisher.com/role/ConsolidatedStatementofIncome", "http://thermofisher.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1000": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1001": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1002": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1003": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1004": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1005": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1006": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1007": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1008": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1009": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1010": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1011": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1012": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1013": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1014": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1015": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1016": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1017": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1018": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1019": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1020": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1021": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1022": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1023": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1024": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1025": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1026": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1027": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1028": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1029": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1030": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1031": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1032": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1033": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1034": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1035": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1036": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1037": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1038": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1039": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1040": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1041": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1042": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1043": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1044": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1045": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1046": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1047": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1048": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1049": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1050": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1051": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1052": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1053": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1054": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1055": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1056": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1057": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1058": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1059": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1060": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1061": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1062": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1063": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1064": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1065": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1066": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1067": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1068": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1069": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1070": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1071": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1072": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1073": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1074": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1075": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1076": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1077": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1078": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1079": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1080": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1081": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1082": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1083": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1084": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1085": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1086": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1087": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3,4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907419&loc=d3e10037-110241", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e12803-110250", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(3)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "https://asc.fasb.org/topic&trid=49130413", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(b)(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "https://asc.fasb.org/topic&trid=2122503", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "https://asc.fasb.org/topic&trid=2155941", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(21))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3581-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4578-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25383-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB TOPIC 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q1)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28200-109314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "https://asc.fasb.org/topic&trid=2134446", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126972413&loc=SL7495116-110257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r825": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342957-244231", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r849": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r914": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6571209&loc=d3e13703-110860", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r961": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r962": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r963": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r964": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r965": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r966": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r967": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r968": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r969": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r970": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r971": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r972": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r973": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r974": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r975": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r976": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(1)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r977": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(3)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r978": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r979": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r980": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r981": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r982": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r983": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r984": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r985": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r986": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r987": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r988": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r989": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r990": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r991": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r992": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r993": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r994": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r995": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r996": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r997": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r998": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r999": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" } }, "version": "2.2" } ZIP 116 0000097745-23-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000097745-23-000008-xbrl.zip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